<SEC-DOCUMENT>0001628280-20-015999.txt : 20201109
<SEC-HEADER>0001628280-20-015999.hdr.sgml : 20201109
<ACCEPTANCE-DATETIME>20201106203430
ACCESSION NUMBER:		0001628280-20-015999
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		94
CONFORMED PERIOD OF REPORT:	20200930
FILED AS OF DATE:		20201109
DATE AS OF CHANGE:		20201106

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MANAGEMENT CONSULTING SERVICES [8742]
		IRS NUMBER:				870042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37392
		FILM NUMBER:		201295844

	BUSINESS ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801
		BUSINESS PHONE:		(626) 282-0288

	MAIL ADDRESS:	
		STREET 1:		1668 S. GARFIELD AVENUE
		STREET 2:		2ND FLOOR
		CITY:			ALHAMBRA
		STATE:			CA
		ZIP:			91801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ameh-20200930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5,d:e94880a2d5df40d2b763e3a0bdef79c1--><html xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ameh="http://www.apollomed.net/20200930" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ameh-20200930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt:booleanfalse" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl8zLTEtMS0xLTA_be899aa2-dbc9-4c6c-8991-765af62745c7">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl80LTEtMS0xLTA_bafde20c-4b10-4654-80d6-18dc73588f97">2020</ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl81LTEtMS0xLTA_b3d3fe1a-3d64-4dfd-a66b-2f45752d147c">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl82LTEtMS0xLTA_6772f517-50b6-4c26-8b36-7a8cc8adfef7">0001083446</ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl83LTEtMS0xLTA_1921a26b-6225-4b49-91cd-3e1650b50152">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i2c841cb894a44b438ddcf5f653a3121e_I20161231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="i1b924b44d11243c79329ffb24703ba48_I20181231" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37">P2Y</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ameh-20200930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i233eb597e897408bb9acd656dcbd1d0c_I20201102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-11-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i6f15713b91eb402cbc19264dd2327c3d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i12392f1820d84e009a3fec747ed05785_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88f29eecb4a54581a1e137030ee84580_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id468dcf3a96c44a884ae2121f3929be4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999f85b1f03348b59973a22d2ce701fd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a96f004265e44acbef5c40e0a7274cb_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0760f54a264410584d47359d3245e54_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85cbed6310784ad1b00d427467f4a809_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie735c2fc161f4a028234f400af312f8e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae35627def147d19d8ab0682325ebca_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5096fa86ff645c4ac88aeaff7eb1d9f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89dce8d40320482793ae915c3b3fda86_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc8b559adf384439909838b82a315ef4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2871d1532647e4bc4f0564a4773c78_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103b982ccc8e4f93858938af7e18a96d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48fce5948a0e4dfdb085803d8face2f4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50f345eb35b24b309883822a3f432a39_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92adae19551f4d33aa3159e1f3b3c333_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c26c34d43944d53b8157c588e4d9832_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb905dbaa5064b25b91dff34aa6ebc5a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd1b1d0644e4537bb0c05e512c38d0c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbf30c3701d24df69116273d7a5e466b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaab6050bdfaa4b99b69a677d9fb18e68_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c8d5c0eb18b40688e3d9ffd255e0a2e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b7fc96fb74e494b8db4e7508d53047b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d6f6c3ab514e87bbe68a7fec5bcd87_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c3f468964da412ebaa0846e50fe0da4_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12c2127d868e4f87a671ff137b7c2981_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabd3dd55e36b43b495789ffa5cc73b36_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59fc236ccce64a608d756612e5db97f1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba7855d202c4906a207a0a7faa251a9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18b992a0d32d458485f04f21e552fb61_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2eceea105e94e54a0c2107e27e00355_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i251eec9a4efe4815a9a119b6820c7de8_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87c42df9ebca4c8ea2878cd65f523941_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90197c93402f41ff9bc61f1754e24165_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09497b34fad5498f8a7379c15692a946_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19924d22b9634738af4fc0857dd5f1db_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e6f52d6af84990b66fae85e26f4b3e_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i672096def723492da951e5ba41de393f_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13676229b94a433bb7999e82d40c9506_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31636c0f849b4fcfac8862fe43198701_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica802434063e4405a1db846371417d7c_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47774eeabb6c4f8a941dafeadf448ab0_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6836300d36448ee8800b32b51ab5107_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i045332a06815470c90c30b39515f8d62_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f9e597672244da19f4a35690c8fb312_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0058c6f89dbc42439fb7e3bd81042bbc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fc323e30b8848c392d11f3447569909_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7fba74c001f4474b00a66afe5cacce5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if17092a524b3431fa61045723b615908_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48930c9adfe945f5b856524fd6f16354_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4d27872ad1a4279809587e20ad0fe15_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4af3abe23145c5a803f5c3e52a8544_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed16704d02b4d98bf8e2256dea906c0_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i761a2357c3064b2594cc6d1ffa6c27db_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f84ac6f64b14be7aec8e4101eced375_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97e0bcf361384859a17578fb87321a54_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e6f19723927433ab20be84a073ed166_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97544ae25cce437ca45e3294de951909_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0eb6717cd0468292846a328415a98e_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77cee32ef46c436d84f0829e3e15ae33_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1abc08966ff44c6c9d37bfc49d295077_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44c7198a292a4cc68b8fabdaafd056cd_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4e33d7899548cf889cdedab733332d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0bff8181370945009acd3344b88456f0_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5a66ee0d984c67b9d7841aeb1f110d_I20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedead393f61c4d1d98fb4fb12d0b9b21_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88138caccd9942feab56d34bfdb5c9e0_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41a9a24bf76640ed9bdb33547fcaacce_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i394648e1fc6a45c1a9b563d94578a33a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i441f160512f24fc3a029ac86e7eb66f2_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9a6b08aae29400da31700f63234c634_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9189b09c063b44b4b87c085f5786c13a_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ddfb33c93414dc69359261cfab93737_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfadcf1ceec24d88b5700a0374a20a18_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bd4252c28a48b9bf1ba1f49f34c298_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422d2bc6f855432dba692b6a8acdf97f_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic92256abd49e475e96a57d58092f2a3d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f8b5692b30549aea2a5a9d8d16e6332_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id523b2ed183c45849c949c14470f0f6a_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e7f6a028994e14996741a361d2e4db_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd29e64a2dec4d29bab58feb5d6061ad_D19990701-19990701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1999-07-01</xbrli:startDate><xbrli:endDate>1999-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea967cdf5b2f471a892ea4697afe0798_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i910be3ba7abf4fbb8a6af6dcabd337ac_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i3271ca437f904f76a750501a6a560262_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i224fec02c801431e8c5aac9b0b456487_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3034d93366647d8945f0fd5c17d5c31_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c72a9bb0cb4b81bd7107492b993265_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107e7a3c6a6544e99b2eb9a20ca8c10a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="primary_care_physician"><xbrli:measure>ameh:primary_care_physician</xbrli:measure></xbrli:unit><xbrli:context id="i8aab34eff41047a39824b386e77f2ab9_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="specialty_care_physician"><xbrli:measure>ameh:specialty_care_physician</xbrli:measure></xbrli:unit><xbrli:unit id="medical_center"><xbrli:measure>ameh:medical_center</xbrli:measure></xbrli:unit><xbrli:unit id="plan"><xbrli:measure>ameh:plan</xbrli:measure></xbrli:unit><xbrli:context id="i21eafb5a353445498a87ec5ef991e89a_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="clinic"><xbrli:measure>ameh:clinic</xbrli:measure></xbrli:unit><xbrli:context id="i4cc46814272a4c91b52259eab36012a6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18773fd9db2d4f019b64dad4ce3bb2ca_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef9a04a9f264372a8deb57e8aa6633a_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1d00ff8efb448b7851f3acd7b67c857_I20140630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib183d084186d4c5bb6d817ef531b2f3d_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b26df8521744f83b689e49598713e48_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fff24e3077f4a3eb1b61025153234f3_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ameh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i6e5cacd19c684cdbb8845f5fa5d3f343_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i268f6180d8c0414395a4e02831546f91_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i615fb686511c4f7b9373dcdd32145e20_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5300706ef0ee464c80f686cc29fef1eb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860551ad800a48b6b48834294a562f6e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia00916d9e42e4e7598a07cc98c911bba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59c65958899a4f40b312082b11ad9972_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie48bb7d5e7164c9087e12aebeca47de4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08e72fdfc6d2440f9a7a619f2bfa27a4_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6b08cbba5ce44a6828427adf1d58d41_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice6d7186a3fa42f2aa021e89451d94a6_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df6da5ef4cc4b969a1fe43c3978041b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24dff7de3f35477897d40e0ce546c0c2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee27b0cd6fa641be9c0346123edc0f7c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6281cd8fd509439da10e97b31b90f99d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8acee0d243214133a46c54e3cafca151_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99ce7ab3879d43af8ed70e1e9d100478_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1864ede366d9428596f507b1ccdf3055_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic009ac2508fe4ddb8d41e1d789d89e2c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ebbea39beeb486097293272d98df046_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35e09b32dfa2485098765d8342e2c09d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41254baa0b494543874e77b5b65806dd_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db53e7069624847940f8b01072d1616_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50b5b61eb68b440ca6b1f08ae563dd55_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c8e4a29ed643d2812e326a13329643_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i215eb1833be2440ab91be38ab300819f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie685084fafd04aabac97138d7d7c72a0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d1826880923498084158c89cee6e00a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50ba8e183602464480aebab3b80942ca_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f060ecdde4a4705b9409b06aa972c41_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id59a584c780448de8be355c36a29f7cd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14a8fdcc013f4900b6aada4fc3f7af4a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dd1feb4e50b4175a4e88a4badb5cb45_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3e458d85614c56bb255ed53fb55e0a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b93d2a3bdc45dea0ee9e341a282b8a_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26496fe9ee64c8ea436ec54656e23b8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if626b3c6137241b29c016703d18f7fb1_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142ee7c619bb459289d0d37e04512563_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b7656f6e67342e29f677b7a1e65c532_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i742706889d86455a834aaba86ebe626d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69df776760514fe6a9114b9121a87a7c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i116b3e9585e9410a873b90bb05603771_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="unit"><xbrli:measure>ameh:unit</xbrli:measure></xbrli:unit><xbrli:context id="i2d04d4b89dd2456bab5a43914120ef3d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c841cb894a44b438ddcf5f653a3121e_I20161231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b924b44d11243c79329ffb24703ba48_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id33eaefc8b5942e9b470aa4f9c9fbf0d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-31</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0a2c6ac04aa49da8a227305158f0d54_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i400a89eea72d482f927a72d7ad593718_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic57f99e455f748c7bd9f72d18cb3b19e_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2f44f37c4f54616bb326a86f03405a3_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if23b273bb3224911ad4440101430e675_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i275a644f4ba94748b1661c63ce54b8bb_I20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i898462389ad24c0b8913adf6b0b29a3b_D20190830-20190830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-30</xbrli:startDate><xbrli:endDate>2019-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4dc99a0ca2e4bfbabef2c87ec9306d0_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bf488f66af84851b3c1d0a9fe304793_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f29d2703f749699c41aad0f5b9c7e0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7694ec30545c4fcdb3e6691905656166_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib036147d021e4632a938ef95e13bcfeb_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47f47905931645f2843f1d0f1c953fd4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a3823bc30347e1bc4a4696c1657ad2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if29bb5f2be9646a1b77a64b7724af7d0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8806313e53624b498a37f7e03713bd8f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91299a0c3df14bb0912f70e6b0c32101_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820337c646004760a5fd30654c3dae01_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307aff6d7c74455f8c12990d253efcfd_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57399d018d8249a39d4044e5041d9d91_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec82f37386d54fcc9539d0fee4b55ef6_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b3382bb05604a72853736390f8d222c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9572fe44439456b89540528dafe8efe_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i155d3af50fd548b19a0650fe1f943242_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8c4d20368234add91f91bbc581e9c85_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87f4db5982be4abd98dbc5f29cd0da48_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b58660aaa264d22a46c25bb967a0695_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f579d4160604e7babd882b0c0d2df3d_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i687f8eb4581848cba1db329c2d343353_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3150290f584e44fb942ebfa558510e67_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida39330ce23947b1a283b27d4e1fd854_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c46a468b494d52959804c3f5b2b176_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id96dff4b93054ab5979c1cc17ea91814_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1208e04262ef4a01a35da5626d1ff666_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37888056e3424c5f8d0dcb6ddf14c929_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i753d549a8e2f4889a19f89e63e84cc3e_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c38a1a7e9ee472f947eea00738b4192_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0b72e4a3daa4a53955968c5168b7655_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec20f66949cb4f86b1a6445e912e304f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie186328fb4c549168d42b7d9a48992e5_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aa118fd35d9488990668d4e47746b7c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="provider"><xbrli:measure>ameh:provider</xbrli:measure></xbrli:unit><xbrli:unit id="patient"><xbrli:measure>ameh:patient</xbrli:measure></xbrli:unit><xbrli:context id="iffa1353ebe6443cd972fce8728b7af34_I20121231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d6f80bd32404fe58031f292d1695804_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce0e75bb6d54e57a2fd9d41415f1fd0_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36d5dfd221ad448cbcffffc8f6478d08_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77f38d9db9c24fb6b7dcd2c1221459f8_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68d4831420054a9caa735c7f1252692b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1f9f8ea17ec45a094548fee58869526_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id90abdab01f44e47b48d561df36836df_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia037d44d0bc04c4a828c637cca06b007_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1424495955004e3094d7f448c52f3fe8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8297f0cd122a4975a2782edec1346e26_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i288e556a87794169a4a86cc7f6c4e55d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b4bf3567dfb4dd790df1e67d2f85991_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71a29ce4a53848648939532cde255536_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2146c6cb823b414e94d6373622631d84_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d5b7766ae84835948bd0dc5b9bad5c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef125c16c3942fab014863ef8783a70_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcba94fccca04cd7b22e774e76edfde4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieda981fa64b9451192fe68d1b530358d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4c48b0482e24d54a35353fe5806ea4a_D20150801-20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-08-01</xbrli:startDate><xbrli:endDate>2015-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia04e6e879820403ab84c417618cac928_I20150831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32f8ada07c6e48c3b9c63debad1daebf_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32e68a9968f5490582115cc17368bef7_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cfb37c8a9b442048185c215ca7ae06b_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i856a3c65a5c24836ba93769ef9f2948a_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-30</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie13a24a9ed274984976f3be0b0ae5d60_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07add4ecbd2749df8612f106ba12945d_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0e8d7a443424c718c847dcf3b912bea_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ea26d47ecf949429fb00155fa3a1100_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45be72031ca0447e97e01053b8c321fb_I20160531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifba98224dfe743d886659a878903bc31_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc91266bda94e86a5ec7f40496f5a5c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0cb473eab6e497599fded63c9f221e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d560d1902504cca8098eacb878eef29_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6184b34ee8134be5b8c421145d39c934_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a9a7002274458a996a2f3572f2742e_I20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3015e3b3bfc74713a36da771c5184b53_D20180601-20180630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-06-01</xbrli:startDate><xbrli:endDate>2018-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f10e9761bc4228abb6d529c3349de6_I20190423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic465b3707abf436089f9fc1143560257_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iabc665a0dbda4c87aeba1b7b7f31c314_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48000cd06bc14fb78d5ac9a135a4817c_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07be705677f8498588d2853c3c7bf749_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib25087f805b748af8715c1809bb3ecb1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8278a3e815674925897c9ef247e29fd6_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e75f05d163f47508aaed53617f817da_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i808a481f8e67463fa27b080f11806844_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2407645ed5864ae5b8cb66de46074353_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4e7c20c772c4b85a99de03a80063147_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e993cf753ad4a0694bf3466d7220468_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b8908c9b1334fe395a61d2ddc0668cf_I20190831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic960b26a1e3f40a1b24e18c623b99240_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4454b081d0384506ab87a132eae22d31_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia915b2c31332442a8d6f15aef9889924_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65347818febf49c7b80dc85ef7ae043f_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f8670c333f043daaa155fb5a0ac3eab_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f60ef2535c14c7bb4a2c7f0b27b0a8c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68c969400a494d9787143ded770b0181_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace017bb848f47dab450c002c3ee6683_D20180501-20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53fb3b2d3c10434fb7ad9df99de6697b_D20190701-20190701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-07-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79b8b4b7485e41828f619cb79928959f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfe7f2d11dba4bf8bfa9cd6b837b86d1_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0faa96915dac498dbda55cbf5243918f_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7caa591d27bf48eab7b5c969cac33e61_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c008ff76ac0426486f735cd9512a068_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i123c7dd6529340df982a5fa9dfc0aa21_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fec8536262a49a0b8b6bcb905d9ed73_I20190628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e6b5986d0843a5a0390ed42f10c1de_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2cab7f77600442608addb240a33cdb9f_I20200228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8dac94597ff94666b83c9ae361507075_I20151231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic615bf6bdf9a47aca957ca50dac11311_I20180629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57568f01843b4e1c8af7407d9814d9a4_I20181128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aca1d8a93354c9e93262133b582edf4_I20191213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f328dbb075463e9e1e6093dfb7ff74_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7be81f0e5b5b4b50b9ea5036ae2b8e02_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba23adf288b04c1f910cffd3bc1a3489_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81d7b1f95e2749528c65d9be013d2d5e_I20200430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b9f8e50331b440ca1d55608976e9518_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f7f861c210b485fa4973087f3191b99_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if381e56ee15348f3bc78b5ba5afe4f5b_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d10f2758e644e3db72c221a182e8ee8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a3eb4ddb0c34022a34f50d0b362b1a2_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bc9c0c0a51d4b37a867a13440d3cdac_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6464448a2a2a4ec5b5a785f7fa5b707c_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89bb37720e6c4641bfa4079cb6d0a971_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1840189675724de797d0b54ed266c606_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea5693feca944ef0a07785d7ed338d09_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97da86c1492849118b5eaf8e60955a49_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i706817fc9f1e4c5591f6224aa27f8969_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b193ff3b0534bf4b1e4ee91abf86721_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7903d4186900495da7128f6613b226b5_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="financial_ratio"><xbrli:measure>ameh:financial_ratio</xbrli:measure></xbrli:unit><xbrli:context id="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58a3a78950614f498d426b1d4c78e52d_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3792f3a4ad1b4e6e9af66d3b5eae396b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98837eb98d97440f9bd5671b34f7d76f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia053d843d611409ea6e794c9fe247e3e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbffe9564ff44d1bab6086b082b64111_I20180614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i664bd167ed344f5b97bb3dcf459676e0_I20180901"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7931a6ac521043ada1f90c0f74afa693_D20181231-20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-12-31</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2255233ea20d48f0a140daa8b2135d19_I20181231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0804ee2cd49c471cb1750e3eb02c9f51_I20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i342f2e70889b49b8b01eb66a3ed09a94_I20180905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i216418c12a70419bacb688b1427cd129_I20190417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b3115de9851458d8e5935842bd881cb_I20190729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie30b8de9297c42469c822858d3e54b70_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478deb2fc38c436bb8671cb70199cee5_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f4624aad0143a38ac09f171403b362_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-05</xbrli:startDate><xbrli:endDate>2018-09-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78348153cd274034948535714f61bce6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2919814c52aa4e6c96480fc7e55b85c0_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ba211b652284a1ba866c7ef68ae48e9_I20180614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88976d0744e74325abde725693423c49_I20190417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-04-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2a2fbcc8b234d85af151b72dc525ee1_I20190611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd06a67515e4d6c816adb0fc9c88a81_I20190910"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7993c591aa442349f5e43bcd84f0f49_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108d951874b443008dbdf9ebfe69c2ab_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f4ba9139fca44899bc4ca327e9849b9_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i583b6b592ac24c3f805e3c210ab44386_I20181002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-02</xbrli:startDate><xbrli:endDate>2018-10-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib720ede0911c4e8d80c33fc1220eba1a_I20190814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04eca9b9464f4a60a87145ab44e5bb1f_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7e3933a8b4246618d18872a39beb676_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d02e70680ae437eab0be807ca3d050a_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6dec8773fada4b24852d9aae4143d84b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b34349d244644a9af65d1269f0191e4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i436d289510454727bc5fddbf12ad2d92_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icece81cce5fb4924bcbe69d05e4dcc7d_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b98657bb40c476d971c44dd0400e363_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2717bab98fa54dc792c95e77b5b141e4_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87dbbc859a844154beab63a0f933c8ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i943e4302b105480e8a3a578a84a18038_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71d1171a6d540fa8cb9f4771cd113ae_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fde585401744bfc8f98fcb6e5d4c55a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccaa606008644356ae9b3ada3f0dee0a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if52999aec2ec48c3a27829576d274249_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01d22b3114f046ea83ddfddc5c0603e6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2649df80d34fa2a5160241cddb24f7_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i682e56c134fe472db3d942dee2c67e9e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic96250cdb31545618a1db18666cefafa_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf5d96c5aa524dee8cf3659f677f11b5_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3710a3c83db42d0805599a74145dff2_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i558ed222ce35492c86d5800acda7c4c6_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3263f1c5abf42b98d4605f4f7284e83_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i23c4dccf62634d3b92148d57ea541c66_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8031dd6b66546c1a3ac173850d16bd4_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56c177ebcb7d435c971aa73fe7a5ef54_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3b51820704a4a93b98fa96a6930977c_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0f9aa10906f4d2c9652027d594046aa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i486cfce3128a43d1b5f0abe01fe3ec4a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d7273f768df4eb690b7413548307158_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeddb663bcd34a33b0a3c19d9b40f607_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29325e7277374944a4b7e5d32f0a71ce_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cbfc093bc14eaf945f211b23c1507e_D20180323-20180403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-03-23</xbrli:startDate><xbrli:endDate>2018-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1163ece356545148c6d18c1e1d66912_I20151116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i358387cf1a564a2297e5f1abdf9f5f42_I20151116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-11-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ameh:agreement</xbrli:measure></xbrli:unit><xbrli:context id="ie07ae9f744764e5291d906d251e2034a_I20181128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aeb75119c51484cb3d7c560edf10ae8_I20180628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5294ed64c44b5086f5be21d0bce6cd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa2e771930d42a3b26e519f82d67bf8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6245ae4c746a41bfae5a0da8935409d9_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4949acae14e04f38821727b357327125_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c3b821bbf14ea68465673f368d6f0c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i976d1979c27d4acc9409bb7743bf49ba_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide80e6a11bd34f8b8a952c62960c82b6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61751c7e250f42118eb2800e45f0c530_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d3d75fad82483eb5813daf8df17cc3_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if932e49636814177a3488a7a9d89c9bb_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibca6368440e848ccacf6e0c6beff4565_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19071814c5784cc8acedf97c43d02aae_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dd1f69283d349a58ae0e8144a4dec4d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2670dfb231c4c36a80048c4600a520f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3717208d1224dd89f9f178d06d05dc2_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbbfbf6e54384685bbdbd24b85b6a70e_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42db88be7eb248ce937d8d0f1e434c23_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf65ddf284dd40dbbade2b730a49906e_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e86290ed094411eacda08c9860c3896_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba42cd3748834d6a9e6d5b22691a39d3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i357239cb3870424c98179560f4e05eb9_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i462e89554ff74f3fa68c411f8685e8cb_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfff017f5079475da112360bcc11bf3d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b280c05e114d2cb9d4d80828861206_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24504ae2154f4155a97794062ff7b4cc_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4915f14b437e4756b8b7d103a441b54d_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i846f7fd44f304e9ea61d6d7acb1c05d7_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i004ed9a138324dc8a6fc0af8d80321d7_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dea7f1f241546c79900d50e5d5b3e39_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8569d927dbfc4be780d7ea409efa6a37_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d5ec46533294b24af622e84d85e1306_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia82c704cff6c42929352454bea170ee6_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaade255737234b709672525b3860eed1_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab4eb5154c94c778081d37fd1fbb9c5_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23eeba47a6d445a1af488e1741954e4a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4f7901609a34f0a8bd5da4fb0dbe4f4_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id45018c024f44bd390ae0a1db7dc7a06_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:DrSimAndDrLamMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7666fdc6c5fb4c1597125f20974dcd69_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e0f7911506b4f7ea6ea22e51fac5416_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12335e3134c84754a4b5a7c9eb42658b_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fb931837c3446e49bfcff46eee3984b_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic079747ecea44c46b7fc2e75b14ca50c_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i557e6e9936fc467ba5080a062ca80496_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c0345d81c4a45029864d5dfc19df1ba_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03688552a194d20bec7b26a63399956_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2beaf01e5bdb4f7aa6d5f3c6a54f063c_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d7dbe836e64485fa477f10dbc512288_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id95fd088a2c9454599c8fb0dc66fac9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4ed9597a9f24e4884d0595ef80c9123_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i467c8f07446f434c888fe2139b1ad2e0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7230ae6b539c41a89c452715bb10fa43_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib374aadcdc4a4479907af99b24bfe82d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d542d36ef9c4c6da7ac374e467eae16_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2293aa631c14249bc1cb90e55c69d12_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0f97d7e0148477d89334ab0a06f9735_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib209ad0feb484341b4b5ea3e1112074a_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i311e4830870b47168a8028481990133c_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9f86dff82b2e4e37819e44daed0c3927_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90b7d7c73e9342ceaea0220fd27ebcb0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37855f5922724980ae2277994e98ea9e_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i536bf5cd23b640f1b9fdc4a22f35cc97_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46ec2cffc1bf4e368fb4d267b14f59e7_D20190101-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef4a834b2704183af5e7a0118b8f10b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc6a9123a8a4ef7b90cc678cd9de887_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1726a5a5ec36427090258ca4b81f8d3f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54547e12a6db466cb506fe342e82cc32_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb2ac8c951874f548946ae72cd81b9fd_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ea08dccbd2246f3821362f61b723f3a_D20190701-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i665d45a4c6ad4e91916ba08f8e851d70_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b8c0038e75540dfa62aff9087a85054_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i671affdf59da40b3b7624c0bdbe08342_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a3f294321d042c0b50b53fcde9f5fbc_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6f513dd37f04d39ad6561182f5f3fea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ca7f6c187cb41feb19b9c86fde64670_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f4020d4b8994854ac803ea6e8d45f6b_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1dd3a2128b451eb4d50a63a91ddd55_D20190101-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i330f7b2e0da941fb9b4510efb972e459_D20191231-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-31</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id94edb672a3f42dca68cdffe56fed10d_D20200930-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-30</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf38a8ac3d85467baeb00dcd1a446031_D20200901-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91c0b71ccc814cd5ba5b3e0b0bf65898_D20201001-20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001083446</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964 id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf" order="1"></ix:relationship></ix:resources></ix:header></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg5_2075f2f6-94c4-41b0-beb5-e60fb662aed6">10-Q</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MzAwNjA4ZWNkNzcxNDdhM2E2YWVmZTJjNzdmMGE2MWQvdGFibGVyYW5nZTozMDA2MDhlY2Q3NzE0N2EzYTZhZWZlMmM3N2YwYTYxZF8wLTAtMS0xLTA_3b0751b4-d9b4-4a38-b202-39c4951a0a6a">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18xMjA5NDYyNzkwNzY5MQ_5fb4fc24-3c31-4c6c-9541-6ddbac3bfb60">September 30, 2020</ix:nonNumeric> </span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.021%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NDM1MWVlZTc4YjY5NDcwM2FkZjFmYWQzYmQwMjJiYmYvdGFibGVyYW5nZTo0MzUxZWVlNzhiNjk0NzAzYWRmMWZhZDNiZDAyMmJiZl8wLTAtMS0xLTA_078f03af-9a2c-4b3f-a1c7-8519a4ffc87f">&#9744;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from &#160;___&#160;to ___.</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File No. <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg4_df7b3e5d-5d7e-469d-8e7d-4e9fd01c3008">001-37392</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk5_7338e85c-d607-4dd8-8137-88bbb4c699de">Apollo Medical Holdings, Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:5pt;margin-top:8pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MWU2MjhhNjRlZmQ4NDliODliMGM0MGQwNGFjNjMxYzYvdGFibGVyYW5nZToxZTYyOGE2NGVmZDg0OWI4OWIwYzQwZDA0YWM2MzFjNl8wLTAtMS0xLTA_ef421936-6dd8-4283-bf80-c5ab4451cd1e">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MWU2MjhhNjRlZmQ4NDliODliMGM0MGQwNGFjNjMxYzYvdGFibGVyYW5nZToxZTYyOGE2NGVmZDg0OWI4OWIwYzQwZDA0YWM2MzFjNl8wLTEtMS0xLTA_dd69db30-1361-4733-8577-9f56e9ee6dcb">95-4472349</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or Other Jurisdiction</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">of Incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Identification Number)</span></td></tr></table></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk3_2c258f15-3837-4b75-b492-24ad32b090a6">1668 S. Garfield Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk0_20e3faec-19e5-47a1-8943-b8d804d31621" continuedAt="ia0021e607ebb46d4a0631f204d601a37">2</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="ia0021e607ebb46d4a0631f204d601a37" continuedAt="i1a26f1e5aeaa4857a149c3889b59e32f">nd</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i1a26f1e5aeaa4857a149c3889b59e32f"> Floor</ix:continuation>, <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk1_50585d1a-c2ea-456c-b40e-8e48b55c0f10">Alhambra</ix:nonNumeric>, <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkw_0602d5a6-a473-4574-87f4-1042ebf0dc40">California</ix:nonNumeric> <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkx_47557812-949f-4bda-8055-e9aadab7d625">91801</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices and zip code)</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDky_fd7e2cb5-2602-4720-9041-3e59467f38fd">626</ix:nonNumeric>) <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk4_d888ae0f-7bf1-412c-b526-1adf5355ed6d">282-0288</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)&#160;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days:&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkz_df010724-5d2c-4dfa-8659-ed55adcdea0b">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg3_e5fa8843-81a2-454a-939d-356fff2da4c7">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:5pt;margin-top:8pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.026%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.675%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18wLTItMS0xLTA_3962d41c-a16c-4c3b-b200-c1a26c38d5cf">Accelerated filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-accelerated filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18xLTMtMS0xLTA_746f3523-3a25-4869-adc2-e6919ccb8d37">&#9744;</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18yLTMtMS0xLTA_e3f7a30d-783f-498f-b3e5-d493bf21ebfb">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act):&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk2_2d266b74-5fd7-489d-a678-eddae5077206">&#9744;</ix:nonNumeric>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Yes&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; No</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.997%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.890%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Title of Each Class</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trading Symbol</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Name of Each Exchange on Which Registered</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NjY0NmRhY2M5ZjVkNDg2ZmJkYTFlZjkwMDBlMGY3ZTYvdGFibGVyYW5nZTo2NjQ2ZGFjYzlmNWQ0ODZmYmRhMWVmOTAwMGUwZjdlNl8xLTAtMS0xLTA_1d7211aa-0327-4a3d-a511-fbcbdd7c81ef">Common Stock, $0.001 par value per share</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NjY0NmRhY2M5ZjVkNDg2ZmJkYTFlZjkwMDBlMGY3ZTYvdGFibGVyYW5nZTo2NjQ2ZGFjYzlmNWQ0ODZmYmRhMWVmOTAwMGUwZjdlNl8xLTItMS0xLTA_2eb2815b-54d7-4e2b-8b72-75a872504d5d">AMEH</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Capital Market</span></td></tr></table></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of November&#160;2, 2020, there were <ix:nonFraction unitRef="shares" contextRef="i233eb597e897408bb9acd656dcbd1d0c_I20201102" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18xOTg5_a45a1a1e-0d5f-40a4-a929-f43db15c6736">54,265,602</ix:nonFraction> shares of common stock of the registrant, $0.001 par value per share, issued and outstanding</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FORM 10-Q FILING</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.258%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAGE</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_13">Introductory Note</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_13">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_13">Note About Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_13">4</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_16">PART I</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_16">FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_19">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_19">Consolidated Financial Statements &#8211; Unaudited</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_19">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_22">Consolidated Balance Sheets as of </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_22">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_22"> 30, 2020 and December 31, 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_22">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25">Consolidated Statements of Income for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28">Consolidated Statements of Mezzanine and Stockholders</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_91">&#8217;</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28"> Equity for the Three and </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_28">8</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31">Consolidated Statements of Cash Flows for the </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31">Nine</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31"> Months Ended </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31">September</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31"> 30, 2020 and 2019</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_34">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_34">12</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_91">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_91">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_91">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_127">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_127">Quantitative and Qualitative Disclosures about Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_127">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_130">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_130">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_130">65</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_133">PART II</a></span></div><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_133">OTHER INFORMATION</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_136">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_136">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_136">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_139">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_139">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_139">67</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_142">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_142">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_142">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_145">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_145">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_145">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_148">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_148">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_148">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_151">Item 5.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_151">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_151">68</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_154">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_154">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#ie94880a2d5df40d2b763e3a0bdef79c1_154">68</a></span></div></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Glossary</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following abbreviations or acronyms that may be used in this document shall have the adjacent meanings set forth below:</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:85.964%"><tr><td style="width:1.0%"></td><td style="width:28.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:69.139%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accountable Health Care IPA, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC Healthcare Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AIPBP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All-Inclusive Population-Based Payments</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Alpha Care Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMG, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ApolloMed Hospitalists, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Apollo Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AP-AMH Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APAACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APA ACO, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Allied Physicians of California, a Professional Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC-LSMA Designated Shareholder Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bay Area Hospitalist Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bright Health Company of California, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDSC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Concourse Diagnostic Surgery Center, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CQMC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Critical Quality Management Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CSI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">College Street Investment LP, a California limited partnership</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California Department of Managed Healthcare</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diagnostic Medical Group</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSMSO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Health Source MSO Inc., a California corporation</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ICC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AHMC International Cancer Center, a Medical Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">independent practice association</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LMA</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LaSalle Medical Associates</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maverick Medical Group, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MPP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical Property Partners</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NGACO</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Next Generation Accountable Care Organization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NMM</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network Medical Management, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PASC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Ambulatory Health Care, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PMIOC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pacific Medical Imaging and Oncology Center, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Southern California Heart Centers</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCAP</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care Acquisition Partners, LLC</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">UCI</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Universal Care, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">VIE</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">variable interest entity</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_13"></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTRODUCTORY NOTE</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context dictates otherwise, references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; and similar words are references to Apollo Medical Holdings, Inc., a Delaware corporation, and its consolidated subsidiaries and affiliated entities, as appropriate, including its consolidated variable interest entities (&#8220;VIEs&#8221;) and &#8220;ApolloMed&#8221; refers to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) have not reviewed any statements contained in this Quarterly Report on Form 10-Q describing the participation of APA ACO, Inc. (&#8220;APAACO&#8221;) in the Next Generation Accountable Care Organization (&#8220;NGACO&#8221;) Model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names and trademarks of the Company and its subsidiaries referred to herein and their respective logos, are our property. This Quarterly Report on Form 10-Q may contain additional trade names and/or trademarks of other companies, which are the property of their respective owners. We do not intend our use or display of other companies&#8217; trade names and/or trademarks, if any, to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">NOTE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;This Quarterly Report on Form 10-Q contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). All statements other than statements of historical fact are &#8220;forward-looking statements&#8221; for purposes of federal and state securities laws, including, but not limited to, statements about the Company's guidance for the year ending December 31, 2020, any statements about our business (including the impact of the 2019 Novel Coronavirus (COVID-19) pandemic on our business), financial condition, operating results, plans, objectives, expectations and intentions, any guidance on, or projections of, earnings, revenue or other financial items, such as our projected capitation from CMS for the year ending December 31, 2020 or otherwise, and our future liquidity, including cash flows and any payments under the $545.0 million loan we made to our VIE, AP-AMH; any statements of any plans, strategies and objectives of management for future operations such as the material opportunities that we believe exist for our Company; any statements concerning proposed services, developments, mergers or acquisitions; any statements regarding the outlook on our NGACO Model or strategic transactions; any statements regarding management&#8217;s view of future expectations and prospects for us; any statements about prospective adoption of new accounting standards or effects of changes in accounting standards; any statements regarding future economic conditions or performance; any statements of belief; any statements of assumptions underlying any of the foregoing; and other statements that are not historical facts. Forward-looking statements may be identified by the use of forward-looking terms such as &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;can,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;believe,&#8221; &#8220;think,&#8221; &#8220;plan,&#8221; &#8220;envision,&#8221; &#8220;intend,&#8221; &#8220;continue,&#8221; &#8220;target,&#8221; &#8220;seek,&#8221; &#8220;contemplate,&#8221; &#8220;budgeted,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and the negative of such terms, other variations on such terms or other similar or comparable words, phrases or terminology. These forward-looking statements present our estimates and assumptions only as of the date of this Quarterly Report on Form 10-Q and are subject to change.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Forward-looking statements involve risks and uncertainties and are based on the current beliefs, expectations and certain assumptions of management. Some or all of such beliefs, expectations and assumptions may not materialize or may vary significantly from actual results. Such statements are qualified by important economic, competitive, governmental and technological factors that could cause our business, strategy, or actual results or events to differ materially from those in our forward-looking statements.  Factors that might cause or contribute to such differences include, but are not limited to, those discussed in our Annual Report on Form 10-K, for the year ended&#160;December 31, 2019, filed with the SEC on March 16, 2020, including, the risk factors discussed under the heading &#8220;Risk Factors&#8221; in Part I, Item IA thereof.  Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed in any of our forward-looking statements. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change, and significant risks and uncertainties that could cause actual conditions, outcomes and results to differ materially from those indicated by such statements.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_16"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I FINANCIAL INFORMATION</span></div><div><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_19"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_22"></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:70.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNS0xLTEtMS0w_f7208f31-6ae7-4385-b5c8-aedb17678e4b">166,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNS0zLTEtMS0w_eacb3849-e9e6-4f3b-9418-566baffdbe2d">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNi0xLTEtMS0w_9356dcee-d850-488f-9104-f36ae41ff985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNi0zLTEtMS0w_b292f3ef-68ab-47b0-9742-07bb1af18cd8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNy0xLTEtMS0w_137a9735-ffdc-4a94-82e1-3cdb5dd5fd1a">118,309</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNy0zLTEtMS0w_8ac9d9bb-a674-4f9b-a811-4206ae991fda">116,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOC0xLTEtMS0w_4a326f68-a50c-44fb-9a48-edeb5f09cfe8">18,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOC0zLTEtMS0w_ee0e8c0c-4541-454b-97b9-2ac875ae3384">11,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOS0xLTEtMS0w_decc70d8-3ace-4fcd-8918-75c6ce4edbeb">41,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOS0zLTEtMS0w_0a8b4b68-cf44-42d2-939e-d4fa3ae36b90">48,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTAtMS0xLTEtMA_68f853bb-2009-468b-a48b-9c43a8de3446">3,988</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTAtMy0xLTEtMA_0d499448-c3c3-48d1-8e21-e70ff0e7c04e">16,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTEtMS0xLTEtMA_af6c7ced-1b06-44e9-b4f9-ec4f5d7716bd">12,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTEtMy0xLTEtMA_50479cc7-0ada-4f7e-94f1-ebedba384a59">10,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTItMS0xLTEtMA_48105cd6-a5fb-4da7-ba89-8910cf093ff6">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTItMy0xLTEtMA_452f00de-90bd-4532-bdd7-435e0d6f9b57">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTMtMS0xLTEtMA_40134c24-fdb9-457e-8ff5-706678b8bae3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTMtMy0xLTEtMA_435a182e-9390-49dc-a478-104e767fa884">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTUtMS0xLTEtMA_3ff538ed-d0a4-4336-a14c-6fe17c532f82">366,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTUtMy0xLTEtMA_d1dd9654-d594-4e51-aa8f-689225bf0d62">329,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTgtMS0xLTEtMA_b13bab76-b702-490d-8ed4-062969781275">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTgtMy0xLTEtMA_bd0d64da-d52c-4944-8ed5-f09e55ae6235">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTktMS0xLTEtMA_62ba6ddd-99a5-4f49-9aac-1e017049526c">10,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTktMy0xLTEtMA_b61e50b8-27fe-4c28-b77f-284166308caa">12,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjAtMS0xLTEtMA_1b3402ff-ab89-4f31-b5fd-541ac8f3fcef">90,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjAtMy0xLTEtMA_c26ce1f7-2924-43de-8a59-1a2917f7424f">103,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjEtMS0xLTEtMA_1363d922-d108-4323-8859-537cf1275618">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjEtMy0xLTEtMA_168245b8-3777-4b4e-ba64-ff3fc1651c4d">238,505</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjItMS0xLTEtMA_698aa765-926e-4958-b765-9fb04ba13328">27,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjItMy0xLTEtMA_57c12b37-e370-490f-8c97-04bf74a0c465">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in privately held entities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjMtMS0xLTEtMA_0f97ae4a-10a7-4450-923c-187c1d78fed2">37,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjMtMy0xLTEtMA_7c6f88f0-1c19-4c70-bed2-9fa6f42812aa">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjQtMS0xLTEtMA_86481baa-d5dc-4e0d-96b0-72fa2a86de9d">19,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjQtMy0xLTEtMA_3ae2514c-b44f-40f9-ad26-bb40a9770e6d">14,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjUtMS0xLTEtMA_17fb6eca-c646-43e0-a6bb-760cc28f3205">22,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjUtMy0xLTEtMA_dac3ea76-4c61-4a00-9429-27f13e82cafe">1,681</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjctMS0xLTEtMA_8585308e-47bd-42bc-873c-cccef2336845">447,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjctMy0xLTEtMA_97fc7917-b00f-470e-8f64-c1ef69993ec7">399,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac">814,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3">728,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liabilities, mezzanine equity and stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzUtMS0xLTEtMA_73ee3789-5db4-4169-b02e-5330813c113e">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzUtMy0xLTEtMA_9daa317b-84ba-4ffb-a17e-cadc21340f86">27,279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzYtMS0xLTEtMA_a8469cf8-7539-4c23-b6ea-e7ea0532aa16">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzYtMy0xLTEtMA_229e0162-2709-4867-b2e0-3b6cb2f3a8ec">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzctMS0xLTEtMA_352f05ce-5a85-422a-a9bc-7d542b04d117">57,455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzctMy0xLTEtMA_6bc11f16-a9c3-44b6-8e75-b11ec88f0c8f">58,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzgtMS0xLTEtMA_e8508774-7981-4f09-9201-b478c46e53a8">16,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedIncomeTaxesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzgtMy0xLTEtMA_2c38d74e-9739-45ee-9dff-0d27c866e4de">4,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzktMS0xLTEtMA_f8405348-dabf-45a4-a039-cef93152c242">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzktMy0xLTEtMA_d82cbfc5-1adb-439a-8e11-94a86c496977">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDAtMS0xLTEtMA_d87dbb0d-baf4-49bd-a2a0-0f705681ea02">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDAtMy0xLTEtMA_e3a554c0-6f75-4dd4-a63f-c60f34b624b9">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDEtMS0xLTEtMA_3fc93305-ba4c-4a73-ac66-ebec65afb22a">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDEtMy0xLTEtMA_489403be-e9bd-4e66-8064-1dc1e5d56032">2,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:81pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:70.770%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.302%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.125%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.303%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDItMS0xLTEtMA_0a4f9928-2328-44c1-8450-41ebc2aa76cd">9,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDItMy0xLTEtMA_4ee63f57-7bc2-4394-bf27-d6706f473f1d">9,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDMtMS0xLTEtMA_5b37d790-fc0c-4a7e-acf7-0da513c4bd40">131,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDMtMy0xLTEtMA_fe425e43-ae36-458d-b310-39ab283a886e">105,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Noncurrent liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDYtMS0xLTEtMA_78b68c9e-f884-4236-9436-e136f5de451c">11,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDYtMy0xLTEtMA_aaaf9893-34c3-4806-be8e-3361991a7971">18,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDctMS0xLTEtMA_57edc8a1-82c3-4cd1-8272-877323f4794a">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDctMy0xLTEtMA_83b69f4c-e7af-4b63-89ba-1d276cff5474">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDgtMS0xLTEtMA_634bfed7-6baa-4078-a1bd-35263383a714">16,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDgtMy0xLTEtMA_eda71a11-84df-476f-844a-8c4b09bf6bc4">11,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of current portion and deferred financing costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDktMS0xLTEtMA_65fb33f1-88be-4ecd-8e72-396637019edb">226,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDktMy0xLTEtMA_b9a86227-5b7b-4382-8423-0903222953b1">232,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTEtMS0xLTEtMA_86dd9945-8e12-472e-9f22-330aff41894e">254,663</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTEtMy0xLTEtMA_24f11037-9174-4311-b1c8-859744fe1bde">262,230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964">386,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab">367,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div style="text-align:right"><span><br/></span></div><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTUtMS0xLTEtMA_5573a956-dffd-4d7b-a415-df911dfa8be4"></ix:nonFraction></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTUtMy0xLTEtMA_9c4acb0b-c28a-472e-a847-737f110b8dc9"></ix:nonFraction>Mezzanine equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTgtMS0xLTEtMA_de6a8200-815f-418f-a9f3-2095bcef35ce">198,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTgtMy0xLTEtMA_affad712-345e-42a7-a024-036c03db7da0">168,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i12392f1820d84e009a3fec747ed05785_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTI_1faf4170-7145-4f4d-b392-64193114a0ed"><ix:nonFraction unitRef="usdPerShare" contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTI_8617ccf6-e4f3-4b25-80ee-8b010c639334">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i12392f1820d84e009a3fec747ed05785_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTU_128ecadf-d6c6-4923-b5b1-c8b505635055"><ix:nonFraction unitRef="shares" contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTU_54f63169-480e-4625-831d-6212f28827f7">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series B Preferred stock); <ix:nonFraction unitRef="shares" contextRef="i12392f1820d84e009a3fec747ed05785_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIyMDA_6c3f440f-2b9a-4686-8a54-0505276d9676"><ix:nonFraction unitRef="shares" contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIyMDA_9e09ca20-4f05-4eb0-b9dd-886c5132d457">1,111,111</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i12392f1820d84e009a3fec747ed05785_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2MQ_0e6ae9c1-010d-47f0-9bc4-802dde7b71d7"><ix:nonFraction unitRef="shares" contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2MQ_81928eeb-4688-4795-8ca2-6e1c3e97567d">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMS0xLTEtMA_c64f5b8e-eb37-454f-be64-a0f2a0ff92d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12392f1820d84e009a3fec747ed05785_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMy0xLTEtMA_426ce0b2-96dc-414b-941c-7a511089e5f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4Mzk_0e53aac8-b5ed-4dd0-b00f-59ca8bde0b52"><ix:nonFraction unitRef="usdPerShare" contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4Mzk_60b574aa-d6af-46e1-ac6b-7ff55bdcc1a0">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzU0_52c24df9-5218-4e26-9891-4b1e1b9b9ebd"><ix:nonFraction unitRef="shares" contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzU0_5dddf8c7-bf69-4953-923d-3526513f8e7b">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized (inclusive of all preferred stock, including Series A Preferred stock); <ix:nonFraction unitRef="shares" contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4NDQ_46597f67-d45b-4038-9427-3577992bcea6"><ix:nonFraction unitRef="shares" contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4NDQ_89c59369-2b45-4c8e-990b-d97b10654e85">555,555</ix:nonFraction></ix:nonFraction> issued and <ix:nonFraction unitRef="shares" contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2MQ_de97730e-f68a-496c-9a74-ebaa9ea152c1"><ix:nonFraction unitRef="shares" contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2MQ_edbeb6ef-d3ae-4061-9299-2a07c85aa96c">zero</ix:nonFraction></ix:nonFraction> outstanding</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMS0xLTEtMA_3d49eab9-e562-45bb-bfef-7cf0af199a5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMy0xLTEtMA_22cae57d-3d9a-40ef-928b-32a5f1f6e140">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjI_9d0a61cd-6169-448e-b509-2d4d9822b493"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjI_c6209370-ad96-48cf-8568-ff33306a2c38">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjY_b48f2894-1500-4413-ae38-4048771f21d2"><ix:nonFraction unitRef="shares" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjY_f8f78e23-0ade-4e9e-91bf-1378e534393a">100,000,000</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzY0_6df3ab8c-0a8f-4fb3-826c-b75f9e54df99">36,775,817</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzcx_efe65e3b-75e2-4d5f-a22c-b9d54bff9bc8">35,908,057</ix:nonFraction> shares outstanding, excluding <ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzEwNA_c73d96de-7e78-4051-9881-11b87d7f9828">17,475,707</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzExMQ_31d5fe05-1a8c-416d-87f3-f3a1a58e951d">17,458,810</ix:nonFraction> treasury shares, as of September&#160;30, 2020 and December&#160;31, 2019, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMS0xLTEtMA_055b73ea-960f-4885-97f0-076af70d0882">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMy0xLTEtMA_c354dfda-97bd-4c9c-99df-641cc3de3719">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional paid-in capital</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjQtMS0xLTEtMA_42844d3c-3155-42ad-a064-51291eb8a64e">168,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjQtMy0xLTEtMA_5917ffe3-ba4b-4a39-b038-275f4f41783f">159,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained earnings</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjUtMS0xLTEtMA_3d79cf31-65bb-48bd-9c0d-0af97786ef0c">59,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjUtMy0xLTEtMA_bdf316ad-40f9-4c12-83a4-665222d94596">31,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjYtMS0xLTEtMA_9a28c76a-0087-4a8f-9128-5bb7e281694a">228,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjYtMy0xLTEtMA_6f42c8fc-4ed8-45f5-afef-3a30c03ead8e">191,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Noncontrolling interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjgtMS0xLTEtMA_8eb43383-2a16-4748-a24f-91d7d022bff6">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:MinorityInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjgtMy0xLTEtMA_88a2f503-20b9-4958-af06-397e98bcc331">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzAtMS0xLTEtMA_f272f349-96db-4413-bb06-5b6d2aee5284">229,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzAtMy0xLTEtMA_46f78c7a-e72c-4615-aa47-78b5c5b7d41c">192,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities, mezzanine equity and stockholders&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzItMS0xLTEtMA_3c2d1429-9fe2-4d16-8f7d-11f216c1990b">814,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzItMy0xLTEtMA_6f1d2163-e1f1-4555-b705-61d4642dbafc">728,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf" footnoteRole="http://www.xbrl.org/2003/role/footnote">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $<ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODM3Ng_83b5105c-ee41-4602-9287-500449510bf7">877.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQwMg_0020b3a4-cfb0-4a76-a5d1-6b6ffd0c4cc3">849.3</ix:nonFraction>&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $<ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQwOQ_75804806-45f6-407b-8d35-e71b33f06831">113.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQxMw_747ce388-a71c-4114-be37-39f110f7f753">114.5</ix:nonFraction>&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</ix:footnote></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.140%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitation, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85cbed6310784ad1b00d427467f4a809_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy0xLTEtMS0w_1d318401-f70d-4df5-8b9a-0292294ff35b">135,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie735c2fc161f4a028234f400af312f8e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy0zLTEtMS0w_6d2667d9-7858-425f-a423-7ae00dc332bd">130,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ae35627def147d19d8ab0682325ebca_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy01LTEtMS0w_a709a4a9-601b-4455-9dd4-dfdf0f6e890b">416,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5096fa86ff645c4ac88aeaff7eb1d9f_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy03LTEtMS0w_b0a68b3f-2c8c-4a89-aef6-9c3dd1d72cc0">305,548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk pool settlements and incentives</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89dce8d40320482793ae915c3b3fda86_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC0xLTEtMS0w_473cdda6-0519-45e3-ae52-8228324527d6">30,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc8b559adf384439909838b82a315ef4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC0zLTEtMS0w_47375d34-9958-4b49-8e60-d99f1799dffb">11,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2871d1532647e4bc4f0564a4773c78_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC01LTEtMS0w_a0bea26f-8301-47b9-bdd0-dbd5659573d5">54,155</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i103b982ccc8e4f93858938af7e18a96d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC03LTEtMS0w_8491d780-4b04-416c-9424-b0a8867aa466">32,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management fee income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48fce5948a0e4dfdb085803d8face2f4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS0xLTEtMS0w_1e7164a7-cf4e-4d12-be5c-525a27b025fd">8,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50f345eb35b24b309883822a3f432a39_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS0zLTEtMS0w_8f667cb7-e1b0-4eca-a836-06c588e2f88f">8,518</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS01LTEtMS0w_254d5f4c-8cc3-47a6-915b-29545f8a6a01">26,212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92adae19551f4d33aa3159e1f3b3c333_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS03LTEtMS0w_a666d6f0-2dfd-49c7-b1bc-faf7518e2416">27,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fee-for-service, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c26c34d43944d53b8157c588e4d9832_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi0xLTEtMS0w_589ef8c2-16fc-424b-8b38-5328001f2997">3,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb905dbaa5064b25b91dff34aa6ebc5a_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi0zLTEtMS0w_a3b8cf3f-cfbb-4e67-a8f1-7698a9d9b2e0">4,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd1b1d0644e4537bb0c05e512c38d0c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi01LTEtMS0w_6fe10df0-cd3a-4e62-bae7-9651d2bff62d">9,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbf30c3701d24df69116273d7a5e466b_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi03LTEtMS0w_686dba78-6816-43cb-b061-7f7d8306f7f1">12,059</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaab6050bdfaa4b99b69a677d9fb18e68_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy0xLTEtMS0w_5e05f4c4-5ed3-41da-82eb-d5de1fb2a626">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c8d5c0eb18b40688e3d9ffd255e0a2e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy0zLTEtMS0w_b0620d78-a17d-4325-942b-2b4118862f78">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b7fc96fb74e494b8db4e7508d53047b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy01LTEtMS0w_3d84b40d-3934-4d19-b880-7fd172d87088">4,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06d6f6c3ab514e87bbe68a7fec5bcd87_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy03LTEtMS0w_131f30cd-2c8f-4fa4-bf4a-be54992cf077">3,753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS0xLTEtMS0w_4b503710-6bc2-48ab-9e8b-923f0bec7553">180,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS0zLTEtMS0w_6469a200-0978-4c34-968b-1e1e9bbb3e10">156,060</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS01LTEtMS0w_6b4b24f2-2927-4bf7-be53-327a037b82d7">510,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS03LTEtMS0w_40d52d32-eff6-4d76-abf4-b9ebcdff4bfa">381,867</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItMS0xLTEtMA_56ea8a66-34e2-4758-9be1-ac4404dcd80e">121,823</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItMy0xLTEtMA_af15ad14-bfdf-43b3-9fc6-d1539daa5542">131,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItNS0xLTEtMA_988d80db-1de0-47fc-8080-3875b21674c4">402,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItNy0xLTEtMA_f903ffd9-359e-4386-b430-fb1e136357f5">315,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtMS0xLTEtMA_3e7fb46a-4490-48ff-abcf-f5b045e18851">16,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtMy0xLTEtMA_a1772895-f31a-4552-bad5-4f9645507169">7,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtNS0xLTEtMA_e1dd7b4a-29bf-432c-85a1-0181958378ca">39,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtNy0xLTEtMA_6020be99-fd11-4b2e-8341-54e9b658b293">30,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtMS0xLTEtMA_2d6edf89-3990-4b40-8323-694871b1c33c">4,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtMy0xLTEtMA_d0c16156-f1a4-4885-bc7a-6cd25dfa8466">4,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtNS0xLTEtMA_c7fb931d-3c2a-4bc5-be3e-0447b1e279c5">14,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtNy0xLTEtMA_fbc15930-f4bc-43a2-ad37-41496f2c5f0b">13,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for doubtful accounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtMS0xLTEtMA_590d465d-ae3c-4685-9e79-decd27bbd8bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtMy0xLTEtMA_6a6d0edd-762f-4a43-acdc-ddd63060f4c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtNS0xLTEtMA_3c35eb80-e777-449f-97a5-c34b351e7b68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtNy0xLTEtMA_1059d568-b5b4-474e-82aa-c43eee7f0deb">1,363</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtMS0xLTEtMzQwNA_9068bf1e-8d1d-4ede-8da1-c626728ff2ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtMy0xLTEtMzMwNg_3c272c0d-515e-455c-b8c6-18824dbf98b7">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtNS0xLTEtMzQwNA_5a2b3c97-6eb6-417a-b0d4-ddb06f77548a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtNy0xLTEtMzQwNA_96b93405-aff9-4b00-8d39-56130c221190">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctMS0xLTEtMA_08b16341-16a8-4387-ba0d-b253bb5165b0">142,767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctMy0xLTEtMA_fe3bd5ac-0d6a-4af0-817a-bf331cb09993">145,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctNS0xLTEtMA_654f8403-4353-4a9e-a9f3-407e0248f5de">455,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctNy0xLTEtMA_55bd4e0c-3139-44b5-8613-5ab6d571f4a5">360,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktMS0xLTEtMA_6e5ff011-08c9-442c-8fc6-5ff063b29be8">37,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktMy0xLTEtMA_232a52fe-c609-4b9e-9048-4f7957474652">10,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktNS0xLTEtMA_6f62dfd6-7c28-4df7-abe8-edb76086b5d2">54,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktNy0xLTEtMA_a130b94f-a493-4ec6-b9db-40aefd7195a4">21,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other (expense) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItMS0xLTEtMA_ce8d26bd-c8da-4971-92b5-079e48197768">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItMy0xLTEtMA_85704570-5dd9-436f-bc4d-68f2a23310ab">2,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItNS0xLTEtMA_6a86c618-70ce-4900-8e17-258f15093246">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItNy0xLTEtMA_5263efa1-d694-47c8-b725-deaabada105d">1,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMS0xLTEtNjU0NQ_9a05bcc4-126d-4026-889d-e156457ff240">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMy0xLTEtNjU0NQ_37af6831-e63e-4b68-ac41-5db712f2bbe9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNS0xLTEtNjMyOA_23edafaf-6362-4f53-991a-3e9fbf57099b">99,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNy0xLTEtNjMyOA_9b022b66-e316-4188-8611-5311f4a7f8f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMS0xLTEtMA_514bc7fd-9ff3-427f-9b9f-711caf38373b">2,466</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMy0xLTEtMA_35aa3d7a-783e-475e-a2d0-673b14e9898c">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNS0xLTEtMA_df24fc4e-487b-484e-9c98-cf1265663a24">8,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNy0xLTEtMA_41d0fd94-7a3a-40e5-aa03-b019fa52bc82">1,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtMS0xLTEtMA_42ec91d8-9578-480d-ac4e-5c9a4e4e9351">752</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtMy0xLTEtMA_4010a8d0-3669-4a66-8dae-fa67cb744de8">509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtNS0xLTEtMA_be0eb7a1-9137-4c3c-b338-672dfd984b0b">2,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtNy0xLTEtMA_60c63348-a008-4bb2-a139-a3581ad32e4b">1,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtMS0xLTEtMA_9eb83300-244f-4df6-8cd1-b978adbfe2d8">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtMy0xLTEtMA_b684723b-484e-476e-ba26-672e64447359">2,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtNS0xLTEtMA_6eaaf027-1b63-4fc7-b9d3-a44b311fd534">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtNy0xLTEtMA_64f8a336-7b28-42d9-804d-494c588f9368">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtMS0xLTEtMA_78517aeb-32cb-481b-8b47-e1bb3c3b90e3">1,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtMy0xLTEtMA_b20c9ac7-fb9d-45db-b89d-7f7ddbbf3ab3">4,355</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtNS0xLTEtMA_199288f7-8e7a-4d9a-9af9-a8775d9c184a">98,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtNy0xLTEtMA_7cf7b37c-0632-453d-ae73-70ee0399ca76">3,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtMS0xLTEtMA_2c10b07f-5d15-4590-a1d4-b856b878885b">36,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtMy0xLTEtMA_25f12a82-3613-436c-9352-fbbcbe1679f2">14,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtNS0xLTEtMA_4f9e4cad-1353-49c4-860b-7cf540ed6064">153,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtNy0xLTEtMA_16f0b380-88a8-4e1d-a2c6-38b473f35ae4">25,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItMS0xLTEtMA_4681234b-afcf-4693-ba3b-099868ec2d1b">10,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItMy0xLTEtMA_2c12b5db-d002-43c8-b4c8-f032dda0d0de">3,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItNS0xLTEtMA_de6575fa-4b9a-4e19-88c5-7744b9a09896">44,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItNy0xLTEtMA_291487b4-5d4d-4d75-8aea-701c0c0edc88">6,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtMS0xLTEtMA_7420a62e-a3ce-46c6-b993-189b07e49f67">25,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtMy0xLTEtMA_a80156df-9650-4abf-b020-0a95a0ae5ac4">10,739</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtNS0xLTEtMA_1da4ce39-e0df-40ee-ad5f-c3084b44419f">109,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtNy0xLTEtMA_40dd38e4-5eb6-482e-b4ad-c42de2d8b56b">18,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtMS0xLTEtMA_c6e7be2d-4f38-406f-9d28-a6a57230d0ae">8,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtMy0xLTEtMA_429f0443-a5d3-4cbc-94bd-91c37a5a7c85">7,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtNS0xLTEtMA_0ba3aa2c-fc84-4b87-a59d-a7b64eef1d2d">81,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtNy0xLTEtMA_b08afea8-1ddd-484a-bb5f-ab09952e577d">11,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtMS0xLTEtMA_84ee8ce4-72f6-4326-b943-fdaf1f929116">16,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtMy0xLTEtMA_a6717cb8-7f9d-4a13-b316-7d623a413db9">3,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtNS0xLTEtMA_4e9b883c-43e4-4a09-a08a-7836b22aa6e8">27,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtNy0xLTEtMA_398e73de-e491-445e-a9d8-c3c97b1a64c4">7,389</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtMS0xLTEtMA_fc0227a9-0f23-4ca2-8cf6-ca12cc9484eb">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtMy0xLTEtMA_41a169fa-71eb-40f3-854b-eee3b2300850">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtNS0xLTEtMA_6a3505c4-4f5b-4962-b577-08b2276445a0">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtNy0xLTEtMA_6219bf89-c652-4f12-8f21-7df878c8f6fd">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings per share &#8211; diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItMS0xLTEtMA_fda765c4-2bbf-40b5-8b84-897fa98275c1">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItMy0xLTEtMA_cc022d93-1832-43e5-85d7-492358606b03">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItNS0xLTEtMA_1314d8be-2ff6-4a72-96b6-3d7d018aa03b">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItNy0xLTEtMA_4075cb54-887b-4e38-a5c5-38c328a3af51">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS, EXCEPT SHARE DATA)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.887%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Mezzanine</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity&#160;&#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Retained</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Earnings</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Paid-in&#160;Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shareholders&#8217;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity</span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2020</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c3f468964da412ebaa0846e50fe0da4_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xLTEtMS0w_6bf5c90d-58a4-426d-ac3f-2cb23a21e39f">168,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i12c2127d868e4f87a671ff137b7c2981_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0zLTEtMS0w_4a894ffa-03a5-48f3-a071-87218de2bbed">35,908,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c2127d868e4f87a671ff137b7c2981_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy01LTEtMS0w_86fe9e53-b8d8-4c83-95e7-6d008fcb48ec">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd3dd55e36b43b495789ffa5cc73b36_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy03LTEtMS0w_22a62879-5a4f-41d7-8855-45ed6328dcd7">159,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59fc236ccce64a608d756612e5db97f1_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy05LTEtMS0w_c64fbdcf-4346-47ca-bf86-429c4be6e7fa">31,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba7855d202c4906a207a0a7faa251a9_I20191231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xMS0xLTEtMA_de87423c-3aaf-4e56-a408-fdfff2bb9889">786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xMy0xLTEtMA_7599dbf1-10f6-469a-b331-c22a2325443f">192,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net (loss) income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xLTEtMS0w_3b728d60-350a-4b61-8e8a-a135ca422b5b">1,161</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b992a0d32d458485f04f21e552fb61_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC05LTEtMS0w_dc6a13ab-1d96-4fe3-975d-7b0698980ac4">4,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2eceea105e94e54a0c2107e27e00355_D20200101-20200331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xMS0xLTEtMA_761c6545-2e56-4365-9b0f-a5ab01daebdd">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xMy0xLTEtMA_dd1c9354-1cf3-4b9f-92ea-4be666351804">4,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Purchase of treasury shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS0zLTEtMS0w_b39308ce-aab4-4819-8dd3-1c87383e0b32">16,897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS03LTEtMS0w_4c9e3b6d-3374-460f-bf4b-42642c00df59">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS0xMy0xLTEtMA_ca2ddada-2431-4cd4-bfed-f5c5ac18a2e0">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNi0xLTEtMS0w_df8c389e-2846-4a0a-bce0-393922de50c9">125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNi0xMy0xLTEtMA_eba78f3c-f170-4cf0-a666-d9bf8a5a3d8d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy0zLTEtMS0w_32d5c229-9887-4f33-85b8-1a38aba7a10b">151,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy03LTEtMS0w_3cc952c2-e32e-4cb7-8132-f960cf718581">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy0xMy0xLTEtMA_f7048c2b-0c99-4484-8ea4-2c25a439afa9">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOC03LTEtMS0w_db16efc9-6572-4f94-891e-23801b7d5f59">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOC0xMy0xLTEtMA_1a7c3bec-37fb-4373-ba4d-a990ecc5248a">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOS0xLTEtMS0w_5cb6e9d6-2121-4dd6-86ff-1a9db41dbb5a">10,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOS0xMy0xLTEtMA_512e59b6-11f7-4937-9e00-be323b5ad486">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Balance at March 31, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251eec9a4efe4815a9a119b6820c7de8_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMS0xLTEtMA_e1855508-4535-473e-9600-c0a40298d41b">157,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87c42df9ebca4c8ea2878cd65f523941_I20200331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMy0xLTEtMA_2fe57556-f7f6-47ef-b94c-ccd01f23d428">36,042,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i87c42df9ebca4c8ea2878cd65f523941_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtNS0xLTEtMA_96cbd090-9341-4107-a812-6389fa2ba311">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i90197c93402f41ff9bc61f1754e24165_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtNy0xLTEtMA_781162a0-cefd-46d9-b97e-75d1f588a8a9">161,087</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09497b34fad5498f8a7379c15692a946_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtOS0xLTEtMA_ab3ae1e5-933b-4dc7-964c-f35530420c6b">35,957</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19924d22b9634738af4fc0857dd5f1db_I20200331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMTEtMS0xLTA_050abe0f-2466-4622-8629-51a8850cb0ec">881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e6f52d6af84990b66fae85e26f4b3e_I20200331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMTMtMS0xLTA_fc8438f2-fa25-47cf-9fb5-044a6a3c8bcc">197,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMS0xLTEtMA_a0f4dfa5-d773-4ac3-81b5-2cba0c77457b">73,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672096def723492da951e5ba41de393f_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtOS0xLTEtMA_51271dc0-c2c4-4624-ac8c-83bc0a7ea150">7,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMTEtMS0xLTA_001d6500-abd4-4e9f-adc4-9daecf430bdf">291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMTMtMS0xLTA_af6e1eef-94ec-489a-97a9-083cfdba9142">7,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTItMS0xLTEtMA_ada6febf-bf9e-4582-a5bd-25e6d87b7531">126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTItMTMtMS0xLTA_c8a7ae94-0c59-418d-99cf-445306d2abad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for vesting of restricted stock awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTMtMy0xLTEtMA_c653a59a-b4ce-498a-82da-8971a821c24b">24,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTMtMTMtMS0xLTA_acabfce4-4356-4842-9d7e-a9e700ca97bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtMy0xLTEtMA_f7bbbaf3-1a11-40a7-b688-bcaa08c9e525">242,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtNy0xLTEtMA_1ab567d7-cb35-4b08-8f48-02b7adaa98f3">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtMTMtMS0xLTA_7d527cf3-e081-4b67-a6b2-72f0c1b8e7d0">2,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTUtNy0xLTEtMA_3126ab44-00d5-45ec-ae99-b276e313350b">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTUtMTMtMS0xLTA_492cd673-16c6-46ff-8ebc-804e37fef97b">852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cancellation of restricted stock awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTYtNy0xLTEtMA_c66530a2-62a8-4df3-a8f8-c2154ea82984">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" name="ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTYtMTMtMS0xLTA_e39725f2-e97a-4fc5-93e1-6ca19d7e0174">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMS0xLTEtMA_8cc6e54d-98bb-41a0-9907-dffdd53547e1">20,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMTEtMS0xLTA_459ca9d2-104a-48ca-98ba-b064690edc41">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMTMtMS0xLTA_d19b1158-cae5-4ee6-b9a6-7649df608cfe">347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13676229b94a433bb7999e82d40c9506_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMS0xLTEtMA_7777b749-e31b-4678-bb60-7a812d2cedae">210,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i31636c0f849b4fcfac8862fe43198701_I20200630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMy0xLTEtMA_05da81b4-b424-4ced-9216-b8239a31ea5b">36,309,513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31636c0f849b4fcfac8862fe43198701_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtNS0xLTEtMA_4129a8be-b00e-4bee-a6d4-d5ae2ad15421">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica802434063e4405a1db846371417d7c_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtNy0xLTEtMA_baedde1a-096a-46a1-a147-7a79a896d803">163,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47774eeabb6c4f8a941dafeadf448ab0_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtOS0xLTEtMA_3d667806-5347-4aa7-ada6-d9535596895b">43,001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6836300d36448ee8800b32b51ab5107_I20200630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMTEtMS0xLTA_1586e611-ca88-417e-8efd-d23723548373">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i045332a06815470c90c30b39515f8d62_I20200630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMTMtMS0xLTA_0f72cf64-c9c9-49ee-b9b8-8a2fca9c66dd">207,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMS0xLTEtMjA0NQ_b5bf3ec6-cb7e-4eb7-a31b-ae0e474aa98e">8,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f9e597672244da19f4a35690c8fb312_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktOS0xLTEtMjA5OA_fbe8280a-4ad2-44b7-b992-1d9ca8047fb1">16,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0058c6f89dbc42439fb7e3bd81042bbc_D20200701-20200930" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMTEtMS0xLTM1MTE_66f8ed27-b326-40c6-87e3-0dc5cbf0aab9">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMTMtMS0xLTE5MTY_ecba4776-77c4-4409-acfa-7460adcf9952">16,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjAtMS0xLTEtMjA1Mw_cba949a9-0cdd-44f4-8a81-623c260eb5a9">771</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjAtMTMtMS0xLTE5MjI_c3ba6570-f7b7-45b2-b7a8-7287287d6f21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for cashless exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjEtMy0xLTEtMjA4Mg_4bfdbaa4-4da5-4f46-b9e0-5470a08f4c88">66,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjEtMTMtMS0xLTE5Mjg_4a4bafcd-6052-443e-a45d-adb454426179">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItMy0xLTEtMjA4Mg_de14d36b-824f-48bd-b993-f71253a0858f">399,787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItNS0xLTEtMjA4OA_efa49149-7f64-4c26-b32c-fede78143f51">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItNy0xLTEtMjA5Mw_63793e15-a6e4-46a7-8bc1-be095b64e7df">4,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItMTMtMS0xLTE5Mzg_2ac30f3e-879f-48ef-b0e2-b36b0992ec4f">4,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjMtNy0xLTEtMjA5Mw_be089747-2ea0-4abc-8f9f-058037ff78d0">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjMtMTMtMS0xLTE5NDQ_067d9129-850b-42cd-8dff-6499f6c8f8c5">648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjUtMS0xLTEtMjA3Nw_f7b53750-adc6-4d1d-b401-96401f01da2e">20,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjUtMTMtMS0xLTE5NTY_2e1e8b10-d05a-4010-9337-94214fa21bcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fc323e30b8848c392d11f3447569909_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMS0xLTEtMTg2OA_b9e3bcfb-6541-408f-a63f-183ff3b0f961">198,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMy0xLTEtMTg3NA_d51ab455-9b36-4e14-91eb-5cd6c451f87a">36,775,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtNS0xLTEtMTg4Mg_c3954f42-cb9f-4af7-91ff-82d434e9d212">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7fba74c001f4474b00a66afe5cacce5_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtNy0xLTEtMTg4OQ_b9d79df6-c01e-45c3-af31-743f77efccd7">168,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if17092a524b3431fa61045723b615908_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtOS0xLTEtMTg5NQ_326ef4b6-5062-46c8-b71c-82249241e33a">59,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48930c9adfe945f5b856524fd6f16354_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMTEtMS0xLTE5MDE_92ab33b9-afb2-4342-9b8b-ad167883aed0">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMTMtMS0xLTE5MDk_c0d83614-276c-41ff-997f-234e1661e29d">229,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.887%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Mezzanine</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Equity&#160;&#8211;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest&#160;in&#160;APC</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Retained</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Earnings</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Common&#160;Stock&#160;Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Additional</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Paid-in&#160;Capital</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Noncontrolling</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Interest</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shareholders&#8217;<br/>Equity</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">Amount</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at January 1, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4d27872ad1a4279809587e20ad0fe15_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xLTEtMS0w_ca7a8292-5935-4c59-bd67-1e32b9ee5a2b">225,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a4af3abe23145c5a803f5c3e52a8544_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0zLTEtMS0w_b4482b3e-5bb5-4d33-9a5a-6badf8d8e72b">34,578,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4af3abe23145c5a803f5c3e52a8544_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy01LTEtMS0w_86aee671-8fc8-4804-8bc6-860dc72e06cd">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed16704d02b4d98bf8e2256dea906c0_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy03LTEtMS0w_322a3e42-8d78-4cbd-a330-4ebc7e5b3f29">162,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i761a2357c3064b2594cc6d1ffa6c27db_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy05LTEtMS0w_0caa3650-03c9-4c04-8b1d-bd06d0d959d8">17,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f84ac6f64b14be7aec8e4101eced375_I20181231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xMS0xLTEtMA_4dd045f5-863d-4d75-b92f-d3a22930542a">998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xMy0xLTEtMA_8fd0c9d0-ff1d-4d83-a23a-52b0ce549f3b">181,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net (loss) income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xLTEtMS0w_53216b08-dc19-44a0-a639-cdde6c4b5591">3,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e6f19723927433ab20be84a073ed166_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC05LTEtMS0w_8415f1ed-a30b-4510-86ac-07c69646e57b">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97544ae25cce437ca45e3294de951909_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xMS0xLTEtMA_8197d44e-1068-44f1-89f4-37efebbd6dfc">410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xMy0xLTEtMA_05a0e6da-314c-4fa8-a5ae-93a9728b1976">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Purchase of treasury shares</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0xLTEtMS0w_69ac26aa-af45-4223-affc-6ac4b88f3e95">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockSharesAcquired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0zLTEtMS0w_51c64108-6002-4b84-b0fb-ab68d45767b2">93,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0xMy0xLTEtMA_d3b342b9-cb00-4914-ad43-924c68421fd8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0xLTEtMS0w_c33a2d9d-d4ad-4a3d-ae86-1a5fc8ec3bd0">155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0zLTEtMS0w_f0423aa7-8f05-430c-a3f6-f86b64f384e0">17,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi03LTEtMS0w_11350f82-612a-46dc-be47-26e8d3de844e">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0xMy0xLTEtMA_8095ce5e-f9a0-477e-94b2-5efd4f794ee7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0xLTEtMS0w_f91747ce-3bc0-47be-b853-a0bcc1e77a98">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0zLTEtMS0w_2a57edb9-3907-45ec-8e3a-09a58a7655f3">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy03LTEtMS0w_89ee32dc-f727-43b1-80d3-88d3231f780f">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0xMy0xLTEtMA_eb67e161-73b0-4ee4-b663-cc8b9ead2095">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOC0xLTEtMS0w_832e8126-5b10-49d5-a325-7d7836e64410">10,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOC0xMy0xLTEtMA_3811c9ed-042e-49cf-944d-60be99bbdcea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at March 31, 2019</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77cee32ef46c436d84f0829e3e15ae33_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xLTEtMS0w_ea2a38ad-5905-4028-9b53-e876cc75f2b7">212,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1abc08966ff44c6c9d37bfc49d295077_I20190331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0zLTEtMS0w_f21b2559-e681-4ad3-9eaa-2fd921de7794">34,504,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1abc08966ff44c6c9d37bfc49d295077_I20190331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS01LTEtMS0w_755157b1-4c7b-4cfa-afeb-2efc69d31335">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44c7198a292a4cc68b8fabdaafd056cd_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS03LTEtMS0w_4468a560-de2c-4f44-958e-665179ef7163">163,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb4e33d7899548cf889cdedab733332d_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS05LTEtMS0w_ab9da25a-1b7d-43f9-be8e-305092449ef9">17,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bff8181370945009acd3344b88456f0_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xMS0xLTEtMA_3f3a2923-95d6-40b2-961b-103d4fb54f96">1,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5a66ee0d984c67b9d7841aeb1f110d_I20190331" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xMy0xLTEtMA_755a308f-8ac6-44e5-8310-2b8d230a33db">182,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMS0xLTEtMA_7bdb5905-0af4-40a1-9e47-bfbb24926206">6,896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedead393f61c4d1d98fb4fb12d0b9b21_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtOS0xLTEtMA_fd296480-b46e-4b31-8102-d72f9a3bdb66">3,545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMTEtMS0xLTA_ac6383d4-bf31-408f-8be9-5cea22d3e550">223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMTMtMS0xLTA_49ac41be-6dc2-440c-923c-ae1e34e3f018">3,768</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMS0xLTEtMA_f2e9f415-2dc1-4621-a750-2452d1d67804">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i88138caccd9942feab56d34bfdb5c9e0_D20190401-20190630" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMy0xLTEtMA_b1175211-f12c-4772-9c12-7382e2de3c81">135,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtNy0xLTEtMA_7632e9f1-5d93-473a-b0b2-75ae66b80cdd">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630" decimals="-3" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMTMtMS0xLTA_f9b2f259-8672-46d3-b641-3f6fe6781967">758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItMS0xLTEtMA_7358dc14-a2af-4b46-b669-5348b572d8ed">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItNy0xLTEtMA_6f2edefb-5a0c-457d-b6b2-76bd4a759227">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItMTMtMS0xLTA_6ebc5199-5a50-439b-97ad-f4cd5d298cf6">128</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTMtMTEtMS0xLTA_fdca573f-7b7a-478b-88f5-ef92f9744c86">942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTMtMTMtMS0xLTA_127a7dc8-95d1-45bb-ae0c-3ffed48f26ab">942</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at June 30, 2019</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41a9a24bf76640ed9bdb33547fcaacce_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMS0xLTEtMA_8fdce319-6a44-48b3-8de3-9948fdd927e9">219,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i394648e1fc6a45c1a9b563d94578a33a_I20190630" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMy0xLTEtMA_3adb61c6-c654-4977-bec5-7469308482c9">34,639,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i394648e1fc6a45c1a9b563d94578a33a_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtNS0xLTEtMA_0746eba2-f246-4d5b-a433-b20c7c2e26b2">35</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i441f160512f24fc3a029ac86e7eb66f2_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtNy0xLTEtMA_5abb52a3-99d4-460b-846e-f174f01f1c72">163,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9a6b08aae29400da31700f63234c634_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtOS0xLTEtMA_4272c897-31ff-4184-9afb-04fc516babdd">21,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9189b09c063b44b4b87c085f5786c13a_I20190630" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMTEtMS0xLTA_e0043a51-aaaf-4c7a-89e4-9dd3f3c6edce">689</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ddfb33c93414dc69359261cfab93737_I20190630" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMTMtMS0xLTA_266d83ba-054f-462c-8eab-f0cea54fb4d1">186,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMS0xLTEtMTUzMw_df63e475-a204-4692-820b-f798549d45e4">6,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfadcf1ceec24d88b5700a0374a20a18_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctOS0xLTEtMTgyMw_99950fb6-9ead-49d5-901d-76ab41eec1ac">3,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bd4252c28a48b9bf1ba1f49f34c298_D20190701-20190930" decimals="-3" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMTEtMS0xLTE4MzQ_4939cfdb-4141-4a7a-98da-4ad8dfb556eb">751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMTMtMS0xLTE4NDM_3d7534d7-3899-4dba-a812-ad1028b0cde8">4,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Shares issued for exercise of options and warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMy0xLTEtMTc4Ng_06a6cc38-c09c-438e-b38d-713aba23cf29">184,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtNy0xLTEtMTgwMQ_83f57d4e-8c12-49ea-8023-f5f5b3e5a3ad">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMTMtMS0xLTE4NDg_6ca70eb7-f662-48e2-a071-a95e93cf0396">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMS0xLTEtMTczOA_7388c8ef-ef6e-4752-a598-d21c2e09e7b2">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktNy0xLTEtMTgwNg_a45978b0-bfbe-469d-82ae-6f298e61d728">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMTMtMS0xLTE4NTU_5c023550-8c52-4bbd-8098-7ea62117024e">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock subscriptions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjAtMS0xLTEtMTc1MA_3cb52f0a-3e11-4165-8bf7-c77d01d569fd">550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMTMtMS0xLTIwMzQ_799d91af-b0c0-46a3-9042-a32b32166c3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Stock issued in connection with a business combination</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjEtMS0xLTEtMTc1Nw_b229df3c-cb2a-422b-bdb9-b1ad08b78057">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssuedDuringPeriodValueAcquisitions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMTMtMS0xLTIwMzQ_bf4600c3-36ff-4e39-b511-02b71acb199e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cost related to issuance of preferred shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjItMS0xLTEtMTc2NA_5fc8cf2e-b7ac-4562-b89f-3f88d60da53b">804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjAtMTMtMS0xLTIwMzQ_2b994ab8-e888-4f83-88d2-c49fd9d72e39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Dividends</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjMtMS0xLTEtMTc3MQ_1c266b7d-eaf0-4fee-b964-f4defb10d337">50,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjEtMTMtMS0xLTIwMzQ_e4b87a1a-bdb3-46c2-a197-d2db6b87a550">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Balance at September 30, 2019</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422d2bc6f855432dba692b6a8acdf97f_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMS0xLTEtMTc3Nw_da7fe98b-b443-47ea-b66d-cf86c6408cd7">176,230</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic92256abd49e475e96a57d58092f2a3d_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMy0xLTEtMTc5Mg_f8c038d9-7a83-4340-9e5a-b973cd65d616">34,823,000</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic92256abd49e475e96a57d58092f2a3d_I20190930" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtNS0xLTEtMTc5Ng_6e6bae00-375a-418c-8a34-6080cff3be9d">35</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f8b5692b30549aea2a5a9d8d16e6332_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtNy0xLTEtMTgxMQ_c73b0345-1a59-489c-bee6-2679b5bd4102">165,522</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id523b2ed183c45849c949c14470f0f6a_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtOS0xLTEtMTgyOA_5986dd1a-9b80-4d00-bc05-1049927c8686">25,177</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23e7f6a028994e14996741a361d2e4db_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMTEtMS0xLTE4Mzg_95d2f7de-7d7b-4f7e-9a2d-0f82656bcde1">1,440</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMTMtMS0xLTE4NjI_bb6445ca-7b6b-41bc-8298-42722d964786">192,174</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(IN THOUSANDS)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(UNAUDITED)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from operating activities</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMy0xLTEtMS0w_16595e14-c22c-4b58-a7e4-d9fbf91a7a61">109,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMy0zLTEtMS0w_b3a691df-9016-4273-81ed-7053a2ff0708">18,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNS0xLTEtMS0w_4f514645-6414-4396-999e-f506194244c5">14,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNS0zLTEtMS0w_38480c4e-b9b8-4fdf-9dd4-f446352b2339">13,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0xLTEtMS02NTg5_285c134d-fdd3-4f0b-a319-f5ba2bcee11e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0zLTEtMS02NTg5_3772e5c5-74b4-4b8e-a26a-18d18589c09c">1,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0xLTEtMS0w_2f4a0599-69e0-4f87-bf73-3c86cd5164ba">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:AmortizationOfFinancingCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0zLTEtMS0w_2b67a3c9-099c-4a02-a3cc-334957a7754f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for doubtful accounts</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNy0xLTEtMS0w_611d5e6a-dc02-48ee-8ce8-acf0ef041900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProvisionForDoubtfulAccounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNy0zLTEtMS0w_5168f611-c54d-4f76-9989-915e1d234fcc">1,363</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOC0xLTEtMS0w_c666e927-9173-462b-aac6-6886903f0538">2,558</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOC0zLTEtMS0w_00db7088-354a-4cd7-b34c-9cb6f0a2d5e7">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized loss (gain) from investment in equity securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOS0xLTEtMS0w_8dedfe32-1d16-4ce4-83a1-1d2c79b8777f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:UnrealizedGainLossOnInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOS0zLTEtMS0w_f0b1a2c5-28fb-4b8a-9ad8-b334c39fded4">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTAtMS0xLTEtMA_773f14dc-04be-4760-9aed-af27a17c1326">3,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTAtMy0xLTEtMA_e48490ca-1a03-4f8e-8040-9e69359572ff">1,162</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMS0xLTEtNjU3Ng_413d9456-fa9e-4c7f-af58-ba4646e74527">99,647</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMy0xLTEtNjU4Mw_49055b83-9225-45b7-b840-b05de51dedb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on loan assumption</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:GainLossOnAssumptionOfLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMS0xLTEtMA_59a9b57d-5e25-4eb0-9732-ac1304a21278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:GainLossOnAssumptionOfLoan" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMy0xLTEtMA_6d51fa99-7082-4438-ae76-483f7b1b397a">2,250</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTItMS0xLTEtMA_d77ecca7-a219-4fcd-8050-f2491dd5f30d">6,137</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxesAndTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTItMy0xLTEtMA_96df6229-dc30-4399-82dc-b0e0ae7b7b85">186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities, net of business combinations:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTQtMS0xLTEtMA_f2644af3-84d0-4a39-b342-f6bd1c854978">6,953</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTQtMy0xLTEtMA_8e4f439b-3a70-4ed1-b8e1-e913d26b4187">1,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 36pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTUtMS0xLTEtMA_edc793ab-628b-4a5d-b83d-f64b6482bc88">6,618</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTUtMy0xLTEtMA_351cd408-16dd-46b2-a460-1855c2d65701">5,864</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other receivables</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTYtMS0xLTEtMA_4dae5397-905e-4542-9539-e26ff0a3188d">12,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTYtMy0xLTEtMA_f4669a78-7969-4047-9c5f-c5aa0aaba5f3">13,719</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTctMS0xLTEtMA_b083f3bc-deaa-4908-9396-20274be5f710">1,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTctMy0xLTEtMA_430dfe28-f7a2-4447-982d-2b4d059aa566">2,914</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTgtMS0xLTEtMA_f200a3bc-8edb-4f63-89c8-139b342a9cf1">2,601</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOperatingLeaseAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTgtMy0xLTEtMA_aec8d9c7-dd5b-4977-a78f-94c2196b412c">1,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTktMS0xLTEtMA_73d0a9a3-0a4e-44d1-bb22-3eec4876be20">5,090</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTktMy0xLTEtMA_b70f5b8e-e855-426b-a2e2-5f5cd6d13388">525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjAtMS0xLTEtMA_a5511657-aec1-4196-9847-ef2c4a64ba88">12,644</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjAtMy0xLTEtMA_d3591e88-9f33-4e63-89a9-799ef64ccfa7">4,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiduciary accounts payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjEtMS0xLTEtMA_c91ba863-4185-4cf0-af5f-caf7a00fcd4c">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjEtMy0xLTEtMA_ef8fb33b-3a55-4022-b866-ce2e8369bdcd">196</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjItMS0xLTEtMA_78dbb7b9-aae6-4a04-b6c9-8fc3edc90c51">1,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjItMy0xLTEtMA_2a27e8a6-95ef-48b1-bdcf-a0cba45aef49">6,226</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjMtMS0xLTEtMA_94b4d17c-401c-4fda-a59c-8cb6576427c1">11,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjMtMy0xLTEtMA_00676691-b496-4327-aeb6-78f1d5489b27">10,229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjQtMS0xLTEtMA_be72595b-1197-49c8-84bf-70611a44881a">2,110</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjQtMy0xLTEtMA_569d4500-a6e0-4926-91d7-13e6c5bd3337">1,790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjUtMS0xLTEtMA_b88115c0-bf04-4528-9f9d-cdb7c28376d1">48,764</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjUtMy0xLTEtMA_45704e04-7346-4e09-b668-e7f8cd20bc26">10,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from investing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for business acquisition, net of cash acquired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjgtMS0xLTEtMA_d910c297-0e26-43a1-88f9-134bd769953f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjgtMy0xLTEtMA_a6a0241d-9492-452c-be79-4e568ffc4f2e">49,403</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from repayment of loans receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjktMS0xLTEtMA_92432e04-ac90-4297-805d-b92dda7fa7e0">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjktMy0xLTEtMA_fef9afbe-91cb-4309-9cee-f564aacf87ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Advances on loans receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzAtMS0xLTEtMA_8cc716d4-90df-44b6-afb5-9aae4aa7b906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToFundLongtermLoansToRelatedParties" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzAtMy0xLTEtMA_5fe47a49-bfe8-41cd-a0ae-84d9330ba991">7,425</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzEtMS0xLTEtMA_1e3c76dc-e0be-4608-9d44-a43c963741ff">1,793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzEtMy0xLTEtMA_42683faf-75f3-4edf-8ea5-4e7a9ae253f6">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of investments &#8211; equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzItMS0xLTEtMA_581f1044-f537-4df5-b92d-5d70aab63887">500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzItMy0xLTEtMA_9413af89-df49-4253-aed1-aeaf86b10047">2,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of equity method investment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzMtMS0xLTEtMA_ab76c938-9442-4052-bc24-11e903b36d9a">52,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzMtMy0xLTEtMA_f0b6bea1-27c7-44cd-8c0a-ad1a3edc7946">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzQtMS0xLTEtMA_6a7ffa11-1548-41b2-b422-9b6fd110925e">553</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzQtMy0xLTEtMA_45af603d-efef-441a-bf6e-fa57ce58367d">807</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzUtMS0xLTEtMA_e80b035d-6023-4840-95f6-ff6fc0637092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzUtMy0xLTEtMA_c1a2a064-1e0d-451b-9733-c99c8bdf3344">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzYtMS0xLTEtMA_395b455b-f775-4276-a4b6-8e9db601ac90">66,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzYtMy0xLTEtMA_54d5542c-181e-4065-9771-a9a1625cb521">60,364</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows from financing activities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of bank loan and lines of credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzktMS0xLTEtMA_5c982502-d8e3-464f-9f3c-e4223ca9a598">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:RepaymentsOfBankLoanAndLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzktMy0xLTEtMA_971430a2-9f1f-4179-a433-d3f5d57bd680">52,640</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends paid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDAtMS0xLTEtMA_e06b2be9-b625-460c-876e-c9ee618a4b20">50,133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDAtMy0xLTEtMA_860e21e5-142d-4988-9d72-caf26dbb8608">60,670</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repayment of term loan</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDEtMS0xLTEtMA_6e6f522b-0b6f-479d-aaac-de160f0257d4">7,125</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDEtMy0xLTEtMA_5ee97354-ad0e-4d03-afc4-16658b1f39f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment of finance lease obligations</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDItMS0xLTEtMA_c8cad8bc-defa-4163-9cec-81e9666e7aee">78</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDItMy0xLTEtMA_59fa98a2-fe83-456a-bb1e-74b758622f85">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from the exercise of stock options and warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDMtMS0xLTEtMA_7f979a52-0b5d-4351-8f17-9f529e7a3e07">6,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDMtMy0xLTEtMA_9a221a5c-458e-429e-a524-f834565a8baa">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase of shares</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDQtMS0xLTEtMA_73138151-4b60-4440-9de9-39f28160aced">1,559</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDQtMy0xLTEtMA_f1e4fce1-9c45-4ba0-a66d-ff3c9dd8a4c0">40</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings on line of credit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDUtMS0xLTEtMA_63d65625-2828-4958-bcb9-ca6236e917d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDUtMy0xLTEtMA_6f161e3f-f978-4bde-9f57-5a569251c216">289,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceeds from common stock offering</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDYtMS0xLTEtMA_a3fb1b6c-ead1-4e34-8a70-26b651b3724a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDYtMy0xLTEtMA_328bab22-1fe8-4ba9-96b9-76507345d72c">755</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of debt and equity issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMS0xLTEtNjYwNw_e4ad9fe4-8e3f-49f0-bf50-1e640020ae39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentOfFinancingAndStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMy0xLTEtNjYwNw_b2f5b978-77b7-4ff1-a257-ebc68632b97b">5,622</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDctMS0xLTEtMA_7170a492-33f8-4ef8-8798-cb8261586208">52,343</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDctMy0xLTEtMA_ad9beacf-df8c-4f36-b60d-87fe397e5c61">173,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMS0xLTEtMA_86441534-5f99-430f-bcf6-b9f495024fd1">62,818</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMy0xLTEtMA_862a2029-2a0a-48f7-9c65-ac8e1c642953">123,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTEtMS0xLTEtMA_8d30d556-514d-41e4-9bd4-c3bf7d6500b3">104,010</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTEtMy0xLTEtMA_10b9cf29-be24-4b6d-aa74-ab5648279856">107,637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash, end of period</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTMtMS0xLTEtMA_1b9092c3-e0ce-4e52-902b-4451a6e0cf89">166,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTMtMy0xLTEtMA_4f283a11-9144-48fe-b5e9-c1a13b9b5763">231,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplementary disclosures of cash flow information:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTYtMS0xLTEtMA_488670d8-9f61-4c55-bc05-2248ad52ab1f">37,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTYtMy0xLTEtMA_7e4b59fa-fb06-47ae-a388-f48ab483ecc1">17,900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for interest</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTctMS0xLTEtMA_45ee8685-8109-4784-b653-a29454e8208d">6,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTctMy0xLTEtMA_3e98da1f-c24a-4254-9423-f7c9e6321fa0">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental disclosures of non-cash investing and financing activities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividend declared included in dividend payable</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjAtMS0xLTEtMA_3142ebfb-1a85-4ad4-afc9-698c50c57e96">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjAtMy0xLTEtMA_a1337bf9-5e21-4e07-aac1-36b17a054797">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability adjustment to goodwill</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:DeferredTaxLiabilitiesAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjEtMS0xLTEtMA_b3a4463a-22e7-4dba-8d94-a2002b9f30bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:DeferredTaxLiabilitiesAdjustedToGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjEtMy0xLTEtMA_b125077e-0a73-47ec-9239-c5d5e635fd72">11,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability adjustment related to warrant exercises</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="ameh:DeferredTaxLiabilitiesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjYtMS0xLTEtNzU5MA_175bb186-15d9-4d7a-add1-57dcda1962c3">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="ameh:DeferredTaxLiabilitiesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjYtMy0xLTEtNzU5MA_c7b9f2c3-2cc5-480f-ba3c-f7d451b85c91">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APC stock issued in exchange for AMG</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjItMS0xLTEtMA_ea7297e4-a7de-4808-9648-58890be02cbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:StockIssued1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjItMy0xLTEtMA_289d5d5e-adc4-41ba-86cf-31020a2e0d0f">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares received from sale of equity method investment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjctMS0xLTEtNzM1OQ_419c5c3a-ce8b-44cc-9352-bc415add72e5">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjctMy0xLTEtNzM1OQ_3bfe10e9-381f-4c68-99c1-bb346ecb0b0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total amounts of cash, cash equivalents and restricted cash shown in the consolidated statements of cash flows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2018</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMi0xLTEtMS0w_0f06f9fe-af99-4b72-bba1-f4063016a2a7">103,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMi0zLTEtMS0w_5a0eca4f-1bac-4a53-9eed-504f70c5be85">106,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0xLTEtMS0zNDM2_9a52b6bd-8477-419c-9efa-8c0943a47081">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0zLTEtMS0zNDM2_b7b7291a-4a8a-4900-b765-5e3db64fc266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0xLTEtMS0w_26f33f3f-7919-4531-a2f9-bf59bee324ef">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0zLTEtMS0w_69e5d3ab-fd7f-4f9f-8175-bf8bf005e123">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfNC0xLTEtMS0w_b62794a2-21eb-4c27-bd5c-e2f482e317c6">104,010</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfNC0zLTEtMS0w_50bc2bd4-82ec-463a-878f-e742b0f40f27">107,637</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMi0xLTEtMS03NzEy_d4027594-f63e-40b6-89a2-8ce7b3d39f9d">166,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMi0zLTEtMS03NzEy_07107208-7cde-440a-a35c-9dd1a8d98044">230,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMy0xLTEtMS03NzEy_6a40cab9-4a7d-4300-b4a2-2ae1bc94f873">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMy0zLTEtMS03NzEy_65a1b930-75bb-4237-9c2f-cef39ec7b541">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash &#8211; non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNC0xLTEtMS03NzEy_3404d14f-b3de-4040-a9e0-54f4c1212557">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNC0zLTEtMS03NzEy_4d6f8fc1-0a90-46d0-aff5-6b1d7672fd28">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNS0xLTEtMS03NzEy_ff524e00-1527-467e-bc7f-d163af89bfd9">166,828</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNS0zLTEtMS03NzEy_908b01f5-e576-458f-b87a-691eab3583fb">231,065</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_37"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTI2NDQzODM3MzQ0NzQ_3c33bdfe-74d9-4363-920f-8bff90b43f77" continuedAt="i70ff789e697f4e7fa3b2a9cf1f4c8927" escape="true">Description of Business</ix:nonNumeric></span></div><ix:continuation id="i70ff789e697f4e7fa3b2a9cf1f4c8927" continuedAt="i15ac74ff0d0c49098fd640fe7f425da5"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. ("ApolloMed") together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a leading physician-centric, technology-enabled healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). The Company's NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare &amp; Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of <ix:nonNumeric contextRef="ifd29e64a2dec4d29bab58feb5d6061ad_D19990701-19990701" format="ixt-sec:duryear" name="ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMjgxMA_568570d2-ed7b-4d18-b684-30555304516d">30</ix:nonNumeric> years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (&#8220;VIE&#8221;) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i15ac74ff0d0c49098fd640fe7f425da5" continuedAt="if3587ccd1bef4a888535662b8d416c05"><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $<ix:nonFraction unitRef="usd" contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMzk4OQ_ab6697ce-415f-48a2-b499-6ade00db8133">545.0</ix:nonFraction> million pursuant to a <ix:nonNumeric contextRef="i910be3ba7abf4fbb8a6af6dcabd337ac_D20190901-20190930" format="ixt-sec:duryear" name="ameh:FinanceReceivableTermOfReceivable" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDAwNg_7e991669-6cb3-4281-9499-5d434f4e9e29">10</ix:nonNumeric>-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of <ix:nonFraction unitRef="number" contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930" decimals="2" name="ameh:FinanceReceivableStatedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDA5NQ_1f1bf4a2-0918-4535-a690-81c1de16dad8">10</ix:nonFraction>% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of <ix:nonFraction unitRef="number" contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930" decimals="4" name="ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDgxMA_e162704d-d83e-4359-a815-397025b4565c">10.75</ix:nonFraction>% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased <ix:nonFraction unitRef="shares" contextRef="i3271ca437f904f76a750501a6a560262_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDg1Nw_97eb4a92-f024-4bc7-a489-77c3d0b95025">1,000,000</ix:nonFraction> shares of APC Series A Preferred Stock for aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDkzMA_2b49a511-e026-4c02-95c6-51abbbbaad4c">545.0</ix:nonFraction> million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased <ix:nonFraction unitRef="shares" contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTQ5Ng_b2253b01-0d32-468b-8f0a-df086f0540f7">15,015,015</ix:nonFraction> shares of ApolloMed&#8217;s common stock for total consideration of $<ix:nonFraction unitRef="usd" contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTU2MQ_af50174f-75ae-444e-92a0-94a51ffa2ba9">300.0</ix:nonFraction> million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of <ix:nonFraction unitRef="number" contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930" decimals="4" name="ameh:StockIssuedDuringPeriodProxyVotesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTc2NQ_2ce36153-a3f6-49ea-add5-eec0aeca8780">9.99</ix:nonFraction>% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transaction, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term excluded assets ("Excluded Assets"). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC's ownership in ApolloMed was <ix:nonFraction unitRef="number" contextRef="i224fec02c801431e8c5aac9b0b456487_I20200930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNjYzMg_2783878b-d049-4331-b307-e22fbf1936bc">32.00</ix:nonFraction>% at September&#160;30, 2020 and <ix:nonFraction unitRef="number" contextRef="ic3034d93366647d8945f0fd5c17d5c31_I20191231" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNjY0NQ_e11d9cf0-6bb4-4777-8982-48d8837d9076">32.50</ix:nonFraction>% at December&#160;31, 2019. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of September&#160;30, 2020, APC owned <ix:nonFraction unitRef="number" contextRef="i31c72a9bb0cb4b81bd7107492b993265_I20200930" decimals="4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNzEzNw_c6958500-6d77-4d96-8500-0c386cf4c358">45.01</ix:nonFraction>% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a <ix:nonFraction unitRef="number" contextRef="i107e7a3c6a6544e99b2eb9a20ca8c10a_I20200930" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfODU2MQ_3b16216f-8951-4af0-add4-f637ffedc19b">100</ix:nonFraction>% ownership interest in Maverick Medical Group, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="if3587ccd1bef4a888535662b8d416c05" continuedAt="i7f112f89e1e64cfba6b17e96d7c7e954"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care currently has a network of over <ix:nonFraction unitRef="primary_care_physician" contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930" decimals="INF" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTY1OA_1e28d691-00a2-4eb4-95f3-6a0ec254d29a">300</ix:nonFraction> primary care physicians and <ix:nonFraction unitRef="specialty_care_physician" contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930" decimals="INF" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTY4OQ_68c846be-af6a-42f0-b838-1bf9b950ceea">600</ix:nonFraction> specialty care physicians, as well as <ix:nonFraction unitRef="medical_center" contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfStores" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTcyMw_fb746505-ef97-499c-8e7f-4847c3deed57">one</ix:nonFraction> community and regional hospital medical center, that provides quality healthcare services to its members of <ix:nonFraction unitRef="plan" contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFederallyQualifiedHealthPlans" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTg0Nw_9501a9e3-1b8a-4183-a250-5e7d7b2e2c94">three</ix:nonFraction> federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising <ix:nonFraction unitRef="number" contextRef="i21eafb5a353445498a87ec5ef991e89a_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAxNTc_7589b6be-5f40-4026-a12e-9edcdfe41867">75</ix:nonFraction>%) for&#160;$<ix:nonFraction unitRef="usd" contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAxNjU_baad8924-dbfc-4806-a1db-8b7a607fc120">7.3</ix:nonFraction> million&#160;in cash (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of <ix:nonFraction unitRef="clinic" contextRef="i4cc46814272a4c91b52259eab36012a6_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:NumberOfFamilyPracticeClinics" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAyNTE_377c6e8a-bbef-4d24-99bb-17ebb84c7cfb">three</ix:nonFraction> main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased <ix:nonFraction unitRef="number" contextRef="i18773fd9db2d4f019b64dad4ce3bb2ca_I20190930" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA0OTg_1fe59f91-d392-4607-8721-4d2ca3b165a3">100</ix:nonFraction>% of the shares of capital stock of AMG for $<ix:nonFraction unitRef="usd" contextRef="i4ef9a04a9f264372a8deb57e8aa6633a_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA1NDM_57afce47-dc7f-4922-a3f6-93970fae53c9">1.2</ix:nonFraction> million in cash and $<ix:nonFraction unitRef="usd" contextRef="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA1NTg_7eb96260-f429-4f09-bf7f-333378d7dcb2">0.4</ix:nonFraction> million of APC common stock (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a <ix:nonFraction unitRef="number" contextRef="if1d00ff8efb448b7851f3acd7b67c857_I20140630" decimals="INF" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA2NDg_19f692d5-963d-4d4b-83da-8764b2905926">100</ix:nonFraction>% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#8220;UCI&#8221;). On April 30, 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="ib183d084186d4c5bb6d817ef531b2f3d_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA4MjU_b0e07e83-7eda-4016-a2ef-b4af495647fb">48.9</ix:nonFraction>% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $<ix:nonFraction unitRef="usd" contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA5Mjg_d995a725-d78c-4745-b264-2f7abf5afec7">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA5NTk_4963ebbf-3664-49f6-9ab1-f3d8bc0b5b0b">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i6fff24e3077f4a3eb1b61025153234f3_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTExNDM_f8e2bb15-2442-49c8-82ab-5be48665d7f8">36.2</ix:nonFraction> million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$<ix:nonFraction unitRef="usd" contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTEzNjc_78a9eb70-554c-45ae-98ab-471b788f98b7">15.7</ix:nonFraction> million (see Note 5). As set forth in the Company&#8217;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#8220;Proxy Statement&#8221;), the <ix:nonFraction unitRef="number" contextRef="ib183d084186d4c5bb6d817ef531b2f3d_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTE1MDY_86d99deb-613b-4813-a172-1fe91b8b2a50">48.9</ix:nonFraction>% interest in UCI is included in Excluded Assets that remain solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#8217;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#8220;NGACO") Model of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. </span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i7f112f89e1e64cfba6b17e96d7c7e954">AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.</ix:continuation> </span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_40"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjAzNDA5NjUxNjI4Mzk_37fb2e12-dcb3-424f-862f-eb62b8442901" continuedAt="i57ae91604f27471aa671f4c324cfa741" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i57ae91604f27471aa671f4c324cfa741" continuedAt="i1cd2b3663a0040a58a75e0837168f6ee"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MjQ_6fd68677-0859-4449-884c-755be88f2b21" continuedAt="i4d4187a203f54e9c8d3a3147d81642b6" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheet at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2020, and for the three and nine months ended September&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i1cd2b3663a0040a58a75e0837168f6ee" continuedAt="i063d3e8f9a6248409604fc92a734a2b9"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4d4187a203f54e9c8d3a3147d81642b6">required by Regulation S-X, Rule 10-01.</ix:continuation> Operating results for the three and nine months ended September&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MzM_b3bc3376-d615-4b55-b81f-597a78ed2c33" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated balance sheets as of September&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, and APAACO, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All material intercompany balances and transactions have been eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzI_7aa5cb5a-5971-445e-96cb-3b395f06f56d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3ODg_7c2206e2-cfb3-467f-a59f-cc1c3bebea4f" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTA5OTUxMTY3NjY0Nw_065a669c-6c58-47ab-81af-5bbef143e397"><ix:nonFraction unitRef="segment" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTA5OTUxMTY3NjY0Nw_e66cc7bf-e0a1-495c-b195-7c22b741d723">one</ix:nonFraction></ix:nonFraction> reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in <ix:nonFraction unitRef="segment" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzczMQ_065a669c-6c58-47ab-81af-5bbef143e397"><ix:nonFraction unitRef="segment" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportableSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzczMQ_e66cc7bf-e0a1-495c-b195-7c22b741d723">one</ix:nonFraction></ix:nonFraction> reportable segment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjA_a686c9aa-e938-4631-afb1-18a226dfd0dd" continuedAt="i390e6d6b9b5b4e1a9357353648a2167d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i390e6d6b9b5b4e1a9357353648a2167d">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</ix:continuation> As of September&#160;30, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDQ4OA_fa1b376e-e85b-4d8f-9ae8-c831f6cecbb0">321.2</ix:nonFraction> million, including approximately $<ix:nonFraction unitRef="usd" contextRef="i6e5cacd19c684cdbb8845f5fa5d3f343_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDUxNg_5e0f8916-0aa0-4189-80e1-1f992ce403fd">118.3</ix:nonFraction> million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTg_153beed6-170e-488d-8b31-1887e48d8ea7" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:MarketableSecuritiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTM_969daa57-7831-405f-99cc-c9e407132987" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNTE4NQ_079de614-9832-4e3e-8acf-3045508f951b">118.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNTE5Mg_a8bc0180-c5e3-4dcb-a6ee-1e75dc6ee761">116.5</ix:nonFraction> million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from <ix:nonNumeric contextRef="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930" format="ixt-sec:durwordsen" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjE_b07cc54c-2d26-4fb6-8b0e-ddd7cd486ff6">four months</ix:nonNumeric> to <ix:nonNumeric contextRef="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930" format="ixt-sec:durmonth" name="ameh:MarketableSecuritiesCurrentMaturityPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Njg_8393a5ea-0c35-4fd4-8c49-51a0a02f66ed">24</ix:nonNumeric> months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i063d3e8f9a6248409604fc92a734a2b9" continuedAt="iafd980aa1ee149d5bfbe48e57ca62231"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjI_a92f37f2-daa2-4edf-8dad-7e565bdb9017" continuedAt="iea903aec803a454ba52ed2ee06a7bb83" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables and Receivables &#8211; Related Parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:durmonth" name="ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjY2OQ_23753f5a-4ce3-4e89-acb5-9e3fa0a7122f">18</ix:nonNumeric> months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iea903aec803a454ba52ed2ee06a7bb83">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model.</ix:continuation> As of September 30, 2020 and December 31, 2019, the Company had $<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfODM0MA_0b3e8a97-c451-4da8-85e9-e50dbd0b4bc5">1.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfODM0OA_1dc1b8af-b774-460d-af57-f2bff7ee649b">2.9</ix:nonFraction>&#160;million of allowance for doubtful accounts, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTQ_336945ed-7119-4649-b7d5-2cf43605110e" continuedAt="ib9a3ff9fde6e4d28b8dafdb81ccfcd4a" escape="true">Concentrations of Risks</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib9a3ff9fde6e4d28b8dafdb81ccfcd4a">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</ix:continuation> <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTk_a6dbc688-2e69-412f-9840-130513a5d232" continuedAt="i2f2c75154bf24b9487b23e59ddf64560" escape="true">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i2f2c75154bf24b9487b23e59ddf64560" continuedAt="ie8850fa0ad3b4f7cb43542cc0f3a32d7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i268f6180d8c0414395a4e02831546f91_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfMy0xLTEtMS0w_86466b34-16e6-4156-b94e-ba50139dcd6e">25,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i615fb686511c4f7b9373dcdd32145e20_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfMy0zLTEtMS0w_497f8608-eb1c-476b-96ea-44839e486fc4">25,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5300706ef0ee464c80f686cc29fef1eb_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNC0xLTEtMS0w_7ea71c50-ec80-48c2-b19a-6f7d786cb189">79,649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860551ad800a48b6b48834294a562f6e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNC0zLTEtMS0w_7c1d68e8-fe43-4342-8e5e-70fb73d391a8">60,737</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00916d9e42e4e7598a07cc98c911bba_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNS0xLTEtMS0w_810ec930-be0c-4b82-8334-37db7348f50c">65,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59c65958899a4f40b312082b11ad9972_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNS0zLTEtMS0w_14158a51-93ba-4701-ab91-6dde8a462388">61,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48bb7d5e7164c9087e12aebeca47de4_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNi0xLTEtMS0w_c24ffccc-8e45-4f1d-a9a7-b65280e148c9">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e72fdfc6d2440f9a7a619f2bfa27a4_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNi0zLTEtMS0w_813fed42-3335-4908-8730-2eea454be1ff">8,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNy0xLTEtMS0w_93277b27-544d-492f-8127-cac93d2c7822">180,123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNy0zLTEtMS0w_a5764889-09da-48ea-9b6e-e23442c21b2b">156,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="iafd980aa1ee149d5bfbe48e57ca62231" continuedAt="i564ad53d722f4b41aff992f25cb2e9f7"><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><ix:continuation id="ie8850fa0ad3b4f7cb43542cc0f3a32d7"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6b08cbba5ce44a6828427adf1d58d41_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfMy0xLTEtMS0w_7ec0272b-8b54-44f8-9f94-34d2152d2ec8">75,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice6d7186a3fa42f2aa021e89451d94a6_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfMy0zLTEtMS0w_5eecefed-e6f9-41bd-adb8-5630f7aca2df">75,883</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df6da5ef4cc4b969a1fe43c3978041b_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNC0xLTEtMS0w_fa9bc63f-ff89-46a9-b7ed-1ef7b5c14434">206,567</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24dff7de3f35477897d40e0ce546c0c2_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNC0zLTEtMS0w_24788d8b-e6d3-471c-9c20-fab8145b8133">155,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee27b0cd6fa641be9c0346123edc0f7c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNS0xLTEtMS0w_213c554a-524d-478f-a609-91c90f5a92fc">200,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6281cd8fd509439da10e97b31b90f99d_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNS0zLTEtMS0w_ca45cdd0-aa62-4117-ab19-1489a6cf6d96">122,837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8acee0d243214133a46c54e3cafca151_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNi0xLTEtMS0w_78d2cd82-5825-4baa-a842-c98a184c6bbd">27,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99ce7ab3879d43af8ed70e1e9d100478_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNi0zLTEtMS0w_98501561-7d3d-4804-bfa0-d8a9bf85d243">27,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNy0xLTEtMS0w_73a701e2-24c3-489b-b31b-6ed3407c66a8">510,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNy0zLTEtMS0w_3c33c483-033b-4e7f-bbed-8e5232611cf9">381,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzA_13fe774b-9b65-472c-9dd5-fe3d27d6e387" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1864ede366d9428596f507b1ccdf3055_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfMy0xLTEtMS0w_3afcba3f-f687-44b3-86c0-8ae17ae53632">12.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic009ac2508fe4ddb8d41e1d789d89e2c_D20190701-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfMy0zLTEtMS0w_222545d6-2dfd-4b09-905d-634ad0a7e6ad">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7ebbea39beeb486097293272d98df046_D20190701-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNC0zLTEtMS0w_17343a68-8959-4b3c-8c51-d67a8d16bfcd">11.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35e09b32dfa2485098765d8342e2c09d_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNi0xLTEtMS0w_c98d2eef-1368-42c1-af52-8542f9258d84">16.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i41254baa0b494543874e77b5b65806dd_D20190701-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNi0zLTEtMS0w_064cd30f-1f6a-4b43-886f-1bf9424b4baa">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5db53e7069624847940f8b01072d1616_D20200701-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNy0xLTEtMS0w_bbfa22c9-d9eb-41e5-b4c7-ff4c831cc067">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50b5b61eb68b440ca6b1f08ae563dd55_D20190701-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNy0zLTEtMS0w_d22af0d5-6f68-46c8-bbeb-6f74c5d421c5">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0c8e4a29ed643d2812e326a13329643_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfMy0xLTEtMS0w_0ab8b378-6646-4820-b192-7fd12fb53eae">12.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i215eb1833be2440ab91be38ab300819f_D20190101-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfMy0zLTEtMS0w_839e86c2-4341-4582-9bc2-f83cf482b582">14.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie685084fafd04aabac97138d7d7c72a0_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNC0xLTEtMS0w_1c5772b3-1123-49bc-bcf6-0ebe0c269b1f">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d1826880923498084158c89cee6e00a_D20190101-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNC0zLTEtMS0w_6b15bcca-8b00-4385-a55e-9fd4404d3ad8">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i50ba8e183602464480aebab3b80942ca_D20190101-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNS0zLTEtMS0w_7033f552-bf4e-465d-b95e-328bb4d0cecc">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1f060ecdde4a4705b9409b06aa972c41_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNi0xLTEtMS0w_d5fb6241-d19d-4068-bdaf-ba8b8ea4e097">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id59a584c780448de8be355c36a29f7cd_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNy0xLTEtMS0w_c8d9c0d6-e039-48d9-8952-5ac530519a16">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i14a8fdcc013f4900b6aada4fc3f7af4a_D20190101-20190930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNy0zLTEtMS0w_c28719bf-5fdf-4bf4-8777-aa0ac52df9a5">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd1feb4e50b4175a4e88a4badb5cb45_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMi0xLTEtMS0w_c2dd557f-37ed-439c-9508-f785179075a8">16.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6e3e458d85614c56bb255ed53fb55e0a_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMy0xLTEtMS0w_238e14ff-477f-4062-b69d-d8171b1ce415">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i93b93d2a3bdc45dea0ee9e341a282b8a_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMy0zLTEtMS0w_bcc8d5c4-8969-4b65-a99b-66e64d71ed2f">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib26496fe9ee64c8ea436ec54656e23b8_D20200101-20200930" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfNC0xLTEtMS0w_2036bc9f-e2f4-4520-9a22-5a214830e064">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if626b3c6137241b29c016703d18f7fb1_D20190101-20191231" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfNC0zLTEtMS0w_581f59d4-6908-457d-8c4a-e34f1d4e5a88">36.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Nzk_f63a53f3-9e44-4f6c-8351-f6ce0b65eeeb" continuedAt="ia7825040a7ad4bb5ae03df1d886c48b7" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i564ad53d722f4b41aff992f25cb2e9f7" continuedAt="idbac75982b474d8bb711b92a619c17dd"><ix:continuation id="ia7825040a7ad4bb5ae03df1d886c48b7"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div></ix:continuation><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTA_29baa4a7-fc32-40e1-b1f9-de60b5dbafb6" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ee7c619bb459289d0d37e04512563_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy0xLTEtMS0w_874e6c84-cd74-43d5-8eb3-d12cf4cfbac3">115,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy0zLTEtMS0w_6940cf7e-332e-4d72-8db7-bcc29d60247a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy01LTEtMS0w_95901217-32a8-4d6d-8b2e-9edaf45d7663">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy03LTEtMS0w_99e9b74a-0e63-4fb3-a941-a4f2febfda68">115,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ee7c619bb459289d0d37e04512563_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC0xLTEtMS0w_c49e813f-ce9c-49b2-a68a-2a74491a742e">118,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC0zLTEtMS0w_6acbb94a-f466-46f9-a622-be1e4da801d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC01LTEtMS0w_8b85b496-adab-4063-82d1-ff84bc032268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC03LTEtMS0w_57759a9b-0c49-408f-a8af-86edfbb7d5d4">118,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ee7c619bb459289d0d37e04512563_I20200930" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS0xLTEtMS0w_a9d48094-e7c7-4d97-bae7-71fef600f25a">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS0zLTEtMS0w_9684643d-7262-4438-b9a0-4a0e3b2dbe26">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS01LTEtMS0w_b69294d8-3e46-429f-9467-ddf19cff6ff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS03LTEtMS0w_816f8841-500b-4731-95df-9a13c6229fb3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142ee7c619bb459289d0d37e04512563_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy0xLTEtMS0w_15604fe3-baba-4d23-9570-45929ecf60f9">233,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy0zLTEtMS0w_8d6da762-7ddb-4f4f-9a3f-9b25ef0285fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy01LTEtMS0w_207c8922-61c0-45e0-94b1-61b2ecbc3be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy03LTEtMS0w_b72c78b2-6f1f-4dce-a513-8ca1f49277a7">233,348</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742706889d86455a834aaba86ebe626d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy0xLTEtMS0w_26a79772-a8df-4e92-9336-3d07556b6d29">50,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy0zLTEtMS0w_fc32dbdd-7dcd-4e99-bb13-af14df2409d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116b3e9585e9410a873b90bb05603771_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy01LTEtMS0w_49fc2337-0b9d-4293-a18b-5c46479887b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy03LTEtMS0w_d2af6d1d-b862-4517-b5aa-9f0280b7cab9">50,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742706889d86455a834aaba86ebe626d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC0xLTEtMS0w_75926a9e-5572-4501-85f3-57cf97825f95">116,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC0zLTEtMS0w_0f0f7c57-9515-441d-b56a-a64b3d1c1203">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116b3e9585e9410a873b90bb05603771_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC01LTEtMS0w_84362ba7-ba4f-4334-a249-cc0e6e1c2c29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC03LTEtMS0w_bc8f29b6-405f-4312-a855-fbedc8f35c37">116,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742706889d86455a834aaba86ebe626d_I20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS0xLTEtMS0w_ec91e761-93ba-454d-8105-ef1543511d2c">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS0zLTEtMS0w_c779f7c6-54f8-4d92-8eab-320e86d462f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116b3e9585e9410a873b90bb05603771_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS01LTEtMS0w_331fe2ab-f8fe-40cd-ab8c-84826a5fbe3b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:EquitySecuritiesFvNi" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS03LTEtMS0w_9d4ef662-5d44-4546-bf8d-01875899af80">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i742706889d86455a834aaba86ebe626d_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy0xLTEtMS0w_8dab6687-9316-43c3-a4c6-f75ec50db653">167,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy0zLTEtMS0w_d38f2f9a-f849-4817-b27f-4222274ce94a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i116b3e9585e9410a873b90bb05603771_I20191231" decimals="-3" format="ixt:zerodash" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy01LTEtMS0w_9c2977da-503a-458c-b2f4-68e037a07ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy03LTEtMS0w_ec6ceff2-d192-430c-b005-20292e96e662">167,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2020.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NDY_edb9f029-3d66-4156-8366-faf59f401cea" continuedAt="i47c0e91f42474afeb1a38b355d8e12b9" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="idbac75982b474d8bb711b92a619c17dd" continuedAt="ib0d563a0fa9d4b3f9bba085bc0e2ba2d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i47c0e91f42474afeb1a38b355d8e12b9">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</ix:continuation> The Company determined that there was <ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_9ccb6466-a5a3-422d-a064-2a066f55a798"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_a903edc0-bb16-40e2-9af8-66bf1a1cf3ed"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_e2bdb628-7f59-49f5-840f-6e54b35896e3"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_e5bc6d17-2b74-4731-ac90-a2873fc4b673">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2020 and 2019.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MjU_37701e8d-259b-400d-a9ea-1e7e75b84974" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s <ix:nonFraction unitRef="unit" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfReportingUnits" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTM3Nzg_a7c9904d-1f42-4f14-8ca1-c501d8ed9333">three</ix:nonFraction> main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had <ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_a4cb3c84-56d8-48ca-992e-23991c37bb17"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_aad936eb-69ec-45a3-a4b9-9c54114c21e0"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_c2b1e653-8196-4518-9359-0de2f6fad110"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:GoodwillImpairmentLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_d99344e3-7f71-4d65-91cb-78f81ae5dacf">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its goodwill or indefinite-lived intangible assets during the three and nine months ended September&#160;30, 2020. However, during the three and nine months ended September 30, 2019, the Company recorded impairment of indefinite-lived intangible assets of $<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNDY_246b9f59-ee63-4b15-8525-4c47ff6ec6ac"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNDY_a98cd687-b664-4499-9133-80efaeb25e4f">2.0</ix:nonFraction></ix:nonFraction>&#160;million related to Medicare licenses it acquired as part of the 2017 merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTA_f6d5788d-8ca5-4379-aa77-bc35a03cb277" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:HealthCareCostsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NDc_95588d5d-758d-4a96-9ce5-5c43a904d1c7" continuedAt="ic42d2863913647cea57c6518e6dc9f59" escape="true"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="ib0d563a0fa9d4b3f9bba085bc0e2ba2d" continuedAt="i453dafeefa3741cba7bbe3f1c6799eb4"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic42d2863913647cea57c6518e6dc9f59">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</ix:continuation></span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjAzNDA5NjUxNjI4NDE_f331f7c1-fd12-4308-a347-13bd78abefc1" continuedAt="i0ca061d9e1e14cc4a68a8d2701ed73a1" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of <ix:nonNumeric contextRef="i2d04d4b89dd2456bab5a43914120ef3d_D20200101-20200930" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjExNDA_de0c0da6-0dda-4507-88b8-0bfc638b0510">one year</ix:nonNumeric> or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i453dafeefa3741cba7bbe3f1c6799eb4" continuedAt="iad1e917062814e1cbadecb457b958232"><ix:continuation id="i0ca061d9e1e14cc4a68a8d2701ed73a1" continuedAt="i3aa189b866844b0d9920c7f2c88e6b2d"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37">two</span> additional renewal years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the </span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="iad1e917062814e1cbadecb457b958232" continuedAt="i2a17fe7b3feb4915baa6d07bd523a7f7"><ix:continuation id="i3aa189b866844b0d9920c7f2c88e6b2d" continuedAt="i77366234b2aa443ab5ca9837ebf974d0"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within <ix:nonNumeric contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjk5MDM_51a193e1-7bfe-4887-a070-d7029382dcfa">30</ix:nonNumeric> days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within <ix:nonNumeric contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzAxNjM_c6b547a3-124b-469f-9db7-383322fce12b">30</ix:nonNumeric> days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within <ix:nonNumeric contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930" format="ixt-sec:durday" name="ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzAyODY_c6b547a3-124b-469f-9db7-383322fce12b">30</ix:nonNumeric> days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:RiskPoolSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNjA_33156231-ee16-4169-aa2f-8d91a34774f3"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:RiskPoolSettlement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNjA_dc49cf21-7c8a-4ac4-87c7-84e32ca9a39a">19.8</ix:nonFraction></ix:nonFraction>&#160;million in risk pool savings related to the 2019 performance year, and has recognized such amount as revenue in the risk pool settlements and incentives line of the accompanying consolidated statements of income for the three and nine months ended September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenueMonthlyAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYwNg_6636e966-dfc0-4b32-9262-e0fd9d518395">7.6</ix:nonFraction> million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYxNg_ff34f8cf-601e-4dec-a734-39902dee9598">22.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentOfRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzE5NDY_7893fd96-64fe-4da5-a8ec-01b178246b99">68.4</ix:nonFraction> million in total AIPBP payments for the three and nine months ended September&#160;30, 2020, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYyMA_1c09f405-e924-42a4-9700-e7d4cf92d5d8">14.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzIwNDE_02bf8e8c-2a45-4c6c-b4aa-3d3069ec1bc3">57.3</ix:nonFraction> million has been recognized as revenue for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i2a17fe7b3feb4915baa6d07bd523a7f7" continuedAt="ic90f30f91d3c45419d5b61ae6ea878d3"><ix:continuation id="i77366234b2aa443ab5ca9837ebf974d0" continuedAt="iee6a673f9fd9479ea576bee5e3f7fcb0"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., <ix:nonNumeric contextRef="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930" name="us-gaap:RevenuePerformanceObligationDescriptionOfTiming" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzQ2MjU_97fce091-b5d5-40c6-ab9d-4fe08e1cd2ec">10 years</ix:nonNumeric>), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the previous accounting guidance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="ic90f30f91d3c45419d5b61ae6ea878d3" continuedAt="i109b3d1d6a864f589547d3b9ca520873"><ix:continuation id="iee6a673f9fd9479ea576bee5e3f7fcb0" continuedAt="i202087981b1c43869610e24150b14828"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i202087981b1c43869610e24150b14828">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</ix:continuation> The Company&#8217;s contract liability balance was $<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDExMDA_5c6d35d8-d6c7-4516-afa4-7ac74b3dee40">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDExMDc_667405f7-9d47-4e6c-8d4c-88254e6e205d">8.9</ix:nonFraction> million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is presented within &#8220;Accounts payable and accrued expenses&#8221; in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2020, $<ix:nonFraction unitRef="usd" contextRef="id33eaefc8b5942e9b470aa4f9c9fbf0d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDEyODY_e900532a-5aed-4ee9-9fbe-11a84cccc6c5">0.4</ix:nonFraction> million of the Company&#8217;s contract liability accrued in 2019 has been recognized as revenue and $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfOTM0NTg0ODg4NTAwOA_84683485-9cb2-47b7-b141-c3ecf763e1d0">8.5</ix:nonFraction>&#160;million was repaid to CMS for AIPBP capitation received and not earned.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Information</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company made a deposit of $<ix:nonFraction unitRef="usd" contextRef="i04e6f52d6af84990b66fae85e26f4b3e_I20200331" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDE1MTk_c33f17b0-3171-4b6d-ada4-ed451fe895c3">4.0</ix:nonFraction> million for future investment opportunities. The deposit was made with cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. The deposit is included in &#8220;Other assets&#8221; in the accompanying consolidated balance sheets. Subsequent to September 30, 2020, an agreement was signed converting this deposit into a promissory note from a related party (see Note 17). </span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MzI_a9832a30-5cb0-4db9-9eea-23c7d19799a4" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Mjg_7e6c630f-be2f-4545-b82d-c3cab26b0289" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg4MDI_6d5af10b-046f-4891-9bf3-ed779eaea295" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i109b3d1d6a864f589547d3b9ca520873"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:MinorityInterestPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzU_8da5e67c-b641-4d3a-a5ba-d457373751e0" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than <ix:nonFraction unitRef="number" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" name="us-gaap:VariableInterestEntityOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDQ1MDA_72d77595-7d8e-42da-9195-ae939745ad47">50</ix:nonFraction>% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:TemporaryEquityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzY_061a1256-3222-40e1-9180-6c962edd7bd3" continuedAt="icb588dda06c549639de4c1609d17802c" escape="true">Mezzanine Equity</ix:nonNumeric></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icb588dda06c549639de4c1609d17802c">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.</ix:continuation> As of September&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTQ_8cc88d42-6e4e-4c2c-8011-33773388c51d" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div></ix:nonNumeric></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_43"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE2OQ_c0341e20-f75d-4435-8caf-d81e822d3892" continuedAt="if7d6dba8509044b5a0cf861e4603ede0" escape="true">Business Combinations and Goodwill</ix:nonNumeric></span></div><ix:continuation id="if7d6dba8509044b5a0cf861e4603ede0" continuedAt="i601a1de0387648ec84da9c666ac2ce77"><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alpha Care Medical Group, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2019, APC and APC-LSMA completed their acquisition of <ix:nonFraction unitRef="number" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="INF" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTQw_aee66529-8a56-44da-815d-8948c5d4a8e7">100</ix:nonFraction>% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMjQ4_8ed6402f-ba90-4dc9-8109-375ce0154671">45.1</ix:nonFraction> million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $<ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EscrowDeposit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzQ2_c2262f92-987d-43b5-bb71-5cf6e1a38bed">2.0</ix:nonFraction> million into an escrow account for potential post-closing adjustments. As of September&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. </span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE3MA_2429c8f4-bd80-4598-9fe2-e0d26bd790e7" continuedAt="i6b1e1814153348b79dff56c06c3db1be" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMi0xLTEtMS0w_d41574e1-110e-4e94-b6e1-1f0238736c20">3,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMy0xLTEtMS0w_aea8b6fa-d14f-41b8-a408-ddc6e8f964cf">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNC0xLTEtMS0w_60ee025e-a3f7-48ad-a2fa-942d4430d8c8">4,675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNS0xLTEtMS0w_7e72f4de-b0f7-4768-bc36-c898e70166bc">22,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNi0xLTEtMS0w_37b22485-ec56-474b-be1a-90605b4dd2ea">28,585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNy0xLTEtMS0w_e0e58a81-7993-4184-ae83-3e619e77a896">2,795</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfOC0xLTEtMS0w_f0c009e8-6d9a-459b-a584-d6509429e7a3">6,334</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfOS0xLTEtMS0w_b844f018-d466-4257-bdcc-5d6269b2e1b7">15,616</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMTAtMS0xLTEtMA_a9066b23-4f0b-4cfe-a59a-02fa288fdbcc">45,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMTItMS0xLTEtMA_cb4b2ca4-47bc-401f-b138-d6d9b596e5a3">45,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accountable Health Care, IPA, a Professional Medical Corporation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising <ix:nonFraction unitRef="number" contextRef="id0a2c6ac04aa49da8a227305158f0d54_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTAzNA_73f26c6f-d6d1-4da6-86c1-aae9aed09159">75</ix:nonFraction>%) in Accountable Health Care in exchange for $<ix:nonFraction unitRef="usd" contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTA4MQ_baad8924-dbfc-4806-a1db-8b7a607fc120">7.3</ix:nonFraction> million. In addition to the payment of $<ix:nonFraction unitRef="usd" contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTExNQ_baad8924-dbfc-4806-a1db-8b7a607fc120">7.3</ix:nonFraction> million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $<ix:nonFraction unitRef="usd" contextRef="i400a89eea72d482f927a72d7ad593718_I20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTIyOA_16ae66dd-6324-4985-a4ec-7b88be80f98d">15.4</ix:nonFraction> million, which have been eliminated upon consolidation and contributed the <ix:nonFraction unitRef="number" contextRef="ic57f99e455f748c7bd9f72d18cb3b19e_I20190830" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTI5OA_65a6cd2d-1444-4f3d-8ddc-0b797c23d4ef">25</ix:nonFraction>% investment totaling $<ix:nonFraction unitRef="usd" contextRef="if2f44f37c4f54616bb326a86f03405a3_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTMyMQ_92f73629-eeab-4524-bce4-ab6db4b3914e">2.4</ix:nonFraction> million, total purchase price was $<ix:nonFraction unitRef="usd" contextRef="if23b273bb3224911ad4440101430e675_D20190830-20190830" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTM1MA_a94031dc-0435-46ed-92bc-1f359781001f">25.1</ix:nonFraction> million (see Note 5). </span></div><ix:continuation id="i6b1e1814153348b79dff56c06c3db1be"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMi0xLTEtMS0w_9dafd207-b69e-40c5-a31d-349056897a10">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMy0xLTEtMS0w_e98cab85-da4a-46f7-9ae7-92445c35794a">5,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNC0xLTEtMS0w_69982953-b1a0-4630-87d2-b09db162c641">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNS0xLTEtMS0w_61dcf3fc-92cd-4ab8-a6e7-86d08f80f408">11,411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNi0xLTEtMS0w_b45635cb-52db-4da6-9ec7-7d3bf354d12c">23,566</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNy0xLTEtMS0w_36777a83-e32f-488d-8a3d-640b062d2c82">3,759</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfOC0xLTEtMS0w_759d8807-b8eb-4af3-b93a-14f1414624b3">12,154</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subordinated loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfOS0xLTEtMS0w_eed47a76-59d6-40c2-831b-15c566b75329">15,327</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net asset acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTAtMS0xLTEtMA_04b3dc76-c4ce-4d86-b34c-236a51e83824">9,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment contributed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTItMS0xLTEtMA_4d8c6ca5-5f0c-4604-b2d3-daba9199f93c">2,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i898462389ad24c0b8913adf6b0b29a3b_D20190830-20190830" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTMtMS0xLTEtMA_68739251-6798-4709-9dff-6520f6e90161">7,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i601a1de0387648ec84da9c666ac2ce77"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMG, a Professional Medical Corporation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired AMG in September 2019, for total consideration of $<ix:nonFraction unitRef="usd" contextRef="ic4dc99a0ca2e4bfbabef2c87ec9306d0_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfOTM0NTg0ODgzOTMxOQ_f40591e4-a01f-4e7c-a050-406fbc70561f">1.6</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTY0Mw_46e8d4de-c9ff-4eb9-9b67-8dd18f217aff">0.4</ix:nonFraction> million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#8217;s consolidated net assets, investments and net income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company acquired have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE2Mg_536ed548-eb3e-4acb-be5d-0210f4c1487d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2020, was as follows (in thousands);</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:79.398%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.402%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMC0xLTEtMS0w_3044ed8c-993a-44d7-8b96-6c07fb1ce29e">238,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMS0xLTEtMS0w_876c1a3e-6d3a-48f9-bc33-c426ea906291">548</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMy0xLTEtMS0w_0c9a9bc6-eb6c-43fb-817d-19a9310ea196">239,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_46"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTY2_e986e8b3-8d3f-44a5-9e37-8edfded858b5" continuedAt="ia081cc6cfb0e4a65a3fea4ca3f88c49c" escape="true">Intangible Assets, Net</ix:nonNumeric></span></div><ix:continuation id="ia081cc6cfb0e4a65a3fea4ca3f88c49c"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTcx_e5711d41-261c-4dd8-a3ee-1eafa13b274e" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.865%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3bf488f66af84851b3c1d0a9fe304793_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0xLTEtMS0wL3RleHRyZWdpb246ZDU0ZTU3ODhkYjExNDEwNDljNzVlYjc5MWZkOGUwOWJfNA_17798ee1-eef2-4ef6-8f4c-617a45a8fb92">11</ix:nonNumeric>-<ix:nonNumeric contextRef="ic1f29d2703f749699c41aad0f5b9c7e0_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0xLTEtMS0wL3RleHRyZWdpb246ZDU0ZTU3ODhkYjExNDEwNDljNzVlYjc5MWZkOGUwOWJfNw_320edf64-be54-4a0e-a279-d31acd5c33be">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0zLTEtMS0w_2ec3b676-9feb-410b-97fd-936ece5e251a">143,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi01LTEtMS0w_30081c29-990e-42fd-8d02-b04626713f05">70,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi03LTEtMS0w_add0cb69-0271-49f2-afc5-da7b6878bbef">73,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib036147d021e4632a938ef95e13bcfeb_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy0xLTEtMS0w_4c28c713-8433-450a-aab7-2fa6a9dee865">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy0zLTEtMS0w_305adb84-cd4d-4c15-a86f-7d5b634b885d">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy01LTEtMS0w_4c46cc3b-38ea-4f90-9d9e-3208a8d8e45e">11,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy03LTEtMS0w_b344af8e-9657-4200-b3ec-06c4195a6880">11,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i22a3823bc30347e1bc4a4696c1657ad2_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC0xLTEtMS0w_0dbe35d0-a62a-48d2-8b9c-afa2e098aa7f">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC0zLTEtMS0w_a4ff1e2e-cae1-4d7e-8348-84b4624d644b">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC01LTEtMS0w_56591dbc-48f0-4da6-9e40-7fe8209df20c">3,013</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC03LTEtMS0w_dc7361cc-129f-4e79-bf9f-315817e2e2ad">3,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8806313e53624b498a37f7e03713bd8f_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS0xLTEtMS0w_f7bdde1d-f694-4209-a0c7-e98af80ce131">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS0zLTEtMS0w_282cfd5a-1b7e-48a7-84d1-2822498e6cb3">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS01LTEtMS0w_d8d6fe1c-613b-4553-9a5d-dc71f9fc2c49">1,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS03LTEtMS0w_4a543329-621a-4305-8fed-d9d40dd405f0">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i820337c646004760a5fd30654c3dae01_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi0xLTEtMS0w_e67625d3-c0d9-4406-ba2e-d984bafa22d8">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi0zLTEtMS0w_9846d0a5-73bc-4a56-a7a0-5f6c1f8018bf">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi01LTEtMS0w_a7dff1a1-c5bd-4040-9f40-44d16d155927">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi03LTEtMS0w_56ac0aef-a455-44c8-92e8-c2caaba85003">868</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy0zLTEtMS0w_3f3461be-333d-4577-90e2-d1893cda18e9">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy01LTEtMS0w_79ed8ca0-e2b7-4886-aba0-4e649ed5be8f">85,748</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy03LTEtMS0w_98907028-034c-4a7b-a0dc-68edd1efad43">90,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.134%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57399d018d8249a39d4044e5041d9d91_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0xLTEtMS0wL3RleHRyZWdpb246ODRhZTQyMjgyNWJjNDBlYWIzNGExNWNmOTFjOTc2YjVfNA_e9802f41-9c5e-4808-8cad-ebfd5671c0ff">11</ix:nonNumeric>-<ix:nonNumeric contextRef="iec82f37386d54fcc9539d0fee4b55ef6_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0xLTEtMS0wL3RleHRyZWdpb246ODRhZTQyMjgyNWJjNDBlYWIzNGExNWNmOTFjOTc2YjVfNw_658dae86-58ac-4477-9f1f-47154a11f39a">15</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3382bb05604a72853736390f8d222c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0zLTEtMS0w_93688f00-0b27-4b28-be4e-d83ff8cb7608">143,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2b3382bb05604a72853736390f8d222c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi01LTEtMS0w_e02fbc3f-955e-4ebd-8805-b750b3567a76">60,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b3382bb05604a72853736390f8d222c_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi03LTEtMS0w_c4b9f7d9-91cd-4c74-a26a-a58f8477241f">83,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id9572fe44439456b89540528dafe8efe_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy0xLTEtMS0w_2f9f1482-6650-4f56-8158-6a6cb51ac14b">15</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy0zLTEtMS0w_e434208b-0d98-4442-ac10-d551694e2cc4">22,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy01LTEtMS0w_96720fc6-fdac-4483-8d6a-3b5f7a2ecabb">9,676</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy03LTEtMS0w_3a29238b-916e-485f-ac21-6f34c3da2e9a">13,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic8c4d20368234add91f91bbc581e9c85_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC0xLTEtMS0w_72b14be5-6cf2-4b82-a3b9-d7895749a28c">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC0zLTEtMS0w_ec8a733a-1633-401e-8f16-70f0a3dfccd7">6,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC01LTEtMS0w_9e5c6ec0-d886-4294-98a1-ebf2b5144963">2,352</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC03LTEtMS0w_4a3a1df3-a247-4823-a813-eb55c5ee65fd">4,344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i87f4db5982be4abd98dbc5f29cd0da48_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS0xLTEtMS0w_55fb93bf-4af3-4363-ba57-867f2c267283">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS0zLTEtMS0w_62f4b576-854c-4e50-9247-c864eb428d0c">2,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS01LTEtMS0w_28ad5bf9-4579-4205-811c-d0caa746e113">858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS03LTEtMS0w_728519c7-0e3d-48ac-8fac-4fd88a804bce">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f579d4160604e7babd882b0c0d2df3d_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi0xLTEtMS0w_7b6489ce-5bbb-4458-be18-06d0d490e7a6">20</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687f8eb4581848cba1db329c2d343353_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi0zLTEtMS0w_241d03f2-4afa-4fdd-8f63-e147afc0d965">1,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i687f8eb4581848cba1db329c2d343353_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi01LTEtMS0w_9361402e-c3e2-431d-bd92-122c83f6befb">105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i687f8eb4581848cba1db329c2d343353_I20191231" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi03LTEtMS0w_d2f8b6b8-d69d-4c2d-882a-7eba60735b05">906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy0zLTEtMS0w_a5342764-52b4-409a-8673-a604155612e6">176,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy01LTEtMS0w_5803faa7-4c3e-4372-b672-1a7992c4e8d4">73,517</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy03LTEtMS0w_92d6e544-a85a-46e0-927b-c1ac63526c51">103,012</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzM1_fbeb1052-3388-4ed4-83b4-010b424d9dee">4.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzQy_187f4474-17db-4881-a66b-6d9cd5cc2168">4.3</ix:nonFraction> million for the three months ended September&#160;30, 2020 and 2019, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzk4_f43636ed-c043-467a-a41d-0e03dbf7b22c">12.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNDA1_c1e372c1-50fa-48ae-bbe3-44b6117c3d91">12.1</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTc0_c2f38c3e-c5a8-4bf3-aad9-924ffc970e48" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:86.162%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.638%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfMi0xLTEtMS0w_5523a78f-5102-4389-b159-921eb66a25fc">3,798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfMy0xLTEtMS0w_790f5f17-c766-4f0f-9121-394d29d5f21c">14,524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNC0xLTEtMS0w_1290d8a0-2e9e-40f3-bb32-321f9e13a038">12,673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNS0xLTEtMS0w_b20a6f39-453e-4a22-9c54-910be3a93a00">10,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNi0xLTEtMS0w_6d23b28b-7f88-4960-9568-988fdd679fca">9,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNy0xLTEtMS0w_664b3fa9-6ed6-493d-a446-5561860eeef5">39,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfOS0xLTEtMS0w_003e9109-90b7-40b4-9789-91544de3679f">90,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:EquityMethodAndOtherEquityInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDM_afc3f0f5-06e5-461b-bacf-562811db9988" continuedAt="ia3b207130d71433fa86157022f86fe66" escape="true">Investments in Other Entities &#8212; Equity Method</ix:nonNumeric></span></div><ix:continuation id="ia3b207130d71433fa86157022f86fe66" continuedAt="i1477c06bf7334aec8d8d353d7bd0c834"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:EquityMethodInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDQ_77bffbb6-f9d7-4409-b1b7-b698904bb6a7" continuedAt="i03d100b7fdee4e76b066aa4a2f67fc39" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.274%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3150290f584e44fb942ebfa558510e67_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS0xLTEtMS0w_f6570245-6135-4606-8b17-caccfc844301">6,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS0zLTEtMS0w_4e679942-fc46-4a32-8db8-07102774bc17">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS01LTEtMS0w_50bd6290-fa5f-4ad7-a162-53d21b166aa4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS05LTEtMS0w_dc2d2b68-f6c7-4e67-9dd2-a2c4cdcc0f10">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69c46a468b494d52959804c3f5b2b176_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi0xLTEtMS0w_11a6bbda-58d2-4659-a953-cc0275a6f27f">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi0zLTEtMS0w_817b89c6-2ac7-4e30-996a-f03470b0c7a6">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi01LTEtMS0w_03ee3741-194e-4a40-95c3-f345b50778d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id96dff4b93054ab5979c1cc17ea91814_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi05LTEtMS0w_66bcab63-3b88-4281-954d-f5f07757599e">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care, Inc.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1208e04262ef4a01a35da5626d1ff666_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy0xLTEtMS0w_7679d197-1431-4b78-98eb-79f486f9d608">1,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy0zLTEtMS0w_e777cb0c-1258-4546-9921-68ab3c731c43">3,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy01LTEtMS0w_d3dec9ab-70dd-4883-8334-fc4ec7e3d7aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy03LTEtMS0w_0668fe21-89fd-4a66-b756-a45578e3d1a0">4,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37888056e3424c5f8d0dcb6ddf14c929_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy05LTEtMS0w_554244ce-3cdb-4f44-bf0a-7900eea8fda7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i753d549a8e2f4889a19f89e63e84cc3e_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC0xLTEtMS0w_b3e3f84d-abfe-4d60-a3fb-35da0d438da1">2,334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC0zLTEtMS0w_016f6307-fdfa-49a5-ac00-0d49f64f7a72">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC01LTEtMS0w_13986d74-ae7f-4c71-8a26-eeac3830b56d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c38a1a7e9ee472f947eea00738b4192_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC05LTEtMS0w_24e88f19-dea1-455c-aebd-8505b593ddf1">2,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0b72e4a3daa4a53955968c5168b7655_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS0xLTEtMS0w_c7309959-4ed1-4063-adec-3722900fc04a">16,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS0zLTEtMS0w_fd677a7b-42ae-4c2e-a804-c72442cf9541">351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS01LTEtMS0w_e7199563-dfd1-46c3-a82d-0c879ae920a5">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS05LTEtMS0w_306e627f-d25c-48c5-89c5-39c97afcae46">16,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie186328fb4c549168d42b7d9a48992e5_I20191231" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi0xLTEtMS0w_7ed7f41f-76ea-4b3b-8023-8c168a685ea1">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930" decimals="-3" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi0zLTEtMS0w_15830c5c-4c35-490c-972e-91d59a2e649c">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi01LTEtMS0w_e5df5d19-3fc7-4a2f-a52d-9d91b07ab5d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0aa118fd35d9488990668d4e47746b7c_I20200930" decimals="-3" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi05LTEtMS0w_7b982303-068a-49ba-8e14-d4d2ee524f51">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy0xLTEtMS0w_377f0e22-a0f7-4416-aa0b-c2dfe70afb64">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy0zLTEtMS0w_4b8f5d89-2f29-490f-9444-691eb809eb9c">3,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="ameh:EquityMethodInvestmentsContribution" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy01LTEtMS0w_602f7de3-a83c-49ba-9849-2c301874a937">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy03LTEtMS0w_17c8b653-dea1-4f8a-86cb-859c7e54d119">4,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy05LTEtMS0w_f6d1ac94-faa2-4fcb-9478-58a88690108a">27,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and currently operates <ix:nonFraction unitRef="medical_center" contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfStores" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjMx_7ff29780-e93e-4258-a22e-1da8c4724fa6">six</ix:nonFraction> neighborhood medical centers through its network of approximately <ix:nonFraction unitRef="provider" contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:NumberOfEmployees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzAw_c3be9b81-ce74-485f-a5f9-55ca7c3cf593">2,300</ix:nonFraction> PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#8217;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately <ix:nonFraction unitRef="patient" contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:NumberOfPatients" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjg2_534437d4-4d74-47c5-9acc-1ecdeaa60c83">290,000</ix:nonFraction> patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="iffa1353ebe6443cd972fce8728b7af34_I20121231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODgw_cb66a264-0da1-4856-9790-873998f00bc6">5.0</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="iffa1353ebe6443cd972fce8728b7af34_I20121231" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODg5_2534b094-1983-4116-8841-f4b8468c0d0b">25</ix:nonFraction>% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended September&#160;30, 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i1d6f80bd32404fe58031f292d1695804_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIxNg_39c1e644-bc19-484c-bd12-abce1ee0634a">0.5</ix:nonFraction> million. For the three months ended September&#160;30, 2019, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="icce0e75bb6d54e57a2fd9d41415f1fd0_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI5NA_39ed5e2b-c537-44a0-b90b-8580a7ac3a78">0.4</ix:nonFraction> million. For the nine months ended September&#160;30, 2020, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i36d5dfd221ad448cbcffffc8f6478d08_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTM1OA_5b4e38c4-b224-464b-ae34-1bb5e34c7fce">28,000</ix:nonFraction> in the accompanying consolidated statements of income. For the nine months ended September&#160;30, 2019, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i77f38d9db9c24fb6b7dcd2c1221459f8_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTgwNzU_525fde24-646f-4a96-8399-f3bfbbe0c406">2.8</ix:nonFraction> million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $<ix:nonFraction unitRef="usd" contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTUyNQ_4b3df9e2-1660-4392-afb3-ab80dbb3a384"><ix:nonFraction unitRef="usd" contextRef="i3150290f584e44fb942ebfa558510e67_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTUyNQ_fe8bae0f-5fc7-4542-8590-f947e2f0dce7">6.4</ix:nonFraction></ix:nonFraction> million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i1477c06bf7334aec8d8d353d7bd0c834" continuedAt="i75ca4c781d67443094e71c303dd1fc24"><ix:continuation id="i03d100b7fdee4e76b066aa4a2f67fc39" continuedAt="i602944071ceb417186a18d117e265645"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the nine months ended September&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMy0xLTEtMS0w_804963e4-31b6-49c5-bc8b-82400ab54af2">3,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMy0zLTEtMS0w_3bf3ac9e-16a1-416b-b6bf-f96510b56eb2">6,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNC0xLTEtMS0w_4d3017fa-3863-475b-b518-dca2ff7ea0be">6,782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNC0zLTEtMS0w_20e42282-8c06-4b5e-9213-59fc56d161c6">5,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNS0xLTEtMS0w_b2e77421-bc0e-48e4-9174-0f15ca1cca90">880</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNS0zLTEtMS0w_e669aa10-439e-498f-aa73-9d03542199bb">3,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNi0xLTEtMS0w_83db0700-4a7b-4774-893d-c965fc277267">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNi0zLTEtMS0w_97c6b26f-f996-48fb-9d25-737f26422031">2,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNy0xLTEtMS0w_5936fca7-1e64-4f0b-bebe-3b5dbcd515ca">690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNy0zLTEtMS0w_fcbfe2f0-831f-488e-bc2c-eaa48bcbbaa6">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfOS0xLTEtMS0w_54d8e771-668d-4069-af8b-58dbec6d91fb">14,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfOS0zLTEtMS0w_b118140b-29fd-4a03-b5a8-bbc1eb9ce050">17,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTItMS0xLTEtMA_34f33fc0-a8f3-4f5b-a613-fa781f8ae1aa">19,886</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTItMy0xLTEtMA_bac4e604-071a-47c1-8ebd-e86e3d612285">23,530</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTMtMS0xLTEtMA_170886e1-cd7d-440b-b94e-ad774cf36843">5,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTMtMy0xLTEtMA_f029ed10-1219-40a8-beba-3a457a188ee9">5,602</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68d4831420054a9caa735c7f1252692b_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTUtMS0xLTEtMA_e598984b-e519-4556-a8bb-13662ba62ea3">14,396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTUtMy0xLTEtMA_f4646ae3-aca6-4989-9e34-c5c354ecdcdb">17,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.767%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfMy0xLTEtMS0w_e58ed5cd-d88e-4751-afc8-cb356102c132">138,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfMy0zLTEtMS0w_e80320fc-4183-422a-9a2b-93b2268d976b">144,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNC0xLTEtMS0w_e2ce5797-0e78-4eed-8ca4-29be778b8276">138,233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNC0zLTEtMS0w_f29bec9c-e98c-4b17-8481-4b6591f2925c">155,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930" decimals="-3" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNi0xLTEtMS0w_94cafe57-7dbf-48a3-a8fa-c3cfb5a4a592">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNi0zLTEtMS0w_d2a0eaae-f2e2-4b40-a8f5-76c7906a7f77">11,012</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $<ix:nonFraction unitRef="usd" contextRef="ia037d44d0bc04c4a828c637cca06b007_I20150731" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjI2Nw_0760449b-0715-4d15-9570-f14c7d5f9b15">1.2</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="ia037d44d0bc04c4a828c637cca06b007_I20150731" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjI3Ng_b8b97357-6d8c-46c1-b041-c2386f2ad900">40</ix:nonFraction>% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i1424495955004e3094d7f448c52f3fe8_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjUzMw_21b13bc0-e835-47fd-928e-9c1f31015564">0.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8297f0cd122a4975a2782edec1346e26_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjU0MA_344f97cc-cb08-4cc7-aefc-022c1bd1429b">0.7</ix:nonFraction> million, for the three months ended September&#160;30, 2020 and 2019, respectively, and fees of approximately $<ix:nonFraction unitRef="usd" contextRef="i288e556a87794169a4a86cc7f6c4e55d_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjYxOQ_d0fe1b5e-3e71-4f71-a78c-597a607f88c1">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i8b4bf3567dfb4dd790df1e67d2f85991_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsForFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjYyNg_7820d039-885d-4015-b4f3-626cce58a4b2">2.1</ix:nonFraction> million for the nine months ended September&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended September&#160;30, 2020, APC recognized a loss from this investment of $<ix:nonFraction unitRef="usd" contextRef="i71a29ce4a53848648939532cde255536_D20200701-20200930" decimals="-2" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjkxNg_f5bbd1cf-6f9e-4183-8acd-fd612d63df53">52,000</ix:nonFraction>. For the three months ended September 30, 2019, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="i2146c6cb823b414e94d6373622631d84_D20190701-20190930" decimals="-2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjk5NA_3408a7f1-b573-4245-aa5d-28c0cead1fb6">31,000</ix:nonFraction>. For the nine months ended September&#160;30, 2020 and 2019, APC recognized income of $<ix:nonFraction unitRef="usd" contextRef="ic1d5b7766ae84835948bd0dc5b9bad5c_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzA1OA_8448dde8-b244-47c1-ace5-8f2f9ccaaece">25,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="idef125c16c3942fab014863ef8783a70_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzA2NQ_97151684-5d13-4a54-8634-5b6e9864885e">0.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $<ix:nonFraction unitRef="usd" contextRef="ibcba94fccca04cd7b22e774e76edfde4_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzIyNQ_727ce674-a91c-4c28-a1fc-b0820699fa08"><ix:nonFraction unitRef="usd" contextRef="ieda981fa64b9451192fe68d1b530358d_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzIyNQ_b12f9b03-abf0-4df8-b455-f6bdfb5eec9a">1.4</ix:nonFraction></ix:nonFraction> million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i75ca4c781d67443094e71c303dd1fc24" continuedAt="i1a6abefea1bd4a90920acd480dfa3f93"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Universal Care, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, UCAP purchased <ix:nonFraction unitRef="shares" contextRef="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzU5Mw_330c7d1e-1a6e-4d1a-b726-63a9f111ee32">100,000</ix:nonFraction> shares of UCI class A-2 voting common stock from UCI for $<ix:nonFraction unitRef="usd" contextRef="id4c48b0482e24d54a35353fe5806ea4a_D20150801-20150831" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzY1Mw_5fe7e4a4-6ac7-4eb9-bc55-2cd39b7f682c">10.0</ix:nonFraction> million, which shares comprise <ix:nonFraction unitRef="number" contextRef="ia04e6e879820403ab84c417618cac928_I20150831" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzY3OQ_77504f2f-096a-4275-b55f-ed535e6be56b">48.9</ix:nonFraction>% of UCI&#8217;s total outstanding shares and <ix:nonFraction unitRef="number" contextRef="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831" decimals="2" name="ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzcyMA_206d493f-1d24-43cf-8b4c-72136ecb0ed1">50</ix:nonFraction>% of UCI&#8217;s voting common stock. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="i32f8ada07c6e48c3b9c63debad1daebf_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzgwNA_80361ef5-9be3-4bec-a10b-c887c1c50b50">48.9</ix:nonFraction>% ownership interest in UCI to Bright for approximately $<ix:nonFraction unitRef="usd" contextRef="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzg2MQ_c0fed042-fdc4-49b8-9081-18175921355d">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i32e68a9968f5490582115cc17368bef7_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzg5Mg_83ae85a7-f51a-45eb-a78e-129c1fcb2522">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i8cfb37c8a9b442048185c215ca7ae06b_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDA3Ng_1c8f939e-faec-48c5-bffe-c1b6cc75dbe8">36.2</ix:nonFraction> million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$<ix:nonFraction unitRef="usd" contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDU5Nw_127418a9-0763-4ecb-a0aa-36b810512c90">15.7</ix:nonFraction> million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $<ix:nonFraction unitRef="usd" contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationCash" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDkxMQ_a424a2e8-56eb-4814-a8b9-9ab75de57746">15.6</ix:nonFraction>&#160;million and preferred shares with an estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDk2Nw_25ba47a6-d837-41a7-98cc-51f223bdd9f1">6.4</ix:nonFraction>&#160;million, total estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNTAwMQ_bbc5c6e3-9fe2-4baa-90cd-7b52b01b7ce3">22.0</ix:nonFraction>&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:EquityMethodInvestmentGainOnSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDk_18dad826-2dab-4c30-8305-847468b0c885" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.016%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfMi0xLTEtMS0w_9b1a8cec-9f48-4de4-a316-b1303453c14c">52,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares in Bright Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie13a24a9ed274984976f3be0b0ae5d60_I20200430" decimals="-3" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfMy0xLTEtMS0w_269774d0-7864-41eb-a6c2-00c3a6d3b443">36,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beneficial interest in UCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNC0xLTEtMS0w_bab7cc70-3a33-4de4-b7a0-44e9bb7cf4f3">15,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Carrying value of equity method investment on date of sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i07add4ecbd2749df8612f106ba12945d_I20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNS0xLTEtMS0w_97b7d565-f9bd-4ebf-bc04-7b7235a35382">4,998</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNy0xLTEtMS0w_9eeece14-af17-4db2-919e-a23f983454e2">99,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2019 APC recorded income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="ic0e8d7a443424c718c847dcf3b912bea_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjY3MQ_0a1e42c1-dd03-49a8-87e9-66c6c1cc23c9">0.6</ix:nonFraction> million. For the nine months ended September&#160;30, 2020 and 2019 APC recorded income from this investment of approximately $<ix:nonFraction unitRef="usd" contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg3OTY_7c551a6b-2e70-4ce4-98e6-58def0b13095">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i1ea26d47ecf949429fb00155fa3a1100_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjc5OA_22fd536a-653c-47e0-be00-01422483974f">6.2</ix:nonFraction> million, respectively, in the accompanying consolidated statements of income. As a result of the sale, there was <ix:nonFraction unitRef="usd" contextRef="i37888056e3424c5f8d0dcb6ddf14c929_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:EquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjkwNQ_1fd81785-07f4-43ea-af47-6e1167932a05">no</ix:nonFraction> investment balance as of September&#160;30, 2020 as compared to an investment balance of $<ix:nonFraction unitRef="usd" contextRef="i1208e04262ef4a01a35da5626d1ff666_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjk3Ng_dabe0ccd-7070-4bee-a340-94ef68e9a8d0">1.4</ix:nonFraction> million as of December&#160;31, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i1a6abefea1bd4a90920acd480dfa3f93" continuedAt="i7f7ea908b0f94888ba72e26efe7bf9e1"><ix:continuation id="i602944071ceb417186a18d117e265645" continuedAt="i3bdc2dc761bd4b5593eaebb85c136853"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and nine months ended September 30, 2019 are as follows (in thousands):</span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.426%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMy0xLTEtMS0w_314aaa14-7095-4a4b-bd63-1cab556b10b6">33,890</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNC0xLTEtMS0w_49ebe28e-b560-4747-8bb4-0ff561179b05">63,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNS0xLTEtMS0w_aded1e54-b85a-4e97-8d36-d144b3d55491">38,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNi0xLTEtMS0w_c3712c07-89d2-41e8-a71e-68b4ae841ae8">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNy0xLTEtMS0w_439b9458-e638-487d-ba14-4732ac30261f">4,021</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfOS0xLTEtMS0w_1c0fba5b-005d-4442-bb67-abba65d5b7d8">140,916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTItMS0xLTEtMA_33e772be-63ea-4553-99f7-2ed35f010670">128,330</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTMtMS0xLTEtMA_67d9f0c4-ff2c-4031-b831-731768db5c57">33,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTQtMS0xLTEtMA_50de87fe-780c-406b-ab20-9984012c6dd7">20,547</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTYtMS0xLTEtMA_c9c56e0c-c8b0-4993-860b-95596bfc1e19">140,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Four Months Ended April 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfMy0xLTEtMS0w_31b3e545-65a3-4c16-938c-42cbdc7bb3f3">195,308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfMy0zLTEtMS0w_2ec100d5-dc9d-4232-a50a-d587d9485383">372,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNC0xLTEtMS0w_50a6a31c-50d1-47a7-b238-c20df3259395">189,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNC0zLTEtMS0w_6ea5afb1-744b-4524-b661-f4aff7ad6db2">370,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNi0xLTEtMS0w_4fbee0c4-c99e-46e9-8609-c56080e5d34b">6,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNi0zLTEtMS0w_6ff117bd-e925-45a3-886d-ecce57d42adf">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNy0xLTEtMS0w_e052aa3f-4ef9-4442-b3d7-09fed8c2fdbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNy0zLTEtMS0w_ff57d08a-58fe-4773-9834-f95f6dac36f8">11,010</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfOS0xLTEtMS0w_b0b3298b-0cef-4eb0-a488-8232515a5411">6,280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfOS0zLTEtMS0w_8b001829-d57f-4e29-abff-0ee542e858a4">12,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a <ix:nonFraction unitRef="number" contextRef="i45be72031ca0447e97e01053b8c321fb_I20160531" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzM2NQ_afaa6d7d-a787-4de2-b5a1-22d05c722d4e">40</ix:nonFraction>% ownership interest in DMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended September&#160;30, 2020 and 2019, APC recognized income from this investment of $<ix:nonFraction unitRef="usd" contextRef="ifba98224dfe743d886659a878903bc31_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzY1OQ_19bc700c-f5fa-48af-85d3-a8151a493fce">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9dc91266bda94e86a5ec7f40496f5a5c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzY2Ng_993bbbc8-ccc2-44a7-92c4-f854fca78cd4">0.3</ix:nonFraction> million, respectively, in the consolidated statements of income. For the nine months ended  September&#160;30, 2020 and 2019, APC recognized income from investment of $<ix:nonFraction unitRef="usd" contextRef="if0cb473eab6e497599fded63c9f221e4_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzgxMw_cb13a293-1561-411b-bf78-98827661c94f">19,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzgyMA_138f6195-556a-40b1-98de-2a80f54c5163">0.7</ix:nonFraction> million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $<ix:nonFraction unitRef="usd" contextRef="i3c38a1a7e9ee472f947eea00738b4192_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzk2OA_3d2e063a-f7bb-453b-94d3-41901e10e652">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i753d549a8e2f4889a19f89e63e84cc3e_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzk3NQ_fa763abc-c144-46c5-bb4d-3cc291237ec6">2.3</ix:nonFraction> million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i7f7ea908b0f94888ba72e26efe7bf9e1" continuedAt="i9a6243cf230c4904837b63924f7130c6"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns <ix:nonFraction unitRef="number" contextRef="i1d560d1902504cca8098eacb878eef29_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM1NA_c345720f-981e-48d1-8515-f7da13e8c15a">50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i6184b34ee8134be5b8c421145d39c934_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM1OA_1d24c24d-c54b-4081-bab8-bb5e48c8d0e3">25</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i46a9a7002274458a996a2f3572f2742e_I20180630" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM2NQ_fcde08f2-1e1f-45a4-8a4a-3daa492c9841">25</ix:nonFraction>%, respectively, of member units based on initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="i1d560d1902504cca8098eacb878eef29_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ0MQ_f148511b-7b7d-44e0-b744-10f2692e1be1">16.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6184b34ee8134be5b8c421145d39c934_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ0NQ_70bbd5d3-a8f6-4823-9da9-81a0f1048762">8.3</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i46a9a7002274458a996a2f3572f2742e_I20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ1Mw_5ca1222d-d469-4d18-ba63-bccbe62934a1">8.3</ix:nonFraction> million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $<ix:nonFraction unitRef="usd" contextRef="i3015e3b3bfc74713a36da771c5184b53_D20180601-20180630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireRealEstate" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODcwOA_76a4a4c3-b95e-419a-ad68-2eada5d39a19">33.3</ix:nonFraction> million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s <ix:nonFraction unitRef="number" contextRef="i51f10e9761bc4228abb6d529c3349de6_I20190423" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODgxMg_71f707c6-f9cf-4777-8053-150f59b64011">25</ix:nonFraction>% membership interest in 531 W. College, LLC for approximately $<ix:nonFraction unitRef="usd" contextRef="i51f10e9761bc4228abb6d529c3349de6_I20190423" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODg3Ng_12a0daf7-252f-41f8-bab4-7f8beaf7b60c">8.3</ix:nonFraction> million. Subsequently, APC has a <ix:nonFraction unitRef="number" contextRef="ic465b3707abf436089f9fc1143560257_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODkwNA_44f01bf2-c006-4bf6-a5b4-8b845caa8e0c">50</ix:nonFraction>% ownership in 531 W. College LLC with a total investment balance of approximately $<ix:nonFraction unitRef="usd" contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODk4OA_25bb50b3-4951-42d3-9c23-5050add32092">16.8</ix:nonFraction> million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2020 and 2019, APC recognized losses of $<ix:nonFraction unitRef="usd" contextRef="iabc665a0dbda4c87aeba1b7b7f31c314_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTI3Mg_913ea568-0d60-4d78-8334-c4ab215e127c"><ix:nonFraction unitRef="usd" contextRef="i48000cd06bc14fb78d5ac9a135a4817c_D20200701-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTI3Mg_cdecb211-27dc-435c-a8a8-84a7011f7f2f">0.1</ix:nonFraction></ix:nonFraction> million, respectively. For the nine months ended September&#160;30, 2020 and 2019, APC recorded losses of $<ix:nonFraction unitRef="usd" contextRef="i07be705677f8498588d2853c3c7bf749_D20200101-20200930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTM1NQ_1c0b2f34-b711-4a88-b8f1-716ef140509d">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTY0OTI2NzQ1NDcwMQ_138f6195-556a-40b1-98de-2a80f54c5163">0.7</ix:nonFraction> million in the accompanying consolidated statements of income, respectively. During the period ended September&#160;30, 2020, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquityMethodInvestmentsContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTQ4Ng_872975ab-c5d7-4041-9a06-7208d4ca953e">0.5</ix:nonFraction> million to 531 W. College LLC as part of its <ix:nonFraction unitRef="number" contextRef="ic465b3707abf436089f9fc1143560257_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTUyNg_6c9f05b9-e0a9-4a5f-9100-3ef42e702d40">50</ix:nonFraction>% interest and had investment balances of $<ix:nonFraction unitRef="usd" contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTU2OQ_25bb50b3-4951-42d3-9c23-5050add32092">16.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ia0b72e4a3daa4a53955968c5168b7655_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTU3Ng_05c05d02-dff7-4ee0-88f7-aa49cf98f8de">16.7</ix:nonFraction> million, respectively, at September&#160;30, 2020 and December&#160;31, 2019. </span></div><ix:continuation id="i3bdc2dc761bd4b5593eaebb85c136853" continuedAt="i1713614a1b034505b072d1d391a6530d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the nine months ended September&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMy0xLTEtMS0w_a3c8b7c4-e35a-4479-99b6-d3ef083c42dc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMy0zLTEtMS0w_e6d9d732-7c54-41d7-956f-634b9fe869a2">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNC0xLTEtMS0w_c36d30ee-2d0f-4aa1-96d0-50d14b0a2996">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNC0zLTEtMS0w_7f1fb475-4c34-456f-8fc8-c92ae3737db1">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNS0xLTEtMS0w_dcbca71a-5e91-40c4-b5fa-1910dfbee2e7">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" name="us-gaap:OtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNS0zLTEtMS0w_1660099f-916f-41f1-a295-da86a8eefcff">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNi0xLTEtMS0w_71dc5a8f-bcc0-467a-99b5-396f70a01c2b">33,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNi0zLTEtMS0w_75f8cdcd-4fec-4848-a5ec-d362c8e06391">33,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfOC0xLTEtMS0w_d9d022f3-3e7d-463c-9f2c-de9eb1594cd5">33,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfOC0zLTEtMS0w_ab2b73f4-724b-436b-8350-ac1c34c6bd63">33,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTItMS0xLTEtMA_87aa7262-a93e-4fbc-a2e5-1cc1e76cde6d">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTItMy0xLTEtMA_96e6bd2e-76b3-4d9a-83ea-f68cc3dac035">1,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTMtMS0xLTEtMA_7abb42ac-303c-42d6-92be-33b2110e73a1">32,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTMtMy0xLTEtMA_a28c05dd-b080-4f71-b382-37673c666301">32,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTUtMS0xLTEtMA_f1f64d8b-910b-45da-a5ba-11ddceb4521f">33,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTUtMy0xLTEtMA_c7131392-bc52-4a40-aced-777d676d9cff">33,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i9a6243cf230c4904837b63924f7130c6"><ix:continuation id="i1713614a1b034505b072d1d391a6530d"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMi0xLTEtMS0w_56027b96-0234-4059-a663-e3206a15b0ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMi0zLTEtMS0w_280f8dba-385a-4cc6-a45b-6c9723249f8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMy0xLTEtMS0w_efdb1b42-578c-4605-8ad7-2b371f0ff841">828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMy0zLTEtMS0w_22071fbf-101c-46c9-b230-08c4ad2e6e24">780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNC0xLTEtMS0w_36de5201-c02e-4a72-890e-8b9512b9e664">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNC0zLTEtMS0w_28e456c8-44f9-4e73-8919-4929160a0d19">780</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNi0xLTEtMS0w_14d7519e-0d59-494c-8cd9-e66483df2635">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNi0zLTEtMS0w_7a0328f3-7fc5-4f80-a526-fa0160baee87">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0xLTEtMS00NTA5_c3d286ef-d97c-4369-b00a-00331b0390e5">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0zLTEtMS00NTA5_87a79041-95e4-404d-bae4-f66314442485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0xLTEtMS0w_10715401-e1eb-4287-9dca-f1bc0b71bc21">799</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0zLTEtMS0w_4cda71a2-bbea-41ea-814e-3ab62ea5ec58">353</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MWN LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#8220;Pacific6&#8221;), and Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;) entered into an operating agreement to govern MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own <ix:nonFraction unitRef="number" contextRef="i0e75f05d163f47508aaed53617f817da_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_2dc6e907-0ea0-429f-8192-754c38680abd"><ix:nonFraction unitRef="number" contextRef="i808a481f8e67463fa27b080f11806844_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_78c34b79-aaa3-4316-bce0-d39e011b216a"><ix:nonFraction unitRef="number" contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_c9affef4-5d5a-4161-87d3-184f421db8ae">33.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the membership shares based on each member&#8217;s initial capital contributions of $<ix:nonFraction unitRef="usd" contextRef="ic4e7c20c772c4b85a99de03a80063147_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_4b22b318-b35e-4684-8687-1487c1b81f50"><ix:nonFraction unitRef="usd" contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_6a88de49-35c0-4b5b-b00d-cbedb3f375cf"><ix:nonFraction unitRef="usd" contextRef="i9e993cf753ad4a0694bf3466d7220468_I20181231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:MembersCapital" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_86490fa8-0a87-4e32-b66d-51842c8b534d">3,000</ix:nonFraction></ix:nonFraction></ix:nonFraction> and working capital contributions of $<ix:nonFraction unitRef="usd" contextRef="i9e993cf753ad4a0694bf3466d7220468_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_4d7ed761-e7d1-4ae1-8fc5-f15f4313dd0e"><ix:nonFraction unitRef="usd" contextRef="ic4e7c20c772c4b85a99de03a80063147_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_5dd7daa1-47ce-416d-a75d-5e1a29a3efa0"><ix:nonFraction unitRef="usd" contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231" decimals="INF" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_a37c2182-a6e3-4ef3-b69d-368bd652a76b">30,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>. NMM invested an additional $<ix:nonFraction unitRef="usd" contextRef="i3b8908c9b1334fe395a61d2ddc0668cf_I20190831" decimals="-5" format="ixt:numdotdecimal" name="ameh:WorkingCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzNjY_ac288879-a2e0-44be-8b7a-f283ba19baf1">0.3</ix:nonFraction> million for working capital purposes in August 2019. For the three and nine months ended September&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $<ix:nonFraction unitRef="usd" contextRef="ic960b26a1e3f40a1b24e18c623b99240_D20200701-20200930" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA1MTI_06ed6684-f0fd-476f-bde6-33fab9d051a6">2,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i4454b081d0384506ab87a132eae22d31_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA1MTk_164c49ea-d287-40ba-8ce7-bd7d7a8f07cf">10,000</ix:nonFraction>, respectively. For the three and nine months ended  September&#160;30, 2019, NMM recorded loss from its investment in MWN LLC of $<ix:nonFraction unitRef="usd" contextRef="ia915b2c31332442a8d6f15aef9889924_D20190701-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg1MjQ_0e983019-c4f1-411c-a66d-9ffd88afc17b"><ix:nonFraction unitRef="usd" contextRef="i65347818febf49c7b80dc85ef7ae043f_D20190101-20190930" decimals="-5" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg1MjQ_4319e650-34c7-457d-9f42-ce459d21277a">0.1</ix:nonFraction></ix:nonFraction> million, respectively, in the accompanying consolidated statements of income and had an investment balance of $<ix:nonFraction unitRef="usd" contextRef="i6f8670c333f043daaa155fb5a0ac3eab_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA2MjQ_03b6f0b3-04e7-4cb6-a4d2-16e2d60db14e"><ix:nonFraction unitRef="usd" contextRef="i2f60ef2535c14c7bb4a2c7f0b27b0a8c_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA2MjQ_d52aab52-2e3b-498b-a57f-897a255dea1f">0.2</ix:nonFraction></ix:nonFraction> million as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased <ix:nonFraction unitRef="shares" contextRef="i68c969400a494d9787143ded770b0181_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA3NjE_96bd5aba-5a27-477c-92bb-bfdd32480553">270,000</ix:nonFraction> membership interests of MediPortal LLC, a New York limited liability company, for $<ix:nonFraction unitRef="usd" contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA4NDY_6db5964f-ac32-420b-b284-b3a838d39a2e">0.4</ix:nonFraction> million or $<ix:nonFraction unitRef="usdPerShare" contextRef="i68c969400a494d9787143ded770b0181_I20180531" decimals="INF" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA4NTI_a7b74361-2ce2-4e4c-a611-ad738c456cc0">1.50</ix:nonFraction> per membership interest, which represented an approximately <ix:nonFraction unitRef="number" contextRef="i68c969400a494d9787143ded770b0181_I20180531" decimals="3" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA5MTU_100b6ed4-f695-41d6-9a29-428027d4b9a9">2.8</ix:nonFraction>% ownership interest. In connection with the initial purchase, APC received a <ix:nonNumeric contextRef="i68c969400a494d9787143ded770b0181_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2Mzg_042d0a86-31b7-4cc8-bbc1-68618ee535e1">five-year</ix:nonNumeric> warrant to purchase an additional <ix:nonFraction unitRef="shares" contextRef="i68c969400a494d9787143ded770b0181_I20180531" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTEwMzY_2a85954d-de32-4879-9507-580e2cb7dd6c">270,000</ix:nonFraction> membership interests. Additionally, APC received a <ix:nonNumeric contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NTE_85a45e68-d0a0-4f7f-9b30-59716938c478">five-year</ix:nonNumeric> option to purchase an additional <ix:nonFraction unitRef="shares" contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTExMzE_9e3ad4f6-9860-4d3e-991c-548c8f48aa58">380,000</ix:nonFraction> membership interests and a <ix:nonNumeric contextRef="i68c969400a494d9787143ded770b0181_I20180531" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDc_17de6d16-11eb-40dd-b9f5-1a2da8066b6a">five-year</ix:nonNumeric> warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i68c969400a494d9787143ded770b0181_I20180531" decimals="INF" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTExODk_cfd5cca3-d421-4bd9-88ba-e4b0299ec8ae">480,000</ix:nonFraction> membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of September&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase <ix:nonFraction unitRef="number" contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE4MDY_c0ea099f-6738-48b4-b124-0da1e689dd0c">50</ix:nonFraction>% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed <ix:nonNumeric contextRef="i53fb3b2d3c10434fb7ad9df99de6697b_D20190701-20190701" format="ixt-sec:durwordsen" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5MDA_d51ec862-0190-4fde-992f-6b174f19711f">five years</ix:nonNumeric>. As a result of this transaction NMM invested $<ix:nonFraction unitRef="usd" contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5NDk_d5496b7f-9509-400d-a446-4a2b262a5052">0.5</ix:nonFraction> million for a <ix:nonFraction unitRef="number" contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701" decimals="2" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5NTg_f4956711-66c6-4288-8497-5b41d2c1603f">10</ix:nonFraction>% interest. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="i79b8b4b7485e41828f619cb79928959f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIwMDU_dfbc6581-ffd1-4e1c-9cba-cb4ea720eb93">0.5</ix:nonFraction> million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of September&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bright Health, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, UCAP completed the sale of its <ix:nonFraction unitRef="number" contextRef="i32f8ada07c6e48c3b9c63debad1daebf_I20200430" decimals="3" name="ameh:EquityMethodInvestmentOwnershipPercentageDisposed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIxODc_80361ef5-9be3-4bec-a10b-c887c1c50b50">48.9</ix:nonFraction>% ownership interest in UCI to Bright for approximately $<ix:nonFraction unitRef="usd" contextRef="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIyNDQ_c0fed042-fdc4-49b8-9081-18175921355d">69.2</ix:nonFraction> million in cash proceeds (including $<ix:nonFraction unitRef="usd" contextRef="i32e68a9968f5490582115cc17368bef7_D20200430-20200430" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIyNzU_83ae85a7-f51a-45eb-a78e-129c1fcb2522">16.5</ix:nonFraction> million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value on the transaction date of approximately $<ix:nonFraction unitRef="usd" contextRef="i8cfb37c8a9b442048185c215ca7ae06b_I20200430" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI0NTk_1c8f939e-faec-48c5-bffe-c1b6cc75dbe8">36.2</ix:nonFraction> million. The related investment balance of $<ix:nonFraction unitRef="usd" contextRef="idfe7f2d11dba4bf8bfa9cd6b837b86d1_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzE0NjgyNTU5NDg0NQ_a4e13840-b369-4b68-abf0-09bf9cbff053">36.2</ix:nonFraction>&#160;million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheet as of September&#160;30, 2020.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_52"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="ameh:LoanReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjYxMg_13600fa0-ee40-41eb-8564-620f899b6823" continuedAt="i4b0a1572f143411284492e448ebf7598" escape="true">Loan Receivable and Loan Receivable &#8211; Related Parties</ix:nonNumeric></span></div><ix:continuation id="i4b0a1572f143411284492e448ebf7598"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr. Albert Arteaga</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#8220;Dr. Arteaga&#8221;), Chief Executive Officer of LMA, to loan $<ix:nonFraction unitRef="usd" contextRef="i0faa96915dac498dbda55cbf5243918f_I20190628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjYx_1e0641a7-2431-4ecf-89c1-350e38327bd0">6.4</ix:nonFraction> million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus <ix:nonFraction unitRef="number" contextRef="i7caa591d27bf48eab7b5c969cac33e61_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMzU4_bb025d35-e341-493f-bb2a-03c0f7d5d2b2">1</ix:nonFraction>% (<ix:nonFraction unitRef="number" contextRef="i1c008ff76ac0426486f735cd9512a068_I20200930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMzYy_3ba377d7-41e1-4239-9fae-11d5805a3714">4.25</ix:nonFraction>% as of September&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal <ix:nonFraction unitRef="number" contextRef="i0faa96915dac498dbda55cbf5243918f_I20190628" decimals="4" name="ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfOTAy_2cade16a-2b0e-4670-b66e-d21170772a04">21.25</ix:nonFraction>% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#8217;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#8217;s designee will collectively own <ix:nonFraction unitRef="number" contextRef="i123c7dd6529340df982a5fa9dfc0aa21_I20190628" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTA5OQ_4ba745c3-8325-4d47-b124-c7bbfb8636d6">46.25</ix:nonFraction>% of the equity of LMA with the remaining <ix:nonFraction unitRef="number" contextRef="i7fec8536262a49a0b8b6bcb905d9ed73_I20190628" decimals="4" name="ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTE0Mg_d02e7f8a-c5af-4898-b679-1eb9b7f417fc">53.75</ix:nonFraction>% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $<ix:nonFraction unitRef="usd" contextRef="i50e6b5986d0843a5a0390ed42f10c1de_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTI5NQ_5f77f11a-b07a-43d2-ae08-12da78361307">6.4</ix:nonFraction> million as of September&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $<ix:nonFraction unitRef="usd" contextRef="i2cab7f77600442608addb240a33cdb9f_I20200228" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTM5Mg_9f4c2e4c-c400-42ac-b2c2-2bec60dba902">2.2</ix:nonFraction> million in the ordinary course of business. As of September&#160;30, 2020 the advance was fully repaid.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Universal Care, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, APC advanced $<ix:nonFraction unitRef="usd" contextRef="i8dac94597ff94666b83c9ae361507075_I20151231" decimals="-5" format="ixt:numdotdecimal" name="ameh:AdvancedForWorkingCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjE2Nw_a6395890-c024-4f92-bd8a-efccf49054ef">5.0</ix:nonFraction> million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $<ix:nonFraction unitRef="usd" contextRef="ic615bf6bdf9a47aca957ca50dac11311_I20180629" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMxMg_f893f9d3-8d5d-4f9c-a0f1-4277a4dc2e82">2.5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i57568f01843b4e1c8af7407d9814d9a4_I20181128" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMxNg_25f91ba3-7887-4191-b8a1-d18f07c0bb9e">5.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8aca1d8a93354c9e93262133b582edf4_I20191213" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityAdditionalAdvances" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMyMw_9c3db626-49dc-4478-a5f5-9103121e755a">4.0</ix:nonFraction> million, respectively. The loans accrue interest at the prime rate, plus <ix:nonFraction unitRef="number" contextRef="ia0f328dbb075463e9e1e6093dfb7ff74_D20200101-20200331" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjM5MQ_32c596c4-67e1-4f5e-9da9-b6eb24a0ce10">1.00</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="i7be81f0e5b5b4b50b9ea5036ae2b8e02_I20200331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjM5OA_848cd029-497f-4ea6-aa67-95b8d9cea47f">4.25</ix:nonFraction>%, as of March 31, 2020, and <ix:nonFraction unitRef="number" contextRef="iba23adf288b04c1f910cffd3bc1a3489_I20191231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjQyOA_a512bc4c-1b88-4c23-bdaa-9203b58980b1">5.75</ix:nonFraction>% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its <ix:nonFraction unitRef="number" contextRef="i81d7b1f95e2749528c65d9be013d2d5e_I20200430" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjU3Mg_b28a590b-affe-4086-a113-bd5775d9e4da">48.9</ix:nonFraction>% ownership interest in UCI to Bright.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_55"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RleHRyZWdpb246MGIzMGRjNjg3Mjc4NDRkNjg3MTgwYWE1MzQzMjJjNDFfMTQ0_0c126dc7-d6ab-4267-af58-a848ac54b53e" continuedAt="ib063678574d34815b45c922c6fe5e114" escape="true">Accounts Payable and Accrued Expenses</ix:nonNumeric></span></div><ix:continuation id="ib063678574d34815b45c922c6fe5e114"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RleHRyZWdpb246MGIzMGRjNjg3Mjc4NDRkNjg3MTgwYWE1MzQzMjJjNDFfMTQ3_4ced53de-54b9-4b40-afbb-c33b4106f48d" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMS0xLTEtMS0w_2aa12a3b-58c6-4876-8978-6ac27bba26ae">9,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMS0zLTEtMS0w_1b8084eb-c559-4464-bbc7-05dd446ae734">6,914</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMi0xLTEtMS0w_e66e4465-ef6d-4973-9409-ec0ec8cea1f4">2,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SpecialtyCapitationPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMi0zLTEtMS0w_beb59a84-f3dd-426c-82c3-63e3604b28f8">2,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMy0xLTEtMS0w_c4a1b27c-a218-4563-9eaa-70baabd264b7">3,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:SubcontractorIPAPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMy0zLTEtMS0w_c95d815b-03e9-4f36-bf63-143edb996a93">3,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNC0xLTEtMS0w_a577d6a7-68fc-4330-85b4-d028c5db4f37">2,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNC0zLTEtMS0w_5211a406-7c31-4ba7-be91-d1ed3a2bfd69">1,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNS0xLTEtMS0w_1323c99d-751d-44ac-af85-a7354405aa92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" name="us-gaap:DueToRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNS0zLTEtMS0w_94f53d62-d772-4c97-9a6a-05342ff4e994">225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNi0xLTEtMS0w_ec9152f0-7e47-4639-94dd-237157ce743a">10,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNi0zLTEtMS0w_33d3a935-b5de-4232-89d7-6c825586c297">3,238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNy0xLTEtMS0w_d8ec083b-128d-4c39-85b6-7a2d08c33746">12,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNy0zLTEtMS0w_95d36bc4-1abe-413e-bb71-3c87204830d2">8,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfOS0xLTEtMS0w_bfcd4d0c-ec57-445f-8b4b-0ef694c100ca">40,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfOS0zLTEtMS0w_d814eb08-1b86-4c9c-9e90-18cc4f9c24b5">27,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_58"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RleHRyZWdpb246M2M5MjcyODQyM2Y0NGQ2NmI4YzE5ZDBmODlhMzM5ZDlfMTEy_8f3a0143-eed6-497e-a508-60366ec6fa1e" continuedAt="ic27c6531a808492b9310fca6d309040b" escape="true">Medical Liabilities</ix:nonNumeric></span></div><ix:continuation id="ic27c6531a808492b9310fca6d309040b"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RleHRyZWdpb246M2M5MjcyODQyM2Y0NGQ2NmI4YzE5ZDBmODlhMzM5ZDlfMTA4_23fd35ed-9903-4d2b-9e07-8033a99ccd76" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMS0xLTEtMS0w_20e9d90e-2694-4fbc-9bea-c882fc40646a">58,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e0bcf361384859a17578fb87321a54_I20181231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMS0zLTEtMS0w_68fc300e-5e0a-4ab9-9025-a7b7bf58c8ed">33,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMy0xLTEtMS0w_9243b087-04ab-4a89-98d1-1abac5aad030">229,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMy0zLTEtMS0w_869e2671-f47a-493f-8ccf-11c0b79b0150">175,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNC0xLTEtMS0w_3ed0db27-486f-48c3-aa46-36d215812792">1,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNC0zLTEtMS0w_88344481-bcb9-4b3d-975f-281d8aa297aa">2,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNS0xLTEtMS0w_3873d166-dca8-4cae-9a86-fa56572230d9">230,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNS0zLTEtMS0w_8e13cc19-e176-405f-9243-55cbf9bcc87b">178,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNy0xLTEtMS0w_ddd5f497-b60e-4cce-9924-6e0410a348c1">178,796</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNy0zLTEtMS0w_7c4a96f8-93ad-416a-8841-00afc682f106">135,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOC0xLTEtMS0w_f14afc36-038c-4279-a5bf-b01746955de4">53,231</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOC0zLTEtMS0w_94de9c62-d5ba-4394-a623-9e2d79452a7d">49,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOS0xLTEtMS0w_f36bd648-7a73-4e86-8a03-aee2e978fbed">232,027</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOS0zLTEtMS0w_11b686f4-27d5-47da-8359-185c91e64c5a">184,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTAtMS0xLTEtMA_2e62178a-abc9-4691-b046-7f1546c04643">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTAtMy0xLTEtMA_e07efb77-6d7c-4ae7-8bc7-1c275381b0a7">26,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTEtMS0xLTEtMA_d6118b00-f823-457d-8019-cdb83dd5a1c0">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTEtMy0xLTEtMA_b662e799-a0ff-4afb-b8cd-e750b22ad00e">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTMtMS0xLTEtMA_9275aa35-a0a8-4cd8-8f82-1345b379b6b8">57,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTMtMy0xLTEtMA_a5392ff0-0b3e-4f30-a063-2034fc767ab9">53,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_61"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyOTk_908afaec-bb44-4593-9d42-1c53808db2fe" continuedAt="i84344449346c49ab95f78d8c6d06c8c4" escape="true">Credit Facility, Bank Loan and Lines of Credit</ix:nonNumeric></span></div><ix:continuation id="i84344449346c49ab95f78d8c6d06c8c4" continuedAt="iabcc67b3180c49ad94c516a2a684dd23"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMzM_5787cab5-8627-403d-aba1-807f450f49ac" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b9f8e50331b440ca1d55608976e9518_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfMi0xLTEtMS0w_650a1a54-d7b4-4c01-9472-d2bfe6af2036">180,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f7f861c210b485fa4973087f3191b99_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfMy0xLTEtMS0w_2d0452e2-10e0-4c9e-950a-039d59a79c02">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNC0xLTEtMS0w_dbdf1480-5b98-4bab-9006-54fc8758b8d3">240,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LinesOfCreditCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNi0xLTEtMS0w_347d3bfb-3272-492c-b36e-e77437c53616">9,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNy0xLTEtMS0w_de60e88c-7d4f-45ee-8aac-c81b8b00b1e8">4,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfOS0xLTEtMS0w_fe24f708-6c3e-4fb9-850a-af69c327b1e7">226,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMjc_e82f5e37-e1c3-40e9-a7c5-0ea4e32fc286" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s credit facility for the years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMS0xLTEtMS0w_b331b61a-12b5-43d7-8146-20f36212fc5f">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMi0xLTEtMS0w_99ee3947-3170-4ed0-9141-374cc1039b41">10,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMy0xLTEtMS0w_3c56ab5d-0989-4922-b1d1-e6f5fdc4b3e0">14,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNC0xLTEtMS0w_061a5644-945c-406b-9cc3-aa5c0e549a1c">15,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNS0xLTEtMS0w_84107bdb-54aa-4234-8ae2-9337dc404105">197,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNy0xLTEtMS0w_5270f1f2-3939-45c2-bb91-302a6ce16b14">240,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="iabcc67b3180c49ad94c516a2a684dd23" continuedAt="i56f8e970d9254f7d96b98fcc137197e3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a <ix:nonNumeric contextRef="if381e56ee15348f3bc78b5ba5afe4f5b_D20190901-20190930" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyMzY_6488c8e0-d426-442f-9d5f-dc8ae9561483">five-year</ix:nonNumeric> revolving credit facility to the Company of $<ix:nonFraction unitRef="usd" contextRef="i7d10f2758e644e3db72c221a182e8ee8_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE4Ng_cff52bf6-393e-4d4d-86eb-d37d9ec5d91e">100.0</ix:nonFraction> million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $<ix:nonFraction unitRef="usd" contextRef="i9a3eb4ddb0c34022a34f50d0b362b1a2_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI2Mw_6df56e9c-9f37-4e1e-890b-e6ac3ea5f11e">25.0</ix:nonFraction> million. The Credit Agreement also provides for a term loan of $<ix:nonFraction unitRef="usd" contextRef="i7bc9c0c0a51d4b37a867a13440d3cdac_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyMQ_f3dc43ea-f23b-4ca1-ba0f-513a3857b277">190.0</ix:nonFraction> million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $<ix:nonFraction unitRef="usd" contextRef="i6464448a2a2a4ec5b5a785f7fa5b707c_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU2NQ_84ccac79-08a6-4e33-89f4-34555a316a53">2.4</ix:nonFraction> million, for the following eight fiscal quarters thereafter is $<ix:nonFraction unitRef="usd" contextRef="i89bb37720e6c4641bfa4079cb6d0a971_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyMw_5ad50658-a5ac-46e6-b283-7db445cd2e2a">3.6</ix:nonFraction> million and for the following three fiscal quarters thereafter is $<ix:nonFraction unitRef="usd" contextRef="i1840189675724de797d0b54ed266c606_D20190901-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTY4NA_52731b82-03ea-4906-a3d6-1a135c3ea8a6">4.8</ix:nonFraction> million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the term loan and up to $<ix:nonFraction unitRef="usd" contextRef="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTgwNw_36f70011-ceff-4efd-bdbb-a9d9c5eb84d0">60.0</ix:nonFraction> million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual facility fee of between <ix:nonFraction unitRef="number" contextRef="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMjQ5OQ_350c8925-c3b8-4a1a-9ea1-67d5f574aee5">0.20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMjUwNQ_a7d1e1f2-ade3-4e43-a36a-16a301695134">0.35</ix:nonFraction>% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc. (now known as Truist Securities Inc.), the lead arranger of the Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between <ix:nonFraction unitRef="number" contextRef="iea5693feca944ef0a07785d7ed338d09_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzIwOA_57ffd025-5aef-484b-8bc8-aaef0959afdf">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i97da86c1492849118b5eaf8e60955a49_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzIxNQ_8e73e6f2-af3e-4ed2-ab8b-2ca0a8bd3162">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between <ix:nonFraction unitRef="number" contextRef="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzMzNQ_0f38a0b4-aa9f-4d7f-ae9e-dedb27eed987">1.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzM0Mg_fb5528f8-397b-4ef3-823a-f3e5fb2471b9">2.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of September&#160;30, 2020, the interest rate on Term Loan A for the 2020 commitment and future commitments was <ix:nonFraction unitRef="number" contextRef="i706817fc9f1e4c5591f6224aa27f8969_D20200101-20200930" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNzE0NjgyNTU5NzMwNg_3bbb7a68-94eb-48bc-a900-e5f00ed45f17">2.72</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0b9f8e50331b440ca1d55608976e9518_I20200930" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzQ4NQ_664c658f-5158-4a41-8901-9109da24ddd6">2.77</ix:nonFraction>%, respectively. As of September&#160;30, 2020, the interest rate on the Revolver Loan was <ix:nonFraction unitRef="number" contextRef="i5f7f861c210b485fa4973087f3191b99_I20200930" decimals="4" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzQ5Mg_a05ca9d4-fdfc-4ef5-a180-723fc89f040d">2.77</ix:nonFraction>%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between <ix:nonFraction unitRef="number" contextRef="i7b193ff3b0534bf4b1e4ee91abf86721_D20200101-20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzY3NA_0fca502d-13f7-4b43-836f-50555f9492d4">2.00</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7903d4186900495da7128f6613b226b5_D20200101-20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzY4MQ_dda4b888-00cc-427a-9989-2b0af49f6489">3.00</ix:nonFraction>%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company to comply with <ix:nonFraction unitRef="financial_ratio" contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:DebtInstrumentNumberOfKeyFinancialRatios" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTYwMw_2bfbc33f-461e-46f6-98da-064ae4cb77d0">two</ix:nonFraction> key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than <ix:nonFraction unitRef="number" contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTc1Mw_9b8b4bc9-31ce-446d-a87f-5c8e01b0345e">3.75</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by <ix:nonFraction unitRef="number" contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTg2MA_5c82b83a-5a3d-4659-9b12-637e9a1d12f4">0.25</ix:nonFraction> each year, until it is reduced to <ix:nonFraction unitRef="number" contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930" decimals="INF" name="ameh:DebtInstrumentCovenantLeverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTg5Nw_72bdcabe-6a5c-44a2-96e7-970d07d51f7f">3.00</ix:nonFraction> to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i56f8e970d9254f7d96b98fcc137197e3" continuedAt="i8dff6e28d4d44db2a2000665086c7c4e"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not less than <ix:nonFraction unitRef="number" contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930" decimals="INF" name="ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNjAzOQ_1aedd370-4daf-4b54-9ad7-25600949b542">3.25</ix:nonFraction> to 1.00 as of the last day of each fiscal quarter. As of September&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $<ix:nonFraction unitRef="usd" contextRef="i58a3a78950614f498d426b1d4c78e52d_I20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNzM1OQ_99bb96fc-fa0e-4daa-bc7f-2eba6f2788d4">10.0</ix:nonFraction> million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than <ix:nonFraction unitRef="number" contextRef="i3792f3a4ad1b4e6e9af66d3b5eae396b_D20200101-20200930" decimals="INF" name="ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODMzMQ_2d7d0249-a2de-4410-a5e1-0610ae7baefe">50.01</ix:nonFraction>% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $<ix:nonFraction unitRef="usd" contextRef="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:DebtDefaultLongtermDebtAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODQzNQ_c6cc17ce-b222-433b-9a2c-ac71994ed832">50.0</ix:nonFraction> million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $<ix:nonFraction unitRef="usd" contextRef="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:DebtInstrumentApprovedThresholdUseOfFunds" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODk2Nw_cd9f78db-a01a-4965-958f-a73ea777d528">125.0</ix:nonFraction> million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA0OTk_11b54a6b-de92-40e3-a9ca-5a9b1bd2eeda">6.5</ix:nonFraction> million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2020 and 2019, was <ix:nonFraction unitRef="number" contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA5MTE_30fa0809-32f1-4491-a693-ea92243bc776">3.79</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930" decimals="4" name="us-gaap:DebtInstrumentInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA5MTg_143c092f-586e-4b57-9f71-8434f9caad96">1.31</ix:nonFraction>%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and nine months ended September&#160;30, 2020 and 2019, of $<ix:nonFraction unitRef="usd" contextRef="i98837eb98d97440f9bd5671b34f7d76f_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTEwOTc_d7fcc91e-3462-4721-a403-ca4c362fb14a">0.3</ix:nonFraction> million and <ix:nonFraction unitRef="usd" contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIwOTQ2Mjc5MjMzNjc_b5a0fd7a-82b1-45bb-a3f9-61c9fe3e34ed">0.1</ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia053d843d611409ea6e794c9fe247e3e_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTExMDQ_d84451eb-65e7-4d04-a37b-a9e6dbab48c2">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTExMjY_b938eee8-830c-416a-92a1-9f96752d1a2e">0.1</ix:nonFraction> million, respectively.</span></div></ix:continuation><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i8dff6e28d4d44db2a2000665086c7c4e" continuedAt="i60fb0fe9e84944b984fc3bfa21d86f1b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NMM Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="icbffe9564ff44d1bab6086b082b64111_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTEzNDk_15f0f98d-8127-4d4b-91c6-f21677a035af">20.0</ix:nonFraction> million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $<ix:nonFraction unitRef="usd" contextRef="icbffe9564ff44d1bab6086b082b64111_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE1NzM_15f0f98d-8127-4d4b-91c6-f21677a035af">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i664bd167ed344f5b97bb3dcf459676e0_I20180901" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE1Nzk_a031c2e5-d032-4adb-9589-4e0eb4de3442">27.0</ix:nonFraction> million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="i7931a6ac521043ada1f90c0f74afa693_D20181231-20181231" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE3OTY_40b7ad45-3ea8-4a2c-803b-99f3865b9a26">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="i2255233ea20d48f0a140daa8b2135d19_I20181231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE4MDM_0be593b1-5200-4b51-8153-813fadb0bbfe">5.625</ix:nonFraction>% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June&#160;30, 2019, of $<ix:nonFraction unitRef="usd" contextRef="i0804ee2cd49c471cb1750e3eb02c9f51_I20190630" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE5OTA_c5edca2a-9837-424c-873f-aaf49069043e">5.0</ix:nonFraction> million was fully repaid on September&#160;11, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="i342f2e70889b49b8b01eb66a3ed09a94_I20180905" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIxNDk_34dfb551-1243-4f27-96e9-ef4498e735c2">20.0</ix:nonFraction> million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $<ix:nonFraction unitRef="usd" contextRef="i342f2e70889b49b8b01eb66a3ed09a94_I20180905" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyNzg_34dfb551-1243-4f27-96e9-ef4498e735c2">20.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i216418c12a70419bacb688b1427cd129_I20190417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyODQ_74b93da8-7177-4ca7-b816-5cacbcc1b75a">16.0</ix:nonFraction> million and from $<ix:nonFraction unitRef="usd" contextRef="i216418c12a70419bacb688b1427cd129_I20190417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyOTY_74b93da8-7177-4ca7-b816-5cacbcc1b75a">16.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i9b3115de9851458d8e5935842bd881cb_I20190729" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIzMDI_6dddbd17-7cf8-444c-8d66-5bc9252b6d7f">2.2</ix:nonFraction> million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="ie30b8de9297c42469c822858d3e54b70_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIzOTM_dcf92fd3-f455-44c9-b2dd-bf4644cdb385">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="i478deb2fc38c436bb8671cb70199cee5_I20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI0MDA_1dc0da65-d68c-426c-b6ea-35944eb480fd">3.375</ix:nonFraction>% as of September&#160;30, 2020, and <ix:nonFraction unitRef="number" contextRef="id5f4624aad0143a38ac09f171403b362_I20191231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI0MTc_79232365-8bfe-47f4-8ee3-7751eba70dfe">4.875</ix:nonFraction>% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a <ix:nonNumeric contextRef="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905" format="ixt-sec:durwordsen" name="ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMTY_1200bf1e-7a43-4c3d-8d34-61cfba633e6d">five-year</ix:nonNumeric> term loan with monthly principal payments, plus interest based on a <ix:nonNumeric contextRef="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyODU_37bd6295-2cf3-4291-8555-d67f12d7d508">five-year</ix:nonNumeric> amortization schedule.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September&#160;30, 2020,  outstanding letters of credit totaled $<ix:nonFraction unitRef="usd" contextRef="i78348153cd274034948535714f61bce6_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LettersOfCreditOutstandingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyNjA_a47235d0-5375-454f-b181-66fc2cfa7e67">8.2</ix:nonFraction> million and the Company has $<ix:nonFraction unitRef="usd" contextRef="i2919814c52aa4e6c96480fc7e55b85c0_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyODM_235c3507-9659-444e-9f44-fb7b1464fc04">10.2</ix:nonFraction> million available under the revolving credit facility for letters of credit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $<ix:nonFraction unitRef="usd" contextRef="i9ba211b652284a1ba866c7ef68ae48e9_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM0ODk_089e931b-4b25-490b-8c13-3786c33721d5">10.0</ix:nonFraction> million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $<ix:nonFraction unitRef="usd" contextRef="i9ba211b652284a1ba866c7ef68ae48e9_I20180614" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM2MjA_089e931b-4b25-490b-8c13-3786c33721d5">10.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i88976d0744e74325abde725693423c49_I20190417" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfOTg5NTYwNDY2NzA5Nw_c8f936a7-b735-47b3-90e5-687fc90e69e3">40.0</ix:nonFraction> million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $<ix:nonFraction unitRef="usd" contextRef="if2a2fbcc8b234d85af151b72dc525ee1_I20190611" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM3NjE_5e02785b-1c80-47e5-85ac-0109125c0aaf">40.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM3Njc_1aaf049c-e740-4679-a6b6-e1f449ff99f4">43.8</ix:nonFraction> million, and decrease loan availability from $<ix:nonFraction unitRef="usd" contextRef="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM4MDc_1aaf049c-e740-4679-a6b6-e1f449ff99f4">43.8</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="i5bd06a67515e4d6c816adb0fc9c88a81_I20190910" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM4MTM_6fa225b9-59b0-4b10-ab7a-fa5465246fa5">4.1</ix:nonFraction> million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus <ix:nonFraction unitRef="number" contextRef="if7993c591aa442349f5e43bcd84f0f49_D20200101-20200930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNjE_915f0c92-bee0-4ba7-81a7-d4f9a25f0b54">0.125</ix:nonFraction>%, or <ix:nonFraction unitRef="number" contextRef="i108d951874b443008dbdf9ebfe69c2ab_I20200930" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNjg_e56dee86-8122-4997-818a-74803605415b">3.375</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i7f4ba9139fca44899bc4ca327e9849b9_I20191231" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNzU_bc50cbc1-bc4c-4fb1-b0fc-5cda189f4372">4.875</ix:nonFraction>% as of September&#160;30, 2020 and December&#160;31, 2019, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there was <ix:nonFraction unitRef="usd" contextRef="i108d951874b443008dbdf9ebfe69c2ab_I20200930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ0Mzg_ada82a30-9f9b-4e99-b8d2-6d043bbfb344"><ix:nonFraction unitRef="usd" contextRef="i7f4ba9139fca44899bc4ca327e9849b9_I20191231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ0Mzg_b886d512-2def-43b9-9699-435864c70dc1">no</ix:nonFraction></ix:nonFraction> availability under this line of credit.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $<ix:nonFraction unitRef="usd" contextRef="i583b6b592ac24c3f805e3c210ab44386_I20181002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ2NDU_e9a5dd37-6b6b-4eb1-a1aa-67969efb3cfe">6.6</ix:nonFraction> million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional <ix:nonNumeric contextRef="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzNDI_de25e6e8-fe31-4e27-ad58-94f7efba9a88">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution to terminate prior to <ix:nonNumeric contextRef="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002" format="ixt-sec:durday" name="ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ4OTI_cc9134cf-6e1b-40a0-a56b-1c5c3046e9c4">90</ix:nonNumeric> days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#8217;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase the amount from $<ix:nonFraction unitRef="usd" contextRef="i583b6b592ac24c3f805e3c210ab44386_I20181002" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTUxMjk_e9a5dd37-6b6b-4eb1-a1aa-67969efb3cfe">6.6</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="ib720ede0911c4e8d80c33fc1220eba1a_I20190814" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTUxMzU_1fe1e709-b2ef-4509-b434-116dc508efe8">14.8</ix:nonFraction> million and extended the expiration date to December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement. As of September 30, 2020, APAACO terminated $<ix:nonFraction unitRef="usd" contextRef="i04eca9b9464f4a60a87145ab44e5bb1f_I20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:LineOfCreditFacilityTerminatedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfOTM0NTg0ODg1MzIwMw_c153ded1-a920-4743-8fdd-c6af10f9a08e">6.6</ix:nonFraction> million of the irrevocable standby letter of credit. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i60fb0fe9e84944b984fc3bfa21d86f1b"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="ic7e3933a8b4246618d18872a39beb676_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU0ODg_38c9f8db-8652-4909-b202-492bb2e273a4">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i7d02e70680ae437eab0be807ca3d050a_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyNDk_8c7b12d7-8dc7-415d-bb39-a39d3944ab5e">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $<ix:nonFraction unitRef="usd" contextRef="i6dec8773fada4b24852d9aae4143d84b_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU5MjU_f7fe0e7b-37cf-40ce-8ae1-a36ec2bfe07d">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i1b34349d244644a9af65d1269f0191e4_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyODY_68f84a40-e5e8-4d9d-b7ed-1f1c03689dcd">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_67"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1NA_d69ad4bb-a30d-46ca-bcdc-ebc7c1422116" continuedAt="i5d0cc2574afe4daebc6cfa6041b399d3" escape="true">Mezzanine and Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i5d0cc2574afe4daebc6cfa6041b399d3" continuedAt="if4643e60fd184fd5baa4c91e66ae5921"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable and it is not probable that the shares will become redeemable as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesMerger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDM5_b6bb4e7b-3e08-4e3c-b9ed-78b869b2147b">302,732</ix:nonFraction> holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1OQ_baf0e2e5-3bc3-4698-81cd-e0f1bd3c636a" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS0xLTEtMS0w_ac96dddc-5699-48f2-b5ee-d6fd5c274489">607,346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS0zLTEtMS0w_d128d948-8fe0-41bb-b86b-91ab136c0db1">9.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS01LTEtMS0w_df260705-918c-40fc-a0e2-549903ec6769">3.42</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS03LTEtMS0w_b20a075c-b61d-440d-8429-960de1e38e9e">5,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMi0xLTEtMS0w_418041dc-ef93-4bbb-a69c-ef25e5120a07">11,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMi0zLTEtMS0w_5c7835b9-7e69-4780-bda2-a43dcbc15bea">18.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy0xLTEtMS0w_760a2468-6d74-43cb-a3cd-b26b9069a6f0">120,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy0zLTEtMS0w_4fca90b2-e85a-44bc-8693-56dd4789e0cc">2.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy03LTEtMS0w_d76d2594-8836-46f8-b7f0-005b8594e033">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNC0xLTEtMS0w_83b0dcd6-6c61-48c9-aa68-7319a8c27426">12,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNC0zLTEtMS0w_5d87063c-133e-4934-bfa3-9448b2048aa4">17.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi0xLTEtMS0w_9be4af04-88bc-4505-ad2c-ae82bff86876">486,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi0zLTEtMS0w_206f2137-0a53-4e03-b959-bc805dc8003b">10.86</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi01LTEtMS0w_e798a05f-a491-4f5e-b373-c5b58eb28b64">3.45</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi03LTEtMS0w_7e1c8d80-6789-457b-b44f-d314bcd8c156">3,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC0xLTEtMS0w_bd5a5120-abfe-4963-a3ab-da5ac662976e">405,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC0zLTEtMS0w_74a9f12d-3c3d-444f-be29-985d66f640e3">7.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC01LTEtMS0w_8dc56bac-8767-465c-9db3-9d44e35cf34c">2.75</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC03LTEtMS0w_245aed07-4936-440b-abf3-f1b337b03dfd">3,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, stock options were exercised for <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTU3OQ_d5e1d0d3-3fde-4181-b8e3-804e3f0ab3b8">120,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTU4Ng_075a4185-8bec-489c-bf9b-393e88132736">203,524</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i436d289510454727bc5fddbf12ad2d92_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY4Ng_241160ba-a9ee-4782-889b-874ba77c246b">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icece81cce5fb4924bcbe69d05e4dcc7d_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY5Mw_64913ab2-3323-45af-bf20-077b7af0f9c0">1.2</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTc0Mg_22d34da4-5885-4bd3-9820-1f4549d00f9d">2.10</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTc0OA_2c2aa8e2-c71b-4afb-84b8-b56f70c083ee">5.00</ix:nonFraction> per share for the exercises during the nine months ended September&#160;30, 2020, and ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i2717bab98fa54dc792c95e77b5b141e4_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTgyNg_0b166342-b690-4df8-b188-764e684eaa8c">1.50</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i87dbbc859a844154beab63a0f933c8ba_I20190930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTgzMg_c0b8ed8d-ffd9-4b00-8004-fb1e51880aa8">10.00</ix:nonFraction> per share for the exercises during the nine months ended September&#160;30, 2019.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="if4643e60fd184fd5baa4c91e66ae5921" continuedAt="i02059de0745a4a1db2e698734bdaa437"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTkzMg_2182e4bf-22fe-448d-b4e7-dfcb7b3c4a17"><ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" format="ixt-sec:numwordsen" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTkzMg_b34df0dc-f52b-407f-bc81-0dc683074258">no</ix:nonFraction></ix:nonFraction> stock options were exercised pursuant to the cashless exercise provision.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1Ng_657a4432-f3ef-4780-923e-eceb5c12267c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted <ix:nonFraction unitRef="shares" contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjA2MA_a6c13dce-9896-49e5-b2eb-6f574a1e5152">11,742</ix:nonFraction> stock options with a vesting period of <ix:nonNumeric contextRef="i943e4302b105480e8a3a578a84a18038_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1OA_f8aa26a7-99af-42c4-b95b-8d94eea36a14">five-years</ix:nonNumeric> to certain ApolloMed board members with an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjE3Mg_da9012f1-6e92-44a9-82e7-fa460ed8feb9">18.41</ix:nonFraction>, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:81.158%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Members</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMS0xLTEtMS0w_c3315e93-d0b8-40eb-94f5-78f300d3cddc">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMi0xLTEtMS0w_34d24013-2707-4dcc-9ad9-3ee9ce77b1e8">90.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMy0xLTEtMS0w_a398562a-491e-42f6-9cd3-f7172a1fef1f">1.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930" decimals="INF" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNC0xLTEtMS0w_79006bfd-990d-4bf3-8c89-8c4b5644b762">10.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNS0xLTEtMS0w_42fcbae6-75d0-403b-8cc8-5a3db4d0c80c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNi0xLTEtMS0w_376f70cf-1570-4784-b3a1-1b77f0cf4247">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the nine months ended September&#160;30, 2020, the Company granted restricted stock awards totaling <ix:nonFraction unitRef="shares" contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjYzOA_620b1fa0-76d7-47e9-b657-2d23457a02d6">97,447</ix:nonFraction> shares with a weighted average grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjY5Nw_2f0ccf66-a34e-4c8b-b4da-fa589b5ffd2a">17.58</ix:nonFraction>. The grant date fair value of the restricted stock was $<ix:nonFraction unitRef="usd" contextRef="if71d1171a6d540fa8cb9f4771cd113ae_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjc1NQ_7908be1b-8b4c-4074-8838-e872ddc282d4">1.6</ix:nonFraction> million and will be recognized on a straight-line basis over the awards&#8217; vesting period of <ix:nonNumeric contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjgzNQ_f14e0a15-ffb2-445f-8917-6e1f8779ad98">three years</ix:nonNumeric>. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, the Company recorded approximately $<ix:nonFraction unitRef="usd" contextRef="i1fde585401744bfc8f98fcb6e5d4c55a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjkxMw_9804994e-4f5e-4d83-8499-939e40c358cd">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjkyMA_13b9d303-554b-4cc7-b5e4-b93bc5c3997b">2.2</ix:nonFraction> million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which are included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2020, was $<ix:nonFraction unitRef="usd" contextRef="if71d1171a6d540fa8cb9f4771cd113ae_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzI3OA_e2ff295d-da23-4701-bb1e-63084ddefef3">3.1</ix:nonFraction> million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY2MA_d498ce74-a223-41a0-96b0-d68b1fda4b1c" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.813%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS0xLTEtMS0w_1852c9b3-e7a3-4f80-b5c5-7966b889f19f">3,154,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS0zLTEtMS0w_e5ba4a24-2022-4668-8499-f2922a717ba2">9.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS01LTEtMS0w_61aa3061-00c2-4cbd-86da-6dc12f9aa981">2.01</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS03LTEtMS0w_011adf66-5575-4faf-a2fc-acd60f2dc6b6">26,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="ameh:NumberOfWarrantsGranted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi0xLTEtMS0w_477fb1f1-e4ea-4ae2-b308-a4bd85fbe8a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi0zLTEtMS0w_07eceac4-b618-4853-bd7a-946e7ef6e797">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi03LTEtMS0w_083ee033-6674-47e4-b9ef-de24dd4a6a4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:NumberOfWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy0xLTEtMS0w_34a5fd67-9d32-466b-9c67-03fe61e1ad7c">800,709</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy0zLTEtMS0w_cc12bd4c-bfd4-4e72-ba83-f2193fc78e96">9.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy03LTEtMS0w_55278e80-35b4-47d0-9a6c-5565b61217bc">6,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:zerodash" name="ameh:ClassOfWarrantOrRightCancelledInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC0xLTEtMS0w_19fa4408-776f-4ca1-9d81-158dbe6bd2cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC0zLTEtMS0w_603b4e47-00cb-49fc-b581-9f4faed6bbc2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC03LTEtMS0w_2fb61c41-7e6c-4163-b05a-03c75120d04d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi0xLTEtMS0w_a165b04a-f445-46f6-8eee-5790a5b0381a">2,353,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi0zLTEtMS0w_1d7258ce-ea69-48c6-b2f8-f4b55fb73e4b">10.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi01LTEtMS0w_c299d31b-0d11-43fc-81b8-ff4bfc2f8a47">1.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi03LTEtMS0w_596e1d44-7c81-48b1-bc05-e86dba1792d7">18,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.467%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS0wLTEtMS0w_9fcb0627-162e-4511-b054-97d00ee3260b">9.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if52999aec2ec48c3a27829576d274249_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS0yLTEtMS0w_41b94bdd-6ad5-429f-a2d2-d0395979ed77">305,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="if52999aec2ec48c3a27829576d274249_D20200101-20200930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS00LTEtMS0w_8e1a9e70-4a38-4a69-b2cb-da02f822587a">0.04</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS02LTEtMS0w_4534228d-2ec5-45aa-8d97-c368bc37e3ae">305,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS04LTEtMS0w_f99eb68e-2279-4e18-9976-e811e507a020">9.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi0wLTEtMS0w_75364ada-f1bc-44d6-9568-dc9ed3efd87d">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi0yLTEtMS0w_51f0f791-65ea-41e9-ae6c-a555c3ac6793">1,248,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi00LTEtMS0w_2ae9bdda-e13f-4da3-8e7b-9a29694e436a">1.64</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi02LTEtMS0w_3320dd46-88f8-4278-a0b2-01b084d6dd35">1,248,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi04LTEtMS0w_36463278-1b8d-401f-9834-ead2d260dd78">10.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy0wLTEtMS0w_bcc94cd2-1305-4552-a03c-20707805d523">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy0yLTEtMS0w_ce3ef543-07ba-4181-b0e8-9611aa099955">799,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy00LTEtMS0w_986e0ecd-e866-4d2e-aded-ab0d8cd2cb10">2.19</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy02LTEtMS0w_7233828b-3fa9-436a-a87b-281b383944d1">799,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy04LTEtMS0w_d3c3ad99-fea4-4eb8-995b-f9bd22885bb3">11.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                                              $                     <ix:nonFraction unitRef="usdPerShare" contextRef="i7d2649df80d34fa2a5160241cddb24f7_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0wLTEtMS0wL3RleHRyZWdpb246NmU3YjQ1YjVlYWIwNDhlNThjNzhmODVhM2ExNTU5NzVfNzM_02441abb-0ee4-46fc-96dd-89ab2bb404d9">9.00</ix:nonFraction> &#8211;<ix:nonFraction unitRef="usdPerShare" contextRef="i682e56c134fe472db3d942dee2c67e9e_I20200930" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0wLTEtMS0wL3RleHRyZWdpb246NmU3YjQ1YjVlYWIwNDhlNThjNzhmODVhM2ExNTU5NzVfNzc_3aa87ea5-a338-400d-8fd7-701bd0d7937b">11.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightIssuedInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0yLTEtMS0w_0c7cc3ec-398f-4b44-b328-e35283d3f740">2,353,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930" format="ixt-sec:duryear" name="ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS00LTEtMS0w_cbe2fd60-dda0-49f7-b6d5-6bb69171682d">1.62</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic96250cdb31545618a1db18666cefafa_I20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ClassOfWarrantOrRightExercisable" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS02LTEtMS0w_67e9a711-d9be-4f44-bd0c-a2438850fdf6">2,353,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic96250cdb31545618a1db18666cefafa_I20200930" decimals="2" name="ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS04LTEtMS0w_25339aa0-93ac-4fd2-bd0d-b7e52ece41f0">10.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i02059de0745a4a1db2e698734bdaa437"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, common stock warrants were exercised for <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzQzOQ_ffaa3763-5a7d-49ef-aa60-22bd101eda2b">800,709</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzQ0Ng_1ee407b0-aef9-4675-957c-51a1ab4e9825">133,221</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzU0Ng_784497a8-e6ae-4889-aff6-02e88bd8f5b6">6.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzU1Mw_2a8fb4ff-f61f-4c74-9188-6d0750914c20">1.2</ix:nonFraction> million, respectively. The exercise price ranged from $<ix:nonFraction unitRef="usdPerShare" contextRef="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwMg_a6996f9d-1642-4851-acf2-9c50f700b185"><ix:nonFraction unitRef="usdPerShare" contextRef="idf5d96c5aa524dee8cf3659f677f11b5_D20190101-20190930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwMg_babf812a-1c0f-40fd-ae3d-31958621c53a">9.00</ix:nonFraction></ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="if3710a3c83db42d0805599a74145dff2_D20190101-20190930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwOA_8e882b6a-6254-4663-9a27-c0e9e9eab47b"><ix:nonFraction unitRef="usdPerShare" contextRef="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930" decimals="2" name="ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwOA_a4af4adb-46da-4282-b951-1e58e148788e">11.00</ix:nonFraction></ix:nonFraction> per share for the exercises during the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, common stock warrants were exercised on a cashless basis for <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY0OTI2NzQ0MjE1MDI_18ae0687-e327-4eda-af61-73feca1a4113">127,022</ix:nonFraction> shares of the Company's common stock which resulted in the Company issuing <ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfOTM0NTg0ODg0MTM3Mw_5e9f2cc2-6ab3-407b-9b6e-876678a03b8a">66,517</ix:nonFraction> net shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned <ix:nonFraction unitRef="shares" contextRef="i558ed222ce35492c86d5800acda7c4c6_I20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzcxNg_661e008b-f018-41f9-8c52-732f340a3cd1">17,307,214</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ic3263f1c5abf42b98d4605f4f7284e83_I20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockCommonShares" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzcyMw_7845f9bf-fe8a-4e15-99d5-c35d611256d2">17,290,317</ix:nonFraction> shares of ApolloMed&#8217;s common stock as of September&#160;30, 2020 and December&#160;31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of September&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$<ix:nonFraction unitRef="usd" contextRef="i23c4dccf62634d3b92148d57ea541c66_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDM3Mg_00668425-15bf-4c1a-9998-11bb0921d633">7.6</ix:nonFraction> million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, APC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDU0Mw_633e8aab-89f4-4dec-898f-1f5149905a0f">49.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if8031dd6b66546c1a3ac173850d16bd4_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDU1MA_93e628fe-4f29-47b2-aaa2-1c6c4938d5a4">59.7</ix:nonFraction> million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended  September&#160;30, 2020 and 2019, CDSC paid dividends of $<ix:nonFraction unitRef="usd" contextRef="i56c177ebcb7d435c971aa73fe7a5ef54_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDYzMQ_ecfb6ea9-6e95-4d46-81fa-8339902dde94">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if3b51820704a4a93b98fa96a6930977c_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDYzOA_0966c212-d877-475d-beb2-a02701aa6205">1.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_70"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2NQ_abdbdfe4-2a5b-45b2-977b-734a53f25ee8" continuedAt="i856f62dc003e493a829d1b44fef49a06" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i856f62dc003e493a829d1b44fef49a06" continuedAt="id0bee730be6e4e9294266962a654f282"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;September&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to <ix:nonFraction unitRef="number" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="ameh:PercentageOfFinancialGuaranteeBenchmarkAmount" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMTg3OQ_f4df55a1-23c6-4054-a35c-86be5fddb9f3">2</ix:nonFraction>% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit under the Credit Agreement for a face amount of $<ix:nonFraction unitRef="usd" contextRef="ic0f9aa10906f4d2c9652027d594046aa_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjA0MQ_47985b41-035a-485e-96fb-b112cb272f78">8.2</ix:nonFraction> million for the 2019 performance year (see Note 9).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with a financial institution for a total of $<ix:nonFraction unitRef="usd" contextRef="i486cfce3128a43d1b5f0abe01fe3ec4a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LineOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjIwMw_48abe2cc-d02c-4b97-8d73-bbef47fe8471">0.3</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i1d7273f768df4eb690b7413548307158_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2Ng_c95ffd6e-242e-4a1b-b3f2-2d72dc3c55e7">one-year</ix:nonNumeric> periods </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="id0bee730be6e4e9294266962a654f282"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $<ix:nonFraction unitRef="usd" contextRef="ifeddb663bcd34a33b0a3c19d9b40f607_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjYyNA_edff611f-9b35-4d1d-b666-b2fb5dcbdc90">3.8</ix:nonFraction> million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional <ix:nonNumeric contextRef="i29325e7277374944a4b7e5d32f0a71ce_D20200101-20200930" format="ixt-sec:durwordsen" name="us-gaap:LineOfCreditFacilityExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2NA_9cd7170b-be33-4306-b26c-d0fdd8a2376a">one-year</ix:nonNumeric> periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prospect Medical Systems</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#8220;Prospect&#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#8217;s purported business plans, seeking damages in excess of $<ix:nonFraction unitRef="usd" contextRef="i94cbfc093bc14eaf945f211b23c1507e_D20180323-20180403" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LossContingencyDamagesSoughtValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMzY4OA_6778cb83-27fd-4fae-99e2-cfd9882be4dc">5.0</ix:nonFraction> million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#8217;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_73"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI2NDQzODM3MjUxMzk_3ff00efa-84f3-492f-8b31-7cabac2d4fc4" continuedAt="i1cfc61def8dd4829992f496e5a085b82" escape="true">Related-Party Transactions</ix:nonNumeric></span></div><ix:continuation id="i1cfc61def8dd4829992f496e5a085b82" continuedAt="i248fcb0c5afb4f91abfd01ff7555aa21"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a <ix:nonFraction unitRef="number" contextRef="ib1163ece356545148c6d18c1e1d66912_I20151116" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTMw_12258715-eca6-4e35-b773-c860809f4e5c">48.9</ix:nonFraction>% owned equity method investee (see Note 5), in the amount of $<ix:nonFraction unitRef="usd" contextRef="i358387cf1a564a2297e5f1abdf9f5f42_I20151116" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTkz_cbf58c23-01fc-4d35-8869-e0acd2e8a976">5.0</ix:nonFraction> million. On June 28, 2018 and November 28, 2018, UCAP entered into <ix:nonFraction unitRef="agreement" contextRef="ie07ae9f744764e5291d906d251e2034a_I20181128" decimals="INF" format="ixt-sec:numwordsen" name="ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjU1_d79df2ad-7a63-42fc-9a16-5b6766f40784">two</ix:nonFraction> additional subordinated note receivable agreements with UCI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i7aeb75119c51484cb3d7c560edf10ae8_I20180628" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzM1_87fb8d58-26a6-435d-9a86-f5a39d263042">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie07ae9f744764e5291d906d251e2034a_I20181128" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AccountsAndOtherReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzQy_46a05f63-1eaa-42e7-a5fb-7e332e9babda">5.0</ix:nonFraction> million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its <ix:nonFraction unitRef="number" contextRef="i81d7b1f95e2749528c65d9be013d2d5e_I20200430" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDU3_b28a590b-affe-4086-a113-bd5775d9e4da">48.9</ix:nonFraction>% ownership interest in UCI to Bright (see Note 6).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM earned approximately $<ix:nonFraction unitRef="usd" contextRef="i7c5294ed64c44b5086f5be21d0bce6cd_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNTgw_83bb547e-602e-43be-9b76-d23cccebc7df">4.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icaa2e771930d42a3b26e519f82d67bf8_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNTg3_a67a38a5-94c0-4049-a63e-eddd0530dd68">4.4</ix:nonFraction> million, respectively, and  $<ix:nonFraction unitRef="usd" contextRef="i6245ae4c746a41bfae5a0da8935409d9_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzE0NjgyNTU4NjEzMw_6f0db10f-adae-4b9b-b3dc-153f75097b8b">12.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4949acae14e04f38821727b357327125_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzE0NjgyNTU4NjExNg_0ef42637-549a-44e8-a4dd-af2ae05c2132">12.9</ix:nonFraction> million, respectively, in management fees from LMA, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="if1c3b821bbf14ea68465673f368d6f0c_I20200930" decimals="INF" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzEy_5cf48f4f-0dac-4afe-8948-78feecf76325"><ix:nonFraction unitRef="number" contextRef="i976d1979c27d4acc9409bb7743bf49ba_I20190930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzEy_d0a61ac7-40c0-431f-9617-4a73799c6048">25</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="ide80e6a11bd34f8b8a952c62960c82b6_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODY1_dc841c60-f835-4894-86d0-85d1af928e3d">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i61751c7e250f42118eb2800e45f0c530_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODcy_25e208d8-d16f-48be-8429-7662507f360e">0.7</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i43d3d75fad82483eb5813daf8df17cc3_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODk0_8776eb02-8a64-411a-9f4e-fd886506f5f3">1.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if932e49636814177a3488a7a9d89c9bb_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTAx_3e3c3cf1-9920-4116-aa31-4e340ef90082">2.1</ix:nonFraction> million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="ibca6368440e848ccacf6e0c6beff4565_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTAwNw_db0db8e5-5031-46e5-9d48-17a0da8e8b62"><ix:nonFraction unitRef="number" contextRef="i19071814c5784cc8acedf97c43d02aae_I20190930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTAwNw_f45918a9-7489-4ff0-b245-0637024977f7">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i248fcb0c5afb4f91abfd01ff7555aa21" continuedAt="ie58b019cc0dc4d109cd76cf6d9fbc9bc"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3dd1f69283d349a58ae0e8144a4dec4d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTEzMA_7a1c583e-9b5e-4389-8a09-f9396176622a">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="id2670dfb231c4c36a80048c4600a520f_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTEzNw_c1922a04-7c14-4e80-bf6c-4d607eff4e9e">2.0</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="ia3717208d1224dd89f9f178d06d05dc2_D20190701-20190930" decimals="-5" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM3Mg_8279e5b3-be2d-4cbd-bc76-d8557b11c516">3.8</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ibbbfbf6e54384685bbdbd24b85b6a70e_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTE2Ng_4ad1a1df-fcc3-435e-a888-e5e8aa7e43f5">5.8</ix:nonFraction> million, respectively, to DMG for provider services, which is accounted for under the equity method based on <ix:nonFraction unitRef="number" contextRef="i42db88be7eb248ce937d8d0f1e434c23_I20190930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI3MA_4e4515c1-160e-4f3e-9816-ae8a08da295f"><ix:nonFraction unitRef="number" contextRef="ibf65ddf284dd40dbbade2b730a49906e_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI3MA_60c4c158-f3b4-48be-b41b-440c66ffc65b">40</ix:nonFraction></ix:nonFraction>% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8e86290ed094411eacda08c9860c3896_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTM5Mw_278ede25-d596-424c-9d63-00d0024affd5"><ix:nonFraction unitRef="usd" contextRef="iba42cd3748834d6a9e6d5b22691a39d3_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTM5Mw_318ece6d-e40b-4295-af4b-7c070fdbd781">0.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i357239cb3870424c98179560f4e05eb9_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTM0NTg0ODg0MTgwNA_128e3eb1-f43d-4dd5-8a21-6ab2f3c160f3"><ix:nonFraction unitRef="usd" contextRef="i462e89554ff74f3fa68c411f8685e8cb_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTM0NTg0ODg0MTgwNA_ec5bb521-3539-44df-9b37-f0d0dc75ce09">0.2</ix:nonFraction></ix:nonFraction>&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately $<ix:nonFraction unitRef="usd" contextRef="ibfff017f5079475da112360bcc11bf3d_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY3MA_de49c643-56ae-4543-8ef0-411eb35139f6">7.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if9b280c05e114d2cb9d4d80828861206_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY3Nw_66525beb-fda0-42bd-b7a9-a69f36fd43e1">6.7</ix:nonFraction> million, respectively,  which include approximately $<ix:nonFraction unitRef="usd" contextRef="i24504ae2154f4155a97794062ff7b4cc_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTcyNA_156ac5ec-cf6d-4212-9d0f-5ae13772f542">1.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i4915f14b437e4756b8b7d103a441b54d_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY0OTI2NzQ0NzA2Ng_42ede263-5794-4cc3-877b-110a946ed60f">1.8</ix:nonFraction> million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $<ix:nonFraction unitRef="usd" contextRef="i846f7fd44f304e9ea61d6d7acb1c05d7_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTg3NQ_9c0d3f28-d3e9-4caf-9536-ed86b2e38083">23.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i004ed9a138324dc8a6fc0af8d80321d7_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTg4Mg_fda46423-8a00-4d72-b829-3b44979e9129">23.1</ix:nonFraction> million, respectively, to shareholders of APC for provider services, which include approximately $<ix:nonFraction unitRef="usd" contextRef="i1dea7f1f241546c79900d50e5d5b3e39_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTk3NA_a33ccc75-5099-45c9-b133-f67cabdcf38d">6.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i8569d927dbfc4be780d7ea409efa6a37_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTk4MQ_8400f868-6553-4d1d-94c2-a29b9f0180d2">6.9</ix:nonFraction> million, respectively, to shareholders who are also officers of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i9d5ec46533294b24af622e84d85e1306_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjExMw_bc2383d8-b9fe-458a-b527-918644dcc9fc"><ix:nonFraction unitRef="usd" contextRef="ia82c704cff6c42929352454bea170ee6_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjExMw_e4b75b3d-7fc0-4dda-8897-619959509d2f">0.3</ix:nonFraction></ix:nonFraction> million, respectively and $<ix:nonFraction unitRef="usd" contextRef="iaade255737234b709672525b3860eed1_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1MDg_7bc8666a-6c20-460e-83da-fda35b68b08b"><ix:nonFraction unitRef="usd" contextRef="i7ab4eb5154c94c778081d37fd1fbb9c5_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1MDg_b478bbfa-3da4-47ba-9821-e492c046f18d">0.8</ix:nonFraction></ix:nonFraction> million, respectively, to Medical Property Partners (&#8220;MPP&#8221;) for an office lease. MPP shares common ownership with certain board members of NMM.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, NMM paid approximately $<ix:nonFraction unitRef="usd" contextRef="i23eeba47a6d445a1af488e1741954e4a_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjMzNA_860c4cf5-8330-403a-b0cc-0cf461db983c">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie4f7901609a34f0a8bd5da4fb0dbe4f4_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjM0MQ_380ae4d1-463f-4bdb-88f0-0728ed8f5980">1.1</ix:nonFraction> million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly <ix:nonFraction unitRef="number" contextRef="id45018c024f44bd390ae0a1db7dc7a06_I20200930" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQzMQ_bc218be2-180c-490c-8da5-6eae3b50ff5e">50</ix:nonFraction>% owned by Drs. Sim and Lam.  As of September&#160;30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i7666fdc6c5fb4c1597125f20974dcd69_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQ5OQ_04dfc840-47eb-4870-b1fe-2378467a8392"><ix:nonFraction unitRef="usd" contextRef="i7666fdc6c5fb4c1597125f20974dcd69_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQ5OQ_794b3fbf-38e1-4900-83c2-3ddc4f4dc390">10.4</ix:nonFraction></ix:nonFraction>&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, the Company paid approximately $<ix:nonFraction unitRef="usd" contextRef="i8e0f7911506b4f7ea6ea22e51fac5416_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjcyNA_90a63327-0fbf-4355-8773-0920c1ee8eac">39,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i12335e3134c84754a4b5a7c9eb42658b_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1NTc_01e93c21-45c5-4c4b-a36a-d2231ae89cf5">0.1</ix:nonFraction> million, respectively, and paid approximately $<ix:nonFraction unitRef="usd" contextRef="i3fb931837c3446e49bfcff46eee3984b_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM5MQ_07c1ffc6-29fc-4ee2-8976-37f82a814f58"><ix:nonFraction unitRef="usd" contextRef="ic079747ecea44c46b7fc2e75b14ca50c_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM5MQ_2e26378b-9828-44df-933a-03489672ba0d">0.3</ix:nonFraction></ix:nonFraction> million for both the nine months ended September&#160;30, 2020 and 2019, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three and nine months ended September&#160;30, 2020 and 2019, SCHC paid approximately $<ix:nonFraction unitRef="usd" contextRef="i557e6e9936fc467ba5080a062ca80496_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjk3MA_8699d081-3a70-4ee1-950b-f8cd7a15794e"><ix:nonFraction unitRef="usd" contextRef="i3c0345d81c4a45029864d5dfc19df1ba_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjk3MA_ef7a6b2b-c350-4381-afa5-13d491fa31a7">0.1</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="id03688552a194d20bec7b26a63399956_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNjA0NzMxMzk1ODMyMg_0b24f73a-5e16-45f9-8f0a-485b40e63c92"><ix:nonFraction unitRef="usd" contextRef="i2beaf01e5bdb4f7aa6d5f3c6a54f063c_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentMadeToRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNjA0NzMxMzk1ODMyMg_7b2a9079-75da-4443-9280-6a9d755c968b">0.3</ix:nonFraction></ix:nonFraction> million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. As of September 30, 2020, the Company had $<ix:nonFraction unitRef="usd" contextRef="i1d7dbe836e64485fa477f10dbc512288_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTIwOTQ2Mjc5MTIxMDI_03eee729-c6ce-4437-8363-1cfe115a5650"><ix:nonFraction unitRef="usd" contextRef="i1d7dbe836e64485fa477f10dbc512288_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTIwOTQ2Mjc5MTIxMDI_ad6bdea1-940e-4be8-997e-4b6b5cb73b8e">1.4</ix:nonFraction></ix:nonFraction>&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with Numen to be amortized over the remaining life of the lease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with HSMSO, Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDc4OQ_4303759e-ad6d-429c-ba2a-7cd0e85f01d2" continuedAt="i2d072f46ff334e85ae34f2b334307c86" escape="true">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO and Aurion (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:5pt;margin-top:5pt"><ix:continuation id="i2d072f46ff334e85ae34f2b334307c86"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:44.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.949%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi0xLTEtMS0w_dc7c9da7-9c7b-4b63-902a-bc2d8cca3397">5,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi0zLTEtMS0w_24e62463-1118-4acf-83ec-517d53497fbb">11,215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi01LTEtMS0w_d35f88cd-129e-47cf-90f0-a785dd5084ee">23,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi03LTEtMS0w_9e74d2fc-7ff0-4322-9aa7-67a7848c3de5">39,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id95fd088a2c9454599c8fb0dc66fac9a_D20200701-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy0xLTEtMS0w_85d3d7c0-1bd5-487d-b50d-b09c37e396a2">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4ed9597a9f24e4884d0595ef80c9123_D20190701-20190930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy0zLTEtMS0w_5b1f33db-05d2-4121-a083-8189a9690334">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i467c8f07446f434c888fe2139b1ad2e0_D20200101-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy01LTEtMS0w_84cd4876-dbc0-416f-b324-f929cd7f5c41">430</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7230ae6b539c41a89c452715bb10fa43_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy03LTEtMS0w_bf6d94b3-b559-45fc-aead-132301066f87">1,075</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib374aadcdc4a4479907af99b24bfe82d_D20200701-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC0xLTEtMS0w_3ebfde7f-8b13-4c85-8c84-938d403d7a3a">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d542d36ef9c4c6da7ac374e467eae16_D20190701-20190930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC0zLTEtMS0w_a8cead94-ea70-4548-98f1-5a7866529d68">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2293aa631c14249bc1cb90e55c69d12_D20200101-20200930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC01LTEtMS0w_1cb99a9d-79d4-43b9-b6c2-994d66aece4b">228</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0f97d7e0148477d89334ab0a06f9735_D20190101-20190930" decimals="-3" name="us-gaap:ManagementFeeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC03LTEtMS0w_4cd2feae-b950-4d34-a313-eafc1a51e8ec">232</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi0xLTEtMS0w_6c57b636-09ba-4636-bd06-5dc7b292c1ef">5,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi0zLTEtMS0w_b33b6d06-8c59-48d3-8770-04668cdcf8cc">10,979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi01LTEtMS0w_96e9b1ba-d78e-46e4-8273-f56566af13e0">23,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi03LTEtMS0w_53f4e325-f9bf-4149-8c1b-dab7523616f5">37,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $<ix:nonFraction unitRef="usd" contextRef="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzkzNw_65dbdc31-3c7b-4111-aacb-e82724f6ba78">10.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzk0NA_8fd9c795-4d2a-469d-a8eb-ef482283b005">11.0</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM3MjY_f1fa7184-e989-4264-be89-77b4ea8e1266">31.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzk2Ng_e8944c06-84de-40be-aea1-528c42e7ab5f">31.9</ix:nonFraction> million, respectively, for which $<ix:nonFraction unitRef="usd" contextRef="ib209ad0feb484341b4b5ea3e1112074a_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDAwMQ_fc757055-51b9-4c09-9332-0eb1b19d2a9f">36.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i311e4830870b47168a8028481990133c_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredCreditsAndOtherLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDAwOA_f5cde11d-0861-499f-9b75-d9f27645f48d">40.4</ix:nonFraction> million remained outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately&#160;$<ix:nonFraction unitRef="usd" contextRef="i9f86dff82b2e4e37819e44daed0c3927_D20200701-20200930" decimals="-6" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDEzMA_7021274d-22d4-48cc-8880-f22e5dc033ea">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i90b7d7c73e9342ceaea0220fd27ebcb0_D20200101-20200930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDEzNw_dadcca70-cbeb-4743-bf9c-7603b45bf47b">0.1</ix:nonFraction> million, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i37855f5922724980ae2277994e98ea9e_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDE1OQ_09441c3e-197f-4dae-91ee-840381910fd9">27,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i536bf5cd23b640f1b9fdc4a22f35cc97_D20190101-20190930" decimals="-5" format="ixt:numdotdecimal" name="ameh:PaymentConsultingFees" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDE2Ng_88aa1c07-0633-4b88-90b0-162e13eea37c">0.2</ix:nonFraction> million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="ie58b019cc0dc4d109cd76cf6d9fbc9bc"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_76"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMjc2Mg_b2956cf1-f55c-4ab6-a50e-9f11c2bd4663" continuedAt="i943413ec367a42c58a149c34608fc2a3" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i943413ec367a42c58a149c34608fc2a3"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the nine months ended September&#160;30, 2020 and September 30, 2019 were <ix:nonFraction unitRef="number" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMTk3OTEyMDkzMDI5MDI_4ecda33f-c854-4445-bdb4-58762f970403">28.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMTk3OTEyMDkzMDI5MDk_6c937d26-0e3c-4af7-9b7d-be72d2daab90">25.5</ix:nonFraction>%, respectively, and differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. However, the benefits of the CARES Act are not expected to impact the Company&#8217;s annual estimated tax rate for the nine months ended September 30, 2020.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_79"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTExOA_12949f2b-fcea-4846-b373-a03df355c67b" continuedAt="i67fd2c83fafa4d1dbc4b80db089584ff" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="i67fd2c83fafa4d1dbc4b80db089584ff" continuedAt="iee79eea717fc4f339a180848ac167ae6"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, APC held <ix:nonFraction unitRef="shares" contextRef="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfNzI3_1b22f1cd-a62c-4c39-8023-e1a70f729f85">17,307,214</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i46ec2cffc1bf4e368fb4d267b14f59e7_D20190101-20191231" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfNzM0_644f0cec-26bf-44b8-accf-dc1c7a420dc6">17,290,317</ix:nonFraction> shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="iee79eea717fc4f339a180848ac167ae6"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTEyNQ_84cfef46-6d46-4f51-80d0-fbdb8968a483" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMS0yLTEtMS0w_168a7d6c-797e-4602-826c-7e6cb1566d8b">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMS00LTEtMS0w_d70b2fda-1b79-41d0-a2a5-bcbdd6c14602">0.11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMi0yLTEtMS0w_1cae93ec-0358-473c-9670-573a21b9fb17">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMi00LTEtMS0w_18ff4a9b-4b37-4d5e-9449-a4f952b9b2c2">0.10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMy0yLTEtMS0w_dba52c2e-3720-4546-8c90-ba3f54e07286">36,364,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMy00LTEtMS0w_19aa5c6a-b283-46f0-a79f-b6fbf3775eba">34,643,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfNC0yLTEtMS0w_efe14a85-6943-47fa-8c6c-dc08195773b7">37,551,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfNC00LTEtMS0w_153ace80-fdd1-4ffb-9ddf-e32e6e6e0421">37,792,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:71.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMS0yLTEtMS0w_fec05c75-ca91-4760-bde0-fb42d1583614">0.77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMS00LTEtMS0w_c319f526-e811-4f28-ba38-ea7694a7e81e">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMi0yLTEtMS0w_852b4dde-b2a3-42ec-9b39-b1f63225b529">0.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMi00LTEtMS0w_f005ea17-abfb-4a9e-97ab-ae3c49f75952">0.20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMy0yLTEtMS0w_d02538f4-9125-46e4-9769-0c3e709dc202">36,149,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMy00LTEtMS0w_4d1cbda3-b3f5-4f59-88f5-cc0591c026d7">34,555,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfNC0yLTEtMS0w_c1ad9453-1a35-4d7a-9822-242a8f0fad02">37,249,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfNC00LTEtMS0w_2c1d283c-25db-4382-8007-bfbe5ca1606f">37,816,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTEyNw_2f2dfcf1-2777-44e9-b7bb-c955c7dc927b" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMS0yLTEtMS0w_5813d3c3-f696-4ba7-9b49-7c0df102d69f">36,364,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMS00LTEtMS0w_b69b4515-59c8-4850-b475-bca89094dde5">34,643,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0wLTEtMS0wL3RleHRyZWdpb246ZmQzZWY1ZjQwZDEwNDhhMjlhZTMyNmFkYmI3ODEwNjJfNA_88e8f26b-8ec0-4df4-9002-2308bc948c1a"><ix:nonFraction unitRef="number" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0wLTEtMS0wL3RleHRyZWdpb246ZmQzZWY1ZjQwZDEwNDhhMjlhZTMyNmFkYmI3ODEwNjJfNA_c048e579-e17e-4a8e-8b32-00485f67c235">10</ix:nonFraction></ix:nonFraction>% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0yLTEtMS0w_3f1ad351-3344-474c-b758-7b893866e874">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi00LTEtMS0w_08d72e6b-7ccf-4df8-87c4-9fe6a9e2fdd9">1,511,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifef4a834b2704183af5e7a0118b8f10b_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMy0yLTEtMS0w_f25c552a-2b4d-4850-b84f-b89bd40f406c">187,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idcc6a9123a8a4ef7b90cc678cd9de887_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMy00LTEtMS0w_0987a93d-3551-4a16-9549-e45f3f19de9d">299,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1726a5a5ec36427090258ca4b81f8d3f_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNC0yLTEtMS0w_9342b47f-8141-46f8-aeeb-5f441097b8c9">960,806</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54547e12a6db466cb506fe342e82cc32_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNC00LTEtMS0w_f0b202b4-dcb0-4162-8fca-f5e4b4dfa75c">1,337,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb2ac8c951874f548946ae72cd81b9fd_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNS0yLTEtMS0w_7957934c-adc4-4567-a996-1e8f8f564bec">38,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ea08dccbd2246f3821362f61b723f3a_D20190701-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNS00LTEtMS0w_52eb651d-fae9-45a4-9035-b6740097c2bf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNi0yLTEtMS0w_06ff7a2d-6f02-4b2b-ac27-93122fec326f">37,551,740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNi00LTEtMS0w_3d8cf797-9dd7-4bbf-be40-972849d7e274">37,792,266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMS0yLTEtMS0w_20fcde1b-c85c-4814-afdb-e2b22e2fd927">36,149,692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMS00LTEtMS0w_112e311a-8d3f-457b-9b30-49b0c08f441d">34,555,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0wLTEtMS0wL3RleHRyZWdpb246YTA3ODljOTMwZmMzNDA4NTg1MThlYWQxNGJjZDUzY2NfNA_8db2b50f-f2b3-46d6-8aa2-af7454512200"><ix:nonFraction unitRef="number" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="INF" name="ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0wLTEtMS0wL3RleHRyZWdpb246YTA3ODljOTMwZmMzNDA4NTg1MThlYWQxNGJjZDUzY2NfNA_f3943b03-e56d-4114-b019-72fadc0f3770">10</ix:nonFraction></ix:nonFraction>% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i665d45a4c6ad4e91916ba08f8e851d70_D20200101-20200930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0yLTEtMS0w_5bb227de-f7f2-4ffa-8508-1c8cfdfc6263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b8c0038e75540dfa62aff9087a85054_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi00LTEtMS0w_66f703a7-67c8-42e9-9656-49c3aaef1404">1,511,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i671affdf59da40b3b7624c0bdbe08342_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMy0yLTEtMS0w_d8cccb02-294b-4022-9659-cdd74f3c2a93">178,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0a3f294321d042c0b50b53fcde9f5fbc_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMy00LTEtMS0w_47980efd-965c-4fc3-b448-5c4ea26c7498">307,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie6f513dd37f04d39ad6561182f5f3fea_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNC0yLTEtMS0w_167e4781-e304-4b46-a348-69deb180e5e0">890,489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ca7f6c187cb41feb19b9c86fde64670_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNC00LTEtMS0w_1175df26-1da3-4f06-9a85-1409509fc252">1,442,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4f4020d4b8994854ac803ea6e8d45f6b_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNS0yLTEtMS0w_00ed7b8c-f943-4ca3-83c8-9da1944e163c">31,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5a1dd3a2128b451eb4d50a63a91ddd55_D20190101-20190930" decimals="0" format="ixt:zerodash" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNS00LTEtMS0w_ecb1a4f9-437a-4530-9fc6-5cf7c0e223c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNi0yLTEtMS0w_e642fd1a-3500-4d1f-a6e6-9c251ebf2992">37,249,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNi00LTEtMS0w_5fe63f32-bdbe-4cbb-aa3f-4c2fb8218f30">37,816,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_82"></div><div style="margin-top:10pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RleHRyZWdpb246N2I5MGExODhmMjIxNGY5ZmI1MTQ1YzI2OGVhNzM1ZGRfMTg4Mw_7809fd99-d091-4263-a689-ad6e7ff569db" continuedAt="ic6042a6cf0cb4d65ad54d794f9b2377c" escape="true">Variable Interest Entities (VIEs)</ix:nonNumeric></span></div><ix:continuation id="ic6042a6cf0cb4d65ad54d794f9b2377c" continuedAt="i589fabd65c4646419606584faadebff8"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:ScheduleOfVariableInterestEntitiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RleHRyZWdpb246N2I5MGExODhmMjIxNGY5ZmI1MTQ1YzI2OGVhNzM1ZGRfMTg4NA_c81721c9-0fa9-4df5-8b00-567a29bd3a03" continuedAt="i0bd1e5695c4f40eab5c5686fac331cff" escape="true"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:71.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNC0xLTEtMS0w_45799ef0-709f-414e-8485-6e98a44336a5">94,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNC0zLTEtMS0w_96dbd6d3-0c64-4ea6-9384-cb1551892f5f">87,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNS0xLTEtMS0w_4a096701-25b7-45da-8fc9-fb188d0dc50c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:RestrictedCashCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNS0zLTEtMS0w_ef36706e-d2d5-4de2-8899-7eb484b1aeb1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNi0xLTEtMS0w_b6831a4e-fe42-4102-adc7-24c680116521">118,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNi0zLTEtMS0w_9466a86c-91c6-4401-97d5-549db62d39d1">123,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNy0xLTEtMS0w_0b6a1bec-5681-4bf6-a9e8-1dc23ca83348">15,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNy0zLTEtMS0w_21399dfc-c76a-4fc6-bb44-709816d3a3cb">9,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOC0xLTEtMS0w_5e26988c-2afa-44a7-975c-b23ec7b66c2c">39,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOC0zLTEtMS0w_b00e273c-c596-49bb-a3ba-4da5aa505b04">42,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOS0xLTEtMS0w_e7818377-c781-47af-b458-10abfd4427d2">734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOS0zLTEtMS0w_cc7a7a07-21db-4b95-9f94-c6828c65c545">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTAtMS0xLTEtMA_33eb2951-0ec8-4038-9cdb-31fbf7c89e42">9,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTAtMy0xLTEtMA_f1daeb2a-4b93-4a93-a8a9-7c3f1c181953">7,403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTEtMS0xLTEtMA_0f56aab9-519c-4b15-9ce6-4323666cd55c">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTEtMy0xLTEtMA_57527cb9-8896-465a-8975-30019e688ed1">6,425</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTItMS0xLTEtMA_0c822ce9-dd8a-4b8b-9d86-86a07b2b9929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableRelatedPartiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTItMy0xLTEtMA_c75b8163-389f-49a6-b239-ac949ea2138c">16,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTMtMS0xLTEtMA_c61ab2d5-5902-476d-8e6f-b45b6dfa2df6">284,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTMtMy0xLTEtMA_f65a0cf6-7888-48f8-a963-ff5739f296ff">294,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTYtMS0xLTEtMA_95282485-ed17-4e9f-85ba-9bdbb0f9173e">8,877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTYtMy0xLTEtMA_6cea4cd4-2625-4bc0-ab30-0966430392b7">9,547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTctMS0xLTEtMA_fb7968bf-c6e8-4b6d-a0ff-4d19e4d356c4">72,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTctMy0xLTEtMA_4d53f752-1ef2-41f3-bcf7-862e78cc84c4">81,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTgtMS0xLTEtMA_f220aa27-306d-451a-adca-f4f41a5ff42a">109,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTgtMy0xLTEtMA_5fb8d575-f3bf-4bce-9c28-021d219f8937">108,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTktMS0xLTEtMA_715b6218-4572-4e40-af4a-5a3fd1a6182a">310,491</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTktMy0xLTEtMA_92501fdb-880c-4783-9ebf-5e86a077d0fb">318,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjAtMS0xLTEtMA_13051d8b-b929-4de6-bc1f-6a296ba31370">36,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjAtMy0xLTEtMA_d90585a3-3fe0-4dbb-89d5-4e2819de7af8">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjEtMS0xLTEtMA_12038952-6e9f-4981-8eee-440f4b7dac31">27,268</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjEtMy0xLTEtMA_0f251da3-620f-49e2-a12d-08d9b3f1a5c9">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjItMS0xLTEtMA_2a7f04e2-4daf-4026-b9e3-5f7ba3769221">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjItMy0xLTEtMA_39ec8b4f-e5a2-450f-9bfc-009939fda07f">746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjMtMS0xLTEtMA_c4429c7b-b4cf-4832-90e3-55718b9cb923">6,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjMtMy0xLTEtMA_f0d390b7-3857-405e-921b-1c20de702a27">4,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjQtMS0xLTEtMA_901dbb51-7a45-4ec6-9548-08249247dbe0">20,736</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjQtMy0xLTEtMA_7596d8e1-2f1b-40f9-8083-883602c68c98">1,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjYtMS0xLTEtMA_ebce6211-9c4b-4869-bd1c-61bd2a98b4b7">592,923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjYtMy0xLTEtMA_b529432b-9211-4eef-b0ca-b94d329dd478">554,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjgtMS0xLTEtMA_fe9a54f9-12bd-4793-8833-c02a526a16c7">877,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjgtMy0xLTEtMA_82b329c0-c59e-45d3-a0bd-d91425ca999e">849,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzEtMS0xLTEtMA_1ea37a39-c022-4a9d-835e-50fbb71393bc">13,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzEtMy0xLTEtMA_00c766a0-e016-444b-b2d7-3be0906bc478">11,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i589fabd65c4646419606584faadebff8"><div style="margin-bottom:5pt;margin-top:14pt"><ix:continuation id="i0bd1e5695c4f40eab5c5686fac331cff"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:71.773%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.658%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzItMS0xLTEtMA_7d150edc-7b4f-4ffa-b852-8aaa4494969d">3,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="ameh:FiduciaryAccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzItMy0xLTEtMA_939cb17c-9dc4-4479-bd6e-cbb19b6f130f">2,027</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzMtMS0xLTEtMA_d2353497-7f76-4b11-ab52-cbc97153692d">42,546</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzMtMy0xLTEtMA_7fb2b6cb-a58f-4529-a811-a21c63516419">49,019</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzQtMS0xLTEtMA_9f185185-35a1-4027-b9a8-b64c1a3dc04e">15,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TaxesPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzQtMy0xLTEtMA_dc0a1e51-11a7-4846-91e7-4fbad55d1412">4,530</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzUtMS0xLTEtMA_66c3f77c-1385-4875-a3b8-107b8d3862f6">22,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DueToAffiliateCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzUtMy0xLTEtMA_4bc4411b-6b8c-4f1a-8be8-1414cc13dbc7">28,058</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzYtMS0xLTEtMA_216c1473-72cb-4ebd-89c6-64ae48084b0d">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:DividendsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzYtMy0xLTEtMA_a9cfe592-c1ec-43ab-b368-a8c7010f1881">271</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzctMS0xLTEtMA_b65493c6-ac34-4291-bbdb-8ba98612c473">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzctMy0xLTEtMA_66f4ace4-05cb-4496-8cff-8b895e51386d">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzgtMS0xLTEtMA_8df57541-a4bb-461a-b765-5500b658c490">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzgtMy0xLTEtMA_7b8b9f22-b54f-4f95-b3b5-cb1f15d871f2">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDAtMS0xLTEtMA_8c19cc56-ceed-4cd4-9517-70672e7fd7aa">99,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDAtMy0xLTEtMA_e7d5f5a9-9b4f-4010-a0eb-19b2c82b9fac">96,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDMtMS0xLTEtMA_f3a71c9c-63f0-4ce3-ae57-8174690a5ba4">7,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDMtMy0xLTEtMA_dd6b2212-dbe2-4741-bf94-4a03cc8e548f">14,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDQtMS0xLTEtMA_495c9f99-203f-40f3-8c3c-133333ef2fcc">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDQtMy0xLTEtMA_2c384370-79ff-4251-86f6-df2b858a553b">416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDUtMS0xLTEtMA_dd395d68-2b1c-4773-a67a-8d926852fbc7">5,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDUtMy0xLTEtMA_524bfcc1-9151-4686-85d3-a5e9c47320f3">3,742</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDctMS0xLTEtMA_829c2d7e-bb12-4a35-8f2e-a4e862f96b8f">13,574</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDctMy0xLTEtMA_0f285704-822b-478a-89b5-50e9e3d6a003">18,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDktMS0xLTEtMA_8ceaebd1-3fa8-4011-a764-2cb6fc2ba646">112,976</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0760f54a264410584d47359d3245e54_I20191231" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDktMy0xLTEtMA_a7536bba-c81f-4ebd-984e-90ceea19637b">114,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_85"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1MQ_847f0aa9-9317-470d-ad3a-e66daf66088e" continuedAt="i58083b020167473da7ce08e302e36b1b" escape="true"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1OQ_beffee30-8cc4-4fd4-b9ee-64e92c2f2315" continuedAt="ie8bf94ac73c64556bc1ce7424a8df4d9" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i58083b020167473da7ce08e302e36b1b" continuedAt="i3121447eca03404993ca74726fb87842"><ix:continuation id="ie8bf94ac73c64556bc1ce7424a8df4d9" continuedAt="i5b6cb10ccdd64225a77c2a30f1e988bb"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of <ix:nonNumeric contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930" format="ixt-sec:durmonth" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTY5_cee1c562-f8f5-4f08-a8ed-ba9a1bbcadf7"><ix:nonNumeric contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930" format="ixt-sec:durmonth" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTY5_d0abd8ce-56d0-4268-8d28-2b4d9f9b4b62">1</ix:nonNumeric></ix:nonNumeric> month to <ix:nonNumeric contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTc1_8a6577c8-c228-4b2c-9499-29086c9b99f0"><ix:nonNumeric contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTc1_af1558af-94d2-477f-af2d-5c2b6e2cacef">5</ix:nonNumeric></ix:nonNumeric> years, some of which may include options to extend the leases for up to <ix:nonNumeric contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMjQ0_0f31fbd0-c004-43d1-a229-428a9bbea136"><ix:nonNumeric contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" format="ixt-sec:duryear" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMjQ0_34bcef26-4e0e-4138-a3a2-d1487c2fd332">10</ix:nonNumeric></ix:nonNumeric> years, and some of which may include options to terminate the leases within <ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:durwordsen" name="ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzIz_2aa2ac4b-e54c-4fb5-92a7-c30df31659f9"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" format="ixt-sec:durwordsen" name="ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzIz_66eab837-37d3-4c58-8dd2-affc620ae6d8">one year</ix:nonNumeric></ix:nonNumeric>. As of September&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $<ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzg2_a4679c77-320b-4ea0-8018-8fbd1616b7a5">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzkz_b6714ef3-7b66-4230-a1e0-741dab3882af">0.5</ix:nonFraction> million, respectively, and accumulated depreciation associated with finance leases were $<ix:nonFraction unitRef="usd" contextRef="i330f7b2e0da941fb9b4510efb972e459_D20191231-20191231" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfNDc1_34449ba1-d39d-4c4b-b768-cea99086c0f2"><ix:nonFraction unitRef="usd" contextRef="id94edb672a3f42dca68cdffe56fed10d_D20200930-20200930" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfNDc1_8cdc9cb8-1a0b-497b-bc81-32d55404b85c">0.3</ix:nonFraction></ix:nonFraction> million, for both periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1MA_4e2773b4-2a24-4201-a5b0-2206c424be78" continuedAt="i6f9331cd4add482683802d44f799ebe1" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.551%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMy0xLTEtMS0w_1a5350e2-e35b-4926-8fef-a06e3e232096">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMy0zLTEtMS0w_cedf5f1b-4fc3-4fa9-bf1c-318df598031c">1,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNi0xLTEtMS0w_71824bb6-032d-454a-b7ac-72e508e924ec">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNi0zLTEtMS0w_e5cb142f-7b58-47b9-b71f-07219e74855d">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNy0xLTEtMS0w_976e31ea-e2bb-40be-a94f-7a231375935e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNy0zLTEtMS0w_c956274b-d495-4fc1-acf7-4d2b00aaa0a3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfOS0xLTEtMS0w_2f160b56-7255-4fff-bc28-5571690312c8">206</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfOS0zLTEtMS0w_8afb95d4-538f-4eaa-9113-5755d5205973">103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMTEtMS0xLTEtMA_cc1b956a-6400-4ce8-b4b8-1cb2ded82ff0">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMTEtMy0xLTEtMA_74519cbb-4659-4af5-9e5e-0838d9c50143">1,416</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMy0xLTEtMS0w_32b56274-7b7d-4470-9e20-6d3aee50cab9">5,172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMy0zLTEtMS0w_669722d9-6ed2-4323-830e-f1b1dd00546c">3,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNi0xLTEtMS0w_1c4b6732-e52e-4d83-b8f0-2c08ad277289">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNi0zLTEtMS0w_3e7bc84e-e8c3-42dc-a4a6-2e7e8b1cd97a">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNy0xLTEtMS0w_da6bd43d-086d-43af-a83c-079ab5fc0ee1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNy0zLTEtMS0w_f940e28c-540e-40c7-ba9f-0cab315744c4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfOS0xLTEtMS0w_a595d74b-f95a-4369-a589-612beddd1102">567</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfOS0zLTEtMS0w_36b7da7b-a06b-4f58-92ad-2cbf666be7b8">309</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMTEtMS0xLTEtMA_0b056084-c911-42c7-aff4-fc2688009cc6">4,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMTEtMy0xLTEtMA_d6c4546f-73bd-45c7-a685-cfc56536b2fe">3,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i3121447eca03404993ca74726fb87842" continuedAt="i99a363f3cfe84318add7d8e1c81c3ad7"><ix:continuation id="i5b6cb10ccdd64225a77c2a30f1e988bb" continuedAt="i6ae777c073b74ae6a96fb7f4c9360fb1"><ix:continuation id="i6f9331cd4add482683802d44f799ebe1"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.697%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNi0xLTEtMS0w_a7611e94-e31b-4879-8534-605d9aba75a0">1,489</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNi0zLTEtMS0w_4d4bbbdb-3a0f-4639-a315-28a15fbb503f">1,677</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNy0xLTEtMS0w_5e29b2c6-9039-4ab6-a68e-220affbf4b69">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNy0zLTEtMS0w_dfa5818c-ddf4-4264-92f5-10e58d66ef1e">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfOC0xLTEtMS0w_a6596698-a6fe-479c-a935-f0ee8070ac6e">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfOC0zLTEtMS0w_ef77bcc5-347f-4138-9375-e1d1b58e3f6d">26</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTEtMS0xLTEtMA_e43f79ba-b6ba-4871-8e87-8c5f4055ff5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930" decimals="-3" format="ixt:zerodash" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTEtMy0xLTEtMA_c4d76bf3-d0dd-4dac-b14d-2ea0e1d26fda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTktMS0xLTEtMA_7787465d-2e29-4050-a336-8313d4a8089d">4,369</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTktMy0xLTEtMA_eeb4c4f5-2799-47a5-a6d9-7f076aaa065d">3,950</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjAtMS0xLTEtMA_c338a596-d3fc-444f-887b-0ea25d83f7ac">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjAtMy0xLTEtMA_289b15d9-787c-4a19-a2c6-1207f8659430">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjEtMS0xLTEtMA_02fae51d-6583-4675-add7-702678d93dfd">78</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjEtMy0xLTEtMA_fc5654db-f792-428d-b45f-78f34dfe26ac">76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjQtMS0xLTEtMA_286de5b7-5fd4-495e-a374-50ddf7bd613b">7,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjQtMy0xLTEtMA_21a93409-b678-4e6f-9e5f-ee73b261f6bb">15,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzEtMS0xLTEtMA_5f6bc13c-ec95-48e8-b4f2-bf9f3e940f11">6.93</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzEtMy0xLTEtMA_555eb140-8c58-4d57-b8c4-056c8a047c20">6.80</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzItMS0xLTEtMA_abb109ba-9540-492d-89c2-e461e5180db4">3.92</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzItMy0xLTEtMA_4b9917dc-a83c-46e5-bd65-e8a124c8d533">4.92</ix:nonNumeric> years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Discount Rate</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzYtMS0xLTEtMA_7a8274b7-a1f6-490b-b45e-db8fb118e029">6.10</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="4" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzYtMy0xLTEtMA_9bb61068-d59e-4ddb-a014-1eaa0a69357b">6.12</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzctMS0xLTEtMA_8bd005ab-c038-46b0-9d4d-99d0a3053497">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930" decimals="4" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzctMy0xLTEtMA_0b914dba-acd8-4611-9532-236cdcee36dc">3.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><ix:continuation id="i99a363f3cfe84318add7d8e1c81c3ad7"><ix:continuation id="i6ae777c073b74ae6a96fb7f4c9360fb1"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA0Nw_6c2821c8-d5f8-44f6-be7a-43e620045fe2" escape="true"><ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1Nw_86581b38-a2ad-4ba4-8aba-626c465c3af4" escape="true"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.145%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMS0xLTEtMS0w_0d8d3deb-9cba-44f5-9c20-82dae44ef368">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMS0zLTEtMS0w_98a4a2a8-bf3b-4638-8e4b-6c1d68dcbe55">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMi0xLTEtMS0w_55fd7e1f-9e67-4c29-932e-ee5daa2b0d39">4,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMi0zLTEtMS0w_41532c31-80a6-4f20-a73e-c2ad4c08dfb2">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMy0xLTEtMS0w_6d844fbe-4b5d-4087-a41c-99ce5df5fc3f">3,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMy0zLTEtMS0w_ca8882ba-1d59-408b-8b48-464cbd967753">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNC0xLTEtMS0w_28c28b88-a996-4796-ba90-cfc0437e1f1a">3,303</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNC0zLTEtMS0w_a18c6fbb-3dc5-4e72-a0fc-91c09f4695ee">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNS0xLTEtMS0w_aed99d7f-03e5-464c-bc86-961cf3c35596">2,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNS0zLTEtMS0w_65924f13-5c47-495f-b768-906741cb81a1">79</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNi0xLTEtMS0w_ead40a6d-ba6d-42eb-b669-d57ffb2e2d47">9,459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:zerodash" name="ameh:FinanceLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNi0zLTEtMS0w_62638c7b-7472-4998-ae31-002b31477a79">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOC0xLTEtMS0w_612c0454-6c27-43fc-9286-8a0ae0a6735b">24,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOC0zLTEtMS0w_31180bf4-5a5f-4f6f-86c8-8337c41ea75c">466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOS0xLTEtMS0w_5f2d7e3b-21ef-4f1c-af23-40e7f6e34998">4,795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOS0zLTEtMS0w_2b8011b2-45e0-48b8-badf-f72ee8eabbd0">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTAtMS0xLTEtMA_9184fbf5-0710-4f24-821b-615e08d2537c">19,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTAtMy0xLTEtMA_f732ee30-e009-4c1f-8c56-75fc4c39f524">439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTEtMS0xLTEtMA_cf172e91-55bb-4c33-9b19-5132800bb971">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTEtMy0xLTEtMA_42cc792c-b19d-4e7f-9b14-36fdee443b67">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTItMS0xLTEtMA_5a720965-1aa3-41aa-9f09-cf92bbc631b7">16,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTItMy0xLTEtMA_b7458562-08e4-4738-a4a2-581fe912fcba">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div></ix:continuation></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_88"></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTk3OTEyMDkzMDA2Njk_6a4e01cf-accb-4d8e-b92e-b1a1edaf7108" continuedAt="ib160f9aeef0e4e3caf0503c00ece13fb" escape="true">Subsequent Events</ix:nonNumeric></span></div><ix:continuation id="ib160f9aeef0e4e3caf0503c00ece13fb"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, APC's board of directors declared an in-kind dividend of <ix:nonFraction unitRef="usd" contextRef="icf38a8ac3d85467baeb00dcd1a446031_D20200901-20200930" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:Dividends" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTIwOTQ2Mjc5MDY5NDY_e356157e-3ddd-42fd-bb17-ffbf57ec57a3">5</ix:nonFraction>&#160;million shares of ApolloMed's common stock on a pro rata basis to APC's shareholders in November 2020. The shares being distributed is from the Excluded Assets that remain solely for the benefit of APC and its shareholders.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promissory note</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC, a related party of the Company, (the &#8220;2020 Note&#8221;) as payee for a principal sum of $<ix:nonFraction unitRef="usd" contextRef="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:NotesReceivableGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTY0OTI2NzQ0MTczNDM_d1fb8510-5539-4e5c-94e9-702e467b0482">4.0</ix:nonFraction> million with a maturity date of <ix:nonNumeric contextRef="i91c0b71ccc814cd5ba5b3e0b0bf65898_D20201001-20201031" format="ixt-sec:durwordsen" name="ameh:FinanceReceivableTermOfReceivable" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTIwOTQ2Mjc5MDk2ODg_21a7125b-361f-40f4-af5f-662bf67bd2e5">two years</ix:nonNumeric> from the date of the agreement. The contractual interest rate on the 2020 Note is <ix:nonFraction unitRef="number" contextRef="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031" decimals="INF" name="ameh:FinanceReceivableInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTY0OTI2NzQ0MTczNTU_ceec8c40-9219-4792-b020-faa1a504c5db">3.75</ix:nonFraction>%  per annum. The funds lent pursuant to the 2020 Note are the same funds that were deposited for investment opportunities in March 2020 (the "March Deposit"). As with the March Deposit, the 2020 Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH.</span></div></ix:continuation><div id="ie94880a2d5df40d2b763e3a0bdef79c1_91"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following management&#8217;s discussion and analysis should be read in conjunction with the unaudited consolidated financial statements and the notes thereto included in Part I, Item 1, &#8220;Financial Statements&#8221; of this Quarterly Report on Form 10-Q. In addition, reference is made to our audited consolidated financial statements and notes thereto and related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC on March 16, 2020.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_94"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We together with our affiliated physician groups and consolidated entities are a leading physician-centric, technology-enabled healthcare management company. Leveraging our proprietary population health management and healthcare delivery platform, we operate an integrated, value-based healthcare model, which aims to empower the providers in our network to deliver the highest quality of care to our patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, our subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). Our NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare &amp; Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our NGACO model and a network of IPAs with more than 7,000 contracted physicians, we are currently responsible for coordinating care for approximately 1.1 million patients in California.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_97"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 5, 2020, the Integrated Healthcare Association ("IHA") recognized Allied Pacific of California IPA for our exceptional performance. Allied Pacific of California IPA performed in the top 10 percent of all participating physicians organizations in the Total Cost of Care Domain during measurement year 2019 in IHA's Align. Measure. Perform. ("AMP") Commercial HMO program. IHA honors physicians organizations with the highest level of performance for each AMP Commercial HMO measurement domain.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_100"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Key Financial Measures and Indicators</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Revenues</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO AIPBP revenue, management fee income and FFS revenue. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our largest expense is the patient care cost paid to contracted physicians, and the cost of providing management and administrative support services to our affiliated physician groups. These services include providing utilization and case management, physician practice billing, revenue cycle services, physician practice management, administrative oversight, coding services and other consulting services.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_103"></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Apollo Medical Holdings, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Unaudited)</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation, net</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135,032&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk pool settlements and incentives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,518&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fee-for-services, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121,823&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,307)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,270&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(246)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment of intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,767&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,227)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,651)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,466)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,638)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">752&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,490)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other (expense) income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,355&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,536)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(127)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,682&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,424&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,685&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 20.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,711&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,713&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,009&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.917%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$ Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation, net</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416,402&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk pool settlements and incentives</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,155&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,212&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,867&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,655)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fee-for-services, net</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,059&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,625)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,867&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,530&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating expenses</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">315,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for doubtful accounts</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,363)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment of intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,994&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,994)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total expenses</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455,770&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,390&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other income (expense)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income  from equity method investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,657)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,544&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,318)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,989&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,040&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income before provision for income taxes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,616&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,436&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,180&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,483&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,721&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:20.25pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 9pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net income attributable to Apollo Medical Holdings, Inc.</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,809&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,389&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,420&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Percentage change of over 500%</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Apollo Medical Holdings, Inc.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the three months ended September&#160;30, 2020, was $16.7 million, as compared to $3.7 million for the same period in 2019, an increase of $13.0 million. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net income attributable to Apollo Medical Holdings, Inc. for the nine months ended September&#160;30, 2020, was $27.8 million, as compared to $7.4 million for the same period in 2019, an increase of $20.4 million. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in net income attributable to Apollo Medical Holdings, Inc. for the three and nine months ended September&#160;30, 2020, was primarily driven by the completion of a series of transactions with APC as further described in Note 1 to our financial statements above, which resulted in preferred, cumulative dividends from APC being allocated to AP-AMH and the results of operations as described below.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physician Groups and Patients</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and 2019, we managed a total of 14 and 12 groups of affiliated physicians, respectively, and the total number of patients for whom we managed the delivery of healthcare services was approximately 1.1 million and 1.0 million, respectively. The increase was attributable to management services agreements we entered into with independent practice associations, Community Family Care Medical Group IPA, Inc. ("CFC") and Beverly Alliance IPA dba Beverly Alianza IPA, which contributed 0.1 million new members.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the three months ended September&#160;30, 2020, was $180.1 million, as compared to $156.1 million for the three months ended September&#160;30, 2019, an increase of $24.0 million, or 15%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $4.2 million driven by the acquisition of Accountable Health Care on August 30, 2019 and organic growth at APC, which contributed additional capitation revenue of approximately $6.5 million and $6.7 million, respectively. This increase was offset with a slight decrease in capitation revenue due to timing of $8.0 million of APAACO capitation revenue and the related claims expenditures incurred and $1.0 million of retroactive adjustments decreasing membership at Alpha Care. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool settlement and incentive revenue increased by $19.6 million primarily due to the shared savings earned related to the settlement of the 2019 ACO performance year of $19.8 million.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue for the nine months ended September&#160;30, 2020 was $510.4 million, as compared to $381.9 million for the nine months ended September&#160;30, 2019, an increase of $128.5 million, or 34%. The increase in revenue was primarily attributable to the following:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) Capitation revenue increased by approximately $110.9 million primarily due to our acquisitions of Alpha Care on May 31, 2019 and Accountable Health Care on August 30, 2019, which contributed additional revenue of approximately $52.0 million and $30.8 million, respectively, in addition to organic growth at APC of $11.2 million due to increased capitation rates. Further, APAACO generated additional capitation revenue of approximately $16.2 million for the nine months ended September 30, 2020 as compared September 30, 2019, due to the delayed start of the 2019 APAACO performance year which began on April 1, 2019 and resulted in less revenue in early 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) Risk pool revenue increased by $21.5 million primarily due to the shared savings earned related to the settlement of the 2019 ACO performance year of $19.8 million and the continued refinement of the assumptions used to estimate the amount of net surplus expected to be received from the affiliated hospitals&#8217; risk pools. Our estimated risk pool receivable is calculated based on reports received from our hospital partners and on management&#8217;s estimate of the Company&#8217;s portion of any estimated risk pool surpluses for which payments have not been received. The actual risk pool surpluses are settled approximately 18 months later.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) Management fee income decreased by $1.7 million mainly due to our acquisition of Accountable Health Care, which reduced management fee income by $5.7 million, a decrease of $0.5 million in management fees due to timing of membership adjustments at LMA and a reduction in hospitalist stipend of $1.0 million as we focused our resources to our core hospital partners. This decrease was offset by management fee income of $5.5 million for the nine months ended September&#160;30, 2020 generated from the management services agreement we entered into with CFC which became effective on January 1, 2020, and Beverly Alianza IPA, which became effective on July 1, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv) Fee-for-service revenue decreased by $2.6 million due to reduced procedures performed at our surgery centers and heart center as a result of the extended COVID-19 outbreak.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the three months ended September&#160;30, 2020, were $121.8 million, as compared to $131.1 million for the same period in 2019, a decrease of $9.3 million, or 7%. The overall decrease was due to a $10.3 million decrease in medical claims, capitation and other health services expenses resulting from reduced elective procedures as a result of the COVID-19 outbreak offset by the $1.0 million increase in payroll expenses related to an increase in the number of employees related to the growth in both the depth and breadth of our operations in multiple markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses related to cost of services for the nine months ended September&#160;30, 2020, were $402.1 million, as compared to $315.9 million for the same period in 2019, an increase of $86.2 million, or 27%. The overall increase was due to a $90.6 million increase in medical claims, capitation and other health services expenses, primarily driven by the acquisition of Alpha Care, Accountable Health Care and AMG, in addition to increased costs at APAACO for the nine month period ended September&#160;30, 2020, as compared to the same period in 2019 due to the delayed start of the 2019 APAACO performance year and a $5.2 million increase in payroll expenses related to an increase in the number of employees related to the growth in both the depth and breadth of our operations in multiple markets. The increased costs were offset by a net decrease of $10.0 million in bonus payments made to providers for the nine months ended September&#160;30, 2020 as compared to the bonus payments made to providers during the same period in 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the three months ended September&#160;30, 2020, were $16.3 million, as compared to $8.0 million for the same period in 2019, an increase of $8.3 million, or 105%. The increase was primarily due to a $4.4 million increase in bonus paid to ACO physicians driven by the increase in shared savings earned related to the settlement of the 2019 ACO performance year and a reduction in professional services costs of $2.0 million specific to the three months ended September 30, 2019. The remaining increase was primarily due to continued growth in the depth and breadth of our operations in multiple markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses for the nine months ended September&#160;30, 2020 were $39.7 million, as compared to $30.0 million for the same period in 2019, an increase of $9.7 million, or 32%. The increase is primarily due to a $4.4 million increase in bonus paid to ACO physicians driven by the increase in shared savings earned related to the settlement of the 2019 ACO performance year and a reduction in professional services costs of $2.0 million specific to the three months ended September 30, 2019. The remaining increase was primarily due to continued growth in the depth and breadth of our operations in multiple markets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the three months ended September&#160;30, 2020 were $4.7 million, as compared to $4.9 million for the same period in 2019. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expenses for the nine months ended September&#160;30, 2020 were $14.0 million, as compared to $13.8 million for the same period in 2019. This amount includes depreciation of property and equipment and the amortization of intangible assets.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Doubtful Accounts</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2019, we released reserves related to certain management fees in the amount of approximately $1.4 million as collectability of the outstanding amount was no longer in doubt. These reserves were related to various preacquisition obligations of Accountable Health Care and were no longer necessary as a result of our acquisition of Accountable Health Care. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Intangibles</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2019, we recorded impairment of intangible assets totaling $2.0 million related to Medicare licenses obtained as part of the 2017 merger between NMM and ApolloMed. We no longer utilize the licenses and will not receive future economic benefits therefrom.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from Equity Method Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments for the three months ended September&#160;30, 2020, was $0.4 million, as compared to income from equity method investments of $2.1 million for the same period in 2019, a decrease of $1.7 million. The decrease was primarily due to a $1.8 million gain recognized related to our investment in Accountable Health Care resulting from our acquisition  in August 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments for the nine months ended September&#160;30, 2020, was $3.3 million, as compared to income from equity method investments of $1.2 million for the same period in 2019, an increase of $2.1 million. The increase was primarily due to equity earnings from our investment in UCI of $3.7 million, offset by equity loss from our investment in 531 W. College of $0.4 million, as the property is in redevelopment to a multi-specialty clinic, for the nine months ended September&#160;30, 2020. This is compared with equity earnings from our investments in UCI, DMG, and PMIOC of $6.1 million, $0.7 million, and $0.2 million, respectively, offset with equity losses from our investments in LMA's IPA line of business and Accountable Health Care of $2.8 million and $2.7 million, respectively, and the recognition of an impairment loss of $0.3 million related to our investment in PASC for the nine months ended September 30, 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of Equity Method Investments</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on sale of equity method investments for the nine months ended September&#160;30, 2020, was $99.6 million resulting from the sale of UCI which closed on April 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the three months ended September&#160;30, 2020, was $2.5 million, as compared to $0.8 million for the same period in 2019, an increase of $1.7 million. The increase was primarily due to the credit facility we secured in September 2019 to fund growth, primarily through acquisitions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense for the nine months ended September&#160;30, 2020, was $8.0 million, as compared to $1.4 million for the same period in 2019, an increase of $6.6 million. The increase was primarily due to the new credit facility we secured in September 2019 to fund growth, primarily through acquisitions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income for the three and nine months ended September&#160;30, 2020, was $0.8 million and $2.5 million, respectively, as compared to $0.5 million and $1.3 million, respectively, for the three and nine months ended September&#160;30, 2019. Interest income reflects interest earned on cash held in money market and certificate of deposit accounts and the interest from notes receivable.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income for the three and nine months ended September&#160;30, 2020, was $0.1 million and $1.5 million as compared to other income of $2.6 million and $2.8 million, respectively, for the same periods in 2019. The decrease in other income was primarily due to the assumption of a loan receivable as a result of the Accountable Health Care acquisition in August 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Tax</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $10.8 million for the three months ended September&#160;30, 2020, as compared to $3.7 million for the same period in 2019. The increase in tax expense was due to increased income in the three months ended September&#160;30, 2020, period as compared to the same period in 2019, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense was $44.2 million for the nine months ended September&#160;30, 2020, as compared to $6.5 million for the same period in 2019. The increase in tax expense was due to increased income in the nine months ended September&#160;30, 2020 period as compared to the same period in 2019, as described above.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests was $8.7 million for the three months ended September&#160;30, 2020, compared to $7.0 million for the same period in 2019, an increase of $1.7 million. The increase was primarily driven by the increased income generated in the current period which resulted in additional income allocated to the noncontrolling interest.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests was $81.6 million for the nine months ended September&#160;30, 2020, compared to $11.6 million for the same period in 2019, an increase of $70.0 million. The increase was primarily due to of sale of UCI in April 2020 where the gain remains strictly with the APC Excluded Assets and increased income generated in the current period which resulted in additional income allocated to the noncontrolling interest.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_106"></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Guidance</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We are raising our previously disclosed full-year 2020 net income, Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;), and adjusted EBITDA guidance as a result of a net shared savings settlement of $13.3 million (net of provider bonus) earned in the third quarter of 2020 as a reward from participating in an attribution-based risk sharing model. ApolloMed is raising its previously disclosed full-year 2020 net income, Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;), and adjusted EBITDA guidance as a result of a net shared savings settlement of $13.3 million (net of provider bonus) earned in the third quarter of 2020 as a reward from participating in an attribution-based risk sharing model. Net income and EBITDA include the impact of the gain of approximately $99.6 million related to the sale of Universal Care Acquisition Partners, LLC's ("UCAP") 48.9% investment in Universal Care, Inc. ("UCI") to Bright Health Company of California, Inc. ("Bright"), which closed on April 30, 2020. As UCI was included in Excluded Assets and remained solely for the benefit of ApolloMed's affiliate, Allied Physicians of California, a Professional Medical Corporation, ("APC") and its shareholders, the gain on sale does not affect the net income attributable to ApolloMed and adjusted EBITDA attributable to ApolloMed.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our guidance for the year ending December 31, 2020, is as follows:</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining total revenue between $665.0 million and $675.0 million due to impact of COVID-19 on FFS revenue,</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising net income from a range of $100.0 million to $110.0 million (disclosed on May 27, 2020) to a range of $110.0 million to $120.0 million,</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising EBITDA from a range of $155.0 million to $167.0 million (disclosed on May 27, 2020) to a range of $182.0 million to $194.0 million, and</span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising adjusted EBITDA from a range of $75.0 million to $90.0 million (disclosed on March 12, 2020) to a range of $97.0 million to $112.0 million.</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;See "Guidance Reconciliation of Net Income to EBITDA and adjusted EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and "Use of Non-GAAP Financial Measures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">"</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" within this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:13pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.321%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ending</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2020</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;(in thousands)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Low</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">High</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,000&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Provision for income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Interest income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Income from equity method investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EBITDA adjustment for recently acquired IPAs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted EBITDA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income and EBITDA include the gain on sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI was included in Excluded Assets and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from equity method investments is mainly attributed to the sale of UCAP's 48.9% investment in UCI to Bright, which closed on April 30, 2020. UCAP is a 100% owned subsidiary of APC and its 48.9% investment in UCI was included in Excluded Assets and as such remained solely for the benefit of APC and its shareholders. As such, any proceeds or gain on sale has not affected the net income and adjusted EBITDA attributable to ApolloMed.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:8pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:144%">Use of Non-GAAP Financial Measures</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains the non-GAAP financial measures EBITDA and adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with GAAP is net (loss) income. These measures are not in accordance with, or an alternative to, U.S. generally accepted accounting principles, (&#8220;GAAP&#8221;), and may be different from other non-GAAP financial measures used by other companies. The Company uses adjusted EBITDA as a supplemental performance measure of our operations,&#160;for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income from equity method investments, provider bonuses, impairment of intangibles, provision of doubtful accounts and other income earned that is not related to the Company's normal operations. Adjusted EBITDA also excludes the effect on EBITDA of certain IPAs we recently acquired. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of ApolloMed's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_109"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investment in marketable securities at September&#160;30, 2020, totaled $284.4 million as compared to $219.7 million at December 31, 2019. Working capital totaled $235.2 million at September&#160;30, 2020, as compared to $223.7 million at December&#160;31, 2019, an increase of $11.5 million, or 5%.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operations primarily through internally generated funds. We generate cash primarily from capitation contracts, risk pool settlements and incentives, fees for medical management services provided to our affiliated physician groups and fee-for-service reimbursements. We generally invest cash in money market accounts, which are classified as cash and cash equivalents. We believe we have sufficient liquidity to fund our operations through at least the next 12 months.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our cash, cash equivalents and restricted cash increased by $62.8 million from $104.0 million at December&#160;31, 2019, to $166.8 million at September&#160;30, 2020. Cash provided by operating activities during the nine months ended September&#160;30, 2020, was $48.8 million, as compared to $10.1 million for the nine months ended September 30, 2019. The increase was primarily driven by the timing of our working capital accounts. For the nine months ended September&#160;30, 2020, receivable, net, receivable, net - related parties, and other receivable resulted in net cash inflow of $12.6 million as compared to cash outflow of $6.0 million for the same period in 2019, while accounts payable and accrued expenses and income taxes payable resulted in net cash inflow of $24.3 million as compared to cash outflow of $5.4 million for the nine months ended September&#160;30, 2020 and September 30, 2019, respectively. This was offset with a non cash adjustment to net income related to deferred taxes of $6.1 million for the nine months ended September 30, 2020 as compared to $0.2 million for the same period in 2019.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by from investing activities during the nine months ended September&#160;30, 2020, was $66.4 million,  primarily due to proceeds received related to the sale of UCI totaling $52.7 million and loan receivables of $16.5 million offset with cash outflow related to the purchase of marketable securities of $1.8 million, funding for an equity method investment of $0.5 million, and capital expenditures (mainly purchases of property and equipment) of $0.5 million. This is compared to cash used of $60.4 million for the nine months ended September 30, 2019 due to payments for business acquisition of $49.4 million, advances on loans receivable of $7.4 million, funding for an equity method investment of $3.0 million, and capital expenditures of $0.8 million offset with dividends received of $0.2 million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities during the nine months ended September&#160;30, 2020, was $52.3 million as compared to cash provided by financing activities of $173.7 million for the nine months ended September 30, 2019. Cash used for the nine  months ended September&#160;30, 2020 was due to the payments of dividends totaling $50.1 million, repayment on our term loan totaling $7.1 million and repurchase of shares of $1.6 million, offset with proceeds from exercise of stock options and warrants of $6.6 million. This is compared to cash provided by for the nine months period ended September 30, 2019 due to proceeds from borrowings on our line of credit of $289.6 million, proceeds from the exercise of stock options and warrants of $2.4 million and proceeds from common stock offering of $0.8 million offset with payments of dividends, repayments on our bank loan and lines of credit and cost of debt and equity issuance totaling $60.7 million,  $52.6 million and $5.6 million respectively.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_1341"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Excluded Assets</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term Excluded Assets. &#8220;Excluded Assets&#8221; means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluded Assets consisted of the following (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.838%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,957&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,013&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,853&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities - equity method</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,070&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Excluded Assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,310&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163,363&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_112"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Credit Facilities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents scheduled commitments of the Company&#8217;s credit facility is to be as follows for the years ending December 31  (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:82.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.883%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual facility fee of between 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc. (now known as Truist Securities Inc.), the lead arranger of the Credit Agreement.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of September&#160;30, 2020, the interest rate on Term Loan A for the 2020 commitment and future commitments was 2.72% and 2.77%, respectively. As of September&#160;30, 2020, the interest rate on the Revolver Loan was 2.77%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Covenant Ratios </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Requirement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">September 30, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated leverage ratio</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less than 3.75 to 1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.79</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consolidated interest coverage ratio</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Greater than 3.25 to 1.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) All covenant ratio titles utilize terms as defined in the respective debt agreements. </span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2020 and 2019, was 3.79% and 1.31%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and nine months ended September&#160;30, 2020 and 2019, of $0.3 million and 0.1&#160;million, respectively, and $1.0 million and $0.1 million, respectively.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NMM Business Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% as of September&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September&#160;30, 2020,  outstanding letters of credit totaled $8.2 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% and 4.875% as of September&#160;30, 2020 and December&#160;31, 2019, respectively.  As of September&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany Loans</span></div><div style="margin-top:10pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of AMH, MMG, BAHA, AKM Medical Group, Inc. ("AKM") and SCHC has entered into an Intercompany Loan Agreement with AMM under which AMM has agreed to provide a revolving loan commitment to each such affiliated entities in an amount set forth in each Intercompany Loan Agreement. Each Intercompany Loan Agreement provides that AMM&#8217;s obligation to make any advances automatically terminates concurrently with the termination of the management agreement with the applicable affiliated entity. In addition, each Intercompany Loan Agreement provides that (i) any material breach by the shareholder of record of the applicable Physician Shareholder Agreement or (ii) the termination of the management agreement with the applicable affiliated entity constitutes an event of default under the Intercompany Loan Agreement. All the intercompany loans have been eliminated in consolidation (in thousands).  </span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.190%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Entity</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facility</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest<br/>Rate<br/>per Annum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Ending</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principal Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During&#160;Period</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Paid</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">During</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Period</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AMH</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMG</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,663&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AKM</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SCHC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,180&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BAHA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,250&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,179&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_115"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements and related disclosures in conformity with U.S. GAAP requires our management to make judgments, assumptions and estimates that affect the amounts of revenue, expenses, income, assets and liabilities, reported in our consolidated financial statements and accompanying notes. Actual results and the timing of recognition of such amounts could differ from those judgments, assumptions and estimates. In addition, judgments, assumptions and estimates routinely require adjustment based on changing circumstances and the receipt of new or better information. Understanding our accounting policies and the extent to which our management uses judgment, assumptions and estimates in applying these policies, therefore, is integral to understanding our financial statements. Critical accounting policies and estimates are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions.&#160;We summarize our most significant accounting policies in relation to the accompanying consolidated financial statements in Note 2 thereto. Please also refer to the Critical Accounting Policies section of Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2019.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_118"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 2 to the accompanying consolidated financial statements for recently issued accounting pronouncements, including information on new accounting standards and the future adoption of such standards.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_121"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we had no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_124"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inflation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation and changing prices have had de minimis effect on our continuing operations over our two most recent fiscal years.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_127"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under our Credit Agreement exposed us to interest rate risk. As of September&#160;30, 2020, we had&#160;$240.5 million&#160;in outstanding borrowings under our Credit Agreement. The amount borrowed under the Credit Agreement bears interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on LIBOR, adjusted for any reserve requirement in effect, plus a spread of 2.00% to 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread of 1.00% to 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. The base rate is defined in a manner such that it will not be less than LIBOR.&#160;The Company will pay fees for standby letters of credit at an annual rate equal to 2.00% to 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit.&#160;A hypothetical 1% change in our interest rates would have increased or decreased our interest expense for the three months ended September&#160;30, 2020, by&#160;$2.4 million.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_130"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;CONTROLS AND PROCEDURES</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, we carried out an evaluation, under the supervision and with the participation of our management, including our Co-Chief Executive Officers and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures. Based on that evaluation, our management, including Co-Chief Executive Officers and Chief Financial Officer, concluded that our disclosure controls and procedures as defined in Rules 13a-15(e) and 15(d)-15(e) under the Exchange Act, were effective as of September&#160;30, 2020, to ensure that information required to be disclosed by us in this Quarterly Report on Form 10-Q or submitted under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission rules and forms and (ii) accumulated and communicated to our management, including our principal executive officers and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule&#160;13a-15(f)&#160;under Exchange Act) during our third fiscal quarter of 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_133"></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II &#8211; OTHER INFORMATION</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_136"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we from time to time become involved in pending and threatened legal actions and proceedings, most of which involve claims of medical malpractice related to medical services that are provided by our affiliated hospitalists. Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services, which may not come to light until a substantial period of time has passed following contract implementation. We may also become subject to other lawsuits which could involve significant claims and/or significant defense costs, but as of the date of this Quarterly Report on Form 10-Q, except as disclosed, we are not a party to any lawsuit or proceeding, which in the opinion of management is expected to individually or in the aggregate have a material adverse effect on us or our business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_139"></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, financial condition and operating results are affected by a number of factors, whether currently known or unknown, including risks specific to us or the healthcare industry, as well as&#160;risks that affect businesses in general. In addition to the information and risk factors set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A, &#8220;Risk Factors&#8221; in our Annual Report on Form 10-K for the year ended December&#160;31, 2019, filed with the SEC on March 16, 2020. The risks disclosed in such Annual Report and in this Quarterly Report could materially adversely affect our business, financial condition, cash flows or results of operations and thus our stock price. We believe there have been no material changes in our risk factors from those disclosed in the Annual Report except as described below. However, additional risks and uncertainties not currently known or which we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risk factors may be important to understanding other statements in this Quarterly Report and should be read in conjunction with the consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Statements&#8221; and Part I, Item 2, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of this Quarterly Report on Form 10-Q. Because of such risk factors, as well as other factors affecting the Company&#8217;s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The current outbreak of the novel coronavirus disease, or COVID-19, or the future outbreak of any other highly infectious or contagious diseases, could adversely impact or cause disruption to our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An epidemic outbreak or other public health crisis nationally or in the markets where we operate could adversely affect our operations and financial results.&#160; For example, the recent outbreak of COVID-19, the World Health Organization declared a pandemic on March 11, 2020, and which the U.S. declared a national emergency on March 13, 2020, has caused governments and the private sector globally to take a number of drastic precautionary measures to contain the spread of the coronavirus, including the restriction and suspension of in-person classes at schools, colleges and universities, the cancellation of public events and other nonessential mass gatherings and the implementation of work from home, stay at home and other quarantine directives.&#160; The potential impact and duration of the COVID-19 pandemic has had, and continues to have, a significant adverse impact across regional and global economies and financial markets. The global impact of the outbreak has been rapidly evolving and as new cases of the virus have continued, particularly in the U.S., countries around the world and states around the U.S., have reacted by instituting quarantines and restrictions on travel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Almost every state implemented shelter-in-place or stay-at-home directives between March and May 2020, including, among others, Los Angeles and San Bernardino counties, and the state of California, where we operate. The lockdown restrictions implemented included quarantines, restrictions on travel, shelter-in-place orders, school closures, restrictions on types of business that may continue to operate, and/or restrictions on types of construction projects that could continue. These quarantines generally came with exceptions for essential healthcare and public health operations, among other essential businesses.  Beginning in early May 2020, the U.S. began to lift the lockdown restrictions and allow for the reopening of businesses. The gradual reopening of retail, manufacturing, and office facilities came with required or recommended safety protocols. There is no assurance that the reopening of businesses, even if those businesses adhere to recommended safety protocols, will enable us or our subsidiaries, VIEs, affiliated IPAs, contracted physician groups, service providers and suppliers to avoid adverse effects on our or their operations and businesses. Due to the increase in the number of COVID-19 cases after the reopening of many states beginning in early June 2020, there is no assurance that local and state governments will not reinstitute new lockdown directives.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our employees, we have implemented a number of precautionary measures, including a work from home policy, under which the vast majority of our employees currently operate. To date, such measures have not had a substantial impact on employee attendance or productivity, and have not adversely affected our ability to recruit, attract or retain skilled personnel. Our operations, including our ability to effectively provide management services to our affiliated IPAs and contracted physician groups in compliance with regulatory requirements have not been impacted, however, if the outbreak continues to worsen&#160;it may cause disruptions to critical infrastructures and our supply chains and the supply chains of our affiliated IPAs and contracted physician groups, including the supply of pharmaceuticals and medical supplies.&#160; The duration and extent of the impact from the coronavirus outbreak depends on future developments that cannot be accurately predicted at this time, such as the severity and transmission rate of the virus, the extent and effectiveness of containment actions. If we are not able to respond to and manage the impact of such events effectively, our business could be harmed.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_142"></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020, the Company issued an aggregate of 499,663 shares of common stock and received approximately $3,404,374 from the exercise of certain warrants at exercise prices ranging between $9.00 and $10.00 per share. The foregoing issuances were exempt from the registration provisions of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof, and/or Regulation D promulgated thereunder.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_145"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None </span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_148"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_151"></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_154"></div><div style="-sec-extract:summary;margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;EXHIBITS</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are either incorporated by reference into or filed or furnished with this Quarterly Report on Form 10-Q, as indicated below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.703%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.188%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">No.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.1&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Agreement and Plan of Merger, dated December 21, 2016, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (the &#8220;Merger Agreement&#8221;) (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment to the Merger Agreement, dated March 30, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">2.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417059199/tv479301_424b3.htm">Amendment No. 2 to the Merger Agreement, dated October 17, 2017, among Apollo Medical Holdings, Inc., Network Medical Management, Inc., Apollo Acquisition Corp. and Kenneth Sim, M.D. (incorporated herein by reference to Annex A to the joint proxy statement/prospectus filed pursuant to Rule 424(b)(3) on November 15, 2017 that is a part of a Registration Statement on Form S-4)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">2.4</a>&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420419025049/tv520199_ex2-4.htm">Stock purchase agreement dated March 15, 2019</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">(incorporated herein by reference to Exhibit 2.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed on May 10, 2019)</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415002897/v398912_ex3-1.htm">Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on January 21, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415025170/v408340_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on April 27, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-1.htm">Certificate of Amendment of Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed June 21, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">3.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420415066090/v423843_ex3-2.htm">Restated Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 16, 2015)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">3.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420417063540/tv481301_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on December 13, 2017)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">3.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1083446/000114420418035195/tv496923_ex3-2.htm">Amendment to Sections 3.1 and 3.2 of Article III of Bylaws (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed on June 21, 2018)</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3112020093010-qng.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex3122020093010-qng.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.3*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex3132020093010-qng.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322020093010-qng.htm">Certification of Principal Executive Officers and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322020093010-qng.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322020093010-qng.htm">as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Instance Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Schema Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Definition Linkbase</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filed herewith.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furnished herewith</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The schedules and exhibits thereof have been omitted pursuant to Item&#160;601(b)(2) of Regulation&#160;S-K. A copy of any omitted schedule or exhibit will be furnished to the SEC upon request.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><div id="ie94880a2d5df40d2b763e3a0bdef79c1_157"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Table of Contents</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</span></div><div style="margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:39.895%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.367%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">APOLLO MEDICAL HOLDINGS, INC.</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth Sim</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kenneth Sim, M.D.<br/>Executive Chairman &amp; Co-Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Thomas Lam</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas Lam, M.D., M.P.H.<br/>Co-Chief Executive Officer &amp; President<br/>(Principal Executive Officer)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: November 9, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Eric Chin</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Eric Chin<br/>Chief Financial Officer and Interim Co-Chief Operating Officer<br/>(Principal Financial Officer)</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex3112020093010-qng.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id0fc6bc561fc4cc88f26dd5b82a2e4d1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth Sim, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Sim</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex3122020093010-qng.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i3b15334b167243dea1a7e0c66cce8152_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> EXHIBIT 31.2</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.3
<SEQUENCE>4
<FILENAME>ex3132020093010-qng.htm
<DESCRIPTION>EX-31.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="id49d4488922a45f2b28258a400e9468c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.3</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">PURSUANT TO</font></div><div style="margin-top:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">I have reviewed this quarterly report on Form 10-Q of Apollo Medical Holdings, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:19.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:45pt;text-align:justify;text-indent:-27pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:6.952%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.699%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Interim Co-Chief Operating Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>5
<FILENAME>ex322020093010-qng.htm
<DESCRIPTION>EX-32
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="ie00c1581fef14508a45b5b8fbe5aa2af_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32</font></div><div style="text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICERS AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350.</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Kenneth Sim, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Kenneth Sim</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth Sim</font></div><div style="margin-bottom:2pt;margin-top:2pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Co-Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas Lam, M.D., certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Thomas Lam</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thomas Lam</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Co-Chief Executive Officer and President</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Eric Chin, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Apollo Medical Holdings, Inc. for the quarter ended September&#160;30, 2020 fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and that the information contained in such report fairly presents, in all material respects, the financial condition and results of operations of Apollo Medical Holdings, Inc.</font></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.317%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.391%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; </font></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 9, 2020</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Eric Chin</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Eric Chin</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Interim Co-Chief Operating Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>ameh-20200930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ameh="http://www.apollomed.net/20200930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.apollomed.net/20200930">
  <xs:import namespace="http://fasb.org/srt/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ameh-20200930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.apollomed.net/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED">
        <link:definition>1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical">
        <link:definition>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
        <link:definition>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED">
        <link:definition>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED">
        <link:definition>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusiness" roleURI="http://www.apollomed.net/role/DescriptionofBusiness">
        <link:definition>2101101 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionofBusinessAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails">
        <link:definition>2402401 - Disclosure - Description of Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
        <link:definition>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
        <link:definition>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
        <link:definition>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
        <link:definition>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwill" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill">
        <link:definition>2111103 - Disclosure - Business Combinations and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillTables" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables">
        <link:definition>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails">
        <link:definition>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
        <link:definition>2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsandGoodwillSummaryofGoodwillDetails" roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails">
        <link:definition>2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNet" roleURI="http://www.apollomed.net/role/IntangibleAssetsNet">
        <link:definition>2116104 - Disclosure - Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetTables" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables">
        <link:definition>2317303 - Disclosure - Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1">
        <link:definition>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsNetFutureAmortizationExpenseDetails" roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails">
        <link:definition>2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethod" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod">
        <link:definition>2121105 - Disclosure - Investments in Other Entities &#8212; Equity Method</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodTables" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables">
        <link:definition>2322304 - Disclosure - Investments in Other Entities &#8212; Equity Method (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
        <link:definition>2423413 - Disclosure - Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
        <link:definition>2424414 - Disclosure - Investments in Other Entities &#8212; Equity Method - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
        <link:definition>2425415 - Disclosure - Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails">
        <link:definition>2426416 - Disclosure - Investments in Other Entities &#8212; Equity Method - Gain on Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedParties" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties">
        <link:definition>2127106 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
        <link:definition>2428417 - Disclosure - Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpenses" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses">
        <link:definition>2129107 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesTables" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables">
        <link:definition>2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails">
        <link:definition>2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilities" roleURI="http://www.apollomed.net/role/MedicalLiabilities">
        <link:definition>2132108 - Disclosure - Medical Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesTables" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables">
        <link:definition>2333306 - Disclosure - Medical Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails">
        <link:definition>2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCredit" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit">
        <link:definition>2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditTables" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables">
        <link:definition>2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
        <link:definition>2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails">
        <link:definition>2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
        <link:definition>2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquity" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity">
        <link:definition>2140110 - Disclosure - Mezzanine and Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityTables" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables">
        <link:definition>2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails">
        <link:definition>2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails">
        <link:definition>2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails">
        <link:definition>2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquitySummaryofWarrantDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails">
        <link:definition>2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MezzanineandStockholdersEquityWarrantsDetails" roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails">
        <link:definition>2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.apollomed.net/role/CommitmentsandContingencies">
        <link:definition>2147111 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactions" roleURI="http://www.apollomed.net/role/RelatedPartyTransactions">
        <link:definition>2149112 - Disclosure - Related-Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsTables" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables">
        <link:definition>2350309 - Disclosure - Related-Party Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
        <link:definition>2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.apollomed.net/role/IncomeTaxes">
        <link:definition>2153113 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>2454431 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.apollomed.net/role/EarningsPerShare">
        <link:definition>2155114 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.apollomed.net/role/EarningsPerShareTables">
        <link:definition>2356310 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails">
        <link:definition>2457432 - Disclosure - Earnings Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails">
        <link:definition>2458433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
        <link:definition>2459434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEs" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs">
        <link:definition>2160115 - Disclosure - Variable Interest Entities (VIEs)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsTables" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables">
        <link:definition>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="VariableInterestEntitiesVIEsDetails" roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails">
        <link:definition>2462435 - Disclosure - Variable Interest Entities (VIEs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.apollomed.net/role/Leases">
        <link:definition>2163116 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.apollomed.net/role/LeasesTables">
        <link:definition>2364312 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesAdditionalinformationDetails" roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails">
        <link:definition>2465436 - Disclosure - Leases - Additional information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2466437 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesOtherInformationRelatedtoLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails">
        <link:definition>2467438 - Disclosure - Leases - Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails">
        <link:definition>2468439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1">
        <link:definition>2468439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.apollomed.net/role/SubsequentEvents">
        <link:definition>2169117 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsAdditionalInformationDetails" roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails">
        <link:definition>2470440 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ameh_MWNCommunityHospitalLLCMember" abstract="true" name="MWNCommunityHospitalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_UniversalCareIncMember" abstract="true" name="UniversalCareIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfFederallyQualifiedHealthPlans" abstract="false" name="NumberOfFederallyQualifiedHealthPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_HSMSOMember" abstract="true" name="HSMSOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PayorEMember" abstract="true" name="PayorEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApcBusinessLoanAgreementMember" abstract="true" name="ApcBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentNumberOfKeyFinancialRatios" abstract="false" name="DebtInstrumentNumberOfKeyFinancialRatios" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" abstract="false" name="BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" abstract="false" name="IncreaseDecreaseInOtherOperatingLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueTable" abstract="true" name="AccountsReceivableAndNetRevenueTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" abstract="false" name="InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" abstract="false" name="FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_PerMemberPerMonthManagedCareContractMember" abstract="true" name="PerMemberPerMonthManagedCareContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_APAMHMedicalCorporationMember" abstract="true" name="APAMHMedicalCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LmaMember" abstract="true" name="LmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" abstract="false" name="InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_AggregateintrinsicvalueAbstract" abstract="true" name="AggregateintrinsicvalueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" abstract="true" name="LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" abstract="false" name="PercentageOfFinancialGuaranteeBenchmarkAmount" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsRollForward" abstract="true" name="EquityMethodInvestmentsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementIncMember" abstract="true" name="NetworkMedicalManagementIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" abstract="false" name="RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_EarningsPerShareTable" abstract="true" name="EarningsPerShareTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessLineItems" abstract="true" name="DescriptionOfBusinessLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" abstract="false" name="AccountsAndOtherReceivablesNumberOfAdditionalAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_NumberOfPatients" abstract="false" name="NumberOfPatients" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" abstract="false" name="DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentMadeToRelatedParty" abstract="false" name="PaymentMadeToRelatedParty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CollegeStreetInvestmentLpMember" abstract="true" name="CollegeStreetInvestmentLpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesMerger" abstract="false" name="StockIssuedDuringPeriodSharesMerger" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" abstract="false" name="EquityMethodAndOtherEquityInvestmentsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_TermLoanAMember" abstract="true" name="TermLoanAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="FinanceLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeOperatingLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" abstract="false" name="StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentOfRevenue" abstract="false" name="PaymentOfRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" abstract="false" name="AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ApcShareholdersMember" abstract="true" name="ApcShareholdersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfFamilyPracticeClinics" abstract="false" name="NumberOfFamilyPracticeClinics" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_PaymentPeriodThreeMember" abstract="true" name="PaymentPeriodThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" abstract="true" name="LeaseWeightedAverageRemainingLeaseTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" abstract="false" name="ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_VotingCommonStockTwoMember" abstract="true" name="VotingCommonStockTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PayorBMember" abstract="true" name="PayorBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" abstract="false" name="ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightExercisable" abstract="false" name="ClassOfWarrantOrRightExercisable" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AlphaCareMedicalGroupInc.Member" abstract="true" name="AlphaCareMedicalGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PacificMedicalImagingAndOncologyCenterIncMember" abstract="true" name="PacificMedicalImagingAndOncologyCenterIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MezzanineMember" abstract="true" name="MezzanineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilitiesWarrantsExercised" abstract="false" name="DeferredTaxLiabilitiesWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" abstract="false" name="InsuranceServicesRevenueCapitationAndClaimsPaymentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_CriticalQualityManagementCorpMember" abstract="true" name="CriticalQualityManagementCorpMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsPurchaseOfShares" abstract="false" name="EquityMethodInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_FinanceReceivableInterestRateStatedPercentage" abstract="false" name="FinanceReceivableInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" abstract="false" name="LineOfCreditFacilityExpirationPeriodPeriodOfNotification" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeThreeMember" abstract="true" name="WarrantExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_OneMSOInc.Member" abstract="true" name="OneMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorAMember" abstract="true" name="PayorAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DiagnosticMedicalGroupMember" abstract="true" name="DiagnosticMedicalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ContractTypeDomain" abstract="true" name="ContractTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsContribution" abstract="false" name="EquityMethodInvestmentsContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AlliedPacificOfCaliforniaIPAMember" abstract="true" name="AlliedPacificOfCaliforniaIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_RepaymentsOfBankLoanAndLinesOfCredit" abstract="false" name="RepaymentsOfBankLoanAndLinesOfCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NmmBusinessLoanAgreementMember" abstract="true" name="NmmBusinessLoanAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" abstract="false" name="DeferredTaxLiabilitiesAdjustedToGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" abstract="false" name="FinanceReceivableModificationsSubsequentDefaultInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_MediPortalLLCMember" abstract="true" name="MediPortalLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsGranted" abstract="false" name="NumberOfWarrantsGranted" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApcLsmaMember" abstract="true" name="ApcLsmaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_FinanceReceivableTermOfReceivable" abstract="false" name="FinanceReceivableTermOfReceivable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_MemberRelationshipsMember" abstract="true" name="MemberRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_SCHCMember" abstract="true" name="SCHCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_HealthCareCapitationRevenueMember" abstract="true" name="HealthCareCapitationRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NextGenerationACOModelParticipationAgreementMember" abstract="true" name="NextGenerationACOModelParticipationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" abstract="true" name="ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NumberOfEmployees" abstract="false" name="NumberOfEmployees" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityAdditionalAdvances" abstract="false" name="LineOfCreditFacilityAdditionalAdvances" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_LeaseWeightedAverageDiscountRateAbstract" abstract="true" name="LeaseWeightedAverageDiscountRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" abstract="false" name="WarrantIssuedDuringPeriodValueStockOptionsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" abstract="false" name="EquityMethodInvestmentGainOnSaleTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_HealthSourceMSOInc.Member" abstract="true" name="HealthSourceMSOInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_ApolloMedicalHoldingsIncMember" abstract="true" name="ApolloMedicalHoldingsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_MedicalCareCostsAbstract" abstract="true" name="MedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NumenLLCMember" abstract="true" name="NumenLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationCash" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationCash" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsPayableAndAccruedExpensesMember" abstract="true" name="AccountsPayableAndAccruedExpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CommercialMember" abstract="true" name="CommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PmiocMember" abstract="true" name="PmiocMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_RiskPoolSettlement" abstract="false" name="RiskPoolSettlement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentOwnershipPercentageDisposed" abstract="false" name="EquityMethodInvestmentOwnershipPercentageDisposed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" abstract="false" name="ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:perShareItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_CreditAgreementMember" abstract="true" name="CreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentOfRevenueMonthlyAmount" abstract="false" name="PaymentOfRevenueMonthlyAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_FiduciaryAccountsPayableCurrent" abstract="false" name="FiduciaryAccountsPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightIssuedInPeriod" abstract="false" name="ClassOfWarrantOrRightIssuedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AncillaryServiceContractMember" abstract="true" name="AncillaryServiceContractMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentConsultingFees" abstract="false" name="PaymentConsultingFees" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" abstract="false" name="ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_ClassOfWarrantOrRightCancelledInPeriod" abstract="false" name="ClassOfWarrantOrRightCancelledInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AurionMember" abstract="true" name="AurionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AmgIncMember" abstract="true" name="AmgIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationPreferredShares" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioMaximum" abstract="false" name="DebtInstrumentCovenantLeverageRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_WorkingCapitalContribution" abstract="false" name="WorkingCapitalContribution" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_NetworkRelationshipsMember" abstract="true" name="NetworkRelationshipsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareholdersAndOfficersMember" abstract="true" name="ShareholdersAndOfficersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AHMCMember" abstract="true" name="AHMCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueCashlessWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DebtInstrumentApprovedThresholdUseOfFunds" abstract="false" name="DebtInstrumentApprovedThresholdUseOfFunds" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MaverickMedicalGroupIncMember" abstract="true" name="MaverickMedicalGroupIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PaymentPeriodTwoMember" abstract="true" name="PaymentPeriodTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInOperatingLeaseAssets" abstract="false" name="IncreaseDecreaseInOperatingLeaseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AchievaMedInc.Member" abstract="true" name="AchievaMedInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NumberOfWarrantsExercised" abstract="false" name="NumberOfWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeOneMember" abstract="true" name="WarrantExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeFourMember" abstract="true" name="WarrantExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" abstract="false" name="EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_PreferredBankMember" abstract="true" name="PreferredBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_WarrantExercisePriceRangeTwoMember" abstract="true" name="WarrantExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_GainLossOnAssumptionOfLoan" abstract="false" name="GainLossOnAssumptionOfLoan" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_WeightedAverageExercisePriceWarrantsRollForward" abstract="true" name="WeightedAverageExercisePriceWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" abstract="false" name="NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MinorityInterestPolicyPolicyTextBlock" abstract="false" name="MinorityInterestPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" abstract="false" name="IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_NMMLineOfCreditAgreementMember" abstract="true" name="NMMLineOfCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AdvanceDiagnosticSurgeryCenterMember" abstract="true" name="AdvanceDiagnosticSurgeryCenterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_TemporaryEquityPolicyTextBlock" abstract="false" name="TemporaryEquityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityTerminatedAmount" abstract="false" name="LineOfCreditFacilityTerminatedAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AdvancedForWorkingCapital" abstract="false" name="AdvancedForWorkingCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_AccountsReceivableAndNetRevenueLineItems" abstract="true" name="AccountsReceivableAndNetRevenueLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_WeightedaverageremainingcontractualtermyearsAbstract" abstract="true" name="WeightedaverageremainingcontractualtermyearsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_SpecialtyCapitationPayableCurrent" abstract="false" name="SpecialtyCapitationPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_APCAndAPCLSMAMember" abstract="true" name="APCAndAPCLSMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApaacoMember" abstract="true" name="ApaacoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" abstract="false" name="EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" abstract="false" name="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PayorFMember" abstract="true" name="PayorFMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" abstract="false" name="StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_PaymentsForMedicalCareCostsAbstract" abstract="true" name="PaymentsForMedicalCareCostsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" abstract="false" name="DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" abstract="false" name="EquityMethodInvestmentSaleContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_BrightHealthCompanyOfCaliforniaInc.Member" abstract="true" name="BrightHealthCompanyOfCaliforniaInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LasalleMedicalAssociatesIpaMember" abstract="true" name="LasalleMedicalAssociatesIpaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CMSMember" abstract="true" name="CMSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DrJayLoanMember" abstract="true" name="DrJayLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" abstract="false" name="LesseeFinanceLeaseTerminationPeriodIfApplicable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" abstract="true" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FinanceReceivableStatedInterestRate" abstract="false" name="FinanceReceivableStatedInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_ManagementContractsMember" abstract="true" name="ManagementContractsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_PatientManagementPlatformMember" abstract="true" name="PatientManagementPlatformMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MedicalPropertyPartnersMember" abstract="true" name="MedicalPropertyPartnersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_IncreaseDecreaseInMedicalLiabilities" abstract="false" name="IncreaseDecreaseInMedicalLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_EarningsPerShareLineItems" abstract="true" name="EarningsPerShareLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_Pacific6EnterprisesMember" abstract="true" name="Pacific6EnterprisesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_OtherThirdPartiesMember" abstract="true" name="OtherThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MezzanineEquityAbstract" abstract="true" name="MezzanineEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_ConcourseDiagnosticSurgeryCenterLlcMember" abstract="true" name="ConcourseDiagnosticSurgeryCenterLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ApcStockOptionMember" abstract="true" name="ApcStockOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" abstract="false" name="LineOfCreditFacilityGuaranteeGivenByRelatedParties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_PayorDMember" abstract="true" name="PayorDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CDSCMember" abstract="true" name="CDSCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" abstract="false" name="ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_StockIssuedDuringPeriodProxyVotesPercentage" abstract="false" name="StockIssuedDuringPeriodProxyVotesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_PayorGMember" abstract="true" name="PayorGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_AccountableHealthCareIPAMember" abstract="true" name="AccountableHealthCareIPAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_Dr.ArteagaMember" abstract="true" name="Dr.ArteagaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_MarketableSecuritiesCurrentMaturityPeriod" abstract="false" name="MarketableSecuritiesCurrentMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" abstract="false" name="DebtInstrumentCovenantInterestCoverageRatioMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ameh_ContractTypeAxis" abstract="true" name="ContractTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" abstract="false" name="EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="num:percentItemType"/>
  <xs:element id="ameh_DmgMember" abstract="true" name="DmgMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_InvestmentDeposit" abstract="false" name="InvestmentDeposit" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_DrSimAndDrLamMember" abstract="true" name="DrSimAndDrLamMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DescriptionOfBusinessTable" abstract="true" name="DescriptionOfBusinessTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ameh_SharesWarrantsRollForward" abstract="true" name="SharesWarrantsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_UniversalCareAcquisitionPartnersLlcMember" abstract="true" name="UniversalCareAcquisitionPartnersLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" abstract="false" name="ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ameh_AlliedPacificofCaliforniaBrokerageAccountMember" abstract="true" name="AlliedPacificofCaliforniaBrokerageAccountMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_NetworkMedicalManagementMember" abstract="true" name="NetworkMedicalManagementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_LoanReceivableTextBlock" abstract="false" name="LoanReceivableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType"/>
  <xs:element id="ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" abstract="true" name="CashPaidForLeaseLiabilitiesAbstractAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_FiveThreeOneW.CollegeLLCMember" abstract="true" name="FiveThreeOneW.CollegeLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_SubcontractorIPAPayable" abstract="false" name="SubcontractorIPAPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ameh_PaymentPeriodOneMember" abstract="true" name="PaymentPeriodOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_Dr.JayMember" abstract="true" name="Dr.JayMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ameh_PayorCMember" abstract="true" name="PayorCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="nonnum:domainItemType"/>
  <xs:element id="ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" abstract="false" name="DebtInstrumentCovenantLeverageRatioIncrementalChange" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>ameh-20200930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200930.xsd#DocumentandEntityInformation"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c77478bd-6805-4ae0-b84e-41df72502c60" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_c77478bd-6805-4ae0-b84e-41df72502c60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_13a9fae8-9cb3-4410-9121-46b65669e951" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_13a9fae8-9cb3-4410-9121-46b65669e951" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_05338380-a097-4a14-8c7c-9ead89640f95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_05338380-a097-4a14-8c7c-9ead89640f95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_20ae7543-342e-4dbe-bbc7-57671f3a63b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_20ae7543-342e-4dbe-bbc7-57671f3a63b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_f58f038d-fe65-4abd-ad29-f3fde4172138" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_DividendsPayableCurrent_f58f038d-fe65-4abd-ad29-f3fde4172138" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7143e85-a445-4dac-8b36-571d1fa7db97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_f7143e85-a445-4dac-8b36-571d1fa7db97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_73e70b3a-5e4e-42f0-9342-6ee93ad3e592" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_73e70b3a-5e4e-42f0-9342-6ee93ad3e592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5c33dea3-3ef8-460c-b2f9-312aeff0b2a8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_4f10308b-575b-435a-81a5-2aff42b4a8c4" xlink:to="loc_us-gaap_LongTermDebtCurrent_5c33dea3-3ef8-460c-b2f9-312aeff0b2a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7d6d117d-41dd-4ce8-a648-ef82a18018ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ec10c8d2-77c3-4665-82ba-46f1af1c4cfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d6d117d-41dd-4ce8-a648-ef82a18018ab" xlink:to="loc_us-gaap_LiabilitiesCurrent_ec10c8d2-77c3-4665-82ba-46f1af1c4cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_57c445a2-585c-4ed8-9a4e-720468cc2399" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7d6d117d-41dd-4ce8-a648-ef82a18018ab" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_57c445a2-585c-4ed8-9a4e-720468cc2399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bb11e425-faf9-426d-841f-a60479825bab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2f477cf8-c8bc-48cf-ac93-8ccbbe865954" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bb11e425-faf9-426d-841f-a60479825bab" xlink:to="loc_us-gaap_StockholdersEquity_2f477cf8-c8bc-48cf-ac93-8ccbbe865954" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8590b26c-2c52-4e17-8ace-a73141a2e0ce" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bb11e425-faf9-426d-841f-a60479825bab" xlink:to="loc_us-gaap_MinorityInterest_8590b26c-2c52-4e17-8ace-a73141a2e0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f6e33861-553a-441c-b628-afcdd20e4e4c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e912f6b2-148b-45ab-baf3-5fb4831ddf55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f6e33861-553a-441c-b628-afcdd20e4e4c" xlink:to="loc_us-gaap_AssetsCurrent_e912f6b2-148b-45ab-baf3-5fb4831ddf55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_82c19114-4655-4299-bf40-98b3a14bd843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f6e33861-553a-441c-b628-afcdd20e4e4c" xlink:to="loc_us-gaap_AssetsNoncurrent_82c19114-4655-4299-bf40-98b3a14bd843" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4e411bb-dfcf-452d-a840-356eea4529cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e4e411bb-dfcf-452d-a840-356eea4529cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3635c244-8647-48cd-9a54-9eb085b39258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_RestrictedCashCurrent_3635c244-8647-48cd-9a54-9eb085b39258" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_927a8b9a-0dda-409f-9352-4e4b3d1cd94c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_927a8b9a-0dda-409f-9352-4e4b3d1cd94c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_67860b24-80e6-4fb7-9d87-5484c54df58f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_67860b24-80e6-4fb7-9d87-5484c54df58f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_6f7f0ccb-851f-4f81-8253-5d872d4bd9bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_6f7f0ccb-851f-4f81-8253-5d872d4bd9bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_476cc88f-add7-40e4-972c-8ddeee313147" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_476cc88f-add7-40e4-972c-8ddeee313147" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22f8003d-b10f-4777-8326-043bead26662" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22f8003d-b10f-4777-8326-043bead26662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_6b675102-5929-472b-90bc-97534b6097a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_6b675102-5929-472b-90bc-97534b6097a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_afbbcc69-041d-420f-91f4-0dc73ac4d91e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_f21dbf0a-829d-4ab2-8be9-7160234df7a5" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_afbbcc69-041d-420f-91f4-0dc73ac4d91e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c693a994-1a4d-48fc-99ef-56b3b241e09a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2f7cf68f-8c70-476f-8e00-c97d185dfb0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c693a994-1a4d-48fc-99ef-56b3b241e09a" xlink:to="loc_us-gaap_CommonStockValue_2f7cf68f-8c70-476f-8e00-c97d185dfb0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6698dc7a-e141-4a52-907d-b4a246918dd4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c693a994-1a4d-48fc-99ef-56b3b241e09a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6698dc7a-e141-4a52-907d-b4a246918dd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5b13d237-0e8f-4b77-801e-871008cf09c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c693a994-1a4d-48fc-99ef-56b3b241e09a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_5b13d237-0e8f-4b77-801e-871008cf09c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_946f7f15-289c-4669-87bf-ce081e09ba64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_c693a994-1a4d-48fc-99ef-56b3b241e09a" xlink:to="loc_us-gaap_PreferredStockValue_946f7f15-289c-4669-87bf-ce081e09ba64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_502bc411-bfec-4f4a-a3c1-1ad101b2cedf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_502bc411-bfec-4f4a-a3c1-1ad101b2cedf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bc545d1e-6cac-4836-8856-4c195f044063" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_bc545d1e-6cac-4836-8856-4c195f044063" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_916087da-7aa7-4d1e-be65-4ddd7fcf5969" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_916087da-7aa7-4d1e-be65-4ddd7fcf5969" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f49eabe7-fcd1-407e-9b81-c03cacf6fc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_Goodwill_f49eabe7-fcd1-407e-9b81-c03cacf6fc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_44c15d16-cb80-4dc6-84cc-729d1e7a3da8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_EquityMethodInvestments_44c15d16-cb80-4dc6-84cc-729d1e7a3da8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_98025f6d-f49c-4038-9171-49169ce7ea94" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_98025f6d-f49c-4038-9171-49169ce7ea94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7575d7a-f1f5-4440-a025-439374e36406" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a7575d7a-f1f5-4440-a025-439374e36406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7b7d345c-3ca1-444a-ad26-7553d267dc8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_563e0075-44e3-46fb-a527-c672004692d7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7b7d345c-3ca1-444a-ad26-7553d267dc8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_ac3c76f7-0ba9-4407-9d09-ca405f54e857" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_72c0df47-a977-44b2-8115-69a23f11d924" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ac3c76f7-0ba9-4407-9d09-ca405f54e857" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_72c0df47-a977-44b2-8115-69a23f11d924" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_374fe087-2f80-42e7-8a22-5837d40acb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ac3c76f7-0ba9-4407-9d09-ca405f54e857" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_374fe087-2f80-42e7-8a22-5837d40acb2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fd4f805-22e2-489f-b250-c1ef8f1744e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ac3c76f7-0ba9-4407-9d09-ca405f54e857" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0fd4f805-22e2-489f-b250-c1ef8f1744e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aab31022-a804-4ece-8701-6610542112c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_ac3c76f7-0ba9-4407-9d09-ca405f54e857" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aab31022-a804-4ece-8701-6610542112c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_51c4f32b-1b69-46d8-b374-c7eb65edba1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f1ff314a-1f6c-474d-a9bc-1f1e03b3026b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51c4f32b-1b69-46d8-b374-c7eb65edba1c" xlink:to="loc_us-gaap_Liabilities_f1ff314a-1f6c-474d-a9bc-1f1e03b3026b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_04ffb4c1-7bf9-46ba-9dd5-495533852960" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51c4f32b-1b69-46d8-b374-c7eb65edba1c" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_04ffb4c1-7bf9-46ba-9dd5-495533852960" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4b6d041a-f6ce-4980-9d10-16ddb7787d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51c4f32b-1b69-46d8-b374-c7eb65edba1c" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4b6d041a-f6ce-4980-9d10-16ddb7787d9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_8d7ca196-a694-492b-94ac-bed98a094f9b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_51c4f32b-1b69-46d8-b374-c7eb65edba1c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_8d7ca196-a694-492b-94ac-bed98a094f9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9fdc2447-440b-4436-8133-aebe3f101eae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_456128a6-9dd1-4b3f-b418-de4434beca07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9fdc2447-440b-4436-8133-aebe3f101eae" xlink:to="loc_us-gaap_ProfitLoss_456128a6-9dd1-4b3f-b418-de4434beca07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6b4c4c42-9dbd-4d29-810e-cc86705cbbef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_9fdc2447-440b-4436-8133-aebe3f101eae" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6b4c4c42-9dbd-4d29-810e-cc86705cbbef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_955db96a-a261-488d-9840-94f2054095bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_955db96a-a261-488d-9840-94f2054095bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_c1d943e5-e896-466f-ad88-8c0a18bf544a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_c1d943e5-e896-466f-ad88-8c0a18bf544a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_38d21aca-a47e-4805-bf77-1eed7ddb235b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:to="loc_us-gaap_InterestExpense_38d21aca-a47e-4805-bf77-1eed7ddb235b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_665e357b-d6b2-499e-8405-08e750713054" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:to="loc_us-gaap_InvestmentIncomeInterest_665e357b-d6b2-499e-8405-08e750713054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_52e0b733-7acb-488e-a55c-7875a84e7e5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a25d15e3-7747-43a8-bdf6-cb76c48c58b3" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_52e0b733-7acb-488e-a55c-7875a84e7e5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e56a5faf-fc13-45e5-98bc-db0fcc169d84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1a3df5c8-1da4-4630-a93e-605cff5f13df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e56a5faf-fc13-45e5-98bc-db0fcc169d84" xlink:to="loc_us-gaap_OperatingIncomeLoss_1a3df5c8-1da4-4630-a93e-605cff5f13df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_484bb783-51cc-467e-9995-13df799afb70" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_e56a5faf-fc13-45e5-98bc-db0fcc169d84" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_484bb783-51cc-467e-9995-13df799afb70" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2b5bb8f2-59fa-4cec-be62-8625e326824f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2b5bb8f2-59fa-4cec-be62-8625e326824f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_486765b0-419d-4021-8c17-f81e940d801f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_486765b0-419d-4021-8c17-f81e940d801f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_24dc248e-7b1e-46dd-8c5f-130a2a4d3146" xlink:href="ameh-20200930.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_24dc248e-7b1e-46dd-8c5f-130a2a4d3146" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_2b12f49f-4176-482b-a7c5-6f98a7a4f17d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_2b12f49f-4176-482b-a7c5-6f98a7a4f17d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8c8c0a3a-7341-46cd-bc26-bc99198fe8d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_77991b53-0f40-4436-9bec-ac744390c33d" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_8c8c0a3a-7341-46cd-bc26-bc99198fe8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85077f4a-4924-4df2-a95c-620453c4e304" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc81632-bd73-4cbc-9bcd-a51fa1992297" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_85077f4a-4924-4df2-a95c-620453c4e304" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc81632-bd73-4cbc-9bcd-a51fa1992297" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_535a7c44-61c9-4bc8-b165-e99dc5d9d965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_85077f4a-4924-4df2-a95c-620453c4e304" xlink:to="loc_us-gaap_CostsAndExpenses_535a7c44-61c9-4bc8-b165-e99dc5d9d965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7711b046-f606-4853-a9fd-25eeb777690c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb2bb0c3-b60c-473b-b7b7-9c1526c8e44b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7711b046-f606-4853-a9fd-25eeb777690c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_fb2bb0c3-b60c-473b-b7b7-9c1526c8e44b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_46c8c46b-963a-4941-a925-5d6535827beb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7711b046-f606-4853-a9fd-25eeb777690c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_46c8c46b-963a-4941-a925-5d6535827beb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3a9b357d-16ce-4633-bd20-f9482ebc2885" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_ProfitLoss_3a9b357d-16ce-4633-bd20-f9482ebc2885" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_89da3893-3a94-45b6-a543-a1c057254b5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_89da3893-3a94-45b6-a543-a1c057254b5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb7bbab7-c295-4d21-85f5-c6c378ba8248" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_cb7bbab7-c295-4d21-85f5-c6c378ba8248" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ed0a76d2-1e15-4b6d-afdc-de53531acd97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ed0a76d2-1e15-4b6d-afdc-de53531acd97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_a0d11b22-d5de-4683-b910-3a8a5f769392" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_a0d11b22-d5de-4683-b910-3a8a5f769392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_ddfe6bf4-ff23-48aa-a0fb-083e396cd135" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_ShareBasedCompensation_ddfe6bf4-ff23-48aa-a0fb-083e396cd135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_b664c00e-beec-4db4-8665-3ecfff74fec6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_b664c00e-beec-4db4-8665-3ecfff74fec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641bc81e-4e71-4156-bff3-87c03da5811b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_641bc81e-4e71-4156-bff3-87c03da5811b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_dbd71339-4e2c-49ad-b586-d9697a9e150b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_dbd71339-4e2c-49ad-b586-d9697a9e150b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan_d9d4272a-18b7-47f9-9469-abb77a529185" xlink:href="ameh-20200930.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_ameh_GainLossOnAssumptionOfLoan_d9d4272a-18b7-47f9-9469-abb77a529185" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1bc1b818-57c5-4404-9a31-a824e89180e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_1bc1b818-57c5-4404-9a31-a824e89180e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f83d47af-ccc1-4f43-a79d-c1ff127ade19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f83d47af-ccc1-4f43-a79d-c1ff127ade19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f47fa38b-6b5e-4fd5-91cb-7fcd3b764140" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_f47fa38b-6b5e-4fd5-91cb-7fcd3b764140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_44679979-0cbf-483d-90ac-f1070f455511" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_44679979-0cbf-483d-90ac-f1070f455511" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_d6d78d13-4886-40f3-94c7-f5b8b4690476" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_d6d78d13-4886-40f3-94c7-f5b8b4690476" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_a17e73a3-f713-4ac9-87e8-e6d2a99c1636" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_a17e73a3-f713-4ac9-87e8-e6d2a99c1636" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a13d99a-18c6-49c8-bfd4-6f0be234f84f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_3a13d99a-18c6-49c8-bfd4-6f0be234f84f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01308016-fa2a-4984-9dc3-38ec813fa15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_01308016-fa2a-4984-9dc3-38ec813fa15b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_92d3f964-ccb8-4cf8-bac3-4a517c5fa566" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_92d3f964-ccb8-4cf8-bac3-4a517c5fa566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_aee907ec-0e38-4154-87e0-b7cb9b66fa20" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:calculationArc order="20" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_aee907ec-0e38-4154-87e0-b7cb9b66fa20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_08c80e2d-a75a-41f3-af11-4d4142b5de1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_08c80e2d-a75a-41f3-af11-4d4142b5de1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_5132aaa5-71af-4f12-8654-557e2e791b4c" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:calculationArc order="22" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_906a6c8f-ba8a-459f-a895-e056676c6b24" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_5132aaa5-71af-4f12-8654-557e2e791b4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b88f3bc-6c2e-4ab3-a535-7cb0a97edc25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efec8111-b361-45d4-8120-cd2f4a215465" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b88f3bc-6c2e-4ab3-a535-7cb0a97edc25" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_efec8111-b361-45d4-8120-cd2f4a215465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_bd38c3ed-6c21-42a8-b72d-2f6940649d7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b88f3bc-6c2e-4ab3-a535-7cb0a97edc25" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_bd38c3ed-6c21-42a8-b72d-2f6940649d7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_cbc58946-6e50-454f-b9e2-501ffbacfc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4b88f3bc-6c2e-4ab3-a535-7cb0a97edc25" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_cbc58946-6e50-454f-b9e2-501ffbacfc3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_1d9e8207-ad20-4ac3-9f71-1cd5806d6177" xlink:href="ameh-20200930.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_1d9e8207-ad20-4ac3-9f71-1cd5806d6177" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_33c63ac0-1896-4a6f-80e7-e4360c9f77a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_PaymentsOfDividends_33c63ac0-1896-4a6f-80e7-e4360c9f77a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_c932d061-0733-4901-bb06-fa3a7251db34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_c932d061-0733-4901-bb06-fa3a7251db34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_ae7ddddf-de4a-49dd-ba77-467c8ee2d72e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_ae7ddddf-de4a-49dd-ba77-467c8ee2d72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_6192b84b-10df-4c35-a4d2-ff30b4b09b92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_6192b84b-10df-4c35-a4d2-ff30b4b09b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0ddf837e-06a9-46a9-8304-3f4e2ac3fc21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0ddf837e-06a9-46a9-8304-3f4e2ac3fc21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_17f5d8f0-cd6e-4853-a537-74bcf528796f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_17f5d8f0-cd6e-4853-a537-74bcf528796f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0824c5e6-c5f8-4173-9092-338ade329d69" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_0824c5e6-c5f8-4173-9092-338ade329d69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_418e9688-55f8-4c1e-a8fc-35d08721c865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_634bc1f9-8956-484c-9258-73134e0870d2" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_418e9688-55f8-4c1e-a8fc-35d08721c865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5c3015f-0e85-4bde-bb0e-d8238f7bcdcb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d5c3015f-0e85-4bde-bb0e-d8238f7bcdcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_ddb40cd3-6e02-4c94-8be1-6a968df56ca5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_ddb40cd3-6e02-4c94-8be1-6a968df56ca5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_35f0e3e6-ab7e-46c4-b93f-0da713d04b6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_35f0e3e6-ab7e-46c4-b93f-0da713d04b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c08f4fdf-2ec0-415c-82e0-03d216ea9425" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c08f4fdf-2ec0-415c-82e0-03d216ea9425" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f72a986e-dedf-4a60-806f-f125851f5d32" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_f72a986e-dedf-4a60-806f-f125851f5d32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_520c3d8e-7fe5-4a77-888e-8b824c26c03f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_520c3d8e-7fe5-4a77-888e-8b824c26c03f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04ffaba4-fd49-499a-8e99-9cb2188a3a19" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_04ffaba4-fd49-499a-8e99-9cb2188a3a19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_dfedf06b-2b5c-49c8-a14e-f2b2404b26a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3a6a1edb-b00c-4de8-b0f6-56e260e419c0" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_dfedf06b-2b5c-49c8-a14e-f2b2404b26a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e99aed-c4a6-4a00-89f9-c6fe14684f33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c85ef8a3-4b89-4a99-9572-05d3caa64c74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e99aed-c4a6-4a00-89f9-c6fe14684f33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c85ef8a3-4b89-4a99-9572-05d3caa64c74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_484f4705-dc56-434b-adb6-c905e50b3990" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e99aed-c4a6-4a00-89f9-c6fe14684f33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_484f4705-dc56-434b-adb6-c905e50b3990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22084389-c663-4fa0-8f8b-4751304d8faa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f8e99aed-c4a6-4a00-89f9-c6fe14684f33" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_22084389-c663-4fa0-8f8b-4751304d8faa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusiness"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_79e10ac2-a016-492f-aa8c-458768015324" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_976c6d65-bac0-4021-8d88-ba4c5f925d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_79e10ac2-a016-492f-aa8c-458768015324" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_976c6d65-bac0-4021-8d88-ba4c5f925d6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a252a210-923c-4c2b-a537-b0bbe49ec9df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_79e10ac2-a016-492f-aa8c-458768015324" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_a252a210-923c-4c2b-a537-b0bbe49ec9df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_ab5cb4df-4ab1-4185-b179-cd6b29a56d91" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_79e10ac2-a016-492f-aa8c-458768015324" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_ab5cb4df-4ab1-4185-b179-cd6b29a56d91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwill"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ec8ce86a-1555-4f38-ad3b-50c68c35d305" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_ec8ce86a-1555-4f38-ad3b-50c68c35d305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_93fdfafe-5164-48df-8716-e7d97539de18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_93fdfafe-5164-48df-8716-e7d97539de18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_ca00ca97-4509-4696-813e-421870a5a051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_ca00ca97-4509-4696-813e-421870a5a051" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_673d38ad-0a33-44f2-99be-ba9f541b073a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_673d38ad-0a33-44f2-99be-ba9f541b073a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_cf68cfd7-a8f8-4432-80e8-1cb3fe3d3246" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_Goodwill_cf68cfd7-a8f8-4432-80e8-1cb3fe3d3246" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_cc873060-5d76-4fb2-aa01-851058894534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_cc873060-5d76-4fb2-aa01-851058894534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_de8be3bd-9672-421e-a201-00a538fe2cec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_de8be3bd-9672-421e-a201-00a538fe2cec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_ea141861-b0b8-4f7d-b7cd-c53257a71b54" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_ea141861-b0b8-4f7d-b7cd-c53257a71b54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_fa9ba8fc-e89d-4203-877a-0004cce8b3c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_1a45a56e-013f-4bdf-b476-b27297691dc5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_fa9ba8fc-e89d-4203-877a-0004cce8b3c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNet"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fa5ab4b0-183c-481d-a555-e59e65e9dc81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_987b0d74-344c-4413-a0a9-98c29c5168cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_fa5ab4b0-183c-481d-a555-e59e65e9dc81" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_987b0d74-344c-4413-a0a9-98c29c5168cd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_04fba7c6-29ff-4bba-80d5-63abf6f162dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f7b30e7d-8599-4daf-8566-a81e155a6652" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_04fba7c6-29ff-4bba-80d5-63abf6f162dd" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f7b30e7d-8599-4daf-8566-a81e155a6652" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba47b687-cee4-4bd1-bd7a-d1cf00d91581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_04fba7c6-29ff-4bba-80d5-63abf6f162dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ba47b687-cee4-4bd1-bd7a-d1cf00d91581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6ffe274-2173-4653-814a-a85ec9773570" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4d2dfc76-74f8-47bf-9ab8-0473543b3681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6ffe274-2173-4653-814a-a85ec9773570" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_4d2dfc76-74f8-47bf-9ab8-0473543b3681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e6ad931-fde8-48ae-b64e-42bf580f4e5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b6ffe274-2173-4653-814a-a85ec9773570" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_5e6ad931-fde8-48ae-b64e-42bf580f4e5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_686d1987-8107-44f3-a278-8837ddc105de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_862c22c9-f931-46a0-a110-80c8aae72f1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_686d1987-8107-44f3-a278-8837ddc105de" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_862c22c9-f931-46a0-a110-80c8aae72f1d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_87cad86b-7521-4f2f-a61f-9b07371f5681" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_87cad86b-7521-4f2f-a61f-9b07371f5681" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be9c2638-cfce-48aa-83cb-1558b9157772" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_be9c2638-cfce-48aa-83cb-1558b9157772" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f24556af-8320-4b63-8e0e-973d44515eab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f24556af-8320-4b63-8e0e-973d44515eab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b845327b-7a51-4622-bd44-c51cdc9571fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b845327b-7a51-4622-bd44-c51cdc9571fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_eebe71aa-d2e2-4148-9e9e-7ac1100d43e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_eebe71aa-d2e2-4148-9e9e-7ac1100d43e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_357fe6ae-a8ad-441c-bc2d-fd2e37600d89" xlink:href="ameh-20200930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c82aa85d-083d-4073-aa86-a0f10c7c72af" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_357fe6ae-a8ad-441c-bc2d-fd2e37600d89" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_039bf326-0a17-4a3e-82f8-93ab832677c6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_039bf326-0a17-4a3e-82f8-93ab832677c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c165cbb-bebf-4ec0-9bbb-114083725d99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c165cbb-bebf-4ec0-9bbb-114083725d99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a5e9388a-1bd7-4ba8-9069-898b4374b864" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_OtherAssetsCurrent_a5e9388a-1bd7-4ba8-9069-898b4374b864" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_649e7e46-7f1a-4098-8098-b5701178dd57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_649e7e46-7f1a-4098-8098-b5701178dd57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_25f5ef2d-7606-4415-81c4-c83f248725e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_RestrictedCashCurrent_25f5ef2d-7606-4415-81c4-c83f248725e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_f9abae51-0ece-47ec-b83c-f11e8b072499" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_OtherAssets_f9abae51-0ece-47ec-b83c-f11e8b072499" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_10b60124-2609-4268-9174-cbcf1980b6e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_849368b1-ad7c-47f5-bca8-1cf08076315f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_10b60124-2609-4268-9174-cbcf1980b6e4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpenses"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e52dadbd-a66b-448d-b355-4ceaecedb72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_us-gaap_AccountsPayableCurrent_e52dadbd-a66b-448d-b355-4ceaecedb72d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_9ed2ba09-bffb-416c-b53e-fd4f5ad4f688" xlink:href="ameh-20200930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_9ed2ba09-bffb-416c-b53e-fd4f5ad4f688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_45f70368-cc9c-4c4b-a3bf-f2b67a068dbd" xlink:href="ameh-20200930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_ameh_SubcontractorIPAPayable_45f70368-cc9c-4c4b-a3bf-f2b67a068dbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_54418e9a-63ab-4527-a79b-d08196dd0178" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_54418e9a-63ab-4527-a79b-d08196dd0178" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_0f41abba-b0d3-497d-884e-dc1d488bfbcf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_0f41abba-b0d3-497d-884e-dc1d488bfbcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d9aa83f-633b-4053-bd9d-141cd975e807" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_4d9aa83f-633b-4053-bd9d-141cd975e807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21e9a685-a279-495c-826c-32452d999f42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_ed361ef1-7cf2-4d9b-a975-ecbece3bd4c9" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_21e9a685-a279-495c-826c-32452d999f42" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilities"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6329b2d8-aeac-4602-a986-c701ac55199f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_a75a2ad0-7764-406c-9616-487763fff698" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6329b2d8-aeac-4602-a986-c701ac55199f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_a75a2ad0-7764-406c-9616-487763fff698" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0650c483-b9f1-4607-b1bc-44e494d2932e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_6329b2d8-aeac-4602-a986-c701ac55199f" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_0650c483-b9f1-4607-b1bc-44e494d2932e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_321b6592-083f-4085-bb88-7d60d6e8d561" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_be938e8d-89fb-45ef-9cbe-5c078ac17c87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_321b6592-083f-4085-bb88-7d60d6e8d561" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_be938e8d-89fb-45ef-9cbe-5c078ac17c87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_827e3020-f8d3-40e2-aeb4-79270ef1be1e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_321b6592-083f-4085-bb88-7d60d6e8d561" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_827e3020-f8d3-40e2-aeb4-79270ef1be1e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_48473387-b9a7-4794-abf4-6d3bd4ad19d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_48473387-b9a7-4794-abf4-6d3bd4ad19d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5eb352cd-6d69-4c60-8540-ab3c3fd89641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_5eb352cd-6d69-4c60-8540-ab3c3fd89641" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5e255d39-283d-4101-ae02-f3f1f701dc41" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_5e255d39-283d-4101-ae02-f3f1f701dc41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bf845b5b-a295-4ce6-a712-dd4befb241d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bf845b5b-a295-4ce6-a712-dd4befb241d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a9cd8ccf-e326-473f-9c81-8fb37db09e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LineOfCredit_a35b0ff0-46e8-4ac0-b953-e389f5f3b8fd" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_a9cd8ccf-e326-473f-9c81-8fb37db09e6f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquity"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingencies"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactions"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_5f29e23b-13eb-408a-a310-2abe03ce8eef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_6aa6671b-c4bd-47d0-a491-41bac92c382a" xlink:href="ameh-20200930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_5f29e23b-13eb-408a-a310-2abe03ce8eef" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_6aa6671b-c4bd-47d0-a491-41bac92c382a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_6487a91c-d834-489f-9523-1b8a606eda90" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_5f29e23b-13eb-408a-a310-2abe03ce8eef" xlink:to="loc_us-gaap_ManagementFeeExpense_6487a91c-d834-489f-9523-1b8a606eda90" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxes"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShare"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8601292c-f46e-4755-a494-9fef46d45904" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62e54f8c-86f8-42b8-9a37-f39ccb6deaf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8601292c-f46e-4755-a494-9fef46d45904" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_62e54f8c-86f8-42b8-9a37-f39ccb6deaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ca9eb51e-81de-4be7-a43b-12baa76a640a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8601292c-f46e-4755-a494-9fef46d45904" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ca9eb51e-81de-4be7-a43b-12baa76a640a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEs"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4a3e0d7-b080-47e2-b866-f6f86ebd314c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_b4a3e0d7-b080-47e2-b866-f6f86ebd314c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_8bee2328-54eb-4006-ad25-4852b89285bb" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_8bee2328-54eb-4006-ad25-4852b89285bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_05347896-6e92-40f2-941e-242dfc8129d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_05347896-6e92-40f2-941e-242dfc8129d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_bf2183fe-4698-4c3c-a8c6-d6e1d703edb8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_TaxesPayableCurrent_bf2183fe-4698-4c3c-a8c6-d6e1d703edb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_c930f686-6360-45b0-b2a8-bb18667467d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_DueToAffiliateCurrent_c930f686-6360-45b0-b2a8-bb18667467d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_75b82271-a599-49cf-b63b-aec05c42c19c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_DividendsPayableCurrent_75b82271-a599-49cf-b63b-aec05c42c19c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_132106b6-7b68-46c6-8a7d-a5038345b1f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_132106b6-7b68-46c6-8a7d-a5038345b1f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_04f0b229-c9b2-4329-9437-d3e906ad96a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_125d33cf-42f5-457e-9864-083a6c0f36aa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_04f0b229-c9b2-4329-9437-d3e906ad96a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f19eac93-4cbb-4b04-b12c-db2b7c2c8b5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f19eac93-4cbb-4b04-b12c-db2b7c2c8b5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21ac35a9-2c8e-4265-a404-fb44d856aa5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_21ac35a9-2c8e-4265-a404-fb44d856aa5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5f620d99-79a6-4b1b-938f-1ac319ee8859" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_Goodwill_5f620d99-79a6-4b1b-938f-1ac319ee8859" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_12e309f7-60b9-4a9c-828a-2862fb310f5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_OtherLongTermInvestments_12e309f7-60b9-4a9c-828a-2862fb310f5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_91c32a62-5468-4e60-91dd-40adc08ab239" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_91c32a62-5468-4e60-91dd-40adc08ab239" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_12e22212-b51b-434c-bff5-57adad4c0164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_EquityMethodInvestments_12e22212-b51b-434c-bff5-57adad4c0164" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_bee1dcee-fae8-4189-97ce-7968e30bebf8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_bee1dcee-fae8-4189-97ce-7968e30bebf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd6aba13-baac-42be-8571-23b05c22006f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bd6aba13-baac-42be-8571-23b05c22006f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7683c54b-1a1a-440a-9115-3ddaf86d068a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_3afa0877-03dd-4e82-b7ef-ec8b5dd8f784" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7683c54b-1a1a-440a-9115-3ddaf86d068a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200930.xsd#Leases"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesTables"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesAdditionalinformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cdf84032-147e-4e40-b851-3eda473bc410" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_011ce8d4-6788-447f-a784-57757dc17143" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf84032-147e-4e40-b851-3eda473bc410" xlink:to="loc_us-gaap_OperatingLeaseCost_011ce8d4-6788-447f-a784-57757dc17143" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7e8e33a-445b-4f41-901c-c56353cc9169" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf84032-147e-4e40-b851-3eda473bc410" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b7e8e33a-445b-4f41-901c-c56353cc9169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_b9a9e732-7593-4ea8-9083-e9c615977fe0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf84032-147e-4e40-b851-3eda473bc410" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_b9a9e732-7593-4ea8-9083-e9c615977fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0f75ead9-6f67-46ea-9c0a-6729dc9e947b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf84032-147e-4e40-b851-3eda473bc410" xlink:to="loc_us-gaap_SubleaseIncome_0f75ead9-6f67-46ea-9c0a-6729dc9e947b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_670d2d5e-1026-4241-93a2-aead7fb5d3a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_e354d6e8-0c72-49dc-8ac1-9f97e4057a84" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_670d2d5e-1026-4241-93a2-aead7fb5d3a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_e354d6e8-0c72-49dc-8ac1-9f97e4057a84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5ecbe8d5-caac-409b-880c-e08b226b1f17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_670d2d5e-1026-4241-93a2-aead7fb5d3a7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_5ecbe8d5-caac-409b-880c-e08b226b1f17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_fd0f9219-5dd0-4ea2-9fbc-b8448a997acf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_fd0f9219-5dd0-4ea2-9fbc-b8448a997acf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a23594c0-50a4-4d60-8eb6-5529f167166f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_a23594c0-50a4-4d60-8eb6-5529f167166f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_40dafaa4-d38a-4ffe-af35-2157beb4a89a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_40dafaa4-d38a-4ffe-af35-2157beb4a89a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0f339fbd-f165-4169-8ecc-1c8af2a3b165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_0f339fbd-f165-4169-8ecc-1c8af2a3b165" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ff98f231-dd6e-444f-bd42-9c2e4e20a78f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ff98f231-dd6e-444f-bd42-9c2e4e20a78f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_a1972d87-e501-4f82-9a02-f97f590226f2" xlink:href="ameh-20200930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_3c018c81-d59a-47f0-8c9d-5aa854c76fb1" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_a1972d87-e501-4f82-9a02-f97f590226f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5a354a7b-b8f8-445c-9d62-dd943cd76d3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_5a354a7b-b8f8-445c-9d62-dd943cd76d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_424d5500-15ce-4622-9a2f-89fb2df9dc95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_424d5500-15ce-4622-9a2f-89fb2df9dc95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b07be93b-6fbb-4b81-a321-b6e121f071c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b07be93b-6fbb-4b81-a321-b6e121f071c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2e54feeb-f876-48ef-b611-d7a16cb40a35" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2e54feeb-f876-48ef-b611-d7a16cb40a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6f17101-e656-44e3-96a2-2d06bb406a8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_e6f17101-e656-44e3-96a2-2d06bb406a8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1a9f7b2e-7a1e-45fc-8481-a04416b451f7" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2945576a-ce3e-4203-9153-47928a6e7db6" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_1a9f7b2e-7a1e-45fc-8481-a04416b451f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_20cfa6ed-8ac9-4ddc-a032-b868877350d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_64e88c9d-dd6b-4d0b-8db5-66937d23121a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_20cfa6ed-8ac9-4ddc-a032-b868877350d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_64e88c9d-dd6b-4d0b-8db5-66937d23121a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ec3c580e-eab3-42aa-abfc-9b065501dd78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_20cfa6ed-8ac9-4ddc-a032-b868877350d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ec3c580e-eab3-42aa-abfc-9b065501dd78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0187bbd2-cb80-48f4-a83a-2d9db95aca17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d9fca12e-dff3-4822-b405-f7949d69bced" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0187bbd2-cb80-48f4-a83a-2d9db95aca17" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_d9fca12e-dff3-4822-b405-f7949d69bced" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_e64577fc-8e33-4479-8496-a1b4b41b2dda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_0187bbd2-cb80-48f4-a83a-2d9db95aca17" xlink:to="loc_us-gaap_FinanceLeaseLiability_e64577fc-8e33-4479-8496-a1b4b41b2dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9101c0aa-00c4-4f45-b17e-9153a22bf792" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c0c70a2c-b814-41da-b3b3-8f8cacbb24b5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9101c0aa-00c4-4f45-b17e-9153a22bf792" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c0c70a2c-b814-41da-b3b3-8f8cacbb24b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f11bd828-43ad-4d82-940b-c522c39c08ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_9101c0aa-00c4-4f45-b17e-9153a22bf792" xlink:to="loc_us-gaap_OperatingLeaseLiability_f11bd828-43ad-4d82-940b-c522c39c08ec" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEvents"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:calculationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>ameh-20200930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200930.xsd#DocumentandEntityInformation"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended" id="i26b29d27520641a8902108f83eae442b_DocumentandEntityInformation"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended" id="ib8c8553362514ec4bf2f11ecd4f58cbf_CONSOLIDATEDBALANCESHEETSUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:to="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3aa5b55-3c35-4f96-86dd-11e65abc1d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3aa5b55-3c35-4f96-86dd-11e65abc1d18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5f1b5547-5510-45f1-b9ca-11254e2fde3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_RestrictedCashCurrent_5f1b5547-5510-45f1-b9ca-11254e2fde3f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d4ab6619-5dfc-4f05-ad50-c1e4273a92a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d4ab6619-5dfc-4f05-ad50-c1e4273a92a2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4136a118-8e1f-4904-b710-351a663f0c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4136a118-8e1f-4904-b710-351a663f0c3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_22fa7140-d3a1-406f-ad09-b1954c9ffc5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_22fa7140-d3a1-406f-ad09-b1954c9ffc5c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7f021049-6e48-418c-87fa-f19ac6e067d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7f021049-6e48-418c-87fa-f19ac6e067d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4fb95b5-5ef2-4659-aeec-f4f4b44e21e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4fb95b5-5ef2-4659-aeec-f4f4b44e21e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_928abff3-10f4-4893-9afb-2c7e368fd309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_928abff3-10f4-4893-9afb-2c7e368fd309" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_f956805c-0846-4167-90d7-bd23a3a7f24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_f956805c-0846-4167-90d7-bd23a3a7f24e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ff94c3c8-593b-4aab-9f0e-9e71d2e4330d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AssetsCurrent_ff94c3c8-593b-4aab-9f0e-9e71d2e4330d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c4d83146-2df3-4446-9bca-7a65a8a21b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c4d83146-2df3-4446-9bca-7a65a8a21b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_27b1601b-d805-44e9-8862-13e24f5c5fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_27b1601b-d805-44e9-8862-13e24f5c5fa3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c4e52f3-e029-4e9d-9183-55cc80846211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c4e52f3-e029-4e9d-9183-55cc80846211" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_122ea520-bae4-4b14-8d48-ab7e35e4f264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_Goodwill_122ea520-bae4-4b14-8d48-ab7e35e4f264" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_428214ed-822d-42ca-8808-7376e800c565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_EquityMethodInvestments_428214ed-822d-42ca-8808-7376e800c565" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ee3c7e0d-3275-4a54-9177-6aec4bd26e65" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ee3c7e0d-3275-4a54-9177-6aec4bd26e65" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_09862287-9847-49f7-a001-c694b76e894c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_09862287-9847-49f7-a001-c694b76e894c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ee4863c-dee1-4cbe-8908-b000955f6174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ee4863c-dee1-4cbe-8908-b000955f6174" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_15cfc972-069c-4216-9279-0b7fa6ee8264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_AssetsNoncurrent_15cfc972-069c-4216-9279-0b7fa6ee8264" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a32ab762-fd32-4f67-9f93-b6419b7c64e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_Assets_a32ab762-fd32-4f67-9f93-b6419b7c64e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb3e8efa-7198-4a1c-8865-30e7e2d6b082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb3e8efa-7198-4a1c-8865-30e7e2d6b082" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6b15d054-9670-4fe1-807c-73b077b8327b" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6b15d054-9670-4fe1-807c-73b077b8327b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfe4ba7a-fcea-45de-ae92-bedce5112dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfe4ba7a-fcea-45de-ae92-bedce5112dab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b0298d6b-b03e-4837-b57a-b468e47eba7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b0298d6b-b03e-4837-b57a-b468e47eba7e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_506d56ba-b175-4ff1-9072-604539e314e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_DividendsPayableCurrent_506d56ba-b175-4ff1-9072-604539e314e8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_23fbb99a-4a10-403d-8065-c3c094f7a965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_23fbb99a-4a10-403d-8065-c3c094f7a965" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c8a7f03-03c6-4105-b667-197728f5fb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c8a7f03-03c6-4105-b667-197728f5fb92" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2c87a887-6532-42c5-8de5-c090d2e3b25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LongTermDebtCurrent_2c87a887-6532-42c5-8de5-c090d2e3b25b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f76146f4-2e85-454a-9c42-33c7e6ee6cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LiabilitiesCurrent_f76146f4-2e85-454a-9c42-33c7e6ee6cb0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08426cdb-28f6-4d94-818a-1f91de993f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08426cdb-28f6-4d94-818a-1f91de993f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6e7e7b6c-9172-4b95-95fd-256792aed6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6e7e7b6c-9172-4b95-95fd-256792aed6ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d13d058-a444-4b3e-bdd0-45c9234b5663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d13d058-a444-4b3e-bdd0-45c9234b5663" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c07b252e-febc-4daf-998c-e729bc756666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c07b252e-febc-4daf-998c-e729bc756666" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_634c18f4-9ba2-4ec4-a9fe-2bba3f8ee1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_634c18f4-9ba2-4ec4-a9fe-2bba3f8ee1cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ffee14da-9850-46dd-a6f3-9ddba0f98696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_Liabilities_ffee14da-9850-46dd-a6f3-9ddba0f98696" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2be97b22-2bf6-43c6-8412-4e98ab9e0211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2be97b22-2bf6-43c6-8412-4e98ab9e0211" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:href="ameh-20200930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bd83cbf4-a0bd-4e23-9107-f6eb9fac67bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bd83cbf4-a0bd-4e23-9107-f6eb9fac67bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5cd5d716-703a-49b6-a5ea-5d6918b79921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_PreferredStockValue_5cd5d716-703a-49b6-a5ea-5d6918b79921" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5eb81479-dae6-4439-9524-269957f6aec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_CommonStockValue_5eb81479-dae6-4439-9524-269957f6aec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6aaea4c2-0afc-4dff-a33e-198d828a2734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6aaea4c2-0afc-4dff-a33e-198d828a2734" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7436d15a-7062-446f-913e-8fc3acda32b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7436d15a-7062-446f-913e-8fc3acda32b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04008e01-8ffa-4f88-a33f-c2cd1b54d828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_StockholdersEquity_04008e01-8ffa-4f88-a33f-c2cd1b54d828" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_54012fe3-b5c8-4f48-837c-21d1dd7ae89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_MinorityInterest_54012fe3-b5c8-4f48-837c-21d1dd7ae89d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9925f634-09f6-4eef-aca8-288438a24537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9925f634-09f6-4eef-aca8-288438a24537" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_377310d5-3d2c-4b83-b2cc-b23a0ed9989b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_377310d5-3d2c-4b83-b2cc-b23a0ed9989b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:to="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a657d31e-0e57-4060-b13e-673558ab97bb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:to="loc_us-gaap_ClassOfStockDomain_a657d31e-0e57-4060-b13e-673558ab97bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:to="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a4426fd9-1f54-430e-b932-c7769c2d9bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a4426fd9-1f54-430e-b932-c7769c2d9bc2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_29e2b155-1930-44bb-9d09-40593ff79a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_29e2b155-1930-44bb-9d09-40593ff79a30" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended" id="i3eebf0b8dcd542cab09c7621542937cb_CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b45453ef-bdfe-43b1-bfa7-e8e6a7bb7060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b45453ef-bdfe-43b1-bfa7-e8e6a7bb7060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a303e6ab-e160-4013-8d2e-e0d1bc219251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a303e6ab-e160-4013-8d2e-e0d1bc219251" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7fb065e7-3329-4f42-9a42-37e88dcd081f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7fb065e7-3329-4f42-9a42-37e88dcd081f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d333e423-522f-4181-95e6-8efd1380dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d333e423-522f-4181-95e6-8efd1380dc12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_49267c0d-12fb-4293-a50f-5262e72c82ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_49267c0d-12fb-4293-a50f-5262e72c82ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5599621-0a99-432a-ab15-77ef8ee58eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5599621-0a99-432a-ab15-77ef8ee58eda" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5db4b4b4-9ca2-4be5-8247-4457a01fa846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5db4b4b4-9ca2-4be5-8247-4457a01fa846" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_eb73efa7-be97-408e-ad3f-14cb0919cbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_TreasuryStockCommonShares_eb73efa7-be97-408e-ad3f-14cb0919cbbf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d220bcdc-6394-4780-8b9a-de03fdec9f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_Assets_d220bcdc-6394-4780-8b9a-de03fdec9f8b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5c2d0769-8763-483b-b980-d9253731d450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_Liabilities_5c2d0769-8763-483b-b980-d9253731d450" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:to="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_48426adf-b62e-4b77-aaae-3a1d29f22a4d_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:to="loc_us-gaap_ClassOfStockDomain_48426adf-b62e-4b77-aaae-3a1d29f22a4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:to="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5f4aed17-8bb6-476d-8ac9-f573b60b9444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5f4aed17-8bb6-476d-8ac9-f573b60b9444" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8794bd5a-a55b-4622-bf78-3b5c2a05724d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8794bd5a-a55b-4622-bf78-3b5c2a05724d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_0d54f571-3713-4f97-aafd-36e7652ad238_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:to="loc_srt_ConsolidatedEntitiesDomain_0d54f571-3713-4f97-aafd-36e7652ad238_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_53816d8b-3b56-4346-b870-3d506afa5d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_53816d8b-3b56-4346-b870-3d506afa5d61" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended" id="ifbc2b425adca47959c39badd3b9f4c9f_CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31f229f5-7bcf-4803-9b47-583ce64a71b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31f229f5-7bcf-4803-9b47-583ce64a71b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_776da002-1d72-432d-a147-628c371d2056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_776da002-1d72-432d-a147-628c371d2056" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1168cdbe-291e-4b90-a93a-05f70dbc8763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1168cdbe-291e-4b90-a93a-05f70dbc8763" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_a5e5c9ae-d34f-4a18-b33e-648ae486c822" xlink:href="ameh-20200930.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_a5e5c9ae-d34f-4a18-b33e-648ae486c822" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c2e94bb7-1f36-491c-a4de-746cc1634c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c2e94bb7-1f36-491c-a4de-746cc1634c42" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ffbd6ce3-2238-48bb-b4d6-f18e913bc3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ffbd6ce3-2238-48bb-b4d6-f18e913bc3d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_730a27ae-a05a-4edf-a0af-595fff28c54c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_CostsAndExpenses_730a27ae-a05a-4edf-a0af-595fff28c54c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f4b13d0d-f444-4e26-ad41-12b2054d9ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_OperatingIncomeLoss_f4b13d0d-f444-4e26-ad41-12b2054d9ace" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb8e418b-e674-43ef-ac53-f44f5cdf82a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb8e418b-e674-43ef-ac53-f44f5cdf82a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_be6a2f91-edcb-4b7b-bc6f-f8626a3fffc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_be6a2f91-edcb-4b7b-bc6f-f8626a3fffc1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_05f3dff3-3ce0-4a64-8fe2-58e921dd7f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_InterestExpense_05f3dff3-3ce0-4a64-8fe2-58e921dd7f07" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6cd907e9-9ab5-4159-a70f-07a50acdc22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6cd907e9-9ab5-4159-a70f-07a50acdc22c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f1b4771d-9901-4aab-9099-08188b10e936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f1b4771d-9901-4aab-9099-08188b10e936" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_97ccde44-1756-465f-b63e-535bede281cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_97ccde44-1756-465f-b63e-535bede281cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85df6220-b1f2-40bb-9aca-0dd000b4c98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85df6220-b1f2-40bb-9aca-0dd000b4c98b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fbd34d1a-d6c9-4d0d-88da-35ddd7283a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fbd34d1a-d6c9-4d0d-88da-35ddd7283a6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_88148c25-4bed-4d95-ac3b-9b30631c146b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_ProfitLoss_88148c25-4bed-4d95-ac3b-9b30631c146b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6169ce0-e04b-41cc-95f5-adc5cb82686b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6169ce0-e04b-41cc-95f5-adc5cb82686b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0db7ad48-8f80-4eb3-b03e-1217787a3947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NetIncomeLoss_0db7ad48-8f80-4eb3-b03e-1217787a3947" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_30d794a1-b364-4e87-8a16-dfb52dac7d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_EarningsPerShareBasic_30d794a1-b364-4e87-8a16-dfb52dac7d85" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b33c507-1e20-471e-b683-ae45ad1145e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b33c507-1e20-471e-b683-ae45ad1145e2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:to="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a94ae3d1-9714-490f-a534-2f5f842ad188_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:to="loc_srt_ProductsAndServicesDomain_a94ae3d1-9714-490f-a534-2f5f842ad188_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:to="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_a8c064bf-65ee-4e05-bd92-6bbc6a3a38a0" xlink:href="ameh-20200930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_a8c064bf-65ee-4e05-bd92-6bbc6a3a38a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_417bd344-7895-45a7-bb07-9e63ad8b5f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_HealthCareOtherMember_417bd344-7895-45a7-bb07-9e63ad8b5f3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_02aee463-2da8-4ca5-9a4f-aa45eece4d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_ManagementServiceMember_02aee463-2da8-4ca5-9a4f-aa45eece4d47" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8c1e1df6-4204-4717-a2ad-01f13ae0d72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8c1e1df6-4204-4717-a2ad-01f13ae0d72d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_1e51d7fb-21de-4cd3-9007-9188b7ff6ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_1e51d7fb-21de-4cd3-9007-9188b7ff6ab0" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended" id="i029fffbc87174bf19de4d0255ed58660_CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59cd1acc-22aa-4085-a97a-47e0575da503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59cd1acc-22aa-4085-a97a-47e0575da503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82a70a20-38a0-4fae-970e-df8b86e83d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_SharesOutstanding_82a70a20-38a0-4fae-970e-df8b86e83d5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_e4f1dacc-7d28-450a-8a7b-12d02dd3c939" xlink:href="ameh-20200930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_e4f1dacc-7d28-450a-8a7b-12d02dd3c939" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_3b795c47-ec40-47cf-9acf-235a79592976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_3b795c47-ec40-47cf-9acf-235a79592976" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_78e91518-d5e2-4f94-8c9b-1747fb7c9bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_78e91518-d5e2-4f94-8c9b-1747fb7c9bfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_56781f36-7ab3-4424-8ee2-7f1a0891ac05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_56781f36-7ab3-4424-8ee2-7f1a0891ac05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3756dffc-0bcb-4b23-bf0d-0f66aaab6507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3756dffc-0bcb-4b23-bf0d-0f66aaab6507" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e3371e0e-f9a6-4521-8c96-806751f5334f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e3371e0e-f9a6-4521-8c96-806751f5334f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_02b8cb9f-e818-49b4-83ef-b3ba9bd13079" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_02b8cb9f-e818-49b4-83ef-b3ba9bd13079" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_f9d585c4-dde0-4911-9a4d-839271e7a02a" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_f9d585c4-dde0-4911-9a4d-839271e7a02a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_1165ca62-ad27-4f8d-878e-25f6ae91e90e" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_1165ca62-ad27-4f8d-878e-25f6ae91e90e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_b56cf85e-713c-4a86-8626-5539601bd7f9" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_b56cf85e-713c-4a86-8626-5539601bd7f9" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_119b1be7-a8ab-4919-8875-652a8bd635ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_119b1be7-a8ab-4919-8875-652a8bd635ec" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e71442f-1066-4367-a75d-7015843f2832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e71442f-1066-4367-a75d-7015843f2832" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e14c022-4154-4b66-8775-3cf2f492ddff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e14c022-4154-4b66-8775-3cf2f492ddff" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa2da91c-f11e-4095-a1f1-96c1046d71a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa2da91c-f11e-4095-a1f1-96c1046d71a9" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e2af9c40-2682-4ae9-9ef4-258b6b7c7ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e2af9c40-2682-4ae9-9ef4-258b6b7c7ccf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_0700ebd8-b61c-421b-b774-a868d40ffcf7" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_0700ebd8-b61c-421b-b774-a868d40ffcf7" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_08e089bd-b86a-4767-b59f-80c74dea9031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_08e089bd-b86a-4767-b59f-80c74dea9031" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05b67898-29c6-40f3-b9e7-bc320e306b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bdfd810c-dd00-48e5-ae86-d6e4e1171a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ff6faf2a-6a79-46db-ae37-84d239baca79_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:to="loc_us-gaap_EquityComponentDomain_ff6faf2a-6a79-46db-ae37-84d239baca79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:to="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb56d066-cd4a-4749-93ed-a660b911ec68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_CommonStockMember_eb56d066-cd4a-4749-93ed-a660b911ec68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5240a7a7-b53b-42ac-b107-3aa707284b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5240a7a7-b53b-42ac-b107-3aa707284b5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1797b9e0-1d8d-4425-b227-675d27cacc64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_RetainedEarningsMember_1797b9e0-1d8d-4425-b227-675d27cacc64" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_04679cb7-6687-4678-b15c-a97b5ace9188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_04679cb7-6687-4678-b15c-a97b5ace9188" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:to="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a775f590-8dde-49d5-9bbe-8670295e48ac_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:to="loc_dei_EntityDomain_a775f590-8dde-49d5-9bbe-8670295e48ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:to="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_4bd22e6c-bfd3-4d23-98b0-7483b2134d66" xlink:href="ameh-20200930.xsd#ameh_MezzanineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:to="loc_ameh_MezzanineMember_4bd22e6c-bfd3-4d23-98b0-7483b2134d66" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended" id="i447d2f39f6d041e8b95741f9f0a9c545_CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusiness"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended" id="id96a5b53040c4c7ea4b7d390c9017217_DescriptionofBusiness"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended" id="i2ded905968eb4bbfab6f49a56d36dfe4_DescriptionofBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_1616aa54-4bc1-4b9d-9bd8-cb5cb3f4382c" xlink:href="ameh-20200930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_1616aa54-4bc1-4b9d-9bd8-cb5cb3f4382c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_94225583-d73a-4b50-80d3-207dbdbe10fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NotesReceivableNet_94225583-d73a-4b50-80d3-207dbdbe10fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_7fd044d9-433f-47eb-803a-11425cc24924" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_7fd044d9-433f-47eb-803a-11425cc24924" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_31c38b65-f7fa-4d3a-b1ff-ef2ca7144af9" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_31c38b65-f7fa-4d3a-b1ff-ef2ca7144af9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_f76c3cd7-0adb-4d59-b850-4d4beb9fd8f2" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_f76c3cd7-0adb-4d59-b850-4d4beb9fd8f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b462746-51c9-4216-9285-9f8126b763b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b462746-51c9-4216-9285-9f8126b763b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d91a0670-2e52-4927-b47b-a2314110ce15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d91a0670-2e52-4927-b47b-a2314110ce15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_a1cfd92a-4418-4d68-b167-d393c2624a89" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_a1cfd92a-4418-4d68-b167-d393c2624a89" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dfbbe41b-5176-4f79-b481-7bbe54130a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dfbbe41b-5176-4f79-b481-7bbe54130a4a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_957ac0d0-ea07-4830-a212-e5c93b83fb33" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_957ac0d0-ea07-4830-a212-e5c93b83fb33" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f04beac-d691-4e70-b9de-60bde7906af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f04beac-d691-4e70-b9de-60bde7906af7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_0b2c2cf1-20e5-42ee-9ed7-687d862f5d07" xlink:href="ameh-20200930.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfEmployees_0b2c2cf1-20e5-42ee-9ed7-687d862f5d07" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_1930a1b6-9893-4f0a-b17a-02989a39c9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NumberOfStores_1930a1b6-9893-4f0a-b17a-02989a39c9fa" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_af8bb047-44c0-4f4a-897b-2d352d5fc6f5" xlink:href="ameh-20200930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_af8bb047-44c0-4f4a-897b-2d352d5fc6f5" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e6da391e-7bd9-4ef9-808e-deb1130fe1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e6da391e-7bd9-4ef9-808e-deb1130fe1d7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7a50553-163d-4ef5-9da5-f5adcd614230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7a50553-163d-4ef5-9da5-f5adcd614230" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_61d3ca0c-94ce-4e76-9fc4-51bf71fa8270" xlink:href="ameh-20200930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_61d3ca0c-94ce-4e76-9fc4-51bf71fa8270" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_397101e2-0399-42ba-8539-393ca164bd2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_397101e2-0399-42ba-8539-393ca164bd2d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b84b50f9-2ab1-4e49-93b4-36987da94913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b84b50f9-2ab1-4e49-93b4-36987da94913" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_485d622e-4ea0-4458-a29e-88d48277980c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_485d622e-4ea0-4458-a29e-88d48277980c" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_3f3ccf3b-d415-4004-aa6c-9972e32d96ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_3f3ccf3b-d415-4004-aa6c-9972e32d96ef" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_590861d2-4b74-447f-a7aa-1e4fccb13875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_590861d2-4b74-447f-a7aa-1e4fccb13875" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_eabfb41a-dc6f-47f9-a63d-2be71ea75b3d" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_eabfb41a-dc6f-47f9-a63d-2be71ea75b3d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6a4c3265-f53a-4445-8dc7-9128ea544b45_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:to="loc_dei_EntityDomain_6a4c3265-f53a-4445-8dc7-9128ea544b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:to="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2b107040-202e-4e16-9d00-ca530cee860c" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2b107040-202e-4e16-9d00-ca530cee860c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_71806854-9f4d-43c1-bf30-b10cf9a5c970" xlink:href="ameh-20200930.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_ApcLsmaMember_71806854-9f4d-43c1-bf30-b10cf9a5c970" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_135fec06-0df1-4d55-8fbe-e9bef5976fa5" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_135fec06-0df1-4d55-8fbe-e9bef5976fa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_d3e12225-043c-4a67-a5e8-2f1bf4f17fb5" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AccountableHealthCareIPAMember_d3e12225-043c-4a67-a5e8-2f1bf4f17fb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_93e746c0-d8ef-44d5-ae60-0014a7e64d83" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_APCAndAPCLSMAMember_93e746c0-d8ef-44d5-ae60-0014a7e64d83" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_f8d8764d-4e56-44dd-9980-4d5ef85b48c8" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AmgIncMember_f8d8764d-4e56-44dd-9980-4d5ef85b48c8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5e0256c3-2d74-4042-adbc-0b5b10687fe2" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5e0256c3-2d74-4042-adbc-0b5b10687fe2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b2df512-6628-41b4-a0fd-4655c779a95c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0b2df512-6628-41b4-a0fd-4655c779a95c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_f1d83ed9-ebad-4ca7-8ab1-810ab0905a96" xlink:href="ameh-20200930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_APAMHMedicalCorporationMember_f1d83ed9-ebad-4ca7-8ab1-810ab0905a96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6b65ebb2-cc2c-41c6-af1f-e1940a1536e9" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6b65ebb2-cc2c-41c6-af1f-e1940a1536e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_a0da8b71-018e-45f9-8a82-850e03bd2a74" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_Dr.JayMember_a0da8b71-018e-45f9-8a82-850e03bd2a74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_c5a4ce8b-b6dc-4a08-a137-e1b5a85f9c8b" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_c5a4ce8b-b6dc-4a08-a137-e1b5a85f9c8b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d9bdf15c-5995-4d0d-8336-48a413cf1ba5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:to="loc_us-gaap_RelatedPartyDomain_d9bdf15c-5995-4d0d-8336-48a413cf1ba5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:to="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_f7944037-c9d4-44cf-b304-7293b2c7e753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:to="loc_srt_AffiliatedEntityMember_f7944037-c9d4-44cf-b304-7293b2c7e753" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ba91f311-828d-4ca8-9b26-5ab909c82ef6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:to="loc_us-gaap_ClassOfStockDomain_ba91f311-828d-4ca8-9b26-5ab909c82ef6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:to="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_53839522-3947-491b-b67a-15880c24c633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_53839522-3947-491b-b67a-15880c24c633" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef0377dd-9085-4c21-a8c0-84e52a460d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:to="loc_us-gaap_PreferredStockMember_ef0377dd-9085-4c21-a8c0-84e52a460d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7d71e94e-2d72-4152-b42f-33f86354c470_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7d71e94e-2d72-4152-b42f-33f86354c470_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_3911b31e-e039-4362-ae53-58237482a576" xlink:href="ameh-20200930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_3911b31e-e039-4362-ae53-58237482a576" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_99b6e982-9af0-486c-a827-1ec3a6687fe0" xlink:href="ameh-20200930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_99b6e982-9af0-486c-a827-1ec3a6687fe0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9419941d-1afe-4d92-bf94-ff393daccd57" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_UniversalCareIncMember_9419941d-1afe-4d92-bf94-ff393daccd57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:to="loc_srt_OwnershipDomain_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:to="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_fed6200e-dfe2-40d6-84d8-c54458ebde69" xlink:href="ameh-20200930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_fed6200e-dfe2-40d6-84d8-c54458ebde69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_97df72f0-c007-45c3-965b-69543119ab11" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_97df72f0-c007-45c3-965b-69543119ab11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65c80403-92cc-4df5-ae78-c2b0afb1aae9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65c80403-92cc-4df5-ae78-c2b0afb1aae9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_713f5e40-1c4d-4dec-ae8f-72953bb73405" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:to="loc_ameh_AccountableHealthCareIPAMember_713f5e40-1c4d-4dec-ae8f-72953bb73405" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_68727040-bc51-4916-b71e-454e23196805" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:to="loc_ameh_AmgIncMember_68727040-bc51-4916-b71e-454e23196805" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended" id="i1dae933ee80d4cefb3c2fc9609feb2cb_BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended" id="ibb4a907a05584f92b5bc165f7870efce_BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended" id="i54aee04a0faf41159f230be40506d8d9_BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="ice94dc29091c4b0897c52d759fcf3392_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_adb3d049-8f57-4604-b981-b9a22b156bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_adb3d049-8f57-4604-b981-b9a22b156bbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c38d4d44-abb3-423c-9471-2fb7d37260ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfReportableSegments_c38d4d44-abb3-423c-9471-2fb7d37260ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_bbe72ed1-b738-43af-b8a6-2653bdb30e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_CashUninsuredAmount_bbe72ed1-b738-43af-b8a6-2653bdb30e80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2f26e1be-5ca9-4e83-bde1-535811545678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2f26e1be-5ca9-4e83-bde1-535811545678" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_33e0b584-20e8-4360-b788-614d753b8374" xlink:href="ameh-20200930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_33e0b584-20e8-4360-b788-614d753b8374" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_b5bd43fd-d328-480b-bc13-4f110e9af473" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_b5bd43fd-d328-480b-bc13-4f110e9af473" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2868d3-6aa8-4e02-a580-45517a9550da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2868d3-6aa8-4e02-a580-45517a9550da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_79d12a38-1681-4d8d-9a16-a4562b1eeea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_79d12a38-1681-4d8d-9a16-a4562b1eeea8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d89261ed-39c0-4295-abe8-d56ec0d41352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d89261ed-39c0-4295-abe8-d56ec0d41352" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_8eea479c-32e9-4104-bbed-d5ca9ae68014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfReportingUnits_8eea479c-32e9-4104-bbed-d5ca9ae68014" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6e3147ea-f487-4b9f-8dfc-5101d8800087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6e3147ea-f487-4b9f-8dfc-5101d8800087" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_30589416-efdb-4510-b61e-67cfe1cdcaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_30589416-efdb-4510-b61e-67cfe1cdcaf5" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_96db9b51-4bdc-446b-ae32-dc751074d81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_96db9b51-4bdc-446b-ae32-dc751074d81f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_7408e43b-3788-46fa-8d4a-4e26dc387505" xlink:href="ameh-20200930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_7408e43b-3788-46fa-8d4a-4e26dc387505" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement_e493c253-eadb-40ea-bf72-be24feddb36f" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RiskPoolSettlement_e493c253-eadb-40ea-bf72-be24feddb36f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_1bf38deb-9aec-426e-88ba-d5050a71fcae" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_1bf38deb-9aec-426e-88ba-d5050a71fcae" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_ad56b32b-3446-44d7-bf56-cddafd8fe161" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_PaymentOfRevenue_ad56b32b-3446-44d7-bf56-cddafd8fe161" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d8e59e89-bf44-4df3-8bd8-97622003ee89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d8e59e89-bf44-4df3-8bd8-97622003ee89" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c6c44c2-e5cb-4889-8641-4034395cf62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c6c44c2-e5cb-4889-8641-4034395cf62d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_2357c98a-96c6-4866-89a5-4b4e16d7c50a" xlink:href="ameh-20200930.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_2357c98a-96c6-4866-89a5-4b4e16d7c50a" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit_816e841a-f68a-44db-b44a-fc519625b457" xlink:href="ameh-20200930.xsd#ameh_InvestmentDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_InvestmentDeposit_816e841a-f68a-44db-b44a-fc519625b457" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_69671973-4946-427b-8594-3e5db67f0993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_69671973-4946-427b-8594-3e5db67f0993" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_61bdeb27-a740-43bd-90ac-60e1e124a5e6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_61bdeb27-a740-43bd-90ac-60e1e124a5e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ecaaa5b4-7df9-4c34-b5a6-1d7dfb09c2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ecaaa5b4-7df9-4c34-b5a6-1d7dfb09c2e3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:to="loc_srt_RangeMember_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:to="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6b58106-77ff-432d-96b5-5c411934695f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:to="loc_srt_MinimumMember_c6b58106-77ff-432d-96b5-5c411934695f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d59238aa-e8b5-4241-a1ba-44e13bf33b96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:to="loc_srt_MaximumMember_d59238aa-e8b5-4241-a1ba-44e13bf33b96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b4b6e7-3d76-4416-acf1-d1105206e6a5_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d6b4b6e7-3d76-4416-acf1-d1105206e6a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_f75279dd-4b39-4771-8191-7e36af99934d" xlink:href="ameh-20200930.xsd#ameh_CMSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:to="loc_ameh_CMSMember_f75279dd-4b39-4771-8191-7e36af99934d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:to="loc_srt_ProductsAndServicesDomain_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:to="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_962d1fdf-0b96-46ee-9f8c-09f35a927416" xlink:href="ameh-20200930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_962d1fdf-0b96-46ee-9f8c-09f35a927416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_b93fa2c4-76f4-4f1b-8e3e-e933c41e4239" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_b93fa2c4-76f4-4f1b-8e3e-e933c41e4239" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_521c8768-41ca-4fb5-9890-c1d32baffc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_us-gaap_ManagementServiceMember_521c8768-41ca-4fb5-9890-c1d32baffc18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_ad798083-81ca-4756-8e3c-397b4acf650c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_ad798083-81ca-4756-8e3c-397b4acf650c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_84d86be1-f59f-4b05-8113-deb7c9d37f25" xlink:href="ameh-20200930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_84d86be1-f59f-4b05-8113-deb7c9d37f25" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended" id="i20da16604e54448791be750604aa1bf4_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_088b7074-77d1-425a-b915-439a63ff099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_088b7074-77d1-425a-b915-439a63ff099f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3dba856-e440-49e9-ab42-6c557b4cbc9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:to="loc_srt_ProductsAndServicesDomain_a3dba856-e440-49e9-ab42-6c557b4cbc9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:to="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended" id="i5c0557ab867f42d4b4d88f343750afbc_BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a3dba856-e440-49e9-ab42-6c557b4cbc9e_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:to="loc_srt_ProductsAndServicesDomain_a3dba856-e440-49e9-ab42-6c557b4cbc9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:to="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended" id="ic9f6fa7f8b7f4261b8679ded9032dd6f_BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad1b0b98-6b28-4963-a524-36980d9ce86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad1b0b98-6b28-4963-a524-36980d9ce86d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:to="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e20cfb9a-4a6e-4a91-9657-62cbd20d6566_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:to="loc_srt_NameOfMajorCustomerDomain_e20cfb9a-4a6e-4a91-9657-62cbd20d6566_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:to="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_e19db2b7-4e83-496f-bfc0-8b2019113bcd" xlink:href="ameh-20200930.xsd#ameh_CommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_CommercialMember_e19db2b7-4e83-496f-bfc0-8b2019113bcd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_4c950816-7f80-42b2-9f98-131f53974ed1" xlink:href="ameh-20200930.xsd#ameh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_MedicareMember_4c950816-7f80-42b2-9f98-131f53974ed1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_ec79c561-9d64-42a9-8029-2bf3f147f145" xlink:href="ameh-20200930.xsd#ameh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_MedicaidMember_ec79c561-9d64-42a9-8029-2bf3f147f145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_0413f544-956c-415b-acb0-59f6f012a833" xlink:href="ameh-20200930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_OtherThirdPartiesMember_0413f544-956c-415b-acb0-59f6f012a833" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended" id="id9c5edffebe34ddf9e6c0175dcf272c9_BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b9f9195d-0764-42cf-96d5-6f596f7e8bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b9f9195d-0764-42cf-96d5-6f596f7e8bae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f4985037-bfc6-4cad-888c-fce08e3172ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:to="loc_us-gaap_SalesRevenueNetMember_f4985037-bfc6-4cad-888c-fce08e3172ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3dab3f68-4d57-4039-a712-335a48d4c181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:to="loc_us-gaap_AccountsReceivableMember_3dab3f68-4d57-4039-a712-335a48d4c181" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:to="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a271f541-fc43-4c01-9b53-172f473ca883_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:to="loc_srt_NameOfMajorCustomerDomain_a271f541-fc43-4c01-9b53-172f473ca883_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:to="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_d19909a0-f4c0-4d7e-8c60-f9714621053a" xlink:href="ameh-20200930.xsd#ameh_PayorAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorAMember_d19909a0-f4c0-4d7e-8c60-f9714621053a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_fbce979d-0c2f-48de-9fb1-c85286f0c446" xlink:href="ameh-20200930.xsd#ameh_PayorBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorBMember_fbce979d-0c2f-48de-9fb1-c85286f0c446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_5879fb08-6368-46ed-a381-743e667a86c9" xlink:href="ameh-20200930.xsd#ameh_PayorCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorCMember_5879fb08-6368-46ed-a381-743e667a86c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_4052a8ab-83f6-4e09-98dd-55bab428fa5c" xlink:href="ameh-20200930.xsd#ameh_PayorDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorDMember_4052a8ab-83f6-4e09-98dd-55bab428fa5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_24109ad0-29e3-47b4-a2e4-f0e27dd7352e" xlink:href="ameh-20200930.xsd#ameh_PayorEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorEMember_24109ad0-29e3-47b4-a2e4-f0e27dd7352e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_31a8cad4-d58d-4bf2-aed9-b20442234791" xlink:href="ameh-20200930.xsd#ameh_PayorFMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorFMember_31a8cad4-d58d-4bf2-aed9-b20442234791" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_b188b291-8cb6-4472-985c-12603de829e3" xlink:href="ameh-20200930.xsd#ameh_PayorGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorGMember_b188b291-8cb6-4472-985c-12603de829e3" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended" id="i4425a48153da45039abd5e1744a65f55_BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a834a298-acea-41e3-9dc1-f985926886b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a834a298-acea-41e3-9dc1-f985926886b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26ab199f-ed2e-4970-a644-16a74fd060a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26ab199f-ed2e-4970-a644-16a74fd060a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4369d706-509a-4db9-a3fe-aa5bb7e32cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4369d706-509a-4db9-a3fe-aa5bb7e32cd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_750ff14b-e5c2-4f34-9309-cd8df5d54632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_750ff14b-e5c2-4f34-9309-cd8df5d54632" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8a1e6a9-6694-4e4a-a7c1-9ddae635fb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8a1e6a9-6694-4e4a-a7c1-9ddae635fb22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1d1bde67-3fb6-4591-b245-78000bab5719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1d1bde67-3fb6-4591-b245-78000bab5719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a377406-2631-4c5b-aec1-1d27d1bd4314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a377406-2631-4c5b-aec1-1d27d1bd4314" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwill"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended" id="i02ef2cc29b4c460dadc7b8c92e86f26b_BusinessCombinationsandGoodwill"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended" id="i8d4659340a314d349b872fc2b0bc874a_BusinessCombinationsandGoodwillTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended" id="i6673eb4b463e449c96c811e62e91e72d_BusinessCombinationsandGoodwillAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_23b0e861-8ecb-44eb-a289-70df451e9b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_23b0e861-8ecb-44eb-a289-70df451e9b58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_456fc3a5-5342-421a-9382-955767367c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_456fc3a5-5342-421a-9382-955767367c61" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2a98bc0b-0b93-4855-b579-292d3a4fa71a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_EscrowDeposit_2a98bc0b-0b93-4855-b579-292d3a4fa71a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_20e2d6e0-c667-4488-9467-c068f79ccc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_20e2d6e0-c667-4488-9467-c068f79ccc01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cba89d60-9dee-475b-86af-f602ab53d554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cba89d60-9dee-475b-86af-f602ab53d554" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_32d1906c-4b9e-462e-819c-6b67e7707786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_32d1906c-4b9e-462e-819c-6b67e7707786" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_10046413-9719-47c5-b850-a09b7dca037c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_10046413-9719-47c5-b850-a09b7dca037c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:to="loc_dei_EntityDomain_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:to="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_7833df22-3b5d-4541-8fce-54dab970fae4" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:to="loc_ameh_APCAndAPCLSMAMember_7833df22-3b5d-4541-8fce-54dab970fae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a6a1483-0e08-474e-a4f3-cfbc374052b9" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a6a1483-0e08-474e-a4f3-cfbc374052b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e27c4179-1398-438b-96ad-8cd8115d6c9a_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e27c4179-1398-438b-96ad-8cd8115d6c9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_96b07639-34f5-4043-9108-7928d65e933a" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_96b07639-34f5-4043-9108-7928d65e933a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_dce75567-a94f-4747-bf68-d6bf5bfdcd37" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AccountableHealthCareIPAMember_dce75567-a94f-4747-bf68-d6bf5bfdcd37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_55a7c346-ed05-4926-b30b-3750177bc183" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AmgIncMember_55a7c346-ed05-4926-b30b-3750177bc183" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e5bcc83-98db-4b60-a13d-2bbcc271b326_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e5bcc83-98db-4b60-a13d-2bbcc271b326_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_6366709d-e8ef-44a1-9d02-5dbd3894cc31" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:to="loc_ameh_Dr.JayMember_6366709d-e8ef-44a1-9d02-5dbd3894cc31" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended" id="if20ace23b06a48e283f30102df4e1ac9_BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b81a534c-95ae-473e-aba8-03a22314c59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b81a534c-95ae-473e-aba8-03a22314c59f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1630d0de-a5ae-4b1e-a782-4035798c6cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1630d0de-a5ae-4b1e-a782-4035798c6cdb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_900cf549-5761-42ab-b929-556844f825d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_900cf549-5761-42ab-b929-556844f825d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84413363-9da3-4d20-b7d9-c8a321eb709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84413363-9da3-4d20-b7d9-c8a321eb709e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f904b5ba-3431-4917-9690-96311640d0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_Goodwill_f904b5ba-3431-4917-9690-96311640d0e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9686a93a-3a34-4326-8b24-d0a11efd4a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9686a93a-3a34-4326-8b24-d0a11efd4a1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18b4ddbc-e285-417d-9d76-454cbccfd266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18b4ddbc-e285-417d-9d76-454cbccfd266" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_9d1673f4-dae7-44ae-ac74-027331bd0e32" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_9d1673f4-dae7-44ae-ac74-027331bd0e32" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_8b37c7ba-24bd-461e-9006-82d235620896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_8b37c7ba-24bd-461e-9006-82d235620896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_24d963a0-0c27-4458-9986-5e2a97bbeb81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_24d963a0-0c27-4458-9986-5e2a97bbeb81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_11489d2c-48f9-4850-981e-69d4ca8d944b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_11489d2c-48f9-4850-981e-69d4ca8d944b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_58abdc8a-8137-4b43-b412-21c5607c91d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_58abdc8a-8137-4b43-b412-21c5607c91d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_19667b90-f8cc-4b2d-a2c7-43d146998e7c_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:to="loc_dei_EntityDomain_19667b90-f8cc-4b2d-a2c7-43d146998e7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:to="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_bbacfb2a-e655-497b-a7c3-e5aa905c36df" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:to="loc_ameh_APCAndAPCLSMAMember_bbacfb2a-e655-497b-a7c3-e5aa905c36df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838dfaa5-c21a-4f7f-a19b-6d3603ebe295_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_838dfaa5-c21a-4f7f-a19b-6d3603ebe295_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_aaaa31b0-7408-4fdd-a991-e6da074137b1" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_aaaa31b0-7408-4fdd-a991-e6da074137b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_c3e69e4c-9a78-47e0-861d-ca6c9ad1d994" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:to="loc_ameh_AccountableHealthCareIPAMember_c3e69e4c-9a78-47e0-861d-ca6c9ad1d994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b726cc17-3d80-4c24-96af-e236ee602316_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b726cc17-3d80-4c24-96af-e236ee602316_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_f6238041-c91a-4eec-a6df-27fbc439f2ee" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:to="loc_ameh_Dr.JayMember_f6238041-c91a-4eec-a6df-27fbc439f2ee" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended" id="i057f6acb4a6f466db7f618f4249693ba_BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNet"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended" id="i065489dd33314e54a7dff2b2d0b79ced_IntangibleAssetsNet"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended" id="i07af0946854a45bea92f5f5fc1056829_IntangibleAssetsNetTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended" id="i75262e4161a04691b199bd3c3b3cce73_IntangibleAssetsNetScheduleofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb0612d6-10a0-4f55-a230-37c9f24c133f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb0612d6-10a0-4f55-a230-37c9f24c133f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a2dbb62-e0b9-41c7-beaa-3ecd78f8b6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a2dbb62-e0b9-41c7-beaa-3ecd78f8b6c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d618a4f-a4a6-4736-8a2c-493164c57ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d618a4f-a4a6-4736-8a2c-493164c57ec9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_710d6ff6-714a-4b41-abf9-8a39239ebb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_710d6ff6-714a-4b41-abf9-8a39239ebb17" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8f4e23b2-afc4-42e3-bf6b-ce5fc3aae358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8f4e23b2-afc4-42e3-bf6b-ce5fc3aae358" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c801fe4-c245-490f-9e92-01de7c782d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c801fe4-c245-490f-9e92-01de7c782d0e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_8c5c754b-0e4a-4301-86af-83e7f7faf710" xlink:href="ameh-20200930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_NetworkRelationshipsMember_8c5c754b-0e4a-4301-86af-83e7f7faf710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_338e177b-7564-4ab3-bef1-693b410a70ee" xlink:href="ameh-20200930.xsd#ameh_ManagementContractsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_ManagementContractsMember_338e177b-7564-4ab3-bef1-693b410a70ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_9e2c8126-4faf-4a89-a2b4-17b83e6fa65b" xlink:href="ameh-20200930.xsd#ameh_MemberRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_MemberRelationshipsMember_9e2c8126-4faf-4a89-a2b4-17b83e6fa65b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_35f7d61a-f85e-4595-8388-bccc5f726811" xlink:href="ameh-20200930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_PatientManagementPlatformMember_35f7d61a-f85e-4595-8388-bccc5f726811" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_51e85760-b3ea-459b-9103-48bb9dc175dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_51e85760-b3ea-459b-9103-48bb9dc175dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:to="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cdf456b2-3a91-473a-b5ae-6afce942de79_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:to="loc_srt_RangeMember_cdf456b2-3a91-473a-b5ae-6afce942de79_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:to="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e82172a-6790-4b2a-9f30-c7b74adb3f9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:to="loc_srt_MinimumMember_1e82172a-6790-4b2a-9f30-c7b74adb3f9f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1c83deb-5b60-4748-ae32-d498cd4ba9b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:to="loc_srt_MaximumMember_c1c83deb-5b60-4748-ae32-d498cd4ba9b9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended" id="i5ed71b810de54dc8b8172f3a3952c920_IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended" id="i11398869cf3541a89158c9abc9fe0529_IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended" id="if6070c9cae7946ef94cc7cc0fe30b931_InvestmentsinOtherEntitiesEquityMethod"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended" id="i973fbc040e9642ceb60390542629f0fc_InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended" id="iff640d6f3e6a4f12b1be164f8c07a64a_InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_26be5cf3-a49a-441d-bded-347cba02cf6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_EquityMethodInvestments_26be5cf3-a49a-441d-bded-347cba02cf6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2cb1e340-3a6e-4bee-a7af-cf4833a7008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2cb1e340-3a6e-4bee-a7af-cf4833a7008c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_f82ff64c-837c-433b-a295-c0d434a1c753" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_f82ff64c-837c-433b-a295-c0d434a1c753" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_f3589f3c-35dd-4cae-9ee8-47f525917c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_f3589f3c-35dd-4cae-9ee8-47f525917c6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35a067df-1b2a-4239-8361-be7bf4a487d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2255c4a7-5230-46d6-85ab-4ad526646219_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2255c4a7-5230-46d6-85ab-4ad526646219_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_33c9702d-6f01-4da4-b6b1-8fc6fd31043d" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_33c9702d-6f01-4da4-b6b1-8fc6fd31043d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_827b9ee4-1c41-47a7-8170-6699f5322d89" xlink:href="ameh-20200930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_827b9ee4-1c41-47a7-8170-6699f5322d89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_b42ac5e4-010d-4b86-8b5a-41a66d985e62" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_UniversalCareIncMember_b42ac5e4-010d-4b86-8b5a-41a66d985e62" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_be79b65d-076f-47d4-9504-4f82dc342a21" xlink:href="ameh-20200930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_be79b65d-076f-47d4-9504-4f82dc342a21" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_e81a149c-13b5-441e-b597-b9d2e3e79f73" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_e81a149c-13b5-441e-b597-b9d2e3e79f73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_39440b13-2447-458c-9faa-7231b1fbbeeb" xlink:href="ameh-20200930.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_39440b13-2447-458c-9faa-7231b1fbbeeb" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended" id="ieac437e9ee4349d9be7c4744d6f0e1d0_InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_8289840f-2399-49b6-9023-ebe77a7c4087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_NumberOfStores_8289840f-2399-49b6-9023-ebe77a7c4087" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_5a04b0f0-d991-4c8f-ace4-2ea132ec7101" xlink:href="ameh-20200930.xsd#ameh_NumberOfEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_NumberOfEmployees_5a04b0f0-d991-4c8f-ace4-2ea132ec7101" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients_57c305d6-db28-4249-9315-ebe0d887ed6a" xlink:href="ameh-20200930.xsd#ameh_NumberOfPatients"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_NumberOfPatients_57c305d6-db28-4249-9315-ebe0d887ed6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_385b54b2-674f-40be-8327-99aa86cfe13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_385b54b2-674f-40be-8327-99aa86cfe13f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fd979f6e-1248-45db-873a-8ee03f6b65f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fd979f6e-1248-45db-873a-8ee03f6b65f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61345407-0584-45c8-8a08-72e36c7d40f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61345407-0584-45c8-8a08-72e36c7d40f9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_53ba7302-b98e-44aa-bd24-d292220d2051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestments_53ba7302-b98e-44aa-bd24-d292220d2051" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_83dd9995-2545-4114-a1fb-cb19babd65af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsForFees_83dd9995-2545-4114-a1fb-cb19babd65af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4d1b7d95-5ef6-4828-bfec-8cb6b93b3dbc" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4d1b7d95-5ef6-4828-bfec-8cb6b93b3dbc" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_68df5efc-b32c-4a20-b521-77bce93d3c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_68df5efc-b32c-4a20-b521-77bce93d3c6c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_451c3511-32b7-4f87-be56-6c3e47b73b8c" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_451c3511-32b7-4f87-be56-6c3e47b73b8c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_26b1ec40-e7ae-49df-81aa-1583dc3b81c3" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_26b1ec40-e7ae-49df-81aa-1583dc3b81c3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_7407b18d-74e2-401a-9dcc-40dbb91f5847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_7407b18d-74e2-401a-9dcc-40dbb91f5847" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_6ed02213-1fbc-43c0-b3ee-43a74f30d843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_6ed02213-1fbc-43c0-b3ee-43a74f30d843" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_9b1a4704-4666-4577-a638-db7e888120f1" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_9b1a4704-4666-4577-a638-db7e888120f1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_24d88e12-b110-4be4-a9c0-5f2476705c3a" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_24d88e12-b110-4be4-a9c0-5f2476705c3a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_094ed274-041a-444c-af9a-ba5f5f979849" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_094ed274-041a-444c-af9a-ba5f5f979849" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2959db6c-a0c7-4886-9d84-db0c3da2721b" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2959db6c-a0c7-4886-9d84-db0c3da2721b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_32742590-823a-417a-b52f-11ddb3c703fd" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_32742590-823a-417a-b52f-11ddb3c703fd" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_e5c844b2-f5b1-496b-8f4f-aa369169fe85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_MembersCapital_e5c844b2-f5b1-496b-8f4f-aa369169fe85" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_ddf46da7-e6b6-44ff-a19d-51fbe25224d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_ddf46da7-e6b6-44ff-a19d-51fbe25224d2" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_203b196e-8e1a-4261-9ef0-ef1c011c3e9d" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_203b196e-8e1a-4261-9ef0-ef1c011c3e9d" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution_2bbfefe3-7f66-45fa-9189-b301df22c2aa" xlink:href="ameh-20200930.xsd#ameh_WorkingCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_WorkingCapitalContribution_2bbfefe3-7f66-45fa-9189-b301df22c2aa" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_f4c7c438-a15a-4bab-992c-e6b3af9e174e" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_f4c7c438-a15a-4bab-992c-e6b3af9e174e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_9052102a-a7a0-419b-9e8e-5ec6d0d14ff1" xlink:href="ameh-20200930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_9052102a-a7a0-419b-9e8e-5ec6d0d14ff1" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_536a875d-bddd-4f52-9ab5-f6def56db618" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_536a875d-bddd-4f52-9ab5-f6def56db618" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_ffe10911-35b6-4bf7-bff6-e959452c23fa" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_ffe10911-35b6-4bf7-bff6-e959452c23fa" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2adc5489-3ebb-4a67-8846-22b976f39b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2adc5489-3ebb-4a67-8846-22b976f39b36" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_faee3ffb-2310-4b45-81cf-dbe4810b0057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_faee3ffb-2310-4b45-81cf-dbe4810b0057" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_4037d1a4-314b-4508-9a03-391e2a7bc191" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_4037d1a4-314b-4508-9a03-391e2a7bc191" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fbbb86a5-bacb-4eea-a097-9daa6f36d518" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fbbb86a5-bacb-4eea-a097-9daa6f36d518" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b8a7c16b-39e0-45c9-b93e-6d4721172c18" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b8a7c16b-39e0-45c9-b93e-6d4721172c18" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_553ccd16-c1b7-4a88-ab04-06edb88f31f2" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_553ccd16-c1b7-4a88-ab04-06edb88f31f2" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_8ed8cc11-4150-4a53-95ca-43f7c384d5cb" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_8ed8cc11-4150-4a53-95ca-43f7c384d5cb" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_a03621da-348e-4865-a724-6ec3b6328db1" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_a03621da-348e-4865-a724-6ec3b6328db1" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_6080b51c-aff7-4cdb-993e-ea05e3050cec" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_6080b51c-aff7-4cdb-993e-ea05e3050cec" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f7d26044-827b-4efa-bfb9-d0caba7e3a4b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f7d26044-827b-4efa-bfb9-d0caba7e3a4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_2de0ec26-6ba2-4510-a7c4-3bfefcd324a7" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_2de0ec26-6ba2-4510-a7c4-3bfefcd324a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_7148c31b-bf04-4d70-a38a-015f38a34748" xlink:href="ameh-20200930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_7148c31b-bf04-4d70-a38a-015f38a34748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_8c0573c4-5727-4d68-bd89-9a8d95c88806" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_UniversalCareIncMember_8c0573c4-5727-4d68-bd89-9a8d95c88806" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_9717144b-b4eb-4fdc-8745-21ec65db62c6" xlink:href="ameh-20200930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_9717144b-b4eb-4fdc-8745-21ec65db62c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_76c23012-271a-44ec-990f-f9a2d5a69344" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_76c23012-271a-44ec-990f-f9a2d5a69344" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_167bff5a-7cb8-4a42-8597-a27b09499c9e" xlink:href="ameh-20200930.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_167bff5a-7cb8-4a42-8597-a27b09499c9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_22577549-4472-4e8b-82a7-0d815243f853_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:to="loc_dei_EntityDomain_22577549-4472-4e8b-82a7-0d815243f853_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:to="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_43363417-c1da-4bf1-8570-b084c54d5e03" xlink:href="ameh-20200930.xsd#ameh_ApcLsmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_ApcLsmaMember_43363417-c1da-4bf1-8570-b084c54d5e03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bc136ea1-c0f3-499f-a7f6-664698fef267" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bc136ea1-c0f3-499f-a7f6-664698fef267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_67743cc4-e7e4-4424-bb81-074151e145f6" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_67743cc4-e7e4-4424-bb81-074151e145f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_b32f6d07-9fe8-4b1a-9017-31a7c012b8c6" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_AccountableHealthCareIPAMember_b32f6d07-9fe8-4b1a-9017-31a7c012b8c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_a95fdb0e-6557-4adf-8489-ff3b7ae22564" xlink:href="ameh-20200930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_a95fdb0e-6557-4adf-8489-ff3b7ae22564" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_b4883ed9-072d-412d-8001-fa689f4e5343" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_b4883ed9-072d-412d-8001-fa689f4e5343" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_315a43e9-dfe6-415b-a305-3e6e341900ef" xlink:href="ameh-20200930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_Pacific6EnterprisesMember_315a43e9-dfe6-415b-a305-3e6e341900ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_7eefc249-5663-4973-8899-098322496d05" xlink:href="ameh-20200930.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_HealthSourceMSOInc.Member_7eefc249-5663-4973-8899-098322496d05" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:href="ameh-20200930.xsd#ameh_ContractTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_36e8062b-1f0e-471f-b1dd-72703f0b9ee8_default" xlink:href="ameh-20200930.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:to="loc_ameh_ContractTypeDomain_36e8062b-1f0e-471f-b1dd-72703f0b9ee8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:href="ameh-20200930.xsd#ameh_ContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:to="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_20c659be-82c5-4a23-aff7-df021f4682d5" xlink:href="ameh-20200930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:to="loc_ameh_AncillaryServiceContractMember_20c659be-82c5-4a23-aff7-df021f4682d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_546c865e-c472-459e-8acc-e7af6fc486c7_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:to="loc_us-gaap_ClassOfStockDomain_546c865e-c472-459e-8acc-e7af6fc486c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:to="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember_e4445e4a-20d7-4adc-b708-053169a0923e" xlink:href="ameh-20200930.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:to="loc_ameh_VotingCommonStockTwoMember_e4445e4a-20d7-4adc-b708-053169a0923e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4d1e2889-c12f-4a89-bd81-1a2d679e7164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:to="loc_us-gaap_PreferredStockMember_4d1e2889-c12f-4a89-bd81-1a2d679e7164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_113d8d7d-17e2-49a5-bf2d-40afafda33a2_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_113d8d7d-17e2-49a5-bf2d-40afafda33a2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_0fc9c8b3-8ae2-4af2-84b9-b38bc55208b2" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_0fc9c8b3-8ae2-4af2-84b9-b38bc55208b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_00dbeb08-fc54-48b0-a988-d83f8608dd91" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_00dbeb08-fc54-48b0-a988-d83f8608dd91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d099a8bf-fe73-4a9f-a1e3-eefb32141903_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:to="loc_srt_OwnershipDomain_d099a8bf-fe73-4a9f-a1e3-eefb32141903_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:to="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_24788df8-43bc-4052-8b96-8c4ca55dbc7c" xlink:href="ameh-20200930.xsd#ameh_MediPortalLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:to="loc_ameh_MediPortalLLCMember_24788df8-43bc-4052-8b96-8c4ca55dbc7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_4cdf0ac9-6c5c-4274-b8ff-84b9a4ab22f4" xlink:href="ameh-20200930.xsd#ameh_AchievaMedInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:to="loc_ameh_AchievaMedInc.Member_4cdf0ac9-6c5c-4274-b8ff-84b9a4ab22f4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended" id="iee71b56ce83c4c5d8b1b89361f2bb2a4_InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6359c9c7-849a-4d2d-ae60-692a4c030167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6359c9c7-849a-4d2d-ae60-692a4c030167" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4bf857f-8419-43a3-bf6e-4c3170476fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4bf857f-8419-43a3-bf6e-4c3170476fb3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f5a88c7f-ebf1-4a4c-9ca0-fadcb9ba9088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_OtherAssetsCurrent_f5a88c7f-ebf1-4a4c-9ca0-fadcb9ba9088" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d5d4ce83-e5ee-494c-ac8f-cd81669c9d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d5d4ce83-e5ee-494c-ac8f-cd81669c9d5e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_960a2d8d-014d-4abf-b1d8-982e741e8367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_RestrictedCashCurrent_960a2d8d-014d-4abf-b1d8-982e741e8367" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_4b8feffe-573c-4c99-8cfb-3029c95a5067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_OtherAssets_4b8feffe-573c-4c99-8cfb-3029c95a5067" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_34aad62b-8d6c-4836-b28e-6a7fccd2af6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_34aad62b-8d6c-4836-b28e-6a7fccd2af6b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_57e66af0-5fe8-4b50-b311-45a4f4ce6fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_Assets_57e66af0-5fe8-4b50-b311-45a4f4ce6fb1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_89a54806-1648-4e91-a2d6-d631d1db2957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_LiabilitiesCurrent_89a54806-1648-4e91-a2d6-d631d1db2957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_40c60220-2d5e-4f79-a2b2-152142b2a8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_OtherLiabilities_40c60220-2d5e-4f79-a2b2-152142b2a8dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16283623-5ed4-405f-9ede-d5ac56969430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16283623-5ed4-405f-9ede-d5ac56969430" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_afa58944-92ec-403f-8ffb-94103f215e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_afa58944-92ec-403f-8ffb-94103f215e17" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc4d17f-a104-4688-8ccc-069fdb6e69de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc4d17f-a104-4688-8ccc-069fdb6e69de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3cf84fea-631b-47f0-9034-d8856053873f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_CostsAndExpenses_3cf84fea-631b-47f0-9034-d8856053873f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c182f6c7-57ad-45b3-8073-f103328bd6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c182f6c7-57ad-45b3-8073-f103328bd6d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_346e6921-13a2-4ca9-840f-5cd0aa85a0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_346e6921-13a2-4ca9-840f-5cd0aa85a0cf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1a59eee4-58ec-4f4c-99f6-3b82d91854c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1a59eee4-58ec-4f4c-99f6-3b82d91854c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dbae429a-27ad-404a-acf4-dfc0096846ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dbae429a-27ad-404a-acf4-dfc0096846ad" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ff28bb2-89f6-41aa-b22c-56dec5211eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_ProfitLoss_1ff28bb2-89f6-41aa-b22c-56dec5211eb1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_5a691691-c9fa-4808-8d2e-bdd8daa6c0f0" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_5a691691-c9fa-4808-8d2e-bdd8daa6c0f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_843995fe-5ef1-49a6-8c80-c4238f960352" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_843995fe-5ef1-49a6-8c80-c4238f960352" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_7c8ee868-eb13-4d25-b59f-0ff40847b81f" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_UniversalCareIncMember_7c8ee868-eb13-4d25-b59f-0ff40847b81f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended" id="iffbd0093b0384f6c9e1e9d6721164429_InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a6008f27-74be-4179-8013-138478d36fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a6008f27-74be-4179-8013-138478d36fd6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_034ff79f-0f06-4b14-9e82-54ea1e7b6373" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_034ff79f-0f06-4b14-9e82-54ea1e7b6373" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_cd9efeec-7bfa-4e65-bca5-7933d29f0415" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_cd9efeec-7bfa-4e65-bca5-7933d29f0415" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1359b3ab-3d9b-4bb7-8138-32944f28f2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_EquityMethodInvestments_1359b3ab-3d9b-4bb7-8138-32944f28f2ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_72d66f4a-0f7a-49ee-a757-2c6c1c84e8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_72d66f4a-0f7a-49ee-a757-2c6c1c84e8a5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_7b33f84c-57c2-40ae-8726-cd90b978b16b_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_7b33f84c-57c2-40ae-8726-cd90b978b16b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_37d425fb-ce1e-4bbf-8e02-f79300cafc30" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:to="loc_ameh_UniversalCareIncMember_37d425fb-ce1e-4bbf-8e02-f79300cafc30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d702e3-a659-49d3-963a-0d87b7126e89_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32d702e3-a659-49d3-963a-0d87b7126e89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_391f7802-bb9a-4162-b3ba-1da8f19c0d33" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_391f7802-bb9a-4162-b3ba-1da8f19c0d33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5d08ea55-7743-465f-83df-ba15d1aaaafd_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:to="loc_us-gaap_ClassOfStockDomain_5d08ea55-7743-465f-83df-ba15d1aaaafd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:to="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bf43906c-3f17-44f0-b4e0-31143b5659e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:to="loc_us-gaap_PreferredStockMember_bf43906c-3f17-44f0-b4e0-31143b5659e5" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended" id="i0165a5fddfee4127a7203fca76f4a484_LoanReceivableandLoanReceivableRelatedParties"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended" id="i67778184fb5d447b96fd7f78ecc3720e_LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4573e895-d89a-458d-909a-cd3e15a995ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_NotesReceivableNet_4573e895-d89a-458d-909a-cd3e15a995ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5f35879-939e-4c67-af9f-dc978573e9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5f35879-939e-4c67-af9f-dc978573e9a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05f636ae-33a7-46ca-9bac-776cf0213be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05f636ae-33a7-46ca-9bac-776cf0213be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_8da777cd-899b-4f97-965f-fa85f0095717" xlink:href="ameh-20200930.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_8da777cd-899b-4f97-965f-fa85f0095717" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b739c953-3276-4b6b-9c3b-e8dbeb937e6d" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b739c953-3276-4b6b-9c3b-e8dbeb937e6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital_2cfa9dd2-34ee-4215-9911-83d12b51102c" xlink:href="ameh-20200930.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_AdvancedForWorkingCapital_2cfa9dd2-34ee-4215-9911-83d12b51102c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances_acdfa548-efc5-4998-b421-c527bec4f25e" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_LineOfCreditFacilityAdditionalAdvances_acdfa548-efc5-4998-b421-c527bec4f25e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_191a5347-d683-414e-9c51-1ac480842705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_191a5347-d683-414e-9c51-1ac480842705" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_9dafdcc9-066e-4819-ac6b-2e5763aa3072_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:to="loc_us-gaap_ReceivableTypeDomain_9dafdcc9-066e-4819-ac6b-2e5763aa3072_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:to="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_e39523c1-02c3-456b-8ce4-524c933a04fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:to="loc_us-gaap_NotesReceivableMember_e39523c1-02c3-456b-8ce4-524c933a04fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_6c1dc591-d02b-43ba-bcc2-85f6e185c32f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:to="loc_us-gaap_FinanceReceivablesMember_6c1dc591-d02b-43ba-bcc2-85f6e185c32f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_5c656407-9efd-4513-ba60-de006e47b533_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:to="loc_us-gaap_RelatedPartyDomain_5c656407-9efd-4513-ba60-de006e47b533_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:to="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_1b284b54-61c7-4060-b61e-921d09fc8f91" xlink:href="ameh-20200930.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:to="loc_ameh_Dr.ArteagaMember_1b284b54-61c7-4060-b61e-921d09fc8f91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember_200fb1a6-3689-4fe2-8aea-bef63838c80a" xlink:href="ameh-20200930.xsd#ameh_DrJayLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:to="loc_ameh_DrJayLoanMember_200fb1a6-3689-4fe2-8aea-bef63838c80a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c5a0347b-75fa-446f-a4e2-3abd46fd71e4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:to="loc_us-gaap_VariableRateDomain_c5a0347b-75fa-446f-a4e2-3abd46fd71e4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:to="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_4f0b25f5-a399-4e6f-a510-b4b42493b663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:to="loc_us-gaap_PrimeRateMember_4f0b25f5-a399-4e6f-a510-b4b42493b663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:to="loc_dei_EntityDomain_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:to="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ce1ea7bb-e676-4124-a896-4c054c3b8aeb" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ce1ea7bb-e676-4124-a896-4c054c3b8aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_af768592-3c43-45db-974c-59e2d9e6b33d" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_APCAndAPCLSMAMember_af768592-3c43-45db-974c-59e2d9e6b33d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_5acff047-2aeb-4947-b44e-f75afd6f9ade" xlink:href="ameh-20200930.xsd#ameh_Dr.ArteagaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_Dr.ArteagaMember_5acff047-2aeb-4947-b44e-f75afd6f9ade" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_0d039f19-3105-405d-a591-d7106109217f" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_0d039f19-3105-405d-a591-d7106109217f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faa687c6-f273-493b-b7ad-9a203692a8e6_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_faa687c6-f273-493b-b7ad-9a203692a8e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6eaf28c3-4e98-47c3-a50c-318a620a9505" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6eaf28c3-4e98-47c3-a50c-318a620a9505" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_5a009668-8f15-45da-b3ea-2603c6cf9d3c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_5a009668-8f15-45da-b3ea-2603c6cf9d3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_48087b98-829b-4943-b032-7dc49dfa5b47" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:to="loc_ameh_LmaMember_48087b98-829b-4943-b032-7dc49dfa5b47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_1fd283ca-2a78-48ac-acc4-5b93eb7a7776" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:to="loc_ameh_UniversalCareIncMember_1fd283ca-2a78-48ac-acc4-5b93eb7a7776" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpenses"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended" id="iee407c4bff014896a1afaff53019a094_AccountsPayableandAccruedExpenses"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended" id="i6ada43c1fdc54e50861b2eca95884a85_AccountsPayableandAccruedExpensesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended" id="id4c0cd1158454213bdd46518e4f69d9b_AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilities"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended" id="i917d7d4159524ff58f63e1af82c3ca19_MedicalLiabilities"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended" id="i168a89a4eba5493898fb11f5b0109731_MedicalLiabilitiesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended" id="ica2aa6ecdee54d4f8725e378f283ad28_MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended" id="i458e21759f8541caa20ff9941d464d44_CreditFacilityBankLoanandLinesofCredit"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended" id="ie830fa9adf484bbb98c71a8f4c6e8c31_CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended" id="ic022bf4e3e1a4f488ddd5b06f3cd7623_CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_635f13b3-cc37-4d13-a17a-cacb3c0a291e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LineOfCredit_635f13b3-cc37-4d13-a17a-cacb3c0a291e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_9b9e4a61-352e-4064-8902-49d5284152ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LinesOfCreditCurrent_9b9e4a61-352e-4064-8902-49d5284152ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_693f8497-fe53-4171-b939-72bdf264e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_693f8497-fe53-4171-b939-72bdf264e165" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b29591a2-2107-4b2b-8f23-12db3119b60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LongTermDebt_b29591a2-2107-4b2b-8f23-12db3119b60c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:to="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5e10cd40-a264-4e0a-b7b4-1460102d5ad4_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:to="loc_us-gaap_CreditFacilityDomain_5e10cd40-a264-4e0a-b7b4-1460102d5ad4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:to="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_1d1c1a18-5429-4d13-97ef-a42f261f4977" xlink:href="ameh-20200930.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:to="loc_ameh_TermLoanAMember_1d1c1a18-5429-4d13-97ef-a42f261f4977" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fbb16e65-67f6-487d-b1fb-fb85874d96ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fbb16e65-67f6-487d-b1fb-fb85874d96ed" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended" id="i2da97a5df5944d30a5bea514c6943ec9_CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended" id="i46a420eedbcb44c18e6034589a82da5a_CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3542ca19-3e0b-4229-b1d2-f5b48a665159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentTerm_3542ca19-3e0b-4229-b1d2-f5b48a665159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_95c6180e-8979-4510-a23a-3b13133a72b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_95c6180e-8979-4510-a23a-3b13133a72b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_80e0f608-c8fa-4920-8cee-3848fb05b979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_80e0f608-c8fa-4920-8cee-3848fb05b979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_83eabb7c-8571-463f-9503-f9c33a365c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCredit_83eabb7c-8571-463f-9503-f9c33a365c47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ebc96e5d-4ea3-4e8e-a0b3-1a4f614c32f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ebc96e5d-4ea3-4e8e-a0b3-1a4f614c32f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d53f2751-b7fc-4660-a1e0-2460525d7020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d53f2751-b7fc-4660-a1e0-2460525d7020" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_4f1ff1b3-f982-4e03-b209-7455bb686398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_4f1ff1b3-f982-4e03-b209-7455bb686398" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_595a1666-8ef8-40a9-9ecf-62a6656e4a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_595a1666-8ef8-40a9-9ecf-62a6656e4a50" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_82169f87-ba8e-49c1-9032-140415f3affb" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_82169f87-ba8e-49c1-9032-140415f3affb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_536f5f03-5fe6-4f3b-add8-d92f2dd3be4e" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_536f5f03-5fe6-4f3b-add8-d92f2dd3be4e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_4aa388e7-67ef-41de-b9ce-ce43b83ae512" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_4aa388e7-67ef-41de-b9ce-ce43b83ae512" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_756b65f0-8ba0-4c96-9711-c8f31fef328d" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_756b65f0-8ba0-4c96-9711-c8f31fef328d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_ba823c8f-d421-44ac-87b6-02611b07cc6f" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_ba823c8f-d421-44ac-87b6-02611b07cc6f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_67a76fce-4515-47fd-9182-594447108aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_67a76fce-4515-47fd-9182-594447108aea" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_835eea80-a2fd-463a-8997-634ab3462190" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_835eea80-a2fd-463a-8997-634ab3462190" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_3e5d4e5d-789c-44af-9fe9-7d0ba2a14894" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_3e5d4e5d-789c-44af-9fe9-7d0ba2a14894" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_28cc5b7e-85d0-4c45-9e30-6e0891cfca82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_28cc5b7e-85d0-4c45-9e30-6e0891cfca82" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_83da103c-b183-4190-afd1-0eefd0af97a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_83da103c-b183-4190-afd1-0eefd0af97a1" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9ce6f6de-ebc2-4ee4-828d-7764ed42ae72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_InterestExpense_9ce6f6de-ebc2-4ee4-828d-7764ed42ae72" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_986a4ca4-bad5-4beb-999f-14725ed716d3" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_986a4ca4-bad5-4beb-999f-14725ed716d3" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_38e87de0-f663-404c-a120-84dc9152ad2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_38e87de0-f663-404c-a120-84dc9152ad2b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_43c4491c-9f65-4692-977d-9343130098b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_43c4491c-9f65-4692-977d-9343130098b9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_36647a84-96cb-402a-9c10-d58b8d542ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_36647a84-96cb-402a-9c10-d58b8d542ed5" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_3c4d08b4-e024-493a-8116-43c4ca343a2f" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_3c4d08b4-e024-493a-8116-43c4ca343a2f" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityTerminatedAmount_8a7f1c86-582d-4c06-ab7d-849892972414" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityTerminatedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityTerminatedAmount_8a7f1c86-582d-4c06-ab7d-849892972414" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_efddabd5-6234-4349-bfed-3e5f8e61ef80_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:to="loc_us-gaap_CreditFacilityDomain_efddabd5-6234-4349-bfed-3e5f8e61ef80_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:to="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_34531e4c-1b09-440b-8ce0-77ae18635212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_34531e4c-1b09-440b-8ce0-77ae18635212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_79d582d8-d4fe-4a19-ba5f-bf9c56c68821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_LetterOfCreditMember_79d582d8-d4fe-4a19-ba5f-bf9c56c68821" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_3f88381b-ced0-4eb9-bdcc-022fd4080000" xlink:href="ameh-20200930.xsd#ameh_TermLoanAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_ameh_TermLoanAMember_3f88381b-ced0-4eb9-bdcc-022fd4080000" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e5de7002-88a6-432b-bc96-79bb135e7d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e5de7002-88a6-432b-bc96-79bb135e7d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3a9c88d4-a27d-44ee-b36b-6c2b66422661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_LineOfCreditMember_3a9c88d4-a27d-44ee-b36b-6c2b66422661" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4b02ef6-b61e-4857-b33b-3f64df37c59e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4b02ef6-b61e-4857-b33b-3f64df37c59e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_91a73a71-83f7-4519-a240-b0dff0a6f5eb" xlink:href="ameh-20200930.xsd#ameh_CreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_CreditAgreementMember_91a73a71-83f7-4519-a240-b0dff0a6f5eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember_96d1741f-0ac9-4eba-87da-2b6ee6ec3655" xlink:href="ameh-20200930.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_NMMLineOfCreditAgreementMember_96d1741f-0ac9-4eba-87da-2b6ee6ec3655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_aa123368-1525-43b7-8a02-f7c16775633b" xlink:href="ameh-20200930.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_aa123368-1525-43b7-8a02-f7c16775633b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_9e454917-1158-4774-b96c-2092ea09bd56" xlink:href="ameh-20200930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_9e454917-1158-4774-b96c-2092ea09bd56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5ef55c1a-beee-45d2-91b6-2cc773d86104_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5ef55c1a-beee-45d2-91b6-2cc773d86104_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_01a018e2-9720-4311-8f20-b75745d89b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:to="loc_us-gaap_LineOfCreditMember_01a018e2-9720-4311-8f20-b75745d89b48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember_8e0a8ab8-f895-4c8b-a11d-b1c409b59a5f" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodOneMember_8e0a8ab8-f895-4c8b-a11d-b1c409b59a5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember_7894dfd4-761a-4e19-a18b-95fc951c084f" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodTwoMember_7894dfd4-761a-4e19-a18b-95fc951c084f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember_4cbbe3f8-688f-45f3-a303-a905e86af1ea" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodThreeMember_4cbbe3f8-688f-45f3-a303-a905e86af1ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:to="loc_srt_RangeMember_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:to="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_092913ea-c80d-4f82-b751-6d2218a55810" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:to="loc_srt_MinimumMember_092913ea-c80d-4f82-b751-6d2218a55810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d414d463-a8ed-464e-a737-5f3dc8415bbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:to="loc_srt_MaximumMember_d414d463-a8ed-464e-a737-5f3dc8415bbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_2fe134e3-1ddd-4273-92a0-edfa464ade7a_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:to="loc_dei_EntityDomain_2fe134e3-1ddd-4273-92a0-edfa464ade7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:to="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_060aa1c9-0933-45d4-877b-725d89876f3f" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_NetworkMedicalManagementMember_060aa1c9-0933-45d4-877b-725d89876f3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_809044a3-77bf-4842-85d2-9ceecf3b9bb6" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_809044a3-77bf-4842-85d2-9ceecf3b9bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_c9d03fa5-cd65-4188-b548-d73f150173c8" xlink:href="ameh-20200930.xsd#ameh_ApaacoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_ApaacoMember_c9d03fa5-cd65-4188-b548-d73f150173c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_d11a963b-1761-468b-b968-3d3608cee0c5" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_d11a963b-1761-468b-b968-3d3608cee0c5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_7d2cadc3-1c09-478d-8269-4bfa4eade49d" xlink:href="ameh-20200930.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_CDSCMember_7d2cadc3-1c09-478d-8269-4bfa4eade49d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_8945af0d-e9f8-4cd9-b211-ef00ced97f10" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AmgIncMember_8945af0d-e9f8-4cd9-b211-ef00ced97f10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_2a41c1b0-a210-433a-aa9c-1406f35ee670_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:to="loc_us-gaap_VariableRateDomain_2a41c1b0-a210-433a-aa9c-1406f35ee670_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:to="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ba4f93b6-45ca-4758-b780-05591ad12d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ba4f93b6-45ca-4758-b780-05591ad12d64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_168dfa5b-715e-4432-8aee-37c539330ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:to="loc_us-gaap_PrimeRateMember_168dfa5b-715e-4432-8aee-37c539330ea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_53512345-7af7-44f1-96b9-96ac0112dbf1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_53512345-7af7-44f1-96b9-96ac0112dbf1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_975fad69-24fb-4a93-974b-3bf11b6129ac" xlink:href="ameh-20200930.xsd#ameh_PreferredBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:to="loc_ameh_PreferredBankMember_975fad69-24fb-4a93-974b-3bf11b6129ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended" id="i1465e5b64bfa4413894dbd471ee49a2e_MezzanineandStockholdersEquity"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended" id="i1da8035e1a2a48f9b37683cd92b6f527_MezzanineandStockholdersEquityTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i16c1a12cd2484de7b35126633f3894af_MezzanineandStockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_f040a259-deb5-46e6-a40b-898b8122b394" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_f040a259-deb5-46e6-a40b-898b8122b394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1e059991-21a5-4e81-a148-76fb7539ed38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1e059991-21a5-4e81-a148-76fb7539ed38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b631113-3096-4d88-a1c4-bcd4096b3678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b631113-3096-4d88-a1c4-bcd4096b3678" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e6075d-f0ad-408b-83ff-5ff8afc8087b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e6075d-f0ad-408b-83ff-5ff8afc8087b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_3fed70c9-2575-4922-867a-7a6e09ae143e" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_3fed70c9-2575-4922-867a-7a6e09ae143e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eada163e-f16e-4288-8b25-a242a3a61397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eada163e-f16e-4288-8b25-a242a3a61397" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_edecc280-6993-4fc0-b28d-8b470f32cde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_edecc280-6993-4fc0-b28d-8b470f32cde6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30c5a0ac-26ed-4ac7-8b68-e98acfb20865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30c5a0ac-26ed-4ac7-8b68-e98acfb20865" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9b35ed77-e0dd-4137-abdb-360c799aea8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9b35ed77-e0dd-4137-abdb-360c799aea8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2021cc7c-070a-4318-bb07-312570ec9e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2021cc7c-070a-4318-bb07-312570ec9e21" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_89c3e863-6eaf-4f39-8468-781a308dfc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_89c3e863-6eaf-4f39-8468-781a308dfc1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_63f0392b-236c-466d-88f9-2c5e5dc20b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensation_63f0392b-236c-466d-88f9-2c5e5dc20b30" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a4a10cdc-1521-45f0-bbc6-2bf58a844d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a4a10cdc-1521-45f0-bbc6-2bf58a844d05" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_7705689f-5a46-4c9f-a4a2-1547ad90e36b" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_7705689f-5a46-4c9f-a4a2-1547ad90e36b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_86bb04a5-860b-4132-a0d4-e4c647589e4d" xlink:href="ameh-20200930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_86bb04a5-860b-4132-a0d4-e4c647589e4d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_8a0a20b8-0232-4a68-9e2c-79fa54c79b78" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_8a0a20b8-0232-4a68-9e2c-79fa54c79b78" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_8c7f436e-2136-43fe-a7fb-067c8fea1eb3" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_8c7f436e-2136-43fe-a7fb-067c8fea1eb3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_49893e52-f6f3-4a26-80d9-6ff9c35d6508" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_49893e52-f6f3-4a26-80d9-6ff9c35d6508" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a7da31e2-a109-4c1f-9a04-aa3fd9600fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a7da31e2-a109-4c1f-9a04-aa3fd9600fa5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_36798a45-1e71-487b-9dd6-dd24fba77a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_TreasuryStockValue_36798a45-1e71-487b-9dd6-dd24fba77a0b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_661a997b-a74b-4f60-8906-ded31385c7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_Dividends_661a997b-a74b-4f60-8906-ded31385c7b9" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_82063c57-bf3c-46e5-8255-74aab0fcf280_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_82063c57-bf3c-46e5-8255-74aab0fcf280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_edda9638-6df3-4705-a274-c778d412a299" xlink:href="ameh-20200930.xsd#ameh_ApcStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:to="loc_ameh_ApcStockOptionMember_edda9638-6df3-4705-a274-c778d412a299" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_46a91a6d-5774-4c7b-832c-b6897b5f147b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:to="loc_srt_DirectorMember_46a91a6d-5774-4c7b-832c-b6897b5f147b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d21d134-b932-40f8-861f-5e33225d699d_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:to="loc_srt_RangeMember_7d21d134-b932-40f8-861f-5e33225d699d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:to="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68bcc73c-07fb-4ae6-b4c1-cfdf1f7b198b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:to="loc_srt_MinimumMember_68bcc73c-07fb-4ae6-b4c1-cfdf1f7b198b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd2f5b17-ae5d-4325-bcf2-7fd1d4bc7ebc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:to="loc_srt_MaximumMember_bd2f5b17-ae5d-4325-bcf2-7fd1d4bc7ebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4712a2c-2051-443e-979d-ac9e816cde65_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f4712a2c-2051-443e-979d-ac9e816cde65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7be922ce-2787-449c-85d2-7669eb9bdb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7be922ce-2787-449c-85d2-7669eb9bdb7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0cc59fc3-b4d2-42a5-9e84-dc0f2a7a00e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:to="loc_us-gaap_RestrictedStockMember_0cc59fc3-b4d2-42a5-9e84-dc0f2a7a00e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a4c01429-8b65-4820-a744-8a0c5bd1d561_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:to="loc_dei_EntityDomain_a4c01429-8b65-4820-a744-8a0c5bd1d561_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:to="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_75c6d1ba-ef33-4857-a84e-df288aacc239" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_75c6d1ba-ef33-4857-a84e-df288aacc239" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_309cda97-9352-4020-9e47-5506ec953cb5" xlink:href="ameh-20200930.xsd#ameh_CDSCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:to="loc_ameh_CDSCMember_309cda97-9352-4020-9e47-5506ec953cb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fadf9fe-58b4-4057-9f52-fc6f711c08c9_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_8fadf9fe-58b4-4057-9f52-fc6f711c08c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_0184fea4-0885-499c-977f-c3b2b23170d3" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_0184fea4-0885-499c-977f-c3b2b23170d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended" id="id7c1bfd1be7c4c9c82102867f3d7b04e_MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended" id="i5b831dbb80504519872e3136addd30f0_MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2adf38f8-1b24-4731-91b9-4bbafaab0279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2adf38f8-1b24-4731-91b9-4bbafaab0279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81e14302-003e-4186-a7ff-731e906e2514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81e14302-003e-4186-a7ff-731e906e2514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_613c1e61-69c6-4a40-8f12-96498f27fc86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_613c1e61-69c6-4a40-8f12-96498f27fc86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_15d0b6ee-f3a9-4d10-8a86-588c515a696e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_SharePrice_15d0b6ee-f3a9-4d10-8a86-588c515a696e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04e06683-b66e-461d-8e13-e774d506e707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04e06683-b66e-461d-8e13-e774d506e707" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_d01298b5-7fc2-4fbb-a60e-11d13b7b2f3a" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_d01298b5-7fc2-4fbb-a60e-11d13b7b2f3a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:to="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0f949897-64f5-4041-ad7b-f0a55ff1ef4f_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_0f949897-64f5-4041-ad7b-f0a55ff1ef4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d863a311-0bd0-46bd-b9f7-d0f646b921c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:to="loc_srt_DirectorMember_d863a311-0bd0-46bd-b9f7-d0f646b921c1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended" id="iccfac4ec26e94b1d8c550b9e17bf65bb_MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended" id="i9618038bbb3d47cfbadf0ada340d5e46_MezzanineandStockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76757110-5cf9-40a9-a48c-c7bf3995a4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76757110-5cf9-40a9-a48c-c7bf3995a4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_683ec559-29f4-478c-8f38-6574209b5dc6" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_683ec559-29f4-478c-8f38-6574209b5dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_ee945668-6085-4ad8-8523-aae78c910f52" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_ee945668-6085-4ad8-8523-aae78c910f52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_82cc9aa5-bc0d-414c-9637-f247d53527c2" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_82cc9aa5-bc0d-414c-9637-f247d53527c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3115343f-a765-404c-9b13-ef8703947772" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3115343f-a765-404c-9b13-ef8703947772" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634b45b3-c643-478d-885d-abb9ca6d7755_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_634b45b3-c643-478d-885d-abb9ca6d7755_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_dc355ce7-175c-4146-911f-578cb6bfdc11" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_dc355ce7-175c-4146-911f-578cb6bfdc11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_4d874b7c-acbf-41c0-bd38-66ef808307ca" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_4d874b7c-acbf-41c0-bd38-66ef808307ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_c2f2adc3-a1f0-45b9-8d4b-78892a431427" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_c2f2adc3-a1f0-45b9-8d4b-78892a431427" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_c06845af-177b-4ea3-9456-87862515f4ac" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_c06845af-177b-4ea3-9456-87862515f4ac" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:to="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:to="loc_srt_RangeMember_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:to="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8180ae42-fa39-4f17-8ac4-b1310cc102da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:to="loc_srt_MinimumMember_8180ae42-fa39-4f17-8ac4-b1310cc102da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a9f2695-2584-4a10-8de4-02c186a64772" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:to="loc_srt_MaximumMember_1a9f2695-2584-4a10-8de4-02c186a64772" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingencies"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended" id="idf4de178286c40b6b357177711ba823e_CommitmentsandContingencies"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended" id="ia8e04ffeeff94571af903861fa6bc863_CommitmentsandContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_706c5bfc-7960-44d9-8ff3-ec38e3f5d4db" xlink:href="ameh-20200930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_706c5bfc-7960-44d9-8ff3-ec38e3f5d4db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c92f1ed1-4b01-4566-a482-d76824aa8031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LineOfCredit_c92f1ed1-4b01-4566-a482-d76824aa8031" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_7b12f877-2745-4ed8-96af-efd81d865420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_7b12f877-2745-4ed8-96af-efd81d865420" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_a979db53-e324-4ead-9d27-f641e526a7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_a979db53-e324-4ead-9d27-f641e526a7b2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_9c88446e-242d-4d30-9552-ba9586f2a076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_9c88446e-242d-4d30-9552-ba9586f2a076" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_319e049f-9254-4c48-a95c-61324c73921e_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:to="loc_us-gaap_CreditFacilityDomain_319e049f-9254-4c48-a95c-61324c73921e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:to="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c752dab6-7506-4f75-8871-86a1ee7eade2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c752dab6-7506-4f75-8871-86a1ee7eade2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_f682b3f0-7eac-47d4-be3b-535ca347297e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_f682b3f0-7eac-47d4-be3b-535ca347297e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f1d01fbe-bb43-419b-ab08-d492089744ae_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:to="loc_dei_EntityDomain_f1d01fbe-bb43-419b-ab08-d492089744ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:to="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ecb95c59-556d-4421-8815-3be2428b8b3c" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ecb95c59-556d-4421-8815-3be2428b8b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_cec347b1-29b0-46a5-8943-cbf71d2d2898" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_cec347b1-29b0-46a5-8943-cbf71d2d2898" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactions"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended" id="idc92d741607143ddbd86c3bf2bba6129_RelatedPartyTransactions"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended" id="i5472f78f23b04814b4f56e9fdc894d20_RelatedPartyTransactionsTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended" id="i71f5d8240b304f6289a4e5dcc497087f_RelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ffa8a220-a167-4858-b36d-c37857a743b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ffa8a220-a167-4858-b36d-c37857a743b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_29d17f9e-b7e6-4a59-95eb-d278580355dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_29d17f9e-b7e6-4a59-95eb-d278580355dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_4dba4baf-316c-442b-8fe2-60147b24d917" xlink:href="ameh-20200930.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_4dba4baf-316c-442b-8fe2-60147b24d917" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_9612cb12-3335-4a45-a650-5fdfb41618a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_RevenueFromRelatedParties_9612cb12-3335-4a45-a650-5fdfb41618a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_9eff6ee3-caaa-4fb0-a50a-bfdf20526b4c" xlink:href="ameh-20200930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_PaymentMadeToRelatedParty_9eff6ee3-caaa-4fb0-a50a-bfdf20526b4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_955c539d-2bdb-4443-aad9-47a574c537f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_955c539d-2bdb-4443-aad9-47a574c537f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0adf4635-faf3-4b0c-8f86-188bd714a826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_OperatingLeaseLiability_0adf4635-faf3-4b0c-8f86-188bd714a826" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_230399bf-0a68-4074-a720-80eedd5878be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_230399bf-0a68-4074-a720-80eedd5878be" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_fa201a98-1c24-4313-92a3-7b9488f24fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_fa201a98-1c24-4313-92a3-7b9488f24fb1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_1d1c655e-0031-4b5b-b59a-2c4124d1ff0e" xlink:href="ameh-20200930.xsd#ameh_PaymentConsultingFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_PaymentConsultingFees_1d1c655e-0031-4b5b-b59a-2c4124d1ff0e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_96094ce5-e006-4d91-95e6-f55bd01a66bb" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_UniversalCareIncMember_96094ce5-e006-4d91-95e6-f55bd01a66bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_63370514-769d-4d6d-bdf8-92592f042e4e" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_LmaMember_63370514-769d-4d6d-bdf8-92592f042e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_3032102e-d325-4c99-ac18-3aacc9a0b6c6" xlink:href="ameh-20200930.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_PmiocMember_3032102e-d325-4c99-ac18-3aacc9a0b6c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_a56ae8ba-8c7a-45f0-b980-f8e72b66154c" xlink:href="ameh-20200930.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_DmgMember_a56ae8ba-8c7a-45f0-b980-f8e72b66154c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_73579be6-f8ac-4487-9e8c-818890dca9e7" xlink:href="ameh-20200930.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_OneMSOInc.Member_73579be6-f8ac-4487-9e8c-818890dca9e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9bb43-6cac-4d22-8206-1d5184a78c59_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4aa9bb43-6cac-4d22-8206-1d5184a78c59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a5f8593a-cb85-44c7-8d22-46a8862c1854" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a5f8593a-cb85-44c7-8d22-46a8862c1854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_376d4f73-87e3-4e33-ab0c-de95e0437aa1_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:to="loc_us-gaap_RelatedPartyDomain_376d4f73-87e3-4e33-ab0c-de95e0437aa1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:to="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_03f1307c-4fdf-42db-97a7-f2ab8f2ede30" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_UniversalCareIncMember_03f1307c-4fdf-42db-97a7-f2ab8f2ede30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_a2318363-6a16-4573-a954-801afdb94875" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_a2318363-6a16-4573-a954-801afdb94875" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_09ad9585-527e-4c1e-a2af-aee1fae06089" xlink:href="ameh-20200930.xsd#ameh_ApcShareholdersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_ApcShareholdersMember_09ad9585-527e-4c1e-a2af-aee1fae06089" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0638d85d-0547-4302-bc38-fc92aa736a27" xlink:href="ameh-20200930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0638d85d-0547-4302-bc38-fc92aa736a27" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_5989c504-e051-479d-954e-ff91fd7eea8f" xlink:href="ameh-20200930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_ShareholdersAndOfficersMember_5989c504-e051-479d-954e-ff91fd7eea8f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember_23cf9819-b7d4-447c-830c-c6c6e1066c43" xlink:href="ameh-20200930.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_MedicalPropertyPartnersMember_23cf9819-b7d4-447c-830c-c6c6e1066c43" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_f40d8bd2-8c1e-4a40-ba10-4e9eddf83174" xlink:href="ameh-20200930.xsd#ameh_OneMSOInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_OneMSOInc.Member_f40d8bd2-8c1e-4a40-ba10-4e9eddf83174" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_98fd60cb-39e6-4ff1-b598-471b0736563b" xlink:href="ameh-20200930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_98fd60cb-39e6-4ff1-b598-471b0736563b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_7f329f07-5f0d-4cbb-894e-3c8d9ae41497" xlink:href="ameh-20200930.xsd#ameh_NumenLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_NumenLLCMember_7f329f07-5f0d-4cbb-894e-3c8d9ae41497" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_8d18051b-5459-46fe-8ba8-c6b51d5a8141" xlink:href="ameh-20200930.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_AHMCMember_8d18051b-5459-46fe-8ba8-c6b51d5a8141" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_331936b6-3088-4cd6-b7ed-8ed65df37a38_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:to="loc_dei_EntityDomain_331936b6-3088-4cd6-b7ed-8ed65df37a38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:to="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_ea216b40-4566-4190-84d2-d63d835bd8fc" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_NetworkMedicalManagementMember_ea216b40-4566-4190-84d2-d63d835bd8fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_57454224-5e91-4e70-bc6e-21bbea126253" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_57454224-5e91-4e70-bc6e-21bbea126253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_d3226427-de2c-4eb9-b0ca-3e7f6f242ec8" xlink:href="ameh-20200930.xsd#ameh_SCHCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_SCHCMember_d3226427-de2c-4eb9-b0ca-3e7f6f242ec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2a9b8cbf-4176-4870-84ad-7ba72221eeaf" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2a9b8cbf-4176-4870-84ad-7ba72221eeaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember_090dff16-4b3a-4a46-ae8e-22fa22eb8185" xlink:href="ameh-20200930.xsd#ameh_DrSimAndDrLamMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_DrSimAndDrLamMember_090dff16-4b3a-4a46-ae8e-22fa22eb8185" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7aac78b3-703c-4385-b889-2baa1cbdf9a4_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7aac78b3-703c-4385-b889-2baa1cbdf9a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_502e001d-5cf2-4c8b-8894-42a07ac1b721" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_LmaMember_502e001d-5cf2-4c8b-8894-42a07ac1b721" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_a247f1bc-d41b-44f0-918a-f5759b3a2815" xlink:href="ameh-20200930.xsd#ameh_PmiocMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_PmiocMember_a247f1bc-d41b-44f0-918a-f5759b3a2815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c0c50839-7c57-4061-95ab-94d82b5c157b" xlink:href="ameh-20200930.xsd#ameh_DmgMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_DmgMember_c0c50839-7c57-4061-95ab-94d82b5c157b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_a652d5ab-c427-4adc-9801-2398cea1eef0_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_a652d5ab-c427-4adc-9801-2398cea1eef0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ffeb7d4f-9f08-496b-b86b-166be7b838c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:to="loc_us-gaap_ServiceMember_ffeb7d4f-9f08-496b-b86b-166be7b838c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_0e921e1e-9ec9-4238-9396-334309739282" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:to="loc_srt_DirectorMember_0e921e1e-9ec9-4238-9396-334309739282" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended" id="i976818fdd9db497e86d1838424d989f3_RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dad94c72-0436-4758-8978-62f65059618a" xlink:href="ameh-20200930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dad94c72-0436-4758-8978-62f65059618a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_874ca86f-089e-4c0f-afe2-8ae130b88688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_us-gaap_ManagementFeeExpense_874ca86f-089e-4c0f-afe2-8ae130b88688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a97f13aa-dd14-4b54-9e5c-dfcebd791a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a97f13aa-dd14-4b54-9e5c-dfcebd791a71" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9ad552e8-e8eb-407e-80f7-b5235f9b2594_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:to="loc_us-gaap_RelatedPartyDomain_9ad552e8-e8eb-407e-80f7-b5235f9b2594_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:to="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_aa06a133-5b62-41ed-a12b-d230ce99718f" xlink:href="ameh-20200930.xsd#ameh_AHMCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_AHMCMember_aa06a133-5b62-41ed-a12b-d230ce99718f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_9284ac54-58d8-469c-a48a-19edcad577b6" xlink:href="ameh-20200930.xsd#ameh_HSMSOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_HSMSOMember_9284ac54-58d8-469c-a48a-19edcad577b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_24753cca-cad8-488b-8dc1-ade633caa292" xlink:href="ameh-20200930.xsd#ameh_AurionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_AurionMember_24753cca-cad8-488b-8dc1-ade633caa292" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxes"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended" id="ibfddda3da23240039fc208a1a1ab3d8d_IncomeTaxes"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="ic4ec61cb386244ddab728bc21de02f1a_IncomeTaxesAdditionalInformationDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShare"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended" id="i4f6736d2bc1242038367591393dd56be_EarningsPerShare"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended" id="i6898c4a57b3e4de398f954ff5666fba7_EarningsPerShareTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended" id="i2bf7c21d25c24828ba0ec089c8fe3ce5_EarningsPerShareAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6139a22a-ec7c-470f-9c4a-e9f64b743282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6139a22a-ec7c-470f-9c4a-e9f64b743282" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:to="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:to="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_36332a29-1999-42e0-9e54-af07a23eb247_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:to="loc_dei_EntityDomain_36332a29-1999-42e0-9e54-af07a23eb247_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:to="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8906aac-64d7-44df-8e25-a313c245338f" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8906aac-64d7-44df-8e25-a313c245338f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended" id="i59b79cf5561b4ecabf8f5bc4889292f5_EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended" id="i5ead2731cf9c4f679957cad1c2fec6cf_EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee86bc1f-b82c-4871-9600-5f854710f42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee86bc1f-b82c-4871-9600-5f854710f42a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b2bfcf2c-d3f5-4bc6-aa10-0f791b6a8524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b2bfcf2c-d3f5-4bc6-aa10-0f791b6a8524" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22fbb7c3-8b63-44b3-8568-83e49be06577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22fbb7c3-8b63-44b3-8568-83e49be06577" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_a3da1b52-0321-4214-b540-6ad0fc3dbaed" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_a3da1b52-0321-4214-b540-6ad0fc3dbaed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_02538dfa-1dcd-400a-9442-9aa14bf7f4d5_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:to="loc_us-gaap_EquityComponentDomain_02538dfa-1dcd-400a-9442-9aa14bf7f4d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:to="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d32d9d99-502f-44f0-8bf3-656813debbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:to="loc_us-gaap_CommonStockMember_d32d9d99-502f-44f0-8bf3-656813debbb0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24e09101-6d1f-4fc4-b0f7-aeeb9b326eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:to="loc_us-gaap_WarrantMember_24e09101-6d1f-4fc4-b0f7-aeeb9b326eb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e07f2e9-d98e-4fa5-a983-89b8ecd14c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e07f2e9-d98e-4fa5-a983-89b8ecd14c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a8a053b-7f42-4814-b799-149c871f4978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:to="loc_us-gaap_RestrictedStockMember_7a8a053b-7f42-4814-b799-149c871f4978" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEs"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended" id="i6f6a91b1621f452e99a4a588c68c7140_VariableInterestEntitiesVIEs"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended" id="i99356cd951b14cd7a35628b7de99d0c7_VariableInterestEntitiesVIEsTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended" id="i1212891cbab8404aa6b78d7a1dcb9de8_VariableInterestEntitiesVIEsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f31abccc-1302-4e11-b20a-0d890fd1a7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f31abccc-1302-4e11-b20a-0d890fd1a7cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_557162af-02dc-4924-8eee-08a0cd0fb7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_RestrictedCashCurrent_557162af-02dc-4924-8eee-08a0cd0fb7e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e47266d1-86a1-4631-a6a8-2a4962219b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e47266d1-86a1-4631-a6a8-2a4962219b71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d6f53425-5b44-429b-852b-227e9aa55086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d6f53425-5b44-429b-852b-227e9aa55086" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dd2b1631-f958-43ae-93fb-9de2574cf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dd2b1631-f958-43ae-93fb-9de2574cf387" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5d1a8d6a-36b2-4d70-bde5-9208cd211357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5d1a8d6a-36b2-4d70-bde5-9208cd211357" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7df3cdd4-e862-44b3-a624-dae1d3a0e641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7df3cdd4-e862-44b3-a624-dae1d3a0e641" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0daa556a-ea75-4966-ba94-e73cac40fcf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0daa556a-ea75-4966-ba94-e73cac40fcf0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_c878cb03-e223-42b1-b4ff-8c0e950543c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_c878cb03-e223-42b1-b4ff-8c0e950543c7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19968317-4067-42cf-8e43-cedf9e8838f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AssetsCurrent_19968317-4067-42cf-8e43-cedf9e8838f9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1bc2c8e9-8cad-4c55-8be7-94664a917794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1bc2c8e9-8cad-4c55-8be7-94664a917794" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d018e59-36af-4495-8503-f9784861c7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d018e59-36af-4495-8503-f9784861c7cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ca4a1e3d-1374-4464-9699-75bf4cda6677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_Goodwill_ca4a1e3d-1374-4464-9699-75bf4cda6677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_efa01cff-2e25-42f7-bbd8-054bc58609ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OtherLongTermInvestments_efa01cff-2e25-42f7-bbd8-054bc58609ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ae8000ed-8e09-4ab4-be6f-8ff600ffe025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ae8000ed-8e09-4ab4-be6f-8ff600ffe025" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_87c43f6a-17b0-4372-b031-cde224dd5cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_EquityMethodInvestments_87c43f6a-17b0-4372-b031-cde224dd5cbf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d313950e-b1e2-4f31-981a-e31095d23452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d313950e-b1e2-4f31-981a-e31095d23452" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3fab7345-f0e2-43fc-ac4e-ea1404000ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3fab7345-f0e2-43fc-ac4e-ea1404000ab5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8a1ac6c7-91f1-4474-85d9-fd2cccbc6be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8a1ac6c7-91f1-4474-85d9-fd2cccbc6be0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e1b7e603-50c8-41bd-b2f9-045415ef4f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_AssetsNoncurrent_e1b7e603-50c8-41bd-b2f9-045415ef4f20" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0394b5cb-52e5-44c7-8477-76f067f8bc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_Assets_0394b5cb-52e5-44c7-8477-76f067f8bc73" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aafc6087-ce63-4ab7-b56b-4e7f3a6ccda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aafc6087-ce63-4ab7-b56b-4e7f3a6ccda3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_09962080-3fd5-4b56-977c-f9d5d940718d" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_09962080-3fd5-4b56-977c-f9d5d940718d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7e3e9f95-f2d3-4d51-a2e6-6e5fc5fe2920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7e3e9f95-f2d3-4d51-a2e6-6e5fc5fe2920" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_47fc3cee-4986-4807-839b-e0e8d4cfebcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_TaxesPayableCurrent_47fc3cee-4986-4807-839b-e0e8d4cfebcd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_bd4af994-42a0-495e-989d-3ed4a2bc9448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_DueToAffiliateCurrent_bd4af994-42a0-495e-989d-3ed4a2bc9448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_14b88134-1776-48cd-9d5b-e25a6afbb9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_DividendsPayableCurrent_14b88134-1776-48cd-9d5b-e25a6afbb9fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5a972d09-aa06-4d0a-807e-f82d020d342b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5a972d09-aa06-4d0a-807e-f82d020d342b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2ebb66ca-4ba9-4c7c-91e9-46d3428b2b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2ebb66ca-4ba9-4c7c-91e9-46d3428b2b21" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdf2cea7-4a3d-41c4-ae33-79665dd4feb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_LiabilitiesCurrent_fdf2cea7-4a3d-41c4-ae33-79665dd4feb5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb1d55c3-d7d1-461a-883f-dc0225da42b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb1d55c3-d7d1-461a-883f-dc0225da42b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1806244a-d234-4ef4-b694-4e342819d4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1806244a-d234-4ef4-b694-4e342819d4d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e70aeb72-894e-4fc1-a80b-edca2ef56b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e70aeb72-894e-4fc1-a80b-edca2ef56b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c141842a-4a5e-4467-8bcf-45eed0e2b9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c141842a-4a5e-4467-8bcf-45eed0e2b9cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_87c7b7a3-8401-4de5-b5f8-29b27aa4343e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_Liabilities_87c7b7a3-8401-4de5-b5f8-29b27aa4343e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_94c7a50a-90e7-4529-a903-f8a4bf6df06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_94c7a50a-90e7-4529-a903-f8a4bf6df06e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200930.xsd#Leases"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended" id="iadf1ccb648684729a3e226bebbff6e11_Leases"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesTables"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended" id="i51e32a746db44353ad59950b62e7290c_LeasesTables"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesAdditionalinformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended" id="i5c28efd79fbd455594212431cde418a2_LeasesAdditionalinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cf5794b4-ed00-460c-bc0b-16b9d0842ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cf5794b4-ed00-460c-bc0b-16b9d0842ea8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_f9614c5b-b69a-47de-9dc6-5a8ca6a1550f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_f9614c5b-b69a-47de-9dc6-5a8ca6a1550f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33905afd-2322-45c6-854d-5b066abb707a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33905afd-2322-45c6-854d-5b066abb707a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_2c25bbcd-4ff1-474d-bf5d-cbcabfb46f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_2c25bbcd-4ff1-474d-bf5d-cbcabfb46f67" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_8450144a-1362-4272-97d8-9b5686add9b4" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_8450144a-1362-4272-97d8-9b5686add9b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_8812aacb-d84c-442d-ade3-269ba9b10da2" xlink:href="ameh-20200930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_8812aacb-d84c-442d-ade3-269ba9b10da2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3d888edf-6af3-43bf-9e93-14bd7d7c8939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3d888edf-6af3-43bf-9e93-14bd7d7c8939" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_73c8af4e-9055-4cea-9785-d98733639a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_73c8af4e-9055-4cea-9785-d98733639a54" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:to="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_73cdcb12-d771-44a4-8122-b472b197352a_default" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:to="loc_srt_RangeMember_73cdcb12-d771-44a4-8122-b472b197352a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:to="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbf29cae-f38a-4c10-9f56-0f651a2cc67a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:to="loc_srt_MinimumMember_fbf29cae-f38a-4c10-9f56-0f651a2cc67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80fbdaa3-9b6c-43bf-b68b-a85cab7c204b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:to="loc_srt_MaximumMember_80fbdaa3-9b6c-43bf-b68b-a85cab7c204b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended" id="i40d5a86c17f044089feab96922cabaa2_LeasesComponentsofLeaseExpenseDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended" id="i5ec1ecab53ef4370ae4961d16011c50f_LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended" id="i929e88b5a7d648d5a8e4f2afd8223f88_LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEvents"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended" id="i97060ab34ff0430f972500be9b4140fa_SubsequentEvents"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended" id="i7b7dcf562cc94ecd9e5b6ec3b29b1f8a_SubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_0154180f-647a-419d-83f1-0541c03b80a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_us-gaap_Dividends_0154180f-647a-419d-83f1-0541c03b80a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_910386ac-f4b4-46e0-8189-91d215446668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_us-gaap_NotesReceivableGross_910386ac-f4b4-46e0-8189-91d215446668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_521c5bec-b219-41da-8be9-4cad0ef4a3c0" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_521c5bec-b219-41da-8be9-4cad0ef4a3c0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_cf3edb09-6a1a-4b75-aaf3-e2a0ca02042b" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_cf3edb09-6a1a-4b75-aaf3-e2a0ca02042b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17_default" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:to="loc_dei_EntityDomain_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:to="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_aee8f4c9-3ec1-4906-a340-3bcbf2278396" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_aee8f4c9-3ec1-4906-a340-3bcbf2278396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_fac9814c-3641-462a-a5eb-4182dfc286eb_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_fac9814c-3641-462a-a5eb-4182dfc286eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f2df30bd-d557-42a6-b63a-e9fcd5dd75c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:to="loc_us-gaap_SubsequentEventMember_f2df30bd-d557-42a6-b63a-e9fcd5dd75c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_729183fb-2e11-49da-a18e-27de8b4c99ec_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:to="loc_us-gaap_ReceivableTypeDomain_729183fb-2e11-49da-a18e-27de8b4c99ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:to="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_0ecd146f-a789-47b5-af2b-a7130d7f1e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:to="loc_us-gaap_NotesReceivableMember_0ecd146f-a789-47b5-af2b-a7130d7f1e53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_3c6b1311-78d0-4ffa-a63e-1264251d31ca_default" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:to="loc_us-gaap_RelatedPartyDomain_3c6b1311-78d0-4ffa-a63e-1264251d31ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:to="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_e3a7cc40-4d07-4437-a28e-faa16c9091ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:to="loc_srt_AffiliatedEntityMember_e3a7cc40-4d07-4437-a28e-faa16c9091ac" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ameh-20200930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_00e78286-f72f-478d-8326-61c589594466_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_8f49229b-0645-4f39-b9bd-b23632f7aac4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion of debt</link:label>
    <link:label id="lab_us-gaap_LinesOfCreditCurrent_label_en-US" xlink:label="lab_us-gaap_LinesOfCreditCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LinesOfCreditCurrent" xlink:to="lab_us-gaap_LinesOfCreditCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_27df1175-029d-4e4d-be64-22f830ca8fb5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f1a780e2-31ae-4caa-abb9-f4eac42c51e2_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2bc99a7a-f5b2-4985-9a68-464647e03e53_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a2d550f1-156e-4a13-bf3f-88519d8ba76d_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d2a24002-4635-49ad-bd07-14c652aa35fe_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_f2a24120-0245-44a4-ace4-0a68a77dc44b_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesAPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesAPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_us-gaap_SeriesAPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_9af2a166-0310-420f-9007-85cb79095408_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated loan</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_f5bc95b2-7246-4298-b870-aba6e1479f37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby letters of credit assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_36637358-8474-4000-b17a-73cd5d358c69_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicaidMember_59826967-53d4-4b37-820b-b9974033d7ab_terseLabel_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ameh_MedicaidMember_label_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ameh_MedicaidMember_documentation_en-US" xlink:label="lab_ameh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicaidMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember" xlink:href="ameh-20200930.xsd#ameh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicaidMember" xlink:to="lab_ameh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_f5e5d42e-d38b-440d-9426-3d41243484db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Outstanding Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_976b58b9-69d5-4f7f-a8cb-661cd620ef0e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options and warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_006990e5-aeff-4950-8d40-3e35520c2445_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4c332bcb-596b-4dfa-9cb4-92301863b48d_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, mezzanine equity and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1b223f45-f018-4d5b-8a99-61b80acbae14_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d9d175ba-409c-4d5c-bec0-6eb64f269408_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_9b999510-5c9e-4a06-9ce2-05b7703cc7e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_4e4a1d12-cd43-4995-a266-67036cc371f8_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation associated with finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_1615c0f5-b6ff-459a-ab9f-987886c7f2bf_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of lease expense</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_9db30a3b-2da8-4679-9ea8-f1e9286d077f_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_d2086b36-a267-4247-90f6-1c023ee1ba8a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_98ae75f6-09c2-42de-a584-ef267f415799_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc.</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementIncMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementIncMember" xlink:to="lab_ameh_NetworkMedicalManagementIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_a1905db0-c601-4001-8c54-8e10f5eeb138_terseLabel_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance for working capital</link:label>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_label_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advanced For Working Capital</link:label>
    <link:label id="lab_ameh_AdvancedForWorkingCapital_documentation_en-US" xlink:label="lab_ameh_AdvancedForWorkingCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount advanced for working capital purposes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital" xlink:href="ameh-20200930.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvancedForWorkingCapital" xlink:to="lab_ameh_AdvancedForWorkingCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_20c44b81-3c2f-4d16-818a-6ea24da19078_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_a67b27fc-78fe-45db-a3ba-9665e042954d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommercialMember_791885f9-d465-49e9-ac9b-86050e6d4a52_terseLabel_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial</link:label>
    <link:label id="lab_ameh_CommercialMember_label_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial [Member]</link:label>
    <link:label id="lab_ameh_CommercialMember_documentation_en-US" xlink:label="lab_ameh_CommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:CommercialMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember" xlink:href="ameh-20200930.xsd#ameh_CommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommercialMember" xlink:to="lab_ameh_CommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3e8710d6-5ab0-4ef4-b77f-06275f1de81d_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_413fa791-b6c9-4626-9f57-14609b5ae065_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_988cc5d1-8a76-4907-b319-a649843bd0be_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_122bb959-50b1-4c1b-a924-55848c177401_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_6bce51bd-c9b1-47c0-9ff6-a8b11df14077_terseLabel_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_AggregateintrinsicvalueAbstract_label_en-US" xlink:label="lab_ameh_AggregateintrinsicvalueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract" xlink:href="ameh-20200930.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract" xlink:to="lab_ameh_AggregateintrinsicvalueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_7c47a379-e9d7-4b40-812c-769468aed5ad_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_5aaa0a2e-c9f3-41da-9cb2-bf6dcaca8fee_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_8797746f-7d73-42a7-b6c7-44a515aaac79_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc4df21c-5380-4d6d-9cd4-8d7272824b30_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CDSCMember_d0324cd2-96a8-415c-a3a4-22c5d4290eac_terseLabel_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:label id="lab_ameh_CDSCMember_label_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC [Member]</link:label>
    <link:label id="lab_ameh_CDSCMember_documentation_en-US" xlink:label="lab_ameh_CDSCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDSC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember" xlink:href="ameh-20200930.xsd#ameh_CDSCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CDSCMember" xlink:to="lab_ameh_CDSCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_04fdf42a-d11d-48c3-a39d-e3bbaa2ca390_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f77ad7b6-ecd0-4096-8ba2-e8865036fbb8_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_82604abf-bf4f-4673-acf0-26176fa3c309_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_1746e44a-1f94-4303-a94c-20e1f408bd3f_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_322c4c15-a833-4c20-a0bc-17b49a771c9c_verboseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to related parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_c7809197-0130-4e7c-9e84-fe8316b406e7_terseLabel_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_label_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy [Policy Text Block]</link:label>
    <link:label id="lab_ameh_MinorityInterestPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minority Interest Policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:href="ameh-20200930.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:to="lab_ameh_MinorityInterestPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_46d80967-65e8-485a-be2f-9e996ef8e510_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_4f955168-a3de-4b6d-b215-65e51750f931_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_d6f4be18-0136-49a9-8a79-794360590883_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AncillaryServiceContractMember_179aa743-06e0-4d6f-b7f8-cd48c2e7b56d_terseLabel_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract</link:label>
    <link:label id="lab_ameh_AncillaryServiceContractMember_label_en-US" xlink:label="lab_ameh_AncillaryServiceContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ancillary Service Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember" xlink:href="ameh-20200930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AncillaryServiceContractMember" xlink:to="lab_ameh_AncillaryServiceContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_c95ea24f-373f-4f1c-85d8-812b2d355a65_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The proportion of investment in Voting common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:to="lab_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_35d51771-0de7-4b92-9911-863b59cd773e_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate in the event of default</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Modifications, Subsequent Default, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:to="lab_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e8cfd381-ddf1-4844-92f4-40d3017e4e62_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_6dab44c4-2a1b-4748-bebb-7cc2c3dba510_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ffe10d2c-2873-4aa8-846e-25a0f06b24d9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_175422eb-bfb9-40ab-b6ea-c898a1afbd69_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5cd42b14-a3dc-40eb-bce0-adcf03b86054_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_d8fa2dd4-5777-47c1-8d18-1ddbe5e6b7fd_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2f52c363-e17b-45b5-a025-1be058ed5e90_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_783993b7-7e5a-4da3-9a41-0b6a437e0419_terseLabel_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to related parties</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_label_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Made To Related Party</link:label>
    <link:label id="lab_ameh_PaymentMadeToRelatedParty_documentation_en-US" xlink:label="lab_ameh_PaymentMadeToRelatedParty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit/Duration (Amount paid to related party in relation to providing services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty" xlink:href="ameh-20200930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentMadeToRelatedParty" xlink:to="lab_ameh_PaymentMadeToRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_6b675403-1818-4352-977b-3c497cf4ccfe_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_4ec45746-5208-4d6b-855f-d418e6a44f4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_b8eedba8-0490-4509-b70e-c3dc48ff32cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of finance lease obligations</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_e22856c7-3fbf-4595-95e8-0a77289c9029_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_07d51f84-5733-4af0-833f-6f64f5abd397_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_569c58ad-42a1-453b-a187-61a19aa8894b_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of short-term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_1f77c594-a395-4992-bca5-2c67d61365c7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SubcontractorIPAPayable_f33e759d-6022-4bee-b773-a38c1d695c04_verboseLabel_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_label_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:label id="lab_ameh_SubcontractorIPAPayable_documentation_en-US" xlink:label="lab_ameh_SubcontractorIPAPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subcontractor IPA Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable" xlink:href="ameh-20200930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SubcontractorIPAPayable" xlink:to="lab_ameh_SubcontractorIPAPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_f3d14a14-6360-44c3-ba27-6600c2007612_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_43357443-7928-439e-bfe6-107fad2f81d6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForFees_1d31ffd3-df5c-4da7-870b-a37c56fae331_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fees paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Other Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForFees" xlink:to="lab_us-gaap_PaymentsForFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_62d4627a-9fe8-4166-b503-ed17013dd765_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_96f98578-7472-444b-9d31-5d66e88a0305_negatedTerseLabel_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on loan assumption</link:label>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_label_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Assumption Of Loan</link:label>
    <link:label id="lab_ameh_GainLossOnAssumptionOfLoan_documentation_en-US" xlink:label="lab_ameh_GainLossOnAssumptionOfLoan" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Assumption Of Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan" xlink:href="ameh-20200930.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_GainLossOnAssumptionOfLoan" xlink:to="lab_ameh_GainLossOnAssumptionOfLoan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_6aa41f66-b07f-4d09-8bda-4011ef481c2d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorEMember_3721980d-a39a-4794-a648-369ea8ead44b_terseLabel_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E</link:label>
    <link:label id="lab_ameh_PayorEMember_label_en-US" xlink:label="lab_ameh_PayorEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor E [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember" xlink:href="ameh-20200930.xsd#ameh_PayorEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorEMember" xlink:to="lab_ameh_PayorEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_f8f80ffe-c1fc-492e-b0ae-3c5de90cbf94_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_b5496378-bb18-4d1d-bbbb-caa3728bba2a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Taxes and Tax Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_9b9953dd-f632-4007-a8b0-69e7d0663ce3_terseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_1595e846-1f7b-4daa-aa72-0cd57f2bb37f_verboseLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional cash and non-cash consideration entitled to be received</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_83c2076a-7fd3-4db5-b4ad-caae96257714_netLabel_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beneficial interest in UCI</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:label id="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:to="lab_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_e7f36923-c097-4e3d-8926-e3f9f57bca4e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_97916beb-f240-44a6-9b14-3a21b6f77dd4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares Included in the Diluted Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_352f0db4-77da-4b77-8af6-a04c94dd2575_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise&#160;Price&#160;Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashUninsuredAmount_ee371d36-329c-4350-906a-8658758a8c8d_terseLabel_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount deposit accounts exceeded FDIC insured limit</link:label>
    <link:label id="lab_us-gaap_CashUninsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashUninsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashUninsuredAmount" xlink:to="lab_us-gaap_CashUninsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_9a3e5001-1399-4af3-aca7-c42277586c60_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MembersCapital_d9e02402-f71a-46d7-9bfa-b9f5546edb44_terseLabel_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial capital contributions</link:label>
    <link:label id="lab_us-gaap_MembersCapital_label_en-US" xlink:label="lab_us-gaap_MembersCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Members' Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MembersCapital" xlink:to="lab_us-gaap_MembersCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_d65efa66-e570-40d2-9789-a7d649532a2f_terseLabel_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term marketable securities, maturity period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_label_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:label id="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod_documentation_en-US" xlink:label="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:href="ameh-20200930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:to="lab_ameh_MarketableSecuritiesCurrentMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9bc52c71-2d39-4dce-9f17-fd156885cbb9_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_58111831-86ec-4f7c-b0f3-c6c8c08b9bdf_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PmiocMember_8a02083c-f17b-4221-ac43-2cb6533cd4f4_terseLabel_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC</link:label>
    <link:label id="lab_ameh_PmiocMember_label_en-US" xlink:label="lab_ameh_PmiocMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMIOC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember" xlink:href="ameh-20200930.xsd#ameh_PmiocMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PmiocMember" xlink:to="lab_ameh_PmiocMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_74ef5f34-a5c4-4573-abc0-e3f5400b1e56_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility, Bank Loan and Lines of Credit</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_900cf077-7349-4c83-a0cf-f75da8dface3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f47de706-49ce-4599-aba5-15032d23c5ec_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_da849550-9302-42f2-8fc4-28840d9c1e17_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_af53912e-73c0-4ae5-ab29-188eeb802202_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investment contributed</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Equity Interest Issued or Issuable, Value Assigned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:to="lab_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_4d9e3806-ed39-41a4-954d-0f95ec55984c_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool surplus or deficits, settlement period after risk pool performance year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_label_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:label id="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_documentation_en-US" xlink:label="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:to="lab_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_9ff1a38a-4729-4154-bb85-85e37c57220e_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable</link:label>
    <link:label id="lab_us-gaap_FinanceReceivablesMember_label_en-US" xlink:label="lab_us-gaap_FinanceReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceReceivablesMember" xlink:to="lab_us-gaap_FinanceReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_4c2e1309-5858-4457-a6ae-0989579d88e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; non-current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_4239b53e-771e-47e5-a97d-ff414fcaf836_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock</link:label>
    <link:label id="lab_us-gaap_SeriesBPreferredStockMember_label_en-US" xlink:label="lab_us-gaap_SeriesBPreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesBPreferredStockMember" xlink:to="lab_us-gaap_SeriesBPreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_59b20bb7-2ddc-4240-a6d4-1e85eff3abbd_verboseLabel_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_label_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificOfCaliforniaIPAMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific Of California IPA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:to="lab_ameh_AlliedPacificOfCaliforniaIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_29956b70-6c40-4262-915d-07155be98b61_terseLabel_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit</link:label>
    <link:label id="lab_us-gaap_StandbyLettersOfCreditMember_label_en-US" xlink:label="lab_us-gaap_StandbyLettersOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standby Letters of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StandbyLettersOfCreditMember" xlink:to="lab_us-gaap_StandbyLettersOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_4f4d5a70-d99c-408c-945b-2822cf8108e5_verboseLabel_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_HealthCareCostsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_84b8e45e-35bf-4ba7-8f73-3017933790fc_verboseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_10d2d4c2-0a31-4752-b575-4abb6f6cdc78_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcShareholdersMember_063a8c25-2f24-47bd-8546-c88467dd7aa3_terseLabel_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders</link:label>
    <link:label id="lab_ameh_ApcShareholdersMember_label_en-US" xlink:label="lab_ameh_ApcShareholdersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember" xlink:href="ameh-20200930.xsd#ameh_ApcShareholdersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcShareholdersMember" xlink:to="lab_ameh_ApcShareholdersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_56a3da73-b97e-4e62-9f55-5498f4df098e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to weighted average shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DrSimAndDrLamMember_b83fe854-a432-47ae-b0bf-f4fb6ab732be_terseLabel_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam</link:label>
    <link:label id="lab_ameh_DrSimAndDrLamMember_label_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam [Member]</link:label>
    <link:label id="lab_ameh_DrSimAndDrLamMember_documentation_en-US" xlink:label="lab_ameh_DrSimAndDrLamMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Sim And Dr. Lam</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember" xlink:href="ameh-20200930.xsd#ameh_DrSimAndDrLamMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DrSimAndDrLamMember" xlink:to="lab_ameh_DrSimAndDrLamMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_b57ac5fd-0b0d-4f21-863e-b23f1ed3ca58_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_dd999d34-d394-4904-80d7-dcca5e4657ea_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued in connection with a business combination</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bec08586-c58c-4e9c-b8db-c464f5b1cdb0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_86334357-176c-4595-a183-9ed43f5e5e99_terseLabel_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:label id="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:to="lab_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalPropertyPartnersMember_d6ba1007-9609-4cf6-b29c-60eb0e7b5ffb_terseLabel_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners</link:label>
    <link:label id="lab_ameh_MedicalPropertyPartnersMember_label_en-US" xlink:label="lab_ameh_MedicalPropertyPartnersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Property Partners [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember" xlink:href="ameh-20200930.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalPropertyPartnersMember" xlink:to="lab_ameh_MedicalPropertyPartnersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e378b2a3-321d-4ca3-bb35-2473104afbf2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_7226da4b-b2d9-444e-8835-def9169b29ec_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired (see Note 3)</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f75d5ff0-655b-4ece-b3fe-ddf74eec81b2_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_2660e01f-09e5-47f2-8452-cd004a537e73_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from repayment of loans receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_d5cc596c-0413-4876-af5d-0e160762aff7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorAMember_618ff3cb-b636-465d-a17d-91c677f2e1a1_terseLabel_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A</link:label>
    <link:label id="lab_ameh_PayorAMember_label_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:label id="lab_ameh_PayorAMember_documentation_en-US" xlink:label="lab_ameh_PayorAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember" xlink:href="ameh-20200930.xsd#ameh_PayorAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorAMember" xlink:to="lab_ameh_PayorAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ce806e3e-6d76-403d-ab0b-dae9bd5b04a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_0c38eb4a-d384-4c7d-8175-6aeaae670b6b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_061fbd68-e796-4c2d-89bb-1c83026f3c78_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_8c5a9f57-a78a-48fa-a302-2476889e19f3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenue_cd083c78-8050-4794-899d-1d7a50ded083_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_label_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:label id="lab_ameh_PaymentOfRevenue_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenue" xlink:to="lab_ameh_PaymentOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_6cf67f73-a29d-4482-bc31-337fced576c6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_5bddff8f-3580-4099-8078-b59828f8b219_terseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_1cf9b44a-72a6-45ee-9854-1b00f2bbb5ec_terseLabel_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_label_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Critical Quality Management Corp [Member]</link:label>
    <link:label id="lab_ameh_CriticalQualityManagementCorpMember_documentation_en-US" xlink:label="lab_ameh_CriticalQualityManagementCorpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Critical Quality Management Corp Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember" xlink:href="ameh-20200930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CriticalQualityManagementCorpMember" xlink:to="lab_ameh_CriticalQualityManagementCorpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_b79ad4d5-bc1e-49d0-a641-872e09cc0450_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related-Party Transactions</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d924a8af-9e8e-4e75-bcc4-1ab092e83a60_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_c9d03f33-33d0-4559-ba95-d29d533c8f24_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of key financial ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_label_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:label id="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Number Of Key Financial Ratios</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:to="lab_ameh_DebtInstrumentNumberOfKeyFinancialRatios" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_75dcc3a8-f968-4104-ac0c-6342095a3e69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfEmployees_cfd9b13b-863f-4428-b6e9-4cefc15c389c_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (over)</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_085154c0-b1b5-4afb-94cf-0f4584e9cc2d_terseLabel_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees (more than)</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_label_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:label id="lab_ameh_NumberOfEmployees_documentation_en-US" xlink:label="lab_ameh_NumberOfEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees" xlink:href="ameh-20200930.xsd#ameh_NumberOfEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfEmployees" xlink:to="lab_ameh_NumberOfEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_1fedfa3c-f283-41cd-a020-dd1bd03b4b6e_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder approval percentage (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_label_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:to="lab_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_3bc720fb-a1ec-4126-baad-6a43ba64147c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_9cfa4468-9c92-4f9c-8ae9-1bec5bfe510b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_35f6fe0b-0e47-44ca-bd13-0b84e1a6ecf5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_78443276-0af4-4721-a1c6-346cbbb79ed9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_65258cd8-9a8e-4c0c-9b3d-a3c55bf62a2c_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional advances</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility Additional Advances</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityAdditionalAdvances_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of line of credit facility additional amount advances as a loan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:to="lab_ameh_LineOfCreditFacilityAdditionalAdvances" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_f7d2e19c-f875-491c-befc-022c4707076e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Risks</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_722d6898-98de-4361-bbbb-307fe631d872_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_928df368-b698-46dc-b9cd-9917215fc87d_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_b42d6358-ca20-456e-8587-5fa9492aec67_terseLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_7f8e15d3-989b-463c-8928-5d2c3d337a36_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Holdback shares not issued to former shareholders (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Merger</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesMerger_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares of stock issued during the period pursuant to merger.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesMerger" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesMerger" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SharesWarrantsRollForward_06fad73a-d8a5-4a29-aa50-2ef16968a61b_terseLabel_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_label_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_SharesWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_SharesWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward" xlink:href="ameh-20200930.xsd#ameh_SharesWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SharesWarrantsRollForward" xlink:to="lab_ameh_SharesWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_68ebfc1a-141b-4823-b6f1-b63774097bea_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages sought</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_a1e09576-e593-423d-9493-fc6f78037a8b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_91a506bb-7fa4-46bb-8d9b-82a91aab6ed9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_b64e62f8-6e44-4228-9b40-79728f689c43_terseLabel_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_ameh_AccountsPayableAndAccruedExpensesMember_label_en-US" xlink:label="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable And Accrued Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:href="ameh-20200930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsPayableAndAccruedExpensesMember" xlink:to="lab_ameh_AccountsPayableAndAccruedExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeDomain_08a93052-6d1e-419c-bc33-df9a02875d21_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:label id="lab_ameh_ContractTypeDomain_label_en-US" xlink:label="lab_ameh_ContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain" xlink:href="ameh-20200930.xsd#ameh_ContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeDomain" xlink:to="lab_ameh_ContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_bc843e95-7647-4024-a82b-abb68ef6ec62_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ebb4352-6f9a-41cb-86bb-3322fa95c139_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApaacoMember_e8085d08-5957-4f8e-992d-cbba8848f833_terseLabel_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO</link:label>
    <link:label id="lab_ameh_ApaacoMember_label_en-US" xlink:label="lab_ameh_ApaacoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APAACO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember" xlink:href="ameh-20200930.xsd#ameh_ApaacoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApaacoMember" xlink:to="lab_ameh_ApaacoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0c4d8762-5a17-42e6-a8f4-67cf91ff094b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_3f3a68c8-5f3e-4714-9a93-74f9463abf98_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_538e9ef9-9687-409b-93e7-fa0e1fa8daf7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_ddc1e41c-932f-4cde-8690-03581bd33e47_terseLabel_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group</link:label>
    <link:label id="lab_ameh_DiagnosticMedicalGroupMember_label_en-US" xlink:label="lab_ameh_DiagnosticMedicalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diagnostic Medical Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember" xlink:href="ameh-20200930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DiagnosticMedicalGroupMember" xlink:to="lab_ameh_DiagnosticMedicalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_eed49684-ff94-47c2-a9c3-ae4ad0783329_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in&#160;Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_0030333f-3803-4ead-9bc2-cf1df5b61ade_terseLabel_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from warrants exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:label id="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_documentation_en-US" xlink:label="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Issued During Period Value Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:href="ameh-20200930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssets_8d533d0e-c9a8-4148-81a4-271462b66e21_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_label_en-US" xlink:label="lab_us-gaap_OtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets" xlink:to="lab_us-gaap_OtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_9a43a32b-3d24-4000-85d3-d573f438153d_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_8e08e6a1-a533-46e9-844d-2d9683528f87_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Duration of investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_4730927a-d005-4a72-8d8c-f63df864bdc7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_58eb3605-143e-4752-ba32-3e5e3b38f7dc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_f62e1e2c-cbea-404e-8f59-76760f76b3e5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OtherThirdPartiesMember_0d1b7c60-fd57-43ae-8d3c-d794339e0be0_terseLabel_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third parties</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_label_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Third Parties [Member]</link:label>
    <link:label id="lab_ameh_OtherThirdPartiesMember_documentation_en-US" xlink:label="lab_ameh_OtherThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:OtherThirdPartiesMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember" xlink:href="ameh-20200930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OtherThirdPartiesMember" xlink:to="lab_ameh_OtherThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_85c137cf-aa24-4e25-8606-edd2d6a806b5_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_4a064110-58c3-4434-b094-84cc8b928439_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_3f0840d5-ee8e-4688-b643-c7e04c4920e1_periodStartLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_2bbcc393-7e59-41d6-b026-d70548315cd8_periodEndLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_5d434663-38fd-4184-beb1-f08373ba3944_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in other entities &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_8ad50133-969b-4a12-b1e0-b0368461bf88_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Carrying value of equity method investment on date of sale</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ac3cc8fa-6f3f-49f1-ac83-2fa5110e49b0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_506121dd-3e9b-4af7-a8af-d1aa44a5a40e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_b14bcb96-b977-4991-9a51-48f3883a0024_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolver Loan</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_d2ba16cd-5fc1-4d16-966a-334bd378fbf4_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entities (VIEs)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_023bb3c4-6290-40ce-9292-78b55a24e726_terseLabel_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_label_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:label id="lab_ameh_APAMHMedicalCorporationMember_documentation_en-US" xlink:label="lab_ameh_APAMHMedicalCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AP-AMH Medical Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember" xlink:href="ameh-20200930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APAMHMedicalCorporationMember" xlink:to="lab_ameh_APAMHMedicalCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeFourMember_9ef15df3-bbc9-491f-b29a-1aacefe610ee_terseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Four</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeFourMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeFourMember" xlink:to="lab_ameh_WarrantExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_753e8096-6f6e-4fbb-b29d-0ec61720dc63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_064fe349-2bcc-4014-8ae6-b34e9c12d837_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f7721638-27ad-4922-a8fb-118c47ad9e2e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4059c82e-4f07-4042-a4ec-29dab1a1da68_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for business acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_a295d195-4699-4e9f-996f-6b3269d5e09d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_44f01244-37b7-4b89-9bd2-f21a03e21b72_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_737feac1-85d7-4129-b596-0fde0db8891a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_31d27a90-2505-4faa-ad41-fbf1d6254cd7_terseLabel_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC</link:label>
    <link:label id="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_label_en-US" xlink:label="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concourse Diagnostic Surgery Center, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:href="ameh-20200930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:to="lab_ameh_ConcourseDiagnosticSurgeryCenterLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_590bc9d1-c484-4f8c-b366-1c05b0af5e62_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_72eff619-734a-4535-830c-afd8b6f74492_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_7b1811bc-2554-410a-a0d6-5094effd0d28_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_cf24b5c5-18ee-4794-add5-ad6b1d938bfb_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_44e4b1d0-2ac5-4926-8273-e5fab391b605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Unamortized financing costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_04c20a9e-38c8-4ce7-b2a9-63c05652584e_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_15d362d1-e8f3-414f-b301-e7899fd85244_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesTable" xlink:to="lab_ameh_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_b9ea795f-29d4-4946-9437-b46da67f4e40_terseLabel_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PMPM Managed Care Contract</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_label_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:label id="lab_ameh_PerMemberPerMonthManagedCareContractMember_documentation_en-US" xlink:label="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per-Member-Per-Month Managed Care Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:href="ameh-20200930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PerMemberPerMonthManagedCareContractMember" xlink:to="lab_ameh_PerMemberPerMonthManagedCareContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_705605f9-a3da-4645-b5b3-d8705a1b0f36_verboseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_Dividends_9fd27b33-f911-4ed2-837f-15a41b16f102_terseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodOneMember_8d256398-25cc-4efd-b877-ab7f2205e933_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Eight Fiscal Quarters</link:label>
    <link:label id="lab_ameh_PaymentPeriodOneMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period One [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodOneMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodOneMember" xlink:to="lab_ameh_PaymentPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_d833ed84-2d9a-422c-95d3-9f33b82df4c6_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_912b4fef-192a-4d97-8911-9a4857c7e6d0_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual&#160;Life</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:to="lab_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_b72bbb4a-d453-4052-a733-dbf0704d317e_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2dcdebc3-4076-4b15-9a1b-d1bcf90bfd0b_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_072bf9d6-31c1-47dd-9888-85d689af0de2_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting common stock, within five years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_91d7b2de-d181-42a7-926f-4b1afc63ab1a_terseLabel_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed term of amended and restated management and administrative services agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_label_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement</link:label>
    <link:label id="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_documentation_en-US" xlink:label="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The initial fixed term of amended and restated management and administrative services agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:href="ameh-20200930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:to="lab_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_f6c4704c-1728-4bd1-b099-d954c986a69b_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Other Operating Lease Liabilities</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:to="lab_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkRelationshipsMember_89d56134-678b-49a8-bfb0-84d14d38e18e_terseLabel_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationships</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_label_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships [Member]</link:label>
    <link:label id="lab_ameh_NetworkRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_NetworkRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember" xlink:href="ameh-20200930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkRelationshipsMember" xlink:to="lab_ameh_NetworkRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_c2264acb-4a56-44e3-83de-7ebfe1ce9218_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Board Members</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_4cbf9b32-4706-4af8-a24c-256bfae4c735_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, preferred shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_8c8b8389-116d-4513-99f3-f086651df6c7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_881861f7-652e-479e-a7f3-b9ff52c9dad9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2ccc9b70-4098-4b11-94e5-14cb68322404_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allocation of Income (Loss)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_3c37d80e-da30-4b0c-8099-96752ab1ffb3_netLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2498c09d-4f68-4f8b-948c-7a3d0858b7dc_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_49d62f0c-a0b6-435f-be3c-3e187bc86f86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before benefit from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_a4423c4e-0f22-474a-9a80-a213bb7d9514_negatedLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Cancelled In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of warrant or right, cancelled in period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightCancelledInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_475ccea1-7165-4ac1-bd93-f7c5752bd8cc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_26b5459d-0100-4a2e-bf82-5c7fb1bbecbf_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_a2aef850-6b51-4dca-acc9-179e0b971266_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_752ff676-4868-497f-bc9d-3102e6b3d178_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_45420fed-5240-47b1-8c3d-7780cf4ee722_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership upon conversion of finance receivable</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:to="lab_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_80c0a9e4-24bf-4eae-b159-926217c5cfb5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0eccab43-a316-42f3-b8f2-fd27fde0176c_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_AffiliatedEntityMember_a9f3f218-050f-44e1-81f6-6bee24aecb5d_terseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_1b0b1958-2a8b-4594-925c-1557f78812f6_verboseLabel_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_srt_AffiliatedEntityMember_label_en-US" xlink:label="lab_srt_AffiliatedEntityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliated Entity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_AffiliatedEntityMember" xlink:to="lab_srt_AffiliatedEntityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e3f8b17e-33fe-4ad3-b127-a9dc6e892a74_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_e18dbd6f-accf-4f68-93f4-2ca2445dc9be_terseLabel_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to purchase membership interests</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20200930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_a61f91bd-c2f6-469e-8bb8-7503cc83889b_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Liabilities [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_9c936142-df6a-4d1e-bd78-ed542c786ae9_terseLabel_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center</link:label>
    <link:label id="lab_ameh_AdvanceDiagnosticSurgeryCenterMember_label_en-US" xlink:label="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advance Diagnostic Surgery Center [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:href="ameh-20200930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:to="lab_ameh_AdvanceDiagnosticSurgeryCenterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_19c76c0e-c77c-44dd-8633-ec2b9bc1f891_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payment on credit agreement</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Periodic Payment, Principal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:to="lab_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f672f388-fb09-42fc-9ecf-d6494b519843_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities &#8211; certificates of deposit</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_c2c119e7-bd35-446e-93ea-6887c19861bf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_OneMSOInc.Member_111beba0-51dd-4154-91b6-87767a583a27_terseLabel_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc.</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_label_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:label id="lab_ameh_OneMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_OneMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One MSO, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member" xlink:href="ameh-20200930.xsd#ameh_OneMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_OneMSOInc.Member" xlink:to="lab_ameh_OneMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_af934ce1-0b95-4f4e-aa97-5a18b028ef14_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_f3ac6f37-38ab-437d-b47f-e9e3ba2c5c2f_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_6fac9f63-d896-4155-b1bb-d9cfe2ccceb4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_dd7e1ad3-b0e9-4e19-a33b-1b4dcfc1666f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_50f93db4-1638-47bd-82e1-f9a6e67324ba_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessTable_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessTable" xlink:to="lab_ameh_DescriptionOfBusinessTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_12d914e5-523d-402f-aebc-94686a06ec09_negatedTerseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_label_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</link:label>
    <link:label id="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:to="lab_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b4e3d852-2120-4078-bd01-623e5c0b33c0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_c5dfeb62-7865-49f8-8344-663d894c5a40_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:to="lab_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_de953760-28be-403a-ac91-97d1ba701ceb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables-Related Parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_05e24ec0-24d9-42d3-ab5e-f3b7736700d0_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_61a69868-86ed-4e81-b469-dc0a66bca74c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_92f45dd5-fe34-4e12-9b83-98c8b8bdf1ac_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting rights held (more than)</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:to="lab_us-gaap_VariableInterestEntityOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_1e25f80f-e64f-42f2-8eb7-6434ef6ac879_terseLabel_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC &#8211; Risk pool, capitation, claims payment, net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_label_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:label id="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_documentation_en-US" xlink:label="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Services Revenue, Capitation, And Claims Payment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:href="ameh-20200930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:to="lab_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_78c5b82e-ea48-4a69-8476-63a4b72a4b0a_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_98c5829d-14e3-4581-ad46-e8dca52c0a1f_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_3fa8e2af-567c-4427-aa0f-0a3977a11942_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_a0de0098-e38d-41a8-97b3-a1b9ed715c57_terseLabel_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_label_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:label id="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_documentation_en-US" xlink:label="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allied Pacific of California Brokerage Account [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:to="lab_ameh_AlliedPacificofCaliforniaBrokerageAccountMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_d97f57a1-8790-4d5d-8972-72fa213d044f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0e2ef4f3-03a8-470d-a1f2-1edcd4f59e8b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentConsultingFees_97bf284a-3d77-4ea3-9df9-f4d71138e858_terseLabel_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consulting services paid</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_label_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:label id="lab_ameh_PaymentConsultingFees_documentation_en-US" xlink:label="lab_ameh_PaymentConsultingFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Consulting Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees" xlink:href="ameh-20200930.xsd#ameh_PaymentConsultingFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentConsultingFees" xlink:to="lab_ameh_PaymentConsultingFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_0cdf3f91-6132-459e-bece-584e2f4c61e4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_fb0aca11-5542-4f7c-862f-8a45694ddd18_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_3b2c5e89-0738-4fa6-8b75-ecc39c294529_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_9b97b3a7-59c5-435b-aaea-c2813dcb70e6_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_ff6698dd-7f52-4cd2-a9cd-0d868c3585c6_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights exercised in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_546490c8-4215-4926-b511-e2a0f646729d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_1e25afd5-45fb-4038-aec0-6c07b3a0500c_terseLabel_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line of Credit Agreement</link:label>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_label_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line Of Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_NMMLineOfCreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_NMMLineOfCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Line Of Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember" xlink:href="ameh-20200930.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NMMLineOfCreditAgreementMember" xlink:to="lab_ameh_NMMLineOfCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_fbfc4f2b-5205-43cd-9e6d-2916d5580f15_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_e6669955-0fae-4541-96a1-1d522e327be7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_6c349bf4-00d7-49e6-b480-f9a56ce6caaa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, operating</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_51e88f73-9293-4741-9260-c97ddd56b63a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_6b1a5db5-1107-4ece-ac45-0ec8162ef83e_terseLabel_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20200930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_f17067be-0044-40d9-accf-7f7c0fa023b1_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_c466a2ab-eef2-4780-8db4-6306c72586bc_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2020</link:label>
    <link:label id="lab_us-gaap_Goodwill_fdd2df8d-494b-42b7-ae10-73e4470c0bce_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, September 30, 2020</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_66f96e28-4a73-470c-a0a7-002d5bfc17ab_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_699276d7-38bc-4f41-ad5a-f14fc3addfb0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_6ab467d5-6ca0-43bc-903d-5afb02961dbe_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_d31cc6db-a38b-425d-a88a-41580ee872f8_verboseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in privately held entities</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_13b0e359-7342-4d1c-a41c-6e2d8fc0a709_terseLabel_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares in Bright Health, Inc.</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_label_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment In Privately Held Entity That Does Not Report Net Asset Value</link:label>
    <link:label id="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_documentation_en-US" xlink:label="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total of Investment in privately held entity that does not report net asset value per share .</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:to="lab_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_f3233bb5-b7aa-443b-b5da-49cbe0042b58_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_a56929c1-3922-4d54-a6f7-e94e21668500_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_55f0b5b0-54e0-4b53-9f13-d4bcdec3d850_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of converted loan</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Guarantee Given By Related Parties</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of guarantee given by related parties for line of credit facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:to="lab_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_dc0edc97-977e-40d1-94a8-1c2a06d1081e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred financing costs</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_12278f66-c5ac-48ff-8aed-1ea27416a002_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_8cf2bbc1-267a-4a67-8099-19765cadaea7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Change in Carrying Value of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_137b1e1d-e180-46f7-b481-16d793104f39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_80974aef-186f-423f-afc0-9bdd6ae9fe20_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_e18762ad-aed0-43a0-9852-4de71782cb85_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_80f2135b-7f6c-4d95-8053-7bab680a9b6b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_59528abc-359e-494c-8ffe-01bf29680bd8_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_88473476-0908-4fa0-a01a-455efd648f53_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8d2d2592-e631-45df-a030-a719c10c3586_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_58ab00be-b60e-422e-9ca2-511ac1af0426_terseLabel_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine Equity</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_label_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:label id="lab_ameh_TemporaryEquityPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:href="ameh-20200930.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TemporaryEquityPolicyTextBlock" xlink:to="lab_ameh_TemporaryEquityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f056679d-bde9-41ac-b386-f85e66c7f427_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2612b37c-f09c-4adf-bf41-bfb01e831409_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7562c31f-e417-49e7-ae34-d5bb8841d794_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_cd700f15-b522-4c9a-821a-946ad5572be5_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_4437e8d8-6874-4a6c-aae4-c60e2e98f444_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Amounts and Fair Values of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_f5bedc9c-2e6e-4f52-bf3d-5c3d78e6184c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_0c3bd3e2-3e6e-42f7-80ad-fa8051fa98bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_99737f0f-7b04-40d4-bc87-77efd259343d_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised, cashless exercise provision (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement, By Share-Based Payment Award, Warrants, Cashless Exercise Provision, Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement, By Share-Based Payment Award, Warrants, Cashless Exercise Provision, Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_7c3e5091-1abd-4a52-ac24-0caf0aebefeb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_3f8a2274-3928-4c3d-97aa-ff075f94dc2a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_8feb6920-4870-49b3-8996-01fbd3a22f24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_3028c5ba-ce84-4b0c-8c0e-7d430ffa5aeb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of indebtedness received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Repayments of) Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.ArteagaMember_30caf6d1-6fee-43b4-af61-b732deda68a1_verboseLabel_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_label_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:label id="lab_ameh_Dr.ArteagaMember_documentation_en-US" xlink:label="lab_ameh_Dr.ArteagaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Arteaga [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember" xlink:href="ameh-20200930.xsd#ameh_Dr.ArteagaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.ArteagaMember" xlink:to="lab_ameh_Dr.ArteagaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1cdd76f1-417a-44a1-a265-dc79d0e8c796_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_46dc02fe-690c-4e3a-b181-8892acdcd567_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,775,817 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, as of September&#160;30, 2020 and December&#160;31, 2019, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_80536ca4-8890-497d-8c09-5bed61e9a7af_verboseLabel_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities &#8212; Equity Method</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method And Other Equity Investments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:href="ameh-20200930.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:to="lab_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_0e3ad764-a3bd-41b7-89b9-1daf59871fb3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_a480fd97-e7a3-4f60-9db0-b8b4523039e2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_7bc02a97-64fa-492d-bd80-72cae6bb65d9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in affiliates</link:label>
    <link:label id="lab_us-gaap_OtherLongTermInvestments_label_en-US" xlink:label="lab_us-gaap_OtherLongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermInvestments" xlink:to="lab_us-gaap_OtherLongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a38271dd-8214-454c-a9b9-88c0f5a29b93_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_44fb6b36-7a2e-47a4-8774-b59819dfa20a_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_11f9cd60-f656-494d-94c4-77e9b32d855b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_86e3516d-f851-4f13-863d-25bfb7b8d329_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_3ffdc18f-bce2-430e-914f-eb79ca650035_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_9fcefe1c-87c9-4353-a5c9-89667e0439c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f50c138e-d5e3-47cd-bc29-a46bc2238557_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_5f960d6f-72df-4d4b-828b-17f9329f4504_verboseLabel_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation, net</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_label_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Capitation Revenue [Member]</link:label>
    <link:label id="lab_ameh_HealthCareCapitationRevenueMember_documentation_en-US" xlink:label="lab_ameh_HealthCareCapitationRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_HealthCareCapitationRevenueMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember" xlink:href="ameh-20200930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthCareCapitationRevenueMember" xlink:to="lab_ameh_HealthCareCapitationRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_9c321373-53e3-47ed-88b7-17282f717aba_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareIncMember_a6163e77-237b-4f22-96ed-5e78ba55a3ca_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care, Inc.</link:label>
    <link:label id="lab_ameh_UniversalCareIncMember_label_en-US" xlink:label="lab_ameh_UniversalCareIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareIncMember" xlink:to="lab_ameh_UniversalCareIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_df8d45aa-47b4-4195-8570-73f8b58a9f34_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_951d2f0f-4cb7-4083-bcfa-fd5369f9a302_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c0a0c04f-4aa2-409a-94a6-7cad28558b56_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8991cfea-aab2-4283-ad20-20780f0c9296_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_5e0ad4a1-7a86-4cb8-aee7-30aae6239272_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_29c5b090-74df-4151-a12f-e9b76e1fb38c_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated rate of note of loan receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_label_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableStatedInterestRate_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableStatedInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Stated Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableStatedInterestRate" xlink:to="lab_ameh_FinanceReceivableStatedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_af2d6d73-40aa-46cd-a2a1-984609e60a31_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_f27c488d-bb6d-443e-aabc-15ace1d1cae3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7e723cc1-1936-45e3-9c47-fba45dafa2a2_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ed33d1fd-80e3-4ff8-b15a-fc929643f864_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_408f2179-805c-4d87-a5e6-de7608a8b868_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c285d65d-f37d-447c-a483-ed56cf0a98c8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of current portion and deferred financing costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_826b84ba-86df-4169-b0a7-3fddb9cea069_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2b852e9b-3b1d-4260-8fde-87617d890a28_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity, parent</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_e22f7942-baaa-4580-b190-7f69884c8eec_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_d0df1921-b36a-4dba-a4a4-3371d47b6a06_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PreferredBankMember_12931061-0928-4fcc-9984-12efb9f3ab70_terseLabel_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank</link:label>
    <link:label id="lab_ameh_PreferredBankMember_label_en-US" xlink:label="lab_ameh_PreferredBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember" xlink:href="ameh-20200930.xsd#ameh_PreferredBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PreferredBankMember" xlink:to="lab_ameh_PreferredBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Dr.JayMember_1f5d8eb2-0688-40ee-a8c2-599d54d75b65_terseLabel_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay</link:label>
    <link:label id="lab_ameh_Dr.JayMember_label_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:label id="lab_ameh_Dr.JayMember_documentation_en-US" xlink:label="lab_ameh_Dr.JayMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Dr.JayMember" xlink:to="lab_ameh_Dr.JayMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_86ae17e6-9e56-4cd6-a39d-d1ece2659621_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6a8eab6b-492f-402a-8cc2-5f0e35a85d07_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfPatients_c26b6757-b779-4a93-a718-ea33a0c6cd60_terseLabel_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients</link:label>
    <link:label id="lab_ameh_NumberOfPatients_label_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:label id="lab_ameh_NumberOfPatients_documentation_en-US" xlink:label="lab_ameh_NumberOfPatients" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Patients</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients" xlink:href="ameh-20200930.xsd#ameh_NumberOfPatients"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfPatients" xlink:to="lab_ameh_NumberOfPatients" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0a7322c0-f957-4c29-bc34-a589034c8692_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_da193dac-8cc9-45a9-8066-a2b9c3590496_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueTable_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cdc7adac-6b66-45b4-bb2a-150703067c89_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_bc196e6d-1e02-4c4b-ad2d-7f9e3dd15934_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AmgIncMember_8c62dd95-5272-4b4a-bc76-e39aec0c19ba_terseLabel_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc</link:label>
    <link:label id="lab_ameh_AmgIncMember_label_en-US" xlink:label="lab_ameh_AmgIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AMG, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AmgIncMember" xlink:to="lab_ameh_AmgIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_b3de6b40-570a-4ef7-a0e7-8f46e159bacd_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_8ea4e7ca-19f6-4f37-8a7f-d75a05323478_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d698fc26-09d9-40bd-aa4a-e14aa1d301f1_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_e8d14a55-69f1-40e3-927f-220cb186bd1b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_a5f316a7-8a69-4284-bc3c-b19413d2cd6f_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_487f7267-cb3f-40f5-b404-cbaaa6249cf8_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of warrant</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_a440813d-8d2f-442f-9612-bc0836544514_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_acc9cd11-c66b-44ca-83d2-815d0a9fc1d6_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_0c80c73b-70e5-48ad-8bca-a68b8b4efd69_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_6d0ad1db-ec57-4144-8f8d-b037f07c3b20_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_4251906f-345f-4441-956f-e66dfbb93158_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MemberRelationshipsMember_c308ab9f-8bdb-498c-a65c-f7809a738496_terseLabel_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member relationships</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_label_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships [Member]</link:label>
    <link:label id="lab_ameh_MemberRelationshipsMember_documentation_en-US" xlink:label="lab_ameh_MemberRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Relationships</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember" xlink:href="ameh-20200930.xsd#ameh_MemberRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MemberRelationshipsMember" xlink:to="lab_ameh_MemberRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_dea39415-2e09-461b-bd72-47eabc1b76c2_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_b262794d-9356-48ec-aa01-02311fe45ed3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_441431ac-b67f-4bd3-bd44-a913b0fa8448_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_877f7586-2266-494f-8ae0-dade16cf3948_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_a682e7fd-f618-43fb-8fc2-cc27604864b7_verboseLabel_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables and Receivables &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_label_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables And Related parties Receivables Policy Text Block [Policy Text Block]</link:label>
    <link:label id="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_documentation_en-US" xlink:label="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Receivables and receivables from related parties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:href="ameh-20200930.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:to="lab_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_86739d82-38c2-4f83-8048-189cc5def5e2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_8d9e9347-e769-4776-9789-44b199b4f495_terseLabel_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Shareholders and Officers</link:label>
    <link:label id="lab_ameh_ShareholdersAndOfficersMember_label_en-US" xlink:label="lab_ameh_ShareholdersAndOfficersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders And Officers [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember" xlink:href="ameh-20200930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareholdersAndOfficersMember" xlink:to="lab_ameh_ShareholdersAndOfficersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_508dfcab-6323-46cf-a2a4-0fc550a0b9ba_verboseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_6ce80586-b4be-4019-b1ad-2c2144ba9e6f_terseLabel_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care, IPA</link:label>
    <link:label id="lab_ameh_AccountableHealthCareIPAMember_label_en-US" xlink:label="lab_ameh_AccountableHealthCareIPAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accountable Health Care IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountableHealthCareIPAMember" xlink:to="lab_ameh_AccountableHealthCareIPAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDefaultLongtermDebtAmount_6dc022b3-704c-456a-acdb-a4f651855340_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Default amount of debt instrument</link:label>
    <link:label id="lab_us-gaap_DebtDefaultLongtermDebtAmount_label_en-US" xlink:label="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Debt Default, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDefaultLongtermDebtAmount" xlink:to="lab_us-gaap_DebtDefaultLongtermDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_b11a12c3-62a4-4976-bbcb-d623b4e102bc_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_ff964ecf-d4c5-4bf9-9beb-b59ab63f01a1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_e0673e4b-09a7-4b5e-a4cb-ee664f864437_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common&#160;Stock&#160;Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_ee7e4713-2377-4047-be55-ea4dc9e67be9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">10% shares held back pursuant to indemnification clause</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_142a6d00-eeec-427f-a502-e8a85697aba8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_6c44051e-9166-4fba-b1b1-b065efdb194c_verboseLabel_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_label_en-US" xlink:label="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:href="ameh-20200930.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:to="lab_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_cb13ee26-fb98-48b2-a35d-4f616345677c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_71df94ea-f980-4717-b005-2d34ef390e84_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Equity Method Investment, Distribution, Return of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:to="lab_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_5d1eecc8-6f81-4368-87ad-a8f63536ab8e_terseLabel_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM</link:label>
    <link:label id="lab_ameh_NetworkMedicalManagementMember_label_en-US" xlink:label="lab_ameh_NetworkMedicalManagementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network Medical Management [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetworkMedicalManagementMember" xlink:to="lab_ameh_NetworkMedicalManagementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_b9aa0401-b9fa-4931-a71a-39999d5b91b1_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</link:label>
    <link:label id="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:to="lab_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_cb012199-dee0-48df-b02b-9323bdf24446_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_13c92c42-8b2b-4848-bb17-f4103c6bef63_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining lease term, finance</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_891add36-421f-4555-883f-d798bf41627f_verboseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0d7ab4ed-89cb-4e5b-a52e-df7fbd93994a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_1d4b4f1a-e264-4db9-9765-0314bce60998_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on loan receivable</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_a86a27ce-240f-45a6-8d29-ac5c434de874_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_d7b86e4e-bda9-4b0e-9b4e-5f950a466d55_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent" xlink:to="lab_us-gaap_DividendsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_9ee8d526-b9c3-4d10-8bbe-62d26bfd06fe_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableGross_f53cb32b-1720-4bb9-89e5-596b3a793d40_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, amount</link:label>
    <link:label id="lab_us-gaap_NotesReceivableGross_label_en-US" xlink:label="lab_us-gaap_NotesReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableGross" xlink:to="lab_us-gaap_NotesReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_531db761-144c-47c7-9f0e-6440829e0723_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeOneMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeOneMember" xlink:to="lab_ameh_WarrantExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_b407879e-85cc-4f97-b481-2d5380f1381f_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred shares received from sale of equity method investment</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:to="lab_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_82274edd-4549-4db6-b53a-43c119e949a9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_b3da526d-1f53-49f1-9a23-8fbbd5497904_terseLabel_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_PaymentsForMedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:href="ameh-20200930.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract" xlink:to="lab_ameh_PaymentsForMedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_2c11a705-1428-498a-ac9d-21408038d737_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio, annual decrease</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Incremental Change</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_7827bef7-d4bd-47dd-b52a-3ea04b350358_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_110a68aa-410c-41b1-a890-36e9944e7ec2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_003df971-ef6f-4a99-aab9-5f220599bebf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_17dfe624-8c1a-4d40-baab-8677b9ff376c_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares purchased from equity method investment entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquityMethodInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_244db9e2-3e8c-4445-8f1e-cfd7f512b32b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_f3625789-8e1a-44a6-b909-7886da81f190_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations and Goodwill</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_b2b8fe9a-e39a-46cb-be28-0114d985c4c6_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareTable_f12e7e98-c244-41d5-b15e-7f2b1921e5f0_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_label_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:label id="lab_ameh_EarningsPerShareTable_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareTable" xlink:to="lab_ameh_EarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_5585c122-9989-4608-8e25-bde9155f901c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_6bd2160d-4f6c-4b5b-b25a-3c4105b0aba4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_2bbfbd91-372e-4f5b-8170-c463f4847535_terseLabel_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General amount of guarantee (as a percent)</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_label_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Financial Guarantee Benchmark Amount</link:label>
    <link:label id="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_documentation_en-US" xlink:label="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of financial guarantee on benchmark Medicare expenditure amount.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:href="ameh-20200930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:to="lab_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_ccfecfdc-a1cb-4c0c-9e4f-f73523f70f78_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ebc0dedd-cee9-4531-8041-4bb1b1bf97f6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_e9ee42b0-f309-4314-a88d-62e9b2f095e2_terseLabel_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, termination period, if applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_label_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:label id="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_documentation_en-US" xlink:label="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Termination Period, If Applicable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:href="ameh-20200930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:to="lab_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c0a1556d-e2bf-436c-a7be-ab000e3752d8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_d0875b20-a54e-435c-93c5-b7326fd0d1b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_579dbc1b-ef48-4767-8b2a-392c4268d060_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_db19f544-142b-4a16-a967-ce7996cce02e_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_2189b94a-3b24-423a-8fc7-e28a98eea17b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_c7cf17a9-3c53-4ecd-bd1a-d6f2febb3e25_terseLabel_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_label_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:label id="lab_ameh_Pacific6EnterprisesMember_documentation_en-US" xlink:label="lab_ameh_Pacific6EnterprisesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific6 Enterprises [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember" xlink:href="ameh-20200930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_Pacific6EnterprisesMember" xlink:to="lab_ameh_Pacific6EnterprisesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_023730d5-d99a-4e3e-9a9d-4094149a5da5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_6de73d6c-0daa-482a-b159-e9aa3b614a83_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_bb4e0dca-773b-45de-8fdc-b41857188ab4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1cda70aa-8fde-4950-876e-6ee1df5de072_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangibles</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c14c6fe6-17fa-46a7-9e46-570f98ac326b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_f373dc7b-5d48-4885-b749-f5ea892f93bb_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_c234194e-fb71-4513-9bd5-95a0b5c323c7_terseLabel_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional subordinated note receivable agreements</link:label>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_label_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts And Other Receivables, Number Of Additional Agreements</link:label>
    <link:label id="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_documentation_en-US" xlink:label="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts And Other Receivables, Number Of Additional Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:href="ameh-20200930.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:to="lab_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_e397b812-8c46-4210-ac18-bde6cea628ed_verboseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the forfeiture rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_28e76b44-aef3-481e-b583-52007b4affc4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_ee235974-be58-49a9-997d-fad18a7b7139_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Value of shares transferred in acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f2c42ae0-a5cc-4ec9-9f64-053a1944f598_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_c6612895-6a96-4dd0-9a55-5fd56c3a594f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_faaeb757-4a7b-4745-9470-45af1650dbc3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrimeRateMember_1326fe64-1762-426d-83df-38727c28dc7c_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember" xlink:to="lab_us-gaap_PrimeRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_7530b071-eaa4-4b1a-aa34-8870e8fd0698_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_5c7f4d4f-d9dc-4a4f-a96d-1c322066f57b_verboseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized risk pool revenue</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_1c701691-45c4-475e-b6f5-72ba71ccc952_totalLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net total</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Other Revenues from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_46025a9c-7658-47ee-9106-f9bc14dcd622_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period shares of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents number of share issued exercise of option and warrants during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_12724c49-7fc4-43ae-b320-b4f2e1372082_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_45788cff-6ef2-4a0b-9969-0da95a0e2daf_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1884bf5e-5fed-49b6-8558-9a396be10ac5_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_d4905983-db0e-442c-bba1-b178bf6f9832_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_aca0f288-59fd-4b49-8e34-d585f754d742_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7b2194b9-4891-48f2-8a32-787dc3c415dc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_b332528a-8fe5-47be-bc11-f65bb3a9c103_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_087e451b-dbd8-43bd-9304-4782584aa511_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d13c7334-e6d5-439b-ad83-f91b900730d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_5391ad48-a839-47ef-bf96-bc11edef258a_terseLabel_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to claims incurred:</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_label_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:label id="lab_ameh_MedicalCareCostsAbstract_documentation_en-US" xlink:label="lab_ameh_MedicalCareCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Care Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract" xlink:href="ameh-20200930.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicalCareCostsAbstract" xlink:to="lab_ameh_MedicalCareCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_38386499-6f39-4742-b68f-7caff78bf1a1_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_5043df2f-d76a-4d22-825a-9c03e977b6f7_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_dc90328a-8b45-436f-a357-2bfe79ce5254_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from related parties</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_6abbc7ed-fed4-4f88-879a-3f95a8ccdadd_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_6e7755d0-43c3-4709-ab9a-fae40233cb1c_verboseLabel_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_label_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]</link:label>
    <link:label id="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_documentation_en-US" xlink:label="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:href="ameh-20200930.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:to="lab_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_4a0d0321-19b4-4829-a184-38be7c62e524_negatedTerseLabel_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of bank loan and lines of credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_label_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:label id="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit_documentation_en-US" xlink:label="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments Of Bank Loan And Lines Of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:href="ameh-20200930.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:to="lab_ameh_RepaymentsOfBankLoanAndLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_835f453c-f945-4f89-91ff-c119eacd3b06_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsRollForward_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward" xlink:to="lab_ameh_EquityMethodInvestmentsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_b6039882-d327-4112-b82c-d67714492349_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of debt and equity issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5bf91796-ffd3-45dd-9eaa-3bad2d46f47e_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_37902696-ecdf-4c4b-a5a7-66d9ba54ed4f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Medical Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2062c350-9b44-4a1d-88c6-98fd9fde09a4_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_53c53c0c-3ed8-44c6-b3a1-9f13c111f357_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_222514c3-015c-4a64-ae55-37b4dc523ee4_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reportable Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_7bacb507-88c9-4bac-b464-74bfaa30b004_terseLabel_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_label_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:label id="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_documentation_en-US" xlink:label="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:href="ameh-20200930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:to="lab_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_97224d80-d6a5-4da9-9bd8-e30e168a82ed_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of real estate</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireRealEstate_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Real Estate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireRealEstate" xlink:to="lab_us-gaap_PaymentsToAcquireRealEstate" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CreditAgreementMember_5a4b2c66-5092-45bd-96f8-0526e98b6b4b_terseLabel_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_label_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:label id="lab_ameh_CreditAgreementMember_documentation_en-US" xlink:label="lab_ameh_CreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember" xlink:href="ameh-20200930.xsd#ameh_CreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CreditAgreementMember" xlink:to="lab_ameh_CreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cecdf4d0-eaa9-415a-9051-dced8adccc67_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_92eb104f-c408-4705-b0ad-13eef192a702_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ab4ce163-5d1a-45dd-bf3f-ac50f8adfa84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_7eccd5bb-92af-4b33-9a21-65395a9a4250_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assets and Liabilities, Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_5471b293-685c-40b2-a796-c27b7754ae10_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceMember_5cebd19a-fce7-41d4-be7c-527a149bd67f_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fee income</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_83cbf53a-27f4-4596-be2f-8598f41896ec_verboseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Income Contract</link:label>
    <link:label id="lab_us-gaap_ManagementServiceMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceMember" xlink:to="lab_us-gaap_ManagementServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a588f6e3-47ff-4910-afca-a06c6b32ca74_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_a473180e-0990-4df8-bd9a-0b55b4e5b64b_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, beginning of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1b42023d-0645-4416-a3e3-1258b75b8223_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical liabilities, end of period</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_0232ff57-8e67-4424-9769-86d49d514e02_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_d6171f98-9967-4781-b4fe-fe87acafdb0c_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_fcd00c6e-23a8-4832-a74c-35ccb7a82171_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_15384bed-e8c2-4f0b-8365-d2eaf0f45c54_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale [Table Text Block]</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Gain On Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentGainOnSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:to="lab_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_b909164b-5b9e-48d2-ad1a-e3b1037370f3_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercisable (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Exercisable</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightExercisable_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightExercisable" xlink:to="lab_ameh_ClassOfWarrantOrRightExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_9352dfc0-20e9-417b-a7be-6ee29be105a5_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_f7b23593-81b3-4ddd-bc06-f6d7f271eae7_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_fce092ca-156f-4995-83df-6086f6879c21_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f42f05ad-cd1d-4f60-9d82-a8d09f970bb5_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_523aeaee-6584-4ea2-891a-4162cef8a701_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e8468707-8d9a-4bcd-8e59-8d80a008e172_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_0d6b8c85-b95b-4d42-a042-a6027b8a1626_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names/trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_5a47eb0f-edf5-4e30-b0e1-eb8c75f50403_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_a729ecb1-ea54-4267-a3fd-163c369c3f99_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_fcf0ac9a-ed2b-436f-aff5-70d545db36bb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c764d64d-e871-4410-ad17-9ab2c3138cdc_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_3e1d6bee-35b6-4010-be7b-7ff428303181_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_9c9c2353-6672-4c80-ba05-ad7c2ea7bc02_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_fa55c96b-6fdc-4b28-921d-bd1555b52c83_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentsContribution_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentsContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentsContribution" xlink:to="lab_ameh_EquityMethodInvestmentsContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_24477432-12f0-4453-9764-11f07332c168_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_ab829b8a-9563-4d85-a0c5-eb7ebd9b8965_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6d8433ef-b8c6-45cd-a8c7-640beb9a6d64_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2633fa47-6e3b-49e0-9079-8503e7668b74_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_3130636f-e122-4900-8c79-73a2c3baa460_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_ce2aa7e2-b13e-40e9-a71c-dda3c97aad38_terseLabel_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc</link:label>
    <link:label id="lab_ameh_ApolloMedicalHoldingsIncMember_label_en-US" xlink:label="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Apollo Medical Holdings, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:href="ameh-20200930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApolloMedicalHoldingsIncMember" xlink:to="lab_ameh_ApolloMedicalHoldingsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_783e116c-a48d-4f3d-841a-da72e0afdce1_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Eight Fiscal Quarters Thereafter</link:label>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Two [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodTwoMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodTwoMember" xlink:to="lab_ameh_PaymentPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_48ca16d8-e1ff-4fcc-9fca-9d44e769c123_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DmgMember_7f89c767-e235-4fc4-8541-fb52b57980c5_terseLabel_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG</link:label>
    <link:label id="lab_ameh_DmgMember_label_en-US" xlink:label="lab_ameh_DmgMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DMG [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember" xlink:href="ameh-20200930.xsd#ameh_DmgMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DmgMember" xlink:to="lab_ameh_DmgMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_55843cc0-414b-4563-9055-c3269dac7768_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_6b373811-48ea-4be8-bf71-5d1794014260_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DrJayLoanMember_f20c8100-e16f-4aeb-8a5b-941bb20c917f_terseLabel_en-US" xlink:label="lab_ameh_DrJayLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay Loan</link:label>
    <link:label id="lab_ameh_DrJayLoanMember_label_en-US" xlink:label="lab_ameh_DrJayLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dr. Jay Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember" xlink:href="ameh-20200930.xsd#ameh_DrJayLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DrJayLoanMember" xlink:to="lab_ameh_DrJayLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityTerminatedAmount_d2ad9443-2f47-47d0-8b7f-f39345a3c950_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit, amount terminated</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityTerminatedAmount_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terminated, Amount</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityTerminatedAmount_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityTerminatedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Terminated, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityTerminatedAmount" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityTerminatedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityTerminatedAmount" xlink:to="lab_ameh_LineOfCreditFacilityTerminatedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_d78802a2-3d6f-4426-b9f1-da128d38cbe1_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests acquired (in dollars per share)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_1bab8ae9-821e-4c2e-8d36-26842f557887_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_ad155563-1654-4873-8694-40089715f11b_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_374c0719-6a13-48a8-ace8-4cde068fa302_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_fe64a119-ee9a-49ae-942d-4739f785823f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under agreement</link:label>
    <link:label id="lab_us-gaap_DeferredCreditsAndOtherLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Credits and Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:to="lab_us-gaap_DeferredCreditsAndOtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_8f13fc81-40f8-4c99-946a-6f5d0fe79de2_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_adae9771-d3df-43b7-b382-6dfca65836d8_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_bf59842a-029e-4058-a1c2-e07f3845b899_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease cost, net</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_d19cfa63-4421-4324-80e9-a4c9f9f77d52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments &#8211; equity method</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_3da8a9e5-abf0-4a55-8b43-6656afe003bf_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash consideration paid for ownership interest</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9573d2f2-2ac5-4ff4-a314-70a0f9b22e4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_fe309044-3dca-42e3-b00e-dd81c0ab87dc_terseLabel_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares held back pursuant to indemnification clause (as a percent)</link:label>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_label_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Held Back To Secure Indemnification, Percentage</link:label>
    <link:label id="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_documentation_en-US" xlink:label="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Shares Held Back To Secure Indemnification, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:to="lab_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MediPortalLLCMember_0ac82d81-e71b-4923-af87-70e4a69275c7_terseLabel_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC</link:label>
    <link:label id="lab_ameh_MediPortalLLCMember_label_en-US" xlink:label="lab_ameh_MediPortalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MediPortal LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember" xlink:href="ameh-20200930.xsd#ameh_MediPortalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MediPortalLLCMember" xlink:to="lab_ameh_MediPortalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_8090f38e-425d-4299-96da-8801dd6a94ae_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash &#8211; current</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_512c7fc0-50e4-45a3-ab63-3848ba907658_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_117a05df-49c7-4587-80ca-37835706728b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9b29278f-d295-4946-b2bd-938c29b4bf67_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_c8ac836d-a801-4c47-803f-d620483c79b7_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights forfeited during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_f68ea301-554c-4b25-9ca3-2ef634eff115_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market value of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_18c24145-f87a-47dc-bd46-85920c7a2b4b_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_d71f5849-7f12-42ca-9378-4acd3fbdc901_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_7da1040b-39e6-454c-9e20-3e55c9b31449_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants expired/forfeited</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights forfeited in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_018a3c75-3df5-4e45-af15-d32ca86af30f_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss (gain) from investment in equity securities</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ManagementContractsMember_ad365888-e3cd-475e-9308-e7fc160a3b64_verboseLabel_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management contracts</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_label_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts [Member]</link:label>
    <link:label id="lab_ameh_ManagementContractsMember_documentation_en-US" xlink:label="lab_ameh_ManagementContractsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember" xlink:href="ameh-20200930.xsd#ameh_ManagementContractsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ManagementContractsMember" xlink:to="lab_ameh_ManagementContractsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_4eef3a62-ceb4-4394-8f19-b81c5f906b71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings on line of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_41ec663f-0d9a-47df-9db2-a678cb902c8f_terseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates &#8211; IPA Line of Business</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_e54c2d49-85e2-4caf-9a45-9103becf1586_verboseLabel_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates</link:label>
    <link:label id="lab_ameh_LasalleMedicalAssociatesIpaMember_label_en-US" xlink:label="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LaSalle Medical Associates IPA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LasalleMedicalAssociatesIpaMember" xlink:to="lab_ameh_LasalleMedicalAssociatesIpaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_5c236b7d-9e2f-461e-a3cd-e88af90015bd_terseLabel_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_MWNCommunityHospitalLLCMember_label_en-US" xlink:label="lab_ameh_MWNCommunityHospitalLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MWN Community Hospital LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember" xlink:href="ameh-20200930.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MWNCommunityHospitalLLCMember" xlink:to="lab_ameh_MWNCommunityHospitalLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_6d63511a-88d1-4e96-a373-0ce728316b60_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_3771a1ca-4122-49bc-bee5-9a9bd50ace37_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_f6724fbe-f954-4a1d-9801-03097c81d366_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HSMSOMember_098c5410-5192-45da-ba3f-a3f266a61183_verboseLabel_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO</link:label>
    <link:label id="lab_ameh_HSMSOMember_label_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HSMSO [Member]</link:label>
    <link:label id="lab_ameh_HSMSOMember_documentation_en-US" xlink:label="lab_ameh_HSMSOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_HSMSO Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember" xlink:href="ameh-20200930.xsd#ameh_HSMSOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HSMSOMember" xlink:to="lab_ameh_HSMSOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e89a6903-7d28-4203-948a-14b3a6d49c7d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_VotingCommonStockTwoMember_c28864b6-5302-4a6e-93e0-6108ac61240c_terseLabel_en-US" xlink:label="lab_ameh_VotingCommonStockTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Common Stock A Two</link:label>
    <link:label id="lab_ameh_VotingCommonStockTwoMember_label_en-US" xlink:label="lab_ameh_VotingCommonStockTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Voting Common Stock A Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember" xlink:href="ameh-20200930.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_VotingCommonStockTwoMember" xlink:to="lab_ameh_VotingCommonStockTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_9a2b38aa-8a2a-4e04-ae6f-92efdf2df78b_terseLabel_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_ameh_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_ameh_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_85f55a13-2ade-4584-aa65-f29b63e889ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from common stock offering</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AurionMember_22b50b57-f90e-4c61-9515-a6e08667cdd1_verboseLabel_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion</link:label>
    <link:label id="lab_ameh_AurionMember_label_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurion [Member]</link:label>
    <link:label id="lab_ameh_AurionMember_documentation_en-US" xlink:label="lab_ameh_AurionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">xxx_Aurion Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember" xlink:href="ameh-20200930.xsd#ameh_AurionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AurionMember" xlink:to="lab_ameh_AurionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_5a5603f0-d04f-4db1-9dca-97432e05f03d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2d0d3503-f094-4ad4-9e3a-371ce90a9469_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share Computations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_7421bc6d-3576-4206-a2fd-f8c606fdd3fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_f266f3b6-9a6d-4eca-b7ac-0e4411abcb55_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of family practice clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_label_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Family Practice Clinics</link:label>
    <link:label id="lab_ameh_NumberOfFamilyPracticeClinics_documentation_en-US" xlink:label="lab_ameh_NumberOfFamilyPracticeClinics" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Family Practice Clinics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics" xlink:href="ameh-20200930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFamilyPracticeClinics" xlink:to="lab_ameh_NumberOfFamilyPracticeClinics" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_c26fb6d9-324d-4d11-910b-de98f27b718b_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_29942994-9cb3-467a-ad2b-4f3511a277bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_a0e64301-8195-46de-9c1e-79a0af2cb576_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_label_en-US" xlink:label="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Support to Nonconsolidated Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="lab_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_57527a18-0b75-4ba6-99b2-848ea82bf09f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_166d9988-fe37-452d-bca3-4dbe26160fab_totalLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_2205e282-0517-4cf0-8152-0c00584a214b_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_33a80e67-46bc-4869-8d87-02fb3c5656de_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_aeafbec9-238a-410a-8e64-dc56387fed9e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_dcf5b03c-434d-4b05-ad15-c8f1a8f55adb_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_007eb665-366d-483f-91bf-a56e6766f69c_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_1b556a4d-449f-441a-b8a0-8d3423147118_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_e62d36dd-ef61-47da-922e-d19150a48854_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of main reporting units</link:label>
    <link:label id="lab_us-gaap_NumberOfReportingUnits_label_en-US" xlink:label="lab_us-gaap_NumberOfReportingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reporting Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportingUnits" xlink:to="lab_us-gaap_NumberOfReportingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8bffccdd-0bc3-4ed7-b3cb-db53a473ebb4_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineEquityAbstract_1d781f5f-d709-4019-b883-808af69f607e_verboseLabel_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine equity</link:label>
    <link:label id="lab_ameh_MezzanineEquityAbstract_label_en-US" xlink:label="lab_ameh_MezzanineEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MEZZANINE EQUITY [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract" xlink:href="ameh-20200930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineEquityAbstract" xlink:to="lab_ameh_MezzanineEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_55850905-0bdc-40c1-b73a-b5d5bf6c45c8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_ea4adf4f-c075-46e0-aa8f-e9216e762fd2_terseLabel_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary accounts payable</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_label_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiduciary Accounts Payable Current</link:label>
    <link:label id="lab_ameh_FiduciaryAccountsPayableCurrent_documentation_en-US" xlink:label="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiduciaryAccountsPayableCurrent" xlink:to="lab_ameh_FiduciaryAccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_6546c63c-3774-4cc9-957a-e446fc6d590c_terseLabel_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding stock convertible</link:label>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_label_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</link:label>
    <link:label id="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_documentation_en-US" xlink:label="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:href="ameh-20200930.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:to="lab_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_d220306c-853c-4678-8b95-a7dbee211f26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_bdef0ca8-781c-42ec-8bb8-5abae4344987_terseLabel_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc</link:label>
    <link:label id="lab_ameh_MaverickMedicalGroupIncMember_label_en-US" xlink:label="lab_ameh_MaverickMedicalGroupIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maverick Medical Group, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember" xlink:href="ameh-20200930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MaverickMedicalGroupIncMember" xlink:to="lab_ameh_MaverickMedicalGroupIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_ddec6a21-dc42-46cb-ae7a-7e0ac7286c84_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposit for potential post-closing adjustments</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_77ef590d-658b-49cf-9762-20292355c63a_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum consolidated interest coverage ratio (not less than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_e4ee057c-9da7-44c6-b44a-53f2a77671fd_negatedTerseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancellation of restricted stock awards</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Cancelled</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Cancelled</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:to="lab_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorCMember_f1b238ce-fbfe-4750-9230-1189af830e89_terseLabel_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C</link:label>
    <link:label id="lab_ameh_PayorCMember_label_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:label id="lab_ameh_PayorCMember_documentation_en-US" xlink:label="lab_ameh_PayorCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor C [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember" xlink:href="ameh-20200930.xsd#ameh_PayorCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorCMember" xlink:to="lab_ameh_PayorCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_992b548e-d43c-4f05-85fd-542c29224dd0_terseLabel_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:label id="lab_ameh_AccountsReceivableAndNetRevenueLineItems_label_en-US" xlink:label="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable And Net Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:to="lab_ameh_AccountsReceivableAndNetRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_1028d5bf-5c04-4a93-9d19-0e1f91f59822_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_6451593c-0f6c-4934-8860-bd00b176b7bd_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_6b13696d-7848-456c-8df1-b4019c0c642a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Line of Credit Facilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:to="lab_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcStockOptionMember_46fe2e98-79c8-436c-817f-7dbb8ca67ea3_terseLabel_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option</link:label>
    <link:label id="lab_ameh_ApcStockOptionMember_label_en-US" xlink:label="lab_ameh_ApcStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember" xlink:href="ameh-20200930.xsd#ameh_ApcStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcStockOptionMember" xlink:to="lab_ameh_ApcStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_69ec7e5e-334c-46b3-a828-4fbd1822a8e6_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_88c9914f-52b6-4105-80e8-d5412fef8c35_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_80859878-a5be-421e-bb31-9899287fbc9f_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_30c686d1-995e-42fa-9a23-fab76152bd4b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_993abd69-bbac-48bf-a78f-2cc4ca7207b3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AHMCMember_34a9c9d8-f891-4639-9bcd-f62caabe4db5_terseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_22cfda47-29f5-43c9-ae65-14faac375d5e_verboseLabel_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC</link:label>
    <link:label id="lab_ameh_AHMCMember_label_en-US" xlink:label="lab_ameh_AHMCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AHMC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember" xlink:href="ameh-20200930.xsd#ameh_AHMCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AHMCMember" xlink:to="lab_ameh_AHMCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8955a776-ca4a-491a-8583-7f502596b9d1_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_07ec699e-d801-40c1-aebd-b4de1af5f592_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_ea690029-94e7-4b7f-b0cb-04fc99ccdbd2_verboseLabel_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease liabilities:</link:label>
    <link:label id="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_label_en-US" xlink:label="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:href="ameh-20200930.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:to="lab_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilities_08616e73-ae2a-4855-9182-ece96dae73db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilities_label_en-US" xlink:label="lab_us-gaap_OtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilities" xlink:to="lab_us-gaap_OtherLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_e5e67125-348e-4922-a71f-56fa2232d858_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock subscriptions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_6aadba46-3c51-4aa7-911a-be644813ccfa_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_13c5c971-e56b-4ab9-bbac-80a2e34d32df_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_b33dabb5-6ca8-487f-a4bb-7b82ca799ec9_verboseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, maturity period</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_label_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:label id="lab_ameh_FinanceReceivableTermOfReceivable_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableTermOfReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Term Of Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableTermOfReceivable" xlink:to="lab_ameh_FinanceReceivableTermOfReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfStores_265937b5-8844-4c55-a9b6-b0c6e6989bf4_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of medical centers</link:label>
    <link:label id="lab_us-gaap_NumberOfStores_label_en-US" xlink:label="lab_us-gaap_NumberOfStores" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Stores</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfStores" xlink:to="lab_us-gaap_NumberOfStores" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_67e7d5c2-c362-4210-a580-b4505c995019_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_165f6c84-e4f1-4830-b59d-cefa68f04754_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_1ddf0858-9945-4877-9be6-9931fb032797_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_InvestmentDeposit_df62b699-f7b3-4c5c-8a6a-38da5aeaae36_terseLabel_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment deposit</link:label>
    <link:label id="lab_ameh_InvestmentDeposit_label_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Deposit</link:label>
    <link:label id="lab_ameh_InvestmentDeposit_documentation_en-US" xlink:label="lab_ameh_InvestmentDeposit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit" xlink:href="ameh-20200930.xsd#ameh_InvestmentDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_InvestmentDeposit" xlink:to="lab_ameh_InvestmentDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_753ab6f2-4a2a-4ea4-897a-0fd4a0671c25_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_d90cffb0-0fb9-4e70-a41e-1b0f713dd9dd_terseLabel_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright</link:label>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_label_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Company Of California, Inc. [Member]</link:label>
    <link:label id="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member_documentation_en-US" xlink:label="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bright Health Company Of California, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:to="lab_ameh_BrightHealthCompanyOfCaliforniaInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_1dee7af6-a6eb-4fff-b065-bf902d4f4be1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_41a2c630-b296-48ee-a7a6-aa7a9d5d7a32_terseLabel_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liability repaid, capitation received and not earned</link:label>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_label_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Repaid Capitation Received And Not Earned</link:label>
    <link:label id="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_documentation_en-US" xlink:label="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Repaid, Capitation Received And Not Earned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:href="ameh-20200930.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:to="lab_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_2bfbaa4d-38fb-4f31-a233-3c86a626d471_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for cashless exercise of warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_ff51ad27-253c-4c3e-bfc7-944c8d44bad2_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_79e4bace-c540-402e-82e1-e6c733647e7f_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_4f61ba6e-ed31-41aa-83ba-8f51d1bfeb76_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_78844778-e375-40b8-91f7-cbd154df59bc_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_7b97e90b-b3e9-4aaa-a306-ea1c72224a0a_terseLabel_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc.</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_label_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AlphaCareMedicalGroupInc.Member_documentation_en-US" xlink:label="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alpha Care Medical Group, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AlphaCareMedicalGroupInc.Member" xlink:to="lab_ameh_AlphaCareMedicalGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_68cc1229-9cf6-4f91-a60d-32988aeb307b_terseLabel_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_label_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member]</link:label>
    <link:label id="lab_ameh_CollegeStreetInvestmentLpMember_documentation_en-US" xlink:label="lab_ameh_CollegeStreetInvestmentLpMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">College Street Investment LP [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember" xlink:href="ameh-20200930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CollegeStreetInvestmentLpMember" xlink:to="lab_ameh_CollegeStreetInvestmentLpMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_44aa2725-70b1-46e2-8280-9fffc80f913e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_659680d8-c0ef-4455-ae68-a29ed560dcb3_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued contract liability recognized</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1ca04719-9843-442e-947b-bb034c27f5f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_c9933f8c-2fae-472b-8603-d39ffd714712_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related investment balance</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_a4d5b715-9ecd-4f01-a3ce-7fb290847415_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date fair value of restricted stock to be recognized straight-line</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_d78773df-1c83-48fd-89dc-9edd3e7e32cb_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Membership interests purchased (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_90defd83-7984-4933-810e-6147551e88ce_verboseLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents increase in operating lease assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:to="lab_ameh_IncreaseDecreaseInOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e2ab8188-a796-422e-91c9-50ef5349bc92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a587f1c7-02b1-406a-a4b1-f94bcd99def0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_3352c3f3-444d-48d1-8dc0-d6a0f34c2914_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0c165d9a-6c64-48bd-b16c-492bc7674f73_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3e3e4310-0ae5-4d25-9130-c48e39c74f96_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_f246f213-1a82-4886-bd6d-95fba9dee5ed_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, fair value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_5ba91f25-bd42-4a6b-af82-a57bb3e37054_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per share of warrants or rights granted during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LoanReceivableTextBlock_81c2e07d-7bcd-472e-878f-bc22954d16dc_verboseLabel_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable and Loan Receivable &#8211; Related Parties</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_label_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable [Text Block]</link:label>
    <link:label id="lab_ameh_LoanReceivableTextBlock_documentation_en-US" xlink:label="lab_ameh_LoanReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock" xlink:href="ameh-20200930.xsd#ameh_LoanReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LoanReceivableTextBlock" xlink:to="lab_ameh_LoanReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_1c1133b9-9652-4f62-a64e-3462fa6b1dd3_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_93195ef1-21d8-4984-81dd-cc116fdfe684_terseLabel_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc.</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_label_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:label id="lab_ameh_HealthSourceMSOInc.Member_documentation_en-US" xlink:label="lab_ameh_HealthSourceMSOInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Source MSO Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member" xlink:href="ameh-20200930.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_HealthSourceMSOInc.Member" xlink:to="lab_ameh_HealthSourceMSOInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumenLLCMember_65ca8174-bbf8-4bf3-91c6-913db9ca2698_terseLabel_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC</link:label>
    <link:label id="lab_ameh_NumenLLCMember_label_en-US" xlink:label="lab_ameh_NumenLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numen LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember" xlink:href="ameh-20200930.xsd#ameh_NumenLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumenLLCMember" xlink:to="lab_ameh_NumenLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_22c13c23-7201-4e2e-8f2b-995f86803cfa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_1f2a0b61-164e-404b-871f-99743d581454_terseLabel_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_ameh_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems" xlink:to="lab_ameh_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_6c1f3019-2fdb-4e21-8aa4-2815e97d8dce_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SCHCMember_2baea6b3-a65e-4656-8c84-5913d419c51d_terseLabel_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC</link:label>
    <link:label id="lab_ameh_SCHCMember_label_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:label id="lab_ameh_SCHCMember_documentation_en-US" xlink:label="lab_ameh_SCHCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCHC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember" xlink:href="ameh-20200930.xsd#ameh_SCHCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SCHCMember" xlink:to="lab_ameh_SCHCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LmaMember_56f213db-b545-4c8d-82b4-c0c3e75e0d3b_terseLabel_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA</link:label>
    <link:label id="lab_ameh_LmaMember_label_en-US" xlink:label="lab_ameh_LmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LmaMember" xlink:to="lab_ameh_LmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_e4c8aaeb-4ed6-4bf4-8712-f2aed43c2f2c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of long-lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_ff748eba-25df-438c-acdd-2f17de2592c7_terseLabel_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_label_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:label id="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_documentation_en-US" xlink:label="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:href="ameh-20200930.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:to="lab_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_df48cdc7-6ee0-480f-bc8c-cda5c8883f6a_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_955ec454-7882-441d-acb8-a45a18db7b14_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_1fce751a-bf33-4a8d-a682-d4e26ed12133_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_890046d5-31f6-4b2c-bf0b-ae547557f716_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total medical care costs</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_b25f5922-388c-4796-9b4f-29cbec93a3f3_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_4da4d9a3-0ac3-4b0b-80a8-41bb7ac548d3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_6cf40370-b128-4edd-959d-01bfed522ff6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_d386636f-15e8-42e5-bf69-ee81ceb516ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b095d523-55f8-4555-9567-f92777a35a74_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MedicareMember_47a74841-ecad-4741-835b-f72cc8242d7f_terseLabel_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ameh_MedicareMember_label_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ameh_MedicareMember_documentation_en-US" xlink:label="lab_ameh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ameh:MedicareMember</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember" xlink:href="ameh-20200930.xsd#ameh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MedicareMember" xlink:to="lab_ameh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_6c18a8d9-7c42-4efe-a44c-05930aa04513_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_CMSMember_23c3d324-5a51-4a6b-9b33-4affaa0b479f_terseLabel_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS</link:label>
    <link:label id="lab_ameh_CMSMember_label_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:label id="lab_ameh_CMSMember_documentation_en-US" xlink:label="lab_ameh_CMSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CMS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember" xlink:href="ameh-20200930.xsd#ameh_CMSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_CMSMember" xlink:to="lab_ameh_CMSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_3a6f4c97-8b4d-4d3d-9141-fdff91f794d1_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_66b851e5-0847-4194-82a5-e858eb5fc3f7_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_92ccfb4c-c445-4c85-a699-fc3664f09fe2_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_636927b4-b474-4b40-9610-4cdb13aaa50f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_969c4224-e3fc-46e5-863b-72bf77fbdc91_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of treasury shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e16c4510-5d3e-4278-a8d4-ea2d05808189_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_72764e90-db80-46dd-87ff-400587c5b94f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_e349937e-9097-48a0-894b-46fc89bc81d9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_3c35a89a-6d16-41af-9a3d-e6555444daa7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net &#8211; related party</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_fa37106e-8b46-4059-8848-dfaec3e53aa4_terseLabel_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments received, monthly</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_label_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:label id="lab_ameh_PaymentOfRevenueMonthlyAmount_documentation_en-US" xlink:label="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Of Revenue, Monthly Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentOfRevenueMonthlyAmount" xlink:to="lab_ameh_PaymentOfRevenueMonthlyAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_90a00de1-8018-41ec-be36-c6cb48df4f01_verboseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregated Revenue by Each Payor Type</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RiskPoolSettlement_37f19e46-df0c-448d-a97c-f393b6f173e6_terseLabel_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlement</link:label>
    <link:label id="lab_ameh_RiskPoolSettlement_label_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Settlement</link:label>
    <link:label id="lab_ameh_RiskPoolSettlement_documentation_en-US" xlink:label="lab_ameh_RiskPoolSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk Pool Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RiskPoolSettlement" xlink:to="lab_ameh_RiskPoolSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_ab0e38b6-3bfb-410e-aad8-3dedc34dee4b_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_d28b4f37-8f16-41e4-a7e5-4f04db525e5c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of subordinated note receivable agreement</link:label>
    <link:label id="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts and Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:to="lab_us-gaap_AccountsAndOtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_AchievaMedInc.Member_00c3548c-8922-4db4-9cfd-234dd9d7f117_terseLabel_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc.</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_label_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:label id="lab_ameh_AchievaMedInc.Member_documentation_en-US" xlink:label="lab_ameh_AchievaMedInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AchievaMed, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member" xlink:href="ameh-20200930.xsd#ameh_AchievaMedInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_AchievaMedInc.Member" xlink:to="lab_ameh_AchievaMedInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_0d9561ac-4eb4-46c1-84fa-cf3b8362a202_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in privately held entities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI and without Readily Determinable Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:to="lab_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_bb18b54a-19ed-4aee-9ab5-b2972e1c0245_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_01f8c252-e27a-4a1d-95b8-15ef7b0ecdb3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e14d392c-28b9-45a9-976d-a2cb88492230_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_53d4520f-cfc3-4a96-9370-8d7a0b181bb2_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Approved use of funds (not to exceed)</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_label_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approved Threshold Use Of Funds</link:label>
    <link:label id="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Approved Threshold Use Of Funds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:to="lab_ameh_DebtInstrumentApprovedThresholdUseOfFunds" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_54ad21aa-cf2f-4d93-8fe1-af1a4cdbc342_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_cc57cba2-5b9d-48c0-9c4f-2508ecaee28a_terseLabel_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract_label_en-US" xlink:label="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Contractual Term Years [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:href="ameh-20200930.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:to="lab_ameh_WeightedaverageremainingcontractualtermyearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_7a09dc6c-eb98-4779-ad74-f5b2a8541722_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_e551ebd5-fcf7-4e35-bdc8-e15a80678abe_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable &#8211; related parties</link:label>
    <link:label id="lab_us-gaap_NotesReceivableRelatedPartiesCurrent_label_en-US" xlink:label="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable, Related Parties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:to="lab_us-gaap_NotesReceivableRelatedPartiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_be069df7-c4dd-4142-9f9d-280b06f165ab_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_400772e3-03e2-4e3d-ac5c-7eeab4fe0b76_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e767d87e-5a3d-4abb-bc76-0dae43f424b8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_e74104ce-0dd0-45b8-a2e8-a426c40f6393_terseLabel_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Note receivable, interest rate</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_label_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_ameh_FinanceReceivableInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Receivable, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:to="lab_ameh_FinanceReceivableInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_92953bf7-3ca3-43ec-8fa6-b2689a78a004_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_492beb69-1373-4d83-ab71-4a9c69df2cc6_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_4f74f3f8-c81a-458f-a491-c46b435d4c73_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_70e0b229-e03f-41e8-b314-0be988acdd99_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_1ee43db0-64af-4963-bf55-b3e40400cba9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_7c3122c0-9ae7-4160-b2b3-2ff2a4e05676_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_0793713d-ba74-4422-9e83-86e2a0993d50_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_21e329d3-b589-4f8f-ae34-4ac576140556_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f0512882-a359-4ce0-b78a-14e4db825cfe_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorDMember_0172b911-8660-49db-9548-1e67b8d48c34_terseLabel_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D</link:label>
    <link:label id="lab_ameh_PayorDMember_label_en-US" xlink:label="lab_ameh_PayorDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor D [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember" xlink:href="ameh-20200930.xsd#ameh_PayorDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorDMember" xlink:to="lab_ameh_PayorDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_7cd2201a-b7ad-4071-875b-cfb01d6d6e5f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_35af5740-0497-446b-be66-236bf5e2e8a1_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_f6703e35-ab0f-4fd2-a2a3-1c52cb476bfd_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_2d28ff98-059f-4e9b-9356-1ccf1dc85dc0_terseLabel_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC</link:label>
    <link:label id="lab_ameh_UniversalCareAcquisitionPartnersLlcMember_label_en-US" xlink:label="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Universal Care Acquisition Partners, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:to="lab_ameh_UniversalCareAcquisitionPartnersLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_345162a3-6597-4b86-9d78-4f3619c3049e_terseLabel_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number federally qualified health plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_label_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:label id="lab_ameh_NumberOfFederallyQualifiedHealthPlans_documentation_en-US" xlink:label="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Federally Qualified Health Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:href="ameh-20200930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:to="lab_ameh_NumberOfFederallyQualifiedHealthPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b7d52674-0761-4b56-958b-5430d6882cf3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_1663cf18-075d-4e22-9a29-0bd1fff4e8a6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_832d5772-feb5-45a7-9cdd-afbf0b4969c5_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b598930d-2e90-41bb-9c8e-49c3c1364a3b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2fc64aa5-d5f5-4433-ab00-a349fabca86d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3c5cd1f7-77ad-40cd-ab71-e56d9cdcb17a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_282ad93a-970e-4a1a-b5f8-bfe5cbf713a0_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_675e30f3-fb44-4621-a943-de761a1fc049_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Option Transactions Under Stock Option Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_96ba143c-5e08-4abb-947c-6193366d998e_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeThreeMember" xlink:to="lab_ameh_WarrantExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_8d37e41a-b9aa-4c5d-919c-c5848ff3960d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required annual facility fee</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_52676342-7d23-4553-b9f0-1f08e4bdc2a3_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Outstanding (in shares)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_label_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Issued In Period</link:label>
    <link:label id="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:to="lab_ameh_ClassOfWarrantOrRightIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a5571c79-912a-46c5-bbf9-5c96d36232a8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the nine months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4b3fad57-001d-4cbb-9ded-c27f81ebd36d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_fd1dfbc7-6ff6-4431-a6b8-70cb83b74eb9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease option to extend (up to)</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_1b6527a2-6227-46d7-a27e-4d423db7f584_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_0f95857e-280e-4a99-95e2-0ebb0b1f3c51_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of cashless warrants (in shares)</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Cashless Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:to="lab_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_b51284ee-9d57-44d0-b229-e6226f9432ac_negatedLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_5781c52e-d6a3-409d-b591-a3e0843e28c1_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_d644c40f-443a-4693-99f3-e0a73021fcd7_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_fd347de2-456f-4c17-ab1c-a628310f46a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_f04c1ae9-c63e-49d7-8a05-dc6fc901f913_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_d2e71039-05b8-422f-b405-e50ac4d024bf_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Discount Rate</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageDiscountRateAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Discount Rate [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:href="ameh-20200930.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:to="lab_ameh_LeaseWeightedAverageDiscountRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_5f169d74-bab3-4b7f-abd4-8991654ee956_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e6972881-9531-4ef9-bfab-9852043fac71_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2904aa3d-a39f-4cfb-9048-ed59bc71efc5_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_827c94d1-6697-4b63-9832-2631c50420fe_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_59c91162-c036-4fe9-b682-f37d39359193_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_a5d1ff74-a953-44da-832f-ba22fea610b5_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EarningsPerShareLineItems_33aa89e4-d13f-4e6a-9fc0-94a7d9bd5556_terseLabel_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_label_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_ameh_EarningsPerShareLineItems_documentation_en-US" xlink:label="lab_ameh_EarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Line Items] for Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EarningsPerShareLineItems" xlink:to="lab_ameh_EarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_3f6df018-420b-44d2-90e4-4e1f8e3bbdf2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Contributions to Revenue and Receivables by Payor</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_8993e9df-b2f5-4dd8-94a9-d83d06716551_terseLabel_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount due to affiliate</link:label>
    <link:label id="lab_us-gaap_DueToAffiliateCurrent_label_en-US" xlink:label="lab_us-gaap_DueToAffiliateCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Affiliate, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToAffiliateCurrent" xlink:to="lab_us-gaap_DueToAffiliateCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_774e77dc-2a06-47b3-8e02-4c49815cfe89_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_bbde0575-3a56-401f-ab56-8f0c8a2fa1c7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_2c7ad36f-9293-4489-a30b-773d6998b06d_terseLabel_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:label id="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_a5faa927-de69-45c0-a41d-6bd081c0e028_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WorkingCapitalContribution_a76afead-f2c1-44ac-8305-33d205967791_terseLabel_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working capital contribution</link:label>
    <link:label id="lab_ameh_WorkingCapitalContribution_label_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Working Capital Contribution</link:label>
    <link:label id="lab_ameh_WorkingCapitalContribution_documentation_en-US" xlink:label="lab_ameh_WorkingCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the working capital contribution in equity method investee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution" xlink:href="ameh-20200930.xsd#ameh_WorkingCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WorkingCapitalContribution" xlink:to="lab_ameh_WorkingCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_108e1577-7f6e-4bb6-949f-832d87794354_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_3abc075f-e155-452d-b7a3-725e7842db61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_be06507b-b9ff-485f-8c5f-21e9cb64c72d_negatedLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_8ee432fe-e917-414e-9d9d-c2935d85bd7b_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_3a486bbd-f007-4e17-b577-6da306b5a7e7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Timing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfTiming" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_cc3ba787-ec77-4270-9b15-f7d4a8b4f35e_terseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_975137d2-d935-4e36-9d5c-eaaba47283c7_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan receivable</link:label>
    <link:label id="lab_us-gaap_NotesAndLoansReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:to="lab_us-gaap_NotesAndLoansReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_190554ee-eaed-4e73-9a20-72852cd43b85_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, cash held in escrow</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Sale, Contingent Consideration, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:to="lab_ameh_EquityMethodInvestmentSaleContingentConsiderationCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_e36f8d62-9185-4948-87c6-3e2aeedf55b3_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_2da66dc8-cff5-4723-bb8f-0abafaa6117f_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment to goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Adjusted To Goodwill</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Adjusted To Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:href="ameh-20200930.xsd#ameh_DeferredTaxLiabilitiesAdjustedToGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:to="lab_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_bfac0318-e508-4f44-8fed-0dc355532788_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_03a1bae2-c95c-443e-a05a-4a2f5cdd0d3b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per share &#8211; basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_befd50ce-1d87-483a-b2a6-8dbf914767fe_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_81c9a435-0446-42ce-bb4d-2b07c224366f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_d1246934-0170-49f9-9965-d8e0c180d2e8_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_8cf104a3-2014-4bef-8cb1-cf8f7668e973_verboseLabel_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Remaining Lease Term</link:label>
    <link:label id="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_label_en-US" xlink:label="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Weighted Average Remaining Lease Term [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:href="ameh-20200930.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:to="lab_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_6a0183f0-3f9f-4dc8-8a8d-80115cd9b601_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_745bd995-cf07-44f4-91aa-f7108172f6ba_terseLabel_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_label_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:label id="lab_ameh_NextGenerationACOModelParticipationAgreementMember_documentation_en-US" xlink:label="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Next Generation ACO Model Participation Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:to="lab_ameh_NextGenerationACOModelParticipationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_e78961a1-1231-49dd-8bf1-49696dbcda8b_terseLabel_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Following Three Fiscal Quarters Thereafter</link:label>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_label_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Three [Member]</link:label>
    <link:label id="lab_ameh_PaymentPeriodThreeMember_documentation_en-US" xlink:label="lab_ameh_PaymentPeriodThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Period Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PaymentPeriodThreeMember" xlink:to="lab_ameh_PaymentPeriodThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorBMember_b21f5ffe-b257-4649-806a-3f2c7f2ed54b_terseLabel_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B</link:label>
    <link:label id="lab_ameh_PayorBMember_label_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:label id="lab_ameh_PayorBMember_documentation_en-US" xlink:label="lab_ameh_PayorBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor B [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember" xlink:href="ameh-20200930.xsd#ameh_PayorBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorBMember" xlink:to="lab_ameh_PayorBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_3dcae1a8-8517-4581-b99d-536f5f1ddeb7_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_ad24beb3-85e1-46c1-905c-43d893872d8e_verboseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for exercise of options and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_label_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issued during the period value of exercise of option and warrants</link:label>
    <link:label id="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">It represents value of stock issued during the period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:to="lab_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_536bde39-a57c-4731-bde2-c098a9cac11b_negatedLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Exercised</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised" xlink:href="ameh-20200930.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsExercised" xlink:to="lab_ameh_NumberOfWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5358b031-3209-48d1-b34a-435f9873582e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_62054dbf-64b1-414e-a097-4e77da7a2d5e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9eda24b6-06c4-460a-bb01-74511db5b6d2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_98b7aaa6-f5b5-437f-a152-a338334f7334_terseLabel_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of notification of termination</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_label_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Expiration Period, Period Of Notification</link:label>
    <link:label id="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_documentation_en-US" xlink:label="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line Of Credit Facility, Expiration Period, Period Of Notification</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:to="lab_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_f905a120-08bd-4fe7-8e1a-11cc1ac0e1f1_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_5af45765-70c0-4a91-b08e-450980550239_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_30696b6d-da04-4c18-abdf-f7c535777666_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_a1c14062-7f2c-4d27-9f5d-db8ebe3a81ed_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_2c5fbc61-9584-4ba9-86bb-a189e93d5df4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_6b49b790-30b3-4aa3-af6b-71d01233a2af_verboseLabel_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_label_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Specialty Capitation Payable Current</link:label>
    <link:label id="lab_ameh_SpecialtyCapitationPayableCurrent_documentation_en-US" xlink:label="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of specialty capitation payable current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:href="ameh-20200930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_SpecialtyCapitationPayableCurrent" xlink:to="lab_ameh_SpecialtyCapitationPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3747c54e-05c1-497c-a3c9-fabf07a73507_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5a798af0-4efd-4c4a-9220-d77c5d6ce26b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_8ef7f0f0-a75b-456f-8cb6-3232999b5982_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_16571779-2f51-4900-9965-fad898edcc74_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_1254279f-c565-4123-a154-4f90f608b7bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_04b851db-06b2-4b72-b230-df8da1b2284c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_59dd2f10-df36-4ff6-bf23-c0afa47ebed5_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_9a01965f-300e-4cbb-9fe6-af1a4600e53f_periodStartLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_2eb270e4-9a6e-4ab3-a3b2-a9787a963692_periodEndLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_b78bab9f-4077-4d44-b074-ee4cbb733729_terseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:to="lab_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_f9eb3db5-72e3-41e2-b0bb-57fe6c7f253b_verboseLabel_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_label_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of warrants or rights granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:to="lab_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_a8375df9-1ead-41eb-9a54-8003b1309cc1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_ce0c654f-ce07-4890-addc-1c790974a0c4_verboseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College, LLC &#8211; related party</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_8924b8ca-e123-42cf-b756-3bea8f6d0787_terseLabel_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">531 W. College LLC</link:label>
    <link:label id="lab_ameh_FiveThreeOneW.CollegeLLCMember_label_en-US" xlink:label="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Five Three One W. College LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiveThreeOneW.CollegeLLCMember" xlink:to="lab_ameh_FiveThreeOneW.CollegeLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCareOtherMember_787cc49b-aba8-4935-996e-edc4f368e348_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk pool settlements and incentives</link:label>
    <link:label id="lab_us-gaap_HealthCareOtherMember_label_en-US" xlink:label="lab_us-gaap_HealthCareOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCareOtherMember" xlink:to="lab_us-gaap_HealthCareOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_b94c4be7-eedc-4d78-8cec-af6df35176a6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, mezzanine equity and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_172f1c95-1838-4e15-8d22-e4d8c8673bf7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_dea8bc4b-1fda-47e0-b949-60493393db7e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_17f88186-7a3c-4094-8444-4edeb4eafc7b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_78e3707e-8200-4daf-a7ee-860edc9b7aff_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_101b72a4-7a77-4a9c-adbc-ed677e154a09_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_667a6bb7-75e2-4a2d-b5e6-af6e06cd9e2b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableNet_7b27b603-d686-4829-b2da-586e8dec674b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of loan</link:label>
    <link:label id="lab_us-gaap_NotesReceivableNet_label_en-US" xlink:label="lab_us-gaap_NotesReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableNet" xlink:to="lab_us-gaap_NotesReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_e3c2a17b-5d83-4dd0-a96f-aa0d9aa7b58d_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f4c9f89b-32c7-4d09-971f-7618e27694a9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares not included in the calculation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_869662b2-895b-491b-9036-44c1f68bd238_terseLabel_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC and APC-LSMA</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_label_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:label id="lab_ameh_APCAndAPCLSMAMember_documentation_en-US" xlink:label="lab_ameh_APCAndAPCLSMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC And APC-LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_APCAndAPCLSMAMember" xlink:to="lab_ameh_APCAndAPCLSMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_21652653-88ae-4746-9569-9c0e53b620a1_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_721c9c01-97d9-4c1d-a62e-188248e8f910_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_ce58a0df-c9c2-4263-93dc-737db9a00803_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_58fca7fe-7fe3-40e9-9707-51d6eb103016_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_4827c811-f81d-4bfd-80c9-b2c9348c2c19_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Nonconsolidated Investee [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:to="lab_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_3f6acb66-7efb-4573-98b9-31e9ee5c6c54_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated leverage ratio minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Minimum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_73a3c1f5-0bfa-4881-bbcb-1c393982e086_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land, property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_7015f853-93ba-42e7-9506-c23ae3321533_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_b164ad97-7e68-4ef0-9ae2-cfb5283b116f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1e554d32-c0da-4a55-9b29-890136db1f6c_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Apollo Medical Holdings, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_50ab642b-6d97-47f6-a407-194f14f1e5d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of business combinations:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_8bd6fa05-6bd3-4efd-ae79-f1514c90d026_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_d9dd10b7-e446-463c-b554-e30eb47a3f83_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_700739ad-a740-4ce4-bf05-7cab2c350189_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_8befd1a6-ddd1-4de2-a40d-ac11657058a8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_6559e381-9957-4837-a67b-289f349f5ce5_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_455665ae-2916-4c2c-bfd5-46a85864e72c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Network relationship intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_a886034f-d340-4167-af92-a6e56402c875_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants received (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_e2727813-beaf-445c-bae1-bd73549ff710_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_2b73a6b7-e72a-4541-8fa7-6ff13eea9c0c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued for vesting of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableMember_6427dabb-1223-447d-802d-17baca51f146_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Secured Promissory Note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_97cae03e-8a15-4ef5-8590-af578d70db6d_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable</link:label>
    <link:label id="lab_us-gaap_NotesReceivableMember_label_en-US" xlink:label="lab_us-gaap_NotesReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableMember" xlink:to="lab_us-gaap_NotesReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_af62c0c2-e580-404b-b777-2afe13de211c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_b7b9c7f5-2c68-4fad-b396-253fd2ab9008_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_4b7718f1-596d-42ee-83ed-529d6b9eaf8e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_15ed66c3-c0ec-4340-8ac9-3aaacdc6e5cc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PatientManagementPlatformMember_8378d525-d679-45ee-81dc-70b96cb179e8_terseLabel_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient management platform</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_label_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform [Member]</link:label>
    <link:label id="lab_ameh_PatientManagementPlatformMember_documentation_en-US" xlink:label="lab_ameh_PatientManagementPlatformMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patient Management Platform</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember" xlink:href="ameh-20200930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PatientManagementPlatformMember" xlink:to="lab_ameh_PatientManagementPlatformMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_7a274763-212b-4bf1-93b8-91cec3013f18_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_b386e8b9-85ca-43b6-ab5f-b08a8f4186e5_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount invested for interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorFMember_74541019-6708-4eac-b182-1c7946240488_terseLabel_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F</link:label>
    <link:label id="lab_ameh_PayorFMember_label_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:label id="lab_ameh_PayorFMember_documentation_en-US" xlink:label="lab_ameh_PayorFMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor F [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember" xlink:href="ameh-20200930.xsd#ameh_PayorFMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorFMember" xlink:to="lab_ameh_PayorFMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_c333f049-e283-4d50-bbae-684454d0f2e3_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service, net</link:label>
    <link:label id="lab_us-gaap_HealthCarePatientServiceMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePatientServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Patient Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePatientServiceMember" xlink:to="lab_us-gaap_HealthCarePatientServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_266a3fd5-b16c-40a1-ae5b-8e890677dd2f_terseLabel_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_label_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:label id="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_documentation_en-US" xlink:label="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Disposed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:to="lab_ameh_EquityMethodInvestmentOwnershipPercentageDisposed" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_54ce2890-11f3-45ee-857c-df2d72972735_terseLabel_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected period of payment upon termination of agreement</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_label_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:label id="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_documentation_en-US" xlink:label="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:href="ameh-20200930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:to="lab_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_8feedcb1-0522-4753-8d35-fb5066e2817e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount available</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_94ffc037-87fe-4931-9048-07f34b1a690b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares purchased by related party</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_MezzanineMember_8cca24e2-e62e-4e6b-8a8b-db6a47596074_terseLabel_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine</link:label>
    <link:label id="lab_ameh_MezzanineMember_label_en-US" xlink:label="lab_ameh_MezzanineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mezzanine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember" xlink:href="ameh-20200930.xsd#ameh_MezzanineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_MezzanineMember" xlink:to="lab_ameh_MezzanineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_e0938985-5912-44bf-b402-d1c7b32f1acd_terseLabel_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement</link:label>
    <link:label id="lab_ameh_ApcBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_ApcBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember" xlink:href="ameh-20200930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcBusinessLoanAgreementMember" xlink:to="lab_ameh_ApcBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a11a2b09-82a7-4a71-9e50-b6e1511903ab_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized intangible assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PayorGMember_93f520eb-0774-4055-8958-ddb920bb0cca_terseLabel_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G</link:label>
    <link:label id="lab_ameh_PayorGMember_label_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:label id="lab_ameh_PayorGMember_documentation_en-US" xlink:label="lab_ameh_PayorGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor G [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember" xlink:href="ameh-20200930.xsd#ameh_PayorGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PayorGMember" xlink:to="lab_ameh_PayorGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_09896239-6642-4e49-9d04-6241e6ed5fac_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_1bd76bdb-906b-4ea3-90d1-dcb07b0560ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_d41eff53-915c-4423-b96a-c583baf90402_negatedLabel_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_label_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Prepaid Expenses And Other Current Assets</link:label>
    <link:label id="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_documentation_en-US" xlink:label="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:to="lab_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_5b7fb397-a376-47da-9867-633f7a9ae122_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_356b3a89-e49b-4339-a93d-41afd512b510_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets recorded under finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_TermLoanAMember_8424440e-a1ea-4869-a010-08ff67e1c0e5_terseLabel_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_ameh_TermLoanAMember_label_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:label id="lab_ameh_TermLoanAMember_documentation_en-US" xlink:label="lab_ameh_TermLoanAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember" xlink:href="ameh-20200930.xsd#ameh_TermLoanAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_TermLoanAMember" xlink:to="lab_ameh_TermLoanAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_6e24f7bc-c23b-4244-8a10-d0bb065a81f3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_26b74ed0-7f72-4ff5-a301-1bbd54a0ff57_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value (in thousands)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_be7bb1e4-b2c1-4577-a37c-f21c4e45a718_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2225622c-b752-4b9d-b2e1-1ee720ccb219_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares of common stock outstanding &#8211; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssued1_4f30b7cc-dc09-443e-a8b9-0baec2dbf275_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC stock issued in exchange for AMG</link:label>
    <link:label id="lab_us-gaap_StockIssued1_label_en-US" xlink:label="lab_us-gaap_StockIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssued1" xlink:to="lab_us-gaap_StockIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_99a7fbc1-bd06-4be2-93f5-ef8abcae506d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_5ea5bc17-6e87-420c-b9bf-5d2cdf0e5a3c_verboseLabel_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two</link:label>
    <link:label id="lab_ameh_WarrantExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WarrantExercisePriceRangeTwoMember" xlink:to="lab_ameh_WarrantExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_75255752-f462-4e9d-8b8e-e6dfa88e3a38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b6833eb5-03a0-4cd6-bf5c-c4dd2b7a1174_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4a374347-fa6d-423a-bd39-4ea0f580b0ec_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_46c582b0-647e-4ac4-a62c-d4fe64176711_terseLabel_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proxy votes</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_label_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:label id="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage_documentation_en-US" xlink:label="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Proxy Votes, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:to="lab_ameh_StockIssuedDuringPeriodProxyVotesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ApcLsmaMember_e50e1b30-8e26-4f3e-bb15-88fe26378589_terseLabel_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA</link:label>
    <link:label id="lab_ameh_ApcLsmaMember_label_en-US" xlink:label="lab_ameh_ApcLsmaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APC LSMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember" xlink:href="ameh-20200930.xsd#ameh_ApcLsmaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ApcLsmaMember" xlink:to="lab_ameh_ApcLsmaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f3540eb3-9db0-42a9-90c4-a568ec9b5dbf_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_8fe75ade-489f-40aa-b94f-657eaae7b3c6_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of warrants available to purchase, contingent upon the portal completion date (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_82a2d9fe-4fad-409b-89bf-28cdb01de64d_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate, 2020 commitments</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_c4af68c7-044f-4f55-b6d6-8f2f597fe357_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_63e30cfa-84c8-4540-9e72-d201215d8be7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_9a6ddf24-6175-44ad-ba39-38f58c49d329_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend declared included in dividend payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_4e3442e7-0f4f-4cfc-bfad-d7565d712980_verboseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_942f0f4e-225f-45b7-8d29-269ed142c744_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase additional membership interests (in shares)</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_4d4426fb-efec-41b7-beef-031615275c5d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 (excluding the six months ended September 30, 2020)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_c6ec002f-f714-4056-8ff1-fba7bffbfec2_terseLabel_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised (in shares)</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_label_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:label id="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_documentation_en-US" xlink:label="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:to="lab_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_bbcc6b42-33f9-40d0-9dd1-8576c87ccc9e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_151456cf-a581-412b-880f-d6c9a033f7f7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances on loans receivable</link:label>
    <link:label id="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_label_en-US" xlink:label="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Fund Long-term Loans to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:to="lab_us-gaap_PaymentsToFundLongtermLoansToRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80e5e0f7-9550-4b48-b8a2-a6462b7945fa_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_02bd8d7d-16b3-4679-a86c-09d2c4e08e3d_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision (benefit) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NmmBusinessLoanAgreementMember_cbbd0c48-5234-46e5-a5da-23023e7e3eff_terseLabel_en-US" xlink:label="lab_ameh_NmmBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Business Loan Agreement</link:label>
    <link:label id="lab_ameh_NmmBusinessLoanAgreementMember_label_en-US" xlink:label="lab_ameh_NmmBusinessLoanAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NMM Business Loan Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember" xlink:href="ameh-20200930.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NmmBusinessLoanAgreementMember" xlink:to="lab_ameh_NmmBusinessLoanAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8fa8b107-1bf2-45d7-8d84-57633873296e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_aa9e4c09-02f3-41ec-a314-f760cf5dc072_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0bce8ea2-9cfd-42c8-bcb7-847d2e93614a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_1b2b2200-27b3-45d5-9ae9-8ed124412785_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Commitments of Credit Facility</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_4ee84f0f-702f-4213-87c9-2ddafaa10ced_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_81337bd1-1189-4557-bcb8-afa8676b4e5c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_7413457f-21ce-48e1-bcf1-a34fa9f5d95e_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_400c347b-bbe7-4ed8-8bd3-4db664c8f946_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_42f6e75a-ccd4-4b03-b9fe-08a1310997b9_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_9f06688f-01da-4556-b276-b61e38798746_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_8a5afead-a6d2-423f-a1b0-33e5a104ba08_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6fd64bb9-2048-4177-b643-7c47833eeab6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2891c596-27bd-4f9f-aabe-4d10e3ed3e91_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_b220b0e6-3c7e-4524-9476-20f427f168dd_verboseLabel_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants granted (in shares)</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_label_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:label id="lab_ameh_NumberOfWarrantsGranted_documentation_en-US" xlink:label="lab_ameh_NumberOfWarrantsGranted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Warrants Granted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted" xlink:href="ameh-20200930.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_NumberOfWarrantsGranted" xlink:to="lab_ameh_NumberOfWarrantsGranted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a1a96bbf-9fc7-4d12-9073-2211094bcdb0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_80545daa-0ec8-4c8c-acba-0d70e23f8a5f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain" xlink:to="lab_us-gaap_RelatedPartyTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_78a23a9c-25e3-4bad-8924-c42b3b9891be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_6bdb3f4d-67e7-4d0e-8c2e-de6012dd12f3_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds of options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_4a06f889-114b-4da7-98a1-2454419360fb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_d4dc9ec6-f67c-42da-820c-a0695ff3f84b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a7b8841d-e357-4168-9f92-9bb2a3d7ee28_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost related to issuance of preferred shares</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_b965abc0-c86d-4a81-b076-0696b1d498aa_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum loan availability</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_82f11be4-6e13-45f8-a9d3-1055ef656a66_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_be3315dd-3e4b-4154-8857-fcd81bb1a567_terseLabel_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:label id="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="ameh-20200930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_ea231953-eacd-4fe6-9904-8051f52022f5_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0a943d8d-cf00-4205-9a7d-1db77733b471_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_e9747fdc-0840-4381-80f0-d3d9cf8a8a27_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_c1e04ba1-bb6a-419d-bda0-393c7a67f759_terseLabel_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment amount</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_label_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:label id="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_documentation_en-US" xlink:label="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:to="lab_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_457af04e-cce3-44f1-a30b-340d3527291a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_d61f057b-840c-4181-bca0-aca0b7a68be0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a226b946-e0f3-43d4-af8e-ac70d22f219b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_00a8d072-ef22-4bf7-865d-6bf56b0c5415_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_bb1f5747-64bf-4fd5-92e6-c5f006fe099e_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_c20428f6-6503-4736-814b-c86fb2caf968_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_0b307fd5-708f-47ba-afc8-e27b56642dfa_terseLabel_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability adjustment related to warrant exercises</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_label_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Warrants Exercised</link:label>
    <link:label id="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised_documentation_en-US" xlink:label="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Warrants Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:href="ameh-20200930.xsd#ameh_DeferredTaxLiabilitiesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:to="lab_ameh_DeferredTaxLiabilitiesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_8f711395-a70c-4402-91f0-cad7b82c7fee_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of exercises during period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_dcb8a287-615d-439f-929e-878b77564596_terseLabel_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum consolidated leverage ratio (not greater than)</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_label_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:label id="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum_documentation_en-US" xlink:label="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Leverage Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:to="lab_ameh_DebtInstrumentCovenantLeverageRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_a3ba0fd0-9fe9-4ebc-bc5c-40ff0a419d3c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_1e9b06f3-ebba-4684-a417-3d86bd096dad_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_52099c6d-526a-49fa-a7ff-bd5f8ab80f22_terseLabel_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging &amp; Oncology Center, Inc.</link:label>
    <link:label id="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember_label_en-US" xlink:label="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pacific Medical Imaging and Oncology Center, Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:href="ameh-20200930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:to="lab_ameh_PacificMedicalImagingAndOncologyCenterIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_fc938512-cf8f-4b05-9994-23bba516e070_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_02ebc818-07dd-40c7-a221-9aa0343e060b_terseLabel_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_label_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:label id="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward_documentation_en-US" xlink:label="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price, Warrants [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:href="ameh-20200930.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:to="lab_ameh_WeightedAverageExercisePriceWarrantsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_0dd356ca-f397-47e0-b14b-50297733da95_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_ContractTypeAxis_52941f35-6a28-4c71-82f2-5b17a332ac06_terseLabel_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:label id="lab_ameh_ContractTypeAxis_label_en-US" xlink:label="lab_ameh_ContractTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis" xlink:href="ameh-20200930.xsd#ameh_ContractTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_ContractTypeAxis" xlink:to="lab_ameh_ContractTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_55bb929f-1613-44a1-b90e-72470214402a_verboseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_a687701e-e815-4fa7-a6b4-6aa3c083cbff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_6745f3b9-b5a4-43f9-a4d2-10b2a1a11d18_terseLabel_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:label id="lab_ameh_DescriptionOfBusinessLineItems_label_en-US" xlink:label="lab_ameh_DescriptionOfBusinessLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description Of Business [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ameh_DescriptionOfBusinessLineItems" xlink:to="lab_ameh_DescriptionOfBusinessLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ameh-20200930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:e5ce14d1-4ebe-4b15-869f-a83f9ee5b0af,g:ff12b0fb-5403-47c3-a36f-fa9450106ed5-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="ameh-20200930.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_74f2fa66-3094-42d7-ac75-74acfa51067b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentType_74f2fa66-3094-42d7-ac75-74acfa51067b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_821437a9-70af-4efa-b395-b12e3dc48156" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentQuarterlyReport_821437a9-70af-4efa-b395-b12e3dc48156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1dbdd298-b2a9-4c21-aac9-750c1fef82d5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentPeriodEndDate_1dbdd298-b2a9-4c21-aac9-750c1fef82d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_24e29811-f4f0-4d3b-91c0-aadfbbe642ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentTransitionReport_24e29811-f4f0-4d3b-91c0-aadfbbe642ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_8ad93bf6-aa1e-4dd5-aa94-8e4b4ccc0cba" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityFileNumber_8ad93bf6-aa1e-4dd5-aa94-8e4b4ccc0cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_eb6747b8-3cc3-4092-84ba-e4c6f3b57a6e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityRegistrantName_eb6747b8-3cc3-4092-84ba-e4c6f3b57a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_96da840f-c14f-46ee-b200-35e66cb84571" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_96da840f-c14f-46ee-b200-35e66cb84571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f821ce38-dcca-4709-8e85-50347cb60a65" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityTaxIdentificationNumber_f821ce38-dcca-4709-8e85-50347cb60a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_e704cdd5-20fd-4eff-b4cc-f00a621ae8bc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityAddressAddressLine1_e704cdd5-20fd-4eff-b4cc-f00a621ae8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_1c390fc3-10ed-4adb-b86d-e6022829df82" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityAddressAddressLine2_1c390fc3-10ed-4adb-b86d-e6022829df82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_231d56e2-4586-401f-bfdd-81c30e34e812" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityAddressCityOrTown_231d56e2-4586-401f-bfdd-81c30e34e812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_8f628018-bdcf-44fb-b007-e48310217a86" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityAddressStateOrProvince_8f628018-bdcf-44fb-b007-e48310217a86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_5b7efd44-b5f9-4601-a0b3-73043e59e2ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityAddressPostalZipCode_5b7efd44-b5f9-4601-a0b3-73043e59e2ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_675f3eec-99b4-436e-9aab-0a414a32bbc7" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_CityAreaCode_675f3eec-99b4-436e-9aab-0a414a32bbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_34a4d3e2-d8ea-4a72-a9fc-b95efb9d81da" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_LocalPhoneNumber_34a4d3e2-d8ea-4a72-a9fc-b95efb9d81da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_d1455740-5e71-43bf-a84b-6014e5b122ec" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityCurrentReportingStatus_d1455740-5e71-43bf-a84b-6014e5b122ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a32785c6-dd2f-4ada-a51e-fa850f0f4dc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityInteractiveDataCurrent_a32785c6-dd2f-4ada-a51e-fa850f0f4dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_cc195eeb-64b3-46b8-a7c7-ef263d7e9bc5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityFilerCategory_cc195eeb-64b3-46b8-a7c7-ef263d7e9bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_471300cd-57a7-4cde-a03a-3423b2b85398" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntitySmallBusiness_471300cd-57a7-4cde-a03a-3423b2b85398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6071175e-2037-43e7-8fdf-5c30d45189d4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityEmergingGrowthCompany_6071175e-2037-43e7-8fdf-5c30d45189d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_b67862f4-6c1b-43a1-a059-3bfc3aeffcc4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityShellCompany_b67862f4-6c1b-43a1-a059-3bfc3aeffcc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_120b11de-c8b0-4ccf-976f-bebc5d20f06c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_Security12bTitle_120b11de-c8b0-4ccf-976f-bebc5d20f06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b6c6d890-1c7b-4df4-937c-204e165afa6b" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_TradingSymbol_b6c6d890-1c7b-4df4-937c-204e165afa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_b17d4c85-c0ff-4e2d-bd9c-ecf3e0fd3f4d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_b17d4c85-c0ff-4e2d-bd9c-ecf3e0fd3f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dda13c92-3b3f-4c05-97d9-4b91a90870ab" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_AmendmentFlag_dda13c92-3b3f-4c05-97d9-4b91a90870ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_f648120f-2b0a-4a01-afe7-981acfbad39a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentFiscalYearFocus_f648120f-2b0a-4a01-afe7-981acfbad39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_cf11773f-6781-405b-a5ce-f9d6812dadbc" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_cf11773f-6781-405b-a5ce-f9d6812dadbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_57b0f7ba-5dbc-442b-8473-e26d0ab43303" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_EntityCentralIndexKey_57b0f7ba-5dbc-442b-8473-e26d0ab43303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_01a602ee-ef57-4b48-ae9e-93f542bb4380" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_48c2cf12-7e92-40b7-b2c8-335482aaa78f" xlink:to="loc_dei_CurrentFiscalYearEndDate_01a602ee-ef57-4b48-ae9e-93f542bb4380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7815dafd-47d5-4e86-8875-44b89c48bf1b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7815dafd-47d5-4e86-8875-44b89c48bf1b" xlink:to="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:to="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_a657d31e-0e57-4060-b13e-673558ab97bb" xlink:to="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_a4426fd9-1f54-430e-b932-c7769c2d9bc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_a4426fd9-1f54-430e-b932-c7769c2d9bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_29e2b155-1930-44bb-9d09-40593ff79a30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_9f9d09bb-c392-4df6-9d38-3e7a7f9aac3b" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_29e2b155-1930-44bb-9d09-40593ff79a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a4a48c78-3846-4bc8-927b-411a76777059" xlink:to="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:to="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3aa5b55-3c35-4f96-86dd-11e65abc1d18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e3aa5b55-3c35-4f96-86dd-11e65abc1d18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_5f1b5547-5510-45f1-b9ca-11254e2fde3f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_RestrictedCashCurrent_5f1b5547-5510-45f1-b9ca-11254e2fde3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_d4ab6619-5dfc-4f05-ad50-c1e4273a92a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_d4ab6619-5dfc-4f05-ad50-c1e4273a92a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4136a118-8e1f-4904-b710-351a663f0c3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4136a118-8e1f-4904-b710-351a663f0c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_22fa7140-d3a1-406f-ad09-b1954c9ffc5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_22fa7140-d3a1-406f-ad09-b1954c9ffc5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_7f021049-6e48-418c-87fa-f19ac6e067d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_7f021049-6e48-418c-87fa-f19ac6e067d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4fb95b5-5ef2-4659-aeec-f4f4b44e21e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4fb95b5-5ef2-4659-aeec-f4f4b44e21e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_928abff3-10f4-4893-9afb-2c7e368fd309" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_928abff3-10f4-4893-9afb-2c7e368fd309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_f956805c-0846-4167-90d7-bd23a3a7f24e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_f956805c-0846-4167-90d7-bd23a3a7f24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ff94c3c8-593b-4aab-9f0e-9e71d2e4330d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_eb0aecd4-2c64-4778-a7a9-fff4e174485f" xlink:to="loc_us-gaap_AssetsCurrent_ff94c3c8-593b-4aab-9f0e-9e71d2e4330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c4d83146-2df3-4446-9bca-7a65a8a21b34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c4d83146-2df3-4446-9bca-7a65a8a21b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_27b1601b-d805-44e9-8862-13e24f5c5fa3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_27b1601b-d805-44e9-8862-13e24f5c5fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c4e52f3-e029-4e9d-9183-55cc80846211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_0c4e52f3-e029-4e9d-9183-55cc80846211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_122ea520-bae4-4b14-8d48-ab7e35e4f264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_Goodwill_122ea520-bae4-4b14-8d48-ab7e35e4f264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_428214ed-822d-42ca-8808-7376e800c565" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_EquityMethodInvestments_428214ed-822d-42ca-8808-7376e800c565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ee3c7e0d-3275-4a54-9177-6aec4bd26e65" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_ee3c7e0d-3275-4a54-9177-6aec4bd26e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_09862287-9847-49f7-a001-c694b76e894c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_09862287-9847-49f7-a001-c694b76e894c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_5ee4863c-dee1-4cbe-8908-b000955f6174" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_5ee4863c-dee1-4cbe-8908-b000955f6174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_15cfc972-069c-4216-9279-0b7fa6ee8264" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_a8431242-be5c-49b9-8a28-4f6645fcecd1" xlink:to="loc_us-gaap_AssetsNoncurrent_15cfc972-069c-4216-9279-0b7fa6ee8264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a32ab762-fd32-4f67-9f93-b6419b7c64e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_df9e3727-a5fd-47ea-871e-cda21abb914d" xlink:to="loc_us-gaap_Assets_a32ab762-fd32-4f67-9f93-b6419b7c64e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ced996c4-5980-4413-8d91-ec84f3777d96" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb3e8efa-7198-4a1c-8865-30e7e2d6b082" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_cb3e8efa-7198-4a1c-8865-30e7e2d6b082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_6b15d054-9670-4fe1-807c-73b077b8327b" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_6b15d054-9670-4fe1-807c-73b077b8327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfe4ba7a-fcea-45de-ae92-bedce5112dab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bfe4ba7a-fcea-45de-ae92-bedce5112dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_b0298d6b-b03e-4837-b57a-b468e47eba7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_b0298d6b-b03e-4837-b57a-b468e47eba7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_506d56ba-b175-4ff1-9072-604539e314e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_DividendsPayableCurrent_506d56ba-b175-4ff1-9072-604539e314e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_23fbb99a-4a10-403d-8065-c3c094f7a965" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_23fbb99a-4a10-403d-8065-c3c094f7a965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c8a7f03-03c6-4105-b667-197728f5fb92" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_7c8a7f03-03c6-4105-b667-197728f5fb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_2c87a887-6532-42c5-8de5-c090d2e3b25b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LongTermDebtCurrent_2c87a887-6532-42c5-8de5-c090d2e3b25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f76146f4-2e85-454a-9c42-33c7e6ee6cb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_91572e75-a2f4-4b66-9cc1-91481958e55d" xlink:to="loc_us-gaap_LiabilitiesCurrent_f76146f4-2e85-454a-9c42-33c7e6ee6cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08426cdb-28f6-4d94-818a-1f91de993f5f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_08426cdb-28f6-4d94-818a-1f91de993f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6e7e7b6c-9172-4b95-95fd-256792aed6ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_6e7e7b6c-9172-4b95-95fd-256792aed6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d13d058-a444-4b3e-bdd0-45c9234b5663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9d13d058-a444-4b3e-bdd0-45c9234b5663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_c07b252e-febc-4daf-998c-e729bc756666" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_c07b252e-febc-4daf-998c-e729bc756666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_634c18f4-9ba2-4ec4-a9fe-2bba3f8ee1cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_ad6fe1d4-efe5-4325-ad8f-e7a72186e5d8" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_634c18f4-9ba2-4ec4-a9fe-2bba3f8ee1cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_ffee14da-9850-46dd-a6f3-9ddba0f98696" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_Liabilities_ffee14da-9850-46dd-a6f3-9ddba0f98696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_2be97b22-2bf6-43c6-8412-4e98ab9e0211" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_CommitmentsAndContingencies_2be97b22-2bf6-43c6-8412-4e98ab9e0211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:href="ameh-20200930.xsd#ameh_MezzanineEquityAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bd83cbf4-a0bd-4e23-9107-f6eb9fac67bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MezzanineEquityAbstract_1f5de894-27cc-422f-88d0-193700452dfb" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests_bd83cbf4-a0bd-4e23-9107-f6eb9fac67bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_5cd5d716-703a-49b6-a5ea-5d6918b79921" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_PreferredStockValue_5cd5d716-703a-49b6-a5ea-5d6918b79921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5eb81479-dae6-4439-9524-269957f6aec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_CommonStockValue_5eb81479-dae6-4439-9524-269957f6aec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_6aaea4c2-0afc-4dff-a33e-198d828a2734" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_6aaea4c2-0afc-4dff-a33e-198d828a2734" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7436d15a-7062-446f-913e-8fc3acda32b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7436d15a-7062-446f-913e-8fc3acda32b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_04008e01-8ffa-4f88-a33f-c2cd1b54d828" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_StockholdersEquity_04008e01-8ffa-4f88-a33f-c2cd1b54d828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_54012fe3-b5c8-4f48-837c-21d1dd7ae89d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_MinorityInterest_54012fe3-b5c8-4f48-837c-21d1dd7ae89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9925f634-09f6-4eef-aca8-288438a24537" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_1389d844-7db2-4717-9cbd-5886dc7d934f" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9925f634-09f6-4eef-aca8-288438a24537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_377310d5-3d2c-4b83-b2cc-b23a0ed9989b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_da0b156b-3677-45c9-a6ec-a2f6fc3b63bb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_377310d5-3d2c-4b83-b2cc-b23a0ed9989b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_29d16c82-287f-43ca-afb9-9aca1a606bc6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_29d16c82-287f-43ca-afb9-9aca1a606bc6" xlink:to="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:to="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_48426adf-b62e-4b77-aaae-3a1d29f22a4d" xlink:to="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_5f4aed17-8bb6-476d-8ac9-f573b60b9444" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_5f4aed17-8bb6-476d-8ac9-f573b60b9444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesBPreferredStockMember_8794bd5a-a55b-4622-bf78-3b5c2a05724d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesBPreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_c6fc598b-8aea-412a-9b26-b6e23f2b0315" xlink:to="loc_us-gaap_SeriesBPreferredStockMember_8794bd5a-a55b-4622-bf78-3b5c2a05724d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:to="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_0d54f571-3713-4f97-aafd-36e7652ad238" xlink:to="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_53816d8b-3b56-4346-b870-3d506afa5d61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_3da90fbb-813d-4a14-960f-0ba60e492e6e" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_53816d8b-3b56-4346-b870-3d506afa5d61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2e391df7-bc91-4dd6-8c26-39f154c55165" xlink:to="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b45453ef-bdfe-43b1-bfa7-e8e6a7bb7060" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b45453ef-bdfe-43b1-bfa7-e8e6a7bb7060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a303e6ab-e160-4013-8d2e-e0d1bc219251" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a303e6ab-e160-4013-8d2e-e0d1bc219251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7fb065e7-3329-4f42-9a42-37e88dcd081f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7fb065e7-3329-4f42-9a42-37e88dcd081f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d333e423-522f-4181-95e6-8efd1380dc12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d333e423-522f-4181-95e6-8efd1380dc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_49267c0d-12fb-4293-a50f-5262e72c82ae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_49267c0d-12fb-4293-a50f-5262e72c82ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b5599621-0a99-432a-ab15-77ef8ee58eda" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b5599621-0a99-432a-ab15-77ef8ee58eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5db4b4b4-9ca2-4be5-8247-4457a01fa846" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5db4b4b4-9ca2-4be5-8247-4457a01fa846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_eb73efa7-be97-408e-ad3f-14cb0919cbbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_TreasuryStockCommonShares_eb73efa7-be97-408e-ad3f-14cb0919cbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d220bcdc-6394-4780-8b9a-de03fdec9f8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_Assets_d220bcdc-6394-4780-8b9a-de03fdec9f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5c2d0769-8763-483b-b980-d9253731d450" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1711b558-b1c3-4ea7-a036-92d7f1018061" xlink:to="loc_us-gaap_Liabilities_5c2d0769-8763-483b-b980-d9253731d450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_584d30d5-8d54-4793-a56d-efe22b68aa25" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_584d30d5-8d54-4793-a56d-efe22b68aa25" xlink:to="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:to="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a94ae3d1-9714-490f-a534-2f5f842ad188" xlink:to="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthCareCapitationRevenueMember_a8c064bf-65ee-4e05-bd92-6bbc6a3a38a0" xlink:href="ameh-20200930.xsd#ameh_HealthCareCapitationRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_ameh_HealthCareCapitationRevenueMember_a8c064bf-65ee-4e05-bd92-6bbc6a3a38a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareOtherMember_417bd344-7895-45a7-bb07-9e63ad8b5f3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_HealthCareOtherMember_417bd344-7895-45a7-bb07-9e63ad8b5f3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_02aee463-2da8-4ca5-9a4f-aa45eece4d47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_ManagementServiceMember_02aee463-2da8-4ca5-9a4f-aa45eece4d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePatientServiceMember_8c1e1df6-4204-4717-a2ad-01f13ae0d72d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCarePatientServiceMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_HealthCarePatientServiceMember_8c1e1df6-4204-4717-a2ad-01f13ae0d72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_1e51d7fb-21de-4cd3-9007-9188b7ff6ab0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cd3d19a-72b1-4743-a136-cd42daa1e260" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_1e51d7fb-21de-4cd3-9007-9188b7ff6ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6481d3fc-542b-4700-9a9e-e4733b5df68e" xlink:to="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31f229f5-7bcf-4803-9b47-583ce64a71b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_5631b8e5-7ad6-47c3-b4dd-0d4628c78389" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_31f229f5-7bcf-4803-9b47-583ce64a71b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_776da002-1d72-432d-a147-628c371d2056" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_776da002-1d72-432d-a147-628c371d2056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1168cdbe-291e-4b90-a93a-05f70dbc8763" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1168cdbe-291e-4b90-a93a-05f70dbc8763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_a5e5c9ae-d34f-4a18-b33e-648ae486c822" xlink:href="ameh-20200930.xsd#ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts_a5e5c9ae-d34f-4a18-b33e-648ae486c822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c2e94bb7-1f36-491c-a4de-746cc1634c42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c2e94bb7-1f36-491c-a4de-746cc1634c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ffbd6ce3-2238-48bb-b4d6-f18e913bc3d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_ffbd6ce3-2238-48bb-b4d6-f18e913bc3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_730a27ae-a05a-4edf-a0af-595fff28c54c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2579ecc6-09d5-402a-b9c1-9a80b6d90e86" xlink:to="loc_us-gaap_CostsAndExpenses_730a27ae-a05a-4edf-a0af-595fff28c54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_f4b13d0d-f444-4e26-ad41-12b2054d9ace" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_OperatingIncomeLoss_f4b13d0d-f444-4e26-ad41-12b2054d9ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb8e418b-e674-43ef-ac53-f44f5cdf82a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_cb8e418b-e674-43ef-ac53-f44f5cdf82a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_be6a2f91-edcb-4b7b-bc6f-f8626a3fffc1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_be6a2f91-edcb-4b7b-bc6f-f8626a3fffc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_05f3dff3-3ce0-4a64-8fe2-58e921dd7f07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_InterestExpense_05f3dff3-3ce0-4a64-8fe2-58e921dd7f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_6cd907e9-9ab5-4159-a70f-07a50acdc22c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_InvestmentIncomeInterest_6cd907e9-9ab5-4159-a70f-07a50acdc22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f1b4771d-9901-4aab-9099-08188b10e936" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f1b4771d-9901-4aab-9099-08188b10e936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_97ccde44-1756-465f-b63e-535bede281cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_7080ab2d-ae14-4606-889c-ddb388bf0b3e" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_97ccde44-1756-465f-b63e-535bede281cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85df6220-b1f2-40bb-9aca-0dd000b4c98b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_85df6220-b1f2-40bb-9aca-0dd000b4c98b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fbd34d1a-d6c9-4d0d-88da-35ddd7283a6d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fbd34d1a-d6c9-4d0d-88da-35ddd7283a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_88148c25-4bed-4d95-ac3b-9b30631c146b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_ProfitLoss_88148c25-4bed-4d95-ac3b-9b30631c146b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6169ce0-e04b-41cc-95f5-adc5cb82686b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_e6169ce0-e04b-41cc-95f5-adc5cb82686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0db7ad48-8f80-4eb3-b03e-1217787a3947" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_NetIncomeLoss_0db7ad48-8f80-4eb3-b03e-1217787a3947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_30d794a1-b364-4e87-8a16-dfb52dac7d85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_EarningsPerShareBasic_30d794a1-b364-4e87-8a16-dfb52dac7d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8b33c507-1e20-471e-b683-ae45ad1145e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_866e9694-c52a-408e-973e-392770f84916" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8b33c507-1e20-471e-b683-ae45ad1145e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_50e79588-fada-42c4-9a6d-3df4027a6dfe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_50e79588-fada-42c4-9a6d-3df4027a6dfe" xlink:to="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ff6faf2a-6a79-46db-ae37-84d239baca79" xlink:to="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_eb56d066-cd4a-4749-93ed-a660b911ec68" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_CommonStockMember_eb56d066-cd4a-4749-93ed-a660b911ec68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5240a7a7-b53b-42ac-b107-3aa707284b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5240a7a7-b53b-42ac-b107-3aa707284b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_1797b9e0-1d8d-4425-b227-675d27cacc64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_RetainedEarningsMember_1797b9e0-1d8d-4425-b227-675d27cacc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_04679cb7-6687-4678-b15c-a97b5ace9188" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_063262f8-b443-4ba3-a5d1-946a8ed74eaa" xlink:to="loc_us-gaap_NoncontrollingInterestMember_04679cb7-6687-4678-b15c-a97b5ace9188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:to="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a775f590-8dde-49d5-9bbe-8670295e48ac" xlink:to="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MezzanineMember_4bd22e6c-bfd3-4d23-98b0-7483b2134d66" xlink:href="ameh-20200930.xsd#ameh_MezzanineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3acc2690-9561-4a8d-b34d-6bd7ee28cbdf" xlink:to="loc_ameh_MezzanineMember_4bd22e6c-bfd3-4d23-98b0-7483b2134d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d434f973-b75f-43e1-8f51-a4528df258e3" xlink:to="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59cd1acc-22aa-4085-a97a-47e0575da503" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_59cd1acc-22aa-4085-a97a-47e0575da503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_82a70a20-38a0-4fae-970e-df8b86e83d5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_SharesOutstanding_82a70a20-38a0-4fae-970e-df8b86e83d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_e4f1dacc-7d28-450a-8a7b-12d02dd3c939" xlink:href="ameh-20200930.xsd#ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity_e4f1dacc-7d28-450a-8a7b-12d02dd3c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_3b795c47-ec40-47cf-9acf-235a79592976" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_3b795c47-ec40-47cf-9acf-235a79592976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_78e91518-d5e2-4f94-8c9b-1747fb7c9bfc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_78e91518-d5e2-4f94-8c9b-1747fb7c9bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_56781f36-7ab3-4424-8ee2-7f1a0891ac05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_56781f36-7ab3-4424-8ee2-7f1a0891ac05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3756dffc-0bcb-4b23-bf0d-0f66aaab6507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_3756dffc-0bcb-4b23-bf0d-0f66aaab6507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e3371e0e-f9a6-4521-8c96-806751f5334f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e3371e0e-f9a6-4521-8c96-806751f5334f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_02b8cb9f-e818-49b4-83ef-b3ba9bd13079" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_02b8cb9f-e818-49b4-83ef-b3ba9bd13079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_f9d585c4-dde0-4911-9a4d-839271e7a02a" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised_f9d585c4-dde0-4911-9a4d-839271e7a02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_1165ca62-ad27-4f8d-878e-25f6ae91e90e" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants_1165ca62-ad27-4f8d-878e-25f6ae91e90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_b56cf85e-713c-4a86-8626-5539601bd7f9" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants_b56cf85e-713c-4a86-8626-5539601bd7f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_119b1be7-a8ab-4919-8875-652a8bd635ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_119b1be7-a8ab-4919-8875-652a8bd635ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e71442f-1066-4367-a75d-7015843f2832" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_7e71442f-1066-4367-a75d-7015843f2832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e14c022-4154-4b66-8775-3cf2f492ddff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_9e14c022-4154-4b66-8775-3cf2f492ddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa2da91c-f11e-4095-a1f1-96c1046d71a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_aa2da91c-f11e-4095-a1f1-96c1046d71a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e2af9c40-2682-4ae9-9ef4-258b6b7c7ccf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_e2af9c40-2682-4ae9-9ef4-258b6b7c7ccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_0700ebd8-b61c-421b-b774-a868d40ffcf7" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled_0700ebd8-b61c-421b-b774-a868d40ffcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_08e089bd-b86a-4767-b59f-80c74dea9031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_08e089bd-b86a-4767-b59f-80c74dea9031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05b67898-29c6-40f3-b9e7-bc320e306b44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_05b67898-29c6-40f3-b9e7-bc320e306b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_bdfd810c-dd00-48e5-ae86-d6e4e1171a75" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_e2238038-1db2-42ad-aa6e-f8f794cb0e5a" xlink:to="loc_us-gaap_SharesOutstanding_bdfd810c-dd00-48e5-ae86-d6e4e1171a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="simple" xlink:href="ameh-20200930.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768dd3ec-cef0-4336-8241-dbe3fe049401" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768dd3ec-cef0-4336-8241-dbe3fe049401" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_005e0fd2-95f8-4a3c-b52b-17590e2bd4a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768dd3ec-cef0-4336-8241-dbe3fe049401" xlink:to="loc_us-gaap_ProfitLoss_005e0fd2-95f8-4a3c-b52b-17590e2bd4a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768dd3ec-cef0-4336-8241-dbe3fe049401" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dca413d6-9898-4e02-b611-6cf11217ec14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dca413d6-9898-4e02-b611-6cf11217ec14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6a28a36c-64b4-4ba6-85f6-35ec7607bc3c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6a28a36c-64b4-4ba6-85f6-35ec7607bc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_ccc0c2c4-a307-4f17-aff9-10a3a71651a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_ccc0c2c4-a307-4f17-aff9-10a3a71651a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_8ff9d201-aad1-43ab-8f12-34d8ecd6ecf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_8ff9d201-aad1-43ab-8f12-34d8ecd6ecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c6781bf0-ca2e-416a-84e6-186102efc307" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_ShareBasedCompensation_c6781bf0-ca2e-416a-84e6-186102efc307" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_2068e723-6f04-40d9-a4e4-7ed31fd0fa3e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_2068e723-6f04-40d9-a4e4-7ed31fd0fa3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ad35012-60c3-492c-bd6f-c8036f086ed2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_9ad35012-60c3-492c-bd6f-c8036f086ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_acae3dad-7643-4cb3-ae0b-ccce66428350" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_acae3dad-7643-4cb3-ae0b-ccce66428350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_GainLossOnAssumptionOfLoan_dabd15da-bebd-427d-846d-790b5d402d3e" xlink:href="ameh-20200930.xsd#ameh_GainLossOnAssumptionOfLoan"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_ameh_GainLossOnAssumptionOfLoan_dabd15da-bebd-427d-846d-790b5d402d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d1b9308d-bbc0-43bb-b02c-807c5d22c154" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_d1b9308d-bbc0-43bb-b02c-807c5d22c154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7badd355-ad4d-4b6d-a12d-8c7465e6f926" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_93952531-6e69-42ae-bb29-4543fffab258" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_93952531-6e69-42ae-bb29-4543fffab258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_bb44c17c-1da0-40e3-82c3-2287b95d2da4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_bb44c17c-1da0-40e3-82c3-2287b95d2da4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_812bfd9e-72b7-45e3-b9ae-d5269a9424dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_812bfd9e-72b7-45e3-b9ae-d5269a9424dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_fecda69e-1662-4b41-b340-5c736dff48a8" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets_fecda69e-1662-4b41-b340-5c736dff48a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_db24e84c-f226-4f4b-a3c9-58bb1b084794" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOperatingLeaseAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_ameh_IncreaseDecreaseInOperatingLeaseAssets_db24e84c-f226-4f4b-a3c9-58bb1b084794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ea0b60a-cff7-4f8d-940a-2305255f8d97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9ea0b60a-cff7-4f8d-940a-2305255f8d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d15726c-0438-4b10-b93d-5ae816c3e906" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3d15726c-0438-4b10-b93d-5ae816c3e906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8078e585-bac5-4cf5-a134-1443b77ac115" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayable_8078e585-bac5-4cf5-a134-1443b77ac115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInMedicalLiabilities_f1629aa1-e282-470d-933c-433acd81c2e4" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInMedicalLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_ameh_IncreaseDecreaseInMedicalLiabilities_f1629aa1-e282-470d-933c-433acd81c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ceed7d8-6523-45a3-978e-44d2222b922c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_9ceed7d8-6523-45a3-978e-44d2222b922c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_307fea1c-dae5-41cc-b3d8-6354707295c3" xlink:href="ameh-20200930.xsd#ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_07cd9620-f878-4f6f-a61d-ffc56478b37a" xlink:to="loc_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities_307fea1c-dae5-41cc-b3d8-6354707295c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_580e221e-79a1-427d-a270-7ea3ba0ce2d1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_768dd3ec-cef0-4336-8241-dbe3fe049401" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_580e221e-79a1-427d-a270-7ea3ba0ce2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_693b394e-bfad-4165-9662-2c34f144f507" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_693b394e-bfad-4165-9662-2c34f144f507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_81807957-66b8-46b0-97f3-b5cfc4241170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties_81807957-66b8-46b0-97f3-b5cfc4241170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_e5882180-6676-419e-9ce7-e5a2c3202387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToFundLongtermLoansToRelatedParties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_PaymentsToFundLongtermLoansToRelatedParties_e5882180-6676-419e-9ce7-e5a2c3202387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_218be804-0b2d-4f0a-a58d-e66bbdd560d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_218be804-0b2d-4f0a-a58d-e66bbdd560d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fe889c4b-6a14-4c60-9aa6-9cf6d558a8c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_fe889c4b-6a14-4c60-9aa6-9cf6d558a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ae89632c-5dec-4d7b-bc33-f1545ddbbbc3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ae89632c-5dec-4d7b-bc33-f1545ddbbbc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d095f442-350b-4d96-a875-aab1c66195fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d095f442-350b-4d96-a875-aab1c66195fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_01d16a26-7026-48bc-84ba-110c03197b96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital_01d16a26-7026-48bc-84ba-110c03197b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fdf304c-0865-42e2-9209-ab1a4b3c3b27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_20bb211d-d74f-44cd-be42-20ae458f54d7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6fdf304c-0865-42e2-9209-ab1a4b3c3b27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_34dcc403-0c06-44f2-92f2-c48d495b71b7" xlink:href="ameh-20200930.xsd#ameh_RepaymentsOfBankLoanAndLinesOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_ameh_RepaymentsOfBankLoanAndLinesOfCredit_34dcc403-0c06-44f2-92f2-c48d495b71b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_88b9065c-89ba-4d65-a1bd-1dd108a03881" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_PaymentsOfDividends_88b9065c-89ba-4d65-a1bd-1dd108a03881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_a0f367f8-bba5-425e-8a19-eeef457ab534" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_a0f367f8-bba5-425e-8a19-eeef457ab534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_aab210ee-1db5-4431-9c74-9e4cf554e9bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_aab210ee-1db5-4431-9c74-9e4cf554e9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e428ad52-57e6-41b1-ac3e-3ae6f34f4d13" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e428ad52-57e6-41b1-ac3e-3ae6f34f4d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a3c56fba-6aa4-4c78-9ae1-b4d3bea0a632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a3c56fba-6aa4-4c78-9ae1-b4d3bea0a632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_36ba16fd-134c-4b95-84eb-b0d96ad649f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_36ba16fd-134c-4b95-84eb-b0d96ad649f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1490c2af-0179-432f-8a65-7c6585409ad7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_1490c2af-0179-432f-8a65-7c6585409ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_13df0b85-5c4d-4a1b-bddf-e06cb240da78" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_PaymentOfFinancingAndStockIssuanceCosts_13df0b85-5c4d-4a1b-bddf-e06cb240da78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a09bd63b-187b-4b28-b048-ac60bf015c07" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e6716609-75b1-4548-bc74-05f38cbd7306" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a09bd63b-187b-4b28-b048-ac60bf015c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71c7fe54-58c7-4597-8242-6e593985ed11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_71c7fe54-58c7-4597-8242-6e593985ed11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8433f0b-bffb-448c-9436-a5abcda2a671" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e8433f0b-bffb-448c-9436-a5abcda2a671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d83e1b8-dccd-4a6e-a3f2-dd3104e9526c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3d83e1b8-dccd-4a6e-a3f2-dd3104e9526c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a107bde-bd68-4149-8857-f3ad9e43957f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a107bde-bd68-4149-8857-f3ad9e43957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_73793174-2434-4284-b5c3-a4fec3e05a6a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a107bde-bd68-4149-8857-f3ad9e43957f" xlink:to="loc_us-gaap_IncomeTaxesPaid_73793174-2434-4284-b5c3-a4fec3e05a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_0451d06d-613a-4240-8899-e5338668850d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_5a107bde-bd68-4149-8857-f3ad9e43957f" xlink:to="loc_us-gaap_InterestPaidNet_0451d06d-613a-4240-8899-e5338668850d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_7da99f7b-667a-4e0f-95ca-11daacb1b37f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_7da99f7b-667a-4e0f-95ca-11daacb1b37f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_3da5040a-fe37-4bd0-984f-710393cdb16d" xlink:href="ameh-20200930.xsd#ameh_DeferredTaxLiabilitiesAdjustedToGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:to="loc_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill_3da5040a-fe37-4bd0-984f-710393cdb16d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised_c7cb1f73-9e90-4da5-a078-1efc61a6b004" xlink:href="ameh-20200930.xsd#ameh_DeferredTaxLiabilitiesWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:to="loc_ameh_DeferredTaxLiabilitiesWarrantsExercised_c7cb1f73-9e90-4da5-a078-1efc61a6b004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssued1_709e0190-b760-4874-bca5-9a485be61639" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssued1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:to="loc_us-gaap_StockIssued1_709e0190-b760-4874-bca5-9a485be61639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_106fb10f-132f-4913-9099-6763ca131b72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_78b9ebe1-f65a-46c0-a20d-2dde723524eb" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_106fb10f-132f-4913-9099-6763ca131b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:href="ameh-20200930.xsd#ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_02b48cee-ae7a-41f5-b182-5fcc4ac69c06" xlink:to="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55dcc4cf-6a8d-4b88-b4e8-daaf469fc862" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55dcc4cf-6a8d-4b88-b4e8-daaf469fc862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_13b0698a-ef41-42eb-833c-fc26fb5472c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_13b0698a-ef41-42eb-833c-fc26fb5472c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_ed29f689-c833-47ad-9761-8d845f3540a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_ed29f689-c833-47ad-9761-8d845f3540a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f60b8643-ee36-4546-bbef-b46526c265db" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract_184a3dc4-1c38-4d05-86a0-9ff1d8e59c3c" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f60b8643-ee36-4546-bbef-b46526c265db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95bd8e61-9a52-4d54-be18-206098d1eeab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_e67e59e1-c541-4aa8-aee0-7a21c02890f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95bd8e61-9a52-4d54-be18-206098d1eeab" xlink:to="loc_us-gaap_NatureOfOperations_e67e59e1-c541-4aa8-aee0-7a21c02890f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#DescriptionofBusinessAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b554babc-32d9-427e-b6cd-ede8301e5f2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b554babc-32d9-427e-b6cd-ede8301e5f2d" xlink:to="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6a4c3265-f53a-4445-8dc7-9128ea544b45" xlink:to="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2b107040-202e-4e16-9d00-ca530cee860c" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2b107040-202e-4e16-9d00-ca530cee860c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_71806854-9f4d-43c1-bf30-b10cf9a5c970" xlink:href="ameh-20200930.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_ApcLsmaMember_71806854-9f4d-43c1-bf30-b10cf9a5c970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_135fec06-0df1-4d55-8fbe-e9bef5976fa5" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_135fec06-0df1-4d55-8fbe-e9bef5976fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_d3e12225-043c-4a67-a5e8-2f1bf4f17fb5" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AccountableHealthCareIPAMember_d3e12225-043c-4a67-a5e8-2f1bf4f17fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_93e746c0-d8ef-44d5-ae60-0014a7e64d83" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_APCAndAPCLSMAMember_93e746c0-d8ef-44d5-ae60-0014a7e64d83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_f8d8764d-4e56-44dd-9980-4d5ef85b48c8" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_AmgIncMember_f8d8764d-4e56-44dd-9980-4d5ef85b48c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5e0256c3-2d74-4042-adbc-0b5b10687fe2" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_516df52c-2fce-4254-9b43-533728b345d0" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_5e0256c3-2d74-4042-adbc-0b5b10687fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_0b2df512-6628-41b4-a0fd-4655c779a95c" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APAMHMedicalCorporationMember_f1d83ed9-ebad-4ca7-8ab1-810ab0905a96" xlink:href="ameh-20200930.xsd#ameh_APAMHMedicalCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_APAMHMedicalCorporationMember_f1d83ed9-ebad-4ca7-8ab1-810ab0905a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6b65ebb2-cc2c-41c6-af1f-e1940a1536e9" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6b65ebb2-cc2c-41c6-af1f-e1940a1536e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_a0da8b71-018e-45f9-8a82-850e03bd2a74" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_Dr.JayMember_a0da8b71-018e-45f9-8a82-850e03bd2a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_c5a4ce8b-b6dc-4a08-a137-e1b5a85f9c8b" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42fdc54a-4ea9-481a-8066-8d6cc452515b" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_c5a4ce8b-b6dc-4a08-a137-e1b5a85f9c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_d9bdf15c-5995-4d0d-8336-48a413cf1ba5" xlink:to="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_f7944037-c9d4-44cf-b304-7293b2c7e753" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_cc7e30a2-3788-4047-b13d-afddfe607f7d" xlink:to="loc_srt_AffiliatedEntityMember_f7944037-c9d4-44cf-b304-7293b2c7e753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ba91f311-828d-4ca8-9b26-5ab909c82ef6" xlink:to="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_53839522-3947-491b-b67a-15880c24c633" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_53839522-3947-491b-b67a-15880c24c633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ef0377dd-9085-4c21-a8c0-84e52a460d9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8435b51d-3544-44a5-955f-a2fd79ab2c98" xlink:to="loc_us-gaap_PreferredStockMember_ef0377dd-9085-4c21-a8c0-84e52a460d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7d71e94e-2d72-4152-b42f-33f86354c470" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApolloMedicalHoldingsIncMember_3911b31e-e039-4362-ae53-58237482a576" xlink:href="ameh-20200930.xsd#ameh_ApolloMedicalHoldingsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_ApolloMedicalHoldingsIncMember_3911b31e-e039-4362-ae53-58237482a576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_99b6e982-9af0-486c-a827-1ec3a6687fe0" xlink:href="ameh-20200930.xsd#ameh_ConcourseDiagnosticSurgeryCenterLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_ConcourseDiagnosticSurgeryCenterLlcMember_99b6e982-9af0-486c-a827-1ec3a6687fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_9419941d-1afe-4d92-bf94-ff393daccd57" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_98f2f2e9-b7b6-4aba-9e95-2a5048fcc20c" xlink:to="loc_ameh_UniversalCareIncMember_9419941d-1afe-4d92-bf94-ff393daccd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ff2caeaf-4b1a-4cf3-bc2f-3e7c48304995" xlink:to="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MaverickMedicalGroupIncMember_fed6200e-dfe2-40d6-84d8-c54458ebde69" xlink:href="ameh-20200930.xsd#ameh_MaverickMedicalGroupIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:to="loc_ameh_MaverickMedicalGroupIncMember_fed6200e-dfe2-40d6-84d8-c54458ebde69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_97df72f0-c007-45c3-965b-69543119ab11" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_b5e00361-63dc-499a-963e-5c3918004f57" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_97df72f0-c007-45c3-965b-69543119ab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_65c80403-92cc-4df5-ae78-c2b0afb1aae9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_713f5e40-1c4d-4dec-ae8f-72953bb73405" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:to="loc_ameh_AccountableHealthCareIPAMember_713f5e40-1c4d-4dec-ae8f-72953bb73405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_68727040-bc51-4916-b71e-454e23196805" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4970fcf8-68a3-4035-b377-f85da12c9c95" xlink:to="loc_ameh_AmgIncMember_68727040-bc51-4916-b71e-454e23196805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:href="ameh-20200930.xsd#ameh_DescriptionOfBusinessLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessTable_20cdc467-263b-4697-842f-a3decc1d5156" xlink:to="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_1616aa54-4bc1-4b9d-9bd8-cb5cb3f4382c" xlink:href="ameh-20200930.xsd#ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement_1616aa54-4bc1-4b9d-9bd8-cb5cb3f4382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_94225583-d73a-4b50-80d3-207dbdbe10fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NotesReceivableNet_94225583-d73a-4b50-80d3-207dbdbe10fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_7fd044d9-433f-47eb-803a-11425cc24924" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_7fd044d9-433f-47eb-803a-11425cc24924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableStatedInterestRate_31c38b65-f7fa-4d3a-b1ff-ef2ca7144af9" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableStatedInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableStatedInterestRate_31c38b65-f7fa-4d3a-b1ff-ef2ca7144af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_f76c3cd7-0adb-4d59-b850-4d4beb9fd8f2" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate_f76c3cd7-0adb-4d59-b850-4d4beb9fd8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b462746-51c9-4216-9285-9f8126b763b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5b462746-51c9-4216-9285-9f8126b763b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d91a0670-2e52-4927-b47b-a2314110ce15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_d91a0670-2e52-4927-b47b-a2314110ce15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_a1cfd92a-4418-4d68-b167-d393c2624a89" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodProxyVotesPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_StockIssuedDuringPeriodProxyVotesPercentage_a1cfd92a-4418-4d68-b167-d393c2624a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dfbbe41b-5176-4f79-b481-7bbe54130a4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_dfbbe41b-5176-4f79-b481-7bbe54130a4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_957ac0d0-ea07-4830-a212-e5c93b83fb33" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_957ac0d0-ea07-4830-a212-e5c93b83fb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f04beac-d691-4e70-b9de-60bde7906af7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_6f04beac-d691-4e70-b9de-60bde7906af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_0b2c2cf1-20e5-42ee-9ed7-687d862f5d07" xlink:href="ameh-20200930.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfEmployees_0b2c2cf1-20e5-42ee-9ed7-687d862f5d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_1930a1b6-9893-4f0a-b17a-02989a39c9fa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NumberOfStores_1930a1b6-9893-4f0a-b17a-02989a39c9fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFederallyQualifiedHealthPlans_af8bb047-44c0-4f4a-897b-2d352d5fc6f5" xlink:href="ameh-20200930.xsd#ameh_NumberOfFederallyQualifiedHealthPlans"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfFederallyQualifiedHealthPlans_af8bb047-44c0-4f4a-897b-2d352d5fc6f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e6da391e-7bd9-4ef9-808e-deb1130fe1d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_e6da391e-7bd9-4ef9-808e-deb1130fe1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7a50553-163d-4ef5-9da5-f5adcd614230" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d7a50553-163d-4ef5-9da5-f5adcd614230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfFamilyPracticeClinics_61d3ca0c-94ce-4e76-9fc4-51bf71fa8270" xlink:href="ameh-20200930.xsd#ameh_NumberOfFamilyPracticeClinics"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_NumberOfFamilyPracticeClinics_61d3ca0c-94ce-4e76-9fc4-51bf71fa8270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_397101e2-0399-42ba-8539-393ca164bd2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_397101e2-0399-42ba-8539-393ca164bd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b84b50f9-2ab1-4e49-93b4-36987da94913" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_b84b50f9-2ab1-4e49-93b4-36987da94913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_485d622e-4ea0-4458-a29e-88d48277980c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_485d622e-4ea0-4458-a29e-88d48277980c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_3f3ccf3b-d415-4004-aa6c-9972e32d96ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_3f3ccf3b-d415-4004-aa6c-9972e32d96ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_590861d2-4b74-447f-a7aa-1e4fccb13875" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1_590861d2-4b74-447f-a7aa-1e4fccb13875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_eabfb41a-dc6f-47f9-a63d-2be71ea75b3d" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_DescriptionOfBusinessLineItems_a395bf81-44a3-4f17-91ec-3d1b18ca93ae" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_eabfb41a-dc6f-47f9-a63d-2be71ea75b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e68aeae-724e-4b89-bf4b-1d210a3e940a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b358a79f-2bee-45fc-a442-79d12113811d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e68aeae-724e-4b89-bf4b-1d210a3e940a" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b358a79f-2bee-45fc-a442-79d12113811d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4d935441-da15-4554-8b2c-2abbeca25e22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_4d935441-da15-4554-8b2c-2abbeca25e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_29c5989f-6fac-4054-b9cf-a46494d64d6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_29c5989f-6fac-4054-b9cf-a46494d64d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_5455c06d-4957-45f5-8fd0-b5a2c6326b9c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_UseOfEstimates_5455c06d-4957-45f5-8fd0-b5a2c6326b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85175a56-7e38-47fa-9d7e-b3318da4fbb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_85175a56-7e38-47fa-9d7e-b3318da4fbb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cff1acb5-4381-4693-8bcf-52520c4fda9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_cff1acb5-4381-4693-8bcf-52520c4fda9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f997d0e3-40f5-4a3e-8c04-38cfce44cc15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f997d0e3-40f5-4a3e-8c04-38cfce44cc15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_4c2d1b12-1690-4dfe-8b74-4aa5ce7ad45c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_4c2d1b12-1690-4dfe-8b74-4aa5ce7ad45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_cd51d088-8eea-45ce-acb5-5cc44370d876" xlink:href="ameh-20200930.xsd#ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock_cd51d088-8eea-45ce-acb5-5cc44370d876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_27c4c452-8e69-478b-9a55-36b2c14e8b1c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_27c4c452-8e69-478b-9a55-36b2c14e8b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2203e568-9c26-4bb4-be12-4e79ad637cac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2203e568-9c26-4bb4-be12-4e79ad637cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a5856d07-6589-4f29-a49b-c0cdf87b47b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_a5856d07-6589-4f29-a49b-c0cdf87b47b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f33d7bc5-2c7a-4050-a980-ad0f58da37bd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_f33d7bc5-2c7a-4050-a980-ad0f58da37bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_98c10653-08d3-42e2-b317-49f27dc08670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy_98c10653-08d3-42e2-b317-49f27dc08670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_ab5159dd-a17d-43f2-b6eb-c6b31596e7f4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_HealthCareCostsPolicyPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_HealthCareCostsPolicyPolicyTextBlock_ab5159dd-a17d-43f2-b6eb-c6b31596e7f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d87b72a-8adb-4396-b6db-2e34d3705be2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_5d87b72a-8adb-4396-b6db-2e34d3705be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_eaac1187-a7d0-4a35-99c9-c21532c82ba6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_eaac1187-a7d0-4a35-99c9-c21532c82ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e68db402-0958-4425-b0e7-d0ddf9e63c33" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_e68db402-0958-4425-b0e7-d0ddf9e63c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_7a8287e0-6e2f-4667-bc41-522fe69286cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_7a8287e0-6e2f-4667-bc41-522fe69286cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MinorityInterestPolicyPolicyTextBlock_16d278fb-b63f-4d68-b070-d556db53a180" xlink:href="ameh-20200930.xsd#ameh_MinorityInterestPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_ameh_MinorityInterestPolicyPolicyTextBlock_16d278fb-b63f-4d68-b070-d556db53a180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TemporaryEquityPolicyTextBlock_59fea0f7-e04f-49d8-951e-2d280fd206aa" xlink:href="ameh-20200930.xsd#ameh_TemporaryEquityPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_ameh_TemporaryEquityPolicyTextBlock_59fea0f7-e04f-49d8-951e-2d280fd206aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_711ea7dd-a0f5-4b82-b6c6-73bbf7e9cd4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_95ade660-a4ac-4b9c-933a-65301a05d891" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_711ea7dd-a0f5-4b82-b6c6-73bbf7e9cd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bafa6ac3-e744-4580-b1a9-eb989b26cc3b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6dd7f6a1-0528-4c29-941b-408a345a3efd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bafa6ac3-e744-4580-b1a9-eb989b26cc3b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_6dd7f6a1-0528-4c29-941b-408a345a3efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_95ae0be4-ff9c-4502-b875-bb67b93c4167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bafa6ac3-e744-4580-b1a9-eb989b26cc3b" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_95ae0be4-ff9c-4502-b875-bb67b93c4167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_74714664-f95f-46f4-88ea-cc98cc6eaa27" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bafa6ac3-e744-4580-b1a9-eb989b26cc3b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_74714664-f95f-46f4-88ea-cc98cc6eaa27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_37d3271d-7a1e-41ff-bbc0-ab9816b44540" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_37d3271d-7a1e-41ff-bbc0-ab9816b44540" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_61bdeb27-a740-43bd-90ac-60e1e124a5e6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_ecaaa5b4-7df9-4c34-b5a6-1d7dfb09c2e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_6b500497-da48-4c21-8f28-3268141b2b55" xlink:to="loc_us-gaap_CertificatesOfDepositMember_ecaaa5b4-7df9-4c34-b5a6-1d7dfb09c2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a49a6fb5-82f2-48fc-9d8c-24e54ae2f00a" xlink:to="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6b58106-77ff-432d-96b5-5c411934695f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:to="loc_srt_MinimumMember_c6b58106-77ff-432d-96b5-5c411934695f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d59238aa-e8b5-4241-a1ba-44e13bf33b96" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5e2a6941-67b9-4baa-b04b-4a21c37be178" xlink:to="loc_srt_MaximumMember_d59238aa-e8b5-4241-a1ba-44e13bf33b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d6b4b6e7-3d76-4416-acf1-d1105206e6a5" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CMSMember_f75279dd-4b39-4771-8191-7e36af99934d" xlink:href="ameh-20200930.xsd#ameh_CMSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2eefda99-7f09-403f-ac17-9ec8899e9e02" xlink:to="loc_ameh_CMSMember_f75279dd-4b39-4771-8191-7e36af99934d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2a571b86-6cec-48d4-bfd3-e94ee70ef5fb" xlink:to="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PerMemberPerMonthManagedCareContractMember_962d1fdf-0b96-46ee-9f8c-09f35a927416" xlink:href="ameh-20200930.xsd#ameh_PerMemberPerMonthManagedCareContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_ameh_PerMemberPerMonthManagedCareContractMember_962d1fdf-0b96-46ee-9f8c-09f35a927416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_b93fa2c4-76f4-4f1b-8e3e-e933c41e4239" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_b93fa2c4-76f4-4f1b-8e3e-e933c41e4239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceMember_521c8768-41ca-4fb5-9890-c1d32baffc18" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9826640a-9e0f-426e-b91b-b0f1871f6ec9" xlink:to="loc_us-gaap_ManagementServiceMember_521c8768-41ca-4fb5-9890-c1d32baffc18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_ad798083-81ca-4756-8e3c-397b4acf650c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsPayableAndAccruedExpensesMember_84d86be1-f59f-4b05-8113-deb7c9d37f25" xlink:href="ameh-20200930.xsd#ameh_AccountsPayableAndAccruedExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a66bf0e5-dbea-4d83-9dc5-0972f213a6cd" xlink:to="loc_ameh_AccountsPayableAndAccruedExpensesMember_84d86be1-f59f-4b05-8113-deb7c9d37f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:href="ameh-20200930.xsd#ameh_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesTable_ac4bd304-e57d-4faf-a6a0-1b72382b4567" xlink:to="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_adb3d049-8f57-4604-b981-b9a22b156bbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_adb3d049-8f57-4604-b981-b9a22b156bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c38d4d44-abb3-423c-9471-2fb7d37260ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfReportableSegments_c38d4d44-abb3-423c-9471-2fb7d37260ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashUninsuredAmount_bbe72ed1-b738-43af-b8a6-2653bdb30e80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashUninsuredAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_CashUninsuredAmount_bbe72ed1-b738-43af-b8a6-2653bdb30e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2f26e1be-5ca9-4e83-bde1-535811545678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2f26e1be-5ca9-4e83-bde1-535811545678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_33e0b584-20e8-4360-b788-614d753b8374" xlink:href="ameh-20200930.xsd#ameh_MarketableSecuritiesCurrentMaturityPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_MarketableSecuritiesCurrentMaturityPeriod_33e0b584-20e8-4360-b788-614d753b8374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_b5bd43fd-d328-480b-bc13-4f110e9af473" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear_b5bd43fd-d328-480b-bc13-4f110e9af473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2868d3-6aa8-4e02-a580-45517a9550da" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_cb2868d3-6aa8-4e02-a580-45517a9550da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_79d12a38-1681-4d8d-9a16-a4562b1eeea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_79d12a38-1681-4d8d-9a16-a4562b1eeea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d89261ed-39c0-4295-abe8-d56ec0d41352" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_d89261ed-39c0-4295-abe8-d56ec0d41352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportingUnits_8eea479c-32e9-4104-bbed-d5ca9ae68014" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfReportingUnits"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_NumberOfReportingUnits_8eea479c-32e9-4104-bbed-d5ca9ae68014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_6e3147ea-f487-4b9f-8dfc-5101d8800087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_6e3147ea-f487-4b9f-8dfc-5101d8800087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_30589416-efdb-4510-b61e-67cfe1cdcaf5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_30589416-efdb-4510-b61e-67cfe1cdcaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_96db9b51-4bdc-446b-ae32-dc751074d81f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfTiming"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfTiming_96db9b51-4bdc-446b-ae32-dc751074d81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_7408e43b-3788-46fa-8d4a-4e26dc387505" xlink:href="ameh-20200930.xsd#ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport_7408e43b-3788-46fa-8d4a-4e26dc387505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_RiskPoolSettlement_e493c253-eadb-40ea-bf72-be24feddb36f" xlink:href="ameh-20200930.xsd#ameh_RiskPoolSettlement"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_RiskPoolSettlement_e493c253-eadb-40ea-bf72-be24feddb36f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenueMonthlyAmount_1bf38deb-9aec-426e-88ba-d5050a71fcae" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenueMonthlyAmount"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_PaymentOfRevenueMonthlyAmount_1bf38deb-9aec-426e-88ba-d5050a71fcae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentOfRevenue_ad56b32b-3446-44d7-bf56-cddafd8fe161" xlink:href="ameh-20200930.xsd#ameh_PaymentOfRevenue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_PaymentOfRevenue_ad56b32b-3446-44d7-bf56-cddafd8fe161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d8e59e89-bf44-4df3-8bd8-97622003ee89" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_d8e59e89-bf44-4df3-8bd8-97622003ee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c6c44c2-e5cb-4889-8641-4034395cf62d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c6c44c2-e5cb-4889-8641-4034395cf62d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_2357c98a-96c6-4866-89a5-4b4e16d7c50a" xlink:href="ameh-20200930.xsd#ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned_2357c98a-96c6-4866-89a5-4b4e16d7c50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentDeposit_816e841a-f68a-44db-b44a-fc519625b457" xlink:href="ameh-20200930.xsd#ameh_InvestmentDeposit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_ameh_InvestmentDeposit_816e841a-f68a-44db-b44a-fc519625b457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityOwnershipPercentage_69671973-4946-427b-8594-3e5db67f0993" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityOwnershipPercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SummaryOfSignificantAccountingPoliciesLineItems_439d7d72-2060-45d1-bcba-b9721aed5b9f" xlink:to="loc_us-gaap_VariableInterestEntityOwnershipPercentage_69671973-4946-427b-8594-3e5db67f0993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_671e1e86-0981-401e-9977-22348ae387aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_671e1e86-0981-401e-9977-22348ae387aa" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_088b7074-77d1-425a-b915-439a63ff099f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_088b7074-77d1-425a-b915-439a63ff099f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a3dba856-e440-49e9-ab42-6c557b4cbc9e" xlink:to="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:href="ameh-20200930.xsd#ameh_NextGenerationACOModelParticipationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4e446ee-fcd5-48d3-aa0a-8274a23c21e7" xlink:to="loc_ameh_NextGenerationACOModelParticipationAgreementMember_f89b72bd-a211-46e5-8cf5-4052ffaa95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_6b145934-62f0-4211-ab5d-58b596d1b47b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_68827ca8-652e-4781-a542-d18925b98a40" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e8039307-cc0c-4d80-be99-d87c83609435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2468e434-0517-4bff-9877-dd9320fcda9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2468e434-0517-4bff-9877-dd9320fcda9a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:to="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e20cfb9a-4a6e-4a91-9657-62cbd20d6566" xlink:to="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommercialMember_e19db2b7-4e83-496f-bfc0-8b2019113bcd" xlink:href="ameh-20200930.xsd#ameh_CommercialMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_CommercialMember_e19db2b7-4e83-496f-bfc0-8b2019113bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicareMember_4c950816-7f80-42b2-9f98-131f53974ed1" xlink:href="ameh-20200930.xsd#ameh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_MedicareMember_4c950816-7f80-42b2-9f98-131f53974ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicaidMember_ec79c561-9d64-42a9-8029-2bf3f147f145" xlink:href="ameh-20200930.xsd#ameh_MedicaidMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_MedicaidMember_ec79c561-9d64-42a9-8029-2bf3f147f145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OtherThirdPartiesMember_0413f544-956c-415b-acb0-59f6f012a833" xlink:href="ameh-20200930.xsd#ameh_OtherThirdPartiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4c900efb-4a0e-4615-8b56-1c5534b8ee71" xlink:to="loc_ameh_OtherThirdPartiesMember_0413f544-956c-415b-acb0-59f6f012a833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_26c6cda4-116a-48b7-a2df-a68fea5cfb2d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad1b0b98-6b28-4963-a524-36980d9ce86d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_cd2d484d-2433-4449-9419-96c7b80ca6b0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ad1b0b98-6b28-4963-a524-36980d9ce86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5313924b-477e-4437-b0c6-d7cf7c730dc7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5313924b-477e-4437-b0c6-d7cf7c730dc7" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a2bcd21a-f1fa-4d2b-a24c-82a1561358d7" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f4985037-bfc6-4cad-888c-fce08e3172ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:to="loc_us-gaap_SalesRevenueNetMember_f4985037-bfc6-4cad-888c-fce08e3172ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3dab3f68-4d57-4039-a712-335a48d4c181" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_6c88ed57-7eb3-4b9c-9d77-81a1a05d7972" xlink:to="loc_us-gaap_AccountsReceivableMember_3dab3f68-4d57-4039-a712-335a48d4c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:to="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_a271f541-fc43-4c01-9b53-172f473ca883" xlink:to="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorAMember_d19909a0-f4c0-4d7e-8c60-f9714621053a" xlink:href="ameh-20200930.xsd#ameh_PayorAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorAMember_d19909a0-f4c0-4d7e-8c60-f9714621053a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorBMember_fbce979d-0c2f-48de-9fb1-c85286f0c446" xlink:href="ameh-20200930.xsd#ameh_PayorBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorBMember_fbce979d-0c2f-48de-9fb1-c85286f0c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorCMember_5879fb08-6368-46ed-a381-743e667a86c9" xlink:href="ameh-20200930.xsd#ameh_PayorCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorCMember_5879fb08-6368-46ed-a381-743e667a86c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorDMember_4052a8ab-83f6-4e09-98dd-55bab428fa5c" xlink:href="ameh-20200930.xsd#ameh_PayorDMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorDMember_4052a8ab-83f6-4e09-98dd-55bab428fa5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorEMember_24109ad0-29e3-47b4-a2e4-f0e27dd7352e" xlink:href="ameh-20200930.xsd#ameh_PayorEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorEMember_24109ad0-29e3-47b4-a2e4-f0e27dd7352e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorFMember_31a8cad4-d58d-4bf2-aed9-b20442234791" xlink:href="ameh-20200930.xsd#ameh_PayorFMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorFMember_31a8cad4-d58d-4bf2-aed9-b20442234791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PayorGMember_b188b291-8cb6-4472-985c-12603de829e3" xlink:href="ameh-20200930.xsd#ameh_PayorGMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b587f7f1-a90f-4d6e-bdd8-c378a6eedf8a" xlink:to="loc_ameh_PayorGMember_b188b291-8cb6-4472-985c-12603de829e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:href="ameh-20200930.xsd#ameh_AccountsReceivableAndNetRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueTable_4ca3f799-7170-41a0-bcb5-7202166d58c8" xlink:to="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_b9f9195d-0764-42cf-96d5-6f596f7e8bae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AccountsReceivableAndNetRevenueLineItems_13cc6175-767f-4209-96ef-dc17cb478945" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_b9f9195d-0764-42cf-96d5-6f596f7e8bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_88e2ffbb-1110-4aaa-81e9-084346466b8b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_88e2ffbb-1110-4aaa-81e9-084346466b8b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_789cc2e3-0ed2-47e2-9b86-00b8dc9adbd9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b8a1e6a9-6694-4e4a-a7c1-9ddae635fb22" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b8a1e6a9-6694-4e4a-a7c1-9ddae635fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1d1bde67-3fb6-4591-b245-78000bab5719" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1d1bde67-3fb6-4591-b245-78000bab5719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6a377406-2631-4c5b-aec1-1d27d1bd4314" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e5a03afd-bf8b-47ff-97ef-dec94508c2c5" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6a377406-2631-4c5b-aec1-1d27d1bd4314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_c7e0652b-f34d-4361-8475-4ecef1fe58fe" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_43e33137-2134-4768-a7e0-7c02948a242b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a834a298-acea-41e3-9dc1-f985926886b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_a834a298-acea-41e3-9dc1-f985926886b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26ab199f-ed2e-4970-a644-16a74fd060a2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_26ab199f-ed2e-4970-a644-16a74fd060a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_4369d706-509a-4db9-a3fe-aa5bb7e32cd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_4369d706-509a-4db9-a3fe-aa5bb7e32cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_750ff14b-e5c2-4f34-9309-cd8df5d54632" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_3c2f8c2f-228b-4a4a-aff4-aaf504b3b361" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_750ff14b-e5c2-4f34-9309-cd8df5d54632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_86fffc3b-4ca5-4456-88df-487cca0e4bea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f1d8da03-4886-4744-94b0-baa08df783e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_86fffc3b-4ca5-4456-88df-487cca0e4bea" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_f1d8da03-4886-4744-94b0-baa08df783e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5da0ee21-e613-43f7-966b-d8c514ba39b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_03e40055-8bf9-4b31-b54b-71ab67eb6bac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5da0ee21-e613-43f7-966b-d8c514ba39b3" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_03e40055-8bf9-4b31-b54b-71ab67eb6bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_8710a5fb-f3ed-4878-be81-255047c23ada" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5da0ee21-e613-43f7-966b-d8c514ba39b3" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_8710a5fb-f3ed-4878-be81-255047c23ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_d5f3930f-c03d-429b-b2b1-b4986ce08af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_d5f3930f-c03d-429b-b2b1-b4986ce08af1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_cf697f26-ee6f-42c3-8e4f-9cceb0b5f6a4" xlink:to="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_7833df22-3b5d-4541-8fce-54dab970fae4" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:to="loc_ameh_APCAndAPCLSMAMember_7833df22-3b5d-4541-8fce-54dab970fae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a6a1483-0e08-474e-a4f3-cfbc374052b9" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6cdf7c17-ef6d-4468-b5ee-b6cb92398aeb" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_2a6a1483-0e08-474e-a4f3-cfbc374052b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e27c4179-1398-438b-96ad-8cd8115d6c9a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_96b07639-34f5-4043-9108-7928d65e933a" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_96b07639-34f5-4043-9108-7928d65e933a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_dce75567-a94f-4747-bf68-d6bf5bfdcd37" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AccountableHealthCareIPAMember_dce75567-a94f-4747-bf68-d6bf5bfdcd37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_55a7c346-ed05-4926-b30b-3750177bc183" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_af6fabcb-ead2-4a79-89d0-6e718e2f98ee" xlink:to="loc_ameh_AmgIncMember_55a7c346-ed05-4926-b30b-3750177bc183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_6e5bcc83-98db-4b60-a13d-2bbcc271b326" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_6366709d-e8ef-44a1-9d02-5dbd3894cc31" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ea1fd97f-7f7f-42c5-945c-d2f9845fcf98" xlink:to="loc_ameh_Dr.JayMember_6366709d-e8ef-44a1-9d02-5dbd3894cc31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_d1033114-7f33-4bc2-a870-645807bbe643" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_23b0e861-8ecb-44eb-a289-70df451e9b58" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_23b0e861-8ecb-44eb-a289-70df451e9b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_456fc3a5-5342-421a-9382-955767367c61" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_456fc3a5-5342-421a-9382-955767367c61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_2a98bc0b-0b93-4855-b579-292d3a4fa71a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_EscrowDeposit_2a98bc0b-0b93-4855-b579-292d3a4fa71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_20e2d6e0-c667-4488-9467-c068f79ccc01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_20e2d6e0-c667-4488-9467-c068f79ccc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cba89d60-9dee-475b-86af-f602ab53d554" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_cba89d60-9dee-475b-86af-f602ab53d554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_32d1906c-4b9e-462e-819c-6b67e7707786" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_32d1906c-4b9e-462e-819c-6b67e7707786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_10046413-9719-47c5-b850-a09b7dca037c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_30425904-1383-4770-849c-aced425a1640" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_10046413-9719-47c5-b850-a09b7dca037c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_8baa2e32-2532-4a53-a740-bb3c163783b4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_8baa2e32-2532-4a53-a740-bb3c163783b4" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_19667b90-f8cc-4b2d-a2c7-43d146998e7c" xlink:to="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_bbacfb2a-e655-497b-a7c3-e5aa905c36df" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_07ec7a3c-00e9-4e82-b427-9f1eb94aceae" xlink:to="loc_ameh_APCAndAPCLSMAMember_bbacfb2a-e655-497b-a7c3-e5aa905c36df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_838dfaa5-c21a-4f7f-a19b-6d3603ebe295" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_aaaa31b0-7408-4fdd-a991-e6da074137b1" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_aaaa31b0-7408-4fdd-a991-e6da074137b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_c3e69e4c-9a78-47e0-861d-ca6c9ad1d994" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fd313a88-0da2-4bec-ad00-d7850c8025e7" xlink:to="loc_ameh_AccountableHealthCareIPAMember_c3e69e4c-9a78-47e0-861d-ca6c9ad1d994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b726cc17-3d80-4c24-96af-e236ee602316" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.JayMember_f6238041-c91a-4eec-a6df-27fbc439f2ee" xlink:href="ameh-20200930.xsd#ameh_Dr.JayMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_60d13314-542d-446a-bd05-3ca6fb9aec6e" xlink:to="loc_ameh_Dr.JayMember_f6238041-c91a-4eec-a6df-27fbc439f2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_51bb8f8f-734d-4a34-9fe7-9ebf55ceaa96" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b81a534c-95ae-473e-aba8-03a22314c59f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_b81a534c-95ae-473e-aba8-03a22314c59f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1630d0de-a5ae-4b1e-a782-4035798c6cdb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_1630d0de-a5ae-4b1e-a782-4035798c6cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_900cf549-5761-42ab-b929-556844f825d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_900cf549-5761-42ab-b929-556844f825d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84413363-9da3-4d20-b7d9-c8a321eb709e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_84413363-9da3-4d20-b7d9-c8a321eb709e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f904b5ba-3431-4917-9690-96311640d0e3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract_f42e0bec-9d52-4aca-92b0-38b136c7a6c5" xlink:to="loc_us-gaap_Goodwill_f904b5ba-3431-4917-9690-96311640d0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9686a93a-3a34-4326-8b24-d0a11efd4a1f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9686a93a-3a34-4326-8b24-d0a11efd4a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18b4ddbc-e285-417d-9d76-454cbccfd266" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_18b4ddbc-e285-417d-9d76-454cbccfd266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_9d1673f4-dae7-44ae-ac74-027331bd0e32" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities_9d1673f4-dae7-44ae-ac74-027331bd0e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_8b37c7ba-24bd-461e-9006-82d235620896" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_8b37c7ba-24bd-461e-9006-82d235620896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_24d963a0-0c27-4458-9986-5e2a97bbeb81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_24d963a0-0c27-4458-9986-5e2a97bbeb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_11489d2c-48f9-4850-981e-69d4ca8d944b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned_11489d2c-48f9-4850-981e-69d4ca8d944b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_58abdc8a-8137-4b43-b412-21c5607c91d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0597bed1-1b89-4726-8646-075e215a86e9" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_58abdc8a-8137-4b43-b412-21c5607c91d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#BusinessCombinationsandGoodwillSummaryofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_bf97c33b-e889-4ba9-86f1-ef1afe31efe4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_7459bb00-388e-4746-afc1-17aa5c58e12f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_bf97c33b-e889-4ba9-86f1-ef1afe31efe4" xlink:to="loc_us-gaap_GoodwillRollForward_7459bb00-388e-4746-afc1-17aa5c58e12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_30d9707d-6fb9-495e-9682-4e1c5e8ef136" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7459bb00-388e-4746-afc1-17aa5c58e12f" xlink:to="loc_us-gaap_Goodwill_30d9707d-6fb9-495e-9682-4e1c5e8ef136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_7fb80d08-903a-4934-97e1-5ea5ca8a7b5a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7459bb00-388e-4746-afc1-17aa5c58e12f" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_7fb80d08-903a-4934-97e1-5ea5ca8a7b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_48cc6675-44df-494b-aff0-8a638ee4c753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_7459bb00-388e-4746-afc1-17aa5c58e12f" xlink:to="loc_us-gaap_Goodwill_48cc6675-44df-494b-aff0-8a638ee4c753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3e07c95-2804-46bc-a220-90eb3143e9c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4ac4ea42-d2c6-429d-9b3c-7e383408afc0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c3e07c95-2804-46bc-a220-90eb3143e9c3" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_4ac4ea42-d2c6-429d-9b3c-7e383408afc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e02311fc-4198-4c1a-85e9-605ad8377bc8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c4585956-8a59-40d6-ab89-ba12e6791c21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e02311fc-4198-4c1a-85e9-605ad8377bc8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c4585956-8a59-40d6-ab89-ba12e6791c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_afd9a172-e885-43c1-9cf7-384709eaaddf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e02311fc-4198-4c1a-85e9-605ad8377bc8" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_afd9a172-e885-43c1-9cf7-384709eaaddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a74c1f8-9f8e-453a-b11a-81ad2c01998c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8a74c1f8-9f8e-453a-b11a-81ad2c01998c" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7b16dc89-df4e-4d4a-8daf-050ecbedc0d6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkRelationshipsMember_8c5c754b-0e4a-4301-86af-83e7f7faf710" xlink:href="ameh-20200930.xsd#ameh_NetworkRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_NetworkRelationshipsMember_8c5c754b-0e4a-4301-86af-83e7f7faf710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ManagementContractsMember_338e177b-7564-4ab3-bef1-693b410a70ee" xlink:href="ameh-20200930.xsd#ameh_ManagementContractsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_ManagementContractsMember_338e177b-7564-4ab3-bef1-693b410a70ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MemberRelationshipsMember_9e2c8126-4faf-4a89-a2b4-17b83e6fa65b" xlink:href="ameh-20200930.xsd#ameh_MemberRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_MemberRelationshipsMember_9e2c8126-4faf-4a89-a2b4-17b83e6fa65b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PatientManagementPlatformMember_35f7d61a-f85e-4595-8388-bccc5f726811" xlink:href="ameh-20200930.xsd#ameh_PatientManagementPlatformMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_ameh_PatientManagementPlatformMember_35f7d61a-f85e-4595-8388-bccc5f726811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_51e85760-b3ea-459b-9103-48bb9dc175dc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bae0feb9-532d-4172-8f7a-bae904d93438" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_51e85760-b3ea-459b-9103-48bb9dc175dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:to="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_cdf456b2-3a91-473a-b5ae-6afce942de79" xlink:to="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1e82172a-6790-4b2a-9f30-c7b74adb3f9f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:to="loc_srt_MinimumMember_1e82172a-6790-4b2a-9f30-c7b74adb3f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c1c83deb-5b60-4748-ae32-d498cd4ba9b9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_285217ae-3544-4494-aa23-5ec144a156f1" xlink:to="loc_srt_MaximumMember_c1c83deb-5b60-4748-ae32-d498cd4ba9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_a8a39e41-7f85-4620-a3ca-a311e919a7e1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb0612d6-10a0-4f55-a230-37c9f24c133f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_cb0612d6-10a0-4f55-a230-37c9f24c133f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a2dbb62-e0b9-41c7-beaa-3ecd78f8b6c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_0a2dbb62-e0b9-41c7-beaa-3ecd78f8b6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d618a4f-a4a6-4736-8a2c-493164c57ec9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_1d618a4f-a4a6-4736-8a2c-493164c57ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_710d6ff6-714a-4b41-abf9-8a39239ebb17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_710d6ff6-714a-4b41-abf9-8a39239ebb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8f4e23b2-afc4-42e3-bf6b-ce5fc3aae358" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_8f4e23b2-afc4-42e3-bf6b-ce5fc3aae358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c801fe4-c245-490f-9e92-01de7c782d0e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_22c69816-c23b-41e9-9fdd-9d64b713c9eb" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4c801fe4-c245-490f-9e92-01de7c782d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e550218-e27d-4b23-8269-3cb6b8ed303b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_b79bc9dc-237d-4e06-8a76-3ccae3976d63" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0e550218-e27d-4b23-8269-3cb6b8ed303b" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_b79bc9dc-237d-4e06-8a76-3ccae3976d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IntangibleAssetsNetFutureAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b4089221-1f10-45e4-a8d3-3db945cdb18c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b4089221-1f10-45e4-a8d3-3db945cdb18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fd5c7ea4-e879-474d-b523-563dc208c686" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_fd5c7ea4-e879-474d-b523-563dc208c686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d0cd498f-6ce1-4ecf-b734-c996e517af8c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d0cd498f-6ce1-4ecf-b734-c996e517af8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cc248637-3275-477f-9628-c24d34804691" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_cc248637-3275-477f-9628-c24d34804691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9f888677-ebc2-4077-bf00-41fc0b0ba128" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_9f888677-ebc2-4077-bf00-41fc0b0ba128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c5a2680b-bd1d-4f81-b257-ede91b715eb3" xlink:href="ameh-20200930.xsd#ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_c5a2680b-bd1d-4f81-b257-ede91b715eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae536738-fb9e-4da2-899c-c305762e4694" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe800bbe-2fc2-4d6c-acd3-52e7f56743fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ae536738-fb9e-4da2-899c-c305762e4694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethod"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_aa49e343-4388-4c8f-bf09-814df80af3d3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_025f715d-cb79-4315-bf53-c91d9ed3f963" xlink:href="ameh-20200930.xsd#ameh_EquityMethodAndOtherEquityInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_aa49e343-4388-4c8f-bf09-814df80af3d3" xlink:to="loc_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock_025f715d-cb79-4315-bf53-c91d9ed3f963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_eaa22f02-921f-45f0-853d-9a6a14590c28" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_29bad0ed-3bdd-497b-a765-a49a25de3d34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_eaa22f02-921f-45f0-853d-9a6a14590c28" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_29bad0ed-3bdd-497b-a765-a49a25de3d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_fa6842e3-684f-45bc-8451-65f2fc071f30" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentGainOnSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_eaa22f02-921f-45f0-853d-9a6a14590c28" xlink:to="loc_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock_fa6842e3-684f-45bc-8451-65f2fc071f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_de0060bf-ac09-43a5-aaa2-626a4b1d50b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_de0060bf-ac09-43a5-aaa2-626a4b1d50b9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_2255c4a7-5230-46d6-85ab-4ad526646219" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_33c9702d-6f01-4da4-b6b1-8fc6fd31043d" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_33c9702d-6f01-4da4-b6b1-8fc6fd31043d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_827b9ee4-1c41-47a7-8170-6699f5322d89" xlink:href="ameh-20200930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_827b9ee4-1c41-47a7-8170-6699f5322d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_b42ac5e4-010d-4b86-8b5a-41a66d985e62" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_UniversalCareIncMember_b42ac5e4-010d-4b86-8b5a-41a66d985e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_be79b65d-076f-47d4-9504-4f82dc342a21" xlink:href="ameh-20200930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_be79b65d-076f-47d4-9504-4f82dc342a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_e81a149c-13b5-441e-b597-b9d2e3e79f73" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_e81a149c-13b5-441e-b597-b9d2e3e79f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_39440b13-2447-458c-9faa-7231b1fbbeeb" xlink:href="ameh-20200930.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_ba2f5c76-fa13-4164-b45a-7788292a0be1" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_39440b13-2447-458c-9faa-7231b1fbbeeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_63e7d426-c756-4b9b-bc9e-98508e6d88a9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_d3c81611-ff36-45b3-8a6b-1c56b40dadf6" xlink:to="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_26be5cf3-a49a-441d-bded-347cba02cf6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_EquityMethodInvestments_26be5cf3-a49a-441d-bded-347cba02cf6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2cb1e340-3a6e-4bee-a7af-cf4833a7008c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2cb1e340-3a6e-4bee-a7af-cf4833a7008c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_f82ff64c-837c-433b-a295-c0d434a1c753" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_f82ff64c-837c-433b-a295-c0d434a1c753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_f3589f3c-35dd-4cae-9ee8-47f525917c6e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_f3589f3c-35dd-4cae-9ee8-47f525917c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_35a067df-1b2a-4239-8361-be7bf4a487d6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EquityMethodInvestmentsRollForward_e39910c5-b8ed-48c6-8aff-15a185000082" xlink:to="loc_us-gaap_EquityMethodInvestments_35a067df-1b2a-4239-8361-be7bf4a487d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f95747f0-d9e7-4ab4-98c4-d407cdd7025e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f95747f0-d9e7-4ab4-98c4-d407cdd7025e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f7d26044-827b-4efa-bfb9-d0caba7e3a4b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_2de0ec26-6ba2-4510-a7c4-3bfefcd324a7" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_2de0ec26-6ba2-4510-a7c4-3bfefcd324a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_7148c31b-bf04-4d70-a38a-015f38a34748" xlink:href="ameh-20200930.xsd#ameh_PacificMedicalImagingAndOncologyCenterIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_PacificMedicalImagingAndOncologyCenterIncMember_7148c31b-bf04-4d70-a38a-015f38a34748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_8c0573c4-5727-4d68-bd89-9a8d95c88806" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_UniversalCareIncMember_8c0573c4-5727-4d68-bd89-9a8d95c88806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DiagnosticMedicalGroupMember_9717144b-b4eb-4fdc-8745-21ec65db62c6" xlink:href="ameh-20200930.xsd#ameh_DiagnosticMedicalGroupMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_DiagnosticMedicalGroupMember_9717144b-b4eb-4fdc-8745-21ec65db62c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_76c23012-271a-44ec-990f-f9a2d5a69344" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_76c23012-271a-44ec-990f-f9a2d5a69344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MWNCommunityHospitalLLCMember_167bff5a-7cb8-4a42-8597-a27b09499c9e" xlink:href="ameh-20200930.xsd#ameh_MWNCommunityHospitalLLCMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1f74fc16-b5fb-4cfd-be35-ed83e18c4836" xlink:to="loc_ameh_MWNCommunityHospitalLLCMember_167bff5a-7cb8-4a42-8597-a27b09499c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_22577549-4472-4e8b-82a7-0d815243f853" xlink:to="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcLsmaMember_43363417-c1da-4bf1-8570-b084c54d5e03" xlink:href="ameh-20200930.xsd#ameh_ApcLsmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_ApcLsmaMember_43363417-c1da-4bf1-8570-b084c54d5e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bc136ea1-c0f3-499f-a7f6-664698fef267" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_bc136ea1-c0f3-499f-a7f6-664698fef267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_67743cc4-e7e4-4424-bb81-074151e145f6" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_67743cc4-e7e4-4424-bb81-074151e145f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountableHealthCareIPAMember_b32f6d07-9fe8-4b1a-9017-31a7c012b8c6" xlink:href="ameh-20200930.xsd#ameh_AccountableHealthCareIPAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_AccountableHealthCareIPAMember_b32f6d07-9fe8-4b1a-9017-31a7c012b8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CollegeStreetInvestmentLpMember_a95fdb0e-6557-4adf-8489-ff3b7ae22564" xlink:href="ameh-20200930.xsd#ameh_CollegeStreetInvestmentLpMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_CollegeStreetInvestmentLpMember_a95fdb0e-6557-4adf-8489-ff3b7ae22564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementIncMember_b4883ed9-072d-412d-8001-fa689f4e5343" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_NetworkMedicalManagementIncMember_b4883ed9-072d-412d-8001-fa689f4e5343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Pacific6EnterprisesMember_315a43e9-dfe6-415b-a305-3e6e341900ef" xlink:href="ameh-20200930.xsd#ameh_Pacific6EnterprisesMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_Pacific6EnterprisesMember_315a43e9-dfe6-415b-a305-3e6e341900ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HealthSourceMSOInc.Member_7eefc249-5663-4973-8899-098322496d05" xlink:href="ameh-20200930.xsd#ameh_HealthSourceMSOInc.Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_0f620a13-5dc0-4b31-b3d3-4e04e3b2da72" xlink:to="loc_ameh_HealthSourceMSOInc.Member_7eefc249-5663-4973-8899-098322496d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:href="ameh-20200930.xsd#ameh_ContractTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:href="ameh-20200930.xsd#ameh_ContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeAxis_36e8062b-1f0e-471f-b1dd-72703f0b9ee8" xlink:to="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AncillaryServiceContractMember_20c659be-82c5-4a23-aff7-df021f4682d5" xlink:href="ameh-20200930.xsd#ameh_AncillaryServiceContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ContractTypeDomain_e80de8aa-d335-47a6-9894-e677179ce4e5" xlink:to="loc_ameh_AncillaryServiceContractMember_20c659be-82c5-4a23-aff7-df021f4682d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_546c865e-c472-459e-8acc-e7af6fc486c7" xlink:to="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_VotingCommonStockTwoMember_e4445e4a-20d7-4adc-b708-053169a0923e" xlink:href="ameh-20200930.xsd#ameh_VotingCommonStockTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:to="loc_ameh_VotingCommonStockTwoMember_e4445e4a-20d7-4adc-b708-053169a0923e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4d1e2889-c12f-4a89-bd81-1a2d679e7164" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3ca8451c-0eac-4e4c-a449-a3332f0a9834" xlink:to="loc_us-gaap_PreferredStockMember_4d1e2889-c12f-4a89-bd81-1a2d679e7164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_113d8d7d-17e2-49a5-bf2d-40afafda33a2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_0fc9c8b3-8ae2-4af2-84b9-b38bc55208b2" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_0fc9c8b3-8ae2-4af2-84b9-b38bc55208b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_00dbeb08-fc54-48b0-a988-d83f8608dd91" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_eda7ba02-ab1f-4fdf-ac9f-6e12b4dfb635" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_00dbeb08-fc54-48b0-a988-d83f8608dd91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_d099a8bf-fe73-4a9f-a1e3-eefb32141903" xlink:to="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MediPortalLLCMember_24788df8-43bc-4052-8b96-8c4ca55dbc7c" xlink:href="ameh-20200930.xsd#ameh_MediPortalLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:to="loc_ameh_MediPortalLLCMember_24788df8-43bc-4052-8b96-8c4ca55dbc7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AchievaMedInc.Member_4cdf0ac9-6c5c-4274-b8ff-84b9a4ab22f4" xlink:href="ameh-20200930.xsd#ameh_AchievaMedInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_16d32134-a451-4a73-8940-820e641ad9d7" xlink:to="loc_ameh_AchievaMedInc.Member_4cdf0ac9-6c5c-4274-b8ff-84b9a4ab22f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8301ede4-6ffc-45a3-b0c3-76ed8680edd9" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfStores_8289840f-2399-49b6-9023-ebe77a7c4087" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NumberOfStores"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_NumberOfStores_8289840f-2399-49b6-9023-ebe77a7c4087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfEmployees_5a04b0f0-d991-4c8f-ace4-2ea132ec7101" xlink:href="ameh-20200930.xsd#ameh_NumberOfEmployees"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_NumberOfEmployees_5a04b0f0-d991-4c8f-ace4-2ea132ec7101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfPatients_57c305d6-db28-4249-9315-ebe0d887ed6a" xlink:href="ameh-20200930.xsd#ameh_NumberOfPatients"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_NumberOfPatients_57c305d6-db28-4249-9315-ebe0d887ed6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_385b54b2-674f-40be-8327-99aa86cfe13f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_385b54b2-674f-40be-8327-99aa86cfe13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fd979f6e-1248-45db-873a-8ee03f6b65f3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_fd979f6e-1248-45db-873a-8ee03f6b65f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61345407-0584-45c8-8a08-72e36c7d40f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_61345407-0584-45c8-8a08-72e36c7d40f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_53ba7302-b98e-44aa-bd24-d292220d2051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_EquityMethodInvestments_53ba7302-b98e-44aa-bd24-d292220d2051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForFees_83dd9995-2545-4114-a1fb-cb19babd65af" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsForFees_83dd9995-2545-4114-a1fb-cb19babd65af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4d1b7d95-5ef6-4828-bfec-8cb6b93b3dbc" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsPurchaseOfShares_4d1b7d95-5ef6-4828-bfec-8cb6b93b3dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_68df5efc-b32c-4a20-b521-77bce93d3c6c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_68df5efc-b32c-4a20-b521-77bce93d3c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_451c3511-32b7-4f87-be56-6c3e47b73b8c" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock_451c3511-32b7-4f87-be56-6c3e47b73b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_26b1ec40-e7ae-49df-81aa-1583dc3b81c3" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentOwnershipPercentageDisposed"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentOwnershipPercentageDisposed_26b1ec40-e7ae-49df-81aa-1583dc3b81c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_7407b18d-74e2-401a-9dcc-40dbb91f5847" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_7407b18d-74e2-401a-9dcc-40dbb91f5847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfDebt_6ed02213-1fbc-43c0-b3ee-43a74f30d843" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfDebt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfDebt_6ed02213-1fbc-43c0-b3ee-43a74f30d843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_9b1a4704-4666-4577-a638-db7e888120f1" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_9b1a4704-4666-4577-a638-db7e888120f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_24d88e12-b110-4be4-a9c0-5f2476705c3a" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_24d88e12-b110-4be4-a9c0-5f2476705c3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_094ed274-041a-444c-af9a-ba5f5f979849" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationCash"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationCash_094ed274-041a-444c-af9a-ba5f5f979849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2959db6c-a0c7-4886-9d84-db0c3da2721b" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares_2959db6c-a0c7-4886-9d84-db0c3da2721b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_32742590-823a-417a-b52f-11ddb3c703fd" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue_32742590-823a-417a-b52f-11ddb3c703fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MembersCapital_e5c844b2-f5b1-496b-8f4f-aa369169fe85" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MembersCapital"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_MembersCapital_e5c844b2-f5b1-496b-8f4f-aa369169fe85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireRealEstate_ddf46da7-e6b6-44ff-a19d-51fbe25224d2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireRealEstate"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_PaymentsToAcquireRealEstate_ddf46da7-e6b6-44ff-a19d-51fbe25224d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentsContribution_203b196e-8e1a-4261-9ef0-ef1c011c3e9d" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentsContribution"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquityMethodInvestmentsContribution_203b196e-8e1a-4261-9ef0-ef1c011c3e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WorkingCapitalContribution_2bbfefe3-7f66-45fa-9189-b301df22c2aa" xlink:href="ameh-20200930.xsd#ameh_WorkingCapitalContribution"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_WorkingCapitalContribution_2bbfefe3-7f66-45fa-9189-b301df22c2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_f4c7c438-a15a-4bab-992c-e6b3af9e174e" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares_f4c7c438-a15a-4bab-992c-e6b3af9e174e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_9052102a-a7a0-419b-9e8e-5ec6d0d14ff1" xlink:href="ameh-20200930.xsd#ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_9052102a-a7a0-419b-9e8e-5ec6d0d14ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_536a875d-bddd-4f52-9ab5-f6def56db618" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest_536a875d-bddd-4f52-9ab5-f6def56db618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_ffe10911-35b6-4bf7-bff6-e959452c23fa" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage_ffe10911-35b6-4bf7-bff6-e959452c23fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2adc5489-3ebb-4a67-8846-22b976f39b36" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2adc5489-3ebb-4a67-8846-22b976f39b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_faee3ffb-2310-4b45-81cf-dbe4810b0057" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_faee3ffb-2310-4b45-81cf-dbe4810b0057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_4037d1a4-314b-4508-9a03-391e2a7bc191" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption_4037d1a4-314b-4508-9a03-391e2a7bc191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fbbb86a5-bacb-4eea-a097-9daa6f36d518" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests_fbbb86a5-bacb-4eea-a097-9daa6f36d518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b8a7c16b-39e0-45c9-b93e-6d4721172c18" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet_b8a7c16b-39e0-45c9-b93e-6d4721172c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_553ccd16-c1b7-4a88-ab04-06edb88f31f2" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears_553ccd16-c1b7-4a88-ab04-06edb88f31f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_8ed8cc11-4150-4a53-95ca-43f7c384d5cb" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment_8ed8cc11-4150-4a53-95ca-43f7c384d5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_a03621da-348e-4865-a724-6ec3b6328db1" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost_a03621da-348e-4865-a724-6ec3b6328db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_6080b51c-aff7-4cdb-993e-ea05e3050cec" xlink:href="ameh-20200930.xsd#ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_3ccb9a74-d12f-4ddf-a478-ea541ccf5526" xlink:to="loc_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments_6080b51c-aff7-4cdb-993e-ea05e3050cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b005014d-aee5-4a3b-86eb-8b1184bfbb8e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_b005014d-aee5-4a3b-86eb-8b1184bfbb8e" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis_c6e7d8e0-2e3d-4654-993c-7c3c271f3e6f" xlink:to="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LasalleMedicalAssociatesIpaMember_5a691691-c9fa-4808-8d2e-bdd8daa6c0f0" xlink:href="ameh-20200930.xsd#ameh_LasalleMedicalAssociatesIpaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_LasalleMedicalAssociatesIpaMember_5a691691-c9fa-4808-8d2e-bdd8daa6c0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiveThreeOneW.CollegeLLCMember_843995fe-5ef1-49a6-8c80-c4238f960352" xlink:href="ameh-20200930.xsd#ameh_FiveThreeOneW.CollegeLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_FiveThreeOneW.CollegeLLCMember_843995fe-5ef1-49a6-8c80-c4238f960352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_7c8ee868-eb13-4d25-b59f-0ff40847b81f" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain_66977492-3dc9-47b2-97e0-7d9c8e37abc9" xlink:to="loc_ameh_UniversalCareIncMember_7c8ee868-eb13-4d25-b59f-0ff40847b81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_eb44ac9e-6e1b-4752-b57c-186aa16752cd" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6359c9c7-849a-4d2d-ae60-692a4c030167" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6359c9c7-849a-4d2d-ae60-692a4c030167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4bf857f-8419-43a3-bf6e-4c3170476fb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4bf857f-8419-43a3-bf6e-4c3170476fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f5a88c7f-ebf1-4a4c-9ca0-fadcb9ba9088" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_OtherAssetsCurrent_f5a88c7f-ebf1-4a4c-9ca0-fadcb9ba9088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d5d4ce83-e5ee-494c-ac8f-cd81669c9d5e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_d5d4ce83-e5ee-494c-ac8f-cd81669c9d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_960a2d8d-014d-4abf-b1d8-982e741e8367" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_RestrictedCashCurrent_960a2d8d-014d-4abf-b1d8-982e741e8367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssets_4b8feffe-573c-4c99-8cfb-3029c95a5067" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_OtherAssets_4b8feffe-573c-4c99-8cfb-3029c95a5067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_34aad62b-8d6c-4836-b28e-6a7fccd2af6b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_34aad62b-8d6c-4836-b28e-6a7fccd2af6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_57e66af0-5fe8-4b50-b311-45a4f4ce6fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_547661ba-0e04-4ae0-9cd4-b2b37c785c2d" xlink:to="loc_us-gaap_Assets_57e66af0-5fe8-4b50-b311-45a4f4ce6fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_89a54806-1648-4e91-a2d6-d631d1db2957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_LiabilitiesCurrent_89a54806-1648-4e91-a2d6-d631d1db2957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilities_40c60220-2d5e-4f79-a2b2-152142b2a8dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_OtherLiabilities_40c60220-2d5e-4f79-a2b2-152142b2a8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16283623-5ed4-405f-9ede-d5ac56969430" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_16283623-5ed4-405f-9ede-d5ac56969430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_afa58944-92ec-403f-8ffb-94103f215e17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_511c1ec5-bd57-4e3b-b66b-f8030d6f8a5b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_afa58944-92ec-403f-8ffb-94103f215e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_dcdc188e-870f-4bb1-9833-da7aa93c958f" xlink:to="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc4d17f-a104-4688-8ccc-069fdb6e69de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_dbc4d17f-a104-4688-8ccc-069fdb6e69de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_3cf84fea-631b-47f0-9034-d8856053873f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_CostsAndExpenses_3cf84fea-631b-47f0-9034-d8856053873f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c182f6c7-57ad-45b3-8073-f103328bd6d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_OperatingIncomeLoss_c182f6c7-57ad-45b3-8073-f103328bd6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_346e6921-13a2-4ca9-840f-5cd0aa85a0cf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_346e6921-13a2-4ca9-840f-5cd0aa85a0cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1a59eee4-58ec-4f4c-99f6-3b82d91854c1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1a59eee4-58ec-4f4c-99f6-3b82d91854c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dbae429a-27ad-404a-acf4-dfc0096846ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dbae429a-27ad-404a-acf4-dfc0096846ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_1ff28bb2-89f6-41aa-b22c-56dec5211eb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_778da34a-982c-421d-8a6c-a27cbc43c87b" xlink:to="loc_us-gaap_ProfitLoss_1ff28bb2-89f6-41aa-b22c-56dec5211eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e1dd009f-0039-4b85-a1c2-c998610f5254" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_e1dd009f-0039-4b85-a1c2-c998610f5254" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_7b33f84c-57c2-40ae-8726-cd90b978b16b" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_37d425fb-ce1e-4bbf-8e02-f79300cafc30" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_77dc3866-873e-47b3-bf59-1fea0b419e77" xlink:to="loc_ameh_UniversalCareIncMember_37d425fb-ce1e-4bbf-8e02-f79300cafc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_32d702e3-a659-49d3-963a-0d87b7126e89" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_391f7802-bb9a-4162-b3ba-1da8f19c0d33" xlink:href="ameh-20200930.xsd#ameh_BrightHealthCompanyOfCaliforniaInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_42723435-54a3-4c9f-bad2-82865867f875" xlink:to="loc_ameh_BrightHealthCompanyOfCaliforniaInc.Member_391f7802-bb9a-4162-b3ba-1da8f19c0d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5d08ea55-7743-465f-83df-ba15d1aaaafd" xlink:to="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_bf43906c-3f17-44f0-b4e0-31143b5659e5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a3303519-eb37-4294-be4a-6d1a3a1eea87" xlink:to="loc_us-gaap_PreferredStockMember_bf43906c-3f17-44f0-b4e0-31143b5659e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_21d5bdd6-85ae-4ad2-814b-4ad897fed1f8" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a6008f27-74be-4179-8013-138478d36fd6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a6008f27-74be-4179-8013-138478d36fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_034ff79f-0f06-4b14-9e82-54ea1e7b6373" xlink:href="ameh-20200930.xsd#ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue_034ff79f-0f06-4b14-9e82-54ea1e7b6373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_cd9efeec-7bfa-4e65-bca5-7933d29f0415" xlink:href="ameh-20200930.xsd#ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet_cd9efeec-7bfa-4e65-bca5-7933d29f0415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_1359b3ab-3d9b-4bb7-8138-32944f28f2ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_EquityMethodInvestments_1359b3ab-3d9b-4bb7-8138-32944f28f2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_72d66f4a-0f7a-49ee-a757-2c6c1c84e8a5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_57dffe0e-fd65-4dfd-818b-c0af23841b97" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_72d66f4a-0f7a-49ee-a757-2c6c1c84e8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedParties"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_7e022b05-f753-498f-95ac-4edcc702bff6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LoanReceivableTextBlock_0f4cd41b-24ce-4575-9c77-24568a2d20ec" xlink:href="ameh-20200930.xsd#ameh_LoanReceivableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_7e022b05-f753-498f-95ac-4edcc702bff6" xlink:to="loc_ameh_LoanReceivableTextBlock_0f4cd41b-24ce-4575-9c77-24568a2d20ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2731d8f8-5d28-4d01-bbf1-cab8c73acbab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2731d8f8-5d28-4d01-bbf1-cab8c73acbab" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9dafdcc9-066e-4819-ac6b-2e5763aa3072" xlink:to="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_e39523c1-02c3-456b-8ce4-524c933a04fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:to="loc_us-gaap_NotesReceivableMember_e39523c1-02c3-456b-8ce4-524c933a04fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceReceivablesMember_6c1dc591-d02b-43ba-bcc2-85f6e185c32f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_79e2edcc-da54-47df-9e56-0335655a8d4b" xlink:to="loc_us-gaap_FinanceReceivablesMember_6c1dc591-d02b-43ba-bcc2-85f6e185c32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_5c656407-9efd-4513-ba60-de006e47b533" xlink:to="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_1b284b54-61c7-4060-b61e-921d09fc8f91" xlink:href="ameh-20200930.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:to="loc_ameh_Dr.ArteagaMember_1b284b54-61c7-4060-b61e-921d09fc8f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrJayLoanMember_200fb1a6-3689-4fe2-8aea-bef63838c80a" xlink:href="ameh-20200930.xsd#ameh_DrJayLoanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_53f9a133-6f92-4da2-a44c-55e310b9f5f8" xlink:to="loc_ameh_DrJayLoanMember_200fb1a6-3689-4fe2-8aea-bef63838c80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c5a0347b-75fa-446f-a4e2-3abd46fd71e4" xlink:to="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_4f0b25f5-a399-4e6f-a510-b4b42493b663" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_7fc890ea-7d0f-4bc6-84dd-8edd2fc403ff" xlink:to="loc_us-gaap_PrimeRateMember_4f0b25f5-a399-4e6f-a510-b4b42493b663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_d48a22cb-d2dc-4f55-a5a9-5e53f6eae88f" xlink:to="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ce1ea7bb-e676-4124-a896-4c054c3b8aeb" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ce1ea7bb-e676-4124-a896-4c054c3b8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_APCAndAPCLSMAMember_af768592-3c43-45db-974c-59e2d9e6b33d" xlink:href="ameh-20200930.xsd#ameh_APCAndAPCLSMAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_APCAndAPCLSMAMember_af768592-3c43-45db-974c-59e2d9e6b33d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_Dr.ArteagaMember_5acff047-2aeb-4947-b44e-f75afd6f9ade" xlink:href="ameh-20200930.xsd#ameh_Dr.ArteagaMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_Dr.ArteagaMember_5acff047-2aeb-4947-b44e-f75afd6f9ade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_0d039f19-3105-405d-a591-d7106109217f" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_1e6ef8e4-6109-4038-a5b2-c764d4d7334e" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_0d039f19-3105-405d-a591-d7106109217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_faa687c6-f273-493b-b7ad-9a203692a8e6" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6eaf28c3-4e98-47c3-a50c-318a620a9505" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4757aa32-ade8-491a-a32c-e10c06769f8f" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_6eaf28c3-4e98-47c3-a50c-318a620a9505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_5a009668-8f15-45da-b3ea-2603c6cf9d3c" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_48087b98-829b-4943-b032-7dc49dfa5b47" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:to="loc_ameh_LmaMember_48087b98-829b-4943-b032-7dc49dfa5b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_1fd283ca-2a78-48ac-acc4-5b93eb7a7776" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_df2d0e68-d1f2-4b0d-87d6-2170eee69b5c" xlink:to="loc_ameh_UniversalCareIncMember_1fd283ca-2a78-48ac-acc4-5b93eb7a7776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_f1b1707a-6126-4388-b44e-056802fd0ecf" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableNet_4573e895-d89a-458d-909a-cd3e15a995ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_NotesReceivableNet_4573e895-d89a-458d-909a-cd3e15a995ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5f35879-939e-4c67-af9f-dc978573e9a3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_e5f35879-939e-4c67-af9f-dc978573e9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05f636ae-33a7-46ca-9bac-776cf0213be4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_05f636ae-33a7-46ca-9bac-776cf0213be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_8da777cd-899b-4f97-965f-fa85f0095717" xlink:href="ameh-20200930.xsd#ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible_8da777cd-899b-4f97-965f-fa85f0095717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b739c953-3276-4b6b-9c3b-e8dbeb937e6d" xlink:href="ameh-20200930.xsd#ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion_b739c953-3276-4b6b-9c3b-e8dbeb937e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvancedForWorkingCapital_2cfa9dd2-34ee-4215-9911-83d12b51102c" xlink:href="ameh-20200930.xsd#ameh_AdvancedForWorkingCapital"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_AdvancedForWorkingCapital_2cfa9dd2-34ee-4215-9911-83d12b51102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityAdditionalAdvances_acdfa548-efc5-4998-b421-c527bec4f25e" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityAdditionalAdvances"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_ameh_LineOfCreditFacilityAdditionalAdvances_acdfa548-efc5-4998-b421-c527bec4f25e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_191a5347-d683-414e-9c51-1ac480842705" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_716fea20-e077-4024-adb6-1a2d41fa7400" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_191a5347-d683-414e-9c51-1ac480842705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpenses"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpenses" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_1529b41a-1ddf-43c3-8d46-ba1b9417795b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7542ceca-19bf-44fe-9c3c-42cc0eba350c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_1529b41a-1ddf-43c3-8d46-ba1b9417795b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_7542ceca-19bf-44fe-9c3c-42cc0eba350c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_adc0dad8-f289-47fd-8dc8-b352210976d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_379fbf5c-126e-49a1-9678-95973cb4a9aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_adc0dad8-f289-47fd-8dc8-b352210976d8" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_379fbf5c-126e-49a1-9678-95973cb4a9aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f689ca70-302b-4073-b16e-7ad8399ea0fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_AccountsPayableCurrent_f689ca70-302b-4073-b16e-7ad8399ea0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SpecialtyCapitationPayableCurrent_f59843f9-68ee-4cb3-ac1f-7ae9c85c3746" xlink:href="ameh-20200930.xsd#ameh_SpecialtyCapitationPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_ameh_SpecialtyCapitationPayableCurrent_f59843f9-68ee-4cb3-ac1f-7ae9c85c3746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SubcontractorIPAPayable_e16a2eda-7fda-42ea-9c44-518561958dd5" xlink:href="ameh-20200930.xsd#ameh_SubcontractorIPAPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_ameh_SubcontractorIPAPayable_e16a2eda-7fda-42ea-9c44-518561958dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_0724c68a-63d1-4ed2-9414-81c0ab390cb2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_0724c68a-63d1-4ed2-9414-81c0ab390cb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_e00f2f53-2d09-4c2f-b64a-a647d57de14c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_e00f2f53-2d09-4c2f-b64a-a647d57de14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4197b73-ee31-41cf-9100-d810e3a16753" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_d4197b73-ee31-41cf-9100-d810e3a16753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_468bc31c-4196-404c-a506-94dad141aba7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_468bc31c-4196-404c-a506-94dad141aba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6976d8-5e6b-4539-bc6e-1ab5f2795898" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_2255c714-cd3b-4e7f-9aef-a94e60a9464b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2c6976d8-5e6b-4539-bc6e-1ab5f2795898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilities"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_b765d794-3c73-4552-81a8-560910f7b602" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_11357c0b-807f-4714-bc08-03fc0836bc52" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_b765d794-3c73-4552-81a8-560910f7b602" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_11357c0b-807f-4714-bc08-03fc0836bc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_11d7d828-a992-476f-9b45-77d4cb9283f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_7e0c8a0e-e322-4773-b296-c08ec86bf7a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_11d7d828-a992-476f-9b45-77d4cb9283f9" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_7e0c8a0e-e322-4773-b296-c08ec86bf7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_44784358-b843-46ec-83e2-054ef64b3ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract_44784358-b843-46ec-83e2-054ef64b3ef5" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d3a5aecc-e501-4945-8ced-6b80d54e1afc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_d3a5aecc-e501-4945-8ced-6b80d54e1afc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalCareCostsAbstract_c5a55129-0e21-40df-b31e-75e3eabba661" xlink:href="ameh-20200930.xsd#ameh_MedicalCareCostsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_ameh_MedicalCareCostsAbstract_c5a55129-0e21-40df-b31e-75e3eabba661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_31aebace-ef81-434d-b289-ff0b5b4697df" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_c5a55129-0e21-40df-b31e-75e3eabba661" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_31aebace-ef81-434d-b289-ff0b5b4697df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ba4259b8-2af4-40d4-88e7-c4ca5a3d337e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_c5a55129-0e21-40df-b31e-75e3eabba661" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_ba4259b8-2af4-40d4-88e7-c4ca5a3d337e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_ccb55efd-3930-4c98-8bd9-612b3f1dbded" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_MedicalCareCostsAbstract_c5a55129-0e21-40df-b31e-75e3eabba661" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_ccb55efd-3930-4c98-8bd9-612b3f1dbded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentsForMedicalCareCostsAbstract_da46e85f-bdf9-4585-b4bc-440f571dd853" xlink:href="ameh-20200930.xsd#ameh_PaymentsForMedicalCareCostsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_ameh_PaymentsForMedicalCareCostsAbstract_da46e85f-bdf9-4585-b4bc-440f571dd853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_99d6e16b-8343-4e90-82db-bf7bfee10944" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_da46e85f-bdf9-4585-b4bc-440f571dd853" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_99d6e16b-8343-4e90-82db-bf7bfee10944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_65cefa09-5ae3-4c29-8716-4552dd698ee8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_da46e85f-bdf9-4585-b4bc-440f571dd853" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_65cefa09-5ae3-4c29-8716-4552dd698ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f47883a9-9f69-47d1-8f81-8a77eb50ea93" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_PaymentsForMedicalCareCostsAbstract_da46e85f-bdf9-4585-b4bc-440f571dd853" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_f47883a9-9f69-47d1-8f81-8a77eb50ea93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_fd0582e1-e58a-4b2c-9e6e-766c70aaa4e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions_fd0582e1-e58a-4b2c-9e6e-766c70aaa4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_203c4029-6ead-44bb-8189-f75210c7b0de" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease_203c4029-6ead-44bb-8189-f75210c7b0de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c9e9c916-449d-4c3c-b75c-62959a0ad2b3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ed59967f-bcbb-4d2e-85c8-0b1cb44315a6" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_c9e9c916-449d-4c3c-b75c-62959a0ad2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCredit"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b5e5e9d6-ddda-416b-b95a-fb2ac6bb0da2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_17d747be-5ad2-49ca-813f-393dcde57cea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b5e5e9d6-ddda-416b-b95a-fb2ac6bb0da2" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_17d747be-5ad2-49ca-813f-393dcde57cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_3de0333b-2423-4707-abab-23a9ff5ca883" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_be51442e-459c-46b0-9b39-274d693f5631" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3de0333b-2423-4707-abab-23a9ff5ca883" xlink:to="loc_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock_be51442e-459c-46b0-9b39-274d693f5631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e5cca481-c47d-4349-ac0b-881b62256b39" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_3de0333b-2423-4707-abab-23a9ff5ca883" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e5cca481-c47d-4349-ac0b-881b62256b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6300080b-ef6f-489e-aa46-f5d816ac768a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6300080b-ef6f-489e-aa46-f5d816ac768a" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:to="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5e10cd40-a264-4e0a-b7b4-1460102d5ad4" xlink:to="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_1d1c1a18-5429-4d13-97ef-a42f261f4977" xlink:href="ameh-20200930.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:to="loc_ameh_TermLoanAMember_1d1c1a18-5429-4d13-97ef-a42f261f4977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_fbb16e65-67f6-487d-b1fb-fb85874d96ed" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_54b8fb00-f4e4-4f7e-8487-49f729e78ee5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_fbb16e65-67f6-487d-b1fb-fb85874d96ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_6f9af63c-c114-4717-967f-9c9713cc2810" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_635f13b3-cc37-4d13-a17a-cacb3c0a291e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LineOfCredit_635f13b3-cc37-4d13-a17a-cacb3c0a291e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LinesOfCreditCurrent_9b9e4a61-352e-4064-8902-49d5284152ac" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LinesOfCreditCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LinesOfCreditCurrent_9b9e4a61-352e-4064-8902-49d5284152ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_693f8497-fe53-4171-b939-72bdf264e165" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_693f8497-fe53-4171-b939-72bdf264e165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_b29591a2-2107-4b2b-8f23-12db3119b60c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_2ad02e9c-211a-44bd-8556-8b2d4d43fc5d" xlink:to="loc_us-gaap_LongTermDebt_b29591a2-2107-4b2b-8f23-12db3119b60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0f278d4b-82a4-40db-ae61-a37e837668ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_0f278d4b-82a4-40db-ae61-a37e837668ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9166f62e-c769-4000-ac71-7f8994b289e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9166f62e-c769-4000-ac71-7f8994b289e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_029007de-8bc5-4bb3-9c25-6627d29f40ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_029007de-8bc5-4bb3-9c25-6627d29f40ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ebadffae-d9c0-4ab6-a2f2-b9f51b67eb42" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ebadffae-d9c0-4ab6-a2f2-b9f51b67eb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_799cb561-398a-4401-ab21-4ec85a3f0a4d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_799cb561-398a-4401-ab21-4ec85a3f0a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_317f5502-a0f1-41ea-90df-1d8abe240d37" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0cc91a07-83d5-4321-95d6-97420abdb029" xlink:to="loc_us-gaap_LineOfCredit_317f5502-a0f1-41ea-90df-1d8abe240d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5b5b1b0c-01dd-4f32-9e83-852a7f4f1a5b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5b5b1b0c-01dd-4f32-9e83-852a7f4f1a5b" xlink:to="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_efddabd5-6234-4349-bfed-3e5f8e61ef80" xlink:to="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_34531e4c-1b09-440b-8ce0-77ae18635212" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_34531e4c-1b09-440b-8ce0-77ae18635212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_79d582d8-d4fe-4a19-ba5f-bf9c56c68821" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_LetterOfCreditMember_79d582d8-d4fe-4a19-ba5f-bf9c56c68821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_TermLoanAMember_3f88381b-ced0-4eb9-bdcc-022fd4080000" xlink:href="ameh-20200930.xsd#ameh_TermLoanAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_ameh_TermLoanAMember_3f88381b-ced0-4eb9-bdcc-022fd4080000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_e5de7002-88a6-432b-bc96-79bb135e7d3d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_e5de7002-88a6-432b-bc96-79bb135e7d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_3a9c88d4-a27d-44ee-b36b-6c2b66422661" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_84b6cce7-2256-492c-9778-62d710cd52d0" xlink:to="loc_us-gaap_LineOfCreditMember_3a9c88d4-a27d-44ee-b36b-6c2b66422661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d4b02ef6-b61e-4857-b33b-3f64df37c59e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CreditAgreementMember_91a73a71-83f7-4519-a240-b0dff0a6f5eb" xlink:href="ameh-20200930.xsd#ameh_CreditAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_CreditAgreementMember_91a73a71-83f7-4519-a240-b0dff0a6f5eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NMMLineOfCreditAgreementMember_96d1741f-0ac9-4eba-87da-2b6ee6ec3655" xlink:href="ameh-20200930.xsd#ameh_NMMLineOfCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_NMMLineOfCreditAgreementMember_96d1741f-0ac9-4eba-87da-2b6ee6ec3655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NmmBusinessLoanAgreementMember_aa123368-1525-43b7-8a02-f7c16775633b" xlink:href="ameh-20200930.xsd#ameh_NmmBusinessLoanAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_NmmBusinessLoanAgreementMember_aa123368-1525-43b7-8a02-f7c16775633b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcBusinessLoanAgreementMember_9e454917-1158-4774-b96c-2092ea09bd56" xlink:href="ameh-20200930.xsd#ameh_ApcBusinessLoanAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_ecec78f1-b212-4d02-af61-ac450e315ddb" xlink:to="loc_ameh_ApcBusinessLoanAgreementMember_9e454917-1158-4774-b96c-2092ea09bd56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ef55c1a-beee-45d2-91b6-2cc773d86104" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_01a018e2-9720-4311-8f20-b75745d89b48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e957d6f3-6218-4843-a95c-4787dcbd430e" xlink:to="loc_us-gaap_LineOfCreditMember_01a018e2-9720-4311-8f20-b75745d89b48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_375e41ef-a1f4-42f4-a36a-fb67f3f40c0c" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodOneMember_8e0a8ab8-f895-4c8b-a11d-b1c409b59a5f" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodOneMember_8e0a8ab8-f895-4c8b-a11d-b1c409b59a5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodTwoMember_7894dfd4-761a-4e19-a18b-95fc951c084f" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodTwoMember_7894dfd4-761a-4e19-a18b-95fc951c084f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentPeriodThreeMember_4cbbe3f8-688f-45f3-a303-a905e86af1ea" xlink:href="ameh-20200930.xsd#ameh_PaymentPeriodThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_e2a63a43-f800-4060-b729-b33663789a99" xlink:to="loc_ameh_PaymentPeriodThreeMember_4cbbe3f8-688f-45f3-a303-a905e86af1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4aa5d527-a6ff-44f2-8f5e-5feb06f0168c" xlink:to="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_092913ea-c80d-4f82-b751-6d2218a55810" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:to="loc_srt_MinimumMember_092913ea-c80d-4f82-b751-6d2218a55810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d414d463-a8ed-464e-a737-5f3dc8415bbd" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_72633ba3-dab7-47a7-a71b-3ce2129a5e1d" xlink:to="loc_srt_MaximumMember_d414d463-a8ed-464e-a737-5f3dc8415bbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2fe134e3-1ddd-4273-92a0-edfa464ade7a" xlink:to="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_060aa1c9-0933-45d4-877b-725d89876f3f" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_NetworkMedicalManagementMember_060aa1c9-0933-45d4-877b-725d89876f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_809044a3-77bf-4842-85d2-9ceecf3b9bb6" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_809044a3-77bf-4842-85d2-9ceecf3b9bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApaacoMember_c9d03fa5-cd65-4188-b548-d73f150173c8" xlink:href="ameh-20200930.xsd#ameh_ApaacoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_ApaacoMember_c9d03fa5-cd65-4188-b548-d73f150173c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_d11a963b-1761-468b-b968-3d3608cee0c5" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_d11a963b-1761-468b-b968-3d3608cee0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_7d2cadc3-1c09-478d-8269-4bfa4eade49d" xlink:href="ameh-20200930.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_CDSCMember_7d2cadc3-1c09-478d-8269-4bfa4eade49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AmgIncMember_8945af0d-e9f8-4cd9-b211-ef00ced97f10" xlink:href="ameh-20200930.xsd#ameh_AmgIncMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a563748d-8b7d-4901-ba97-1e62d4d31d1e" xlink:to="loc_ameh_AmgIncMember_8945af0d-e9f8-4cd9-b211-ef00ced97f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_2a41c1b0-a210-433a-aa9c-1406f35ee670" xlink:to="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ba4f93b6-45ca-4758-b780-05591ad12d64" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_ba4f93b6-45ca-4758-b780-05591ad12d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrimeRateMember_168dfa5b-715e-4432-8aee-37c539330ea2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrimeRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_ec6b1cca-a2e5-468a-8b9f-190483287d81" xlink:to="loc_us-gaap_PrimeRateMember_168dfa5b-715e-4432-8aee-37c539330ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_53512345-7af7-44f1-96b9-96ac0112dbf1" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PreferredBankMember_975fad69-24fb-4a93-974b-3bf11b6129ac" xlink:href="ameh-20200930.xsd#ameh_PreferredBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_229084b6-0c9e-434d-a2d4-627ac30b0b21" xlink:to="loc_ameh_PreferredBankMember_975fad69-24fb-4a93-974b-3bf11b6129ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_67dd02c8-9b23-4b36-a538-2092995b52f1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_3542ca19-3e0b-4229-b1d2-f5b48a665159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentTerm_3542ca19-3e0b-4229-b1d2-f5b48a665159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_95c6180e-8979-4510-a23a-3b13133a72b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_95c6180e-8979-4510-a23a-3b13133a72b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_80e0f608-c8fa-4920-8cee-3848fb05b979" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal_80e0f608-c8fa-4920-8cee-3848fb05b979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_83eabb7c-8571-463f-9503-f9c33a365c47" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCredit_83eabb7c-8571-463f-9503-f9c33a365c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ebc96e5d-4ea3-4e8e-a0b3-1a4f614c32f6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_ebc96e5d-4ea3-4e8e-a0b3-1a4f614c32f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d53f2751-b7fc-4660-a1e0-2460525d7020" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_d53f2751-b7fc-4660-a1e0-2460525d7020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_4f1ff1b3-f982-4e03-b209-7455bb686398" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_4f1ff1b3-f982-4e03-b209-7455bb686398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_595a1666-8ef8-40a9-9ecf-62a6656e4a50" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_595a1666-8ef8-40a9-9ecf-62a6656e4a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_82169f87-ba8e-49c1-9032-140415f3affb" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentNumberOfKeyFinancialRatios"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentNumberOfKeyFinancialRatios_82169f87-ba8e-49c1-9032-140415f3affb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_536f5f03-5fe6-4f3b-add8-d92f2dd3be4e" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMaximum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMaximum_536f5f03-5fe6-4f3b-add8-d92f2dd3be4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_4aa388e7-67ef-41de-b9ce-ce43b83ae512" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange_4aa388e7-67ef-41de-b9ce-ce43b83ae512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_756b65f0-8ba0-4c96-9711-c8f31fef328d" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantLeverageRatioMinimum"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantLeverageRatioMinimum_756b65f0-8ba0-4c96-9711-c8f31fef328d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_ba823c8f-d421-44ac-87b6-02611b07cc6f" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum_ba823c8f-d421-44ac-87b6-02611b07cc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDefaultLongtermDebtAmount_67a76fce-4515-47fd-9182-594447108aea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtDefaultLongtermDebtAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtDefaultLongtermDebtAmount_67a76fce-4515-47fd-9182-594447108aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_835eea80-a2fd-463a-8997-634ab3462190" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage_835eea80-a2fd-463a-8997-634ab3462190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_3e5d4e5d-789c-44af-9fe9-7d0ba2a14894" xlink:href="ameh-20200930.xsd#ameh_DebtInstrumentApprovedThresholdUseOfFunds"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_DebtInstrumentApprovedThresholdUseOfFunds_3e5d4e5d-789c-44af-9fe9-7d0ba2a14894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_28cc5b7e-85d0-4c45-9e30-6e0891cfca82" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_28cc5b7e-85d0-4c45-9e30-6e0891cfca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_83da103c-b183-4190-afd1-0eefd0af97a1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_83da103c-b183-4190-afd1-0eefd0af97a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_9ce6f6de-ebc2-4ee4-828d-7764ed42ae72" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_InterestExpense_9ce6f6de-ebc2-4ee4-828d-7764ed42ae72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_986a4ca4-bad5-4beb-999f-14725ed716d3" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties_986a4ca4-bad5-4beb-999f-14725ed716d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_38e87de0-f663-404c-a120-84dc9152ad2b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_38e87de0-f663-404c-a120-84dc9152ad2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_43c4491c-9f65-4692-977d-9343130098b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_43c4491c-9f65-4692-977d-9343130098b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_36647a84-96cb-402a-9c10-d58b8d542ed5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_36647a84-96cb-402a-9c10-d58b8d542ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_3c4d08b4-e024-493a-8116-43c4ca343a2f" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification_3c4d08b4-e024-493a-8116-43c4ca343a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LineOfCreditFacilityTerminatedAmount_8a7f1c86-582d-4c06-ab7d-849892972414" xlink:href="ameh-20200930.xsd#ameh_LineOfCreditFacilityTerminatedAmount"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_01481462-83cb-4aef-b1a8-444974867f0a" xlink:to="loc_ameh_LineOfCreditFacilityTerminatedAmount_8a7f1c86-582d-4c06-ab7d-849892972414" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7b5ba8c5-5b63-4866-be53-176da3c2fb48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c79b05e2-013d-4b06-b1d3-09fa5dab3820" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b5ba8c5-5b63-4866-be53-176da3c2fb48" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_c79b05e2-013d-4b06-b1d3-09fa5dab3820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_7b6292f4-d4cf-4346-b62f-e2eeb1828957" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_704fbc19-b155-4f51-a2fa-5b2686c5c897" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b6292f4-d4cf-4346-b62f-e2eeb1828957" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_704fbc19-b155-4f51-a2fa-5b2686c5c897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_768d7481-87ca-43d4-aa7c-7134c730e0b8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b6292f4-d4cf-4346-b62f-e2eeb1828957" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_768d7481-87ca-43d4-aa7c-7134c730e0b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e78ce692-beac-4b11-9899-b7b6afad4d1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_7b6292f4-d4cf-4346-b62f-e2eeb1828957" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e78ce692-beac-4b11-9899-b7b6afad4d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c271e572-2150-4032-b698-5e53f9dcad7a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c271e572-2150-4032-b698-5e53f9dcad7a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_82063c57-bf3c-46e5-8255-74aab0fcf280" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcStockOptionMember_edda9638-6df3-4705-a274-c778d412a299" xlink:href="ameh-20200930.xsd#ameh_ApcStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:to="loc_ameh_ApcStockOptionMember_edda9638-6df3-4705-a274-c778d412a299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_46a91a6d-5774-4c7b-832c-b6897b5f147b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3dce86f4-2ac0-482b-a4c7-f56059acf886" xlink:to="loc_srt_DirectorMember_46a91a6d-5774-4c7b-832c-b6897b5f147b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7d21d134-b932-40f8-861f-5e33225d699d" xlink:to="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_68bcc73c-07fb-4ae6-b4c1-cfdf1f7b198b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:to="loc_srt_MinimumMember_68bcc73c-07fb-4ae6-b4c1-cfdf1f7b198b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bd2f5b17-ae5d-4325-bcf2-7fd1d4bc7ebc" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8c474840-a3df-4f6f-aeee-8a6a56d9383b" xlink:to="loc_srt_MaximumMember_bd2f5b17-ae5d-4325-bcf2-7fd1d4bc7ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_f4712a2c-2051-443e-979d-ac9e816cde65" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7be922ce-2787-449c-85d2-7669eb9bdb7e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7be922ce-2787-449c-85d2-7669eb9bdb7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_0cc59fc3-b4d2-42a5-9e84-dc0f2a7a00e0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70602d5f-bdbb-4edf-89fe-47f3455edc34" xlink:to="loc_us-gaap_RestrictedStockMember_0cc59fc3-b4d2-42a5-9e84-dc0f2a7a00e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_a4c01429-8b65-4820-a744-8a0c5bd1d561" xlink:to="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_75c6d1ba-ef33-4857-a84e-df288aacc239" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_75c6d1ba-ef33-4857-a84e-df288aacc239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CDSCMember_309cda97-9352-4020-9e47-5506ec953cb5" xlink:href="ameh-20200930.xsd#ameh_CDSCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_88145f63-2548-42ed-8aa8-5c532346fca1" xlink:to="loc_ameh_CDSCMember_309cda97-9352-4020-9e47-5506ec953cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_8fadf9fe-58b4-4057-9f52-fc6f711c08c9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_0184fea4-0885-499c-977f-c3b2b23170d3" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificofCaliforniaBrokerageAccountMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7b21c88b-f7f2-4058-a5f4-d4c7a22b813d" xlink:to="loc_ameh_AlliedPacificofCaliforniaBrokerageAccountMember_0184fea4-0885-499c-977f-c3b2b23170d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_442fd9a5-4182-454e-a101-1cc505458790" xlink:to="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesMerger_f040a259-deb5-46e6-a40b-898b8122b394" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesMerger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesMerger_f040a259-deb5-46e6-a40b-898b8122b394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1e059991-21a5-4e81-a148-76fb7539ed38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1e059991-21a5-4e81-a148-76fb7539ed38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b631113-3096-4d88-a1c4-bcd4096b3678" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_5b631113-3096-4d88-a1c4-bcd4096b3678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e6075d-f0ad-408b-83ff-5ff8afc8087b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_62e6075d-f0ad-408b-83ff-5ff8afc8087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_3fed70c9-2575-4922-867a-7a6e09ae143e" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod_3fed70c9-2575-4922-867a-7a6e09ae143e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eada163e-f16e-4288-8b25-a242a3a61397" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_eada163e-f16e-4288-8b25-a242a3a61397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_edecc280-6993-4fc0-b28d-8b470f32cde6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_edecc280-6993-4fc0-b28d-8b470f32cde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30c5a0ac-26ed-4ac7-8b68-e98acfb20865" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_30c5a0ac-26ed-4ac7-8b68-e98acfb20865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9b35ed77-e0dd-4137-abdb-360c799aea8f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9b35ed77-e0dd-4137-abdb-360c799aea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2021cc7c-070a-4318-bb07-312570ec9e21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2021cc7c-070a-4318-bb07-312570ec9e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_89c3e863-6eaf-4f39-8468-781a308dfc1d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_89c3e863-6eaf-4f39-8468-781a308dfc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_63f0392b-236c-466d-88f9-2c5e5dc20b30" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_ShareBasedCompensation_63f0392b-236c-466d-88f9-2c5e5dc20b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a4a10cdc-1521-45f0-bbc6-2bf58a844d05" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_a4a10cdc-1521-45f0-bbc6-2bf58a844d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_7705689f-5a46-4c9f-a4a2-1547ad90e36b" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod_7705689f-5a46-4c9f-a4a2-1547ad90e36b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_86bb04a5-860b-4132-a0d4-e4c647589e4d" xlink:href="ameh-20200930.xsd#ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised_86bb04a5-860b-4132-a0d4-e4c647589e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_8a0a20b8-0232-4a68-9e2c-79fa54c79b78" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice_8a0a20b8-0232-4a68-9e2c-79fa54c79b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_8c7f436e-2136-43fe-a7fb-067c8fea1eb3" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod_8c7f436e-2136-43fe-a7fb-067c8fea1eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_49893e52-f6f3-4a26-80d9-6ff9c35d6508" xlink:href="ameh-20200930.xsd#ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised_49893e52-f6f3-4a26-80d9-6ff9c35d6508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_a7da31e2-a109-4c1f-9a04-aa3fd9600fa5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_TreasuryStockCommonShares_a7da31e2-a109-4c1f-9a04-aa3fd9600fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_36798a45-1e71-487b-9dd6-dd24fba77a0b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_TreasuryStockValue_36798a45-1e71-487b-9dd6-dd24fba77a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_661a997b-a74b-4f60-8906-ded31385c7b9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_92667230-d78a-48b6-b90e-3aeefa55b9f1" xlink:to="loc_us-gaap_Dividends_661a997b-a74b-4f60-8906-ded31385c7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5aea1287-444d-4bd5-8c1e-096d7e2220e8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_5aea1287-444d-4bd5-8c1e-096d7e2220e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a47ccc16-2dff-490d-b0fd-588546a76a98" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_a47ccc16-2dff-490d-b0fd-588546a76a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_415114d9-a814-4f35-9bff-bfec2659ee76" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_415114d9-a814-4f35-9bff-bfec2659ee76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_218bfe9c-529a-4b1a-9952-a86ec54f7d0d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_218bfe9c-529a-4b1a-9952-a86ec54f7d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d327bd1b-130b-4026-883e-f32ed21973dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_9d395493-895e-41c7-91b7-9b09971a8ef5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d327bd1b-130b-4026-883e-f32ed21973dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c26452f4-1732-4960-aaff-284739e8d71d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_c26452f4-1732-4960-aaff-284739e8d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2034b300-da11-4205-85db-4d23f401e5cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2034b300-da11-4205-85db-4d23f401e5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80a739fc-f69c-4e70-b4f0-bdee9d9fd995" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_80a739fc-f69c-4e70-b4f0-bdee9d9fd995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_95257bca-fc37-4211-8203-ed9d2295be03" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_95257bca-fc37-4211-8203-ed9d2295be03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_408e8175-9439-4f95-8007-b82157b0859d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_408e8175-9439-4f95-8007-b82157b0859d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddc79f12-352a-4c25-a477-be73e9d99066" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract_1bbdc556-0cb4-46a7-98a4-507957e3f2e4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ddc79f12-352a-4c25-a477-be73e9d99066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c7af4fa8-e30f-448c-99c6-c81fc453be48" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_c7af4fa8-e30f-448c-99c6-c81fc453be48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c19d736a-7707-4079-a4ba-0b7e5d448cc7" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c19d736a-7707-4079-a4ba-0b7e5d448cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8136634b-3773-4049-aad4-60ce12c7636f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c19d736a-7707-4079-a4ba-0b7e5d448cc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8136634b-3773-4049-aad4-60ce12c7636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cc7d7b9a-224c-4cb6-b920-7bf30f629af8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_c19d736a-7707-4079-a4ba-0b7e5d448cc7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_cc7d7b9a-224c-4cb6-b920-7bf30f629af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f5b9d358-c855-4afe-acbd-c48163e5ceb7" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f5b9d358-c855-4afe-acbd-c48163e5ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a09c5d56-0aea-47d7-b206-7f289e18596e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f5b9d358-c855-4afe-acbd-c48163e5ceb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_a09c5d56-0aea-47d7-b206-7f289e18596e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bea4883-9a4c-47c3-bb3b-63b3b09c7457" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f5b9d358-c855-4afe-acbd-c48163e5ceb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_5bea4883-9a4c-47c3-bb3b-63b3b09c7457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7891689a-013c-48f8-b970-113353aaf351" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract_f5b9d358-c855-4afe-acbd-c48163e5ceb7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_7891689a-013c-48f8-b970-113353aaf351" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc913c0f-6427-49f2-b432-e19215f55978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_5dd8bcae-370e-4d86-aba7-bc96f3a14ad6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bc913c0f-6427-49f2-b432-e19215f55978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_f5eaf9d6-a27f-4803-95a7-902fa90a6ac1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_f5eaf9d6-a27f-4803-95a7-902fa90a6ac1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:to="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_0f949897-64f5-4041-ad7b-f0a55ff1ef4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_d863a311-0bd0-46bd-b9f7-d0f646b921c1" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_ecf9e897-f68b-4582-81f4-01c6c9fd4f2e" xlink:to="loc_srt_DirectorMember_d863a311-0bd0-46bd-b9f7-d0f646b921c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b9ad5033-6015-454c-992c-698d40bffe57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2adf38f8-1b24-4731-91b9-4bbafaab0279" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2adf38f8-1b24-4731-91b9-4bbafaab0279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81e14302-003e-4186-a7ff-731e906e2514" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_81e14302-003e-4186-a7ff-731e906e2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_613c1e61-69c6-4a40-8f12-96498f27fc86" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_613c1e61-69c6-4a40-8f12-96498f27fc86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_15d0b6ee-f3a9-4d10-8a86-588c515a696e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_SharePrice_15d0b6ee-f3a9-4d10-8a86-588c515a696e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04e06683-b66e-461d-8e13-e774d506e707" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_04e06683-b66e-461d-8e13-e774d506e707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_d01298b5-7fc2-4fbb-a60e-11d13b7b2f3a" xlink:href="ameh-20200930.xsd#ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8471b7fe-c783-479c-933f-dc5d3f6ccae7" xlink:to="loc_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate_d01298b5-7fc2-4fbb-a60e-11d13b7b2f3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquitySummaryofWarrantDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c87f0a8e-372c-414d-8129-8bdf4dd852bc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:href="ameh-20200930.xsd#ameh_SharesWarrantsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c87f0a8e-372c-414d-8129-8bdf4dd852bc" xlink:to="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_81b7badb-e8c3-4380-98c9-0912f21c38e2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_81b7badb-e8c3-4380-98c9-0912f21c38e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsGranted_1b2c47fe-44be-417d-911c-03512758230d" xlink:href="ameh-20200930.xsd#ameh_NumberOfWarrantsGranted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:to="loc_ameh_NumberOfWarrantsGranted_1b2c47fe-44be-417d-911c-03512758230d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumberOfWarrantsExercised_66ebe0eb-a3b0-4e41-bc71-7c87421b8869" xlink:href="ameh-20200930.xsd#ameh_NumberOfWarrantsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:to="loc_ameh_NumberOfWarrantsExercised_66ebe0eb-a3b0-4e41-bc71-7c87421b8869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_54ec9f66-f000-4509-8f1d-4f04b092f2dd" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightCancelledInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:to="loc_ameh_ClassOfWarrantOrRightCancelledInPeriod_54ec9f66-f000-4509-8f1d-4f04b092f2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_39ab7d28-c02b-4c09-892e-b6bf0c5bc03d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_SharesWarrantsRollForward_836836b0-aad0-40a4-bf9a-6fd0dbbc565d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_39ab7d28-c02b-4c09-892e-b6bf0c5bc03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:href="ameh-20200930.xsd#ameh_WeightedAverageExercisePriceWarrantsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c87f0a8e-372c-414d-8129-8bdf4dd852bc" xlink:to="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_d7e7b4d2-e043-4860-a81a-3be976a672d4" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_d7e7b4d2-e043-4860-a81a-3be976a672d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_f883a10e-fb88-4b2f-9177-2ccd67338535" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod_f883a10e-fb88-4b2f-9177-2ccd67338535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_714ee9a7-276a-450c-b572-22749acfe056" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod_714ee9a7-276a-450c-b572-22749acfe056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_6a0448f7-25eb-41a1-841e-99ba0815f0d6" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod_6a0448f7-25eb-41a1-841e-99ba0815f0d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_6d6a822f-ad91-433c-9ef0-001e79ed42ab" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedAverageExercisePriceWarrantsRollForward_d65f40c6-0c4b-44ee-a16d-5ad0b037c428" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_6d6a822f-ad91-433c-9ef0-001e79ed42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_f447e77c-354c-40e6-a63b-bbe234fab06b" xlink:href="ameh-20200930.xsd#ameh_WeightedaverageremainingcontractualtermyearsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c87f0a8e-372c-414d-8129-8bdf4dd852bc" xlink:to="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_f447e77c-354c-40e6-a63b-bbe234fab06b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_a9c8c13c-f925-4626-96e4-9cab5d8a862f" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_WeightedaverageremainingcontractualtermyearsAbstract_f447e77c-354c-40e6-a63b-bbe234fab06b" xlink:to="loc_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm_a9c8c13c-f925-4626-96e4-9cab5d8a862f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:href="ameh-20200930.xsd#ameh_AggregateintrinsicvalueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c87f0a8e-372c-414d-8129-8bdf4dd852bc" xlink:to="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_3b4a2c1b-382e-46cb-83b2-b297b41d174d" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_3b4a2c1b-382e-46cb-83b2-b297b41d174d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_b0ce3049-734a-41bc-8463-e03c52a96384" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:to="loc_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue_b0ce3049-734a-41bc-8463-e03c52a96384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_997607f9-c728-44b0-ab84-44eb56393e4c" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:to="loc_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue_997607f9-c728-44b0-ab84-44eb56393e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_eb0d1063-8bf9-4dbd-ac05-1f4f0b6f795f" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:to="loc_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue_eb0d1063-8bf9-4dbd-ac05-1f4f0b6f795f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_9e872c15-ff4b-430a-855e-c2a8a121a9cc" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_AggregateintrinsicvalueAbstract_2d6da12f-9f32-4ec6-9079-7991297665c2" xlink:to="loc_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue_9e872c15-ff4b-430a-855e-c2a8a121a9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#MezzanineandStockholdersEquityWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_171f7f8d-61a1-476f-8915-30fedab54478" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_171f7f8d-61a1-476f-8915-30fedab54478" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_634b45b3-c643-478d-885d-abb9ca6d7755" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeOneMember_dc355ce7-175c-4146-911f-578cb6bfdc11" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeOneMember_dc355ce7-175c-4146-911f-578cb6bfdc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeTwoMember_4d874b7c-acbf-41c0-bd38-66ef808307ca" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeTwoMember_4d874b7c-acbf-41c0-bd38-66ef808307ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeThreeMember_c2f2adc3-a1f0-45b9-8d4b-78892a431427" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeThreeMember_c2f2adc3-a1f0-45b9-8d4b-78892a431427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_WarrantExercisePriceRangeFourMember_c06845af-177b-4ea3-9456-87862515f4ac" xlink:href="ameh-20200930.xsd#ameh_WarrantExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0b9710c8-c868-4a22-9f58-af7b39601216" xlink:to="loc_ameh_WarrantExercisePriceRangeFourMember_c06845af-177b-4ea3-9456-87862515f4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:to="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_57bd29b7-b4ac-44ab-8fb5-535e12ab64d4" xlink:to="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8180ae42-fa39-4f17-8ac4-b1310cc102da" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:to="loc_srt_MinimumMember_8180ae42-fa39-4f17-8ac4-b1310cc102da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1a9f2695-2584-4a10-8de4-02c186a64772" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6c01117a-d086-4e82-8a96-bad063b0fecf" xlink:to="loc_srt_MaximumMember_1a9f2695-2584-4a10-8de4-02c186a64772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e2d4b255-c40f-4e11-b181-e983c98ec2fe" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76757110-5cf9-40a9-a48c-c7bf3995a4c4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_76757110-5cf9-40a9-a48c-c7bf3995a4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_683ec559-29f4-478c-8f38-6574209b5dc6" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightIssuedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightIssuedInPeriod_683ec559-29f4-478c-8f38-6574209b5dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_ee945668-6085-4ad8-8523-aae78c910f52" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm_ee945668-6085-4ad8-8523-aae78c910f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantOrRightExercisable_82cc9aa5-bc0d-414c-9637-f247d53527c2" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantOrRightExercisable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantOrRightExercisable_82cc9aa5-bc0d-414c-9637-f247d53527c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3115343f-a765-404c-9b13-ef8703947772" xlink:href="ameh-20200930.xsd#ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_418608ba-69f1-44e1-af37-b4d3a4ae3c17" xlink:to="loc_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants_3115343f-a765-404c-9b13-ef8703947772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0ed3dcd-5244-4f22-a400-7ee98e7136ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eed91b68-5ba3-48bc-970b-0dd0263e956d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e0ed3dcd-5244-4f22-a400-7ee98e7136ec" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_eed91b68-5ba3-48bc-970b-0dd0263e956d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f62fa24-7a40-4c94-bc0c-66294bb548d9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_3f62fa24-7a40-4c94-bc0c-66294bb548d9" xlink:to="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_319e049f-9254-4c48-a95c-61324c73921e" xlink:to="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_c752dab6-7506-4f75-8871-86a1ee7eade2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_fd21bb96-bbea-4753-abba-4d66d320f85b" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_c752dab6-7506-4f75-8871-86a1ee7eade2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_b6e6cc92-4aeb-42ff-bdb8-9b1686049b4f" xlink:to="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StandbyLettersOfCreditMember_f682b3f0-7eac-47d4-be3b-535ca347297e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StandbyLettersOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_0cac3404-80ec-4c33-becd-bfdb8295ff12" xlink:to="loc_us-gaap_StandbyLettersOfCreditMember_f682b3f0-7eac-47d4-be3b-535ca347297e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f1d01fbe-bb43-419b-ab08-d492089744ae" xlink:to="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ecb95c59-556d-4421-8815-3be2428b8b3c" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_ecb95c59-556d-4421-8815-3be2428b8b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlphaCareMedicalGroupInc.Member_cec347b1-29b0-46a5-8943-cbf71d2d2898" xlink:href="ameh-20200930.xsd#ameh_AlphaCareMedicalGroupInc.Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_a32d6813-7617-4c0d-b837-070c13178c2c" xlink:to="loc_ameh_AlphaCareMedicalGroupInc.Member_cec347b1-29b0-46a5-8943-cbf71d2d2898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:href="ameh-20200930.xsd#ameh_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesTable_af52e6fe-2205-4f87-962f-ba9a19b21a44" xlink:to="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_706c5bfc-7960-44d9-8ff3-ec38e3f5d4db" xlink:href="ameh-20200930.xsd#ameh_PercentageOfFinancialGuaranteeBenchmarkAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount_706c5bfc-7960-44d9-8ff3-ec38e3f5d4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_c92f1ed1-4b01-4566-a482-d76824aa8031" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LineOfCredit_c92f1ed1-4b01-4566-a482-d76824aa8031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_7b12f877-2745-4ed8-96af-efd81d865420" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LineOfCreditFacilityExpirationPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LineOfCreditFacilityExpirationPeriod_7b12f877-2745-4ed8-96af-efd81d865420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_a979db53-e324-4ead-9d27-f641e526a7b2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities_a979db53-e324-4ead-9d27-f641e526a7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_9c88446e-242d-4d30-9552-ba9586f2a076" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CommitmentsAndContingenciesLineItems_21cb6da1-9f73-47a4-9803-01dc639f7f2e" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_9c88446e-242d-4d30-9552-ba9586f2a076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactions"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_471b22ce-e987-4f4e-977f-09afd696064e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1233294c-b82a-4842-98d9-823340e17186" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_471b22ce-e987-4f4e-977f-09afd696064e" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1233294c-b82a-4842-98d9-823340e17186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_e6753257-e4e7-4364-92dc-f23f5c2eec6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_114fda25-320e-4c28-8b2a-74fceb10c170" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_e6753257-e4e7-4364-92dc-f23f5c2eec6f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock_114fda25-320e-4c28-8b2a-74fceb10c170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_9d5efbd1-0d26-4cac-9b61-c4527647deb3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_9d5efbd1-0d26-4cac-9b61-c4527647deb3" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96ef9bea-9555-4405-bcdc-5ea7fc0be1e3" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_96094ce5-e006-4d91-95e6-f55bd01a66bb" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_UniversalCareIncMember_96094ce5-e006-4d91-95e6-f55bd01a66bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_63370514-769d-4d6d-bdf8-92592f042e4e" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_LmaMember_63370514-769d-4d6d-bdf8-92592f042e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_3032102e-d325-4c99-ac18-3aacc9a0b6c6" xlink:href="ameh-20200930.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_PmiocMember_3032102e-d325-4c99-ac18-3aacc9a0b6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_a56ae8ba-8c7a-45f0-b980-f8e72b66154c" xlink:href="ameh-20200930.xsd#ameh_DmgMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_DmgMember_a56ae8ba-8c7a-45f0-b980-f8e72b66154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_73579be6-f8ac-4487-9e8c-818890dca9e7" xlink:href="ameh-20200930.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_269b7a4d-78fe-4319-88a1-6437fa78b801" xlink:to="loc_ameh_OneMSOInc.Member_73579be6-f8ac-4487-9e8c-818890dca9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4aa9bb43-6cac-4d22-8206-1d5184a78c59" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a5f8593a-cb85-44c7-8d22-46a8862c1854" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5383cc50-27a7-4f7d-b2c3-f8165ced36b8" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_a5f8593a-cb85-44c7-8d22-46a8862c1854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_376d4f73-87e3-4e33-ab0c-de95e0437aa1" xlink:to="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareIncMember_03f1307c-4fdf-42db-97a7-f2ab8f2ede30" xlink:href="ameh-20200930.xsd#ameh_UniversalCareIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_UniversalCareIncMember_03f1307c-4fdf-42db-97a7-f2ab8f2ede30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_a2318363-6a16-4573-a954-801afdb94875" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_a2318363-6a16-4573-a954-801afdb94875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ApcShareholdersMember_09ad9585-527e-4c1e-a2af-aee1fae06089" xlink:href="ameh-20200930.xsd#ameh_ApcShareholdersMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_ApcShareholdersMember_09ad9585-527e-4c1e-a2af-aee1fae06089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0638d85d-0547-4302-bc38-fc92aa736a27" xlink:href="ameh-20200930.xsd#ameh_AdvanceDiagnosticSurgeryCenterMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_AdvanceDiagnosticSurgeryCenterMember_0638d85d-0547-4302-bc38-fc92aa736a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_ShareholdersAndOfficersMember_5989c504-e051-479d-954e-ff91fd7eea8f" xlink:href="ameh-20200930.xsd#ameh_ShareholdersAndOfficersMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_ShareholdersAndOfficersMember_5989c504-e051-479d-954e-ff91fd7eea8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_MedicalPropertyPartnersMember_23cf9819-b7d4-447c-830c-c6c6e1066c43" xlink:href="ameh-20200930.xsd#ameh_MedicalPropertyPartnersMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_MedicalPropertyPartnersMember_23cf9819-b7d4-447c-830c-c6c6e1066c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_OneMSOInc.Member_f40d8bd2-8c1e-4a40-ba10-4e9eddf83174" xlink:href="ameh-20200930.xsd#ameh_OneMSOInc.Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_OneMSOInc.Member_f40d8bd2-8c1e-4a40-ba10-4e9eddf83174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CriticalQualityManagementCorpMember_98fd60cb-39e6-4ff1-b598-471b0736563b" xlink:href="ameh-20200930.xsd#ameh_CriticalQualityManagementCorpMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_CriticalQualityManagementCorpMember_98fd60cb-39e6-4ff1-b598-471b0736563b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NumenLLCMember_7f329f07-5f0d-4cbb-894e-3c8d9ae41497" xlink:href="ameh-20200930.xsd#ameh_NumenLLCMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_NumenLLCMember_7f329f07-5f0d-4cbb-894e-3c8d9ae41497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_8d18051b-5459-46fe-8ba8-c6b51d5a8141" xlink:href="ameh-20200930.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_686342e1-2989-41b9-acea-ef3c06088f53" xlink:to="loc_ameh_AHMCMember_8d18051b-5459-46fe-8ba8-c6b51d5a8141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_331936b6-3088-4cd6-b7ed-8ed65df37a38" xlink:to="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_NetworkMedicalManagementMember_ea216b40-4566-4190-84d2-d63d835bd8fc" xlink:href="ameh-20200930.xsd#ameh_NetworkMedicalManagementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_NetworkMedicalManagementMember_ea216b40-4566-4190-84d2-d63d835bd8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_57454224-5e91-4e70-bc6e-21bbea126253" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_57454224-5e91-4e70-bc6e-21bbea126253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_SCHCMember_d3226427-de2c-4eb9-b0ca-3e7f6f242ec8" xlink:href="ameh-20200930.xsd#ameh_SCHCMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_SCHCMember_d3226427-de2c-4eb9-b0ca-3e7f6f242ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2a9b8cbf-4176-4870-84ad-7ba72221eeaf" xlink:href="ameh-20200930.xsd#ameh_UniversalCareAcquisitionPartnersLlcMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_UniversalCareAcquisitionPartnersLlcMember_2a9b8cbf-4176-4870-84ad-7ba72221eeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DrSimAndDrLamMember_090dff16-4b3a-4a46-ae8e-22fa22eb8185" xlink:href="ameh-20200930.xsd#ameh_DrSimAndDrLamMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9a02df2c-bb0b-4f6a-a687-ecd5832caaf5" xlink:to="loc_ameh_DrSimAndDrLamMember_090dff16-4b3a-4a46-ae8e-22fa22eb8185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_7aac78b3-703c-4385-b889-2baa1cbdf9a4" xlink:to="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LmaMember_502e001d-5cf2-4c8b-8894-42a07ac1b721" xlink:href="ameh-20200930.xsd#ameh_LmaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_LmaMember_502e001d-5cf2-4c8b-8894-42a07ac1b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PmiocMember_a247f1bc-d41b-44f0-918a-f5759b3a2815" xlink:href="ameh-20200930.xsd#ameh_PmiocMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_PmiocMember_a247f1bc-d41b-44f0-918a-f5759b3a2815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_DmgMember_c0c50839-7c57-4061-95ab-94d82b5c157b" xlink:href="ameh-20200930.xsd#ameh_DmgMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_10394d80-3683-485a-a518-415ddcb90018" xlink:to="loc_ameh_DmgMember_c0c50839-7c57-4061-95ab-94d82b5c157b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionAxis_a652d5ab-c427-4adc-9801-2398cea1eef0" xlink:to="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_ffeb7d4f-9f08-496b-b86b-166be7b838c3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionDomain_13b82c8c-9029-43a1-91a4-5ad27c195159" xlink:to="loc_us-gaap_ServiceMember_ffeb7d4f-9f08-496b-b86b-166be7b838c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_b1d85ea4-979b-4dfb-a7ad-1ec430fc0909" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_0e921e1e-9ec9-4238-9396-334309739282" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_d27bb430-81ab-4a47-9fe0-0e7b1d8943ae" xlink:to="loc_srt_DirectorMember_0e921e1e-9ec9-4238-9396-334309739282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_74202cbf-0858-428a-84ad-e42f7a85d458" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ffa8a220-a167-4858-b36d-c37857a743b7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_ffa8a220-a167-4858-b36d-c37857a743b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_29d17f9e-b7e6-4a59-95eb-d278580355dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsAndOtherReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_AccountsAndOtherReceivablesNetCurrent_29d17f9e-b7e6-4a59-95eb-d278580355dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_4dba4baf-316c-442b-8fe2-60147b24d917" xlink:href="ameh-20200930.xsd#ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements_4dba4baf-316c-442b-8fe2-60147b24d917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_9612cb12-3335-4a45-a650-5fdfb41618a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_RevenueFromRelatedParties_9612cb12-3335-4a45-a650-5fdfb41618a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentMadeToRelatedParty_9eff6ee3-caaa-4fb0-a50a-bfdf20526b4c" xlink:href="ameh-20200930.xsd#ameh_PaymentMadeToRelatedParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_PaymentMadeToRelatedParty_9eff6ee3-caaa-4fb0-a50a-bfdf20526b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_955c539d-2bdb-4443-aad9-47a574c537f7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_955c539d-2bdb-4443-aad9-47a574c537f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0adf4635-faf3-4b0c-8f86-188bd714a826" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_OperatingLeaseLiability_0adf4635-faf3-4b0c-8f86-188bd714a826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_230399bf-0a68-4074-a720-80eedd5878be" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_230399bf-0a68-4074-a720-80eedd5878be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCreditsAndOtherLiabilities_fa201a98-1c24-4313-92a3-7b9488f24fb1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCreditsAndOtherLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_us-gaap_DeferredCreditsAndOtherLiabilities_fa201a98-1c24-4313-92a3-7b9488f24fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_PaymentConsultingFees_1d1c655e-0031-4b5b-b59a-2c4124d1ff0e" xlink:href="ameh-20200930.xsd#ameh_PaymentConsultingFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_532e3849-c42c-42a8-a002-35c2825c3b4a" xlink:to="loc_ameh_PaymentConsultingFees_1d1c655e-0031-4b5b-b59a-2c4124d1ff0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0ca0f548-7f3f-4667-9bc5-a90a8b45feec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0ca0f548-7f3f-4667-9bc5-a90a8b45feec" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9ad552e8-e8eb-407e-80f7-b5235f9b2594" xlink:to="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AHMCMember_aa06a133-5b62-41ed-a12b-d230ce99718f" xlink:href="ameh-20200930.xsd#ameh_AHMCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_AHMCMember_aa06a133-5b62-41ed-a12b-d230ce99718f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_HSMSOMember_9284ac54-58d8-469c-a48a-19edcad577b6" xlink:href="ameh-20200930.xsd#ameh_HSMSOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_HSMSOMember_9284ac54-58d8-469c-a48a-19edcad577b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AurionMember_24753cca-cad8-488b-8dc1-ade633caa292" xlink:href="ameh-20200930.xsd#ameh_AurionMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_6543258a-be92-4468-a44f-a14470d73d79" xlink:to="loc_ameh_AurionMember_24753cca-cad8-488b-8dc1-ade633caa292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_87b7034c-ed4c-4591-bc8a-21600277a6f2" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dad94c72-0436-4758-8978-62f65059618a" xlink:href="ameh-20200930.xsd#ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet_dad94c72-0436-4758-8978-62f65059618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_874ca86f-089e-4c0f-afe2-8ae130b88688" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_us-gaap_ManagementFeeExpense_874ca86f-089e-4c0f-afe2-8ae130b88688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a97f13aa-dd14-4b54-9e5c-dfcebd791a71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_7425f48e-fc45-4268-92a9-48934a66cbfb" xlink:to="loc_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty_a97f13aa-dd14-4b54-9e5c-dfcebd791a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxes" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cd7c467e-6add-4a4a-8e6c-d77e343ef4a4" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_f162e4c5-a097-47cc-ae48-9892b0ac2302" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cd7c467e-6add-4a4a-8e6c-d77e343ef4a4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_f162e4c5-a097-47cc-ae48-9892b0ac2302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fac6bae2-73a5-4ad5-a327-aa09523a040f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_abffab7c-53b1-4624-9e08-8b88fc56bd14" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fac6bae2-73a5-4ad5-a327-aa09523a040f" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_abffab7c-53b1-4624-9e08-8b88fc56bd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShare" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_506193f7-4108-44af-b5c1-ddc02422022a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_7d776cc5-93a9-4f56-af66-2a21011ae13b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_506193f7-4108-44af-b5c1-ddc02422022a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_7d776cc5-93a9-4f56-af66-2a21011ae13b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_93354936-f483-4e98-924a-970c4a5d5b11" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_30b5dfa6-3eae-4989-9a1f-476904edf9ba" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93354936-f483-4e98-924a-970c4a5d5b11" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_30b5dfa6-3eae-4989-9a1f-476904edf9ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_67d23281-947e-48f2-830f-9fc51c096809" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_93354936-f483-4e98-924a-970c4a5d5b11" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_67d23281-947e-48f2-830f-9fc51c096809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_80cfbc86-6298-4d8d-aca7-8617dba3e462" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_80cfbc86-6298-4d8d-aca7-8617dba3e462" xlink:to="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:to="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_36332a29-1999-42e0-9e54-af07a23eb247" xlink:to="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8906aac-64d7-44df-8e25-a313c245338f" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_e8e5b02d-411d-4b91-a40e-baa34f7d6d87" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_f8906aac-64d7-44df-8e25-a313c245338f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_fed66055-a36b-47d8-bfab-8ec798023219" xlink:to="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6139a22a-ec7c-470f-9c4a-e9f64b743282" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_878e2c50-1dc8-4858-b122-be3033d9406a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6139a22a-ec7c-470f-9c4a-e9f64b743282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_98480060-ffe1-4f27-b4f7-c6753cf32952" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f543f26e-1b26-4deb-a71e-84cbd4d00152" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98480060-ffe1-4f27-b4f7-c6753cf32952" xlink:to="loc_us-gaap_EarningsPerShareBasic_f543f26e-1b26-4deb-a71e-84cbd4d00152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_b747a08f-7022-4ca4-8125-9ec1e7914016" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98480060-ffe1-4f27-b4f7-c6753cf32952" xlink:to="loc_us-gaap_EarningsPerShareDiluted_b747a08f-7022-4ca4-8125-9ec1e7914016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_087ff310-9ef5-4834-a728-ec65de5055f1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98480060-ffe1-4f27-b4f7-c6753cf32952" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_087ff310-9ef5-4834-a728-ec65de5055f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f1a5f992-79aa-436f-8376-6792b3d0b93c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_98480060-ffe1-4f27-b4f7-c6753cf32952" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f1a5f992-79aa-436f-8376-6792b3d0b93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_efa5e3de-ea3f-4078-b074-d1be43fe3d9e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_efa5e3de-ea3f-4078-b074-d1be43fe3d9e" xlink:to="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_02538dfa-1dcd-400a-9442-9aa14bf7f4d5" xlink:to="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d32d9d99-502f-44f0-8bf3-656813debbb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:to="loc_us-gaap_CommonStockMember_d32d9d99-502f-44f0-8bf3-656813debbb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_24e09101-6d1f-4fc4-b0f7-aeeb9b326eb0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a5b94836-3c03-4cdf-9f36-b2edac8730a9" xlink:to="loc_us-gaap_WarrantMember_24e09101-6d1f-4fc4-b0f7-aeeb9b326eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_fd2457ea-d60a-4461-85a8-cb83cc5d7f7c" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2e07f2e9-d98e-4fa5-a983-89b8ecd14c9d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2e07f2e9-d98e-4fa5-a983-89b8ecd14c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_7a8a053b-7f42-4814-b799-149c871f4978" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1dc21555-3984-4ca5-aea5-58e8cb61e245" xlink:to="loc_us-gaap_RestrictedStockMember_7a8a053b-7f42-4814-b799-149c871f4978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:href="ameh-20200930.xsd#ameh_EarningsPerShareLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareTable_1b37ca68-ff67-40d4-97e2-8c125c1b0204" xlink:to="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee86bc1f-b82c-4871-9600-5f854710f42a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ee86bc1f-b82c-4871-9600-5f854710f42a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b2bfcf2c-d3f5-4bc6-aa10-0f791b6a8524" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b2bfcf2c-d3f5-4bc6-aa10-0f791b6a8524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22fbb7c3-8b63-44b3-8568-83e49be06577" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_22fbb7c3-8b63-44b3-8568-83e49be06577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_a3da1b52-0321-4214-b540-6ad0fc3dbaed" xlink:href="ameh-20200930.xsd#ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_EarningsPerShareLineItems_e4e3d218-2d7b-4175-99af-52009a86bb4f" xlink:to="loc_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage_a3da1b52-0321-4214-b540-6ad0fc3dbaed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEs"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEs" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_806d3b54-e105-4432-8af7-4edc3f3404a0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_f0e32171-9109-4fcd-9065-9ba93baccaad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_806d3b54-e105-4432-8af7-4edc3f3404a0" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_f0e32171-9109-4fcd-9065-9ba93baccaad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4480d15f-1be4-4a9e-a91f-1c8992ba8536" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_8c0d2186-6604-42fa-a606-8857ce98825b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4480d15f-1be4-4a9e-a91f-1c8992ba8536" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock_8c0d2186-6604-42fa-a606-8857ce98825b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#VariableInterestEntitiesVIEsDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbff5521-d874-4388-9b52-2df8ce7752d0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_dbff5521-d874-4388-9b52-2df8ce7752d0" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_e77bbff9-94ce-4ed6-8a69-35d2ab6968f3" xlink:to="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_94c7a50a-90e7-4529-a903-f8a4bf6df06e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_aebd5623-9a61-4469-8003-4ed91a39eaee" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_94c7a50a-90e7-4529-a903-f8a4bf6df06e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_326d6804-7403-4a57-9442-f21125dac86a" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f31abccc-1302-4e11-b20a-0d890fd1a7cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f31abccc-1302-4e11-b20a-0d890fd1a7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_557162af-02dc-4924-8eee-08a0cd0fb7e9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_RestrictedCashCurrent_557162af-02dc-4924-8eee-08a0cd0fb7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_e47266d1-86a1-4631-a6a8-2a4962219b71" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_e47266d1-86a1-4631-a6a8-2a4962219b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d6f53425-5b44-429b-852b-227e9aa55086" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d6f53425-5b44-429b-852b-227e9aa55086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dd2b1631-f958-43ae-93fb-9de2574cf387" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_dd2b1631-f958-43ae-93fb-9de2574cf387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_5d1a8d6a-36b2-4d70-bde5-9208cd211357" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_5d1a8d6a-36b2-4d70-bde5-9208cd211357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7df3cdd4-e862-44b3-a624-dae1d3a0e641" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7df3cdd4-e862-44b3-a624-dae1d3a0e641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0daa556a-ea75-4966-ba94-e73cac40fcf0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesAndLoansReceivableNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_NotesAndLoansReceivableNetCurrent_0daa556a-ea75-4966-ba94-e73cac40fcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_c878cb03-e223-42b1-b4ff-8c0e950543c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableRelatedPartiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_NotesReceivableRelatedPartiesCurrent_c878cb03-e223-42b1-b4ff-8c0e950543c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19968317-4067-42cf-8e43-cedf9e8838f9" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_440b6672-74fd-4643-bb48-c857c3a373f2" xlink:to="loc_us-gaap_AssetsCurrent_19968317-4067-42cf-8e43-cedf9e8838f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1bc2c8e9-8cad-4c55-8be7-94664a917794" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1bc2c8e9-8cad-4c55-8be7-94664a917794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d018e59-36af-4495-8503-f9784861c7cb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_9d018e59-36af-4495-8503-f9784861c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ca4a1e3d-1374-4464-9699-75bf4cda6677" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_Goodwill_ca4a1e3d-1374-4464-9699-75bf4cda6677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLongTermInvestments_efa01cff-2e25-42f7-bbd8-054bc58609ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLongTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OtherLongTermInvestments_efa01cff-2e25-42f7-bbd8-054bc58609ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ae8000ed-8e09-4ab4-be6f-8ff600ffe025" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue_ae8000ed-8e09-4ab4-be6f-8ff600ffe025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_87c43f6a-17b0-4372-b031-cde224dd5cbf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_EquityMethodInvestments_87c43f6a-17b0-4372-b031-cde224dd5cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_d313950e-b1e2-4f31-981a-e31095d23452" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_d313950e-b1e2-4f31-981a-e31095d23452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3fab7345-f0e2-43fc-ac4e-ea1404000ab5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3fab7345-f0e2-43fc-ac4e-ea1404000ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8a1ac6c7-91f1-4474-85d9-fd2cccbc6be0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8a1ac6c7-91f1-4474-85d9-fd2cccbc6be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_e1b7e603-50c8-41bd-b2f9-045415ef4f20" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_81f0f2bf-bff6-4097-80e0-88802a7ae051" xlink:to="loc_us-gaap_AssetsNoncurrent_e1b7e603-50c8-41bd-b2f9-045415ef4f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0394b5cb-52e5-44c7-8477-76f067f8bc73" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_56df43a5-8f11-4202-a0ce-7e928f1b45b6" xlink:to="loc_us-gaap_Assets_0394b5cb-52e5-44c7-8477-76f067f8bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aafc6087-ce63-4ab7-b56b-4e7f3a6ccda3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aafc6087-ce63-4ab7-b56b-4e7f3a6ccda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FiduciaryAccountsPayableCurrent_09962080-3fd5-4b56-977c-f9d5d940718d" xlink:href="ameh-20200930.xsd#ameh_FiduciaryAccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_ameh_FiduciaryAccountsPayableCurrent_09962080-3fd5-4b56-977c-f9d5d940718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7e3e9f95-f2d3-4d51-a2e6-6e5fc5fe2920" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7e3e9f95-f2d3-4d51-a2e6-6e5fc5fe2920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_47fc3cee-4986-4807-839b-e0e8d4cfebcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_TaxesPayableCurrent_47fc3cee-4986-4807-839b-e0e8d4cfebcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToAffiliateCurrent_bd4af994-42a0-495e-989d-3ed4a2bc9448" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DueToAffiliateCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_DueToAffiliateCurrent_bd4af994-42a0-495e-989d-3ed4a2bc9448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrent_14b88134-1776-48cd-9d5b-e25a6afbb9fe" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_DividendsPayableCurrent_14b88134-1776-48cd-9d5b-e25a6afbb9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5a972d09-aa06-4d0a-807e-f82d020d342b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5a972d09-aa06-4d0a-807e-f82d020d342b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2ebb66ca-4ba9-4c7c-91e9-46d3428b2b21" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2ebb66ca-4ba9-4c7c-91e9-46d3428b2b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_fdf2cea7-4a3d-41c4-ae33-79665dd4feb5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a3cca1ec-f8e1-4e5a-8d09-cd6ceba67bd0" xlink:to="loc_us-gaap_LiabilitiesCurrent_fdf2cea7-4a3d-41c4-ae33-79665dd4feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb1d55c3-d7d1-461a-883f-dc0225da42b0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_eb1d55c3-d7d1-461a-883f-dc0225da42b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1806244a-d234-4ef4-b694-4e342819d4d8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1806244a-d234-4ef4-b694-4e342819d4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e70aeb72-894e-4fc1-a80b-edca2ef56b15" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e70aeb72-894e-4fc1-a80b-edca2ef56b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c141842a-4a5e-4467-8bcf-45eed0e2b9cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_5af85e0b-fb3a-47a4-8be0-ab3ab29055e7" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_c141842a-4a5e-4467-8bcf-45eed0e2b9cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_87c7b7a3-8401-4de5-b5f8-29b27aa4343e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_a12545b8-cad8-43a6-b24d-228e17ba5225" xlink:to="loc_us-gaap_Liabilities_87c7b7a3-8401-4de5-b5f8-29b27aa4343e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/Leases" xlink:type="simple" xlink:href="ameh-20200930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_ed23903c-da55-4aeb-b982-393bdb1575fd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_54bd8314-7dde-442c-a1f7-d9ac4c3322ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed23903c-da55-4aeb-b982-393bdb1575fd" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_54bd8314-7dde-442c-a1f7-d9ac4c3322ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ad38f8fc-b45a-4ee6-80de-4061b5479e74" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_ed23903c-da55-4aeb-b982-393bdb1575fd" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ad38f8fc-b45a-4ee6-80de-4061b5479e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesTables" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_29caa618-b087-42fb-835a-ef85bb96cd66" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_165e138f-2cda-490e-a5f6-a262da1e4d2d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_29caa618-b087-42fb-835a-ef85bb96cd66" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_165e138f-2cda-490e-a5f6-a262da1e4d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_560a1681-bd3b-4209-bb59-6fc870126701" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_29caa618-b087-42fb-835a-ef85bb96cd66" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_560a1681-bd3b-4209-bb59-6fc870126701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2c151b95-f200-4290-9b39-bb7d44083391" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_29caa618-b087-42fb-835a-ef85bb96cd66" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_2c151b95-f200-4290-9b39-bb7d44083391" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesAdditionalinformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesAdditionalinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f8085359-8fe1-4798-98a9-e64810ba3cd3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f8085359-8fe1-4798-98a9-e64810ba3cd3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:to="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_73cdcb12-d771-44a4-8122-b472b197352a" xlink:to="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fbf29cae-f38a-4c10-9f56-0f651a2cc67a" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:to="loc_srt_MinimumMember_fbf29cae-f38a-4c10-9f56-0f651a2cc67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_80fbdaa3-9b6c-43bf-b68b-a85cab7c204b" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b25d512e-35ec-4d8a-afeb-d88253d953d9" xlink:to="loc_srt_MaximumMember_80fbdaa3-9b6c-43bf-b68b-a85cab7c204b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_addc22ca-0411-4ff4-9267-da1ecf7a5bcd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cf5794b4-ed00-460c-bc0b-16b9d0842ea8" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_cf5794b4-ed00-460c-bc0b-16b9d0842ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_f9614c5b-b69a-47de-9dc6-5a8ca6a1550f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_f9614c5b-b69a-47de-9dc6-5a8ca6a1550f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33905afd-2322-45c6-854d-5b066abb707a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_33905afd-2322-45c6-854d-5b066abb707a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_2c25bbcd-4ff1-474d-bf5d-cbcabfb46f67" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_2c25bbcd-4ff1-474d-bf5d-cbcabfb46f67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_8450144a-1362-4272-97d8-9b5686add9b4" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable_8450144a-1362-4272-97d8-9b5686add9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_8812aacb-d84c-442d-ade3-269ba9b10da2" xlink:href="ameh-20200930.xsd#ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable_8812aacb-d84c-442d-ade3-269ba9b10da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_3d888edf-6af3-43bf-9e93-14bd7d7c8939" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_3d888edf-6af3-43bf-9e93-14bd7d7c8939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_73c8af4e-9055-4cea-9785-d98733639a54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c63cea04-b9fb-449b-9da1-b0206ff6087c" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_73c8af4e-9055-4cea-9785-d98733639a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_224fd25a-be21-4a99-b7b8-7395153ea15b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:to="loc_us-gaap_OperatingLeaseCost_224fd25a-be21-4a99-b7b8-7395153ea15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c50c3baa-ef91-40d7-a20a-412cba62812b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_c50c3baa-ef91-40d7-a20a-412cba62812b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_c543dac7-194f-4696-bb24-0c195e283d44" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_c543dac7-194f-4696-bb24-0c195e283d44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_c87ec8a3-1a5b-4e34-a6ba-fcd2346f5e96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:to="loc_us-gaap_SubleaseIncome_c87ec8a3-1a5b-4e34-a6ba-fcd2346f5e96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_3c1ef01c-3f15-4b32-b99d-d09d1fa15679" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_395260a7-b6b3-45c3-b7c1-e10db19d46aa" xlink:to="loc_us-gaap_LeaseCost_3c1ef01c-3f15-4b32-b99d-d09d1fa15679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bed8370b-d8de-4464-8d5c-32656a999cef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_c110c8b6-24d6-42ca-883e-b6390afd39a1" xlink:href="ameh-20200930.xsd#ameh_CashPaidForLeaseLiabilitiesAbstractAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bed8370b-d8de-4464-8d5c-32656a999cef" xlink:to="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_c110c8b6-24d6-42ca-883e-b6390afd39a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_588272f5-b58c-4361-8d23-2702bcc7124c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_c110c8b6-24d6-42ca-883e-b6390afd39a1" xlink:to="loc_us-gaap_OperatingLeasePayments_588272f5-b58c-4361-8d23-2702bcc7124c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_02fedd5c-60c3-484d-9eaf-33d1aae4bc2a" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_c110c8b6-24d6-42ca-883e-b6390afd39a1" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_02fedd5c-60c3-484d-9eaf-33d1aae4bc2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_da050081-092e-4e88-9992-922ee279e581" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract_c110c8b6-24d6-42ca-883e-b6390afd39a1" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_da050081-092e-4e88-9992-922ee279e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_942ca9dd-ed03-40cb-9684-176ac8d039ae" xlink:href="ameh-20200930.xsd#ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bed8370b-d8de-4464-8d5c-32656a999cef" xlink:to="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_942ca9dd-ed03-40cb-9684-176ac8d039ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8a1f966e-5515-4332-9a17-b3ef60f81f4e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract_942ca9dd-ed03-40cb-9684-176ac8d039ae" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8a1f966e-5515-4332-9a17-b3ef60f81f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_69ad0f16-65a6-44e7-a6d6-04a94cf6e7af" xlink:href="ameh-20200930.xsd#ameh_LeaseWeightedAverageRemainingLeaseTermAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bed8370b-d8de-4464-8d5c-32656a999cef" xlink:to="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_69ad0f16-65a6-44e7-a6d6-04a94cf6e7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_00cc63b0-a84b-4520-9990-addee32fd5bf" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_69ad0f16-65a6-44e7-a6d6-04a94cf6e7af" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_00cc63b0-a84b-4520-9990-addee32fd5bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_6accb661-d28b-4f68-a96d-aa55a9297476" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract_69ad0f16-65a6-44e7-a6d6-04a94cf6e7af" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_6accb661-d28b-4f68-a96d-aa55a9297476" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_e758b7fa-2b95-4a5c-9ce2-0791629465e6" xlink:href="ameh-20200930.xsd#ameh_LeaseWeightedAverageDiscountRateAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bed8370b-d8de-4464-8d5c-32656a999cef" xlink:to="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_e758b7fa-2b95-4a5c-9ce2-0791629465e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0cb2d3ac-ad49-46b8-ae8c-cdd2cc5163ab" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_e758b7fa-2b95-4a5c-9ce2-0791629465e6" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0cb2d3ac-ad49-46b8-ae8c-cdd2cc5163ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ceb6c49f-5964-4511-903d-41aec804f61d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ameh_LeaseWeightedAverageDiscountRateAbstract_e758b7fa-2b95-4a5c-9ce2-0791629465e6" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_ceb6c49f-5964-4511-903d-41aec804f61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_43042867-b20e-44ad-95f9-d4de3e0a7656" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43042867-b20e-44ad-95f9-d4de3e0a7656" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_07fd5b1b-7e80-4969-8472-082074a7d08f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_07fd5b1b-7e80-4969-8472-082074a7d08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e88d7548-3a0c-4a30-841c-3ea7c1cb6e54" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e88d7548-3a0c-4a30-841c-3ea7c1cb6e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77b37b8e-7c9c-4791-938d-abb7259df5ef" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_77b37b8e-7c9c-4791-938d-abb7259df5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_679c2d1d-3d40-42c0-ad24-2c50bc2b84ad" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_679c2d1d-3d40-42c0-ad24-2c50bc2b84ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8da40f69-faf8-4211-b072-e5b7a54e0ef3" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_8da40f69-faf8-4211-b072-e5b7a54e0ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8fb2c203-612b-4080-8271-703577118423" xlink:href="ameh-20200930.xsd#ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_8fb2c203-612b-4080-8271-703577118423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_91f8cb88-a905-4bec-a375-20d5cdfccbae" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_91f8cb88-a905-4bec-a375-20d5cdfccbae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f174a064-c7fd-46c2-92a0-f7f32bfc1b5c" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_f174a064-c7fd-46c2-92a0-f7f32bfc1b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f65851af-17e7-404f-981e-3a2fccbd7b38" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_OperatingLeaseLiability_f65851af-17e7-404f-981e-3a2fccbd7b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_586ea918-df83-449e-b419-4c9f9338b80d" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_586ea918-df83-449e-b419-4c9f9338b80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20341881-3cd9-4a32-a2e5-6c1d7552c736" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1ba8366e-eaf5-4180-82ef-9f5cf1ed2480" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_20341881-3cd9-4a32-a2e5-6c1d7552c736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_43042867-b20e-44ad-95f9-d4de3e0a7656" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9a86a6a4-fa58-47bb-9e91-de4a6d65ceb7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear_9a86a6a4-fa58-47bb-9e91-de4a6d65ceb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_58ada5bd-0726-4181-8195-a1f0a91fe0f2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_58ada5bd-0726-4181-8195-a1f0a91fe0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8f001686-742f-466c-9219-350a87c7db6f" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_8f001686-742f-466c-9219-350a87c7db6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bb0ae45a-64e0-4753-98ab-1c69229294dd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_bb0ae45a-64e0-4753-98ab-1c69229294dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ae22a7c5-8c7a-4188-aece-c6eb5845fd40" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_ae22a7c5-8c7a-4188-aece-c6eb5845fd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_3e6d7878-8dc7-4ca4-ae79-f88aa7bb98fb" xlink:href="ameh-20200930.xsd#ameh_FinanceLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour_3e6d7878-8dc7-4ca4-ae79-f88aa7bb98fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40920a2e-aecf-41e0-8689-e72910d44045" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_40920a2e-aecf-41e0-8689-e72910d44045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83b487c0-2e6d-4cf9-8646-46d766b4cdc2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_83b487c0-2e6d-4cf9-8646-46d766b4cdc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_eb692b36-9eab-4ae5-95ec-82f0ff99afdd" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiability_eb692b36-9eab-4ae5-95ec-82f0ff99afdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_ded85545-bfa6-45c2-ab8f-2da42ae3d42b" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_ded85545-bfa6-45c2-ab8f-2da42ae3d42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f1f8b2c1-2a80-4078-9428-f76ffefe0af1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_d4414565-fbc0-4b2c-b1d4-f9b4858877c2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_f1f8b2c1-2a80-4078-9428-f76ffefe0af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="simple" xlink:href="ameh-20200930.xsd#LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEvents" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_55089636-6905-45e8-8544-5e625dd290ea" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_3612fadf-dc25-41bc-b696-155eef5a732e" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_55089636-6905-45e8-8544-5e625dd290ea" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_3612fadf-dc25-41bc-b696-155eef5a732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="simple" xlink:href="ameh-20200930.xsd#SubsequentEventsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_66979737-59d1-4eb5-86f5-3fcde555c829" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_66979737-59d1-4eb5-86f5-3fcde555c829" xlink:to="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6e138d3c-0cca-4dfc-948e-dde8a2dd5e17" xlink:to="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_AlliedPacificOfCaliforniaIPAMember_aee8f4c9-3ec1-4906-a340-3bcbf2278396" xlink:href="ameh-20200930.xsd#ameh_AlliedPacificOfCaliforniaIPAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_031b6253-1de2-4e17-ac4c-2cd25d5b3c5d" xlink:to="loc_ameh_AlliedPacificOfCaliforniaIPAMember_aee8f4c9-3ec1-4906-a340-3bcbf2278396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_fac9814c-3641-462a-a5eb-4182dfc286eb" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_f2df30bd-d557-42a6-b63a-e9fcd5dd75c5" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c67c8fcc-5ccb-4eff-969f-99e97ccd98cc" xlink:to="loc_us-gaap_SubsequentEventMember_f2df30bd-d557-42a6-b63a-e9fcd5dd75c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_729183fb-2e11-49da-a18e-27de8b4c99ec" xlink:to="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableMember_0ecd146f-a789-47b5-af2b-a7130d7f1e53" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_582d4c31-fed9-4bf4-ba21-5f7ee72a2a96" xlink:to="loc_us-gaap_NotesReceivableMember_0ecd146f-a789-47b5-af2b-a7130d7f1e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_3c6b1311-78d0-4ffa-a63e-1264251d31ca" xlink:to="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_AffiliatedEntityMember_e3a7cc40-4d07-4437-a28e-faa16c9091ac" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_AffiliatedEntityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_d90717f1-9330-4ae7-9cc1-4550947f4427" xlink:to="loc_srt_AffiliatedEntityMember_e3a7cc40-4d07-4437-a28e-faa16c9091ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1dff06b4-f745-45b9-8dda-b103cef40d01" xlink:to="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_0154180f-647a-419d-83f1-0541c03b80a7" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_us-gaap_Dividends_0154180f-647a-419d-83f1-0541c03b80a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableGross_910386ac-f4b4-46e0-8189-91d215446668" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NotesReceivableGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_us-gaap_NotesReceivableGross_910386ac-f4b4-46e0-8189-91d215446668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableTermOfReceivable_521c5bec-b219-41da-8be9-4cad0ef4a3c0" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableTermOfReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_ameh_FinanceReceivableTermOfReceivable_521c5bec-b219-41da-8be9-4cad0ef4a3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ameh_FinanceReceivableInterestRateStatedPercentage_cf3edb09-6a1a-4b75-aaf3-e2a0ca02042b" xlink:href="ameh-20200930.xsd#ameh_FinanceReceivableInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_c6921dff-74ac-495a-aee4-6cf7b97ff0c7" xlink:to="loc_ameh_FinanceReceivableInterestRateStatedPercentage_cf3edb09-6a1a-4b75-aaf3-e2a0ca02042b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ameh-20200930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:ameh="http://www.apollomed.net/20200930"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ameh-20200930.xsd" xlink:type="simple"/>
    <context id="i52b79e80b0334de886124ca554069b1e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i233eb597e897408bb9acd656dcbd1d0c_I20201102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-11-02</instant>
        </period>
    </context>
    <context id="i6f15713b91eb402cbc19264dd2327c3d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i30b785ad17374d349aaafe08c2aa1d7a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12392f1820d84e009a3fec747ed05785_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i88f29eecb4a54581a1e137030ee84580_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id468dcf3a96c44a884ae2121f3929be4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i999f85b1f03348b59973a22d2ce701fd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a96f004265e44acbef5c40e0a7274cb_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id0760f54a264410584d47359d3245e54_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i85cbed6310784ad1b00d427467f4a809_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie735c2fc161f4a028234f400af312f8e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0ae35627def147d19d8ab0682325ebca_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia5096fa86ff645c4ac88aeaff7eb1d9f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:HealthCareCapitationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i89dce8d40320482793ae915c3b3fda86_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idc8b559adf384439909838b82a315ef4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifb2871d1532647e4bc4f0564a4773c78_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i103b982ccc8e4f93858938af7e18a96d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCareOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i48fce5948a0e4dfdb085803d8face2f4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50f345eb35b24b309883822a3f432a39_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i92adae19551f4d33aa3159e1f3b3c333_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7c26c34d43944d53b8157c588e4d9832_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb905dbaa5064b25b91dff34aa6ebc5a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9dd1b1d0644e4537bb0c05e512c38d0c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibbf30c3701d24df69116273d7a5e466b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePatientServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iaab6050bdfaa4b99b69a677d9fb18e68_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7c8d5c0eb18b40688e3d9ffd255e0a2e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5b7fc96fb74e494b8db4e7508d53047b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i06d6f6c3ab514e87bbe68a7fec5bcd87_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4c3f468964da412ebaa0846e50fe0da4_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i12c2127d868e4f87a671ff137b7c2981_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iabd3dd55e36b43b495789ffa5cc73b36_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i59fc236ccce64a608d756612e5db97f1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibba7855d202c4906a207a0a7faa251a9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i18b992a0d32d458485f04f21e552fb61_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id2eceea105e94e54a0c2107e27e00355_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i251eec9a4efe4815a9a119b6820c7de8_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i87c42df9ebca4c8ea2878cd65f523941_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i90197c93402f41ff9bc61f1754e24165_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i09497b34fad5498f8a7379c15692a946_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i19924d22b9634738af4fc0857dd5f1db_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i04e6f52d6af84990b66fae85e26f4b3e_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i672096def723492da951e5ba41de393f_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i722d022bc60341a4957154974aaa0f71_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i13676229b94a433bb7999e82d40c9506_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i31636c0f849b4fcfac8862fe43198701_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ica802434063e4405a1db846371417d7c_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i47774eeabb6c4f8a941dafeadf448ab0_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="ib6836300d36448ee8800b32b51ab5107_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i045332a06815470c90c30b39515f8d62_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f9e597672244da19f4a35690c8fb312_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0058c6f89dbc42439fb7e3bd81042bbc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9fc323e30b8848c392d11f3447569909_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia7fba74c001f4474b00a66afe5cacce5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if17092a524b3431fa61045723b615908_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i48930c9adfe945f5b856524fd6f16354_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if4d27872ad1a4279809587e20ad0fe15_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0a4af3abe23145c5a803f5c3e52a8544_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="iaed16704d02b4d98bf8e2256dea906c0_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i761a2357c3064b2594cc6d1ffa6c27db_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i5f84ac6f64b14be7aec8e4101eced375_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i97e0bcf361384859a17578fb87321a54_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i5e6f19723927433ab20be84a073ed166_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i97544ae25cce437ca45e3294de951909_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="icd0eb6717cd0468292846a328415a98e_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="i77cee32ef46c436d84f0829e3e15ae33_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i1abc08966ff44c6c9d37bfc49d295077_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i44c7198a292a4cc68b8fabdaafd056cd_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="ifb4e33d7899548cf889cdedab733332d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i0bff8181370945009acd3344b88456f0_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i9e5a66ee0d984c67b9d7841aeb1f110d_I20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-03-31</instant>
        </period>
    </context>
    <context id="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iedead393f61c4d1d98fb4fb12d0b9b21_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i88138caccd9942feab56d34bfdb5c9e0_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="i41a9a24bf76640ed9bdb33547fcaacce_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i394648e1fc6a45c1a9b563d94578a33a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i441f160512f24fc3a029ac86e7eb66f2_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="id9a6b08aae29400da31700f63234c634_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i9189b09c063b44b4b87c085f5786c13a_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6ddfb33c93414dc69359261cfab93737_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idfadcf1ceec24d88b5700a0374a20a18_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie1bd4252c28a48b9bf1ba1f49f34c298_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i422d2bc6f855432dba692b6a8acdf97f_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:MezzanineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ic92256abd49e475e96a57d58092f2a3d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i8f8b5692b30549aea2a5a9d8d16e6332_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="id523b2ed183c45849c949c14470f0f6a_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i23e7f6a028994e14996741a361d2e4db_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6832502be8ae4cd5b8fe7d88754bda80_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ifd29e64a2dec4d29bab58feb5d6061ad_D19990701-19990701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>1999-07-01</startDate>
            <endDate>1999-07-01</endDate>
        </period>
    </context>
    <context id="iea967cdf5b2f471a892ea4697afe0798_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i910be3ba7abf4fbb8a6af6dcabd337ac_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3271ca437f904f76a750501a6a560262_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:APAMHMedicalCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i224fec02c801431e8c5aac9b0b456487_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic3034d93366647d8945f0fd5c17d5c31_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ApolloMedicalHoldingsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i31c72a9bb0cb4b81bd7107492b993265_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:ConcourseDiagnosticSurgeryCenterLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i107e7a3c6a6544e99b2eb9a20ca8c10a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MaverickMedicalGroupIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8aab34eff41047a39824b386e77f2ab9_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i21eafb5a353445498a87ec5ef991e89a_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i4cc46814272a4c91b52259eab36012a6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i18773fd9db2d4f019b64dad4ce3bb2ca_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i4ef9a04a9f264372a8deb57e8aa6633a_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if1d00ff8efb448b7851f3acd7b67c857_I20140630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-06-30</instant>
        </period>
    </context>
    <context id="ib183d084186d4c5bb6d817ef531b2f3d_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i3b26df8521744f83b689e49598713e48_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6fff24e3077f4a3eb1b61025153234f3_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i6e5cacd19c684cdbb8845f5fa5d3f343_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i268f6180d8c0414395a4e02831546f91_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i615fb686511c4f7b9373dcdd32145e20_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5300706ef0ee464c80f686cc29fef1eb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i860551ad800a48b6b48834294a562f6e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia00916d9e42e4e7598a07cc98c911bba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i59c65958899a4f40b312082b11ad9972_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie48bb7d5e7164c9087e12aebeca47de4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i08e72fdfc6d2440f9a7a619f2bfa27a4_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia6b08cbba5ce44a6828427adf1d58d41_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ice6d7186a3fa42f2aa021e89451d94a6_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:CommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2df6da5ef4cc4b969a1fe43c3978041b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i24dff7de3f35477897d40e0ce546c0c2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iee27b0cd6fa641be9c0346123edc0f7c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6281cd8fd509439da10e97b31b90f99d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i8acee0d243214133a46c54e3cafca151_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i99ce7ab3879d43af8ed70e1e9d100478_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:OtherThirdPartiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1864ede366d9428596f507b1ccdf3055_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic009ac2508fe4ddb8d41e1d789d89e2c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ebbea39beeb486097293272d98df046_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i35e09b32dfa2485098765d8342e2c09d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i41254baa0b494543874e77b5b65806dd_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5db53e7069624847940f8b01072d1616_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i50b5b61eb68b440ca6b1f08ae563dd55_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if0c8e4a29ed643d2812e326a13329643_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i215eb1833be2440ab91be38ab300819f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie685084fafd04aabac97138d7d7c72a0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2d1826880923498084158c89cee6e00a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i50ba8e183602464480aebab3b80942ca_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1f060ecdde4a4705b9409b06aa972c41_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id59a584c780448de8be355c36a29f7cd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i14a8fdcc013f4900b6aada4fc3f7af4a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0dd1feb4e50b4175a4e88a4badb5cb45_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6e3e458d85614c56bb255ed53fb55e0a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i93b93d2a3bdc45dea0ee9e341a282b8a_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorFMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib26496fe9ee64c8ea436ec54656e23b8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if626b3c6137241b29c016703d18f7fb1_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ameh:PayorGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i142ee7c619bb459289d0d37e04512563_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2b7656f6e67342e29f677b7a1e65c532_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i742706889d86455a834aaba86ebe626d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i69df776760514fe6a9114b9121a87a7c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i116b3e9585e9410a873b90bb05603771_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2d04d4b89dd2456bab5a43914120ef3d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:PerMemberPerMonthManagedCareContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2c841cb894a44b438ddcf5f653a3121e_I20161231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2017-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="i1b924b44d11243c79329ffb24703ba48_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ameh:NextGenerationACOModelParticipationAgreementMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2019-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:CMSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id33eaefc8b5942e9b470aa4f9c9fbf0d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">ameh:AccountsPayableAndAccruedExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-31</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="id0a2c6ac04aa49da8a227305158f0d54_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i400a89eea72d482f927a72d7ad593718_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="ic57f99e455f748c7bd9f72d18cb3b19e_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="if2f44f37c4f54616bb326a86f03405a3_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="if23b273bb3224911ad4440101430e675_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="i275a644f4ba94748b1661c63ce54b8bb_I20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="i898462389ad24c0b8913adf6b0b29a3b_D20190830-20190830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:Dr.JayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AccountableHealthCareIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-30</startDate>
            <endDate>2019-08-30</endDate>
        </period>
    </context>
    <context id="ic4dc99a0ca2e4bfbabef2c87ec9306d0_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ameh:AmgIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3bf488f66af84851b3c1d0a9fe304793_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic1f29d2703f749699c41aad0f5b9c7e0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7694ec30545c4fcdb3e6691905656166_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib036147d021e4632a938ef95e13bcfeb_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i47f47905931645f2843f1d0f1c953fd4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i22a3823bc30347e1bc4a4696c1657ad2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if29bb5f2be9646a1b77a64b7724af7d0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8806313e53624b498a37f7e03713bd8f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i91299a0c3df14bb0912f70e6b0c32101_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i820337c646004760a5fd30654c3dae01_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i307aff6d7c74455f8c12990d253efcfd_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i57399d018d8249a39d4044e5041d9d91_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="iec82f37386d54fcc9539d0fee4b55ef6_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i2b3382bb05604a72853736390f8d222c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:NetworkRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id9572fe44439456b89540528dafe8efe_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i155d3af50fd548b19a0650fe1f943242_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:ManagementContractsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic8c4d20368234add91f91bbc581e9c85_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:MemberRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i87f4db5982be4abd98dbc5f29cd0da48_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i5b58660aaa264d22a46c25bb967a0695_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ameh:PatientManagementPlatformMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7f579d4160604e7babd882b0c0d2df3d_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i687f8eb4581848cba1db329c2d343353_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3150290f584e44fb942ebfa558510e67_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ida39330ce23947b1a283b27d4e1fd854_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i69c46a468b494d52959804c3f5b2b176_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id96dff4b93054ab5979c1cc17ea91814_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1208e04262ef4a01a35da5626d1ff666_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i37888056e3424c5f8d0dcb6ddf14c929_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i753d549a8e2f4889a19f89e63e84cc3e_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c38a1a7e9ee472f947eea00738b4192_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ia0b72e4a3daa4a53955968c5168b7655_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iec20f66949cb4f86b1a6445e912e304f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ie186328fb4c549168d42b7d9a48992e5_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0aa118fd35d9488990668d4e47746b7c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iffa1353ebe6443cd972fce8728b7af34_I20121231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-12-31</instant>
        </period>
    </context>
    <context id="i1d6f80bd32404fe58031f292d1695804_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icce0e75bb6d54e57a2fd9d41415f1fd0_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i36d5dfd221ad448cbcffffc8f6478d08_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i77f38d9db9c24fb6b7dcd2c1221459f8_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i68d4831420054a9caa735c7f1252692b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib1f9f8ea17ec45a094548fee58869526_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="id90abdab01f44e47b48d561df36836df_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:LasalleMedicalAssociatesIpaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ia037d44d0bc04c4a828c637cca06b007_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApcLsmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="i1424495955004e3094d7f448c52f3fe8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8297f0cd122a4975a2782edec1346e26_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i288e556a87794169a4a86cc7f6c4e55d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8b4bf3567dfb4dd790df1e67d2f85991_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i71a29ce4a53848648939532cde255536_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2146c6cb823b414e94d6373622631d84_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic1d5b7766ae84835948bd0dc5b9bad5c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idef125c16c3942fab014863ef8783a70_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibcba94fccca04cd7b22e774e76edfde4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ieda981fa64b9451192fe68d1b530358d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PacificMedicalImagingAndOncologyCenterIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="id4c48b0482e24d54a35353fe5806ea4a_D20150801-20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="ia04e6e879820403ab84c417618cac928_I20150831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ameh:VotingCommonStockTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ameh:ContractTypeAxis">ameh:AncillaryServiceContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-08-31</instant>
        </period>
    </context>
    <context id="i32f8ada07c6e48c3b9c63debad1daebf_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i32e68a9968f5490582115cc17368bef7_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="i8cfb37c8a9b442048185c215ca7ae06b_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i856a3c65a5c24836ba93769ef9f2948a_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-30</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="ie13a24a9ed274984976f3be0b0ae5d60_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i07add4ecbd2749df8612f106ba12945d_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="ic0e8d7a443424c718c847dcf3b912bea_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1ea26d47ecf949429fb00155fa3a1100_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icb5b9a12e29e496699cd7e52d210ebb2_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-04-30</endDate>
        </period>
    </context>
    <context id="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i45be72031ca0447e97e01053b8c321fb_I20160531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-05-31</instant>
        </period>
    </context>
    <context id="ifba98224dfe743d886659a878903bc31_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9dc91266bda94e86a5ec7f40496f5a5c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if0cb473eab6e497599fded63c9f221e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DiagnosticMedicalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1d560d1902504cca8098eacb878eef29_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CollegeStreetInvestmentLpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i6184b34ee8134be5b8c421145d39c934_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i46a9a7002274458a996a2f3572f2742e_I20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="i3015e3b3bfc74713a36da771c5184b53_D20180601-20180630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="i51f10e9761bc4228abb6d529c3349de6_I20190423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-23</instant>
        </period>
    </context>
    <context id="ic465b3707abf436089f9fc1143560257_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="iabc665a0dbda4c87aeba1b7b7f31c314_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i48000cd06bc14fb78d5ac9a135a4817c_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i07be705677f8498588d2853c3c7bf749_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib25087f805b748af8715c1809bb3ecb1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8278a3e815674925897c9ef247e29fd6_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ic15b75dc348c49258108d27228c78e88_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeAxis">ameh:FiveThreeOneW.CollegeLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i0e75f05d163f47508aaed53617f817da_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i808a481f8e67463fa27b080f11806844_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i2407645ed5864ae5b8cb66de46074353_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="ic4e7c20c772c4b85a99de03a80063147_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Pacific6EnterprisesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i9e993cf753ad4a0694bf3466d7220468_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:HealthSourceMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i3b8908c9b1334fe395a61d2ddc0668cf_I20190831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-31</instant>
        </period>
    </context>
    <context id="ic960b26a1e3f40a1b24e18c623b99240_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4454b081d0384506ab87a132eae22d31_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia915b2c31332442a8d6f15aef9889924_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i65347818febf49c7b80dc85ef7ae043f_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i6f8670c333f043daaa155fb5a0ac3eab_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2f60ef2535c14c7bb4a2c7f0b27b0a8c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:MWNCommunityHospitalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i68c969400a494d9787143ded770b0181_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="iace017bb848f47dab450c002c3ee6683_D20180501-20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:MediPortalLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-01</instant>
        </period>
    </context>
    <context id="i53fb3b2d3c10434fb7ad9df99de6697b_D20190701-20190701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="i79b8b4b7485e41828f619cb79928959f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ameh:AchievaMedInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idfe7f2d11dba4bf8bfa9cd6b837b86d1_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:BrightHealthCompanyOfCaliforniaInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i0faa96915dac498dbda55cbf5243918f_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i7caa591d27bf48eab7b5c969cac33e61_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1c008ff76ac0426486f735cd9512a068_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i123c7dd6529340df982a5fa9dfc0aa21_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:APCAndAPCLSMAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i7fec8536262a49a0b8b6bcb905d9ed73_I20190628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="i50e6b5986d0843a5a0390ed42f10c1de_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2cab7f77600442608addb240a33cdb9f_I20200228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:Dr.ArteagaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-28</instant>
        </period>
    </context>
    <context id="i8dac94597ff94666b83c9ae361507075_I20151231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="ic615bf6bdf9a47aca957ca50dac11311_I20180629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="i57568f01843b4e1c8af7407d9814d9a4_I20181128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-28</instant>
        </period>
    </context>
    <context id="i8aca1d8a93354c9e93262133b582edf4_I20191213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-13</instant>
        </period>
    </context>
    <context id="ia0f328dbb075463e9e1e6093dfb7ff74_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i7be81f0e5b5b4b50b9ea5036ae2b8e02_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="iba23adf288b04c1f910cffd3bc1a3489_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:FinanceReceivablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:DrJayLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i81d7b1f95e2749528c65d9be013d2d5e_I20200430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-30</instant>
        </period>
    </context>
    <context id="i0b9f8e50331b440ca1d55608976e9518_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f7f861c210b485fa4973087f3191b99_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if381e56ee15348f3bc78b5ba5afe4f5b_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7d10f2758e644e3db72c221a182e8ee8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9a3eb4ddb0c34022a34f50d0b362b1a2_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i7bc9c0c0a51d4b37a867a13440d3cdac_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i6464448a2a2a4ec5b5a785f7fa5b707c_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i89bb37720e6c4641bfa4079cb6d0a971_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1840189675724de797d0b54ed266c606_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">ameh:PaymentPeriodThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="iea5693feca944ef0a07785d7ed338d09_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i97da86c1492849118b5eaf8e60955a49_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i706817fc9f1e4c5591f6224aa27f8969_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ameh:TermLoanAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7b193ff3b0534bf4b1e4ee91abf86721_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7903d4186900495da7128f6613b226b5_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i58a3a78950614f498d426b1d4c78e52d_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3792f3a4ad1b4e6e9af66d3b5eae396b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i98837eb98d97440f9bd5671b34f7d76f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia053d843d611409ea6e794c9fe247e3e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="icbffe9564ff44d1bab6086b082b64111_I20180614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="i664bd167ed344f5b97bb3dcf459676e0_I20180901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-01</instant>
        </period>
    </context>
    <context id="i7931a6ac521043ada1f90c0f74afa693_D20181231-20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-31</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="i2255233ea20d48f0a140daa8b2135d19_I20181231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="i0804ee2cd49c471cb1750e3eb02c9f51_I20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NmmBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="i342f2e70889b49b8b01eb66a3ed09a94_I20180905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-05</instant>
        </period>
    </context>
    <context id="i216418c12a70419bacb688b1427cd129_I20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-17</instant>
        </period>
    </context>
    <context id="i9b3115de9851458d8e5935842bd881cb_I20190729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-29</instant>
        </period>
    </context>
    <context id="ie30b8de9297c42469c822858d3e54b70_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i478deb2fc38c436bb8671cb70199cee5_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="id5f4624aad0143a38ac09f171403b362_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:NMMLineOfCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-05</startDate>
            <endDate>2018-09-05</endDate>
        </period>
    </context>
    <context id="i78348153cd274034948535714f61bce6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2919814c52aa4e6c96480fc7e55b85c0_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:CreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9ba211b652284a1ba866c7ef68ae48e9_I20180614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-14</instant>
        </period>
    </context>
    <context id="i88976d0744e74325abde725693423c49_I20190417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-17</instant>
        </period>
    </context>
    <context id="if2a2fbcc8b234d85af151b72dc525ee1_I20190611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-11</instant>
        </period>
    </context>
    <context id="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-01</instant>
        </period>
    </context>
    <context id="i5bd06a67515e4d6c816adb0fc9c88a81_I20190910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-10</instant>
        </period>
    </context>
    <context id="if7993c591aa442349f5e43bcd84f0f49_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i108d951874b443008dbdf9ebfe69c2ab_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7f4ba9139fca44899bc4ca327e9849b9_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ameh:ApcBusinessLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i583b6b592ac24c3f805e3c210ab44386_I20181002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-02</instant>
        </period>
    </context>
    <context id="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-02</startDate>
            <endDate>2018-10-02</endDate>
        </period>
    </context>
    <context id="ib720ede0911c4e8d80c33fc1220eba1a_I20190814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-14</instant>
        </period>
    </context>
    <context id="i04eca9b9464f4a60a87145ab44e5bb1f_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:ApaacoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic7e3933a8b4246618d18872a39beb676_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7d02e70680ae437eab0be807ca3d050a_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6dec8773fada4b24852d9aae4143d84b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1b34349d244644a9af65d1269f0191e4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ameh:PreferredBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i436d289510454727bc5fddbf12ad2d92_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icece81cce5fb4924bcbe69d05e4dcc7d_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ameh:ApcStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i5b98657bb40c476d971c44dd0400e363_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2717bab98fa54dc792c95e77b5b141e4_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i87dbbc859a844154beab63a0f933c8ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i943e4302b105480e8a3a578a84a18038_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if71d1171a6d540fa8cb9f4771cd113ae_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1fde585401744bfc8f98fcb6e5d4c55a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iccaa606008644356ae9b3ada3f0dee0a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="if52999aec2ec48c3a27829576d274249_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01d22b3114f046ea83ddfddc5c0603e6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7d2649df80d34fa2a5160241cddb24f7_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i682e56c134fe472db3d942dee2c67e9e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic96250cdb31545618a1db18666cefafa_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ameh:WarrantExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="idf5d96c5aa524dee8cf3659f677f11b5_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if3710a3c83db42d0805599a74145dff2_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i558ed222ce35492c86d5800acda7c4c6_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic3263f1c5abf42b98d4605f4f7284e83_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i23c4dccf62634d3b92148d57ea541c66_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ameh:AlliedPacificofCaliforniaBrokerageAccountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if8031dd6b66546c1a3ac173850d16bd4_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i56c177ebcb7d435c971aa73fe7a5ef54_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if3b51820704a4a93b98fa96a6930977c_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:CDSCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic0f9aa10906f4d2c9652027d594046aa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i486cfce3128a43d1b5f0abe01fe3ec4a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i1d7273f768df4eb690b7413548307158_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifeddb663bcd34a33b0a3c19d9b40f607_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i29325e7277374944a4b7e5d32f0a71ce_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:StandbyLettersOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlphaCareMedicalGroupInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i94cbfc093bc14eaf945f211b23c1507e_D20180323-20180403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2018-03-23</startDate>
            <endDate>2018-04-03</endDate>
        </period>
    </context>
    <context id="ib1163ece356545148c6d18c1e1d66912_I20151116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-16</instant>
        </period>
    </context>
    <context id="i358387cf1a564a2297e5f1abdf9f5f42_I20151116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-11-16</instant>
        </period>
    </context>
    <context id="ie07ae9f744764e5291d906d251e2034a_I20181128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-28</instant>
        </period>
    </context>
    <context id="i7aeb75119c51484cb3d7c560edf10ae8_I20180628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:UniversalCareAcquisitionPartnersLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-28</instant>
        </period>
    </context>
    <context id="i7c5294ed64c44b5086f5be21d0bce6cd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icaa2e771930d42a3b26e519f82d67bf8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6245ae4c746a41bfae5a0da8935409d9_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4949acae14e04f38821727b357327125_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if1c3b821bbf14ea68465673f368d6f0c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i976d1979c27d4acc9409bb7743bf49ba_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:LmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ide80e6a11bd34f8b8a952c62960c82b6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i61751c7e250f42118eb2800e45f0c530_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i43d3d75fad82483eb5813daf8df17cc3_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="if932e49636814177a3488a7a9d89c9bb_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibca6368440e848ccacf6e0c6beff4565_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i19071814c5784cc8acedf97c43d02aae_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:PmiocMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="i3dd1f69283d349a58ae0e8144a4dec4d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id2670dfb231c4c36a80048c4600a520f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia3717208d1224dd89f9f178d06d05dc2_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibbbfbf6e54384685bbdbd24b85b6a70e_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i42db88be7eb248ce937d8d0f1e434c23_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ibf65ddf284dd40dbbade2b730a49906e_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:DmgMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8e86290ed094411eacda08c9860c3896_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iba42cd3748834d6a9e6d5b22691a39d3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i357239cb3870424c98179560f4e05eb9_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i462e89554ff74f3fa68c411f8685e8cb_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AdvanceDiagnosticSurgeryCenterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ibfff017f5079475da112360bcc11bf3d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if9b280c05e114d2cb9d4d80828861206_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i24504ae2154f4155a97794062ff7b4cc_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4915f14b437e4756b8b7d103a441b54d_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i846f7fd44f304e9ea61d6d7acb1c05d7_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i004ed9a138324dc8a6fc0af8d80321d7_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ApcShareholdersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1dea7f1f241546c79900d50e5d5b3e39_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8569d927dbfc4be780d7ea409efa6a37_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:ShareholdersAndOfficersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i9d5ec46533294b24af622e84d85e1306_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia82c704cff6c42929352454bea170ee6_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaade255737234b709672525b3860eed1_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i7ab4eb5154c94c778081d37fd1fbb9c5_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:MedicalPropertyPartnersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i23eeba47a6d445a1af488e1741954e4a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie4f7901609a34f0a8bd5da4fb0dbe4f4_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id45018c024f44bd390ae0a1db7dc7a06_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:DrSimAndDrLamMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7666fdc6c5fb4c1597125f20974dcd69_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:OneMSOInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i8e0f7911506b4f7ea6ea22e51fac5416_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i12335e3134c84754a4b5a7c9eb42658b_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3fb931837c3446e49bfcff46eee3984b_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic079747ecea44c46b7fc2e75b14ca50c_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:CriticalQualityManagementCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i557e6e9936fc467ba5080a062ca80496_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3c0345d81c4a45029864d5dfc19df1ba_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id03688552a194d20bec7b26a63399956_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i2beaf01e5bdb4f7aa6d5f3c6a54f063c_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:SCHCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1d7dbe836e64485fa477f10dbc512288_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:NumenLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="id95fd088a2c9454599c8fb0dc66fac9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="id4ed9597a9f24e4884d0595ef80c9123_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i467c8f07446f434c888fe2139b1ad2e0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7230ae6b539c41a89c452715bb10fa43_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:HSMSOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib374aadcdc4a4479907af99b24bfe82d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i6d542d36ef9c4c6da7ac374e467eae16_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ic2293aa631c14249bc1cb90e55c69d12_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ib0f97d7e0148477d89334ab0a06f9735_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AurionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ib209ad0feb484341b4b5ea3e1112074a_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i311e4830870b47168a8028481990133c_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">ameh:AHMCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i9f86dff82b2e4e37819e44daed0c3927_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90b7d7c73e9342ceaea0220fd27ebcb0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i37855f5922724980ae2277994e98ea9e_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i536bf5cd23b640f1b9fdc4a22f35cc97_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:NetworkMedicalManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i46ec2cffc1bf4e368fb4d267b14f59e7_D20190101-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ifef4a834b2704183af5e7a0118b8f10b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idcc6a9123a8a4ef7b90cc678cd9de887_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i1726a5a5ec36427090258ca4b81f8d3f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i54547e12a6db466cb506fe342e82cc32_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="idb2ac8c951874f548946ae72cd81b9fd_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0ea08dccbd2246f3821362f61b723f3a_D20190701-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i665d45a4c6ad4e91916ba08f8e851d70_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i2b8c0038e75540dfa62aff9087a85054_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i671affdf59da40b3b7624c0bdbe08342_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0a3f294321d042c0b50b53fcde9f5fbc_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ie6f513dd37f04d39ad6561182f5f3fea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5ca7f6c187cb41feb19b9c86fde64670_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i4f4020d4b8994854ac803ea6e8d45f6b_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5a1dd3a2128b451eb4d50a63a91ddd55_D20190101-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="i330f7b2e0da941fb9b4510efb972e459_D20191231-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="id94edb672a3f42dca68cdffe56fed10d_D20200930-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
        </entity>
        <period>
            <startDate>2020-09-30</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icf38a8ac3d85467baeb00dcd1a446031_D20200901-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i91c0b71ccc814cd5ba5b3e0b0bf65898_D20201001-20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001083446</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">srt:AffiliatedEntityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ameh:AlliedPacificOfCaliforniaIPAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="primary_care_physician">
        <measure>ameh:primary_care_physician</measure>
    </unit>
    <unit id="specialty_care_physician">
        <measure>ameh:specialty_care_physician</measure>
    </unit>
    <unit id="medical_center">
        <measure>ameh:medical_center</measure>
    </unit>
    <unit id="plan">
        <measure>ameh:plan</measure>
    </unit>
    <unit id="clinic">
        <measure>ameh:clinic</measure>
    </unit>
    <unit id="segment">
        <measure>ameh:segment</measure>
    </unit>
    <unit id="unit">
        <measure>ameh:unit</measure>
    </unit>
    <unit id="provider">
        <measure>ameh:provider</measure>
    </unit>
    <unit id="patient">
        <measure>ameh:patient</measure>
    </unit>
    <unit id="financial_ratio">
        <measure>ameh:financial_ratio</measure>
    </unit>
    <unit id="agreement">
        <measure>ameh:agreement</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl8zLTEtMS0xLTA_be899aa2-dbc9-4c6c-8991-765af62745c7">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl80LTEtMS0xLTA_bafde20c-4b10-4654-80d6-18dc73588f97">2020</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl81LTEtMS0xLTA_b3d3fe1a-3d64-4dfd-a66b-2f45752d147c">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl82LTEtMS0xLTA_6772f517-50b6-4c26-8b36-7a8cc8adfef7">0001083446</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80L2ZyYWc6OGQ2NmJkNmU0NGIzNDcxMmFjMTUxMGQ4NmUyYTRjMjQvdGFibGU6YWI4ZjQ2ZmRlMDYxNGUzM2I3YTIwZTgzOWFkZjRiNmYvdGFibGVyYW5nZTphYjhmNDZmZGUwNjE0ZTMzYjdhMjBlODM5YWRmNGI2Zl83LTEtMS0xLTA_1921a26b-6225-4b49-91cd-3e1650b50152">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i2c841cb894a44b438ddcf5f653a3121e_I20161231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i1b924b44d11243c79329ffb24703ba48_I20181231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <dei:DocumentType
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg5_2075f2f6-94c4-41b0-beb5-e60fb662aed6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MzAwNjA4ZWNkNzcxNDdhM2E2YWVmZTJjNzdmMGE2MWQvdGFibGVyYW5nZTozMDA2MDhlY2Q3NzE0N2EzYTZhZWZlMmM3N2YwYTYxZF8wLTAtMS0xLTA_3b0751b4-d9b4-4a38-b202-39c4951a0a6a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18xMjA5NDYyNzkwNzY5MQ_5fb4fc24-3c31-4c6c-9541-6ddbac3bfb60">2020-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NDM1MWVlZTc4YjY5NDcwM2FkZjFmYWQzYmQwMjJiYmYvdGFibGVyYW5nZTo0MzUxZWVlNzhiNjk0NzAzYWRmMWZhZDNiZDAyMmJiZl8wLTAtMS0xLTA_078f03af-9a2c-4b3f-a1c7-8519a4ffc87f">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg4_df7b3e5d-5d7e-469d-8e7d-4e9fd01c3008">001-37392</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk5_7338e85c-d607-4dd8-8137-88bbb4c699de">Apollo Medical Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MWU2MjhhNjRlZmQ4NDliODliMGM0MGQwNGFjNjMxYzYvdGFibGVyYW5nZToxZTYyOGE2NGVmZDg0OWI4OWIwYzQwZDA0YWM2MzFjNl8wLTAtMS0xLTA_ef421936-6dd8-4283-bf80-c5ab4451cd1e">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MWU2MjhhNjRlZmQ4NDliODliMGM0MGQwNGFjNjMxYzYvdGFibGVyYW5nZToxZTYyOGE2NGVmZDg0OWI4OWIwYzQwZDA0YWM2MzFjNl8wLTEtMS0xLTA_dd69db30-1361-4733-8577-9f56e9ee6dcb">95-4472349</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk3_2c258f15-3837-4b75-b492-24ad32b090a6">1668 S. Garfield Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk0_20e3faec-19e5-47a1-8943-b8d804d31621">2nd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk1_50585d1a-c2ea-456c-b40e-8e48b55c0f10">Alhambra</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkw_0602d5a6-a473-4574-87f4-1042ebf0dc40">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkx_47557812-949f-4bda-8055-e9aadab7d625">91801</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDky_fd7e2cb5-2602-4720-9041-3e59467f38fd">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk4_d888ae0f-7bf1-412c-b526-1adf5355ed6d">282-0288</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDkz_df010724-5d2c-4dfa-8659-ed55adcdea0b">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDg3_e5fa8843-81a2-454a-939d-356fff2da4c7">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18wLTItMS0xLTA_3962d41c-a16c-4c3b-b200-c1a26c38d5cf">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18xLTMtMS0xLTA_746f3523-3a25-4869-adc2-e6919ccb8d37">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6MGRlMzgyODhlMzdhNDFmYjk0NDY0MWRiMWUzYWM1YjMvdGFibGVyYW5nZTowZGUzODI4OGUzN2E0MWZiOTQ0NjQxZGIxZTNhYzViM18yLTMtMS0xLTA_e3f7a30d-783f-498f-b3e5-d493bf21ebfb">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18yMDk2_2d266b74-5fd7-489d-a678-eddae5077206">false</dei:EntityShellCompany>
    <dei:Security12bTitle
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NjY0NmRhY2M5ZjVkNDg2ZmJkYTFlZjkwMDBlMGY3ZTYvdGFibGVyYW5nZTo2NjQ2ZGFjYzlmNWQ0ODZmYmRhMWVmOTAwMGUwZjdlNl8xLTAtMS0xLTA_1d7211aa-0327-4a3d-a511-fbcbdd7c81ef">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGFibGU6NjY0NmRhY2M5ZjVkNDg2ZmJkYTFlZjkwMDBlMGY3ZTYvdGFibGVyYW5nZTo2NjQ2ZGFjYzlmNWQ0ODZmYmRhMWVmOTAwMGUwZjdlNl8xLTItMS0xLTA_2eb2815b-54d7-4e2b-8b72-75a872504d5d">AMEH</dei:TradingSymbol>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i233eb597e897408bb9acd656dcbd1d0c_I20201102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8xL2ZyYWc6YjhjYTIzNzZjZTQ0NDY0YzgyYmFlOTVlMDIzODg1NTMvdGV4dHJlZ2lvbjpiOGNhMjM3NmNlNDQ0NjRjODJiYWU5NWUwMjM4ODU1M18xOTg5_a45a1a1e-0d5f-40a4-a929-f43db15c6736"
      unitRef="shares">54265602</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNS0xLTEtMS0w_f7208f31-6ae7-4385-b5c8-aedb17678e4b"
      unitRef="usd">166082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNS0zLTEtMS0w_eacb3849-e9e6-4f3b-9418-566baffdbe2d"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNi0xLTEtMS0w_9356dcee-d850-488f-9104-f36ae41ff985"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNi0zLTEtMS0w_b292f3ef-68ab-47b0-9742-07bb1af18cd8"
      unitRef="usd">75000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNy0xLTEtMS0w_137a9735-ffdc-4a94-82e1-3cdb5dd5fd1a"
      unitRef="usd">118309000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNy0zLTEtMS0w_8ac9d9bb-a674-4f9b-a811-4206ae991fda"
      unitRef="usd">116539000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOC0xLTEtMS0w_4a326f68-a50c-44fb-9a48-edeb5f09cfe8"
      unitRef="usd">18257000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOC0zLTEtMS0w_ee0e8c0c-4541-454b-97b9-2ac875ae3384"
      unitRef="usd">11004000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOS0xLTEtMS0w_decc70d8-3ace-4fcd-8918-75c6ce4edbeb"
      unitRef="usd">41518000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfOS0zLTEtMS0w_0a8b4b68-cf44-42d2-939e-d4fa3ae36b90"
      unitRef="usd">48136000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTAtMS0xLTEtMA_68f853bb-2009-468b-a48b-9c43a8de3446"
      unitRef="usd">3988000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTAtMy0xLTEtMA_0d499448-c3c3-48d1-8e21-e70ff0e7c04e"
      unitRef="usd">16885000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTEtMS0xLTEtMA_af6c7ced-1b06-44e9-b4f9-ec4f5d7716bd"
      unitRef="usd">12119000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTEtMy0xLTEtMA_50479cc7-0ada-4f7e-94f1-ebedba384a59"
      unitRef="usd">10315000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTItMS0xLTEtMA_48105cd6-a5fb-4da7-ba89-8910cf093ff6"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTItMy0xLTEtMA_452f00de-90bd-4532-bdd7-435e0d6f9b57"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTMtMS0xLTEtMA_40134c24-fdb9-457e-8ff5-706678b8bae3"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTMtMy0xLTEtMA_435a182e-9390-49dc-a478-104e767fa884"
      unitRef="usd">16500000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTUtMS0xLTEtMA_3ff538ed-d0a4-4336-a14c-6fe17c532f82"
      unitRef="usd">366698000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTUtMy0xLTEtMA_d1dd9654-d594-4e51-aa8f-689225bf0d62"
      unitRef="usd">329068000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTgtMS0xLTEtMA_b13bab76-b702-490d-8ed4-062969781275"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTgtMy0xLTEtMA_bd0d64da-d52c-4944-8ed5-f09e55ae6235"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTktMS0xLTEtMA_62ba6ddd-99a5-4f49-9aac-1e017049526c"
      unitRef="usd">10929000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMTktMy0xLTEtMA_b61e50b8-27fe-4c28-b77f-284166308caa"
      unitRef="usd">12130000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjAtMS0xLTEtMA_1b3402ff-ab89-4f31-b5fd-541ac8f3fcef"
      unitRef="usd">90781000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjAtMy0xLTEtMA_c26ce1f7-2924-43de-8a59-1a2917f7424f"
      unitRef="usd">103012000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjEtMS0xLTEtMA_1363d922-d108-4323-8859-537cf1275618"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjEtMy0xLTEtMA_168245b8-3777-4b4e-ba64-ff3fc1651c4d"
      unitRef="usd">238505000</us-gaap:Goodwill>
    <us-gaap:EquityMethodInvestments
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjItMS0xLTEtMA_698aa765-926e-4958-b765-9fb04ba13328"
      unitRef="usd">27220000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjItMy0xLTEtMA_57c12b37-e370-490f-8c97-04bf74a0c465"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjMtMS0xLTEtMA_0f97ae4a-10a7-4450-923c-187c1d78fed2"
      unitRef="usd">37075000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjMtMy0xLTEtMA_7c6f88f0-1c19-4c70-bed2-9fa6f42812aa"
      unitRef="usd">896000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjQtMS0xLTEtMA_86481baa-d5dc-4e0d-96b0-72fa2a86de9d"
      unitRef="usd">19298000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjQtMy0xLTEtMA_3ae2514c-b44f-40f9-ad26-bb40a9770e6d"
      unitRef="usd">14248000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjUtMS0xLTEtMA_17fb6eca-c646-43e0-a6bb-760cc28f3205"
      unitRef="usd">22473000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjUtMy0xLTEtMA_dac3ea76-4c61-4a00-9429-27f13e82cafe"
      unitRef="usd">1681000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjctMS0xLTEtMA_8585308e-47bd-42bc-873c-cccef2336845"
      unitRef="usd">447575000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjctMy0xLTEtMA_97fc7917-b00f-470e-8f64-c1ef69993ec7"
      unitRef="usd">399645000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac"
      unitRef="usd">814273000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3"
      unitRef="usd">728713000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzUtMS0xLTEtMA_73ee3789-5db4-4169-b02e-5330813c113e"
      unitRef="usd">40474000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzUtMy0xLTEtMA_9daa317b-84ba-4ffb-a17e-cadc21340f86"
      unitRef="usd">27279000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzYtMS0xLTEtMA_a8469cf8-7539-4c23-b6ea-e7ea0532aa16"
      unitRef="usd">3986000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzYtMy0xLTEtMA_229e0162-2709-4867-b2e0-3b6cb2f3a8ec"
      unitRef="usd">2027000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzctMS0xLTEtMA_352f05ce-5a85-422a-a9bc-7d542b04d117"
      unitRef="usd">57455000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzctMy0xLTEtMA_6bc11f16-a9c3-44b6-8e75-b11ec88f0c8f"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzgtMS0xLTEtMA_e8508774-7981-4f09-9201-b478c46e53a8"
      unitRef="usd">16169000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzgtMy0xLTEtMA_2c38d74e-9739-45ee-9dff-0d27c866e4de"
      unitRef="usd">4529000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzktMS0xLTEtMA_f8405348-dabf-45a4-a039-cef93152c242"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMzktMy0xLTEtMA_d82cbfc5-1adb-439a-8e11-94a86c496977"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDAtMS0xLTEtMA_d87dbb0d-baf4-49bd-a2a0-0f705681ea02"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDAtMy0xLTEtMA_e3a554c0-6f75-4dd4-a63f-c60f34b624b9"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDEtMS0xLTEtMA_3fc93305-ba4c-4a73-ac66-ebec65afb22a"
      unitRef="usd">3290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDEtMy0xLTEtMA_489403be-e9bd-4e66-8064-1dc1e5d56032"
      unitRef="usd">2990000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDItMS0xLTEtMA_0a4f9928-2328-44c1-8450-41ebc2aa76cd"
      unitRef="usd">9500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDItMy0xLTEtMA_4ee63f57-7bc2-4394-bf27-d6706f473f1d"
      unitRef="usd">9500000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDMtMS0xLTEtMA_5b37d790-fc0c-4a7e-acf7-0da513c4bd40"
      unitRef="usd">131461000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDMtMy0xLTEtMA_fe425e43-ae36-458d-b310-39ab283a886e"
      unitRef="usd">105423000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDYtMS0xLTEtMA_78b68c9e-f884-4236-9436-e136f5de451c"
      unitRef="usd">11659000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDYtMy0xLTEtMA_aaaf9893-34c3-4806-be8e-3361991a7971"
      unitRef="usd">18269000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDctMS0xLTEtMA_57edc8a1-82c3-4cd1-8272-877323f4794a"
      unitRef="usd">337000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDctMy0xLTEtMA_83b69f4c-e7af-4b63-89ba-1d276cff5474"
      unitRef="usd">416000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDgtMS0xLTEtMA_634bfed7-6baa-4078-a1bd-35263383a714"
      unitRef="usd">16616000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDgtMy0xLTEtMA_eda71a11-84df-476f-844a-8c4b09bf6bc4"
      unitRef="usd">11373000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDktMS0xLTEtMA_65fb33f1-88be-4ecd-8e72-396637019edb"
      unitRef="usd">226051000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNDktMy0xLTEtMA_b9a86227-5b7b-4382-8423-0903222953b1"
      unitRef="usd">232172000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTEtMS0xLTEtMA_86dd9945-8e12-472e-9f22-330aff41894e"
      unitRef="usd">254663000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTEtMy0xLTEtMA_24f11037-9174-4311-b1c8-859744fe1bde"
      unitRef="usd">262230000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964"
      unitRef="usd">386124000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab"
      unitRef="usd">367653000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTUtMS0xLTEtMA_5573a956-dffd-4d7b-a415-df911dfa8be4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTUtMy0xLTEtMA_9c4acb0b-c28a-472e-a847-737f110b8dc9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTgtMS0xLTEtMA_de6a8200-815f-418f-a9f3-2095bcef35ce"
      unitRef="usd">198731000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTgtMy0xLTEtMA_affad712-345e-42a7-a024-036c03db7da0"
      unitRef="usd">168725000</us-gaap:TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i12392f1820d84e009a3fec747ed05785_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTI_1faf4170-7145-4f4d-b392-64193114a0ed"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTI_8617ccf6-e4f3-4b25-80ee-8b010c639334"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i12392f1820d84e009a3fec747ed05785_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTU_128ecadf-d6c6-4923-b5b1-c8b505635055"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIxOTU_54f63169-480e-4625-831d-6212f28827f7"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i12392f1820d84e009a3fec747ed05785_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIyMDA_6c3f440f-2b9a-4686-8a54-0505276d9676"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2NDkyNjc0NDIyMDA_9e09ca20-4f05-4eb0-b9dd-886c5132d457"
      unitRef="shares">1111111</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i12392f1820d84e009a3fec747ed05785_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2MQ_0e6ae9c1-010d-47f0-9bc4-802dde7b71d7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMC0xLTEtMC90ZXh0cmVnaW9uOjFjMjQwYmEzY2E3ZjQ1YWY4ODE0ZWRhNDkwNTRlZDQ4XzE2MQ_81928eeb-4688-4795-8ca2-6e1c3e97567d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i88f29eecb4a54581a1e137030ee84580_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMS0xLTEtMA_c64f5b8e-eb37-454f-be64-a0f2a0ff92d2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i12392f1820d84e009a3fec747ed05785_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjEtMy0xLTEtMA_426ce0b2-96dc-414b-941c-7a511089e5f2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4Mzk_0e53aac8-b5ed-4dd0-b00f-59ca8bde0b52"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4Mzk_60b574aa-d6af-46e1-ac6b-7ff55bdcc1a0"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzU0_52c24df9-5218-4e26-9891-4b1e1b9b9ebd"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzU0_5dddf8c7-bf69-4953-923d-3526513f8e7b"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4NDQ_46597f67-d45b-4038-9427-3577992bcea6"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2NDkyNjc0NDE4NDQ_89c59369-2b45-4c8e-990b-d97b10654e85"
      unitRef="shares">555555</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2MQ_de97730e-f68a-496c-9a74-ebaa9ea152c1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMC0xLTEtMC90ZXh0cmVnaW9uOjE1NTg1Y2FjOWVjOTQ1MTFhN2ZjZDcwMTY0YWJhZjJlXzE2MQ_edbeb6ef-d3ae-4061-9299-2a07c85aa96c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i999f85b1f03348b59973a22d2ce701fd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMS0xLTEtMA_3d49eab9-e562-45bb-bfef-7cf0af199a5c"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="id468dcf3a96c44a884ae2121f3929be4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjItMy0xLTEtMA_22cae57d-3d9a-40ef-928b-32a5f1f6e140"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjI_9d0a61cd-6169-448e-b509-2d4d9822b493"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjI_c6209370-ad96-48cf-8568-ff33306a2c38"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjY_b48f2894-1500-4413-ae38-4048771f21d2"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzE2NDkyNjc0NDE4MjY_f8f78e23-0ade-4e9e-91bf-1378e534393a"
      unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzY0_6df3ab8c-0a8f-4fb3-826c-b75f9e54df99"
      unitRef="shares">36775817</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzcx_efe65e3b-75e2-4d5f-a22c-b9d54bff9bc8"
      unitRef="shares">35908057</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzEwNA_c73d96de-7e78-4051-9881-11b87d7f9828"
      unitRef="shares">17475707</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMC0xLTEtMC90ZXh0cmVnaW9uOmUyMjViYjZiMzk3ZjRmZGU4N2ZmYmU0YTBlYzE1MGYxXzExMQ_31d5fe05-1a8c-416d-87f3-f3a1a58e951d"
      unitRef="shares">17458810</us-gaap:TreasuryStockCommonShares>
    <us-gaap:CommonStockValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMS0xLTEtMA_055b73ea-960f-4885-97f0-076af70d0882"
      unitRef="usd">37000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjMtMy0xLTEtMA_c354dfda-97bd-4c9c-99df-641cc3de3719"
      unitRef="usd">36000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjQtMS0xLTEtMA_42844d3c-3155-42ad-a064-51291eb8a64e"
      unitRef="usd">168653000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjQtMy0xLTEtMA_5917ffe3-ba4b-4a39-b038-275f4f41783f"
      unitRef="usd">159608000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjUtMS0xLTEtMA_3d79cf31-65bb-48bd-9c0d-0af97786ef0c"
      unitRef="usd">59714000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjUtMy0xLTEtMA_bdf316ad-40f9-4c12-83a4-665222d94596"
      unitRef="usd">31905000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjYtMS0xLTEtMA_9a28c76a-0087-4a8f-9128-5bb7e281694a"
      unitRef="usd">228404000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjYtMy0xLTEtMA_6f42c8fc-4ed8-45f5-afef-3a30c03ead8e"
      unitRef="usd">191549000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjgtMS0xLTEtMA_8eb43383-2a16-4748-a24f-91d7d022bff6"
      unitRef="usd">1014000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNjgtMy0xLTEtMA_88a2f503-20b9-4958-af06-397e98bcc331"
      unitRef="usd">786000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzAtMS0xLTEtMA_f272f349-96db-4413-bb06-5b6d2aee5284"
      unitRef="usd">229418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzAtMy0xLTEtMA_46f78c7a-e72c-4615-aa47-78b5c5b7d41c"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzItMS0xLTEtMA_3c2d1429-9fe2-4d16-8f7d-11f216c1990b"
      unitRef="usd">814273000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNzItMy0xLTEtMA_6f1d2163-e1f1-4555-b705-61d4642dbafc"
      unitRef="usd">728713000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Assets
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODM3Ng_83b5105c-ee41-4602-9287-500449510bf7"
      unitRef="usd">877600000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQwMg_0020b3a4-cfb0-4a76-a5d1-6b6ffd0c4cc3"
      unitRef="usd">849300000</us-gaap:Assets>
    <us-gaap:Liabilities
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQwOQ_75804806-45f6-407b-8d35-e71b33f06831"
      unitRef="usd">113000000.0</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfNjU5NzA2OTc2ODQxMw_747ce388-a71c-4114-be37-39f110f7f753"
      unitRef="usd">114500000</us-gaap:Liabilities>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85cbed6310784ad1b00d427467f4a809_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy0xLTEtMS0w_1d318401-f70d-4df5-8b9a-0292294ff35b"
      unitRef="usd">135032000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie735c2fc161f4a028234f400af312f8e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy0zLTEtMS0w_6d2667d9-7858-425f-a423-7ae00dc332bd"
      unitRef="usd">130807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0ae35627def147d19d8ab0682325ebca_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy01LTEtMS0w_a709a4a9-601b-4455-9dd4-dfdf0f6e890b"
      unitRef="usd">416402000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia5096fa86ff645c4ac88aeaff7eb1d9f_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMy03LTEtMS0w_b0a68b3f-2c8c-4a89-aef6-9c3dd1d72cc0"
      unitRef="usd">305548000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89dce8d40320482793ae915c3b3fda86_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC0xLTEtMS0w_473cdda6-0519-45e3-ae52-8228324527d6"
      unitRef="usd">30916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idc8b559adf384439909838b82a315ef4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC0zLTEtMS0w_47375d34-9958-4b49-8e60-d99f1799dffb"
      unitRef="usd">11355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb2871d1532647e4bc4f0564a4773c78_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC01LTEtMS0w_a0bea26f-8301-47b9-bdd0-dbd5659573d5"
      unitRef="usd">54155000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i103b982ccc8e4f93858938af7e18a96d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNC03LTEtMS0w_8491d780-4b04-416c-9424-b0a8867aa466"
      unitRef="usd">32640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i48fce5948a0e4dfdb085803d8face2f4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS0xLTEtMS0w_1e7164a7-cf4e-4d12-be5c-525a27b025fd"
      unitRef="usd">8707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50f345eb35b24b309883822a3f432a39_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS0zLTEtMS0w_8f667cb7-e1b0-4eca-a836-06c588e2f88f"
      unitRef="usd">8518000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS01LTEtMS0w_254d5f4c-8cc3-47a6-915b-29545f8a6a01"
      unitRef="usd">26212000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92adae19551f4d33aa3159e1f3b3c333_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNS03LTEtMS0w_a666d6f0-2dfd-49c7-b1bc-faf7518e2416"
      unitRef="usd">27867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c26c34d43944d53b8157c588e4d9832_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi0xLTEtMS0w_589ef8c2-16fc-424b-8b38-5328001f2997"
      unitRef="usd">3737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb905dbaa5064b25b91dff34aa6ebc5a_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi0zLTEtMS0w_a3b8cf3f-cfbb-4e67-a8f1-7698a9d9b2e0"
      unitRef="usd">4100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9dd1b1d0644e4537bb0c05e512c38d0c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi01LTEtMS0w_6fe10df0-cd3a-4e62-bae7-9651d2bff62d"
      unitRef="usd">9434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibbf30c3701d24df69116273d7a5e466b_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNi03LTEtMS0w_686dba78-6816-43cb-b061-7f7d8306f7f1"
      unitRef="usd">12059000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaab6050bdfaa4b99b69a677d9fb18e68_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy0xLTEtMS0w_5e05f4c4-5ed3-41da-82eb-d5de1fb2a626"
      unitRef="usd">1731000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c8d5c0eb18b40688e3d9ffd255e0a2e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy0zLTEtMS0w_b0620d78-a17d-4325-942b-2b4118862f78"
      unitRef="usd">1280000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b7fc96fb74e494b8db4e7508d53047b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy01LTEtMS0w_3d84b40d-3934-4d19-b880-7fd172d87088"
      unitRef="usd">4194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06d6f6c3ab514e87bbe68a7fec5bcd87_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNy03LTEtMS0w_131f30cd-2c8f-4fa4-bf4a-be54992cf077"
      unitRef="usd">3753000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS0xLTEtMS0w_4b503710-6bc2-48ab-9e8b-923f0bec7553"
      unitRef="usd">180123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS0zLTEtMS0w_6469a200-0978-4c34-968b-1e1e9bbb3e10"
      unitRef="usd">156060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS01LTEtMS0w_6b4b24f2-2927-4bf7-be53-327a037b82d7"
      unitRef="usd">510397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfOS03LTEtMS0w_40d52d32-eff6-4d76-abf4-b9ebcdff4bfa"
      unitRef="usd">381867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItMS0xLTEtMA_56ea8a66-34e2-4758-9be1-ac4404dcd80e"
      unitRef="usd">121823000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItMy0xLTEtMA_af15ad14-bfdf-43b3-9fc6-d1539daa5542"
      unitRef="usd">131130000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItNS0xLTEtMA_988d80db-1de0-47fc-8080-3875b21674c4"
      unitRef="usd">402106000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTItNy0xLTEtMA_f903ffd9-359e-4386-b430-fb1e136357f5"
      unitRef="usd">315925000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtMS0xLTEtMA_3e7fb46a-4490-48ff-abcf-f5b045e18851"
      unitRef="usd">16270000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtMy0xLTEtMA_a1772895-f31a-4552-bad5-4f9645507169"
      unitRef="usd">7950000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtNS0xLTEtMA_e1dd7b4a-29bf-432c-85a1-0181958378ca"
      unitRef="usd">39660000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTMtNy0xLTEtMA_6020be99-fd11-4b2e-8341-54e9b658b293"
      unitRef="usd">30031000</us-gaap:GeneralAndAdministrativeExpense>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtMS0xLTEtMA_2d6edf89-3990-4b40-8323-694871b1c33c"
      unitRef="usd">4674000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtMy0xLTEtMA_d0c16156-f1a4-4885-bc7a-6cd25dfa8466"
      unitRef="usd">4920000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtNS0xLTEtMA_c7fb931d-3c2a-4bc5-be3e-0447b1e279c5"
      unitRef="usd">14004000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTQtNy0xLTEtMA_fbc15930-f4bc-43a2-ad37-41496f2c5f0b"
      unitRef="usd">13793000</ameh:DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtMS0xLTEtMA_590d465d-ae3c-4685-9e79-decd27bbd8bd"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtMy0xLTEtMA_6a6d0edd-762f-4a43-acdc-ddd63060f4c5"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtNS0xLTEtMA_3c35eb80-e777-449f-97a5-c34b351e7b68"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTUtNy0xLTEtMA_1059d568-b5b4-474e-82aa-c43eee7f0deb"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtMS0xLTEtMzQwNA_9068bf1e-8d1d-4ede-8da1-c626728ff2ad"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtMy0xLTEtMzMwNg_3c272c0d-515e-455c-b8c6-18824dbf98b7"
      unitRef="usd">1994000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtNS0xLTEtMzQwNA_5a2b3c97-6eb6-417a-b0d4-ddb06f77548a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTYtNy0xLTEtMzQwNA_96b93405-aff9-4b00-8d39-56130c221190"
      unitRef="usd">1994000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:CostsAndExpenses
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctMS0xLTEtMA_08b16341-16a8-4387-ba0d-b253bb5165b0"
      unitRef="usd">142767000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctMy0xLTEtMA_fe3bd5ac-0d6a-4af0-817a-bf331cb09993"
      unitRef="usd">145994000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctNS0xLTEtMA_654f8403-4353-4a9e-a9f3-407e0248f5de"
      unitRef="usd">455770000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTctNy0xLTEtMA_55bd4e0c-3139-44b5-8613-5ab6d571f4a5"
      unitRef="usd">360380000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktMS0xLTEtMA_6e5ff011-08c9-442c-8fc6-5ff063b29be8"
      unitRef="usd">37356000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktMy0xLTEtMA_232a52fe-c609-4b9e-9048-4f7957474652"
      unitRef="usd">10066000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktNS0xLTEtMA_6f62dfd6-7c28-4df7-abe8-edb76086b5d2"
      unitRef="usd">54627000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMTktNy0xLTEtMA_a130b94f-a493-4ec6-b9db-40aefd7195a4"
      unitRef="usd">21487000</us-gaap:OperatingIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItMS0xLTEtMA_ce8d26bd-c8da-4971-92b5-079e48197768"
      unitRef="usd">403000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItMy0xLTEtMA_85704570-5dd9-436f-bc4d-68f2a23310ab"
      unitRef="usd">2054000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItNS0xLTEtMA_6a86c618-70ce-4900-8e17-258f15093246"
      unitRef="usd">3291000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjItNy0xLTEtMA_5263efa1-d694-47c8-b725-deaabada105d"
      unitRef="usd">1162000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMS0xLTEtNjU0NQ_9a05bcc4-126d-4026-889d-e156457ff240"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMy0xLTEtNjU0NQ_37af6831-e63e-4b68-ac41-5db712f2bbe9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNS0xLTEtNjMyOA_23edafaf-6362-4f53-991a-3e9fbf57099b"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNy0xLTEtNjMyOA_9b022b66-e316-4188-8611-5311f4a7f8f9"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:InterestExpense
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMS0xLTEtMA_514bc7fd-9ff3-427f-9b9f-711caf38373b"
      unitRef="usd">2466000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtMy0xLTEtMA_35aa3d7a-783e-475e-a2d0-673b14e9898c"
      unitRef="usd">828000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNS0xLTEtMA_df24fc4e-487b-484e-9c98-cf1265663a24"
      unitRef="usd">8007000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjQtNy0xLTEtMA_41d0fd94-7a3a-40e5-aa03-b019fa52bc82"
      unitRef="usd">1350000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtMS0xLTEtMA_42ec91d8-9578-480d-ac4e-5c9a4e4e9351"
      unitRef="usd">752000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtMy0xLTEtMA_4010a8d0-3669-4a66-8dae-fa67cb744de8"
      unitRef="usd">509000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtNS0xLTEtMA_be0eb7a1-9137-4c3c-b338-672dfd984b0b"
      unitRef="usd">2544000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjUtNy0xLTEtMA_60c63348-a008-4bb2-a139-a3581ad32e4b"
      unitRef="usd">1305000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtMS0xLTEtMA_9eb83300-244f-4df6-8cd1-b978adbfe2d8"
      unitRef="usd">130000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtMy0xLTEtMA_b684723b-484e-476e-ba26-672e64447359"
      unitRef="usd">2620000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtNS0xLTEtMA_6eaaf027-1b63-4fc7-b9d3-a44b311fd534"
      unitRef="usd">1514000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjYtNy0xLTEtMA_64f8a336-7b28-42d9-804d-494c588f9368"
      unitRef="usd">2832000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtMS0xLTEtMA_78517aeb-32cb-481b-8b47-e1bb3c3b90e3"
      unitRef="usd">-1181000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtMy0xLTEtMA_b20c9ac7-fb9d-45db-b89d-7f7ddbbf3ab3"
      unitRef="usd">4355000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtNS0xLTEtMA_199288f7-8e7a-4d9a-9af9-a8775d9c184a"
      unitRef="usd">98989000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMjgtNy0xLTEtMA_7cf7b37c-0632-453d-ae73-70ee0399ca76"
      unitRef="usd">3949000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtMS0xLTEtMA_2c10b07f-5d15-4590-a1d4-b856b878885b"
      unitRef="usd">36175000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtMy0xLTEtMA_25f12a82-3613-436c-9352-fbbcbe1679f2"
      unitRef="usd">14421000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtNS0xLTEtMA_4f9e4cad-1353-49c4-860b-7cf540ed6064"
      unitRef="usd">153616000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzAtNy0xLTEtMA_16f0b380-88a8-4e1d-a2c6-38b473f35ae4"
      unitRef="usd">25436000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItMS0xLTEtMA_4681234b-afcf-4693-ba3b-099868ec2d1b"
      unitRef="usd">10751000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItMy0xLTEtMA_2c12b5db-d002-43c8-b4c8-f032dda0d0de"
      unitRef="usd">3682000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItNS0xLTEtMA_de6575fa-4b9a-4e19-88c5-7744b9a09896"
      unitRef="usd">44204000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzItNy0xLTEtMA_291487b4-5d4d-4d75-8aea-701c0c0edc88"
      unitRef="usd">6483000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtMS0xLTEtMA_7420a62e-a3ce-46c6-b993-189b07e49f67"
      unitRef="usd">25424000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtMy0xLTEtMA_a80156df-9650-4abf-b020-0a95a0ae5ac4"
      unitRef="usd">10739000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtNS0xLTEtMA_1da4ce39-e0df-40ee-ad5f-c3084b44419f"
      unitRef="usd">109412000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzQtNy0xLTEtMA_40dd38e4-5eb6-482e-b4ad-c42de2d8b56b"
      unitRef="usd">18953000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtMS0xLTEtMA_c6e7be2d-4f38-406f-9d28-a6a57230d0ae"
      unitRef="usd">8711000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtMy0xLTEtMA_429f0443-a5d3-4cbc-94bd-91c37a5a7c85"
      unitRef="usd">7035000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtNS0xLTEtMA_0ba3aa2c-fc84-4b87-a59d-a7b64eef1d2d"
      unitRef="usd">81603000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzYtNy0xLTEtMA_b08afea8-1ddd-484a-bb5f-ab09952e577d"
      unitRef="usd">11564000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtMS0xLTEtMA_84ee8ce4-72f6-4326-b943-fdaf1f929116"
      unitRef="usd">16713000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtMy0xLTEtMA_a6717cb8-7f9d-4a13-b316-7d623a413db9"
      unitRef="usd">3704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtNS0xLTEtMA_4e9b883c-43e4-4a09-a08a-7836b22aa6e8"
      unitRef="usd">27809000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfMzgtNy0xLTEtMA_398e73de-e491-445e-a9d8-c3c97b1a64c4"
      unitRef="usd">7389000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtMS0xLTEtMA_fc0227a9-0f23-4ca2-8cf6-ca12cc9484eb"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtMy0xLTEtMA_41a169fa-71eb-40f3-854b-eee3b2300850"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtNS0xLTEtMA_6a3505c4-4f5b-4962-b577-08b2276445a0"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDAtNy0xLTEtMA_6219bf89-c652-4f12-8f21-7df878c8f6fd"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItMS0xLTEtMA_fda765c4-2bbf-40b5-8b84-897fa98275c1"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItMy0xLTEtMA_cc022d93-1832-43e5-85d7-492358606b03"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItNS0xLTEtMA_1314d8be-2ff6-4a72-96b6-3d7d018aa03b"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yNS9mcmFnOmQ1YzgxYWJlMGUzMjQ2OWU4MmQ1YTI3ZWU2ZTM2MDk5L3RhYmxlOjk3YzAzN2JlZWRiYzQ5NzFhMmU3OTQyMmIyZDQ3MTgzL3RhYmxlcmFuZ2U6OTdjMDM3YmVlZGJjNDk3MWEyZTc5NDIyYjJkNDcxODNfNDItNy0xLTEtMA_4075cb54-887b-4e38-a5c5-38c328a3af51"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4c3f468964da412ebaa0846e50fe0da4_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xLTEtMS0w_6bf5c90d-58a4-426d-ac3f-2cb23a21e39f"
      unitRef="usd">168725000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i12c2127d868e4f87a671ff137b7c2981_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0zLTEtMS0w_4a894ffa-03a5-48f3-a071-87218de2bbed"
      unitRef="shares">35908057</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i12c2127d868e4f87a671ff137b7c2981_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy01LTEtMS0w_86fe9e53-b8d8-4c83-95e7-6d008fcb48ec"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iabd3dd55e36b43b495789ffa5cc73b36_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy03LTEtMS0w_22a62879-5a4f-41d7-8855-45ed6328dcd7"
      unitRef="usd">159608000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i59fc236ccce64a608d756612e5db97f1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy05LTEtMS0w_c64fbdcf-4346-47ca-bf86-429c4be6e7fa"
      unitRef="usd">31905000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibba7855d202c4906a207a0a7faa251a9_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xMS0xLTEtMA_de87423c-3aaf-4e56-a408-fdfff2bb9889"
      unitRef="usd">786000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMy0xMy0xLTEtMA_7599dbf1-10f6-469a-b331-c22a2325443f"
      unitRef="usd">192335000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xLTEtMS0w_3b728d60-350a-4b61-8e8a-a135ca422b5b"
      unitRef="usd">-1161000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i18b992a0d32d458485f04f21e552fb61_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC05LTEtMS0w_dc6a13ab-1d96-4fe3-975d-7b0698980ac4"
      unitRef="usd">4052000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="id2eceea105e94e54a0c2107e27e00355_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xMS0xLTEtMA_761c6545-2e56-4365-9b0f-a5ab01daebdd"
      unitRef="usd">95000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNC0xMy0xLTEtMA_dd1c9354-1cf3-4b9f-92ea-4be666351804"
      unitRef="usd">4147000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS0zLTEtMS0w_b39308ce-aab4-4819-8dd3-1c87383e0b32"
      unitRef="shares">16897</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS03LTEtMS0w_4c9e3b6d-3374-460f-bf4b-42642c00df59"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNS0xMy0xLTEtMA_ca2ddada-2431-4cd4-bfed-f5c5ac18a2e0"
      unitRef="usd">301000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNi0xLTEtMS0w_df8c389e-2846-4a0a-bce0-393922de50c9"
      unitRef="usd">125000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNi0xMy0xLTEtMA_eba78f3c-f170-4cf0-a666-d9bf8a5a3d8d"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i17d1050d12f04ea786b324ce83c5fcd6_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy0zLTEtMS0w_32d5c229-9887-4f33-85b8-1a38aba7a10b"
      unitRef="shares">151601</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy03LTEtMS0w_3cc952c2-e32e-4cb7-8132-f960cf718581"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfNy0xMy0xLTEtMA_f7048c2b-0c99-4484-8ea4-2c25a439afa9"
      unitRef="usd">722000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iceee1ca29c6b4d68b3932bd36d916d25_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOC03LTEtMS0w_db16efc9-6572-4f94-891e-23801b7d5f59"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOC0xMy0xLTEtMA_1a7c3bec-37fb-4373-ba4d-a990ecc5248a"
      unitRef="usd">1058000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i28aa85de7b9443daae973556389a0cd0_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOS0xLTEtMS0w_5cb6e9d6-2121-4dd6-86ff-1a9db41dbb5a"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3672be9d2473460199bb2df91d8bb7ba_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfOS0xMy0xLTEtMA_512e59b6-11f7-4937-9e00-be323b5ad486"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i251eec9a4efe4815a9a119b6820c7de8_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMS0xLTEtMA_e1855508-4535-473e-9600-c0a40298d41b"
      unitRef="usd">157439000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i87c42df9ebca4c8ea2878cd65f523941_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMy0xLTEtMA_2fe57556-f7f6-47ef-b94c-ccd01f23d428"
      unitRef="shares">36042761</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i87c42df9ebca4c8ea2878cd65f523941_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtNS0xLTEtMA_96cbd090-9341-4107-a812-6389fa2ba311"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i90197c93402f41ff9bc61f1754e24165_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtNy0xLTEtMA_781162a0-cefd-46d9-b97e-75d1f588a8a9"
      unitRef="usd">161087000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i09497b34fad5498f8a7379c15692a946_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtOS0xLTEtMA_ab3ae1e5-933b-4dc7-964c-f35530420c6b"
      unitRef="usd">35957000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i19924d22b9634738af4fc0857dd5f1db_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMTEtMS0xLTA_050abe0f-2466-4622-8629-51a8850cb0ec"
      unitRef="usd">881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i04e6f52d6af84990b66fae85e26f4b3e_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTAtMTMtMS0xLTA_fc8438f2-fa25-47cf-9fb5-044a6a3c8bcc"
      unitRef="usd">197961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMS0xLTEtMA_a0f4dfa5-d773-4ac3-81b5-2cba0c77457b"
      unitRef="usd">73667000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i672096def723492da951e5ba41de393f_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtOS0xLTEtMA_51271dc0-c2c4-4624-ac8c-83bc0a7ea150"
      unitRef="usd">7044000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMTEtMS0xLTA_001d6500-abd4-4e9f-adc4-9daecf430bdf"
      unitRef="usd">291000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTEtMTMtMS0xLTA_af6e1eef-94ec-489a-97a9-083cfdba9142"
      unitRef="usd">7335000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTItMS0xLTEtMA_ada6febf-bf9e-4582-a5bd-25e6d87b7531"
      unitRef="usd">126000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTItMTMtMS0xLTA_c8a7ae94-0c59-418d-99cf-445306d2abad"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTMtMy0xLTEtMA_c653a59a-b4ce-498a-82da-8971a821c24b"
      unitRef="shares">24453</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTMtMTMtMS0xLTA_acabfce4-4356-4842-9d7e-a9e700ca97bb"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i5a834a9b45d9449792b39e389d6e07d5_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtMy0xLTEtMA_f7bbbaf3-1a11-40a7-b688-bcaa08c9e525"
      unitRef="shares">242299</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtNy0xLTEtMA_1ab567d7-cb35-4b08-8f48-02b7adaa98f3"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTQtMTMtMS0xLTA_7d527cf3-e081-4b67-a6b2-72f0c1b8e7d0"
      unitRef="usd">2283000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTUtNy0xLTEtMA_3126ab44-00d5-45ec-ae99-b276e313350b"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTUtMTMtMS0xLTA_492cd673-16c6-46ff-8ebc-804e37fef97b"
      unitRef="usd">852000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled
      contextRef="i2e4fc314bdb54ad1a93096e7ca9257d5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTYtNy0xLTEtMA_c66530a2-62a8-4df3-a8f8-c2154ea82984"
      unitRef="usd">236000</ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled>
    <ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTYtMTMtMS0xLTA_e39725f2-e97a-4fc5-93e1-6ca19d7e0174"
      unitRef="usd">236000</ameh:StockIssuedDuringPeriodValueRestrictedStockAwardCancelled>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i2f6b67e879f746aa9a9ef86509edaf66_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMS0xLTEtMA_8cc6e54d-98bb-41a0-9907-dffdd53547e1"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia92c3d78cbaf463ab05d2da24f7e488a_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMTEtMS0xLTA_459ca9d2-104a-48ca-98ba-b064690edc41"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i722d022bc60341a4957154974aaa0f71_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTctMTMtMS0xLTA_d19b1158-cae5-4ee6-b9a6-7649df608cfe"
      unitRef="usd">347000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i13676229b94a433bb7999e82d40c9506_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMS0xLTEtMA_7777b749-e31b-4678-bb60-7a812d2cedae"
      unitRef="usd">210980000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i31636c0f849b4fcfac8862fe43198701_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMy0xLTEtMA_05da81b4-b424-4ced-9216-b8239a31ea5b"
      unitRef="shares">36309513</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i31636c0f849b4fcfac8862fe43198701_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtNS0xLTEtMA_4129a8be-b00e-4bee-a6d4-d5ae2ad15421"
      unitRef="usd">36000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ica802434063e4405a1db846371417d7c_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtNy0xLTEtMA_baedde1a-096a-46a1-a147-7a79a896d803"
      unitRef="usd">163986000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47774eeabb6c4f8a941dafeadf448ab0_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtOS0xLTEtMA_3d667806-5347-4aa7-ada6-d9535596895b"
      unitRef="usd">43001000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib6836300d36448ee8800b32b51ab5107_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMTEtMS0xLTA_1586e611-ca88-417e-8efd-d23723548373"
      unitRef="usd">825000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i045332a06815470c90c30b39515f8d62_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTgtMTMtMS0xLTA_0f72cf64-c9c9-49ee-b9b8-8a2fca9c66dd"
      unitRef="usd">207848000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMS0xLTEtMjA0NQ_b5bf3ec6-cb7e-4eb7-a31b-ae0e474aa98e"
      unitRef="usd">8522000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i3f9e597672244da19f4a35690c8fb312_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktOS0xLTEtMjA5OA_fbe8280a-4ad2-44b7-b992-1d9ca8047fb1"
      unitRef="usd">16713000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i0058c6f89dbc42439fb7e3bd81042bbc_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMTEtMS0xLTM1MTE_66f8ed27-b326-40c6-87e3-0dc5cbf0aab9"
      unitRef="usd">189000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMTktMTMtMS0xLTE5MTY_ecba4776-77c4-4409-acfa-7460adcf9952"
      unitRef="usd">16902000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjAtMS0xLTEtMjA1Mw_cba949a9-0cdd-44f4-8a81-623c260eb5a9"
      unitRef="usd">771000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjAtMTMtMS0xLTE5MjI_c3ba6570-f7b7-45b2-b7a8-7287287d6f21"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised
      contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjEtMy0xLTEtMjA4Mg_4bfdbaa4-4da5-4f46-b9e0-5470a08f4c88"
      unitRef="shares">66517</ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised>
    <ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjEtMTMtMS0xLTE5Mjg_4a4bafcd-6052-443e-a45d-adb454426179"
      unitRef="usd">0</ameh:StockIssuedDuringPeriodValueCashlessWarrantsExercised>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItMy0xLTEtMjA4Mg_de14d36b-824f-48bd-b993-f71253a0858f"
      unitRef="shares">399787</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItNS0xLTEtMjA4OA_efa49149-7f64-4c26-b32c-fede78143f51"
      unitRef="usd">1000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItNy0xLTEtMjA5Mw_63793e15-a6e4-46a7-8bc1-be095b64e7df"
      unitRef="usd">4019000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjItMTMtMS0xLTE5Mzg_2ac30f3e-879f-48ef-b0e2-b36b0992ec4f"
      unitRef="usd">4020000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="if968a5db2b304a59b6ab39bb4916f745_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjMtNy0xLTEtMjA5Mw_be089747-2ea0-4abc-8f9f-058037ff78d0"
      unitRef="usd">648000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjMtMTMtMS0xLTE5NDQ_067d9129-850b-42cd-8dff-6499f6c8f8c5"
      unitRef="usd">648000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i95dc69cc5c4e400ea5af0f76d75ca64a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjUtMS0xLTEtMjA3Nw_f7b53750-adc6-4d1d-b401-96401f01da2e"
      unitRef="usd">20000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjUtMTMtMS0xLTE5NTY_2e1e8b10-d05a-4010-9337-94214fa21bcb"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fc323e30b8848c392d11f3447569909_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMS0xLTEtMTg2OA_b9e3bcfb-6541-408f-a63f-183ff3b0f961"
      unitRef="usd">198731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMy0xLTEtMTg3NA_d51ab455-9b36-4e14-91eb-5cd6c451f87a"
      unitRef="shares">36775817</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a9b4ab660364470994fc62a0c0ed4a1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtNS0xLTEtMTg4Mg_c3954f42-cb9f-4af7-91ff-82d434e9d212"
      unitRef="usd">37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia7fba74c001f4474b00a66afe5cacce5_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtNy0xLTEtMTg4OQ_b9d79df6-c01e-45c3-af31-743f77efccd7"
      unitRef="usd">168653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if17092a524b3431fa61045723b615908_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtOS0xLTEtMTg5NQ_326ef4b6-5062-46c8-b71c-82249241e33a"
      unitRef="usd">59714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i48930c9adfe945f5b856524fd6f16354_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMTEtMS0xLTE5MDE_92ab33b9-afb2-4342-9b8b-ad167883aed0"
      unitRef="usd">1014000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOjcyODFmYTg2N2QyYzRjMjU5OWI5YWJiNTI4NDJiYWNhL3RhYmxlcmFuZ2U6NzI4MWZhODY3ZDJjNGMyNTk5YjlhYmI1Mjg0MmJhY2FfMjYtMTMtMS0xLTE5MDk_c0d83614-276c-41ff-997f-234e1661e29d"
      unitRef="usd">229418000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4d27872ad1a4279809587e20ad0fe15_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xLTEtMS0w_ca7a8292-5935-4c59-bd67-1e32b9ee5a2b"
      unitRef="usd">225117000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i0a4af3abe23145c5a803f5c3e52a8544_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0zLTEtMS0w_b4482b3e-5bb5-4d33-9a5a-6badf8d8e72b"
      unitRef="shares">34578000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0a4af3abe23145c5a803f5c3e52a8544_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy01LTEtMS0w_86aee671-8fc8-4804-8bc6-860dc72e06cd"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaed16704d02b4d98bf8e2256dea906c0_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy03LTEtMS0w_322a3e42-8d78-4cbd-a330-4ebc7e5b3f29"
      unitRef="usd">162723000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i761a2357c3064b2594cc6d1ffa6c27db_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy05LTEtMS0w_0caa3650-03c9-4c04-8b1d-bd06d0d959d8"
      unitRef="usd">17788000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5f84ac6f64b14be7aec8e4101eced375_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xMS0xLTEtMA_4dd045f5-863d-4d75-b92f-d3a22930542a"
      unitRef="usd">998000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMy0xMy0xLTEtMA_8fd0c9d0-ff1d-4d83-a23a-52b0ce549f3b"
      unitRef="usd">181544000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xLTEtMS0w_53216b08-dc19-44a0-a639-cdde6c4b5591"
      unitRef="usd">-3000000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i5e6f19723927433ab20be84a073ed166_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC05LTEtMS0w_8415f1ed-a30b-4510-86ac-07c69646e57b"
      unitRef="usd">140000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i97544ae25cce437ca45e3294de951909_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xMS0xLTEtMA_8197d44e-1068-44f1-89f4-37efebbd6dfc"
      unitRef="usd">410000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNC0xMy0xLTEtMA_05a0e6da-314c-4fa8-a5ae-93a9728b1976"
      unitRef="usd">550000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0xLTEtMS0w_69ac26aa-af45-4223-affc-6ac4b88f3e95"
      unitRef="usd">40000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0zLTEtMS0w_51c64108-6002-4b84-b0fb-ab68d45767b2"
      unitRef="shares">93000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod
      contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNS0xMy0xLTEtMA_d3b342b9-cb00-4914-ad43-924c68421fd8"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0xLTEtMS0w_c33a2d9d-d4ad-4a3d-ae86-1a5fc8ec3bd0"
      unitRef="usd">155000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0zLTEtMS0w_f0423aa7-8f05-430c-a3f6-f86b64f384e0"
      unitRef="shares">17000</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi03LTEtMS0w_11350f82-612a-46dc-be47-26e8d3de844e"
      unitRef="usd">140000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNi0xMy0xLTEtMA_8095ce5e-f9a0-477e-94b2-5efd4f794ee7"
      unitRef="usd">140000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0xLTEtMS0w_f91747ce-3bc0-47be-b853-a0bcc1e77a98"
      unitRef="usd">202000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="icd0eb6717cd0468292846a328415a98e_D20190101-20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0zLTEtMS0w_2a57edb9-3907-45ec-8e3a-09a58a7655f3"
      unitRef="shares">2000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i15b05713304f4a43b8ec50ec45400469_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy03LTEtMS0w_89ee32dc-f727-43b1-80d3-88d3231f780f"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfNy0xMy0xLTEtMA_eb67e161-73b0-4ee4-b663-cc8b9ead2095"
      unitRef="usd">143000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i81dd608120f24b59b7083cd54cf0be29_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOC0xLTEtMS0w_832e8126-5b10-49d5-a325-7d7836e64410"
      unitRef="usd">10000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i3dc9097e74ef44178a3c8b4100c23456_D20190101-20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOC0xMy0xLTEtMA_3811c9ed-042e-49cf-944d-60be99bbdcea"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i77cee32ef46c436d84f0829e3e15ae33_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xLTEtMS0w_ea2a38ad-5905-4028-9b53-e876cc75f2b7"
      unitRef="usd">212434000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i1abc08966ff44c6c9d37bfc49d295077_I20190331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0zLTEtMS0w_f21b2559-e681-4ad3-9eaa-2fd921de7794"
      unitRef="shares">34504000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1abc08966ff44c6c9d37bfc49d295077_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS01LTEtMS0w_755157b1-4c7b-4cfa-afeb-2efc69d31335"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i44c7198a292a4cc68b8fabdaafd056cd_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS03LTEtMS0w_4468a560-de2c-4f44-958e-665179ef7163"
      unitRef="usd">163006000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ifb4e33d7899548cf889cdedab733332d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS05LTEtMS0w_ab9da25a-1b7d-43f9-be8e-305092449ef9"
      unitRef="usd">17928000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0bff8181370945009acd3344b88456f0_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xMS0xLTEtMA_3f3a2923-95d6-40b2-961b-103d4fb54f96"
      unitRef="usd">1408000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e5a66ee0d984c67b9d7841aeb1f110d_I20190331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfOS0xMy0xLTEtMA_755a308f-8ac6-44e5-8310-2b8d230a33db"
      unitRef="usd">182377000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMS0xLTEtMA_7bdb5905-0af4-40a1-9e47-bfbb24926206"
      unitRef="usd">6896000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iedead393f61c4d1d98fb4fb12d0b9b21_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtOS0xLTEtMA_fd296480-b46e-4b31-8102-d72f9a3bdb66"
      unitRef="usd">3545000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMTEtMS0xLTA_ac6383d4-bf31-408f-8be9-5cea22d3e550"
      unitRef="usd">223000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTAtMTMtMS0xLTA_49ac41be-6dc2-440c-923c-ae1e34e3f018"
      unitRef="usd">3768000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMS0xLTEtMA_f2e9f415-2dc1-4621-a750-2452d1d67804"
      unitRef="usd">50000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i88138caccd9942feab56d34bfdb5c9e0_D20190401-20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMy0xLTEtMA_b1175211-f12c-4772-9c12-7382e2de3c81"
      unitRef="shares">135000</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtNy0xLTEtMA_7632e9f1-5d93-473a-b0b2-75ae66b80cdd"
      unitRef="usd">758000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTEtMTMtMS0xLTA_f9b2f259-8672-46d3-b641-3f6fe6781967"
      unitRef="usd">758000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i480c64e35aa54b7cbf608f4099b09626_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItMS0xLTEtMA_7358dc14-a2af-4b46-b669-5348b572d8ed"
      unitRef="usd">203000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i62ce85aeee06484c851f44a3060494b9_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItNy0xLTEtMA_6f2edefb-5a0c-457d-b6b2-76bd4a759227"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTItMTMtMS0xLTA_6ebc5199-5a50-439b-97ad-f4cd5d298cf6"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i36785330df8444068c2eec03e15b8a8e_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTMtMTEtMS0xLTA_fdca573f-7b7a-478b-88f5-ef92f9744c86"
      unitRef="usd">942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="iebbfc871faf2436b8c74d2682e143801_D20190401-20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTMtMTMtMS0xLTA_127a7dc8-95d1-45bb-ae0c-3ffed48f26ab"
      unitRef="usd">942000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i41a9a24bf76640ed9bdb33547fcaacce_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMS0xLTEtMA_8fdce319-6a44-48b3-8de3-9948fdd927e9"
      unitRef="usd">219583000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="i394648e1fc6a45c1a9b563d94578a33a_I20190630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMy0xLTEtMA_3adb61c6-c654-4977-bec5-7469308482c9"
      unitRef="shares">34639000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i394648e1fc6a45c1a9b563d94578a33a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtNS0xLTEtMA_0746eba2-f246-4d5b-a433-b20c7c2e26b2"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i441f160512f24fc3a029ac86e7eb66f2_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtNy0xLTEtMA_5abb52a3-99d4-460b-846e-f174f01f1c72"
      unitRef="usd">163892000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id9a6b08aae29400da31700f63234c634_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtOS0xLTEtMA_4272c897-31ff-4184-9afb-04fc516babdd"
      unitRef="usd">21473000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9189b09c063b44b4b87c085f5786c13a_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMTEtMS0xLTA_e0043a51-aaaf-4c7a-89e4-9dd3f3c6edce"
      unitRef="usd">689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6ddfb33c93414dc69359261cfab93737_I20190630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTQtMTMtMS0xLTA_266d83ba-054f-462c-8eab-f0cea54fb4d1"
      unitRef="usd">186089000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMS0xLTEtMTUzMw_df63e475-a204-4692-820b-f798549d45e4"
      unitRef="usd">6285000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="idfadcf1ceec24d88b5700a0374a20a18_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctOS0xLTEtMTgyMw_99950fb6-9ead-49d5-901d-76ab41eec1ac"
      unitRef="usd">3704000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="ie1bd4252c28a48b9bf1ba1f49f34c298_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMTEtMS0xLTE4MzQ_4939cfdb-4141-4a7a-98da-4ad8dfb556eb"
      unitRef="usd">751000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTctMTMtMS0xLTE4NDM_3d7534d7-3899-4dba-a812-ad1028b0cde8"
      unitRef="usd">4455000</ameh:NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity>
    <ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants
      contextRef="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMy0xLTEtMTc4Ng_06a6cc38-c09c-438e-b38d-713aba23cf29"
      unitRef="shares">184000</ameh:StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtNy0xLTEtMTgwMQ_83f57d4e-8c12-49ea-8023-f5f5b3e5a3ad"
      unitRef="usd">1502000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMTMtMS0xLTE4NDg_6ca70eb7-f662-48e2-a071-a95e93cf0396"
      unitRef="usd">1502000</ameh:StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMS0xLTEtMTczOA_7388c8ef-ef6e-4752-a598-d21c2e09e7b2"
      unitRef="usd">202000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i99cf982c389a4ab3bbfbfd15a246a748_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktNy0xLTEtMTgwNg_a45978b0-bfbe-469d-82ae-6f298e61d728"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMTMtMS0xLTE4NTU_5c023550-8c52-4bbd-8098-7ea62117024e"
      unitRef="usd">128000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjAtMS0xLTEtMTc1MA_3cb52f0a-3e11-4165-8bf7-c77d01d569fd"
      unitRef="usd">550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTgtMTMtMS0xLTIwMzQ_799d91af-b0c0-46a3-9042-a32b32166c3f"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjEtMS0xLTEtMTc1Nw_b229df3c-cb2a-422b-bdb9-b1ad08b78057"
      unitRef="usd">414000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMTktMTMtMS0xLTIwMzQ_bf4600c3-36ff-4e39-b511-02b71acb199e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjItMS0xLTEtMTc2NA_5fc8cf2e-b7ac-4562-b89f-3f88d60da53b"
      unitRef="usd">804000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjAtMTMtMS0xLTIwMzQ_2b994ab8-e888-4f83-88d2-c49fd9d72e39"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i6add1b5b69ae48129a797af100f9aa3b_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjMtMS0xLTEtMTc3MQ_1c266b7d-eaf0-4fee-b964-f4defb10d337"
      unitRef="usd">50000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjEtMTMtMS0xLTIwMzQ_e4b87a1a-bdb3-46c2-a197-d2db6b87a550"
      unitRef="usd">0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i422d2bc6f855432dba692b6a8acdf97f_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMS0xLTEtMTc3Nw_da7fe98b-b443-47ea-b66d-cf86c6408cd7"
      unitRef="usd">176230000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="ic92256abd49e475e96a57d58092f2a3d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMy0xLTEtMTc5Mg_f8c038d9-7a83-4340-9e5a-b973cd65d616"
      unitRef="shares">34823000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic92256abd49e475e96a57d58092f2a3d_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtNS0xLTEtMTc5Ng_6e6bae00-375a-418c-8a34-6080cff3be9d"
      unitRef="usd">35000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8f8b5692b30549aea2a5a9d8d16e6332_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtNy0xLTEtMTgxMQ_c73b0345-1a59-489c-bee6-2679b5bd4102"
      unitRef="usd">165522000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id523b2ed183c45849c949c14470f0f6a_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtOS0xLTEtMTgyOA_5986dd1a-9b80-4d00-bc05-1049927c8686"
      unitRef="usd">25177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i23e7f6a028994e14996741a361d2e4db_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMTEtMS0xLTE4Mzg_95d2f7de-7d7b-4f7e-9a2d-0f82656bcde1"
      unitRef="usd">1440000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yOC9mcmFnOmFiZWVhMmJlOWU2ODRmM2E4MDllYjQzZDU2ZDNhMTEyL3RhYmxlOmRiODQzNGI1MDU1OTRiOGE4ODAzMGE4ZDE0ODM3MTBjL3RhYmxlcmFuZ2U6ZGI4NDM0YjUwNTU5NGI4YTg4MDMwYThkMTQ4MzcxMGNfMjQtMTMtMS0xLTE4NjI_bb6445ca-7b6b-41bc-8298-42722d964786"
      unitRef="usd">192174000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMy0xLTEtMS0w_16595e14-c22c-4b58-a7e4-d9fbf91a7a61"
      unitRef="usd">109412000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMy0zLTEtMS0w_b3a691df-9016-4273-81ed-7053a2ff0708"
      unitRef="usd">18953000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNS0xLTEtMS0w_4f514645-6414-4396-999e-f506194244c5"
      unitRef="usd">14004000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNS0zLTEtMS0w_38480c4e-b9b8-4fdf-9dd4-f446352b2339"
      unitRef="usd">13793000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0xLTEtMS02NTg5_285c134d-fdd3-4f0b-a319-f5ba2bcee11e"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0zLTEtMS02NTg5_3772e5c5-74b4-4b8e-a26a-18d18589c09c"
      unitRef="usd">1994000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0xLTEtMS0w_2f4a0599-69e0-4f87-bf73-3c86cd5164ba"
      unitRef="usd">1004000</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNi0zLTEtMS0w_2b67a3c9-099c-4a02-a3cc-334957a7754f"
      unitRef="usd">0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNy0xLTEtMS0w_611d5e6a-dc02-48ee-8ce8-acf0ef041900"
      unitRef="usd">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNy0zLTEtMS0w_5168f611-c54d-4f76-9989-915e1d234fcc"
      unitRef="usd">-1363000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOC0xLTEtMS0w_c666e927-9173-462b-aac6-6886903f0538"
      unitRef="usd">2558000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOC0zLTEtMS0w_00db7088-354a-4cd7-b34c-9cb6f0a2d5e7"
      unitRef="usd">1006000</us-gaap:ShareBasedCompensation>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOS0xLTEtMS0w_8dedfe32-1d16-4ce4-83a1-1d2c79b8777f"
      unitRef="usd">-23000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:UnrealizedGainLossOnInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfOS0zLTEtMS0w_f0b1a2c5-28fb-4b8a-9ad8-b334c39fded4"
      unitRef="usd">6000</us-gaap:UnrealizedGainLossOnInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTAtMS0xLTEtMA_773f14dc-04be-4760-9aed-af27a17c1326"
      unitRef="usd">3291000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTAtMy0xLTEtMA_e48490ca-1a03-4f8e-8040-9e69359572ff"
      unitRef="usd">1162000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMS0xLTEtNjU3Ng_413d9456-fa9e-4c7f-af58-ba4646e74527"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMy0xLTEtNjU4Mw_49055b83-9225-45b7-b840-b05de51dedb8"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <ameh:GainLossOnAssumptionOfLoan
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMS0xLTEtMA_59a9b57d-5e25-4eb0-9732-ac1304a21278"
      unitRef="usd">0</ameh:GainLossOnAssumptionOfLoan>
    <ameh:GainLossOnAssumptionOfLoan
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTEtMy0xLTEtMA_6d51fa99-7082-4438-ae76-483f7b1b397a"
      unitRef="usd">2250000</ameh:GainLossOnAssumptionOfLoan>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTItMS0xLTEtMA_d77ecca7-a219-4fcd-8050-f2491dd5f30d"
      unitRef="usd">-6137000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:DeferredIncomeTaxesAndTaxCredits
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTItMy0xLTEtMA_96df6229-dc30-4399-82dc-b0e0ae7b7b85"
      unitRef="usd">-186000</us-gaap:DeferredIncomeTaxesAndTaxCredits>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTQtMS0xLTEtMA_f2644af3-84d0-4a39-b342-f6bd1c854978"
      unitRef="usd">6953000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTQtMy0xLTEtMA_8e4f439b-3a70-4ed1-b8e1-e913d26b4187"
      unitRef="usd">-1904000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTUtMS0xLTEtMA_edc793ab-628b-4a5d-b83d-f64b6482bc88"
      unitRef="usd">-6618000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTUtMy0xLTEtMA_351cd408-16dd-46b2-a460-1855c2d65701"
      unitRef="usd">-5864000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTYtMS0xLTEtMA_4dae5397-905e-4542-9539-e26ff0a3188d"
      unitRef="usd">-12898000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTYtMy0xLTEtMA_f4669a78-7969-4047-9c5f-c5aa0aaba5f3"
      unitRef="usd">13719000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTctMS0xLTEtMA_b083f3bc-deaa-4908-9396-20274be5f710"
      unitRef="usd">1804000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTctMy0xLTEtMA_430dfe28-f7a2-4447-982d-2b4d059aa566"
      unitRef="usd">2914000</ameh:IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTgtMS0xLTEtMA_f200a3bc-8edb-4f63-89c8-139b342a9cf1"
      unitRef="usd">2601000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <ameh:IncreaseDecreaseInOperatingLeaseAssets
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTgtMy0xLTEtMA_aec8d9c7-dd5b-4977-a78f-94c2196b412c"
      unitRef="usd">1877000</ameh:IncreaseDecreaseInOperatingLeaseAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTktMS0xLTEtMA_73d0a9a3-0a4e-44d1-bb22-3eec4876be20"
      unitRef="usd">5090000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMTktMy0xLTEtMA_b70f5b8e-e855-426b-a2e2-5f5cd6d13388"
      unitRef="usd">525000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjAtMS0xLTEtMA_a5511657-aec1-4196-9847-ef2c4a64ba88"
      unitRef="usd">12644000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjAtMy0xLTEtMA_d3591e88-9f33-4e63-89a9-799ef64ccfa7"
      unitRef="usd">4868000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjEtMS0xLTEtMA_c91ba863-4185-4cf0-af5f-caf7a00fcd4c"
      unitRef="usd">1958000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjEtMy0xLTEtMA_ef8fb33b-3a55-4022-b866-ce2e8369bdcd"
      unitRef="usd">196000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjItMS0xLTEtMA_78dbb7b9-aae6-4a04-b6c9-8fc3edc90c51"
      unitRef="usd">-1566000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <ameh:IncreaseDecreaseInMedicalLiabilities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjItMy0xLTEtMA_2a27e8a6-95ef-48b1-bdcf-a0cba45aef49"
      unitRef="usd">-6226000</ameh:IncreaseDecreaseInMedicalLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjMtMS0xLTEtMA_94b4d17c-401c-4fda-a59c-8cb6576427c1"
      unitRef="usd">11642000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjMtMy0xLTEtMA_00676691-b496-4327-aeb6-78f1d5489b27"
      unitRef="usd">-10229000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjQtMS0xLTEtMA_be72595b-1197-49c8-84bf-70611a44881a"
      unitRef="usd">-2110000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjQtMy0xLTEtMA_569d4500-a6e0-4926-91d7-13e6c5bd3337"
      unitRef="usd">-1790000</ameh:IncreaseDecreaseInOtherOperatingLeaseLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjUtMS0xLTEtMA_b88115c0-bf04-4528-9f9d-cdb7c28376d1"
      unitRef="usd">48764000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjUtMy0xLTEtMA_45704e04-7346-4e09-b668-e7f8cd20bc26"
      unitRef="usd">10085000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjgtMS0xLTEtMA_d910c297-0e26-43a1-88f9-134bd769953f"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjgtMy0xLTEtMA_a6a0241d-9492-452c-be79-4e568ffc4f2e"
      unitRef="usd">49403000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjktMS0xLTEtMA_92432e04-ac90-4297-805d-b92dda7fa7e0"
      unitRef="usd">16500000</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMjktMy0xLTEtMA_fef9afbe-91cb-4309-9cee-f564aacf87ed"
      unitRef="usd">0</us-gaap:ProceedsFromCollectionOfLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzAtMS0xLTEtMA_8cc716d4-90df-44b6-afb5-9aae4aa7b906"
      unitRef="usd">0</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToFundLongtermLoansToRelatedParties
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzAtMy0xLTEtMA_5fe47a49-bfe8-41cd-a0ae-84d9330ba991"
      unitRef="usd">7425000</us-gaap:PaymentsToFundLongtermLoansToRelatedParties>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzEtMS0xLTEtMA_1e3c76dc-e0be-4608-9d44-a43c963741ff"
      unitRef="usd">1793000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzEtMy0xLTEtMA_42683faf-75f3-4edf-8ea5-4e7a9ae253f6"
      unitRef="usd">20000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzItMS0xLTEtMA_581f1044-f537-4df5-b92d-5d70aab63887"
      unitRef="usd">500000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzItMy0xLTEtMA_9413af89-df49-4253-aed1-aeaf86b10047"
      unitRef="usd">2949000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzMtMS0xLTEtMA_ab76c938-9442-4052-bc24-11e903b36d9a"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzMtMy0xLTEtMA_f0b6bea1-27c7-44cd-8c0a-ad1a3edc7946"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzQtMS0xLTEtMA_6a7ffa11-1548-41b2-b422-9b6fd110925e"
      unitRef="usd">553000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzQtMy0xLTEtMA_45af603d-efef-441a-bf6e-fa57ce58367d"
      unitRef="usd">807000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzUtMS0xLTEtMA_e80b035d-6023-4840-95f6-ff6fc0637092"
      unitRef="usd">0</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzUtMy0xLTEtMA_c1a2a064-1e0d-451b-9733-c99c8bdf3344"
      unitRef="usd">240000</us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzYtMS0xLTEtMA_395b455b-f775-4276-a4b6-8e9db601ac90"
      unitRef="usd">66397000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzYtMy0xLTEtMA_54d5542c-181e-4065-9771-a9a1625cb521"
      unitRef="usd">-60364000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzktMS0xLTEtMA_5c982502-d8e3-464f-9f3c-e4223ca9a598"
      unitRef="usd">0</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <ameh:RepaymentsOfBankLoanAndLinesOfCredit
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfMzktMy0xLTEtMA_971430a2-9f1f-4179-a433-d3f5d57bd680"
      unitRef="usd">52640000</ameh:RepaymentsOfBankLoanAndLinesOfCredit>
    <us-gaap:PaymentsOfDividends
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDAtMS0xLTEtMA_e06b2be9-b625-460c-876e-c9ee618a4b20"
      unitRef="usd">50133000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDAtMy0xLTEtMA_860e21e5-142d-4988-9d72-caf26dbb8608"
      unitRef="usd">60670000</us-gaap:PaymentsOfDividends>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDEtMS0xLTEtMA_6e6f522b-0b6f-479d-aaac-de160f0257d4"
      unitRef="usd">7125000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDEtMy0xLTEtMA_5ee97354-ad0e-4d03-afc4-16658b1f39f9"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDItMS0xLTEtMA_c8cad8bc-defa-4163-9cec-81e9666e7aee"
      unitRef="usd">78000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDItMy0xLTEtMA_59fa98a2-fe83-456a-bb1e-74b758622f85"
      unitRef="usd">76000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDMtMS0xLTEtMA_7f979a52-0b5d-4351-8f17-9f529e7a3e07"
      unitRef="usd">6552000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDMtMy0xLTEtMA_9a221a5c-458e-429e-a524-f834565a8baa"
      unitRef="usd">2400000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDQtMS0xLTEtMA_73138151-4b60-4440-9de9-39f28160aced"
      unitRef="usd">1559000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDQtMy0xLTEtMA_f1e4fce1-9c45-4ba0-a66d-ff3c9dd8a4c0"
      unitRef="usd">40000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDUtMS0xLTEtMA_63d65625-2828-4958-bcb9-ca6236e917d4"
      unitRef="usd">0</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDUtMy0xLTEtMA_6f161e3f-f978-4bde-9f57-5a569251c216"
      unitRef="usd">289600000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDYtMS0xLTEtMA_a3fb1b6c-ead1-4e34-8a70-26b651b3724a"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDYtMy0xLTEtMA_328bab22-1fe8-4ba9-96b9-76507345d72c"
      unitRef="usd">755000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMS0xLTEtNjYwNw_e4ad9fe4-8e3f-49f0-bf50-1e640020ae39"
      unitRef="usd">0</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMy0xLTEtNjYwNw_b2f5b978-77b7-4ff1-a257-ebc68632b97b"
      unitRef="usd">5622000</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDctMS0xLTEtMA_7170a492-33f8-4ef8-8798-cb8261586208"
      unitRef="usd">-52343000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDctMy0xLTEtMA_ad9beacf-df8c-4f36-b60d-87fe397e5c61"
      unitRef="usd">173707000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMS0xLTEtMA_86441534-5f99-430f-bcf6-b9f495024fd1"
      unitRef="usd">62818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNDktMy0xLTEtMA_862a2029-2a0a-48f7-9c65-ac8e1c642953"
      unitRef="usd">123428000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTEtMS0xLTEtMA_8d30d556-514d-41e4-9bd4-c3bf7d6500b3"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTEtMy0xLTEtMA_10b9cf29-be24-4b6d-aa74-ab5648279856"
      unitRef="usd">107637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTMtMS0xLTEtMA_1b9092c3-e0ce-4e52-902b-4451a6e0cf89"
      unitRef="usd">166828000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTMtMy0xLTEtMA_4f283a11-9144-48fe-b5e9-c1a13b9b5763"
      unitRef="usd">231065000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTYtMS0xLTEtMA_488670d8-9f61-4c55-bc05-2248ad52ab1f"
      unitRef="usd">37900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTYtMy0xLTEtMA_7e4b59fa-fb06-47ae-a388-f48ab483ecc1"
      unitRef="usd">17900000</us-gaap:IncomeTaxesPaid>
    <us-gaap:InterestPaidNet
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTctMS0xLTEtMA_45ee8685-8109-4784-b653-a29454e8208d"
      unitRef="usd">6961000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNTctMy0xLTEtMA_3e98da1f-c24a-4254-9423-f7c9e6321fa0"
      unitRef="usd">1000000</us-gaap:InterestPaidNet>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjAtMS0xLTEtMA_3142ebfb-1a85-4ad4-afc9-698c50c57e96"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjAtMy0xLTEtMA_a1337bf9-5e21-4e07-aac1-36b17a054797"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <ameh:DeferredTaxLiabilitiesAdjustedToGoodwill
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjEtMS0xLTEtMA_b3a4463a-22e7-4dba-8d94-a2002b9f30bb"
      unitRef="usd">0</ameh:DeferredTaxLiabilitiesAdjustedToGoodwill>
    <ameh:DeferredTaxLiabilitiesAdjustedToGoodwill
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjEtMy0xLTEtMA_b125077e-0a73-47ec-9239-c5d5e635fd72"
      unitRef="usd">11540000</ameh:DeferredTaxLiabilitiesAdjustedToGoodwill>
    <ameh:DeferredTaxLiabilitiesWarrantsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjYtMS0xLTEtNzU5MA_175bb186-15d9-4d7a-add1-57dcda1962c3"
      unitRef="usd">473000</ameh:DeferredTaxLiabilitiesWarrantsExercised>
    <ameh:DeferredTaxLiabilitiesWarrantsExercised
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjYtMy0xLTEtNzU5MA_c7b9f2c3-2cc5-480f-ba3c-f7d451b85c91"
      unitRef="usd">0</ameh:DeferredTaxLiabilitiesWarrantsExercised>
    <us-gaap:StockIssued1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjItMS0xLTEtMA_ea7297e4-a7de-4808-9648-58890be02cbe"
      unitRef="usd">0</us-gaap:StockIssued1>
    <us-gaap:StockIssued1
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjItMy0xLTEtMA_289d5d5e-adc4-41ba-86cf-31020a2e0d0f"
      unitRef="usd">414000</us-gaap:StockIssued1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjctMS0xLTEtNzM1OQ_419c5c3a-ce8b-44cc-9352-bc415add72e5"
      unitRef="usd">36179000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjk5OTVmYWFkNTllYzQ3OTZiYTM1OGYyYTlmMGNkZTEwL3RhYmxlcmFuZ2U6OTk5NWZhYWQ1OWVjNDc5NmJhMzU4ZjJhOWYwY2RlMTBfNjctMy0xLTEtNzM1OQ_3bfe10e9-381f-4c68-99c1-bb346ecb0b0f"
      unitRef="usd">0</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMi0xLTEtMS0w_0f06f9fe-af99-4b72-bba1-f4063016a2a7"
      unitRef="usd">103189000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMi0zLTEtMS0w_5a0eca4f-1bac-4a53-9eed-504f70c5be85"
      unitRef="usd">106892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0xLTEtMS0zNDM2_9a52b6bd-8477-419c-9efa-8c0943a47081"
      unitRef="usd">75000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0zLTEtMS0zNDM2_b7b7291a-4a8a-4900-b765-5e3db64fc266"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0xLTEtMS0w_26f33f3f-7919-4531-a2f9-bf59bee324ef"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfMy0zLTEtMS0w_69e5d3ab-fd7f-4f9f-8175-bf8bf005e123"
      unitRef="usd">745000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfNC0xLTEtMS0w_b62794a2-21eb-4c27-bd5c-e2f482e317c6"
      unitRef="usd">104010000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjY1M2U3ZjgyOWYyMjQ5ZjliZDM1OWYwYmU5MjU3MjM3L3RhYmxlcmFuZ2U6NjUzZTdmODI5ZjIyNDlmOWJkMzU5ZjBiZTkyNTcyMzdfNC0zLTEtMS0w_50bc2bd4-82ec-463a-878f-e742b0f40f27"
      unitRef="usd">107637000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMi0xLTEtMS03NzEy_d4027594-f63e-40b6-89a2-8ce7b3d39f9d"
      unitRef="usd">166082000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMi0zLTEtMS03NzEy_07107208-7cde-440a-a35c-9dd1a8d98044"
      unitRef="usd">230299000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMy0xLTEtMS03NzEy_6a40cab9-4a7d-4300-b4a2-2ae1bc94f873"
      unitRef="usd">0</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfMy0zLTEtMS03NzEy_65a1b930-75bb-4237-9c2f-cef39ec7b541"
      unitRef="usd">20000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNC0xLTEtMS03NzEy_3404d14f-b3de-4040-a9e0-54f4c1212557"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNC0zLTEtMS03NzEy_4d6f8fc1-0a90-46d0-aff5-6b1d7672fd28"
      unitRef="usd">746000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNS0xLTEtMS03NzEy_ff524e00-1527-467e-bc7f-d163af89bfd9"
      unitRef="usd">166828000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zMS9mcmFnOmMzMmE5MWNiZjI1YzQ1MzFhZWE4N2U2NTU1YTVmZmQzL3RhYmxlOjhkMjQyMzUwMTBiNjQ3NmE5ZTgyOTY4ZDkwNmM1YmRjL3RhYmxlcmFuZ2U6OGQyNDIzNTAxMGI2NDc2YTllODI5NjhkOTA2YzViZGNfNS0zLTEtMS03NzEy_908b01f5-e576-458f-b87a-691eab3583fb"
      unitRef="usd">231065000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:NatureOfOperations
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTI2NDQzODM3MzQ0NzQ_3c33bdfe-74d9-4363-920f-8bff90b43f77">Description of Business&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Apollo Medical Holdings, Inc. ("ApolloMed") together with its affiliated physician groups and consolidated entities (collectively, the &#x201c;Company&#x201d;) is a leading physician-centric, technology-enabled healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). The Company's NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare &amp;amp; Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#x2019;s physician network consists of primary care physicians, specialist physicians, and hospitalists. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#x201c;HMOs&#x201d;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#x201c;PMPM&#x201d;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (&#x201c;VIE&#x201d;) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#x2019;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AP-AMH Medical Corporation (&#x201c;AP-AMH&#x201d;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#x201c;AP-AMH Loan&#x201d;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#x201c;Certificate of Determination&#x201d;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#x2019;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#x2019;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;APC purchased 15,015,015 shares of ApolloMed&#x2019;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#x2019;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#x2019;s then outstanding shares will be voted by proxy given to ApolloMed&#x2019;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#x2019;s stockholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the series of transaction, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term excluded assets ("Excluded Assets"). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#x2019;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC's ownership in ApolloMed was 32.00% at September&#160;30, 2020 and 32.50% at December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Concourse Diagnostic Surgery Center, LLC (&#x201c;CDSC&#x201d;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of September&#160;30, 2020, APC owned 45.01% of CDSC&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#x2019;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC-LSMA Designated Shareholder Medical Corporation (&#x201c;APC-LSMA&#x201d;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#x2019;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#x201c;LMA&#x201d;), Pacific Medical Imaging and Oncology Center, Inc. (&#x201c;PMIOC&#x201d;), Diagnostic Medical Group (&#x201c;DMG&#x201d;) and AHMC International Cancer Center, a Medical Corporation (&#x201c;ICC&#x201d;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inc. (&#x201c;MMG&#x201d;), Alpha Care Medical Group, Inc. (&#x201c;Alpha Care&#x201d;), Accountable Health Care IPA, a Professional Medical Corporation (&#x201c;Accountable Health Care&#x201d;), and AMG, a Professional Medical Corporation (&#x201c;AMG&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care currently has a network of over 300 primary care physicians and 600 specialty care physicians, as well as one community and regional hospital medical center, that provides quality healthcare services to its members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#x2019;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Universal Care Acquisition Partners, LLC (&#x201c;UCAP&#x201d;), a 100% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#x201c;UCI&#x201d;). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million (see Note 5). As set forth in the Company&#x2019;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#x201c;Proxy Statement&#x201d;), the 48.9% interest in UCI is included in Excluded Assets that remain solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#x2019;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#x201c;NGACO") Model of the Centers for Medicare &amp;amp; Medicaid Services (&#x201c;CMS&#x201d;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. &lt;/span&gt;&lt;/div&gt;AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#x201c;AMH&#x201d;) and Southern California Heart Centers, a Medical Corporation (&#x201c;SCHC&#x201d;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.</us-gaap:NatureOfOperations>
    <ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement
      contextRef="ifd29e64a2dec4d29bab58feb5d6061ad_D19990701-19990701"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMjgxMA_568570d2-ed7b-4d18-b684-30555304516d">P30Y</ameh:InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement>
    <us-gaap:NotesReceivableNet
      contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMzk4OQ_ab6697ce-415f-48a2-b499-6ade00db8133"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i910be3ba7abf4fbb8a6af6dcabd337ac_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDAwNg_7e991669-6cb3-4281-9499-5d434f4e9e29">P10Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableStatedInterestRate
      contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDA5NQ_1f1bf4a2-0918-4535-a690-81c1de16dad8"
      unitRef="number">0.10</ameh:FinanceReceivableStatedInterestRate>
    <ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate
      contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDgxMA_e162704d-d83e-4359-a815-397025b4565c"
      unitRef="number">0.1075</ameh:FinanceReceivableModificationsSubsequentDefaultInterestRate>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i3271ca437f904f76a750501a6a560262_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDg1Nw_97eb4a92-f024-4bc7-a489-77c3d0b95025"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:NotesReceivableNet
      contextRef="iea967cdf5b2f471a892ea4697afe0798_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNDkzMA_2b49a511-e026-4c02-95c6-51abbbbaad4c"
      unitRef="usd">545000000.0</us-gaap:NotesReceivableNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTQ5Ng_b2253b01-0d32-468b-8f0a-df086f0540f7"
      unitRef="shares">15015015</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTU2MQ_af50174f-75ae-444e-92a0-94a51ffa2ba9"
      unitRef="usd">300000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <ameh:StockIssuedDuringPeriodProxyVotesPercentage
      contextRef="i098439fbd5d54baaa3fd94f6a1a5cb25_D20190901-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNTc2NQ_2ce36153-a3f6-49ea-add5-eec0aeca8780"
      unitRef="number">0.0999</ameh:StockIssuedDuringPeriodProxyVotesPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i224fec02c801431e8c5aac9b0b456487_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNjYzMg_2783878b-d049-4331-b307-e22fbf1936bc"
      unitRef="number">0.3200</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic3034d93366647d8945f0fd5c17d5c31_I20191231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNjY0NQ_e11d9cf0-6bb4-4777-8982-48d8837d9076"
      unitRef="number">0.3250</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i31c72a9bb0cb4b81bd7107492b993265_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfNzEzNw_c6958500-6d77-4d96-8500-0c386cf4c358"
      unitRef="number">0.4501</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="i107e7a3c6a6544e99b2eb9a20ca8c10a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfODU2MQ_3b16216f-8951-4af0-add4-f637ffedc19b"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:NumberOfEmployees
      contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTY1OA_1e28d691-00a2-4eb4-95f3-6a0ec254d29a"
      unitRef="primary_care_physician">300</ameh:NumberOfEmployees>
    <ameh:NumberOfEmployees
      contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTY4OQ_68c846be-af6a-42f0-b838-1bf9b950ceea"
      unitRef="specialty_care_physician">600</ameh:NumberOfEmployees>
    <us-gaap:NumberOfStores
      contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTcyMw_fb746505-ef97-499c-8e7f-4847c3deed57"
      unitRef="medical_center">1</us-gaap:NumberOfStores>
    <ameh:NumberOfFederallyQualifiedHealthPlans
      contextRef="i8aab34eff41047a39824b386e77f2ab9_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfOTg0Nw_9501a9e3-1b8a-4183-a250-5e7d7b2e2c94"
      unitRef="plan">3</ameh:NumberOfFederallyQualifiedHealthPlans>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i21eafb5a353445498a87ec5ef991e89a_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAxNTc_7589b6be-5f40-4026-a12e-9edcdfe41867"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAxNjU_baad8924-dbfc-4806-a1db-8b7a607fc120"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <ameh:NumberOfFamilyPracticeClinics
      contextRef="i4cc46814272a4c91b52259eab36012a6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTAyNTE_377c6e8a-bbef-4d24-99bb-17ebb84c7cfb"
      unitRef="clinic">3</ameh:NumberOfFamilyPracticeClinics>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i18773fd9db2d4f019b64dad4ce3bb2ca_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA0OTg_1fe59f91-d392-4607-8721-4d2ca3b165a3"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i4ef9a04a9f264372a8deb57e8aa6633a_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA1NDM_57afce47-dc7f-4922-a3f6-93970fae53c9"
      unitRef="usd">1200000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA1NTg_7eb96260-f429-4f09-bf7f-333378d7dcb2"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="if1d00ff8efb448b7851f3acd7b67c857_I20140630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA2NDg_19f692d5-963d-4d4b-83da-8764b2905926"
      unitRef="number">1</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="ib183d084186d4c5bb6d817ef531b2f3d_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA4MjU_b0e07e83-7eda-4016-a2ef-b4af495647fb"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA5Mjg_d995a725-d78c-4745-b264-2f7abf5afec7"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTA5NTk_4963ebbf-3664-49f6-9ab1-f3d8bc0b5b0b"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
      contextRef="i6fff24e3077f4a3eb1b61025153234f3_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTExNDM_f8e2bb15-2442-49c8-82ab-5be48665d7f8"
      unitRef="usd">36200000</us-gaap:NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTEzNjc_78a9eb70-554c-45ae-98ab-471b788f98b7"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="ib183d084186d4c5bb6d817ef531b2f3d_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8zNy9mcmFnOmI4NGIwZTg1MzJlZDRhNDA4MTgwMGNlOTk4Y2RiMDAzL3RleHRyZWdpb246Yjg0YjBlODUzMmVkNGE0MDgxODAwY2U5OThjZGIwMDNfMTE1MDY_86d99deb-613b-4813-a172-1fe91b8b2a50"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjAzNDA5NjUxNjI4Mzk_37fb2e12-dcb3-424f-862f-eb62b8442901">Basis of Presentation and Summary of Significant Accounting Policies&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheet at December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2020, and for the three and nine months ended September&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;required by Regulation S-X, Rule 10-01. Operating results for the three and nine months ended September&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated balance sheets as of September&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, and APAACO, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#x2019;s subsidiary, UCAP, and APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#x2019;s consolidated subsidiaries Alpha Care and Accountable Health Care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#x201c;MLR&#x201d;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of September&#160;30, 2020, the Company&#x2019;s deposit accounts with banks exceeded the FDIC&#x2019;s insured limit by approximately $321.2 million, including approximately $118.3 million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#x2019;s concentration of risk exposure.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $118.3 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables and Receivables &#x2013; Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of September 30, 2020 and December 31, 2019, the Company had $1.3&#160;million and $2.9&#160;million of allowance for doubtful accounts, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risks&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of September&#160;30, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2020 and 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three and nine months ended September&#160;30, 2020. However, during the three and nine months ended September 30, 2019, the Company recorded impairment of indefinite-lived intangible assets of $2.0&#160;million related to Medicare licenses it acquired as part of the 2017 merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296"&gt;two&lt;/span&gt; performance years through December&#160;31, 2018, which term was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37"&gt;two&lt;/span&gt; additional renewal years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $19.8&#160;million in risk pool savings related to the 2019 performance year, and has recognized such amount as revenue in the risk pool settlements and incentives line of the accompanying consolidated statements of income for the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9 million and $68.4 million in total AIPBP payments for the three and nine months ended September&#160;30, 2020, respectively, of which $14.8 million and $57.3 million has been recognized as revenue for the three and nine months ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#x2019;s method to recognize revenue under ASC 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#x2019;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#x2019;s contract liability balance was $12.3 million and $8.9 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is presented within &#x201c;Accounts payable and accrued expenses&#x201d; in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2020, $0.4 million of the Company&#x2019;s contract liability accrued in 2019 has been recognized as revenue and $8.5&#160;million was repaid to CMS for AIPBP capitation received and not earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Financial Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2020, the Company made a deposit of $4.0 million for future investment opportunities. The deposit was made with cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. The deposit is included in &#x201c;Other assets&#x201d; in the accompanying consolidated balance sheets. Subsequent to September 30, 2020, an agreement was signed converting this deposit into a promissory note from a related party (see Note 17). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU No. 2018-17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-17&#x201d;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU No. 2020-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-01&#x201d;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MjQ_6fd68677-0859-4449-884c-755be88f2b21">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated balance sheet at December&#160;31, 2019, has been derived from the Company&#x2019;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2020, and for the three and nine months ended September&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as &lt;/span&gt;&lt;/div&gt;required by Regulation S-X, Rule 10-01.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MzM_b3bc3376-d615-4b55-b81f-597a78ed2c33">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The consolidated balance sheets as of September&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, and APAACO, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#x2019;s subsidiary, UCAP, and APC&#x2019;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#x2019;s consolidated subsidiaries Alpha Care and Accountable Health Care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All material intercompany balances and transactions have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzI_7aa5cb5a-5971-445e-96cb-3b395f06f56d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#x201c;IBNR&#x201d;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#x201c;MLR&#x201d;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3ODg_7c2206e2-cfb3-467f-a59f-cc1c3bebea4f">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reportable Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTA5OTUxMTY3NjY0Nw_065a669c-6c58-47ab-81af-5bbef143e397"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTA5OTUxMTY3NjY0Nw_e66cc7bf-e0a1-495c-b195-7c22b741d723"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzczMQ_065a669c-6c58-47ab-81af-5bbef143e397"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzczMQ_e66cc7bf-e0a1-495c-b195-7c22b741d723"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjA_a686c9aa-e938-4631-afb1-18a226dfd0dd">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashUninsuredAmount
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDQ4OA_fa1b376e-e85b-4d8f-9ae8-c831f6cecbb0"
      unitRef="usd">321200000</us-gaap:CashUninsuredAmount>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6e5cacd19c684cdbb8845f5fa5d3f343_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDUxNg_5e0f8916-0aa0-4189-80e1-1f992ce403fd"
      unitRef="usd">118300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTg_153beed6-170e-488d-8b31-1887e48d8ea7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTM_969daa57-7831-405f-99cc-c9e407132987">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Marketable Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $118.3 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNTE4NQ_079de614-9832-4e3e-8acf-3045508f951b"
      unitRef="usd">118300000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNTE5Mg_a8bc0180-c5e3-4dcb-a6ee-1e75dc6ee761"
      unitRef="usd">116500000</us-gaap:MarketableSecuritiesCurrent>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjE_b07cc54c-2d26-4fb6-8b0e-ddd7cd486ff6">P4M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:MarketableSecuritiesCurrentMaturityPeriod
      contextRef="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Njg_8393a5ea-0c35-4fd4-8c49-51a0a02f66ed">P24M</ameh:MarketableSecuritiesCurrentMaturityPeriod>
    <ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NjI_a92f37f2-daa2-4edf-8dad-7e565bdb9017">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables and Receivables &#x2013; Related Parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables &#x2013; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#x2013; related parties are recorded and stated at the amount expected to be collected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation and claims receivable relate to each health plan&#x2019;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#x2019;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#x2019;s hospital partners and management&#x2019;s estimate of the Company&#x2019;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#x201c;FFS&#x201d;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.&lt;/span&gt;&lt;/div&gt;Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model.</ameh:ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock>
    <ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjY2OQ_23753f5a-4ce3-4e89-acb5-9e3fa0a7122f">P18M</ameh:RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfODM0MA_0b3e8a97-c451-4da8-85e9-e50dbd0b4bc5"
      unitRef="usd">1300000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfODM0OA_1dc1b8af-b774-460d-af57-f2bff7ee649b"
      unitRef="usd">2900000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTQ_336945ed-7119-4649-b7d5-2cf43605110e">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTk_a6dbc688-2e69-412f-9840-130513a5d232">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,705&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Commercial&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206,567&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medicaid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other third parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;381,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i268f6180d8c0414395a4e02831546f91_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfMy0xLTEtMS0w_86466b34-16e6-4156-b94e-ba50139dcd6e"
      unitRef="usd">25041000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i615fb686511c4f7b9373dcdd32145e20_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfMy0zLTEtMS0w_497f8608-eb1c-476b-96ea-44839e486fc4"
      unitRef="usd">25429000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5300706ef0ee464c80f686cc29fef1eb_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNC0xLTEtMS0w_7ea71c50-ec80-48c2-b19a-6f7d786cb189"
      unitRef="usd">79649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i860551ad800a48b6b48834294a562f6e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNC0zLTEtMS0w_7c1d68e8-fe43-4342-8e5e-70fb73d391a8"
      unitRef="usd">60737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia00916d9e42e4e7598a07cc98c911bba_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNS0xLTEtMS0w_810ec930-be0c-4b82-8334-37db7348f50c"
      unitRef="usd">65849000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59c65958899a4f40b312082b11ad9972_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNS0zLTEtMS0w_14158a51-93ba-4701-ab91-6dde8a462388"
      unitRef="usd">61189000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie48bb7d5e7164c9087e12aebeca47de4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNi0xLTEtMS0w_c24ffccc-8e45-4f1d-a9a7-b65280e148c9"
      unitRef="usd">9584000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i08e72fdfc6d2440f9a7a619f2bfa27a4_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNi0zLTEtMS0w_813fed42-3335-4908-8730-2eea454be1ff"
      unitRef="usd">8705000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNy0xLTEtMS0w_93277b27-544d-492f-8127-cac93d2c7822"
      unitRef="usd">180123000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjdiNTMzZDgwZTlmZDQ3NDM4ZTZiMzU1ODNjMjRmOTFmL3RhYmxlcmFuZ2U6N2I1MzNkODBlOWZkNDc0MzhlNmIzNTU4M2MyNGY5MWZfNy0zLTEtMS0w_a5764889-09da-48ea-9b6e-e23442c21b2b"
      unitRef="usd">156060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia6b08cbba5ce44a6828427adf1d58d41_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfMy0xLTEtMS0w_7ec0272b-8b54-44f8-9f94-34d2152d2ec8"
      unitRef="usd">75233000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice6d7186a3fa42f2aa021e89451d94a6_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfMy0zLTEtMS0w_5eecefed-e6f9-41bd-adb8-5630f7aca2df"
      unitRef="usd">75883000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2df6da5ef4cc4b969a1fe43c3978041b_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNC0xLTEtMS0w_fa9bc63f-ff89-46a9-b7ed-1ef7b5c14434"
      unitRef="usd">206567000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24dff7de3f35477897d40e0ce546c0c2_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNC0zLTEtMS0w_24788d8b-e6d3-471c-9c20-fab8145b8133"
      unitRef="usd">155730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee27b0cd6fa641be9c0346123edc0f7c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNS0xLTEtMS0w_213c554a-524d-478f-a609-91c90f5a92fc"
      unitRef="usd">200746000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6281cd8fd509439da10e97b31b90f99d_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNS0zLTEtMS0w_ca45cdd0-aa62-4117-ab19-1489a6cf6d96"
      unitRef="usd">122837000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8acee0d243214133a46c54e3cafca151_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNi0xLTEtMS0w_78d2cd82-5825-4baa-a842-c98a184c6bbd"
      unitRef="usd">27851000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99ce7ab3879d43af8ed70e1e9d100478_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNi0zLTEtMS0w_98501561-7d3d-4804-bfa0-d8a9bf85d243"
      unitRef="usd">27417000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNy0xLTEtMS0w_73a701e2-24c3-489b-b31b-6ed3407c66a8"
      unitRef="usd">510397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmRkMDVhMjNlZmU5NjQ3NDQ4ZmIyMDJmNDNkZDRiYWQ5L3RhYmxlcmFuZ2U6ZGQwNWEyM2VmZTk2NDc0NDhmYjIwMmY0M2RkNGJhZDlfNy0zLTEtMS0w_3c33c483-033b-4e7f-bbed-8e5232611cf9"
      unitRef="usd">381867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzA_13fe774b-9b65-472c-9dd5-fe3d27d6e387">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed the following percentages of net revenue:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor C&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total net revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had major payors that contributed to the following percentages of receivables and receivables &#x2013; related parties:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payor G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#x2014; related parties, net&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1864ede366d9428596f507b1ccdf3055_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfMy0xLTEtMS0w_3afcba3f-f687-44b3-86c0-8ae17ae53632"
      unitRef="number">0.127</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic009ac2508fe4ddb8d41e1d789d89e2c_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfMy0zLTEtMS0w_222545d6-2dfd-4b09-905d-634ad0a7e6ad"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7ebbea39beeb486097293272d98df046_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNC0zLTEtMS0w_17343a68-8959-4b3c-8c51-d67a8d16bfcd"
      unitRef="number">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i35e09b32dfa2485098765d8342e2c09d_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNi0xLTEtMS0w_c98d2eef-1368-42c1-af52-8542f9258d84"
      unitRef="number">0.162</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i41254baa0b494543874e77b5b65806dd_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNi0zLTEtMS0w_064cd30f-1f6a-4b43-886f-1bf9424b4baa"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5db53e7069624847940f8b01072d1616_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNy0xLTEtMS0w_bbfa22c9-d9eb-41e5-b4c7-ff4c831cc067"
      unitRef="number">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50b5b61eb68b440ca6b1f08ae563dd55_D20190701-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmMzMjYzYjgyODZkYTQxYWU4OTdlMzE0MmZiNGYwMzdmL3RhYmxlcmFuZ2U6YzMyNjNiODI4NmRhNDFhZTg5N2UzMTQyZmI0ZjAzN2ZfNy0zLTEtMS0w_d22af0d5-6f68-46c8-bbeb-6f74c5d421c5"
      unitRef="number">0.199</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if0c8e4a29ed643d2812e326a13329643_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfMy0xLTEtMS0w_0ab8b378-6646-4820-b192-7fd12fb53eae"
      unitRef="number">0.121</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i215eb1833be2440ab91be38ab300819f_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfMy0zLTEtMS0w_839e86c2-4341-4582-9bc2-f83cf482b582"
      unitRef="number">0.143</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie685084fafd04aabac97138d7d7c72a0_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNC0xLTEtMS0w_1c5772b3-1123-49bc-bcf6-0ebe0c269b1f"
      unitRef="number">0.101</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d1826880923498084158c89cee6e00a_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNC0zLTEtMS0w_6b15bcca-8b00-4385-a55e-9fd4404d3ad8"
      unitRef="number">0.133</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i50ba8e183602464480aebab3b80942ca_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNS0zLTEtMS0w_7033f552-bf4e-465d-b95e-328bb4d0cecc"
      unitRef="number">0.100</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i1f060ecdde4a4705b9409b06aa972c41_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNi0xLTEtMS0w_d5fb6241-d19d-4068-bdaf-ba8b8ea4e097"
      unitRef="number">0.170</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id59a584c780448de8be355c36a29f7cd_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNy0xLTEtMS0w_c8d9c0d6-e039-48d9-8952-5ac530519a16"
      unitRef="number">0.142</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i14a8fdcc013f4900b6aada4fc3f7af4a_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOmFhMTdkMTUzMmRkZTQxYmU5Y2Q3OWE5OGQ5ZGNhOTliL3RhYmxlcmFuZ2U6YWExN2QxNTMyZGRlNDFiZTljZDc5YTk4ZDlkY2E5OWJfNy0zLTEtMS0w_c28719bf-5fdf-4bf4-8777-aa0ac52df9a5"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0dd1feb4e50b4175a4e88a4badb5cb45_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMi0xLTEtMS0w_c2dd557f-37ed-439c-9508-f785179075a8"
      unitRef="number">0.167</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i6e3e458d85614c56bb255ed53fb55e0a_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMy0xLTEtMS0w_238e14ff-477f-4062-b69d-d8171b1ce415"
      unitRef="number">0.325</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i93b93d2a3bdc45dea0ee9e341a282b8a_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfMy0zLTEtMS0w_bcc8d5c4-8969-4b65-a99b-66e64d71ed2f"
      unitRef="number">0.304</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib26496fe9ee64c8ea436ec54656e23b8_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfNC0xLTEtMS0w_2036bc9f-e2f4-4520-9a22-5a214830e064"
      unitRef="number">0.292</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if626b3c6137241b29c016703d18f7fb1_D20190101-20191231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjlhMDEyNzViYTAzNzQ5ZTY4N2NkYzhiMDI1ZWQ1MzVkL3RhYmxlcmFuZ2U6OWEwMTI3NWJhMDM3NDllNjg3Y2RjOGIwMjVlZDUzNWRfNC0zLTEtMS0w_581f59d4-6908-457d-8c4a-e34f1d4e5a88"
      unitRef="number">0.360</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Nzk_f63a53f3-9e44-4f6c-8351-f6ce0b65eeeb">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Accounting Standards Codification (&#x201c;ASC&#x201d;) 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 820&#x201d;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This hierarchy prioritizes the inputs into three broad levels as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level&#160;3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#x2019;s own data.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTA_29baa4a7-fc32-40e1-b1f9-de60b5dbafb6">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of September&#160;30, 2020, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Money market funds*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and fair values of the Company&#x2019;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds*&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116,469&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities &#x2013; equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&#160;&#160;&#160;&#160;Included in cash and cash equivalents&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i142ee7c619bb459289d0d37e04512563_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy0xLTEtMS0w_874e6c84-cd74-43d5-8eb3-d12cf4cfbac3"
      unitRef="usd">115039000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy0zLTEtMS0w_6940cf7e-332e-4d72-8db7-bcc29d60247a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy01LTEtMS0w_95901217-32a8-4d6d-8b2e-9edaf45d7663"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfMy03LTEtMS0w_99e9b74a-0e63-4fb3-a941-a4f2febfda68"
      unitRef="usd">115039000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i142ee7c619bb459289d0d37e04512563_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC0xLTEtMS0w_c49e813f-ce9c-49b2-a68a-2a74491a742e"
      unitRef="usd">118262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC0zLTEtMS0w_6acbb94a-f466-46f9-a622-be1e4da801d8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC01LTEtMS0w_8b85b496-adab-4063-82d1-ff84bc032268"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNC03LTEtMS0w_57759a9b-0c49-408f-a8af-86edfbb7d5d4"
      unitRef="usd">118262000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i142ee7c619bb459289d0d37e04512563_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS0xLTEtMS0w_a9d48094-e7c7-4d97-bae7-71fef600f25a"
      unitRef="usd">47000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS0zLTEtMS0w_9684643d-7262-4438-b9a0-4a0e3b2dbe26"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS01LTEtMS0w_b69294d8-3e46-429f-9467-ddf19cff6ff4"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNS03LTEtMS0w_816f8841-500b-4731-95df-9a13c6229fb3"
      unitRef="usd">47000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i142ee7c619bb459289d0d37e04512563_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy0xLTEtMS0w_15604fe3-baba-4d23-9570-45929ecf60f9"
      unitRef="usd">233348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3f75399fdeea49b5b9bcb8f0e226e89b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy0zLTEtMS0w_8d6da762-7ddb-4f4f-9a3f-9b25ef0285fd"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i2b7656f6e67342e29f677b7a1e65c532_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy01LTEtMS0w_207c8922-61c0-45e0-94b1-61b2ecbc3be7"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjI5ZDg0ZTJkNTBiYTQ1M2Q4N2JmYmQ1N2I2NjU5OGE2L3RhYmxlcmFuZ2U6MjlkODRlMmQ1MGJhNDUzZDg3YmZiZDU3YjY2NTk4YTZfNy03LTEtMS0w_b72c78b2-6f1f-4dce-a513-8ca1f49277a7"
      unitRef="usd">233348000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i742706889d86455a834aaba86ebe626d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy0xLTEtMS0w_26a79772-a8df-4e92-9336-3d07556b6d29"
      unitRef="usd">50731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy0zLTEtMS0w_fc32dbdd-7dcd-4e99-bb13-af14df2409d4"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i116b3e9585e9410a873b90bb05603771_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy01LTEtMS0w_49fc2337-0b9d-4293-a18b-5c46479887b8"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfMy03LTEtMS0w_d2af6d1d-b862-4517-b5aa-9f0280b7cab9"
      unitRef="usd">50731000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i742706889d86455a834aaba86ebe626d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC0xLTEtMS0w_75926a9e-5572-4501-85f3-57cf97825f95"
      unitRef="usd">116469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC0zLTEtMS0w_0f0f7c57-9515-441d-b56a-a64b3d1c1203"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i116b3e9585e9410a873b90bb05603771_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC01LTEtMS0w_84362ba7-ba4f-4334-a249-cc0e6e1c2c29"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNC03LTEtMS0w_bc8f29b6-405f-4312-a855-fbedc8f35c37"
      unitRef="usd">116469000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i742706889d86455a834aaba86ebe626d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS0xLTEtMS0w_ec91e761-93ba-454d-8105-ef1543511d2c"
      unitRef="usd">70000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS0zLTEtMS0w_c779f7c6-54f8-4d92-8eab-320e86d462f2"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i116b3e9585e9410a873b90bb05603771_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS01LTEtMS0w_331fe2ab-f8fe-40cd-ab8c-84826a5fbe3b"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNS03LTEtMS0w_9d4ef662-5d44-4546-bf8d-01875899af80"
      unitRef="usd">70000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i742706889d86455a834aaba86ebe626d_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy0xLTEtMS0w_8dab6687-9316-43c3-a4c6-f75ec50db653"
      unitRef="usd">167270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i69df776760514fe6a9114b9121a87a7c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy0zLTEtMS0w_d38f2f9a-f849-4817-b27f-4222274ce94a"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i116b3e9585e9410a873b90bb05603771_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy01LTEtMS0w_9c2977da-503a-458c-b2f4-68e037a07ea3"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RhYmxlOjBmNzZmZGZjOGM4ZDQ1ZDE4NGJmNTc4YThkZTllNmQ5L3RhYmxlcmFuZ2U6MGY3NmZkZmM4YzhkNDVkMTg0YmY1NzhhOGRlOWU2ZDlfNy03LTEtMS0w_ec6ceff2-d192-430c-b005-20292e96e662"
      unitRef="usd">167270000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NDY_edb9f029-3d66-4156-8366-faf59f401cea">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.&lt;/span&gt;&lt;/div&gt;Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_9ccb6466-a5a3-422d-a064-2a066f55a798"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_a903edc0-bb16-40e2-9af8-66bf1a1cf3ed"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_e2bdb628-7f59-49f5-840f-6e54b35896e3"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTMwNDQ_e5bc6d17-2b74-4731-ac90-a2873fc4b673"
      unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MjU_37701e8d-259b-400d-a9ea-1e7e75b84974">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill and Indefinite-Lived Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under ASC 350, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles &#x2013; Goodwill and Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, at the Company&#x2019;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#x2019;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#x2019;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:NumberOfReportingUnits
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTM3Nzg_a7c9904d-1f42-4f14-8ca1-c501d8ed9333"
      unitRef="unit">3</us-gaap:NumberOfReportingUnits>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_a4cb3c84-56d8-48ca-992e-23991c37bb17"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_aad936eb-69ec-45a3-a4b9-9c54114c21e0"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_c2b1e653-8196-4518-9359-0de2f6fad110"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTUxMDY_d99344e3-7f71-4d65-91cb-78f81ae5dacf"
      unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNDY_246b9f59-ee63-4b15-8525-4c47ff6ec6ac"
      unitRef="usd">2000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNDY_a98cd687-b664-4499-9133-80efaeb25e4f"
      unitRef="usd">2000000.0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NTA_f6d5788d-8ca5-4379-aa77-bc35a03cb277">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Other Entities &#x2014; Equity Method&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#x2019;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#x2019;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#x201c;Income (loss) from equity method investments&#x201d; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in Privately Held Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy>
    <us-gaap:HealthCareCostsPolicyPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NDc_95588d5d-758d-4a96-9ce5-5c43a904d1c7">&lt;div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</us-gaap:HealthCareCostsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjAzNDA5NjUxNjI4NDE_f331f7c1-fd12-4308-a347-13bd78abefc1">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Nature of Services and Revenue Streams&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#x201c;AIPBP&#x201d;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#x2019;s billing arrangements and how revenue is recognized for each.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Capitation, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#x2019; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#x201c;Risk Adjustment&#x201d; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#x2019;s net PMPM transaction price relates specifically to the Company&#x2019;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Pool Settlements and Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#x2019;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#x2019;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#x2019; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#x2019;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to risk-sharing revenues, the Company also receives incentives under &#x201c;pay-for-performance&#x201d; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#x2019;s incentives under &#x201c;pay-for-performance&#x201d; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#x2019;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NGACO AIPBP Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APAACO and CMS entered into a NGACO Model Participation Agreement (the &#x201c;Participation Agreement&#x201d;) with an initial term of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296"&gt;two&lt;/span&gt; performance years through December&#160;31, 2018, which term was extended for &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37"&gt;two&lt;/span&gt; additional renewal years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&#x2019;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#x2019;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#x2019;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#x2019;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#x2019;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $19.8&#160;million in risk pool savings related to the 2019 performance year, and has recognized such amount as revenue in the risk pool settlements and incentives line of the accompanying consolidated statements of income for the three and nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9 million and $68.4 million in total AIPBP payments for the three and nine months ended September&#160;30, 2020, respectively, of which $14.8 million and $57.3 million has been recognized as revenue for the three and nine months ended September 30, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Management Fee Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides a significant service of integrating the services selected by the Company&#x2019;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#x2019;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#x2019;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#x2019;s performance obligation is satisfied as the Company completes each period&#x2019;s obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#x2019;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#x2019;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fee-for-Service Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#x2019;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#x2019;s billing center for medical coding and entering into the Company&#x2019;s billing system and the verification of each patient&#x2019;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#x2019;s billing systems, as well as an estimate of the revenue associated with medical services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#x2019;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#x2019;s method to recognize revenue under ASC 606 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from the previous accounting guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#x2019;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#x2019;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#x2019;s contract assets are comprised of receivables and receivables &#x2013; related parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Liabilities (Deferred Revenue)&lt;/span&gt;&lt;/div&gt;Contract liabilities are recorded when cash payments are received in advance of the Company&#x2019;s performance, or in the case of the Company&#x2019;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i2d04d4b89dd2456bab5a43914120ef3d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjExNDA_de0c0da6-0dda-4507-88b8-0bfc638b0510">one year</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjk5MDM_51a193e1-7bfe-4887-a070-d7029382dcfa">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzAxNjM_c6b547a3-124b-469f-9db7-383322fce12b">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport
      contextRef="i1baaafbe16c8403fad186d2ecf758754_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzAyODY_c6b547a3-124b-469f-9db7-383322fce12b">P30D</ameh:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport>
    <ameh:RiskPoolSettlement
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNjA_33156231-ee16-4169-aa2f-8d91a34774f3"
      unitRef="usd">19800000</ameh:RiskPoolSettlement>
    <ameh:RiskPoolSettlement
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMTIwOTQ2Mjc5NTYzNjA_dc49cf21-7c8a-4ac4-87c7-84e32ca9a39a"
      unitRef="usd">19800000</ameh:RiskPoolSettlement>
    <ameh:PaymentOfRevenueMonthlyAmount
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYwNg_6636e966-dfc0-4b32-9262-e0fd9d518395"
      unitRef="usd">7600000</ameh:PaymentOfRevenueMonthlyAmount>
    <ameh:PaymentOfRevenue
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYxNg_ff34f8cf-601e-4dec-a734-39902dee9598"
      unitRef="usd">22900000</ameh:PaymentOfRevenue>
    <ameh:PaymentOfRevenue
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzE5NDY_7893fd96-64fe-4da5-a8ec-01b178246b99"
      unitRef="usd">68400000</ameh:PaymentOfRevenue>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNjU5NzA2OTgxNTYyMA_1c09f405-e924-42a4-9700-e7d4cf92d5d8"
      unitRef="usd">14800000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzIwNDE_02bf8e8c-2a45-4c6c-b4aa-3d3069ec1bc3"
      unitRef="usd">57300000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:RevenuePerformanceObligationDescriptionOfTiming
      contextRef="i011b6c6b63c84878bb34a810a3c77aaa_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMzQ2MjU_97fce091-b5d5-40c6-ab9d-4fe08e1cd2ec">10 years</us-gaap:RevenuePerformanceObligationDescriptionOfTiming>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDExMDA_5c6d35d8-d6c7-4516-afa4-7ac74b3dee40"
      unitRef="usd">12300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDExMDc_667405f7-9d47-4e6c-8d4c-88254e6e205d"
      unitRef="usd">8900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="id33eaefc8b5942e9b470aa4f9c9fbf0d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDEyODY_e900532a-5aed-4ee9-9fbe-11a84cccc6c5"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfOTM0NTg0ODg4NTAwOA_84683485-9cb2-47b7-b141-c3ecf763e1d0"
      unitRef="usd">8500000</ameh:ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned>
    <ameh:InvestmentDeposit
      contextRef="i04e6f52d6af84990b66fae85e26f4b3e_I20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDE1MTk_c33f17b0-3171-4b6d-ada4-ed451fe895c3"
      unitRef="usd">4000000.0</ameh:InvestmentDeposit>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3MzI_a9832a30-5cb0-4db9-9eea-23c7d19799a4">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3Mjg_7e6c630f-be2f-4545-b82d-c3cab26b0289">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#x2019;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg4MDI_6d5af10b-046f-4891-9bf3-ed779eaea295">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basic and Diluted Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net income attributable to holders of the Company&#x2019;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <ameh:MinorityInterestPolicyPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzU_8da5e67c-b641-4d3a-a5ba-d457373751e0">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interests&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#x2019;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</ameh:MinorityInterestPolicyPolicyTextBlock>
    <us-gaap:VariableInterestEntityOwnershipPercentage
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDQ1MDA_72d77595-7d8e-42da-9195-ae939745ad47"
      unitRef="number">0.50</us-gaap:VariableInterestEntityOwnershipPercentage>
    <ameh:TemporaryEquityPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3NzY_061a1256-3222-40e1-9180-6c962edd7bd3">Mezzanine EquityPursuant to APC&#x2019;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.</ameh:TemporaryEquityPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfNDg3OTQ_8cc88d42-6e4e-4c2c-8011-33773388c51d">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2016-13&#x201d;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, the FASB issued ASU No. 2018-17, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2018-17&#x201d;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASU 2019-12&#x201d;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the FASB issued ASU No. 2020-01, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2020-01&#x201d;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#x2019;s financial position, results of operations and cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE2OQ_c0341e20-f75d-4435-8caf-d81e822d3892">Business Combinations and Goodwill&lt;div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Alpha Care Medical Group, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of September&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accountable Health Care, IPA, a Professional Medical Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising 75%) in Accountable Health Care in exchange for $7.3 million. In addition to the payment of $7.3 million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which have been eliminated upon consolidation and contributed the 25% investment totaling $2.4 million, total purchase price was $25.1 million (see Note 5). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subordinated loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net asset acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment contributed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;AMG, a Professional Medical Corporation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company acquired AMG in September 2019, for total consideration of $1.6&#160;million, of which $0.4 million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#x2019;s consolidated net assets, investments and net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company acquired have been included in the Company&#x2019;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill is not deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the nine months ended September&#160;30, 2020, was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTQw_aee66529-8a56-44da-815d-8948c5d4a8e7"
      unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMjQ4_8ed6402f-ba90-4dc9-8109-375ce0154671"
      unitRef="usd">45100000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:EscrowDeposit
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzQ2_c2262f92-987d-43b5-bb71-5cf6e1a38bed"
      unitRef="usd">2000000.0</us-gaap:EscrowDeposit>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE3MA_2429c8f4-bd80-4598-9fe2-e0d26bd790e7">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,795)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,616)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;Assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Network relationship intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,154)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subordinated loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,327)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net asset acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investment contributed&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMi0xLTEtMS0w_d41574e1-110e-4e94-b6e1-1f0238736c20"
      unitRef="usd">3569000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMy0xLTEtMS0w_aea8b6fa-d14f-41b8-a408-ddc6e8f964cf"
      unitRef="usd">10336000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNC0xLTEtMS0w_60ee025e-a3f7-48ad-a2fa-942d4430d8c8"
      unitRef="usd">4675000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNS0xLTEtMS0w_7e72f4de-b0f7-4768-bc36-c898e70166bc"
      unitRef="usd">22636000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNi0xLTEtMS0w_37b22485-ec56-474b-be1a-90605b4dd2ea"
      unitRef="usd">28585000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfNy0xLTEtMS0w_e0e58a81-7993-4184-ae83-3e619e77a896"
      unitRef="usd">2795000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfOC0xLTEtMS0w_f0c009e8-6d9a-459b-a584-d6509429e7a3"
      unitRef="usd">6334000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfOS0xLTEtMS0w_b844f018-d466-4257-bdcc-5d6269b2e1b7"
      unitRef="usd">15616000</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i7dc6fc1c89564c609ad41bc7cd83477a_I20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMTAtMS0xLTEtMA_a9066b23-4f0b-4cfe-a59a-02fa288fdbcc"
      unitRef="usd">45056000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ibc5ab682990b4acbac0334f7e3d2903d_D20190531-20190531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOjIyYmViYTVkZjk0MDQ2NjBiZDc3YzcwYTBlODU5YzI1L3RhYmxlcmFuZ2U6MjJiZWJhNWRmOTQwNDY2MGJkNzdjNzBhMGU4NTljMjVfMTItMS0xLTEtMA_cb4b2ca4-47bc-401f-b138-d6d9b596e5a3"
      unitRef="usd">45056000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="id0a2c6ac04aa49da8a227305158f0d54_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTAzNA_73f26c6f-d6d1-4da6-86c1-aae9aed09159"
      unitRef="number">0.75</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTA4MQ_baad8924-dbfc-4806-a1db-8b7a607fc120"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ia8fc49f8dfaf4572af4b9e12d6972dd1_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTExNQ_baad8924-dbfc-4806-a1db-8b7a607fc120"
      unitRef="usd">7300000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i400a89eea72d482f927a72d7ad593718_I20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTIyOA_16ae66dd-6324-4985-a4ec-7b88be80f98d"
      unitRef="usd">15400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ic57f99e455f748c7bd9f72d18cb3b19e_I20190830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTI5OA_65a6cd2d-1444-4f3d-8ddc-0b797c23d4ef"
      unitRef="number">0.25</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="if2f44f37c4f54616bb326a86f03405a3_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTMyMQ_92f73629-eeab-4524-bce4-ab6db4b3914e"
      unitRef="usd">2400000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="if23b273bb3224911ad4440101430e675_D20190830-20190830"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTM1MA_a94031dc-0435-46ed-92bc-1f359781001f"
      unitRef="usd">25100000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMi0xLTEtMS0w_9dafd207-b69e-40c5-a31d-349056897a10"
      unitRef="usd">582000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMy0xLTEtMS0w_e98cab85-da4a-46f7-9ae7-92445c35794a"
      unitRef="usd">5150000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNC0xLTEtMS0w_69982953-b1a0-4630-87d2-b09db162c641"
      unitRef="usd">198000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNS0xLTEtMS0w_61dcf3fc-92cd-4ab8-a6e7-86d08f80f408"
      unitRef="usd">11411000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNi0xLTEtMS0w_b45635cb-52db-4da6-9ec7-7d3bf354d12c"
      unitRef="usd">23566000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfNy0xLTEtMS0w_36777a83-e32f-488d-8a3d-640b062d2c82"
      unitRef="usd">3759000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfOC0xLTEtMS0w_759d8807-b8eb-4af3-b93a-14f1414624b3"
      unitRef="usd">12154000</ameh:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfOS0xLTEtMS0w_eed47a76-59d6-40c2-831b-15c566b75329"
      unitRef="usd">15327000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTAtMS0xLTEtMA_04b3dc76-c4ce-4d86-b34c-236a51e83824"
      unitRef="usd">9667000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned
      contextRef="i275a644f4ba94748b1661c63ce54b8bb_I20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTItMS0xLTEtMA_4d8c6ca5-5f0c-4604-b2d3-daba9199f93c"
      unitRef="usd">2417000</us-gaap:BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i898462389ad24c0b8913adf6b0b29a3b_D20190830-20190830"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmI1MjY4NDkzNWVmNjQ0MDY4MTUxNjBiM2JlYzNhZGNiL3RhYmxlcmFuZ2U6YjUyNjg0OTM1ZWY2NDQwNjgxNTE2MGIzYmVjM2FkY2JfMTMtMS0xLTEtMA_68739251-6798-4709-9dff-6520f6e90161"
      unitRef="usd">7250000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="ic4dc99a0ca2e4bfbabef2c87ec9306d0_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfOTM0NTg0ODgzOTMxOQ_f40591e4-a01f-4e7c-a050-406fbc70561f"
      unitRef="usd">1600000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="i56fc72924ddd434bb0007e80a4e7a89b_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMTY0Mw_46e8d4de-c9ff-4eb9-9b67-8dd18f217aff"
      unitRef="usd">400000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RleHRyZWdpb246ZWI2ZTlmOGY5N2MzNGMyZmJlOTUzM2VmNGYwZGYyY2FfMzE2Mg_536ed548-eb3e-4acb-be5d-0210f4c1487d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The change in the carrying value of goodwill for the nine months ended September&#160;30, 2020, was as follows (in thousands);&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.398%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, January 1, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;238,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMC0xLTEtMS0w_3044ed8c-993a-44d7-8b96-6c07fb1ce29e"
      unitRef="usd">238505000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMS0xLTEtMS0w_876c1a3e-6d3a-48f9-bc33-c426ea906291"
      unitRef="usd">548000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80My9mcmFnOmViNmU5ZjhmOTdjMzRjMmZiZTk1MzNlZjRmMGRmMmNhL3RhYmxlOmRkNTE4YjhiZTY2YzQwMDU4NTExNDI4YTBiZmRjNzhiL3RhYmxlcmFuZ2U6ZGQ1MThiOGJlNjZjNDAwNTg1MTE0MjhhMGJmZGM3OGJfMy0xLTEtMS0w_0c9a9bc6-eb6c-43fb-817d-19a9310ea196"
      unitRef="usd">239053000</us-gaap:Goodwill>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTY2_e986e8b3-8d3f-44a5-9e37-8edfded858b5">Intangible Assets, Net&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2019, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $4.0 million and $4.3 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $12.3 million and $12.1 million for the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTcx_e5711d41-261c-4dd8-a3ee-1eafa13b274e">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2020, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.028%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.865%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(85,748)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2019, the Company&#x2019;s intangible assets, net, consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.759%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.134%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Useful&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Life&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net December 31, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortized intangible assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Network relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11-15&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,676)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Member relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,352)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Patient management platform&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trade names/trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73,517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i3bf488f66af84851b3c1d0a9fe304793_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0xLTEtMS0wL3RleHRyZWdpb246ZDU0ZTU3ODhkYjExNDEwNDljNzVlYjc5MWZkOGUwOWJfNA_17798ee1-eef2-4ef6-8f4c-617a45a8fb92">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic1f29d2703f749699c41aad0f5b9c7e0_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0xLTEtMS0wL3RleHRyZWdpb246ZDU0ZTU3ODhkYjExNDEwNDljNzVlYjc5MWZkOGUwOWJfNw_320edf64-be54-4a0e-a279-d31acd5c33be">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi0zLTEtMS0w_2ec3b676-9feb-410b-97fd-936ece5e251a"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi01LTEtMS0w_30081c29-990e-42fd-8d02-b04626713f05"
      unitRef="usd">70200000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i7694ec30545c4fcdb3e6691905656166_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMi03LTEtMS0w_add0cb69-0271-49f2-afc5-da7b6878bbef"
      unitRef="usd">73730000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ib036147d021e4632a938ef95e13bcfeb_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy0xLTEtMS0w_4c28c713-8433-450a-aab7-2fa6a9dee865">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy0zLTEtMS0w_305adb84-cd4d-4c15-a86f-7d5b634b885d"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy01LTEtMS0w_4c46cc3b-38ea-4f90-9d9e-3208a8d8e45e"
      unitRef="usd">11225000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i47f47905931645f2843f1d0f1c953fd4_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfMy03LTEtMS0w_b344af8e-9657-4200-b3ec-06c4195a6880"
      unitRef="usd">11607000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i22a3823bc30347e1bc4a4696c1657ad2_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC0xLTEtMS0w_0dbe35d0-a62a-48d2-8b9c-afa2e098aa7f">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC0zLTEtMS0w_a4ff1e2e-cae1-4d7e-8348-84b4624d644b"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC01LTEtMS0w_56591dbc-48f0-4da6-9e40-7fe8209df20c"
      unitRef="usd">3013000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if29bb5f2be9646a1b77a64b7724af7d0_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNC03LTEtMS0w_dc7361cc-129f-4e79-bf9f-315817e2e2ad"
      unitRef="usd">3683000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i8806313e53624b498a37f7e03713bd8f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS0xLTEtMS0w_f7bdde1d-f694-4209-a0c7-e98af80ce131">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS0zLTEtMS0w_282cfd5a-1b7e-48a7-84d1-2822498e6cb3"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS01LTEtMS0w_d8d6fe1c-613b-4553-9a5d-dc71f9fc2c49"
      unitRef="usd">1167000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i91299a0c3df14bb0912f70e6b0c32101_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNS03LTEtMS0w_4a543329-621a-4305-8fed-d9d40dd405f0"
      unitRef="usd">893000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i820337c646004760a5fd30654c3dae01_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi0xLTEtMS0w_e67625d3-c0d9-4406-ba2e-d984bafa22d8">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi0zLTEtMS0w_9846d0a5-73bc-4a56-a7a0-5f6c1f8018bf"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi01LTEtMS0w_a7dff1a1-c5bd-4040-9f40-44d16d155927"
      unitRef="usd">143000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i307aff6d7c74455f8c12990d253efcfd_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNi03LTEtMS0w_56ac0aef-a455-44c8-92e8-c2caaba85003"
      unitRef="usd">868000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy0zLTEtMS0w_3f3461be-333d-4577-90e2-d1893cda18e9"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy01LTEtMS0w_79ed8ca0-e2b7-4886-aba0-4e649ed5be8f"
      unitRef="usd">85748000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjdkZTk1M2IwN2UxMzQzYjdhYzMyYzg3NTg4MDVmN2E0L3RhYmxlcmFuZ2U6N2RlOTUzYjA3ZTEzNDNiN2FjMzJjODc1ODgwNWY3YTRfNy03LTEtMS0w_98907028-034c-4a7b-a0dc-68edd1efad43"
      unitRef="usd">90781000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i57399d018d8249a39d4044e5041d9d91_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0xLTEtMS0wL3RleHRyZWdpb246ODRhZTQyMjgyNWJjNDBlYWIzNGExNWNmOTFjOTc2YjVfNA_e9802f41-9c5e-4808-8cad-ebfd5671c0ff">P11Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iec82f37386d54fcc9539d0fee4b55ef6_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0xLTEtMS0wL3RleHRyZWdpb246ODRhZTQyMjgyNWJjNDBlYWIzNGExNWNmOTFjOTc2YjVfNw_658dae86-58ac-4477-9f1f-47154a11f39a">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2b3382bb05604a72853736390f8d222c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi0zLTEtMS0w_93688f00-0b27-4b28-be4e-d83ff8cb7608"
      unitRef="usd">143930000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2b3382bb05604a72853736390f8d222c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi01LTEtMS0w_e02fbc3f-955e-4ebd-8805-b750b3567a76"
      unitRef="usd">60526000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2b3382bb05604a72853736390f8d222c_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMi03LTEtMS0w_c4b9f7d9-91cd-4c74-a26a-a58f8477241f"
      unitRef="usd">83404000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id9572fe44439456b89540528dafe8efe_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy0xLTEtMS0w_2f9f1482-6650-4f56-8158-6a6cb51ac14b">P15Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy0zLTEtMS0w_e434208b-0d98-4442-ac10-d551694e2cc4"
      unitRef="usd">22832000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy01LTEtMS0w_96720fc6-fdac-4483-8d6a-3b5f7a2ecabb"
      unitRef="usd">9676000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i155d3af50fd548b19a0650fe1f943242_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfMy03LTEtMS0w_3a29238b-916e-485f-ac21-6f34c3da2e9a"
      unitRef="usd">13156000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ic8c4d20368234add91f91bbc581e9c85_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC0xLTEtMS0w_72b14be5-6cf2-4b82-a3b9-d7895749a28c">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC0zLTEtMS0w_ec8a733a-1633-401e-8f16-70f0a3dfccd7"
      unitRef="usd">6696000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC01LTEtMS0w_9e5c6ec0-d886-4294-98a1-ebf2b5144963"
      unitRef="usd">2352000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ic34de72bdcc94d44ac64fc0eb3296e8a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNC03LTEtMS0w_4a3a1df3-a247-4823-a813-eb55c5ee65fd"
      unitRef="usd">4344000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i87f4db5982be4abd98dbc5f29cd0da48_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS0xLTEtMS0w_55fb93bf-4af3-4363-ba57-867f2c267283">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS0zLTEtMS0w_62f4b576-854c-4e50-9247-c864eb428d0c"
      unitRef="usd">2060000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS01LTEtMS0w_28ad5bf9-4579-4205-811c-d0caa746e113"
      unitRef="usd">858000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i5b58660aaa264d22a46c25bb967a0695_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNS03LTEtMS0w_728519c7-0e3d-48ac-8fac-4fd88a804bce"
      unitRef="usd">1202000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i7f579d4160604e7babd882b0c0d2df3d_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi0xLTEtMS0w_7b6489ce-5bbb-4458-be18-06d0d490e7a6">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i687f8eb4581848cba1db329c2d343353_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi0zLTEtMS0w_241d03f2-4afa-4fdd-8f63-e147afc0d965"
      unitRef="usd">1011000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i687f8eb4581848cba1db329c2d343353_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi01LTEtMS0w_9361402e-c3e2-431d-bd92-122c83f6befb"
      unitRef="usd">105000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i687f8eb4581848cba1db329c2d343353_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNi03LTEtMS0w_d2f8b6b8-d69d-4c2d-882a-7eba60735b05"
      unitRef="usd">906000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy0zLTEtMS0w_a5342764-52b4-409a-8673-a604155612e6"
      unitRef="usd">176529000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy01LTEtMS0w_5803faa7-4c3e-4372-b672-1a7992c4e8d4"
      unitRef="usd">73517000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjNkOTk4MmI4N2I0MTRmZGU5ZDQ1NDk4ZGE1ZmE5ZjEzL3RhYmxlcmFuZ2U6M2Q5OTgyYjg3YjQxNGZkZTlkNDU0OThkYTVmYTlmMTNfNy03LTEtMS0w_92d6e544-a85a-46e0-927b-c1ac63526c51"
      unitRef="usd">103012000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzM1_fbeb1052-3388-4ed4-83b4-010b424d9dee"
      unitRef="usd">4000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzQy_187f4474-17db-4881-a66b-6d9cd5cc2168"
      unitRef="usd">4300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfMzk4_f43636ed-c043-467a-a41d-0e03dbf7b22c"
      unitRef="usd">12300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNDA1_c1e372c1-50fa-48ae-bbe3-44b6117c3d91"
      unitRef="usd">12100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RleHRyZWdpb246MjBkMTYyYTg5OWJkNDZiOWJiMGQwZjI3NGViNjc5NzRfNTc0_c2f38c3e-c5a8-4bf3-aad9-924ffc970e48">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.162%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.638%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfMi0xLTEtMS0w_5523a78f-5102-4389-b159-921eb66a25fc"
      unitRef="usd">3798000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfMy0xLTEtMS0w_790f5f17-c766-4f0f-9121-394d29d5f21c"
      unitRef="usd">14524000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNC0xLTEtMS0w_1290d8a0-2e9e-40f3-bb32-321f9e13a038"
      unitRef="usd">12673000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNS0xLTEtMS0w_b20a6f39-453e-4a22-9c54-910be3a93a00"
      unitRef="usd">10842000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNi0xLTEtMS0w_6d23b28b-7f88-4960-9568-988fdd679fca"
      unitRef="usd">9830000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfNy0xLTEtMS0w_664b3fa9-6ed6-493d-a446-5561860eeef5"
      unitRef="usd">39114000</ameh:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80Ni9mcmFnOjIwZDE2MmE4OTliZDQ2YjliYjBkMGYyNzRlYjY3OTc0L3RhYmxlOjc5Y2ExNTkzNWMyMzQ1MDFiZjk4NDFlMzU5YzEzZGFjL3RhYmxlcmFuZ2U6NzljYTE1OTM1YzIzNDUwMWJmOTg0MWUzNTljMTNkYWNfOS0xLTEtMS0w_003e9109-90b7-40b4-9789-91544de3679f"
      unitRef="usd">90781000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <ameh:EquityMethodAndOtherEquityInvestmentsTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDM_afc3f0f5-06e5-461b-bacf-562811db9988">Investments in Other Entities &#x2014; Equity Method&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MWN, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA was founded by Dr. Albert Arteaga in 1996 and currently operates six neighborhood medical centers through its network of approximately 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#x2019;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately 290,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#x2019;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#x2019;s operations. For the three months ended September&#160;30, 2020, APC recognized income from this investment of $0.5 million. For the three months ended September&#160;30, 2019, APC recognized a loss from this investment of $0.4 million. For the nine months ended September&#160;30, 2020, APC recognized income from this investment of $28,000 in the accompanying consolidated statements of income. For the nine months ended September&#160;30, 2019, APC recognized a loss from this investment of $2.8 million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $6.4 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the nine months ended September&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging and Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.5 million and $0.7 million, for the three months ended September&#160;30, 2020 and 2019, respectively, and fees of approximately $1.5&#160;million and $2.1 million for the nine months ended September&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#x2019;s operations. For the three months ended September&#160;30, 2020, APC recognized a loss from this investment of $52,000. For the three months ended September 30, 2019, APC recognized income from this investment of $31,000. For the nine months ended September&#160;30, 2020 and 2019, APC recognized income of $25,000 and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $1.4 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI&#x2019;s total outstanding shares and 50% of UCI&#x2019;s voting common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#x2019;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred shares in Bright Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beneficial interest in UCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Carrying value of equity method investment on date of sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended September 30, 2019 APC recorded income from this investment of approximately $0.6 million. For the nine months ended September&#160;30, 2020 and 2019 APC recorded income from this investment of approximately $3.6 million and $6.2 million, respectively, in the accompanying consolidated statements of income. As a result of the sale, there was no investment balance as of September&#160;30, 2020 as compared to an investment balance of $1.4 million as of December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and nine months ended September 30, 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Four Months Ended April 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#x2019;s operations. For the three months ended September&#160;30, 2020 and 2019, APC recognized income from this investment of $0.1&#160;million and $0.3 million, respectively, in the consolidated statements of income. For the nine months ended  September&#160;30, 2020 and 2019, APC recognized income from investment of $19,000 and $0.7 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.4 million and $2.3 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;531 W. College LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, College Street Investment LP, a California limited partnership (&#x201c;CSI&#x201d;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns 50%, 25% and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#x2019;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.8 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2020 and 2019, APC recognized losses of $0.1 million, respectively. For the nine months ended September&#160;30, 2020 and 2019, APC recorded losses of $0.4 million and $0.7 million in the accompanying consolidated statements of income, respectively. During the period ended September&#160;30, 2020, the Company contributed $0.5 million to 531 W. College LLC as part of its 50% interest and had investment balances of $16.8 million and $16.7 million, respectively, at September&#160;30, 2020 and December&#160;31, 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the nine months ended September&#160;30, 2020 and 2019, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MWN LLC &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#x201c;Pacific6&#x201d;), and Health Source MSO Inc., a California corporation (&#x201c;HSMSO&#x201d;) entered into an operating agreement to govern MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own 33.3% of the membership shares based on each member&#x2019;s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million for working capital purposes in August 2019. For the three and nine months ended September&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $2,000 and $10,000, respectively. For the three and nine months ended  September&#160;30, 2019, NMM recorded loss from its investment in MWN LLC of $0.1 million, respectively, in the accompanying consolidated statements of income and had an investment balance of $0.2 million as of September&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments in privately held entities that do not report net asset value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;MediPortal, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. Additionally, APC received a five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of September&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AchievaMed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#x201c;AchievaMed&#x201d;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in &#x201c;Investment in privately held entities&#x201d; in the accompanying consolidated balance sheets as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Bright Health, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#x2019;s preferred stock having an estimated fair value on the transaction date of approximately $36.2 million. The related investment balance of $36.2&#160;million is included in &#x201c;Investment in privately held entities&#x201d; in the accompanying consolidated balance sheet as of September&#160;30, 2020.&lt;/span&gt;&lt;/div&gt;</ameh:EquityMethodAndOtherEquityInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDQ_77bffbb6-f9d7-4409-b1b7-b698904bb6a7">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rollforward of Equity Method Investment (in thousands)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.274%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.034%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Allocation of Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contribution&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LaSalle Medical Associates &#x2013; IPA Line of Business&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pacific Medical Imaging &amp;amp; Oncology Center, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Diagnostic Medical Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(351)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MWN, LLC &#x2013; related party&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LMA&#x2019;s summarized balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the nine months ended September&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,886&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,490)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,602)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,012)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and nine months ended September 30, 2019 are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;63,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,021&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Stockholders&#x2019; Deficit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and stockholders&#x2019; deficit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Four Months Ended April 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30, 2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;195,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income before benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefit from income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,010)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;531 W. College LLC&#x2019;s balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the nine months ended September&#160;30, 2020 and 2019, are as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Balance sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Liabilities and Members&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total liabilities and members&#x2019; equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Statements of Operation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:73.169%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;780&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Loss from operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(828)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(353)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestments
      contextRef="i3150290f584e44fb942ebfa558510e67_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS0xLTEtMS0w_f6570245-6135-4606-8b17-caccfc844301"
      unitRef="usd">6397000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS0zLTEtMS0w_4e679942-fc46-4a32-8db8-07102774bc17"
      unitRef="usd">28000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i7ce9e9350026435b94aef16bc0d946bd_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS01LTEtMS0w_50bd6290-fa5f-4ad7-a162-53d21b166aa4"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMS05LTEtMS0w_dc2d2b68-f6c7-4e67-9dd2-a2c4cdcc0f10"
      unitRef="usd">6425000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i69c46a468b494d52959804c3f5b2b176_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi0xLTEtMS0w_11a6bbda-58d2-4659-a953-cc0275a6f27f"
      unitRef="usd">1396000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi0zLTEtMS0w_817b89c6-2ac7-4e30-996a-f03470b0c7a6"
      unitRef="usd">25000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i3fcde74ccf794fb2b32d4a8b95774973_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi01LTEtMS0w_03ee3741-194e-4a40-95c3-f345b50778d6"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="id96dff4b93054ab5979c1cc17ea91814_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMi05LTEtMS0w_66bcab63-3b88-4281-954d-f5f07757599e"
      unitRef="usd">1421000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1208e04262ef4a01a35da5626d1ff666_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy0xLTEtMS0w_7679d197-1431-4b78-98eb-79f486f9d608"
      unitRef="usd">1438000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy0zLTEtMS0w_e777cb0c-1258-4546-9921-68ab3c731c43"
      unitRef="usd">3560000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy01LTEtMS0w_d3dec9ab-70dd-4883-8334-fc4ec7e3d7aa"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy03LTEtMS0w_0668fe21-89fd-4a66-b756-a45578e3d1a0"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i37888056e3424c5f8d0dcb6ddf14c929_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfMy05LTEtMS0w_554244ce-3cdb-4f44-bf0a-7900eea8fda7"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i753d549a8e2f4889a19f89e63e84cc3e_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC0xLTEtMS0w_b3e3f84d-abfe-4d60-a3fb-35da0d438da1"
      unitRef="usd">2334000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC0zLTEtMS0w_016f6307-fdfa-49a5-ac00-0d49f64f7a72"
      unitRef="usd">19000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i251492bf4e8a47099a6fad4bedbab59f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC01LTEtMS0w_13986d74-ae7f-4c71-8a26-eeac3830b56d"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="i3c38a1a7e9ee472f947eea00738b4192_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNC05LTEtMS0w_24e88f19-dea1-455c-aebd-8505b593ddf1"
      unitRef="usd">2353000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia0b72e4a3daa4a53955968c5168b7655_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS0xLTEtMS0w_c7309959-4ed1-4063-adec-3722900fc04a"
      unitRef="usd">16698000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS0zLTEtMS0w_fd677a7b-42ae-4c2e-a804-c72442cf9541"
      unitRef="usd">-351000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS01LTEtMS0w_e7199563-dfd1-46c3-a82d-0c879ae920a5"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNS05LTEtMS0w_306e627f-d25c-48c5-89c5-39c97afcae46"
      unitRef="usd">16847000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ie186328fb4c549168d42b7d9a48992e5_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi0xLTEtMS0w_7ed7f41f-76ea-4b3b-8023-8c168a685ea1"
      unitRef="usd">164000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi0zLTEtMS0w_15830c5c-4c35-490c-972e-91d59a2e649c"
      unitRef="usd">10000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="if1b294463bdf4f6eb45f6e32ba20cae0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi01LTEtMS0w_e5df5d19-3fc7-4a2f-a52d-9d91b07ab5d3"
      unitRef="usd">0</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestments
      contextRef="i0aa118fd35d9488990668d4e47746b7c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNi05LTEtMS0w_7b982303-068a-49ba-8e14-d4d2ee524f51"
      unitRef="usd">174000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy0xLTEtMS0w_377f0e22-a0f7-4416-aa0b-c2dfe70afb64"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy0zLTEtMS0w_4b8f5d89-2f29-490f-9444-691eb809eb9c"
      unitRef="usd">3291000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy01LTEtMS0w_602f7de3-a83c-49ba-9849-2c301874a937"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy03LTEtMS0w_17c8b653-dea1-4f8a-86cb-859c7e54d119"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:EquityMethodInvestments
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjg2MWM4NzJhODllMjRkNGFiNzBlMzg5OTAyNWUxNzk1L3RhYmxlcmFuZ2U6ODYxYzg3MmE4OWUyNGQ0YWI3MGUzODk5MDI1ZTE3OTVfNy05LTEtMS0w_f6d1ac94-faa2-4fcb-9478-58a88690108a"
      unitRef="usd">27220000</us-gaap:EquityMethodInvestments>
    <us-gaap:NumberOfStores
      contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjMx_7ff29780-e93e-4258-a22e-1da8c4724fa6"
      unitRef="medical_center">6</us-gaap:NumberOfStores>
    <ameh:NumberOfEmployees
      contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzAw_c3be9b81-ce74-485f-a5f9-55ca7c3cf593"
      unitRef="provider">2300</ameh:NumberOfEmployees>
    <ameh:NumberOfPatients
      contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjg2_534437d4-4d74-47c5-9acc-1ecdeaa60c83"
      unitRef="patient">290000</ameh:NumberOfPatients>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="iffa1353ebe6443cd972fce8728b7af34_I20121231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODgw_cb66a264-0da1-4856-9790-873998f00bc6"
      unitRef="usd">5000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="iffa1353ebe6443cd972fce8728b7af34_I20121231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODg5_2534b094-1983-4116-8841-f4b8468c0d0b"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1d6f80bd32404fe58031f292d1695804_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIxNg_39c1e644-bc19-484c-bd12-abce1ee0634a"
      unitRef="usd">500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="icce0e75bb6d54e57a2fd9d41415f1fd0_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI5NA_39ed5e2b-c537-44a0-b90b-8580a7ac3a78"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i36d5dfd221ad448cbcffffc8f6478d08_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTM1OA_5b4e38c4-b224-464b-ae34-1bb5e34c7fce"
      unitRef="usd">28000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i77f38d9db9c24fb6b7dcd2c1221459f8_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTgwNzU_525fde24-646f-4a96-8399-f3bfbbe0c406"
      unitRef="usd">-2800000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ida39330ce23947b1a283b27d4e1fd854_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTUyNQ_4b3df9e2-1660-4392-afb3-ab80dbb3a384"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3150290f584e44fb942ebfa558510e67_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTUyNQ_fe8bae0f-5fc7-4542-8590-f947e2f0dce7"
      unitRef="usd">6400000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMy0xLTEtMS0w_804963e4-31b6-49c5-bc8b-82400ab54af2"
      unitRef="usd">3794000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMy0zLTEtMS0w_3bf3ac9e-16a1-416b-b6bf-f96510b56eb2"
      unitRef="usd">6345000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNC0xLTEtMS0w_4d3017fa-3863-475b-b518-dca2ff7ea0be"
      unitRef="usd">6782000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNC0zLTEtMS0w_20e42282-8c06-4b5e-9213-59fc56d161c6"
      unitRef="usd">5124000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNS0xLTEtMS0w_b2e77421-bc0e-48e4-9174-0f15ca1cca90"
      unitRef="usd">880000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNS0zLTEtMS0w_e669aa10-439e-498f-aa73-9d03542199bb"
      unitRef="usd">3526000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNi0xLTEtMS0w_83db0700-4a7b-4774-893d-c965fc277267"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNi0zLTEtMS0w_97c6b26f-f996-48fb-9d25-737f26422031"
      unitRef="usd">2250000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNy0xLTEtMS0w_5936fca7-1e64-4f0b-bebe-3b5dbcd515ca"
      unitRef="usd">690000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfNy0zLTEtMS0w_fcbfe2f0-831f-488e-bc2c-eaa48bcbbaa6"
      unitRef="usd">683000</us-gaap:RestrictedCashCurrent>
    <us-gaap:Assets
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfOS0xLTEtMS0w_54d8e771-668d-4069-af8b-58dbec6d91fb"
      unitRef="usd">14396000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfOS0zLTEtMS0w_b118140b-29fd-4a03-b5a8-bbc1eb9ce050"
      unitRef="usd">17928000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTItMS0xLTEtMA_34f33fc0-a8f3-4f5b-a613-fa781f8ae1aa"
      unitRef="usd">19886000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTItMy0xLTEtMA_bac4e604-071a-47c1-8ebd-e86e3d612285"
      unitRef="usd">23530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTMtMS0xLTEtMA_170886e1-cd7d-440b-b94e-ad774cf36843"
      unitRef="usd">-5490000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTMtMy0xLTEtMA_f029ed10-1219-40a8-beba-3a457a188ee9"
      unitRef="usd">-5602000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i68d4831420054a9caa735c7f1252692b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTUtMS0xLTEtMA_e598984b-e519-4556-a8bb-13662ba62ea3"
      unitRef="usd">14396000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib1f9f8ea17ec45a094548fee58869526_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmFjYzY5ZTZiYjVkMzQ1ODg4NGIxNTI2YzJhODc3OWNlL3RhYmxlcmFuZ2U6YWNjNjllNmJiNWQzNDU4ODg0YjE1MjZjMmE4Nzc5Y2VfMTUtMy0xLTEtMA_f4646ae3-aca6-4989-9e34-c5c354ecdcdb"
      unitRef="usd">17928000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfMy0xLTEtMS0w_e58ed5cd-d88e-4751-afc8-cb356102c132"
      unitRef="usd">138490000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfMy0zLTEtMS0w_e80320fc-4183-422a-9a2b-93b2268d976b"
      unitRef="usd">144570000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNC0xLTEtMS0w_e2ce5797-0e78-4eed-8ca4-29be778b8276"
      unitRef="usd">138233000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNC0zLTEtMS0w_f29bec9c-e98c-4b17-8481-4b6591f2925c"
      unitRef="usd">155582000</us-gaap:CostsAndExpenses>
    <us-gaap:ProfitLoss
      contextRef="id90abdab01f44e47b48d561df36836df_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNi0xLTEtMS0w_94cafe57-7dbf-48a3-a8fa-c3cfb5a4a592"
      unitRef="usd">257000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ie1677e6fb22740d4bbed75663fb367c0_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjA3MGY4ZWViNGI4YzRlNzI5ZjY0MTk2Njc2ZjNlZGI0L3RhYmxlcmFuZ2U6MDcwZjhlZWI0YjhjNGU3MjlmNjQxOTY2NzZmM2VkYjRfNi0zLTEtMS0w_d2a0eaae-f2e2-4b40-a8f5-76c7906a7f77"
      unitRef="usd">-11012000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="ia037d44d0bc04c4a828c637cca06b007_I20150731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjI2Nw_0760449b-0715-4d15-9570-f14c7d5f9b15"
      unitRef="usd">1200000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia037d44d0bc04c4a828c637cca06b007_I20150731"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjI3Ng_b8b97357-6d8c-46c1-b041-c2386f2ad900"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsForFees
      contextRef="i1424495955004e3094d7f448c52f3fe8_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjUzMw_21b13bc0-e835-47fd-928e-9c1f31015564"
      unitRef="usd">500000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i8297f0cd122a4975a2782edec1346e26_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjU0MA_344f97cc-cb08-4cc7-aefc-022c1bd1429b"
      unitRef="usd">700000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i288e556a87794169a4a86cc7f6c4e55d_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjYxOQ_d0fe1b5e-3e71-4f71-a78c-597a607f88c1"
      unitRef="usd">1500000</us-gaap:PaymentsForFees>
    <us-gaap:PaymentsForFees
      contextRef="i8b4bf3567dfb4dd790df1e67d2f85991_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjYyNg_7820d039-885d-4015-b4f3-626cce58a4b2"
      unitRef="usd">2100000</us-gaap:PaymentsForFees>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i71a29ce4a53848648939532cde255536_D20200701-20200930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjkxNg_f5bbd1cf-6f9e-4183-8acd-fd612d63df53"
      unitRef="usd">-52000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2146c6cb823b414e94d6373622631d84_D20190701-20190930"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMjk5NA_3408a7f1-b573-4245-aa5d-28c0cead1fb6"
      unitRef="usd">31000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic1d5b7766ae84835948bd0dc5b9bad5c_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzA1OA_8448dde8-b244-47c1-ace5-8f2f9ccaaece"
      unitRef="usd">25000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="idef125c16c3942fab014863ef8783a70_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzA2NQ_97151684-5d13-4a54-8634-5b6e9864885e"
      unitRef="usd">200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ibcba94fccca04cd7b22e774e76edfde4_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzIyNQ_727ce674-a91c-4c28-a1fc-b0820699fa08"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ieda981fa64b9451192fe68d1b530358d_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzIyNQ_b12f9b03-abf0-4df8-b455-f6bdfb5eec9a"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <ameh:EquityMethodInvestmentsPurchaseOfShares
      contextRef="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzU5Mw_330c7d1e-1a6e-4d1a-b726-63a9f111ee32"
      unitRef="shares">100000</ameh:EquityMethodInvestmentsPurchaseOfShares>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="id4c48b0482e24d54a35353fe5806ea4a_D20150801-20150831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzY1Mw_5fe7e4a4-6ac7-4eb9-bc55-2cd39b7f682c"
      unitRef="usd">10000000.0</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ia04e6e879820403ab84c417618cac928_I20150831"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzY3OQ_77504f2f-096a-4275-b55f-ed535e6be56b"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock
      contextRef="ia8bc25be722f4aa4a401ae02a6f9cf03_I20150831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzcyMA_206d493f-1d24-43cf-8b4c-72136ecb0ed1"
      unitRef="number">0.50</ameh:EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i32f8ada07c6e48c3b9c63debad1daebf_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzgwNA_80361ef5-9be3-4bec-a10b-c887c1c50b50"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzg2MQ_c0fed042-fdc4-49b8-9081-18175921355d"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i32e68a9968f5490582115cc17368bef7_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMzg5Mg_83ae85a7-f51a-45eb-a78e-129c1fcb2522"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i8cfb37c8a9b442048185c215ca7ae06b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDA3Ng_1c8f939e-faec-48c5-bffe-c1b6cc75dbe8"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="i3b26df8521744f83b689e49598713e48_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDU5Nw_127418a9-0763-4ecb-a0aa-36b810512c90"
      unitRef="usd">15700000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationCash
      contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDkxMQ_a424a2e8-56eb-4814-a8b9-9ab75de57746"
      unitRef="usd">15600000</ameh:EquityMethodInvestmentSaleContingentConsiderationCash>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares
      contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNDk2Nw_25ba47a6-d837-41a7-98cc-51f223bdd9f1"
      unitRef="usd">6400000</ameh:EquityMethodInvestmentSaleContingentConsiderationPreferredShares>
    <ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue
      contextRef="i856a3c65a5c24836ba93769ef9f2948a_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNTAwMQ_bbc5c6e3-9fe2-4baa-90cd-7b52b01b7ce3"
      unitRef="usd">22000000.0</ameh:EquityMethodInvestmentSaleContingentConsiderationFairValue>
    <ameh:EquityMethodInvestmentGainOnSaleTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDk_18dad826-2dab-4c30-8305-847468b0c885">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:79.016%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.784%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred shares in Bright Health, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beneficial interest in UCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Carrying value of equity method investment on date of sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,998)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ameh:EquityMethodInvestmentGainOnSaleTableTextBlock>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfMi0xLTEtMS0w_9b1a8cec-9f48-4de4-a316-b1303453c14c"
      unitRef="usd">52743000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="ie13a24a9ed274984976f3be0b0ae5d60_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfMy0xLTEtMS0w_269774d0-7864-41eb-a6c2-00c3a6d3b443"
      unitRef="usd">36179000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet
      contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNC0xLTEtMS0w_bab7cc70-3a33-4de4-b7a0-44e9bb7cf4f3"
      unitRef="usd">15723000</ameh:AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet>
    <us-gaap:EquityMethodInvestments
      contextRef="i07add4ecbd2749df8612f106ba12945d_I20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNS0xLTEtMS0w_97b7d565-f9bd-4ebf-bc04-7b7235a35382"
      unitRef="usd">4998000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmM3MzYxMDQ4OWU4YzRiMmM5ZDExMTI4MjA1OTI5Y2JlL3RhYmxlcmFuZ2U6YzczNjEwNDg5ZThjNGIyYzlkMTExMjgyMDU5MjljYmVfNy0xLTEtMS0w_9eeece14-af17-4db2-919e-a23f983454e2"
      unitRef="usd">99647000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic0e8d7a443424c718c847dcf3b912bea_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjY3MQ_0a1e42c1-dd03-49a8-87e9-66c6c1cc23c9"
      unitRef="usd">600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i7b6475e8a8e54e32afd2c9d884cd3aab_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg3OTY_7c551a6b-2e70-4ce4-98e6-58def0b13095"
      unitRef="usd">3600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1ea26d47ecf949429fb00155fa3a1100_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjc5OA_22fd536a-653c-47e0-be00-01422483974f"
      unitRef="usd">6200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i37888056e3424c5f8d0dcb6ddf14c929_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjkwNQ_1fd81785-07f4-43ea-af47-6e1167932a05"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1208e04262ef4a01a35da5626d1ff666_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNjk3Ng_dabe0ccd-7070-4bee-a340-94ef68e9a8d0"
      unitRef="usd">1400000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMy0xLTEtMS0w_314aaa14-7095-4a4b-bd63-1cab556b10b6"
      unitRef="usd">33890000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNC0xLTEtMS0w_49ebe28e-b560-4747-8bb4-0ff561179b05"
      unitRef="usd">63843000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNS0xLTEtMS0w_aded1e54-b85a-4e97-8d36-d144b3d55491"
      unitRef="usd">38280000</us-gaap:OtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNi0xLTEtMS0w_c3712c07-89d2-41e8-a71e-68b4ae841ae8"
      unitRef="usd">882000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfNy0xLTEtMS0w_439b9458-e638-487d-ba14-4732ac30261f"
      unitRef="usd">4021000</us-gaap:RestrictedCashCurrent>
    <us-gaap:Assets
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfOS0xLTEtMS0w_1c0fba5b-005d-4442-bb67-abba65d5b7d8"
      unitRef="usd">140916000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTItMS0xLTEtMA_33e772be-63ea-4553-99f7-2ed35f010670"
      unitRef="usd">128330000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OtherLiabilities
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTMtMS0xLTEtMA_67d9f0c4-ff2c-4031-b831-731768db5c57"
      unitRef="usd">33133000</us-gaap:OtherLiabilities>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTQtMS0xLTEtMA_50de87fe-780c-406b-ab20-9984012c6dd7"
      unitRef="usd">-20547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="icb5b9a12e29e496699cd7e52d210ebb2_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjAzMDE3YmYyMGJlYTQ2MzZhMDNhOWFiOTRkNmRlZjFlL3RhYmxlcmFuZ2U6MDMwMTdiZjIwYmVhNDYzNmEwM2E5YWI5NGQ2ZGVmMWVfMTYtMS0xLTEtMA_c9c56e0c-c8b0-4993-860b-95596bfc1e19"
      unitRef="usd">140916000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfMy0xLTEtMS0w_31b3e545-65a3-4c16-938c-42cbdc7bb3f3"
      unitRef="usd">195308000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfMy0zLTEtMS0w_2ec100d5-dc9d-4232-a50a-d587d9485383"
      unitRef="usd">372181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNC0xLTEtMS0w_50a6a31c-50d1-47a7-b238-c20df3259395"
      unitRef="usd">189028000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNC0zLTEtMS0w_6ea5afb1-744b-4524-b661-f4aff7ad6db2"
      unitRef="usd">370597000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNi0xLTEtMS0w_4fbee0c4-c99e-46e9-8609-c56080e5d34b"
      unitRef="usd">6280000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNi0zLTEtMS0w_6ff117bd-e925-45a3-886d-ecce57d42adf"
      unitRef="usd">1584000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNy0xLTEtMS0w_e052aa3f-4ef9-4442-b3d7-09fed8c2fdbe"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfNy0zLTEtMS0w_ff57d08a-58fe-4773-9834-f95f6dac36f8"
      unitRef="usd">-11010000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="i2016a634e9d142b4bebff39c4d7771a2_D20200101-20200430"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfOS0xLTEtMS0w_b0b3298b-0cef-4eb0-a488-8232515a5411"
      unitRef="usd">6280000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="if93dda2fb9164cd2b36516ecb1994ab1_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOmU1OWExYjRkYmRhMzRlMWE4OTlhYzQ1ZDVmZDNmNDE0L3RhYmxlcmFuZ2U6ZTU5YTFiNGRiZGEzNGUxYTg5OWFjNDVkNWZkM2Y0MTRfOS0zLTEtMS0w_8b001829-d57f-4e29-abff-0ee542e858a4"
      unitRef="usd">12594000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i45be72031ca0447e97e01053b8c321fb_I20160531"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzM2NQ_afaa6d7d-a787-4de2-b5a1-22d05c722d4e"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ifba98224dfe743d886659a878903bc31_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzY1OQ_19bc700c-f5fa-48af-85d3-a8151a493fce"
      unitRef="usd">100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i9dc91266bda94e86a5ec7f40496f5a5c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzY2Ng_993bbbc8-ccc2-44a7-92c4-f854fca78cd4"
      unitRef="usd">300000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if0cb473eab6e497599fded63c9f221e4_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzgxMw_cb13a293-1561-411b-bf78-98827661c94f"
      unitRef="usd">19000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzgyMA_138f6195-556a-40b1-98de-2a80f54c5163"
      unitRef="usd">-700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i3c38a1a7e9ee472f947eea00738b4192_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzk2OA_3d2e063a-f7bb-453b-94d3-41901e10e652"
      unitRef="usd">2400000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i753d549a8e2f4889a19f89e63e84cc3e_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzk3NQ_fa763abc-c144-46c5-bb4d-3cc291237ec6"
      unitRef="usd">2300000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1d560d1902504cca8098eacb878eef29_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM1NA_c345720f-981e-48d1-8515-f7da13e8c15a"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i6184b34ee8134be5b8c421145d39c934_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM1OA_1d24c24d-c54b-4081-bab8-bb5e48c8d0e3"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i46a9a7002274458a996a2f3572f2742e_I20180630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODM2NQ_fcde08f2-1e1f-45a4-8a4a-3daa492c9841"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="i1d560d1902504cca8098eacb878eef29_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ0MQ_f148511b-7b7d-44e0-b744-10f2692e1be1"
      unitRef="usd">16700000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i6184b34ee8134be5b8c421145d39c934_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ0NQ_70bbd5d3-a8f6-4823-9da9-81a0f1048762"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i46a9a7002274458a996a2f3572f2742e_I20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODQ1Mw_5ca1222d-d469-4d18-ba63-bccbe62934a1"
      unitRef="usd">8300000</us-gaap:MembersCapital>
    <us-gaap:PaymentsToAcquireRealEstate
      contextRef="i3015e3b3bfc74713a36da771c5184b53_D20180601-20180630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODcwOA_76a4a4c3-b95e-419a-ad68-2eada5d39a19"
      unitRef="usd">33300000</us-gaap:PaymentsToAcquireRealEstate>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i51f10e9761bc4228abb6d529c3349de6_I20190423"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODgxMg_71f707c6-f9cf-4777-8053-150f59b64011"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentAggregateCost
      contextRef="i51f10e9761bc4228abb6d529c3349de6_I20190423"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODg3Ng_12a0daf7-252f-41f8-bab4-7f8beaf7b60c"
      unitRef="usd">8300000</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic465b3707abf436089f9fc1143560257_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODkwNA_44f01bf2-c006-4bf6-a5b4-8b845caa8e0c"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfODk4OA_25bb50b3-4951-42d3-9c23-5050add32092"
      unitRef="usd">16800000</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="iabc665a0dbda4c87aeba1b7b7f31c314_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTI3Mg_913ea568-0d60-4d78-8334-c4ab215e127c"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i48000cd06bc14fb78d5ac9a135a4817c_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTI3Mg_cdecb211-27dc-435c-a8a8-84a7011f7f2f"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i07be705677f8498588d2853c3c7bf749_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTM1NQ_1c0b2f34-b711-4a88-b8f1-716ef140509d"
      unitRef="usd">-400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4da43e02c62b4eebbd74168961d55841_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTY0OTI2NzQ1NDcwMQ_138f6195-556a-40b1-98de-2a80f54c5163"
      unitRef="usd">-700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <ameh:EquityMethodInvestmentsContribution
      contextRef="i7c68eb6c381c4f0b92feeea7e74fbd42_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTQ4Ng_872975ab-c5d7-4041-9a06-7208d4ca953e"
      unitRef="usd">500000</ameh:EquityMethodInvestmentsContribution>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ic465b3707abf436089f9fc1143560257_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTUyNg_6c9f05b9-e0a9-4a5f-9100-3ef42e702d40"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="iec20f66949cb4f86b1a6445e912e304f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTU2OQ_25bb50b3-4951-42d3-9c23-5050add32092"
      unitRef="usd">16800000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="ia0b72e4a3daa4a53955968c5168b7655_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfOTU3Ng_05c05d02-dff7-4ee0-88f7-aa49cf98f8de"
      unitRef="usd">16700000</us-gaap:EquityMethodInvestments>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMy0xLTEtMS0w_a3c8b7c4-e35a-4479-99b6-d3ef083c42dc"
      unitRef="usd">8000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMy0zLTEtMS0w_e6d9d732-7c54-41d7-956f-634b9fe869a2"
      unitRef="usd">139000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsCurrent
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNC0xLTEtMS0w_c36d30ee-2d0f-4aa1-96d0-50d14b0a2996"
      unitRef="usd">25000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNC0zLTEtMS0w_7f1fb475-4c34-456f-8fc8-c92ae3737db1"
      unitRef="usd">17000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssets
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNS0xLTEtMS0w_dcbca71a-5e91-40c4-b5fa-1910dfbee2e7"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNS0zLTEtMS0w_1660099f-916f-41f1-a295-da86a8eefcff"
      unitRef="usd">70000</us-gaap:OtherAssets>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNi0xLTEtMS0w_71dc5a8f-bcc0-467a-99b5-396f70a01c2b"
      unitRef="usd">33697000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfNi0zLTEtMS0w_75f8cdcd-4fec-4848-a5ec-d362c8e06391"
      unitRef="usd">33581000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:Assets
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfOC0xLTEtMS0w_d9d022f3-3e7d-463c-9f2c-de9eb1594cd5"
      unitRef="usd">33800000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfOC0zLTEtMS0w_ab2b73f4-724b-436b-8350-ac1c34c6bd63"
      unitRef="usd">33807000</us-gaap:Assets>
    <us-gaap:LiabilitiesCurrent
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTItMS0xLTEtMA_87aa7262-a93e-4fbc-a2e5-1cc1e76cde6d"
      unitRef="usd">1257000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTItMy0xLTEtMA_96e6bd2e-76b3-4d9a-83ea-f68cc3dac035"
      unitRef="usd">1062000</us-gaap:LiabilitiesCurrent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTMtMS0xLTEtMA_7abb42ac-303c-42d6-92be-33b2110e73a1"
      unitRef="usd">32543000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTMtMy0xLTEtMA_a28c05dd-b080-4f71-b382-37673c666301"
      unitRef="usd">32745000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ib25087f805b748af8715c1809bb3ecb1_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTUtMS0xLTEtMA_f1f64d8b-910b-45da-a5ba-11ddceb4521f"
      unitRef="usd">33800000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8278a3e815674925897c9ef247e29fd6_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjZkZTk4NDI0YzRhMDQ1MTZiMmY4MmYxOWQ4OGZhZDVkL3RhYmxlcmFuZ2U6NmRlOTg0MjRjNGEwNDUxNmIyZjgyZjE5ZDg4ZmFkNWRfMTUtMy0xLTEtMA_c7131392-bc52-4a40-aced-777d676d9cff"
      unitRef="usd">33807000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMi0xLTEtMS0w_56027b96-0234-4059-a663-e3206a15b0ae"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMi0zLTEtMS0w_280f8dba-385a-4cc6-a45b-6c9723249f8f"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostsAndExpenses
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMy0xLTEtMS0w_efdb1b42-578c-4605-8ad7-2b371f0ff841"
      unitRef="usd">828000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfMy0zLTEtMS0w_22071fbf-101c-46c9-b230-08c4ad2e6e24"
      unitRef="usd">780000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNC0xLTEtMS0w_36de5201-c02e-4a72-890e-8b9512b9e664"
      unitRef="usd">-828000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNC0zLTEtMS0w_28e456c8-44f9-4e73-8919-4929160a0d19"
      unitRef="usd">-780000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNi0xLTEtMS0w_14d7519e-0d59-494c-8cd9-e66483df2635"
      unitRef="usd">32000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfNi0zLTEtMS0w_7a0328f3-7fc5-4f80-a526-fa0160baee87"
      unitRef="usd">427000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0xLTEtMS00NTA5_c3d286ef-d97c-4369-b00a-00331b0390e5"
      unitRef="usd">3000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0zLTEtMS00NTA5_87a79041-95e4-404d-bae4-f66314442485"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss
      contextRef="ic15b75dc348c49258108d27228c78e88_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0xLTEtMS0w_10715401-e1eb-4287-9dca-f1bc0b71bc21"
      unitRef="usd">-799000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibb20069b4df54ea38bbc5958ae95bfb9_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RhYmxlOjhlOGNlOGRlNzVjMDQwODNiYWIxMGE5NGRiMWYwZDIyL3RhYmxlcmFuZ2U6OGU4Y2U4ZGU3NWMwNDA4M2JhYjEwYTk0ZGIxZjBkMjJfOC0zLTEtMS0w_4cda71a2-bbea-41ea-814e-3ab62ea5ec58"
      unitRef="usd">-353000</us-gaap:ProfitLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i0e75f05d163f47508aaed53617f817da_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_2dc6e907-0ea0-429f-8192-754c38680abd"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i808a481f8e67463fa27b080f11806844_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_78c34b79-aaa3-4316-bce0-d39e011b216a"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyMTE_c9affef4-5d5a-4161-87d3-184f421db8ae"
      unitRef="number">0.333</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MembersCapital
      contextRef="ic4e7c20c772c4b85a99de03a80063147_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_4b22b318-b35e-4684-8687-1487c1b81f50"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_6a88de49-35c0-4b5b-b00d-cbedb3f375cf"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <us-gaap:MembersCapital
      contextRef="i9e993cf753ad4a0694bf3466d7220468_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAyOTU_86490fa8-0a87-4e32-b66d-51842c8b534d"
      unitRef="usd">3000</us-gaap:MembersCapital>
    <ameh:WorkingCapitalContribution
      contextRef="i9e993cf753ad4a0694bf3466d7220468_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_4d7ed761-e7d1-4ae1-8fc5-f15f4313dd0e"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="ic4e7c20c772c4b85a99de03a80063147_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_5dd7daa1-47ce-416d-a75d-5e1a29a3efa0"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="i2407645ed5864ae5b8cb66de46074353_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzMzU_a37c2182-a6e3-4ef3-b69d-368bd652a76b"
      unitRef="usd">30000</ameh:WorkingCapitalContribution>
    <ameh:WorkingCapitalContribution
      contextRef="i3b8908c9b1334fe395a61d2ddc0668cf_I20190831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTAzNjY_ac288879-a2e0-44be-8b7a-f283ba19baf1"
      unitRef="usd">300000</ameh:WorkingCapitalContribution>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic960b26a1e3f40a1b24e18c623b99240_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA1MTI_06ed6684-f0fd-476f-bde6-33fab9d051a6"
      unitRef="usd">-2000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i4454b081d0384506ab87a132eae22d31_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA1MTk_164c49ea-d287-40ba-8ce7-bd7d7a8f07cf"
      unitRef="usd">10000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ia915b2c31332442a8d6f15aef9889924_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg1MjQ_0e983019-c4f1-411c-a66d-9ffd88afc17b"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i65347818febf49c7b80dc85ef7ae043f_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTc1OTIxODYwNTg1MjQ_4319e650-34c7-457d-9f42-ce459d21277a"
      unitRef="usd">-100000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i6f8670c333f043daaa155fb5a0ac3eab_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA2MjQ_03b6f0b3-04e7-4cb6-a4d2-16e2d60db14e"
      unitRef="usd">200000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i2f60ef2535c14c7bb4a2c7f0b27b0a8c_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA2MjQ_d52aab52-2e3b-498b-a57f-897a255dea1f"
      unitRef="usd">200000</us-gaap:EquityMethodInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA3NjE_96bd5aba-5a27-477c-92bb-bfdd32480553"
      unitRef="shares">270000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares>
    <ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA4NDY_6db5964f-ac32-420b-b284-b3a838d39a2e"
      unitRef="usd">400000</ameh:PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA4NTI_a7b74361-2ce2-4e4c-a611-ad738c456cc0"
      unitRef="usdPerShare">1.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTA5MTU_100b6ed4-f695-41d6-9a29-428027d4b9a9"
      unitRef="number">0.028</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2Mzg_042d0a86-31b7-4cc8-bbc1-68618ee535e1">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTEwMzY_2a85954d-de32-4879-9507-580e2cb7dd6c"
      unitRef="shares">270000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption
      contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NTE_85a45e68-d0a0-4f7f-9b30-59716938c478">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests
      contextRef="iace017bb848f47dab450c002c3ee6683_D20180501-20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTExMzE_9e3ad4f6-9860-4d3e-991c-548c8f48aa58"
      unitRef="shares">380000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI2NDc_17de6d16-11eb-40dd-b9f5-1a2da8066b6a">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet
      contextRef="i68c969400a494d9787143ded770b0181_I20180531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTExODk_cfd5cca3-d421-4bd9-88ba-e4b0299ec8ae"
      unitRef="shares">480000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears
      contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE4MDY_c0ea099f-6738-48b4-b124-0da1e689dd0c"
      unitRef="number">0.50</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment
      contextRef="i53fb3b2d3c10434fb7ad9df99de6697b_D20190701-20190701"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5MDA_d51ec862-0190-4fde-992f-6b174f19711f">P5Y</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost
      contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5NDk_d5496b7f-9509-400d-a446-4a2b262a5052"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage
      contextRef="i7af1eb4eec284746ab0ea8fca2ab66c9_I20190701"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTE5NTg_f4956711-66c6-4288-8497-5b41d2c1603f"
      unitRef="number">0.10</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage>
    <ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments
      contextRef="i79b8b4b7485e41828f619cb79928959f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIwMDU_dfbc6581-ffd1-4e1c-9cba-cb4ea720eb93"
      unitRef="usd">500000</ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments>
    <ameh:EquityMethodInvestmentOwnershipPercentageDisposed
      contextRef="i32f8ada07c6e48c3b9c63debad1daebf_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIxODc_80361ef5-9be3-4bec-a10b-c887c1c50b50"
      unitRef="number">0.489</ameh:EquityMethodInvestmentOwnershipPercentageDisposed>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i08a7c47285ab43ecbc7778fae6e46a51_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIyNDQ_c0fed042-fdc4-49b8-9081-18175921355d"
      unitRef="usd">69200000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="i32e68a9968f5490582115cc17368bef7_D20200430-20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTIyNzU_83ae85a7-f51a-45eb-a78e-129c1fcb2522"
      unitRef="usd">16500000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="i8cfb37c8a9b442048185c215ca7ae06b_I20200430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfMTI0NTk_1c8f939e-faec-48c5-bffe-c1b6cc75dbe8"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue
      contextRef="idfe7f2d11dba4bf8bfa9cd6b837b86d1_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80OS9mcmFnOjZiMjkwNzMwZmZhZDRhOTRiMmY0ODM4MTQ5ZjE5OGJiL3RleHRyZWdpb246NmIyOTA3MzBmZmFkNGE5NGIyZjQ4MzgxNDlmMTk4YmJfNzE0NjgyNTU5NDg0NQ_a4e13840-b369-4b68-abf0-09bf9cbff053"
      unitRef="usd">36200000</ameh:InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue>
    <ameh:LoanReceivableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjYxMg_13600fa0-ee40-41eb-8564-620f899b6823">Loan Receivable and Loan Receivable &#x2013; Related Parties&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dr. Albert Arteaga&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#x201c;Dr. Arteaga&#x201d;), Chief Executive Officer of LMA, to loan $6.4 million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus 1% (4.25% as of September&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#x2019;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#x2019;s designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $6.4 million as of September&#160;30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $2.2 million in the ordinary course of business. As of September&#160;30, 2020 the advance was fully repaid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company assessed the outstanding loan receivable under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2013;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; related parties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Universal Care, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015, APC advanced $5.0 million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $2.5 million, $5.0 million and $4.0 million, respectively. The loans accrue interest at the prime rate, plus 1.00%, or 4.25%, as of March 31, 2020, and 5.75% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright.&lt;/span&gt;&lt;/div&gt;</ameh:LoanReceivableTextBlock>
    <us-gaap:NotesReceivableNet
      contextRef="i0faa96915dac498dbda55cbf5243918f_I20190628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjYx_1e0641a7-2431-4ecf-89c1-350e38327bd0"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7caa591d27bf48eab7b5c969cac33e61_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMzU4_bb025d35-e341-493f-bb2a-03c0f7d5d2b2"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1c008ff76ac0426486f735cd9512a068_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMzYy_3ba377d7-41e1-4239-9fae-11d5805a3714"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible
      contextRef="i0faa96915dac498dbda55cbf5243918f_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfOTAy_2cade16a-2b0e-4670-b66e-d21170772a04"
      unitRef="number">0.2125</ameh:FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="i123c7dd6529340df982a5fa9dfc0aa21_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTA5OQ_4ba745c3-8325-4d47-b124-c7bbfb8636d6"
      unitRef="number">0.4625</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion
      contextRef="i7fec8536262a49a0b8b6bcb905d9ed73_I20190628"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTE0Mg_d02e7f8a-c5af-4898-b679-1eb9b7f417fc"
      unitRef="number">0.5375</ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion>
    <us-gaap:NotesReceivableNet
      contextRef="i50e6b5986d0843a5a0390ed42f10c1de_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTI5NQ_5f77f11a-b07a-43d2-ae08-12da78361307"
      unitRef="usd">6400000</us-gaap:NotesReceivableNet>
    <us-gaap:NotesReceivableNet
      contextRef="i2cab7f77600442608addb240a33cdb9f_I20200228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMTM5Mg_9f4c2e4c-c400-42ac-b2c2-2bec60dba902"
      unitRef="usd">2200000</us-gaap:NotesReceivableNet>
    <ameh:AdvancedForWorkingCapital
      contextRef="i8dac94597ff94666b83c9ae361507075_I20151231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjE2Nw_a6395890-c024-4f92-bd8a-efccf49054ef"
      unitRef="usd">5000000.0</ameh:AdvancedForWorkingCapital>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="ic615bf6bdf9a47aca957ca50dac11311_I20180629"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMxMg_f893f9d3-8d5d-4f9c-a0f1-4277a4dc2e82"
      unitRef="usd">2500000</ameh:LineOfCreditFacilityAdditionalAdvances>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="i57568f01843b4e1c8af7407d9814d9a4_I20181128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMxNg_25f91ba3-7887-4191-b8a1-d18f07c0bb9e"
      unitRef="usd">5000000.0</ameh:LineOfCreditFacilityAdditionalAdvances>
    <ameh:LineOfCreditFacilityAdditionalAdvances
      contextRef="i8aca1d8a93354c9e93262133b582edf4_I20191213"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjMyMw_9c3db626-49dc-4478-a5f5-9103121e755a"
      unitRef="usd">4000000.0</ameh:LineOfCreditFacilityAdditionalAdvances>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia0f328dbb075463e9e1e6093dfb7ff74_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjM5MQ_32c596c4-67e1-4f5e-9da9-b6eb24a0ce10"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7be81f0e5b5b4b50b9ea5036ae2b8e02_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjM5OA_848cd029-497f-4ea6-aa67-95b8d9cea47f"
      unitRef="number">0.0425</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iba23adf288b04c1f910cffd3bc1a3489_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjQyOA_a512bc4c-1b88-4c23-bdaa-9203b58980b1"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i81d7b1f95e2749528c65d9be013d2d5e_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81Mi9mcmFnOjBiYzEzZjE0MjcwYjRjYzliMGUyMTRmMmE3ODVmYzcxL3RleHRyZWdpb246MGJjMTNmMTQyNzBiNGNjOWIwZTIxNGYyYTc4NWZjNzFfMjU3Mg_b28a590b-affe-4086-a113-bd5775d9e4da"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RleHRyZWdpb246MGIzMGRjNjg3Mjc4NDRkNjg3MTgwYWE1MzQzMjJjNDFfMTQ0_0c126dc7-d6ab-4267-af58-a848ac54b53e">Accounts Payable and Accrued Expenses&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RleHRyZWdpb246MGIzMGRjNjg3Mjc4NDRkNjg3MTgwYWE1MzQzMjJjNDFfMTQ3_4ced53de-54b9-4b40-afbb-c33b4106f48d">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s accounts payable and accrued expenses consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.329%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,914&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Capitation payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subcontractor IPA payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Professional fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to related parties&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,892&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total accounts payable and accrued expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMS0xLTEtMS0w_2aa12a3b-58c6-4876-8978-6ac27bba26ae"
      unitRef="usd">9569000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMS0zLTEtMS0w_1b8084eb-c559-4464-bbc7-05dd446ae734"
      unitRef="usd">6914000</us-gaap:AccountsPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMi0xLTEtMS0w_e66e4465-ef6d-4973-9409-ec0ec8cea1f4"
      unitRef="usd">2583000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SpecialtyCapitationPayableCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMi0zLTEtMS0w_beb59a84-f3dd-426c-82c3-63e3604b28f8"
      unitRef="usd">2813000</ameh:SpecialtyCapitationPayableCurrent>
    <ameh:SubcontractorIPAPayable
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMy0xLTEtMS0w_c4a1b27c-a218-4563-9eaa-70baabd264b7"
      unitRef="usd">3413000</ameh:SubcontractorIPAPayable>
    <ameh:SubcontractorIPAPayable
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfMy0zLTEtMS0w_c95d815b-03e9-4f36-bf63-143edb996a93"
      unitRef="usd">3360000</ameh:SubcontractorIPAPayable>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNC0xLTEtMS0w_a577d6a7-68fc-4330-85b4-d028c5db4f37"
      unitRef="usd">2481000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNC0zLTEtMS0w_5211a406-7c31-4ba7-be91-d1ed3a2bfd69"
      unitRef="usd">1837000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNS0xLTEtMS0w_1323c99d-751d-44ac-af85-a7354405aa92"
      unitRef="usd">0</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNS0zLTEtMS0w_94f53d62-d772-4c97-9a6a-05342ff4e994"
      unitRef="usd">225000</us-gaap:DueToRelatedPartiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNi0xLTEtMS0w_ec9152f0-7e47-4639-94dd-237157ce743a"
      unitRef="usd">10176000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNi0zLTEtMS0w_33d3a935-b5de-4232-89d7-6c825586c297"
      unitRef="usd">3238000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNy0xLTEtMS0w_d8ec083b-128d-4c39-85b6-7a2d08c33746"
      unitRef="usd">12252000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfNy0zLTEtMS0w_95d36bc4-1abe-413e-bb71-3c87204830d2"
      unitRef="usd">8892000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfOS0xLTEtMS0w_bfcd4d0c-ec57-445f-8b4b-0ef694c100ca"
      unitRef="usd">40474000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81NS9mcmFnOjBiMzBkYzY4NzI3ODQ0ZDY4NzE4MGFhNTM0MzIyYzQxL3RhYmxlOjMwM2QwMDQzYzBjNTQ3N2RhZTMyMzg1MGJmYTI2YzFmL3RhYmxlcmFuZ2U6MzAzZDAwNDNjMGM1NDc3ZGFlMzIzODUwYmZhMjZjMWZfOS0zLTEtMS0w_d814eb08-1b86-4c9c-9e90-18cc4f9c24b5"
      unitRef="usd">27279000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RleHRyZWdpb246M2M5MjcyODQyM2Y0NGQ2NmI4YzE5ZDBmODlhMzM5ZDlfMTEy_8f3a0143-eed6-497e-a508-60366ec6fa1e">Medical Liabilities&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RleHRyZWdpb246M2M5MjcyODQyM2Y0NGQ2NmI4YzE5ZDBmODlhMzM5ZDlfMTA4_23fd35ed-9903-4d2b-9e07-8033a99ccd76">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s medical liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to claims incurred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(178,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53,231)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232,027)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Acquired (see Note 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical liabilities, end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMS0xLTEtMS0w_20e9d90e-2694-4fbc-9bea-c882fc40646a"
      unitRef="usd">58725000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i97e0bcf361384859a17578fb87321a54_I20181231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMS0zLTEtMS0w_68fc300e-5e0a-4ab9-9025-a7b7bf58c8ed"
      unitRef="usd">33642000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMy0xLTEtMS0w_9243b087-04ab-4a89-98d1-1abac5aad030"
      unitRef="usd">229194000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMy0zLTEtMS0w_869e2671-f47a-493f-8ccf-11c0b79b0150"
      unitRef="usd">175598000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNC0xLTEtMS0w_3ed0db27-486f-48c3-aa46-36d215812792"
      unitRef="usd">1731000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNC0zLTEtMS0w_88344481-bcb9-4b3d-975f-281d8aa297aa"
      unitRef="usd">2875000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNS0xLTEtMS0w_3873d166-dca8-4cae-9a86-fa56572230d9"
      unitRef="usd">230925000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNS0zLTEtMS0w_8e13cc19-e176-405f-9243-55cbf9bcc87b"
      unitRef="usd">178473000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNy0xLTEtMS0w_ddd5f497-b60e-4cce-9924-6e0410a348c1"
      unitRef="usd">178796000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfNy0zLTEtMS0w_7c4a96f8-93ad-416a-8841-00afc682f106"
      unitRef="usd">135580000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOC0xLTEtMS0w_f14afc36-038c-4279-a5bf-b01746955de4"
      unitRef="usd">53231000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOC0zLTEtMS0w_94de9c62-d5ba-4394-a623-9e2d79452a7d"
      unitRef="usd">49164000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOS0xLTEtMS0w_f36bd648-7a73-4e86-8a03-aee2e978fbed"
      unitRef="usd">232027000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfOS0zLTEtMS0w_11b686f4-27d5-47da-8359-185c91e64c5a"
      unitRef="usd">184744000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTAtMS0xLTEtMA_2e62178a-abc9-4691-b046-7f1546c04643"
      unitRef="usd">0</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTAtMy0xLTEtMA_e07efb77-6d7c-4ae7-8bc7-1c275381b0a7"
      unitRef="usd">26404000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTEtMS0xLTEtMA_d6118b00-f823-457d-8019-cdb83dd5a1c0"
      unitRef="usd">-168000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTEtMy0xLTEtMA_b662e799-a0ff-4afb-b8cd-e750b22ad00e"
      unitRef="usd">45000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTMtMS0xLTEtMA_9275aa35-a0a8-4cd8-8f82-1345b379b6b8"
      unitRef="usd">57455000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV81OC9mcmFnOjNjOTI3Mjg0MjNmNDRkNjZiOGMxOWQwZjg5YTMzOWQ5L3RhYmxlOjNmZjZiMThlMzMyYzRhYTg5YTYzOTQxNzY0MGEwMDJjL3RhYmxlcmFuZ2U6M2ZmNmIxOGUzMzJjNGFhODlhNjM5NDE3NjQwYTAwMmNfMTMtMy0xLTEtMA_a5392ff0-0b3e-4f30-a063-2034fc767ab9"
      unitRef="usd">53820000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyOTk_908afaec-bb44-4593-9d42-1c53808db2fe">Credit Facility, Bank Loan and Lines of Credit&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s credit facility consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s credit facility for the years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company entered into a secured credit agreement (the &#x201c;Credit Agreement,&#x201d; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#x201c;Agent&#x201d;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#x201c;Lenders&#x201d;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#x201c;Guaranty and Security Agreement&#x201d;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#x201c;Revolver Loan&#x201d;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#x201c;Term Loan A&#x201d;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to pay an annual facility fee of between 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#x2019;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc. (now known as Truist Securities Inc.), the lead arranger of the Credit Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#x2019;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#x201c;LIBOR&#x201d;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio. As of September&#160;30, 2020, the interest rate on Term Loan A for the 2020 commitment and future commitments was 2.72% and 2.77%, respectively. As of September&#160;30, 2020, the interest rate on the Revolver Loan was 2.77%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#x2019;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of September&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#x2019;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#x2019;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Deferred Financing Costs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Effective Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2020 and 2019, was 3.79% and 1.31%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and nine months ended September&#160;30, 2020 and 2019, of $0.3 million and 0.1&#160;million, respectively, and $1.0 million and $0.1 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lines of Credit &#x2013; Related Party&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;NMM Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#x201c;NMM Business Loan Agreement&#x201d;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#x2019;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 3.375% as of September&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September&#160;30, 2020,  outstanding letters of credit totaled $8.2 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;APC Business Loan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#x2019;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#x201c;prime rate,&#x201d; plus 0.125%, or 3.375% and 4.875% as of September&#160;30, 2020 and December&#160;31, 2019, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $6.6 million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#x2019;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase the amount from $6.6 million to $14.8 million and extended the expiration date to December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement. As of September 30, 2020, APAACO terminated $6.6 million of the irrevocable standby letter of credit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMzM_5787cab5-8627-403d-aba1-807f450f49ac">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s credit facility consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Term Loan A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;180,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revolver loan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,500)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Unamortized financing costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock>
    <us-gaap:LineOfCredit
      contextRef="i0b9f8e50331b440ca1d55608976e9518_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfMi0xLTEtMS0w_650a1a54-d7b4-4c01-9472-d2bfe6af2036"
      unitRef="usd">180500000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i5f7f861c210b485fa4973087f3191b99_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfMy0xLTEtMS0w_2d0452e2-10e0-4c9e-950a-039d59a79c02"
      unitRef="usd">60000000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNC0xLTEtMS0w_dbdf1480-5b98-4bab-9006-54fc8758b8d3"
      unitRef="usd">240500000</us-gaap:LineOfCredit>
    <us-gaap:LinesOfCreditCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNi0xLTEtMS0w_347d3bfb-3272-492c-b36e-e77437c53616"
      unitRef="usd">9500000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfNy0xLTEtMS0w_de60e88c-7d4f-45ee-8aac-c81b8b00b1e8"
      unitRef="usd">4949000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjhiNTg0MDQwYjdmYjQ1YWRiMDEzZGZiODY4YzUwYmRhL3RhYmxlcmFuZ2U6OGI1ODQwNDBiN2ZiNDVhZGIwMTNkZmI4NjhjNTBiZGFfOS0xLTEtMS0w_fe24f708-6c3e-4fb9-850a-af69c327b1e7"
      unitRef="usd">226051000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMjc_e82f5e37-e1c3-40e9-a7c5-0ea4e32fc286">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following are the future commitments of the Company&#x2019;s credit facility for the years ending December&#160;31 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.883%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMS0xLTEtMS0w_b331b61a-12b5-43d7-8146-20f36212fc5f"
      unitRef="usd">2375000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMi0xLTEtMS0w_99ee3947-3170-4ed0-9141-374cc1039b41"
      unitRef="usd">10688000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfMy0xLTEtMS0w_3c56ab5d-0989-4922-b1d1-e6f5fdc4b3e0"
      unitRef="usd">14250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNC0xLTEtMS0w_061a5644-945c-406b-9cc3-aa5c0e549a1c"
      unitRef="usd">15437000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNS0xLTEtMS0w_84107bdb-54aa-4234-8ae2-9337dc404105"
      unitRef="usd">197750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LineOfCredit
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RhYmxlOjdkYWU5YWIyY2IyOTQzNDY5NjM4YjYzYmQwMjVjZTcxL3RhYmxlcmFuZ2U6N2RhZTlhYjJjYjI5NDM0Njk2MzhiNjNiZDAyNWNlNzFfNy0xLTEtMS0w_5270f1f2-3939-45c2-bb91-302a6ce16b14"
      unitRef="usd">240500000</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentTerm
      contextRef="if381e56ee15348f3bc78b5ba5afe4f5b_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyMzY_6488c8e0-d426-442f-9d5f-dc8ae9561483">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7d10f2758e644e3db72c221a182e8ee8_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE4Ng_cff52bf6-393e-4d4d-86eb-d37d9ec5d91e"
      unitRef="usd">100000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9a3eb4ddb0c34022a34f50d0b362b1a2_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI2Mw_6df56e9c-9f37-4e1e-890b-e6ac3ea5f11e"
      unitRef="usd">25000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i7bc9c0c0a51d4b37a867a13440d3cdac_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyMQ_f3dc43ea-f23b-4ca1-ba0f-513a3857b277"
      unitRef="usd">190000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i6464448a2a2a4ec5b5a785f7fa5b707c_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU2NQ_84ccac79-08a6-4e33-89f4-34555a316a53"
      unitRef="usd">2400000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i89bb37720e6c4641bfa4079cb6d0a971_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyMw_5ad50658-a5ac-46e6-b283-7db445cd2e2a"
      unitRef="usd">3600000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal
      contextRef="i1840189675724de797d0b54ed266c606_D20190901-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTY4NA_52731b82-03ea-4906-a3d6-1a135c3ea8a6"
      unitRef="usd">4800000</us-gaap:LineOfCreditFacilityPeriodicPaymentPrincipal>
    <us-gaap:LineOfCredit
      contextRef="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTgwNw_36f70011-ceff-4efd-bdbb-a9d9c5eb84d0"
      unitRef="usd">60000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMjQ5OQ_350c8925-c3b8-4a1a-9ea1-67d5f574aee5"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMjUwNQ_a7d1e1f2-ade3-4e43-a36a-16a301695134"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="iea5693feca944ef0a07785d7ed338d09_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzIwOA_57ffd025-5aef-484b-8bc8-aaef0959afdf"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i97da86c1492849118b5eaf8e60955a49_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzIxNQ_8e73e6f2-af3e-4ed2-ab8b-2ca0a8bd3162"
      unitRef="number">0.0300</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ifafd2a01ba954cf5a4fa6b8a6898eb70_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzMzNQ_0f38a0b4-aa9f-4d7f-ae9e-dedb27eed987"
      unitRef="number">0.0100</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9bf1f7feadeb485ea755c6837a829a0a_D20190901-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzM0Mg_fb5528f8-397b-4ef3-823a-f3e5fb2471b9"
      unitRef="number">0.0200</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="i706817fc9f1e4c5591f6224aa27f8969_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNzE0NjgyNTU5NzMwNg_3bbb7a68-94eb-48bc-a900-e5f00ed45f17"
      unitRef="number">0.0272</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i0b9f8e50331b440ca1d55608976e9518_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzQ4NQ_664c658f-5158-4a41-8901-9109da24ddd6"
      unitRef="number">0.0277</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i5f7f861c210b485fa4973087f3191b99_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzQ5Mg_a05ca9d4-fdfc-4ef5-a180-723fc89f040d"
      unitRef="number">0.0277</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7b193ff3b0534bf4b1e4ee91abf86721_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzY3NA_0fca502d-13f7-4b43-836f-50555f9492d4"
      unitRef="number">0.0200</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i7903d4186900495da7128f6613b226b5_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMzY4MQ_dda4b888-00cc-427a-9989-2b0af49f6489"
      unitRef="number">0.0300</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ameh:DebtInstrumentNumberOfKeyFinancialRatios
      contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTYwMw_2bfbc33f-461e-46f6-98da-064ae4cb77d0"
      unitRef="financial_ratio">2</ameh:DebtInstrumentNumberOfKeyFinancialRatios>
    <ameh:DebtInstrumentCovenantLeverageRatioMaximum
      contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTc1Mw_9b8b4bc9-31ce-446d-a87f-5c8e01b0345e"
      unitRef="number">0.0375</ameh:DebtInstrumentCovenantLeverageRatioMaximum>
    <ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange
      contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTg2MA_5c82b83a-5a3d-4659-9b12-637e9a1d12f4"
      unitRef="number">0.0025</ameh:DebtInstrumentCovenantLeverageRatioIncrementalChange>
    <ameh:DebtInstrumentCovenantLeverageRatioMinimum
      contextRef="i19ea8be5b0d148fa96b05e8fc0ed2e02_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNTg5Nw_72bdcabe-6a5c-44a2-96e7-970d07d51f7f"
      unitRef="number">0.0300</ameh:DebtInstrumentCovenantLeverageRatioMinimum>
    <ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum
      contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNjAzOQ_1aedd370-4daf-4b54-9ad7-25600949b542"
      unitRef="number">0.0325</ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="i58a3a78950614f498d426b1d4c78e52d_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfNzM1OQ_99bb96fc-fa0e-4daa-bc7f-2eba6f2788d4"
      unitRef="usd">10000000.0</us-gaap:DebtDefaultLongtermDebtAmount>
    <ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage
      contextRef="i3792f3a4ad1b4e6e9af66d3b5eae396b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODMzMQ_2d7d0249-a2de-4410-a5e1-0610ae7baefe"
      unitRef="number">0.5001</ameh:DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage>
    <us-gaap:DebtDefaultLongtermDebtAmount
      contextRef="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODQzNQ_c6cc17ce-b222-433b-9a2c-ac71994ed832"
      unitRef="usd">50000000.0</us-gaap:DebtDefaultLongtermDebtAmount>
    <ameh:DebtInstrumentApprovedThresholdUseOfFunds
      contextRef="ia22f6a5e59424099a3b2c4cdbe84fd48_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfODk2Nw_cd9f78db-a01a-4965-958f-a73ea777d528"
      unitRef="usd">125000000.0</ameh:DebtInstrumentApprovedThresholdUseOfFunds>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet
      contextRef="i93cfaa8005fd4643a526cc34f2d3e6c8_I20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA0OTk_11b54a6b-de92-40e3-a9ca-5a9b1bd2eeda"
      unitRef="usd">6500000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA5MTE_30fa0809-32f1-4491-a693-ea92243bc776"
      unitRef="number">0.0379</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTA5MTg_143c092f-586e-4b57-9f71-8434f9caad96"
      unitRef="number">0.0131</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:InterestExpense
      contextRef="i98837eb98d97440f9bd5671b34f7d76f_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTEwOTc_d7fcc91e-3462-4721-a403-ca4c362fb14a"
      unitRef="usd">300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIwOTQ2Mjc5MjMzNjc_b5a0fd7a-82b1-45bb-a3f9-61c9fe3e34ed"
      unitRef="usd">100000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia053d843d611409ea6e794c9fe247e3e_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTExMDQ_d84451eb-65e7-4d04-a37b-a9e6dbab48c2"
      unitRef="usd">1000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2d2faa056f9d41c4b1afb2d3b5737129_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTExMjY_b938eee8-830c-416a-92a1-9f96752d1a2e"
      unitRef="usd">100000</us-gaap:InterestExpense>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icbffe9564ff44d1bab6086b082b64111_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTEzNDk_15f0f98d-8127-4d4b-91c6-f21677a035af"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="icbffe9564ff44d1bab6086b082b64111_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE1NzM_15f0f98d-8127-4d4b-91c6-f21677a035af"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i664bd167ed344f5b97bb3dcf459676e0_I20180901"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE1Nzk_a031c2e5-d032-4adb-9589-4e0eb4de3442"
      unitRef="usd">27000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i7931a6ac521043ada1f90c0f74afa693_D20181231-20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE3OTY_40b7ad45-3ea8-4a2c-803b-99f3865b9a26"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i2255233ea20d48f0a140daa8b2135d19_I20181231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE4MDM_0be593b1-5200-4b51-8153-813fadb0bbfe"
      unitRef="number">0.05625</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCredit
      contextRef="i0804ee2cd49c471cb1750e3eb02c9f51_I20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTE5OTA_c5edca2a-9837-424c-873f-aaf49069043e"
      unitRef="usd">5000000.0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i342f2e70889b49b8b01eb66a3ed09a94_I20180905"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIxNDk_34dfb551-1243-4f27-96e9-ef4498e735c2"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i342f2e70889b49b8b01eb66a3ed09a94_I20180905"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyNzg_34dfb551-1243-4f27-96e9-ef4498e735c2"
      unitRef="usd">20000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i216418c12a70419bacb688b1427cd129_I20190417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyODQ_74b93da8-7177-4ca7-b816-5cacbcc1b75a"
      unitRef="usd">16000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i216418c12a70419bacb688b1427cd129_I20190417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIyOTY_74b93da8-7177-4ca7-b816-5cacbcc1b75a"
      unitRef="usd">16000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9b3115de9851458d8e5935842bd881cb_I20190729"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIzMDI_6dddbd17-7cf8-444c-8d66-5bc9252b6d7f"
      unitRef="usd">2200000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ie30b8de9297c42469c822858d3e54b70_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTIzOTM_dcf92fd3-f455-44c9-b2dd-bf4644cdb385"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i478deb2fc38c436bb8671cb70199cee5_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI0MDA_1dc0da65-d68c-426c-b6ea-35944eb480fd"
      unitRef="number">0.03375</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="id5f4624aad0143a38ac09f171403b362_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTI0MTc_79232365-8bfe-47f4-8ee3-7751eba70dfe"
      unitRef="number">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties
      contextRef="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzMTY_1200bf1e-7a43-4c3d-8d34-61cfba633e6d">P5Y</ameh:LineOfCreditFacilityGuaranteeGivenByRelatedParties>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i4cf9746ed2f14e76a70fe0edf24c3d3d_D20180905-20180905"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyODU_37bd6295-2cf3-4291-8555-d67f12d7d508">P5Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="i78348153cd274034948535714f61bce6_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyNjA_a47235d0-5375-454f-b181-66fc2cfa7e67"
      unitRef="usd">8200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i2919814c52aa4e6c96480fc7e55b85c0_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTMyODM_235c3507-9659-444e-9f44-fb7b1464fc04"
      unitRef="usd">10200000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9ba211b652284a1ba866c7ef68ae48e9_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM0ODk_089e931b-4b25-490b-8c13-3786c33721d5"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i9ba211b652284a1ba866c7ef68ae48e9_I20180614"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM2MjA_089e931b-4b25-490b-8c13-3786c33721d5"
      unitRef="usd">10000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i88976d0744e74325abde725693423c49_I20190417"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfOTg5NTYwNDY2NzA5Nw_c8f936a7-b735-47b3-90e5-687fc90e69e3"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="if2a2fbcc8b234d85af151b72dc525ee1_I20190611"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM3NjE_5e02785b-1c80-47e5-85ac-0109125c0aaf"
      unitRef="usd">40000000.0</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM3Njc_1aaf049c-e740-4679-a6b6-e1f449ff99f4"
      unitRef="usd">43800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic3b1d557c3db4e3d8a71c42c5837e75e_I20190801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM4MDc_1aaf049c-e740-4679-a6b6-e1f449ff99f4"
      unitRef="usd">43800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i5bd06a67515e4d6c816adb0fc9c88a81_I20190910"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTM4MTM_6fa225b9-59b0-4b10-ab7a-fa5465246fa5"
      unitRef="usd">4100000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if7993c591aa442349f5e43bcd84f0f49_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNjE_915f0c92-bee0-4ba7-81a7-d4f9a25f0b54"
      unitRef="number">0.00125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i108d951874b443008dbdf9ebfe69c2ab_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNjg_e56dee86-8122-4997-818a-74803605415b"
      unitRef="number">0.03375</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="i7f4ba9139fca44899bc4ca327e9849b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQzNzU_bc50cbc1-bc4c-4fb1-b0fc-5cda189f4372"
      unitRef="number">0.04875</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i108d951874b443008dbdf9ebfe69c2ab_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ0Mzg_ada82a30-9f9b-4e99-b8d2-6d043bbfb344"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="i7f4ba9139fca44899bc4ca327e9849b9_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ0Mzg_b886d512-2def-43b9-9699-435864c70dc1"
      unitRef="usd">0</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i583b6b592ac24c3f805e3c210ab44386_I20181002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ2NDU_e9a5dd37-6b6b-4eb1-a1aa-67969efb3cfe"
      unitRef="usd">6600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYzNDI_de25e6e8-fe31-4e27-ad58-94f7efba9a88">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification
      contextRef="i07023ae17c5a4884ae4aef4219d8fe01_D20181002-20181002"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTQ4OTI_cc9134cf-6e1b-40a0-a56b-1c5c3046e9c4">P90D</ameh:LineOfCreditFacilityExpirationPeriodPeriodOfNotification>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i583b6b592ac24c3f805e3c210ab44386_I20181002"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTUxMjk_e9a5dd37-6b6b-4eb1-a1aa-67969efb3cfe"
      unitRef="usd">6600000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ib720ede0911c4e8d80c33fc1220eba1a_I20190814"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTUxMzU_1fe1e709-b2ef-4509-b434-116dc508efe8"
      unitRef="usd">14800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <ameh:LineOfCreditFacilityTerminatedAmount
      contextRef="i04eca9b9464f4a60a87145ab44e5bb1f_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfOTM0NTg0ODg1MzIwMw_c153ded1-a920-4743-8fdd-c6af10f9a08e"
      unitRef="usd">6600000</ameh:LineOfCreditFacilityTerminatedAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic7e3933a8b4246618d18872a39beb676_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU0ODg_38c9f8db-8652-4909-b202-492bb2e273a4"
      unitRef="usd">300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i7d02e70680ae437eab0be807ca3d050a_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyNDk_8c7b12d7-8dc7-415d-bb39-a39d3944ab5e">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i6dec8773fada4b24852d9aae4143d84b_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTU5MjU_f7fe0e7b-37cf-40ce-8ae1-a36ec2bfe07d"
      unitRef="usd">3800000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i1b34349d244644a9af65d1269f0191e4_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82MS9mcmFnOjAwNGQ0ZjE2ZTUzOTRjMjdiNTFiMmM5YjY5ZmQ0NDNiL3RleHRyZWdpb246MDA0ZDRmMTZlNTM5NGMyN2I1MWIyYzliNjlmZDQ0M2JfMTYyODY_68f84a40-e5e8-4d9d-b7ed-1f1c03689dcd">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1NA_d69ad4bb-a30d-46ca-bcdc-ebc7c1422116">Mezzanine and Stockholders&#x2019; Equity&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mezzanine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#x2019;s shares are not redeemable and it is not probable that the shares will become redeemable as of September&#160;30, 2020 and December&#160;31, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, 302,732 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020 and 2019, stock options were exercised for 120,000 and 203,524 shares, respectively, of the Company&#x2019;s common stock, which resulted in proceeds of approximately $0.3 million and $1.2 million, respectively. The exercise price ranged from $2.10 to $5.00 per share for the exercises during the nine months ended September&#160;30, 2020, and ranged from $1.50 to $10.00 per share for the exercises during the nine months ended September&#160;30, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020 and 2019, no stock options were exercised pursuant to the cashless exercise provision.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Board Members&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#x2019;s closing market price of the Company&#x2019;s common stock. During the nine months ended September&#160;30, 2020, the Company granted restricted stock awards totaling 97,447 shares with a weighted average grant date fair value of $17.58. The grant date fair value of the restricted stock was $1.6 million and will be recognized on a straight-line basis over the awards&#x2019; vesting period of three years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020, the Company recorded approximately $0.6 million and $2.2 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which are included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2020, was $3.1 million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                                              $                     9.00 &#x2013;11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020 and 2019, common stock warrants were exercised for 800,709 and 133,221 shares, respectively, of the Company&#x2019;s common stock, which resulted in proceeds of approximately $6.2 million and $1.2 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the nine months ended September&#160;30, 2020 and 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, common stock warrants were exercised on a cashless basis for 127,022 shares of the Company's common stock which resulted in the Company issuing 66,517 net shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Treasury Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC owned 17,307,214 and 17,290,317 shares of ApolloMed&#x2019;s common stock as of September&#160;30, 2020 and December&#160;31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of September&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$7.6 million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020 and 2019, APC paid dividends of $49.5 million and $59.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended  September&#160;30, 2020 and 2019, CDSC paid dividends of $0.6 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <ameh:StockIssuedDuringPeriodSharesMerger
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDM5_b6bb4e7b-3e08-4e3c-b9ed-78b869b2147b"
      unitRef="shares">302732</ameh:StockIssuedDuringPeriodSharesMerger>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1OQ_baf0e2e5-3bc3-4698-81cd-e0f1bd3c636a">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding stock options consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.853%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.917%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;607,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(120,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.45&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercisable at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS0xLTEtMS0w_ac96dddc-5699-48f2-b5ee-d6fd5c274489"
      unitRef="shares">607346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS0zLTEtMS0w_d128d948-8fe0-41bb-b86b-91ab136c0db1"
      unitRef="usdPerShare">9.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS01LTEtMS0w_df260705-918c-40fc-a0e2-549903ec6769">P3Y5M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMS03LTEtMS0w_b20a075c-b61d-440d-8429-960de1e38e9e"
      unitRef="usd">5600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMi0xLTEtMS0w_418041dc-ef93-4bbb-a69c-ef25e5120a07"
      unitRef="shares">11742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMi0zLTEtMS0w_5c7835b9-7e69-4780-bda2-a43dcbc15bea"
      unitRef="usdPerShare">18.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy0xLTEtMS0w_760a2468-6d74-43cb-a3cd-b26b9069a6f0"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy0zLTEtMS0w_4fca90b2-e85a-44bc-8693-56dd4789e0cc"
      unitRef="usdPerShare">2.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfMy03LTEtMS0w_d76d2594-8836-46f8-b7f0-005b8594e033"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNC0xLTEtMS0w_83b0dcd6-6c61-48c9-aa68-7319a8c27426"
      unitRef="shares">12228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNC0zLTEtMS0w_5d87063c-133e-4934-bfa3-9448b2048aa4"
      unitRef="usdPerShare">17.57</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi0xLTEtMS0w_9be4af04-88bc-4505-ad2c-ae82bff86876"
      unitRef="shares">486860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi0zLTEtMS0w_206f2137-0a53-4e03-b959-bc805dc8003b"
      unitRef="usdPerShare">10.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi01LTEtMS0w_e798a05f-a491-4f5e-b373-c5b58eb28b64">P3Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfNi03LTEtMS0w_7e1c8d80-6789-457b-b44f-d314bcd8c156"
      unitRef="usd">3300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC0xLTEtMS0w_bd5a5120-abfe-4963-a3ab-da5ac662976e"
      unitRef="shares">405833</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC0zLTEtMS0w_74a9f12d-3c3d-444f-be29-985d66f640e3"
      unitRef="usdPerShare">7.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC01LTEtMS0w_8dc56bac-8767-465c-9db3-9d44e35cf34c">P2Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOmYyZjkzMDE2NzVmNDQ5ZGM5Y2NhNmE0NzY5NjNlYTQ4L3RhYmxlcmFuZ2U6ZjJmOTMwMTY3NWY0NDlkYzljY2E2YTQ3Njk2M2VhNDhfOC03LTEtMS0w_245aed07-4936-440b-abf3-f1b337b03dfd"
      unitRef="usd">3500000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTU3OQ_d5e1d0d3-3fde-4181-b8e3-804e3f0ab3b8"
      unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTU4Ng_075a4185-8bec-489c-bf9b-393e88132736"
      unitRef="shares">203524</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i436d289510454727bc5fddbf12ad2d92_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY4Ng_241160ba-a9ee-4782-889b-874ba77c246b"
      unitRef="usd">300000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="icece81cce5fb4924bcbe69d05e4dcc7d_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY5Mw_64913ab2-3323-45af-bf20-077b7af0f9c0"
      unitRef="usd">1200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTc0Mg_22d34da4-5885-4bd3-9820-1f4549d00f9d"
      unitRef="usdPerShare">2.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTc0OA_2c2aa8e2-c71b-4afb-84b8-b56f70c083ee"
      unitRef="usdPerShare">5.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2717bab98fa54dc792c95e77b5b141e4_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTgyNg_0b166342-b690-4df8-b188-764e684eaa8c"
      unitRef="usdPerShare">1.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i87dbbc859a844154beab63a0f933c8ba_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTgzMg_c0b8ed8d-ffd9-4b00-8004-fb1e51880aa8"
      unitRef="usdPerShare">10.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTkzMg_2182e4bf-22fe-448d-b4e7-dfcb7b3c4a17"
      unitRef="shares">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTkzMg_b34df0dc-f52b-407f-bc81-0dc683074258"
      unitRef="shares">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1Ng_657a4432-f3ef-4780-923e-eceb5c12267c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the nine months ended September&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.158%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Board Members&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Market value of common stock&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Annual dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forfeiture rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjA2MA_a6c13dce-9896-49e5-b2eb-6f574a1e5152"
      unitRef="shares">11742</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i943e4302b105480e8a3a578a84a18038_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY1OA_f8aa26a7-99af-42c4-b95b-8d94eea36a14">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjE3Mg_da9012f1-6e92-44a9-82e7-fa460ed8feb9"
      unitRef="usdPerShare">18.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMS0xLTEtMS0w_c3315e93-d0b8-40eb-94f5-78f300d3cddc">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMi0xLTEtMS0w_34d24013-2707-4dcc-9ad9-3ee9ce77b1e8"
      unitRef="number">0.9001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfMy0xLTEtMS0w_a398562a-491e-42f6-9cd3-f7172a1fef1f"
      unitRef="number">0.0143</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharePrice
      contextRef="i7345dd7c68aa43a186e8ee7e384e34d2_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNC0xLTEtMS0w_79006bfd-990d-4bf3-8c89-8c4b5644b762"
      unitRef="usdPerShare">10.56</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNS0xLTEtMS0w_42fcbae6-75d0-403b-8cc8-5a3db4d0c80c"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
      contextRef="i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjIyODllNmZhYThlODQyMjg4OGFmMDc4OTQ1ZWM0NDM5L3RhYmxlcmFuZ2U6MjI4OWU2ZmFhOGU4NDIyODg4YWYwNzg5NDVlYzQ0MzlfNi0xLTEtMS0w_376f70cf-1570-4784-b3a1-1b77f0cf4247"
      unitRef="number">0</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjYzOA_620b1fa0-76d7-47e9-b657-2d23457a02d6"
      unitRef="shares">97447</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjY5Nw_2f0ccf66-a34e-4c8b-b4da-fa589b5ffd2a"
      unitRef="usdPerShare">17.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="if71d1171a6d540fa8cb9f4771cd113ae_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjc1NQ_7908be1b-8b4c-4074-8838-e872ddc282d4"
      unitRef="usd">1600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjgzNQ_f14e0a15-ffb2-445f-8917-6e1f8779ad98">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensation
      contextRef="i1fde585401744bfc8f98fcb6e5d4c55a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjkxMw_9804994e-4f5e-4d83-8499-939e40c358cd"
      unitRef="usd">600000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i23e0d39597534b0cb2e0780e98c762e1_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMjkyMA_13b9d303-554b-4cc7-b5e4-b93bc5c3997b"
      unitRef="usd">2200000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="if71d1171a6d540fa8cb9f4771cd113ae_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzI3OA_e2ff295d-da23-4701-bb1e-63084ddefef3"
      unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDY2MA_d498ce74-a223-41a0-96b0-d68b1fda4b1c">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s outstanding warrants consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.813%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants outstanding at January&#160;1, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,154,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(800,709)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants expired/forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants outstanding at September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.052%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.467%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.642%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&#160;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;br/&gt;Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual&#160;Life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercisable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Exercise&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.19&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;799,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$                                              $                     9.00 &#x2013;11.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,353,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS0xLTEtMS0w_1852c9b3-e7a3-4f80-b5c5-7966b889f19f"
      unitRef="shares">3154590</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS0zLTEtMS0w_e5ba4a24-2022-4668-8499-f2922a717ba2"
      unitRef="usdPerShare">9.96</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i8c74afc1b063473b8d5e4045f13ebe92_D20190101-20191231"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS01LTEtMS0w_61aa3061-00c2-4cbd-86da-6dc12f9aa981">P2Y3D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMS03LTEtMS0w_011adf66-5575-4faf-a2fc-acd60f2dc6b6"
      unitRef="usd">26700000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsGranted
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi0xLTEtMS0w_477fb1f1-e4ea-4ae2-b308-a4bd85fbe8a3"
      unitRef="shares">0</ameh:NumberOfWarrantsGranted>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi0zLTEtMS0w_07eceac4-b618-4853-bd7a-946e7ef6e797"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod>
    <ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMi03LTEtMS0w_083ee033-6674-47e4-b9ef-de24dd4a6a4e"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue>
    <ameh:NumberOfWarrantsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy0xLTEtMS0w_34a5fd67-9d32-466b-9c67-03fe61e1ad7c"
      unitRef="shares">800709</ameh:NumberOfWarrantsExercised>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy0zLTEtMS0w_cc12bd4c-bfd4-4e72-ba83-f2193fc78e96"
      unitRef="usdPerShare">9.22</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod>
    <ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfMy03LTEtMS0w_55278e80-35b4-47d0-9a6c-5565b61217bc"
      unitRef="usd">6000000</ameh:ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue>
    <ameh:ClassOfWarrantOrRightCancelledInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC0xLTEtMS0w_19fa4408-776f-4ca1-9d81-158dbe6bd2cf"
      unitRef="shares">0</ameh:ClassOfWarrantOrRightCancelledInPeriod>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC0zLTEtMS0w_603b4e47-00cb-49fc-b581-9f4faed6bbc2"
      unitRef="usdPerShare">0</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod>
    <ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNC03LTEtMS0w_2fb61c41-7e6c-4163-b05a-03c75120d04d"
      unitRef="usd">0</ameh:ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi0xLTEtMS0w_a165b04a-f445-46f6-8eee-5790a5b0381a"
      unitRef="shares">2353881</us-gaap:ClassOfWarrantOrRightOutstanding>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi0zLTEtMS0w_1d7258ce-ea69-48c6-b2f8-f4b55fb73e4b"
      unitRef="usdPerShare">10.21</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi01LTEtMS0w_c299d31b-0d11-43fc-81b8-ff4bfc2f8a47">P1Y7M13D</ameh:ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjYwZDI3OGE2OTRjNjRhM2U4ZmNiMzZlYjU5YmVmYmZkL3RhYmxlcmFuZ2U6NjBkMjc4YTY5NGM2NGEzZThmY2IzNmViNTliZWZiZmRfNi03LTEtMS0w_596e1d44-7c81-48b1-bc05-e86dba1792d7"
      unitRef="usd">18200000</ameh:ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS0wLTEtMS0w_9fcb0627-162e-4511-b054-97d00ee3260b"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="if52999aec2ec48c3a27829576d274249_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS0yLTEtMS0w_41b94bdd-6ad5-429f-a2d2-d0395979ed77"
      unitRef="shares">305812</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="if52999aec2ec48c3a27829576d274249_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS00LTEtMS0w_8e1a9e70-4a38-4a69-b2cb-da02f822587a">P0Y14D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS02LTEtMS0w_4534228d-2ec5-45aa-8d97-c368bc37e3ae"
      unitRef="shares">305812</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="iccaa606008644356ae9b3ada3f0dee0a_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMS04LTEtMS0w_f99eb68e-2279-4e18-9976-e811e507a020"
      unitRef="usdPerShare">9.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi0wLTEtMS0w_75364ada-f1bc-44d6-9568-dc9ed3efd87d"
      unitRef="usdPerShare">10.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi0yLTEtMS0w_51f0f791-65ea-41e9-ae6c-a555c3ac6793"
      unitRef="shares">1248779</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i9a42c03d1f424fcb8bae56b607e70e1b_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi00LTEtMS0w_2ae9bdda-e13f-4da3-8e7b-9a29694e436a">P1Y7M20D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi02LTEtMS0w_3320dd46-88f8-4278-a0b2-01b084d6dd35"
      unitRef="shares">1248779</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="i01d22b3114f046ea83ddfddc5c0603e6_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMi04LTEtMS0w_36463278-1b8d-401f-9834-ead2d260dd78"
      unitRef="usdPerShare">10.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy0wLTEtMS0w_bcc94cd2-1305-4552-a03c-20707805d523"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy0yLTEtMS0w_ce3ef543-07ba-4181-b0e8-9611aa099955"
      unitRef="shares">799290</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i5f2733f3b30540428e5098191eeec09d_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy00LTEtMS0w_986e0ecd-e866-4d2e-aded-ab0d8cd2cb10">P2Y2M8D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy02LTEtMS0w_7233828b-3fa9-436a-a87b-281b383944d1"
      unitRef="shares">799290</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="iad5fbe5e3ab34ec19cb0ab26ccdb8338_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfMy04LTEtMS0w_d3c3ad99-fea4-4eb8-995b-f9bd22885bb3"
      unitRef="usdPerShare">11.00</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i7d2649df80d34fa2a5160241cddb24f7_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0wLTEtMS0wL3RleHRyZWdpb246NmU3YjQ1YjVlYWIwNDhlNThjNzhmODVhM2ExNTU5NzVfNzM_02441abb-0ee4-46fc-96dd-89ab2bb404d9"
      unitRef="usdPerShare">9.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i682e56c134fe472db3d942dee2c67e9e_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0wLTEtMS0wL3RleHRyZWdpb246NmU3YjQ1YjVlYWIwNDhlNThjNzhmODVhM2ExNTU5NzVfNzc_3aa87ea5-a338-400d-8fd7-701bd0d7937b"
      unitRef="usdPerShare">11.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ameh:ClassOfWarrantOrRightIssuedInPeriod
      contextRef="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS0yLTEtMS0w_0c7cc3ec-398f-4b44-b328-e35283d3f740"
      unitRef="shares">2353881</ameh:ClassOfWarrantOrRightIssuedInPeriod>
    <ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm
      contextRef="i83075f5b5af94e93a32ffe72f78caffd_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS00LTEtMS0w_cbe2fd60-dda0-49f7-b6d5-6bb69171682d">P1Y7M13D</ameh:ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm>
    <ameh:ClassOfWarrantOrRightExercisable
      contextRef="ic96250cdb31545618a1db18666cefafa_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS02LTEtMS0w_67e9a711-d9be-4f44-bd0c-a2438850fdf6"
      unitRef="shares">2353881</ameh:ClassOfWarrantOrRightExercisable>
    <ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants
      contextRef="ic96250cdb31545618a1db18666cefafa_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RhYmxlOjNlNTUyYTJjMTc3ZDQ0MjY4YTM3MGM1NWMyZjFiZTcyL3RhYmxlcmFuZ2U6M2U1NTJhMmMxNzdkNDQyNjhhMzcwYzU1YzJmMWJlNzJfNS04LTEtMS0w_25339aa0-93ac-4fd2-bd0d-b7e52ece41f0"
      unitRef="usdPerShare">10.21</ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzQzOQ_ffaa3763-5a7d-49ef-aa60-22bd101eda2b"
      unitRef="shares">800709</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzQ0Ng_1ee407b0-aef9-4675-957c-51a1ab4e9825"
      unitRef="shares">133221</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzU0Ng_784497a8-e6ae-4889-aff6-02e88bd8f5b6"
      unitRef="usd">6200000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzU1Mw_2a8fb4ff-f61f-4c74-9188-6d0750914c20"
      unitRef="usd">1200000</ameh:WarrantIssuedDuringPeriodValueStockOptionsExercised>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i7fffdf8dcd1749a7ace51d887d2f7aee_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwMg_a6996f9d-1642-4851-acf2-9c50f700b185"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="idf5d96c5aa524dee8cf3659f677f11b5_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwMg_babf812a-1c0f-40fd-ae3d-31958621c53a"
      unitRef="usdPerShare">9.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="if3710a3c83db42d0805599a74145dff2_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwOA_8e882b6a-6254-4663-9a27-c0e9e9eab47b"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice
      contextRef="i667dccd4fd1249cd8140d4285faf7f12_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzYwOA_a4af4adb-46da-4282-b951-1e58e148788e"
      unitRef="usdPerShare">11.00</ameh:ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice>
    <ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMTY0OTI2NzQ0MjE1MDI_18ae0687-e327-4eda-af61-73feca1a4113"
      unitRef="shares">127022</ameh:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod>
    <ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfOTM0NTg0ODg0MTM3Mw_5e9f2cc2-6ab3-407b-9b6e-876678a03b8a"
      unitRef="shares">66517</ameh:StockIssuedDuringPeriodSharesCashlessWarrantsExercised>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i558ed222ce35492c86d5800acda7c4c6_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzcxNg_661e008b-f018-41f9-8c52-732f340a3cd1"
      unitRef="shares">17307214</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ic3263f1c5abf42b98d4605f4f7284e83_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfMzcyMw_7845f9bf-fe8a-4e15-99d5-c35d611256d2"
      unitRef="shares">17290317</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockValue
      contextRef="i23c4dccf62634d3b92148d57ea541c66_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDM3Mg_00668425-15bf-4c1a-9998-11bb0921d633"
      unitRef="usd">7600000</us-gaap:TreasuryStockValue>
    <us-gaap:Dividends
      contextRef="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDU0Mw_633e8aab-89f4-4dec-898f-1f5149905a0f"
      unitRef="usd">49500000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="if8031dd6b66546c1a3ac173850d16bd4_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDU1MA_93e628fe-4f29-47b2-aaa2-1c6c4938d5a4"
      unitRef="usd">59700000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="i56c177ebcb7d435c971aa73fe7a5ef54_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDYzMQ_ecfb6ea9-6e95-4d46-81fa-8339902dde94"
      unitRef="usd">600000</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="if3b51820704a4a93b98fa96a6930977c_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV82Ny9mcmFnOmRiZDljMTZiN2E0ODQ2ZmM4YjBmYjQ0NmRjMDA3NTZjL3RleHRyZWdpb246ZGJkOWMxNmI3YTQ4NDZmYzhiMGZiNDQ2ZGMwMDc1NmNfNDYzOA_0966c212-d877-475d-beb2-a02701aa6205"
      unitRef="usd">1200000</us-gaap:Dividends>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2NQ_abdbdfe4-2a5b-45b2-977b-734a53f25ee8">Commitments and Contingencies&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#x201c;TNE&#x201d;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;September&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of the Company&#x2019;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Standby Letters of Credit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to 2% of the Company&#x2019;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit under the Credit Agreement for a face amount of $8.2 million for the 2019 performance year (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#x2019;s financial condition, cash flows or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Prospect Medical Systems&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#x201c;Prospect&#x201d;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#x2019;s purported business plans, seeking damages in excess of $5.0 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#x2019;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that its insurance coverage is appropriate based upon the Company&#x2019;s claims experience and the nature and risks of the Company&#x2019;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#x2019;s affiliated professional organizations or the Company&#x2019;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#x2019;s insurance coverage, will not have a material adverse effect on the Company&#x2019;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#x2019;s business. Contracted physicians are required to obtain their own insurance coverage.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <ameh:PercentageOfFinancialGuaranteeBenchmarkAmount
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMTg3OQ_f4df55a1-23c6-4054-a35c-86be5fddb9f3"
      unitRef="number">0.02</ameh:PercentageOfFinancialGuaranteeBenchmarkAmount>
    <us-gaap:LineOfCredit
      contextRef="ic0f9aa10906f4d2c9652027d594046aa_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjA0MQ_47985b41-035a-485e-96fb-b112cb272f78"
      unitRef="usd">8200000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit
      contextRef="i486cfce3128a43d1b5f0abe01fe3ec4a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjIwMw_48abe2cc-d02c-4b97-8d73-bbef47fe8471"
      unitRef="usd">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i1d7273f768df4eb690b7413548307158_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2Ng_c95ffd6e-242e-4a1b-b3f2-2d72dc3c55e7">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities
      contextRef="ifeddb663bcd34a33b0a3c19d9b40f607_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMjYyNA_edff611f-9b35-4d1d-b666-b2fb5dcbdc90"
      unitRef="usd">3800000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities>
    <us-gaap:LineOfCreditFacilityExpirationPeriod
      contextRef="i29325e7277374944a4b7e5d32f0a71ce_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfNTk2NA_9cd7170b-be33-4306-b26c-d0fdd8a2376a">P1Y</us-gaap:LineOfCreditFacilityExpirationPeriod>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i94cbfc093bc14eaf945f211b23c1507e_D20180323-20180403"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83MC9mcmFnOmNkYmIxMTdjM2Q3MDRlNTI4ZmU4M2MwODRlYWVhOTUzL3RleHRyZWdpb246Y2RiYjExN2MzZDcwNGU1MjhmZTgzYzA4NGVhZWE5NTNfMzY4OA_6778cb83-27fd-4fae-99e2-cfd9882be4dc"
      unitRef="usd">5000000.0</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI2NDQzODM3MjUxMzk_3ff00efa-84f3-492f-8b31-7cabac2d4fc4">Related-Party Transactions&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5.0 million. On June 28, 2018 and November 28, 2018, UCAP entered into two additional subordinated note receivable agreements with UCI in the amount of $2.5 million and $5.0 million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright (see Note 6).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, NMM earned approximately $4.2&#160;million and $4.4 million, respectively, and  $12.6 million and $12.9 million, respectively, in management fees from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC in LMA&#x2019;s IPA line of business (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $0.5&#160;million and $0.7 million, respectively, and $1.5 million and $2.1 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $1.2&#160;million and $2.0 million, respectively, and $3.8 and $5.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $0.1&#160;million, respectively, and $0.2&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately $7.1&#160;million and $6.7 million, respectively,  which include approximately $1.7&#160;million and $1.8 million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $23.4 million and $23.1 million, respectively, to shareholders of APC for provider services, which include approximately $6.5 million and $6.9 million, respectively, to shareholders who are also officers of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately $0.3 million, respectively and $0.8 million, respectively, to Medical Property Partners (&#x201c;MPP&#x201d;) for an office lease. MPP shares common ownership with certain board members of NMM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020, NMM paid approximately $0.4&#160;million and $1.1 million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly 50% owned by Drs. Sim and Lam.  As of September&#160;30, 2020, the Company had $10.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended September&#160;30, 2020 and 2019, the Company paid approximately $39,000 and $0.1 million, respectively, and paid approximately $0.3 million for both the nine months ended September&#160;30, 2020 and 2019, to Critical Quality Management Corporation (&#x201c;CQMC&#x201d;) for an office lease. CQMC shares common ownership with certain board members of APC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For both the three and nine months ended September&#160;30, 2020 and 2019, SCHC paid approximately $0.1&#160;million, respectively, and $0.3 million, respectively, to Numen, LLC (&#x201c;Numen&#x201d;) for an office lease. Numen is owned by a shareholder of APC. As of September 30, 2020, the Company had $1.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with Numen to be amortized over the remaining life of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreements with HSMSO, Aurion Corporation (&#x201c;Aurion&#x201d;), and AHMC Healthcare (&#x201c;AHMC&#x201d;) for services provided to the Company. One of the Company&#x2019;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#x2019;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO and Aurion (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $10.5 million and $11.0 million, respectively, and $31.5&#160;million and $31.9 million, respectively, for which $36.9 million and $40.4 million remained outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately&#160;$0 and $0.1 million, respectively, and $27,000 and $0.2 million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, affiliates wholly owned by the Company&#x2019;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#x2019;s &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#x2019;s subsidiaries as related-party transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ib1163ece356545148c6d18c1e1d66912_I20151116"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTMw_12258715-eca6-4e35-b773-c860809f4e5c"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i358387cf1a564a2297e5f1abdf9f5f42_I20151116"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTkz_cbf58c23-01fc-4d35-8869-e0acd2e8a976"
      unitRef="usd">5000000.0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements
      contextRef="ie07ae9f744764e5291d906d251e2034a_I20181128"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjU1_d79df2ad-7a63-42fc-9a16-5b6766f40784"
      unitRef="agreement">2</ameh:AccountsAndOtherReceivablesNumberOfAdditionalAgreements>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="i7aeb75119c51484cb3d7c560edf10ae8_I20180628"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzM1_87fb8d58-26a6-435d-9a86-f5a39d263042"
      unitRef="usd">2500000</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:AccountsAndOtherReceivablesNetCurrent
      contextRef="ie07ae9f744764e5291d906d251e2034a_I20181128"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzQy_46a05f63-1eaa-42e7-a5fb-7e332e9babda"
      unitRef="usd">5000000.0</us-gaap:AccountsAndOtherReceivablesNetCurrent>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i81d7b1f95e2749528c65d9be013d2d5e_I20200430"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDU3_b28a590b-affe-4086-a113-bd5775d9e4da"
      unitRef="number">0.489</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i7c5294ed64c44b5086f5be21d0bce6cd_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNTgw_83bb547e-602e-43be-9b76-d23cccebc7df"
      unitRef="usd">4200000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="icaa2e771930d42a3b26e519f82d67bf8_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNTg3_a67a38a5-94c0-4049-a63e-eddd0530dd68"
      unitRef="usd">4400000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i6245ae4c746a41bfae5a0da8935409d9_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzE0NjgyNTU4NjEzMw_6f0db10f-adae-4b9b-b3dc-153f75097b8b"
      unitRef="usd">12600000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i4949acae14e04f38821727b357327125_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzE0NjgyNTU4NjExNg_0ef42637-549a-44e8-a4dd-af2ae05c2132"
      unitRef="usd">12900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="if1c3b821bbf14ea68465673f368d6f0c_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzEy_5cf48f4f-0dac-4afe-8948-78feecf76325"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i976d1979c27d4acc9409bb7743bf49ba_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNzEy_d0a61ac7-40c0-431f-9617-4a73799c6048"
      unitRef="number">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ide80e6a11bd34f8b8a952c62960c82b6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODY1_dc841c60-f835-4894-86d0-85d1af928e3d"
      unitRef="usd">500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i61751c7e250f42118eb2800e45f0c530_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODcy_25e208d8-d16f-48be-8429-7662507f360e"
      unitRef="usd">700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i43d3d75fad82483eb5813daf8df17cc3_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfODk0_8776eb02-8a64-411a-9f4e-fd886506f5f3"
      unitRef="usd">1500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if932e49636814177a3488a7a9d89c9bb_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTAx_3e3c3cf1-9920-4116-aa31-4e340ef90082"
      unitRef="usd">2100000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ibca6368440e848ccacf6e0c6beff4565_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTAwNw_db0db8e5-5031-46e5-9d48-17a0da8e8b62"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i19071814c5784cc8acedf97c43d02aae_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTAwNw_f45918a9-7489-4ff0-b245-0637024977f7"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3dd1f69283d349a58ae0e8144a4dec4d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTEzMA_7a1c583e-9b5e-4389-8a09-f9396176622a"
      unitRef="usd">1200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id2670dfb231c4c36a80048c4600a520f_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTEzNw_c1922a04-7c14-4e80-bf6c-4d607eff4e9e"
      unitRef="usd">2000000.0</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia3717208d1224dd89f9f178d06d05dc2_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM3Mg_8279e5b3-be2d-4cbd-bc76-d8557b11c516"
      unitRef="usd">3800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ibbbfbf6e54384685bbdbd24b85b6a70e_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTE2Ng_4ad1a1df-fcc3-435e-a888-e5e8aa7e43f5"
      unitRef="usd">5800000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i42db88be7eb248ce937d8d0f1e434c23_I20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI3MA_4e4515c1-160e-4f3e-9816-ae8a08da295f"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="ibf65ddf284dd40dbbade2b730a49906e_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTI3MA_60c4c158-f3b4-48be-b41b-440c66ffc65b"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8e86290ed094411eacda08c9860c3896_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTM5Mw_278ede25-d596-424c-9d63-00d0024affd5"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iba42cd3748834d6a9e6d5b22691a39d3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTM5Mw_318ece6d-e40b-4295-af4b-7c070fdbd781"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i357239cb3870424c98179560f4e05eb9_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTM0NTg0ODg0MTgwNA_128e3eb1-f43d-4dd5-8a21-6ab2f3c160f3"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i462e89554ff74f3fa68c411f8685e8cb_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfOTM0NTg0ODg0MTgwNA_ec5bb521-3539-44df-9b37-f0d0dc75ce09"
      unitRef="usd">200000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ibfff017f5079475da112360bcc11bf3d_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY3MA_de49c643-56ae-4543-8ef0-411eb35139f6"
      unitRef="usd">7100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="if9b280c05e114d2cb9d4d80828861206_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY3Nw_66525beb-fda0-42bd-b7a9-a69f36fd43e1"
      unitRef="usd">6700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i24504ae2154f4155a97794062ff7b4cc_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTcyNA_156ac5ec-cf6d-4212-9d0f-5ae13772f542"
      unitRef="usd">1700000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i4915f14b437e4756b8b7d103a441b54d_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTY0OTI2NzQ0NzA2Ng_42ede263-5794-4cc3-877b-110a946ed60f"
      unitRef="usd">1800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i846f7fd44f304e9ea61d6d7acb1c05d7_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTg3NQ_9c0d3f28-d3e9-4caf-9536-ed86b2e38083"
      unitRef="usd">23400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i004ed9a138324dc8a6fc0af8d80321d7_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTg4Mg_fda46423-8a00-4d72-b829-3b44979e9129"
      unitRef="usd">23100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i1dea7f1f241546c79900d50e5d5b3e39_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTk3NA_a33ccc75-5099-45c9-b133-f67cabdcf38d"
      unitRef="usd">6500000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8569d927dbfc4be780d7ea409efa6a37_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTk4MQ_8400f868-6553-4d1d-94c2-a29b9f0180d2"
      unitRef="usd">6900000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i9d5ec46533294b24af622e84d85e1306_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjExMw_bc2383d8-b9fe-458a-b527-918644dcc9fc"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ia82c704cff6c42929352454bea170ee6_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjExMw_e4b75b3d-7fc0-4dda-8897-619959509d2f"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="iaade255737234b709672525b3860eed1_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1MDg_7bc8666a-6c20-460e-83da-fda35b68b08b"
      unitRef="usd">800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i7ab4eb5154c94c778081d37fd1fbb9c5_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1MDg_b478bbfa-3da4-47ba-9821-e492c046f18d"
      unitRef="usd">800000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i23eeba47a6d445a1af488e1741954e4a_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjMzNA_860c4cf5-8330-403a-b0cc-0cf461db983c"
      unitRef="usd">400000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ie4f7901609a34f0a8bd5da4fb0dbe4f4_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjM0MQ_380ae4d1-463f-4bdb-88f0-0728ed8f5980"
      unitRef="usd">1100000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="id45018c024f44bd390ae0a1db7dc7a06_I20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQzMQ_bc218be2-180c-490c-8da5-6eae3b50ff5e"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7666fdc6c5fb4c1597125f20974dcd69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQ5OQ_04dfc840-47eb-4870-b1fe-2378467a8392"
      unitRef="usd">10400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7666fdc6c5fb4c1597125f20974dcd69_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjQ5OQ_794b3fbf-38e1-4900-83c2-3ddc4f4dc390"
      unitRef="usd">10400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i8e0f7911506b4f7ea6ea22e51fac5416_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjcyNA_90a63327-0fbf-4355-8773-0920c1ee8eac"
      unitRef="usd">39000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i12335e3134c84754a4b5a7c9eb42658b_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM1NTc_01e93c21-45c5-4c4b-a36a-d2231ae89cf5"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3fb931837c3446e49bfcff46eee3984b_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM5MQ_07c1ffc6-29fc-4ee2-8976-37f82a814f58"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="ic079747ecea44c46b7fc2e75b14ca50c_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTA5OTUxMTYzMzM5MQ_2e26378b-9828-44df-933a-03489672ba0d"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i557e6e9936fc467ba5080a062ca80496_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjk3MA_8699d081-3a70-4ee1-950b-f8cd7a15794e"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i3c0345d81c4a45029864d5dfc19df1ba_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjk3MA_ef7a6b2b-c350-4381-afa5-13d491fa31a7"
      unitRef="usd">100000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="id03688552a194d20bec7b26a63399956_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNjA0NzMxMzk1ODMyMg_0b24f73a-5e16-45f9-8f0a-485b40e63c92"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <ameh:PaymentMadeToRelatedParty
      contextRef="i2beaf01e5bdb4f7aa6d5f3c6a54f063c_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNjA0NzMxMzk1ODMyMg_7b2a9079-75da-4443-9280-6a9d755c968b"
      unitRef="usd">300000</ameh:PaymentMadeToRelatedParty>
    <us-gaap:OperatingLeaseLiability
      contextRef="i1d7dbe836e64485fa477f10dbc512288_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTIwOTQ2Mjc5MTIxMDI_03eee729-c6ce-4437-8363-1cfe115a5650"
      unitRef="usd">1400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i1d7dbe836e64485fa477f10dbc512288_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMTIwOTQ2Mjc5MTIxMDI_ad6bdea1-940e-4be8-997e-4b6b5cb73b8e"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDc4OQ_4303759e-ad6d-429c-ba2a-7cd0e85f01d2">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO and Aurion (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.501%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.949%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.953%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;AHMC &#x2013; Risk pool, capitation, claims payment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HSMSO &#x2013; Management fees, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,075)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aurion &#x2013; Management fees&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(232)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi0xLTEtMS0w_dc7c9da7-9c7b-4b63-902a-bc2d8cca3397"
      unitRef="usd">5683000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi0zLTEtMS0w_24e62463-1118-4acf-83ec-517d53497fbb"
      unitRef="usd">11215000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi01LTEtMS0w_d35f88cd-129e-47cf-90f0-a785dd5084ee"
      unitRef="usd">23739000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet
      contextRef="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMi03LTEtMS0w_9e74d2fc-7ff0-4322-9aa7-67a7848c3de5"
      unitRef="usd">39165000</ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet>
    <us-gaap:ManagementFeeExpense
      contextRef="id95fd088a2c9454599c8fb0dc66fac9a_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy0xLTEtMS0w_85d3d7c0-1bd5-487d-b50d-b09c37e396a2"
      unitRef="usd">109000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="id4ed9597a9f24e4884d0595ef80c9123_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy0zLTEtMS0w_5b1f33db-05d2-4121-a083-8189a9690334"
      unitRef="usd">160000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i467c8f07446f434c888fe2139b1ad2e0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy01LTEtMS0w_84cd4876-dbc0-416f-b324-f929cd7f5c41"
      unitRef="usd">430000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i7230ae6b539c41a89c452715bb10fa43_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfMy03LTEtMS0w_bf6d94b3-b559-45fc-aead-132301066f87"
      unitRef="usd">1075000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ib374aadcdc4a4479907af99b24bfe82d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC0xLTEtMS0w_3ebfde7f-8b13-4c85-8c84-938d403d7a3a"
      unitRef="usd">100000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="i6d542d36ef9c4c6da7ac374e467eae16_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC0zLTEtMS0w_a8cead94-ea70-4548-98f1-5a7866529d68"
      unitRef="usd">76000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ic2293aa631c14249bc1cb90e55c69d12_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC01LTEtMS0w_1cb99a9d-79d4-43b9-b6c2-994d66aece4b"
      unitRef="usd">228000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense
      contextRef="ib0f97d7e0148477d89334ab0a06f9735_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNC03LTEtMS0w_4cd2feae-b950-4d34-a313-eafc1a51e8ec"
      unitRef="usd">232000</us-gaap:ManagementFeeExpense>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi0xLTEtMS0w_6c57b636-09ba-4636-bd06-5dc7b292c1ef"
      unitRef="usd">5474000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi0zLTEtMS0w_b33b6d06-8c59-48d3-8770-04668cdcf8cc"
      unitRef="usd">10979000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi01LTEtMS0w_96e9b1ba-d78e-46e4-8273-f56566af13e0"
      unitRef="usd">23081000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RhYmxlOjQ1OGU4ODlhNTk3ZDRjNDhhNTkwNzFmYmQ1ZTQ3ODhiL3RhYmxlcmFuZ2U6NDU4ZTg4OWE1OTdkNGM0OGE1OTA3MWZiZDVlNDc4OGJfNi03LTEtMS0w_53f4e325-f9bf-4149-8c1b-dab7523616f5"
      unitRef="usd">37858000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzkzNw_65dbdc31-3c7b-4111-aacb-e82724f6ba78"
      unitRef="usd">10500000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i3285f3fb7c4040c69c1ba82b26bb1eed_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzk0NA_8fd9c795-4d2a-469d-a8eb-ef482283b005"
      unitRef="usd">11000000.0</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="iaecb8c96a31e4ee999f3717f1c44fa26_D20190701-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMjA4OTA3MjA5MzM3MjY_f1fa7184-e989-4264-be89-77b4ea8e1266"
      unitRef="usd">31500000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty
      contextRef="i42a71a5249994053a5bb96a0031d5d5a_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfMzk2Ng_e8944c06-84de-40be-aea1-528c42e7ab5f"
      unitRef="usd">31900000</us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="ib209ad0feb484341b4b5ea3e1112074a_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDAwMQ_fc757055-51b9-4c09-9332-0eb1b19d2a9f"
      unitRef="usd">36900000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <us-gaap:DeferredCreditsAndOtherLiabilities
      contextRef="i311e4830870b47168a8028481990133c_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDAwOA_f5cde11d-0861-499f-9b75-d9f27645f48d"
      unitRef="usd">40400000</us-gaap:DeferredCreditsAndOtherLiabilities>
    <ameh:PaymentConsultingFees
      contextRef="i9f86dff82b2e4e37819e44daed0c3927_D20200701-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDEzMA_7021274d-22d4-48cc-8880-f22e5dc033ea"
      unitRef="usd">0</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i90b7d7c73e9342ceaea0220fd27ebcb0_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDEzNw_dadcca70-cbeb-4743-bf9c-7603b45bf47b"
      unitRef="usd">100000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i37855f5922724980ae2277994e98ea9e_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDE1OQ_09441c3e-197f-4dae-91ee-840381910fd9"
      unitRef="usd">27000</ameh:PaymentConsultingFees>
    <ameh:PaymentConsultingFees
      contextRef="i536bf5cd23b640f1b9fdc4a22f35cc97_D20190101-20190930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83My9mcmFnOmIzMjM0MzJlNmMxNzRiNGU5MTQ3MWQxYWZhZDBiY2ZiL3RleHRyZWdpb246YjMyMzQzMmU2YzE3NGI0ZTkxNDcxZDFhZmFkMGJjZmJfNDE2Ng_88aa1c07-0633-4b88-90b0-162e13eea37c"
      unitRef="usd">200000</ameh:PaymentConsultingFees>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMjc2Mg_b2956cf1-f55c-4ab6-a50e-9f11c2bd4663">Income Taxes&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#x2019;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#x2019;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s effective income tax rate for the nine months ended September&#160;30, 2020 and September 30, 2019 were 28.8% and 25.5%, respectively, and differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#x2019; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. However, the benefits of the CARES Act are not expected to impact the Company&#x2019;s annual estimated tax rate for the nine months ended September 30, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMTk3OTEyMDkzMDI5MDI_4ecda33f-c854-4445-bdb4-58762f970403"
      unitRef="number">0.288</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83Ni9mcmFnOmQwNjAwOTBmNTQ1NTQ1OTdhNjk4OGMyN2U0MDM0ZGZjL3RleHRyZWdpb246ZDA2MDA5MGY1NDU1NDU5N2E2OTg4YzI3ZTQwMzRkZmNfMTk3OTEyMDkzMDI5MDk_6c937d26-0e3c-4af7-9b7d-be72d2daab90"
      unitRef="number">0.255</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTExOA_12949f2b-fcea-4846-b373-a03df355c67b">Earnings Per Share&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is calculated using the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#x2019;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020 and December&#160;31, 2019, APC held 17,307,214 and 17,290,317 shares of ApolloMed&#x2019;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,643,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,555,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,816,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,643,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,555,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,816,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfNzI3_1b22f1cd-a62c-4c39-8023-e1a70f729f85"
      unitRef="shares">17307214</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i46ec2cffc1bf4e368fb4d267b14f59e7_D20190101-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfNzM0_644f0cec-26bf-44b8-accf-dc1c7a420dc6"
      unitRef="shares">17290317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTEyNQ_84cfef46-6d46-4f51-80d0-fbdb8968a483">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,643,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Earnings per share &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,555,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,816,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMS0yLTEtMS0w_168a7d6c-797e-4602-826c-7e6cb1566d8b"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMS00LTEtMS0w_d70b2fda-1b79-41d0-a2a5-bcbdd6c14602"
      unitRef="usdPerShare">0.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMi0yLTEtMS0w_1cae93ec-0358-473c-9670-573a21b9fb17"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMi00LTEtMS0w_18ff4a9b-4b37-4d5e-9449-a4f952b9b2c2"
      unitRef="usdPerShare">0.10</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMy0yLTEtMS0w_dba52c2e-3720-4546-8c90-ba3f54e07286"
      unitRef="shares">36364839</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfMy00LTEtMS0w_19aa5c6a-b283-46f0-a79f-b6fbf3775eba"
      unitRef="shares">34643754</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfNC0yLTEtMS0w_efe14a85-6943-47fa-8c6c-dc08195773b7"
      unitRef="shares">37551740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjIxYmQxZTMyNDRiOTQ2ZmVhNjAxMTAyNTI2OGQxYmQ3L3RhYmxlcmFuZ2U6MjFiZDFlMzI0NGI5NDZmZWE2MDExMDI1MjY4ZDFiZDdfNC00LTEtMS0w_153ace80-fdd1-4ffb-9ddf-e32e6e6e0421"
      unitRef="shares">37792266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMS0yLTEtMS0w_fec05c75-ca91-4760-bde0-fb42d1583614"
      unitRef="usdPerShare">0.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMS00LTEtMS0w_c319f526-e811-4f28-ba38-ea7694a7e81e"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMi0yLTEtMS0w_852b4dde-b2a3-42ec-9b39-b1f63225b529"
      unitRef="usdPerShare">0.75</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMi00LTEtMS0w_f005ea17-abfb-4a9e-97ab-ae3c49f75952"
      unitRef="usdPerShare">0.20</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMy0yLTEtMS0w_d02538f4-9125-46e4-9769-0c3e709dc202"
      unitRef="shares">36149692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfMy00LTEtMS0w_4d1cbda3-b3f5-4f59-88f5-cc0591c026d7"
      unitRef="shares">34555124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfNC0yLTEtMS0w_c1ad9453-1a35-4d7a-9822-242a8f0fad02"
      unitRef="shares">37249967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2OTU3MjAzZDY0YzRlYjliYmFmYWFiNzRhMGFkYjcwL3RhYmxlcmFuZ2U6MzY5NTcyMDNkNjRjNGViOWJiYWZhYWI3NGEwYWRiNzBfNC00LTEtMS0w_2c1d283c-25db-4382-8007-bfbe5ca1606f"
      unitRef="shares">37816698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RleHRyZWdpb246NjJkYjY3OTc0YmFmNGIxNGE5MjhlMWJlMDMzZDEwOTNfMTEyNw_2f2dfcf1-2777-44e9-b7bb-c955c7dc927b">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Below is a summary of the shares included in the diluted earnings per share computations:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,364,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,643,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;299,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;960,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,337,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,551,740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,792,266&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Weighted average shares of common stock outstanding &#x2013; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,149,692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34,555,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10% shares held back pursuant to indemnification clause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;890,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,442,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares of common stock outstanding &#x2013; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,249,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,816,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMS0yLTEtMS0w_5813d3c3-f696-4ba7-9b49-7c0df102d69f"
      unitRef="shares">36364839</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMS00LTEtMS0w_b69b4515-59c8-4850-b475-bca89094dde5"
      unitRef="shares">34643754</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0wLTEtMS0wL3RleHRyZWdpb246ZmQzZWY1ZjQwZDEwNDhhMjlhZTMyNmFkYmI3ODEwNjJfNA_88e8f26b-8ec0-4df4-9002-2308bc948c1a"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0wLTEtMS0wL3RleHRyZWdpb246ZmQzZWY1ZjQwZDEwNDhhMjlhZTMyNmFkYmI3ODEwNjJfNA_c048e579-e17e-4a8e-8b32-00485f67c235"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7683bf47a0bb49668ad242eb60b43155_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi0yLTEtMS0w_3f1ad351-3344-474c-b758-7b893866e874"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i3c10ebb4c41c48ebb66f85f644f9e58b_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMi00LTEtMS0w_08d72e6b-7ccf-4df8-87c4-9fe6a9e2fdd9"
      unitRef="shares">1511332</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ifef4a834b2704183af5e7a0118b8f10b_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMy0yLTEtMS0w_f25c552a-2b4d-4850-b84f-b89bd40f406c"
      unitRef="shares">187843</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="idcc6a9123a8a4ef7b90cc678cd9de887_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfMy00LTEtMS0w_0987a93d-3551-4a16-9549-e45f3f19de9d"
      unitRef="shares">299536</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i1726a5a5ec36427090258ca4b81f8d3f_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNC0yLTEtMS0w_9342b47f-8141-46f8-aeeb-5f441097b8c9"
      unitRef="shares">960806</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i54547e12a6db466cb506fe342e82cc32_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNC00LTEtMS0w_f0b202b4-dcb0-4162-8fca-f5e4b4dfa75c"
      unitRef="shares">1337644</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="idb2ac8c951874f548946ae72cd81b9fd_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNS0yLTEtMS0w_7957934c-adc4-4567-a996-1e8f8f564bec"
      unitRef="shares">38252</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0ea08dccbd2246f3821362f61b723f3a_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNS00LTEtMS0w_52eb651d-fae9-45a4-9035-b6740097c2bf"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNi0yLTEtMS0w_06ff7a2d-6f02-4b2b-ac27-93122fec326f"
      unitRef="shares">37551740</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOjM2ODM1NzExYTMyMzQwNDViZTY1NmJlMDhhNWE0MzRiL3RhYmxlcmFuZ2U6MzY4MzU3MTFhMzIzNDA0NWJlNjU2YmUwOGE1YTQzNGJfNi00LTEtMS0w_3d8cf797-9dd7-4bbf-be40-972849d7e274"
      unitRef="shares">37792266</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMS0yLTEtMS0w_20fcde1b-c85c-4814-afdb-e2b22e2fd927"
      unitRef="shares">36149692</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMS00LTEtMS0w_112e311a-8d3f-457b-9b30-49b0c08f441d"
      unitRef="shares">34555124</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0wLTEtMS0wL3RleHRyZWdpb246YTA3ODljOTMwZmMzNDA4NTg1MThlYWQxNGJjZDUzY2NfNA_8db2b50f-f2b3-46d6-8aa2-af7454512200"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0wLTEtMS0wL3RleHRyZWdpb246YTA3ODljOTMwZmMzNDA4NTg1MThlYWQxNGJjZDUzY2NfNA_f3943b03-e56d-4114-b019-72fadc0f3770"
      unitRef="number">0.10</ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i665d45a4c6ad4e91916ba08f8e851d70_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi0yLTEtMS0w_5bb227de-f7f2-4ffa-8508-1c8cfdfc6263"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2b8c0038e75540dfa62aff9087a85054_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMi00LTEtMS0w_66f703a7-67c8-42e9-9656-49c3aaef1404"
      unitRef="shares">1511332</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i671affdf59da40b3b7624c0bdbe08342_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMy0yLTEtMS0w_d8cccb02-294b-4022-9659-cdd74f3c2a93"
      unitRef="shares">178445</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i0a3f294321d042c0b50b53fcde9f5fbc_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfMy00LTEtMS0w_47980efd-965c-4fc3-b448-5c4ea26c7498"
      unitRef="shares">307665</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="ie6f513dd37f04d39ad6561182f5f3fea_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNC0yLTEtMS0w_167e4781-e304-4b46-a348-69deb180e5e0"
      unitRef="shares">890489</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5ca7f6c187cb41feb19b9c86fde64670_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNC00LTEtMS0w_1175df26-1da3-4f06-9a85-1409509fc252"
      unitRef="shares">1442577</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i4f4020d4b8994854ac803ea6e8d45f6b_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNS0yLTEtMS0w_00ed7b8c-f943-4ca3-83c8-9da1944e163c"
      unitRef="shares">31341</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i5a1dd3a2128b451eb4d50a63a91ddd55_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNS00LTEtMS0w_ecb1a4f9-437a-4530-9fc6-5cf7c0e223c6"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNi0yLTEtMS0w_e642fd1a-3500-4d1f-a6e6-9c251ebf2992"
      unitRef="shares">37249967</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV83OS9mcmFnOjYyZGI2Nzk3NGJhZjRiMTRhOTI4ZTFiZTAzM2QxMDkzL3RhYmxlOmI5MDNhY2NkNjA1MjRhNWVhZDg5YzA1MmExYTMwZWE3L3RhYmxlcmFuZ2U6YjkwM2FjY2Q2MDUyNGE1ZWFkODljMDUyYTFhMzBlYTdfNi00LTEtMS0w_5fe63f32-bdbe-4cbb-aa3f-4c2fb8218f30"
      unitRef="shares">37816698</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RleHRyZWdpb246N2I5MGExODhmMjIxNGY5ZmI1MTQ1YzI2OGVhNzM1ZGRfMTg4Mw_7809fd99-d091-4263-a689-ad6e7ff569db">Variable Interest Entities (VIEs)&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#x2019;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#x2013; &#x201c;Basis of Presentation and Summary of Significant Accounting Policies&#x201d; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assets of the Company&#x2019;s other consolidated VIEs were not considered significant.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <us-gaap:ScheduleOfVariableInterestEntitiesTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RleHRyZWdpb246N2I5MGExODhmMjIxNGY5ZmI1MTQ1YzI2OGVhNzM1ZGRfMTg4NA_c81721c9-0fa9-4df5-8b00-567a29bd3a03">&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:14pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables, net &#x2013; related party&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loan receivable &#x2013; related parties&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land, property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investment in privately held entities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Investments in other entities &#x2013; equity method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,268&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,736&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877,633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accounts payable and accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.773%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.658%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30,&lt;br/&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;br/&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fiduciary accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,027&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income taxes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,530&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amount due to affiliate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfVariableInterestEntitiesTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNC0xLTEtMS0w_45799ef0-709f-414e-8485-6e98a44336a5"
      unitRef="usd">94751000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNC0zLTEtMS0w_96dbd6d3-0c64-4ea6-9384-cb1551892f5f"
      unitRef="usd">87110000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNS0xLTEtMS0w_4a096701-25b7-45da-8fc9-fb188d0dc50c"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNS0zLTEtMS0w_ef36706e-d2d5-4de2-8899-7eb484b1aeb1"
      unitRef="usd">75000</us-gaap:RestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNi0xLTEtMS0w_b6831a4e-fe42-4102-adc7-24c680116521"
      unitRef="usd">118262000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNi0zLTEtMS0w_9466a86c-91c6-4401-97d5-549db62d39d1"
      unitRef="usd">123948000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNy0xLTEtMS0w_0b6a1bec-5681-4bf6-a9e8-1dc23ca83348"
      unitRef="usd">15365000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNy0zLTEtMS0w_21399dfc-c76a-4fc6-bb44-709816d3a3cb"
      unitRef="usd">9300000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOC0xLTEtMS0w_5e26988c-2afa-44a7-975c-b23ec7b66c2c"
      unitRef="usd">39506000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOC0zLTEtMS0w_b00e273c-c596-49bb-a3ba-4da5aa505b04"
      unitRef="usd">42976000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOS0xLTEtMS0w_e7818377-c781-47af-b458-10abfd4427d2"
      unitRef="usd">734000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfOS0zLTEtMS0w_cc7a7a07-21db-4b95-9f94-c6828c65c545"
      unitRef="usd">744000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTAtMS0xLTEtMA_33eb2951-0ec8-4038-9cdb-31fbf7c89e42"
      unitRef="usd">9667000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTAtMy0xLTEtMA_f1daeb2a-4b93-4a93-a8a9-7c3f1c181953"
      unitRef="usd">7403000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTEtMS0xLTEtMA_0f56aab9-519c-4b15-9ce6-4323666cd55c"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesAndLoansReceivableNetCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTEtMy0xLTEtMA_57527cb9-8896-465a-8975-30019e688ed1"
      unitRef="usd">6425000</us-gaap:NotesAndLoansReceivableNetCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTItMS0xLTEtMA_0c822ce9-dd8a-4b8b-9d86-86a07b2b9929"
      unitRef="usd">0</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:NotesReceivableRelatedPartiesCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTItMy0xLTEtMA_c75b8163-389f-49a6-b239-ac949ea2138c"
      unitRef="usd">16500000</us-gaap:NotesReceivableRelatedPartiesCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTMtMS0xLTEtMA_c61ab2d5-5902-476d-8e6f-b45b6dfa2df6"
      unitRef="usd">284710000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTMtMy0xLTEtMA_f65a0cf6-7888-48f8-a963-ff5739f296ff"
      unitRef="usd">294481000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTYtMS0xLTEtMA_95282485-ed17-4e9f-85ba-9bdbb0f9173e"
      unitRef="usd">8877000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTYtMy0xLTEtMA_6cea4cd4-2625-4bc0-ab30-0966430392b7"
      unitRef="usd">9547000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTctMS0xLTEtMA_fb7968bf-c6e8-4b6d-a0ff-4d19e4d356c4"
      unitRef="usd">72107000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTctMy0xLTEtMA_4d53f752-1ef2-41f3-bcf7-862e78cc84c4"
      unitRef="usd">81439000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTgtMS0xLTEtMA_f220aa27-306d-451a-adca-f4f41a5ff42a"
      unitRef="usd">109460000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTgtMy0xLTEtMA_5fb8d575-f3bf-4bce-9c28-021d219f8937"
      unitRef="usd">108913000</us-gaap:Goodwill>
    <us-gaap:OtherLongTermInvestments
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTktMS0xLTEtMA_715b6218-4572-4e40-af4a-5a3fd1a6182a"
      unitRef="usd">310491000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMTktMy0xLTEtMA_92501fdb-880c-4783-9ebf-5e86a077d0fb"
      unitRef="usd">318315000</us-gaap:OtherLongTermInvestments>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjAtMS0xLTEtMA_13051d8b-b929-4de6-bc1f-6a296ba31370"
      unitRef="usd">36584000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjAtMy0xLTEtMA_d90585a3-3fe0-4dbb-89d5-4e2819de7af8"
      unitRef="usd">1615000</us-gaap:EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue>
    <us-gaap:EquityMethodInvestments
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjEtMS0xLTEtMA_12038952-6e9f-4981-8eee-440f4b7dac31"
      unitRef="usd">27268000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjEtMy0xLTEtMA_0f251da3-620f-49e2-a12d-08d9b3f1a5c9"
      unitRef="usd">28427000</us-gaap:EquityMethodInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjItMS0xLTEtMA_2a7f04e2-4daf-4026-b9e3-5f7ba3769221"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjItMy0xLTEtMA_39ec8b4f-e5a2-450f-9bfc-009939fda07f"
      unitRef="usd">746000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjMtMS0xLTEtMA_c4429c7b-b4cf-4832-90e3-55718b9cb923"
      unitRef="usd">6654000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjMtMy0xLTEtMA_f0d390b7-3857-405e-921b-1c20de702a27"
      unitRef="usd">4751000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjQtMS0xLTEtMA_901dbb51-7a45-4ec6-9548-08249247dbe0"
      unitRef="usd">20736000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjQtMy0xLTEtMA_7596d8e1-2f1b-40f9-8083-883602c68c98"
      unitRef="usd">1057000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjYtMS0xLTEtMA_ebce6211-9c4b-4869-bd1c-61bd2a98b4b7"
      unitRef="usd">592923000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjYtMy0xLTEtMA_b529432b-9211-4eef-b0ca-b94d329dd478"
      unitRef="usd">554810000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjgtMS0xLTEtMA_fe9a54f9-12bd-4793-8833-c02a526a16c7"
      unitRef="usd">877633000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMjgtMy0xLTEtMA_82b329c0-c59e-45d3-a0bd-d91425ca999e"
      unitRef="usd">849291000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzEtMS0xLTEtMA_1ea37a39-c022-4a9d-835e-50fbb71393bc"
      unitRef="usd">13444000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzEtMy0xLTEtMA_00c766a0-e016-444b-b2d7-3be0906bc478"
      unitRef="usd">11187000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzItMS0xLTEtMA_7d150edc-7b4f-4ffa-b852-8aaa4494969d"
      unitRef="usd">3986000</ameh:FiduciaryAccountsPayableCurrent>
    <ameh:FiduciaryAccountsPayableCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzItMy0xLTEtMA_939cb17c-9dc4-4479-bd6e-cbb19b6f130f"
      unitRef="usd">2027000</ameh:FiduciaryAccountsPayableCurrent>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzMtMS0xLTEtMA_d2353497-7f76-4b11-ab52-cbc97153692d"
      unitRef="usd">42546000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzMtMy0xLTEtMA_7fb2b6cb-a58f-4529-a811-a21c63516419"
      unitRef="usd">49019000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:TaxesPayableCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzQtMS0xLTEtMA_9f185185-35a1-4027-b9a8-b64c1a3dc04e"
      unitRef="usd">15408000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzQtMy0xLTEtMA_dc0a1e51-11a7-4846-91e7-4fbad55d1412"
      unitRef="usd">4530000</us-gaap:TaxesPayableCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzUtMS0xLTEtMA_66c3f77c-1385-4875-a3b8-107b8d3862f6"
      unitRef="usd">22131000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DueToAffiliateCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzUtMy0xLTEtMA_4bc4411b-6b8c-4f1a-8be8-1414cc13dbc7"
      unitRef="usd">28058000</us-gaap:DueToAffiliateCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzYtMS0xLTEtMA_216c1473-72cb-4ebd-89c6-64ae48084b0d"
      unitRef="usd">485000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzYtMy0xLTEtMA_a9cfe592-c1ec-43ab-b368-a8c7010f1881"
      unitRef="usd">271000</us-gaap:DividendsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzctMS0xLTEtMA_b65493c6-ac34-4291-bbdb-8ba98612c473"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzctMy0xLTEtMA_66f4ace4-05cb-4496-8cff-8b895e51386d"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzgtMS0xLTEtMA_8df57541-a4bb-461a-b765-5500b658c490"
      unitRef="usd">1300000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfMzgtMy0xLTEtMA_7b8b9f22-b54f-4f95-b3b5-cb1f15d871f2"
      unitRef="usd">1088000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDAtMS0xLTEtMA_8c19cc56-ceed-4cd4-9517-70672e7fd7aa"
      unitRef="usd">99402000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDAtMy0xLTEtMA_e7d5f5a9-9b4f-4010-a0eb-19b2c82b9fac"
      unitRef="usd">96282000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDMtMS0xLTEtMA_f3a71c9c-63f0-4ce3-ae57-8174690a5ba4"
      unitRef="usd">7725000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDMtMy0xLTEtMA_dd6b2212-dbe2-4741-bf94-4a03cc8e548f"
      unitRef="usd">14059000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDQtMS0xLTEtMA_495c9f99-203f-40f3-8c3c-133333ef2fcc"
      unitRef="usd">337000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDQtMy0xLTEtMA_2c384370-79ff-4251-86f6-df2b858a553b"
      unitRef="usd">416000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDUtMS0xLTEtMA_dd395d68-2b1c-4773-a67a-8d926852fbc7"
      unitRef="usd">5512000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDUtMy0xLTEtMA_524bfcc1-9151-4686-85d3-a5e9c47320f3"
      unitRef="usd">3742000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDctMS0xLTEtMA_829c2d7e-bb12-4a35-8f2e-a4e862f96b8f"
      unitRef="usd">13574000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDctMy0xLTEtMA_0f285704-822b-478a-89b5-50e9e3d6a003"
      unitRef="usd">18217000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5a96f004265e44acbef5c40e0a7274cb_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDktMS0xLTEtMA_8ceaebd1-3fa8-4011-a764-2cb6fc2ba646"
      unitRef="usd">112976000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="id0760f54a264410584d47359d3245e54_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84Mi9mcmFnOjdiOTBhMTg4ZjIyMTRmOWZiNTE0NWMyNjhlYTczNWRkL3RhYmxlOmRkZDgxMmUyZDhlNjRkYjU5NDU5ZGMyZWMzYjYxNWMwL3RhYmxlcmFuZ2U6ZGRkODEyZTJkOGU2NGRiNTk0NTlkYzJlYzNiNjE1YzBfNDktMy0xLTEtMA_a7536bba-c81f-4ebd-984e-90ceea19637b"
      unitRef="usd">114499000</us-gaap:Liabilities>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1MQ_847f0aa9-9317-470d-ad3a-e66daf66088e">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, doctors&#x2019; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases were $0.3 million, for both periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1OQ_beffee30-8cc4-4fd4-b9ee-64e92c2f2315">Leases&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating and finance leases for corporate offices, doctors&#x2019; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases were $0.3 million, for both periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTY5_cee1c562-f8f5-4f08-a8ed-ba9a1bbcadf7">P1M</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i5b98657bb40c476d971c44dd0400e363_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTY5_d0abd8ce-56d0-4268-8d28-2b4d9f9b4b62">P1M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTc1_8a6577c8-c228-4b2c-9499-29086c9b99f0">P5Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="ice32aa9eb6d14a458a5edcd707c9f91c_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTc1_af1558af-94d2-477f-af2d-5c2b6e2cacef">P5Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMjQ0_0f31fbd0-c004-43d1-a229-428a9bbea136">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMjQ0_34bcef26-4e0e-4138-a3a2-d1487c2fd332">P10Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzIz_2aa2ac4b-e54c-4fb5-92a7-c30df31659f9">P1Y</ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable>
    <ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzIz_66eab837-37d3-4c58-8dd2-affc620ae6d8">P1Y</ameh:LesseeFinanceLeaseTerminationPeriodIfApplicable>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzg2_a4679c77-320b-4ea0-8018-8fbd1616b7a5"
      unitRef="usd">400000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i30b785ad17374d349aaafe08c2aa1d7a_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMzkz_b6714ef3-7b66-4230-a1e0-741dab3882af"
      unitRef="usd">500000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i330f7b2e0da941fb9b4510efb972e459_D20191231-20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfNDc1_34449ba1-d39d-4c4b-b768-cea99086c0f2"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="id94edb672a3f42dca68cdffe56fed10d_D20200930-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfNDc1_8cdc9cb8-1a0b-497b-bc81-32d55404b85c"
      unitRef="usd">300000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1MA_4e2773b4-2a24-4201-a5b0-2206c424be78">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(206)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization of lease expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(567)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(309)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total finance lease cost, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other information related to leases was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Supplemental Cash Flows Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financing cash flows from finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchange for lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Remaining Lease Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.93 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.92 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.92 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Discount Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Finance leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMy0xLTEtMS0w_1a5350e2-e35b-4926-8fef-a06e3e232096"
      unitRef="usd">1784000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMy0zLTEtMS0w_cedf5f1b-4fc3-4fa9-bf1c-318df598031c"
      unitRef="usd">1489000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNi0xLTEtMS0w_71824bb6-032d-454a-b7ac-72e508e924ec"
      unitRef="usd">26000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNi0zLTEtMS0w_e5cb142f-7b58-47b9-b71f-07219e74855d"
      unitRef="usd">26000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNy0xLTEtMS0w_976e31ea-e2bb-40be-a94f-7a231375935e"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfNy0zLTEtMS0w_c956274b-d495-4fc1-acf7-4d2b00aaa0a3"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfOS0xLTEtMS0w_2f160b56-7255-4fff-bc28-5571690312c8"
      unitRef="usd">206000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfOS0zLTEtMS0w_8afb95d4-538f-4eaa-9113-5755d5205973"
      unitRef="usd">103000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMTEtMS0xLTEtMA_cc1b956a-6400-4ce8-b4b8-1cb2ded82ff0"
      unitRef="usd">1607000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjE4NGUwZjY5OWI1NDQ5YTM4ZWMyMWExNTMyYTVmMDcxL3RhYmxlcmFuZ2U6MTg0ZTBmNjk5YjU0NDlhMzhlYzIxYTE1MzJhNWYwNzFfMTEtMy0xLTEtMA_74519cbb-4659-4af5-9e5e-0838d9c50143"
      unitRef="usd">1416000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMy0xLTEtMS0w_32b56274-7b7d-4470-9e20-6d3aee50cab9"
      unitRef="usd">5172000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMy0zLTEtMS0w_669722d9-6ed2-4323-830e-f1b1dd00546c"
      unitRef="usd">3832000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNi0xLTEtMS0w_1c4b6732-e52e-4d83-b8f0-2c08ad277289"
      unitRef="usd">78000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNi0zLTEtMS0w_3e7bc84e-e8c3-42dc-a4a6-2e7e8b1cd97a"
      unitRef="usd">76000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNy0xLTEtMS0w_da6bd43d-086d-43af-a83c-079ab5fc0ee1"
      unitRef="usd">11000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfNy0zLTEtMS0w_f940e28c-540e-40c7-ba9f-0cab315744c4"
      unitRef="usd">13000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:SubleaseIncome
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfOS0xLTEtMS0w_a595d74b-f95a-4369-a589-612beddd1102"
      unitRef="usd">567000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfOS0zLTEtMS0w_36b7da7b-a06b-4f58-92ad-2cbf666be7b8"
      unitRef="usd">309000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMTEtMS0xLTEtMA_0b056084-c911-42c7-aff4-fc2688009cc6"
      unitRef="usd">4694000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmYzNjAyM2NiMmU1NjRiYTNhMDcxZDg3ZTk5NWY0OWU5L3RhYmxlcmFuZ2U6ZjM2MDIzY2IyZTU2NGJhM2EwNzFkODdlOTk1ZjQ5ZTlfMTEtMy0xLTEtMA_d6c4546f-73bd-45c7-a685-cfc56536b2fe"
      unitRef="usd">3612000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNi0xLTEtMS0w_a7611e94-e31b-4879-8534-605d9aba75a0"
      unitRef="usd">1489000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNi0zLTEtMS0w_4d4bbbdb-3a0f-4639-a315-28a15fbb503f"
      unitRef="usd">1677000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNy0xLTEtMS0w_5e29b2c6-9039-4ab6-a68e-220affbf4b69"
      unitRef="usd">3000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfNy0zLTEtMS0w_dfa5818c-ddf4-4264-92f5-10e58d66ef1e"
      unitRef="usd">4000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfOC0xLTEtMS0w_a6596698-a6fe-479c-a935-f0ee8070ac6e"
      unitRef="usd">26000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfOC0zLTEtMS0w_ef77bcc5-347f-4138-9375-e1d1b58e3f6d"
      unitRef="usd">26000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTEtMS0xLTEtMA_e43f79ba-b6ba-4871-8e87-8c5f4055ff5f"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTEtMy0xLTEtMA_c4d76bf3-d0dd-4dac-b14d-2ea0e1d26fda"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTktMS0xLTEtMA_7787465d-2e29-4050-a336-8313d4a8089d"
      unitRef="usd">4369000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMTktMy0xLTEtMA_eeb4c4f5-2799-47a5-a6d9-7f076aaa065d"
      unitRef="usd">3950000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjAtMS0xLTEtMA_c338a596-d3fc-444f-887b-0ea25d83f7ac"
      unitRef="usd">11000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjAtMy0xLTEtMA_289b15d9-787c-4a19-a2c6-1207f8659430"
      unitRef="usd">13000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjEtMS0xLTEtMA_02fae51d-6583-4675-add7-702678d93dfd"
      unitRef="usd">78000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjEtMy0xLTEtMA_fc5654db-f792-428d-b45f-78f34dfe26ac"
      unitRef="usd">76000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjQtMS0xLTEtMA_286de5b7-5fd4-495e-a374-50ddf7bd613b"
      unitRef="usd">7652000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="iee628442c57b4303900dfbc7fd17d20c_D20190101-20190930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMjQtMy0xLTEtMA_21a93409-b678-4e6f-9e5f-ee73b261f6bb"
      unitRef="usd">15417000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzEtMS0xLTEtMA_5f6bc13c-ec95-48e8-b4f2-bf9f3e940f11">P6Y11M4D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzEtMy0xLTEtMA_555eb140-8c58-4d57-b8c4-056c8a047c20">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzItMS0xLTEtMA_abb109ba-9540-492d-89c2-e461e5180db4">P3Y11M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzItMy0xLTEtMA_4b9917dc-a83c-46e5-bd65-e8a124c8d533">P4Y11M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzYtMS0xLTEtMA_7a8274b7-a1f6-490b-b45e-db8fb118e029"
      unitRef="number">0.0610</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzYtMy0xLTEtMA_9bb61068-d59e-4ddb-a014-1eaa0a69357b"
      unitRef="number">0.0612</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzctMS0xLTEtMA_8bd005ab-c038-46b0-9d4d-99d0a3053497"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i6832502be8ae4cd5b8fe7d88754bda80_I20190930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOjAzZjZhYjA0OTdjZjQwZGM4ZThmY2U3M2E4MTk2YWJhL3RhYmxlcmFuZ2U6MDNmNmFiMDQ5N2NmNDBkYzhlOGZjZTczYTgxOTZhYmFfMzctMy0xLTEtMA_0b914dba-acd8-4611-9532-236cdcee36dc"
      unitRef="number">0.0300</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA0Nw_6c2821c8-d5f8-44f6-be7a-43e620045fe2">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RleHRyZWdpb246ODJmYTg1NDQ5MmNjNGMzOWE3MzE0NzQ0NzgzZDUzODdfMTA1Nw_86581b38-a2ad-4ba4-8aba-626c465c3af4">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.145%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.914%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;September 30, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Operating Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Finance Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020 (excluding the nine months ended September 30, 2020)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Less: current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMS0xLTEtMS0w_0d8d3deb-9cba-44f5-9c20-82dae44ef368"
      unitRef="usd">1173000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMS0zLTEtMS0w_98a4a2a8-bf3b-4638-8e4b-6c1d68dcbe55"
      unitRef="usd">30000</us-gaap:FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMi0xLTEtMS0w_55fd7e1f-9e67-4c29-932e-ee5daa2b0d39"
      unitRef="usd">4297000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMi0zLTEtMS0w_41532c31-80a6-4f20-a73e-c2ad4c08dfb2"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMy0xLTEtMS0w_6d844fbe-4b5d-4087-a41c-99ce5df5fc3f"
      unitRef="usd">3529000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMy0zLTEtMS0w_ca8882ba-1d59-408b-8b48-464cbd967753"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNC0xLTEtMS0w_28c28b88-a996-4796-ba90-cfc0437e1f1a"
      unitRef="usd">3303000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNC0zLTEtMS0w_a18c6fbb-3dc5-4e72-a0fc-91c09f4695ee"
      unitRef="usd">119000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNS0xLTEtMS0w_aed99d7f-03e5-464c-bc86-961cf3c35596"
      unitRef="usd">2940000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNS0zLTEtMS0w_65924f13-5c47-495f-b768-906741cb81a1"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNi0xLTEtMS0w_ead40a6d-ba6d-42eb-b669-d57ffb2e2d47"
      unitRef="usd">9459000</ameh:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <ameh:FinanceLeaseLiabilityToBePaidAfterYearFour
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfNi0zLTEtMS0w_62638c7b-7472-4998-ae31-002b31477a79"
      unitRef="usd">0</ameh:FinanceLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOC0xLTEtMS0w_612c0454-6c27-43fc-9286-8a0ae0a6735b"
      unitRef="usd">24701000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOC0zLTEtMS0w_31180bf4-5a5f-4f6f-86c8-8337c41ea75c"
      unitRef="usd">466000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOS0xLTEtMS0w_5f2d7e3b-21ef-4f1c-af23-40e7f6e34998"
      unitRef="usd">4795000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfOS0zLTEtMS0w_2b8011b2-45e0-48b8-badf-f72ee8eabbd0"
      unitRef="usd">27000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTAtMS0xLTEtMA_9184fbf5-0710-4f24-821b-615e08d2537c"
      unitRef="usd">19906000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTAtMy0xLTEtMA_f732ee30-e009-4c1f-8c56-75fc4c39f524"
      unitRef="usd">439000</us-gaap:FinanceLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTEtMS0xLTEtMA_cf172e91-55bb-4c33-9b19-5132800bb971"
      unitRef="usd">3290000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTEtMy0xLTEtMA_42cc792c-b19d-4e7f-9b14-36fdee443b67"
      unitRef="usd">102000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTItMS0xLTEtMA_5a720965-1aa3-41aa-9f09-cf92bbc631b7"
      unitRef="usd">16616000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6f15713b91eb402cbc19264dd2327c3d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84NS9mcmFnOjgyZmE4NTQ0OTJjYzRjMzlhNzMxNDc0NDc4M2Q1Mzg3L3RhYmxlOmY4ZTBmNTYzZDFkOTQyMDY5NTg5NTY1MzhjYzQxYzJkL3RhYmxlcmFuZ2U6ZjhlMGY1NjNkMWQ5NDIwNjk1ODk1NjUzOGNjNDFjMmRfMTItMy0xLTEtMA_b7458562-08e4-4738-a4a2-581fe912fcba"
      unitRef="usd">337000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i52b79e80b0334de886124ca554069b1e_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTk3OTEyMDkzMDA2Njk_6a4e01cf-accb-4d8e-b92e-b1a1edaf7108">Subsequent Events&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, APC's board of directors declared an in-kind dividend of 5&#160;million shares of ApolloMed's common stock on a pro rata basis to APC's shareholders in November 2020. The shares being distributed is from the Excluded Assets that remain solely for the benefit of APC and its shareholders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Promissory note&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, APC entered into a promissory note with AHMC, a related party of the Company, (the &#x201c;2020 Note&#x201d;) as payee for a principal sum of $4.0 million with a maturity date of two years from the date of the agreement. The contractual interest rate on the 2020 Note is 3.75%  per annum. The funds lent pursuant to the 2020 Note are the same funds that were deposited for investment opportunities in March 2020 (the "March Deposit"). As with the March Deposit, the 2020 Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:Dividends
      contextRef="icf38a8ac3d85467baeb00dcd1a446031_D20200901-20200930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTIwOTQ2Mjc5MDY5NDY_e356157e-3ddd-42fd-bb17-ffbf57ec57a3"
      unitRef="usd">5000000</us-gaap:Dividends>
    <us-gaap:NotesReceivableGross
      contextRef="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTY0OTI2NzQ0MTczNDM_d1fb8510-5539-4e5c-94e9-702e467b0482"
      unitRef="usd">4000000.0</us-gaap:NotesReceivableGross>
    <ameh:FinanceReceivableTermOfReceivable
      contextRef="i91c0b71ccc814cd5ba5b3e0b0bf65898_D20201001-20201031"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTIwOTQ2Mjc5MDk2ODg_21a7125b-361f-40f4-af5f-662bf67bd2e5">P2Y</ameh:FinanceReceivableTermOfReceivable>
    <ameh:FinanceReceivableInterestRateStatedPercentage
      contextRef="i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV84OC9mcmFnOmExMWU4MzZmYTE2ZDQ5M2E4OTlmNDJmYzE1YjkzZjYxL3RleHRyZWdpb246YTExZTgzNmZhMTZkNDkzYTg5OWY0MmZjMTViOTNmNjFfMTY0OTI2NzQ0MTczNTU_ceec8c40-9219-4792-b020-faa1a504c5db"
      unitRef="number">0.0375</ameh:FinanceReceivableInterestRateStatedPercentage>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf" xlink:label="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#x2019;s consolidated VIEs totaling $877.6&#160;million and $849.3&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#x2019;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $113.0&#160;million and $114.5&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#x2013; Variable Interest Entities (VIEs) for further detail.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMS0xLTEtMA_78af95be-3a3d-4f09-9dad-4e84f4d73964"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMS0xLTEtMA_10101fc7-6e67-4c31-b038-590e7b70f9ac"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfNTMtMy0xLTEtMA_a9859b3d-a068-4535-8bc3-f8d44e6587ab"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RhYmxlOjQzNDU4ZjQ1M2NhZTRmYTFiOTdlNTQ4NDM3YTA1NTU3L3RhYmxlcmFuZ2U6NDM0NThmNDUzY2FlNGZhMWI5N2U1NDg0MzdhMDU1NTdfMjktMy0xLTEtMA_169108f3-cebe-4fc0-b4ad-4d0522f676b3"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV8yMi9mcmFnOjc0MDc5MmRlOTUyZjQ2ZWE4N2ZjMzI3MWRiNGQ4OGExL3RleHRyZWdpb246NzQwNzkyZGU5NTJmNDZlYTg3ZmMzMjcxZGI0ZDg4YTFfMTIwOTQ2Mjc5MDcyNTI_6a875c50-7e7d-467a-88ad-b826fe83f5bf"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665233120392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Nov. 02, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Apollo Medical Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">95-4472349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1668 S. Garfield Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">2nd Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alhambra<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">282-0288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AMEH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,265,602<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001083446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665233052472">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,309<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,257<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,518<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,988<span></span>
</td>
<td class="nump">16,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,119<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">366,698<span></span>
</td>
<td class="nump">329,068<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,929<span></span>
</td>
<td class="nump">12,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,781<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,220<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,075<span></span>
</td>
<td class="nump">896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,298<span></span>
</td>
<td class="nump">14,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,473<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447,575<span></span>
</td>
<td class="nump">399,645<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">814,273<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,474<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,455<span></span>
</td>
<td class="nump">58,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,169<span></span>
</td>
<td class="nump">4,529<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividend payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,500<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131,461<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,659<span></span>
</td>
<td class="nump">18,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">337<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,616<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion and deferred financing costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">226,051<span></span>
</td>
<td class="nump">232,172<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254,663<span></span>
</td>
<td class="nump">262,230<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">386,124<span></span>
</td>
<td class="nump">367,653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MezzanineEquityAbstract', window );"><strong>Mezzanine equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests', window );">Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">198,731<span></span>
</td>
<td class="nump">168,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,775,817 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, as of September&#160;30, 2020 and December&#160;31, 2019, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">159,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,714<span></span>
</td>
<td class="nump">31,905<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity, parent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">228,404<span></span>
</td>
<td class="nump">191,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">786<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">192,335<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, mezzanine equity and stockholders&#8217; equity</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">814,273<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $877.6&#160;million and $849.3&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $113.0&#160;million and $114.5&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MezzanineEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MezzanineEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.27(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231989976">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common Stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,775,817<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,475,707<span></span>
</td>
<td class="nump">17,458,810<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 814,273<span></span>
</td>
<td class="nump">$ 728,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">386,124<span></span>
</td>
<td class="nump">367,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">877,633<span></span>
</td>
<td class="nump">849,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 112,976<span></span>
</td>
<td class="nump">$ 114,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,111,111<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember', window );">Series B Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">555,555<span></span>
</td>
<td class="nump">555,555<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $877.6&#160;million and $849.3&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $113.0&#160;million and $114.5&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230733112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 180,123<span></span>
</td>
<td class="nump">$ 156,060<span></span>
</td>
<td class="nump">$ 510,397<span></span>
</td>
<td class="nump">$ 381,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services</a></td>
<td class="nump">121,823<span></span>
</td>
<td class="nump">131,130<span></span>
</td>
<td class="nump">402,106<span></span>
</td>
<td class="nump">315,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">16,270<span></span>
</td>
<td class="nump">7,950<span></span>
</td>
<td class="nump">39,660<span></span>
</td>
<td class="nump">30,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts', window );">Depreciation and amortization</a></td>
<td class="nump">4,674<span></span>
</td>
<td class="nump">4,920<span></span>
</td>
<td class="nump">14,004<span></span>
</td>
<td class="nump">13,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total expenses</a></td>
<td class="nump">142,767<span></span>
</td>
<td class="nump">145,994<span></span>
</td>
<td class="nump">455,770<span></span>
</td>
<td class="nump">360,380<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">37,356<span></span>
</td>
<td class="nump">10,066<span></span>
</td>
<td class="nump">54,627<span></span>
</td>
<td class="nump">21,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other (expense) income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investments</a></td>
<td class="nump">403<span></span>
</td>
<td class="nump">2,054<span></span>
</td>
<td class="nump">3,291<span></span>
</td>
<td class="nump">1,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Equity Method Investment, Realized Gain (Loss) on Disposal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">99,647<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,466)<span></span>
</td>
<td class="num">(828)<span></span>
</td>
<td class="num">(8,007)<span></span>
</td>
<td class="num">(1,350)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">752<span></span>
</td>
<td class="nump">509<span></span>
</td>
<td class="nump">2,544<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income, net</a></td>
<td class="num">(1,181)<span></span>
</td>
<td class="nump">4,355<span></span>
</td>
<td class="nump">98,989<span></span>
</td>
<td class="nump">3,949<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before provision for income taxes</a></td>
<td class="nump">36,175<span></span>
</td>
<td class="nump">14,421<span></span>
</td>
<td class="nump">153,616<span></span>
</td>
<td class="nump">25,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">10,751<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
<td class="nump">44,204<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">25,424<span></span>
</td>
<td class="nump">10,739<span></span>
</td>
<td class="nump">109,412<span></span>
</td>
<td class="nump">18,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interest</a></td>
<td class="nump">8,711<span></span>
</td>
<td class="nump">7,035<span></span>
</td>
<td class="nump">81,603<span></span>
</td>
<td class="nump">11,564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Apollo Medical Holdings, Inc.</a></td>
<td class="nump">$ 16,713<span></span>
</td>
<td class="nump">$ 3,704<span></span>
</td>
<td class="nump">$ 27,809<span></span>
</td>
<td class="nump">$ 7,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember', window );">Capitation, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 135,032<span></span>
</td>
<td class="nump">$ 130,807<span></span>
</td>
<td class="nump">$ 416,402<span></span>
</td>
<td class="nump">$ 305,548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember', window );">Risk pool settlements and incentives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">30,916<span></span>
</td>
<td class="nump">11,355<span></span>
</td>
<td class="nump">54,155<span></span>
</td>
<td class="nump">32,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management fee income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">8,707<span></span>
</td>
<td class="nump">8,518<span></span>
</td>
<td class="nump">26,212<span></span>
</td>
<td class="nump">27,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember', window );">Fee-for-service, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">3,737<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">9,434<span></span>
</td>
<td class="nump">12,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 1,731<span></span>
</td>
<td class="nump">$ 1,280<span></span>
</td>
<td class="nump">$ 4,194<span></span>
</td>
<td class="nump">$ 3,753<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_HealthCareCapitationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCareOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePatientServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231194360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common&#160;Stock&#160;Outstanding</div></th>
<th class="th"><div>Additional Paid-in&#160;Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Noncontrolling Interest</div></th>
<th class="th">
<div>Noncontrolling Interest </div>
<div>Mezzanine</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2018</a></td>
<td class="nump">$ 181,544<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 162,723<span></span>
</td>
<td class="nump">$ 17,788<span></span>
</td>
<td class="nump">$ 998<span></span>
</td>
<td class="nump">$ 225,117<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,578,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">410<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2019</a></td>
<td class="nump">182,377<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">163,006<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="nump">1,408<span></span>
</td>
<td class="nump">212,434<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">3,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">6,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(942)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2019</a></td>
<td class="nump">186,089<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">163,892<span></span>
</td>
<td class="nump">21,473<span></span>
</td>
<td class="nump">689<span></span>
</td>
<td class="nump">219,583<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,639,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">4,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,704<span></span>
</td>
<td class="nump">751<span></span>
</td>
<td class="nump">6,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscriptions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Stock issued in connection with a business combination</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Cost related to issuance of preferred shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(804)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Sep. 30, 2019</a></td>
<td class="nump">192,174<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">165,522<span></span>
</td>
<td class="nump">25,177<span></span>
</td>
<td class="nump">1,440<span></span>
</td>
<td class="nump">176,230<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,823,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">192,335<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">159,608<span></span>
</td>
<td class="nump">31,905<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">168,725<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">4,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,052<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="num">(1,161)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Purchase of treasury shares</a></td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchase of treasury shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,897)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151,601<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Mar. 31, 2020</a></td>
<td class="nump">197,961<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">35,957<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">157,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,042,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 192,335<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">159,608<span></span>
</td>
<td class="nump">31,905<span></span>
</td>
<td class="nump">786<span></span>
</td>
<td class="nump">168,725<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,908,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised', window );">Shares issued for exercise of cashless warrants (in shares)</a></td>
<td class="nump">66,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 229,418<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">59,714<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="nump">198,731<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,775,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, beginning balance at Mar. 31, 2020</a></td>
<td class="nump">197,961<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">161,087<span></span>
</td>
<td class="nump">35,957<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="nump">157,439<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,042,761<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">7,335<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,044<span></span>
</td>
<td class="nump">291<span></span>
</td>
<td class="nump">73,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(126)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Shares issued for vesting of restricted stock awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled', window );">Cancellation of restricted stock awards</a></td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(236)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="num">(347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(347)<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Jun. 30, 2020</a></td>
<td class="nump">207,848<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">163,986<span></span>
</td>
<td class="nump">43,001<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">210,980<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,309,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity', window );">Net (loss) income</a></td>
<td class="nump">16,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,713<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">8,522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Purchase of noncontrolling interest</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(771)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised', window );">Shares issued for exercise of cashless warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised', window );">Shares issued for cashless exercise of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">399,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants', window );">Shares issued for exercise of options and warrants</a></td>
<td class="nump">4,020<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">648<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Dividends</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Equity, ending balance at Sep. 30, 2020</a></td>
<td class="nump">$ 229,418<span></span>
</td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 168,653<span></span>
</td>
<td class="nump">$ 59,714<span></span>
</td>
<td class="nump">$ 1,014<span></span>
</td>
<td class="nump">$ 198,731<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Equity, ending balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,775,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Restricted Stock Award, Cancelled</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents number of share issued exercise of option and warrants during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents value of stock issued during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569655-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4616395-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665225145400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 109,412<span></span>
</td>
<td class="nump">$ 18,953<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">14,004<span></span>
</td>
<td class="nump">13,793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,994<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">1,004<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,363)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">2,558<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized loss (gain) from investment in equity securities</a></td>
<td class="nump">23<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income from equity method investments</a></td>
<td class="num">(3,291)<span></span>
</td>
<td class="num">(1,162)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity method investments</a></td>
<td class="num">(99,647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_GainLossOnAssumptionOfLoan', window );">Gain on loan assumption</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred tax</a></td>
<td class="num">(6,137)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of business combinations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Receivables, net</a></td>
<td class="num">(6,953)<span></span>
</td>
<td class="nump">1,904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Receivables, net &#8211; related parties</a></td>
<td class="nump">6,618<span></span>
</td>
<td class="nump">5,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">12,898<span></span>
</td>
<td class="num">(13,719)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(1,804)<span></span>
</td>
<td class="num">(2,914)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOperatingLeaseAssets', window );">Right-of-use assets</a></td>
<td class="nump">2,601<span></span>
</td>
<td class="nump">1,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(5,090)<span></span>
</td>
<td class="num">(525)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">12,644<span></span>
</td>
<td class="nump">4,868<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Fiduciary accounts payable</a></td>
<td class="nump">1,958<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="num">(1,566)<span></span>
</td>
<td class="num">(6,226)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="nump">11,642<span></span>
</td>
<td class="num">(10,229)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(2,110)<span></span>
</td>
<td class="num">(1,790)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">48,764<span></span>
</td>
<td class="nump">10,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payments for business acquisition, net of cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(49,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties', window );">Proceeds from repayment of loans receivable &#8211; related parties</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties', window );">Advances on loans receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7,425)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(1,793)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Purchases of investments &#8211; equity method</a></td>
<td class="num">(500)<span></span>
</td>
<td class="num">(2,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">52,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(553)<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital', window );">Dividend received</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">66,397<span></span>
</td>
<td class="num">(60,364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit', window );">Repayment of bank loan and lines of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(52,640)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(50,133)<span></span>
</td>
<td class="num">(60,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of term loan</a></td>
<td class="num">(7,125)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligations</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of stock options and warrants</a></td>
<td class="nump">6,552<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares</a></td>
<td class="num">(1,559)<span></span>
</td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Borrowings on line of credit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">289,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from common stock offering</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Cost of debt and equity issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5,622)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(52,343)<span></span>
</td>
<td class="nump">173,707<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">62,818<span></span>
</td>
<td class="nump">123,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of period</a></td>
<td class="nump">104,010<span></span>
</td>
<td class="nump">107,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of period</a></td>
<td class="nump">166,828<span></span>
</td>
<td class="nump">231,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">37,900<span></span>
</td>
<td class="nump">17,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">6,961<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill', window );">Deferred tax liability adjustment to goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DeferredTaxLiabilitiesWarrantsExercised', window );">Deferred tax liability adjustment related to warrant exercises</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">APC stock issued in exchange for AMG</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Preferred shares received from sale of equity method investment</a></td>
<td class="nump">36,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract', window );"><strong>Reconciliation of cash, cash equivalents, and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">166,082<span></span>
</td>
<td class="nump">230,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash &#8211; non-current</a></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 104,010<span></span>
</td>
<td class="nump">$ 231,065<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilitiesAdjustedToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Adjusted To Goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilitiesAdjustedToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DeferredTaxLiabilitiesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DeferredTaxLiabilitiesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_GainLossOnAssumptionOfLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Assumption Of Loan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_GainLossOnAssumptionOfLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in operating lease assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents increase in lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RepaymentsOfBankLoanAndLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayments Of Bank Loan And Lines Of Credit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RepaymentsOfBankLoanAndLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToFundLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToFundLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21D<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=SL94080555-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665344161512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Description of Business</a></td>
<td class="text">Description of Business<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apollo Medical Holdings, Inc. ("ApolloMed") together with its affiliated physician groups and consolidated entities (collectively, the &#8220;Company&#8221;) is a leading physician-centric, technology-enabled healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, ApolloMed operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Headquartered in Alhambra, California, ApolloMed's subsidiaries include management services organizations ("MSOs"), affiliated independent practice associations ("IPAs") and a Next Generation Accountable Care Organization ("NGACO"). Network Medical Management, Inc. ("NMM") and Apollo Medical Management, Inc. ("AMM") are the administrative and managerial services companies for the affiliated physician owned professional corporations that contract with independent physicians to deliver medical services in-office and virtually under the Allied Physicians of California, a Professional Medical Corporation d.b.a. Allied Pacific of California IPA ("APC"), Alpha Care Medical Group, Inc. and Accountable Health Care IPA brands. These affiliates are supported by ApolloMed Hospitalists, a Medical Corporation ("AMH") and Southern California Heart Centers, a Medical Corporation ("SCHC"). The Company's NGACO operates under the APA ACO, Inc. ("APAACO") brand and participates in the Centers for Medicare &amp; Medicaid Services program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participation in the program's attribution-based risk sharing model.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides care coordination services to each major constituent of the healthcare delivery system, including patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups and health plans. The Company&#8217;s physician network consists of primary care physicians, specialist physicians, and hospitalists. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NMM was formed in 1994 as an MSO for the purposes of providing management services to medical companies and IPAs. The management services primarily include billing, collection, accounting, administration, quality assurance, marketing, compliance, and education. Following a business combination, NMM became a wholly-owned subsidiary of ApolloMed in December 2017. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC was incorporated in 1992, for the purpose of arranging healthcare services as an IPA. APC has contracts with various health maintenance organizations (&#8220;HMOs&#8221;) and other licensed healthcare service plans as defined in the California Knox-Keene Health Care Service Plan Act of 1975. Each HMO negotiates a fixed amount per member per month (&#8220;PMPM&#8221;) that is to be paid to APC. In return, APC arranges for the delivery of healthcare services by contracting with physicians or professional medical corporations for primary care and specialty care services. APC assumes the financial risk of the cost of delivering healthcare services in excess of the fixed amounts received. Some of the risk is transferred to the contracted physicians or professional corporations. The risk is also minimized by stop-loss provisions in contracts with HMOs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 1999, APC entered into an amended and restated management and administrative services agreement with NMM (the initial management services agreement was entered into in 1997) for an initial fixed term of 30 years. In accordance with relevant accounting guidance, APC is determined to be a variable interest entity (&#8220;VIE&#8221;) of the Company as NMM is the primary beneficiary with the ability to direct the activities (excluding clinical decisions) that most significantly affect APC&#8217;s economic performance through its majority representation on the APC Joint Planning Board; therefore APC is consolidated by NMM.  </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AP-AMH Medical Corporation (&#8220;AP-AMH&#8221;) was formed in May 2019, as a designated shareholder professional corporation. Dr. Thomas Lam, a shareholder, and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is the sole shareholder of AP-AMH. ApolloMed makes all the decisions on behalf of AP-AMH and funds and receives all the distributions from its operations. ApolloMed has the rights to receive benefits from the operations of AP-AMH and has the option, but not the obligation, to cover losses. Therefore, AP-AMH is controlled and consolidated by ApolloMed as the primary beneficiary of this VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, ApolloMed completed the following series of transactions with its affiliates, AP-AMH and APC;</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed loaned AP-AMH $545.0 million pursuant to a 10-year secured loan agreement (the &#8220;AP-AMH Loan&#8221;). The loan bears interest at a rate of 10% per annum simple interest, is not prepayable (except in certain limited circumstances), requires quarterly payments of interest only in arrears, and is secured by a first priority security interest in all of AP-AMH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s assets, including the shares of APC Series A Preferred Stock purchased by AP-AMH, as described below. To the extent that AP-AMH is unable to make any interest payment when due because it has received dividends on the APC Series A Preferred Stock insufficient to pay in full such interest payment, then the outstanding principal amount of the loan will be increased by the amount of any such accrued but unpaid interest, and any such increased principal amounts will bear interest at the rate of 10.75% per annum simple interest.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">AP-AMH purchased 1,000,000 shares of APC Series A Preferred Stock for aggregate consideration of $545.0 million in a private placement. Under the terms of the APC Certificate of Determination of Preferences of Series A Preferred Stock (the &#8220;Certificate of Determination&#8221;), AP-AMH is entitled to receive preferential, cumulative dividends that accrue on a daily basis and that are equal to the sum of (i) APC&#8217;s net income from healthcare services (as defined in the Certificate of Determination), plus (ii) any dividends received by APC from certain of APC&#8217;s affiliated entities, less (iii) any Retained Amounts (as defined in the Certificate of Determination).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">APC purchased 15,015,015 shares of ApolloMed&#8217;s common stock for total consideration of $300.0 million in private placement. In connection therewith, ApolloMed granted APC certain registration rights with respect to ApolloMed&#8217;s common stock that APC purchased, and APC agreed that APC votes in excess of 9.99% of ApolloMed&#8217;s then outstanding shares will be voted by proxy given to ApolloMed&#8217;s management, and that those proxy holders will cast the excess votes in the same proportion as all other votes cast on any specific proposal coming before ApolloMed&#8217;s stockholders.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">ApolloMed licensed to AP-AMH the right to use certain trade names for certain specified purposes for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The license fee is payable out of any Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Through its subsidiary, NMM, the Company agreed to provide certain administrative services to AP-AMH for a fee equal to a percentage of the aggregate gross revenues of AP-AMH. The administrative fee also is payable out of any APC Series A Preferred Stock dividends received by AP-AMH from APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the series of transaction, APC and AP-AMH entered into Second Amendment to Series A Preferred Stock Purchase Agreement clarifying the term excluded assets ("Excluded Assets"). Excluded Assets means (i) assets received from the sale of shares of the Series A Preferred equal to the Series A Purchase Price, (ii) the assets of the Company that are not Healthcare Services Assets, including the Company&#8217;s equity interests in Universal Care, Inc., Apollo Medical Holdings, Inc., and any entity that is primarily engaged in the business of owning, leasing, developing or otherwise operating real estate, (iii) any assets acquired with the proceeds of the sale, assignment or other disposition of any of the assets described in clauses (i) or (ii), and (iv) any proceeds of the assets described in clauses (i), (ii) and (iii). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC's ownership in ApolloMed was 32.00% at September&#160;30, 2020 and 32.50% at December&#160;31, 2019. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concourse Diagnostic Surgery Center, LLC (&#8220;CDSC&#8221;) was formed in March&#160;2010 in the state of California. CDSC is an ambulatory surgery center in City of Industry, California organized by a group of highly qualified physicians, which utilizes some of the most advanced equipment in the eastern part of Los Angeles County and the San Gabriel Valley. The facility is Medicare certified and accredited by the Accreditation Association for Ambulatory Healthcare, Inc. As of September&#160;30, 2020, APC owned 45.01% of CDSC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s capital stock. CDSC is determined to be a VIE and APC is determined to be the primary beneficiary. APC has the ability to direct the activities that most significantly affect CDSC&#8217;s economic performance and receives the most economic benefits; therefore CDSC is consolidated by APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC-LSMA Designated Shareholder Medical Corporation (&#8220;APC-LSMA&#8221;) was formed in October&#160;2012 as a designated shareholder professional corporation. Dr. Thomas Lam, a stockholder and the Chief Executive Officer and Chief Financial Officer of APC and Co-Chief Executive Officer of ApolloMed, is a nominee shareholder of APC. APC makes all investment decisions on behalf of APC-LSMA, funds all investments and receives all distributions from the investments. APC has the obligation to absorb losses and right to receive benefits from all investments made by APC-LSMA. APC-LSMA&#8217;s sole function is to act as the nominee shareholder for APC in other California medical professional corporations. Therefore, APC-LSMA is controlled and consolidated by APC as the primary beneficiary of this VIE. The only activity of APC-LSMA is to hold the investments in medical corporations, including the IPA lines of business of LaSalle Medical Associates (&#8220;LMA&#8221;), Pacific Medical Imaging and Oncology Center, Inc. (&#8220;PMIOC&#8221;), Diagnostic Medical Group (&#8220;DMG&#8221;) and AHMC International Cancer Center, a Medical Corporation (&#8220;ICC&#8221;). APC-LSMA also holds a 100% ownership interest in Maverick Medical Group, </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inc. (&#8220;MMG&#8221;), Alpha Care Medical Group, Inc. (&#8220;Alpha Care&#8221;), Accountable Health Care IPA, a Professional Medical Corporation (&#8220;Accountable Health Care&#8221;), and AMG, a Professional Medical Corporation (&#8220;AMG&#8221;). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care, an IPA acquired by the Company in May 2019, has been operating in California since 1993 as a risk bearing organization engaged in providing professional services under capitation arrangements with its contracted health plans through a provider network consisting of primary care and specialty care physicians. Alpha Care specializes in delivering high-quality healthcare to its enrollees and focuses on Medi-Cal/Medicaid, Commercial, and Medicare and Dual Eligible members in the Riverside and San Bernardino counties of Southern California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accountable Health Care is a California-based IPA that has served the local community in the greater Los Angeles County area through a network of physicians and healthcare providers for more than 20 years. Accountable Health Care currently has a network of over 300 primary care physicians and 600 specialty care physicians, as well as one community and regional hospital medical center, that provides quality healthcare services to its members of three federally qualified health plans and multiple product lines, including Medi-Cal, Commercial, Medicare and the California Healthy Families program. In August 2019, APC and APC-LSMA acquired the remaining outstanding shares of Accountable Health Care&#8217;s capital stock that they did not already own (comprising 75%) for&#160;$7.3 million&#160;in cash (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AMG is a network of family practice clinics operating out of three main locations in Southern California. AMG provides professional and post-acute care services to Medicare, Medi-Cal/Medicaid, and Commercial patients through its network of doctors and nurse practitioners. In September 2019, APC-LSMA purchased 100% of the shares of capital stock of AMG for $1.2 million in cash and $0.4 million of APC common stock (see Note 3).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care Acquisition Partners, LLC (&#8220;UCAP&#8221;), a 100% owned subsidiary of APC, was formed in June&#160;2014, for the purpose of holding an investment in Universal Care, Inc. (&#8220;UCI&#8221;). On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright Health Company of California, Inc. ("Bright") for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.'s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million (see Note 5). As set forth in the Company&#8217;s definitive proxy statement filed with the SEC on July 31, 2019 (the &#8220;Proxy Statement&#8221;), the 48.9% interest in UCI is included in Excluded Assets that remain solely for the benefit of APC and its shareholders. As such, any proceeds or gain on the sale of APC&#8217;s indirect ownership interest in UCI has no impact on the Series A Dividend payable by APC to AP-AMH Medical Corporation as described in the Proxy Statement and consequently the sale did not affect net income attributable to ApolloMed.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO, jointly owned by NMM and AMM, began participating in the Next Generation Accountable Care Organization (&#8220;NGACO") Model of the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;) in January 2017. The NGACO Model is a CMS program that allows provider groups to assume higher levels of financial risk and potentially achieve a higher reward from participating in this new attribution-based risk sharing model. </span></div>AMM, a wholly-owned subsidiary of ApolloMed, manages affiliated medical groups, ApolloMed Hospitalists, a Medical Corporation (&#8220;AMH&#8221;) and Southern California Heart Centers, a Medical Corporation (&#8220;SCHC&#8221;). AMH provides hospitalist, intensivist, and physician advisory services. SCHC is a specialty clinic that focuses on cardiac care and diagnostic testing.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221552472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheet at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2020, and for the three and nine months ended September&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">required by Regulation S-X, Rule 10-01. Operating results for the three and nine months ended September&#160;30, 2020, are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2020, or any future periods.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated balance sheets as of September&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, and APAACO, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All material intercompany balances and transactions have been eliminated in consolidation.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash. As of September&#160;30, 2020, the Company&#8217;s deposit accounts with banks exceeded the FDIC&#8217;s insured limit by approximately $321.2 million, including approximately $118.3 million in certificates of deposit that were recognized as investments in marketable securities. The Company has not experienced any losses to date and performs ongoing evaluations of these financial institutions to limit the Company&#8217;s concentration of risk exposure.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $118.3 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables and Receivables &#8211; Related Parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model. As of September 30, 2020 and December 31, 2019, the Company had $1.3&#160;million and $2.9&#160;million of allowance for doubtful accounts, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risks</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type. The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in Level 1, Level 2, or Level 3 classification and no changes in valuation techniques for these assets for the nine months ended September&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques. The Company determined that there was no impairment of its finite-lived intangible or long-lived assets during the nine months ended September&#160;30, 2020 and 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no impairment of its goodwill or indefinite-lived intangible assets during the three and nine months ended September&#160;30, 2020. However, during the three and nine months ended September 30, 2019, the Company recorded impairment of indefinite-lived intangible assets of $2.0&#160;million related to Medicare licenses it acquired as part of the 2017 merger between ApolloMed and NMM. The Company will no longer utilize the licenses and as such will not receive future economic benefits therefrom.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37">two</span> additional renewal years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $19.8&#160;million in risk pool savings related to the 2019 performance year, and has recognized such amount as revenue in the risk pool settlements and incentives line of the accompanying consolidated statements of income for the three and nine months ended September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9 million and $68.4 million in total AIPBP payments for the three and nine months ended September&#160;30, 2020, respectively, of which $14.8 million and $57.3 million has been recognized as revenue for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the previous accounting guidance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred. The Company&#8217;s contract liability balance was $12.3 million and $8.9 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and is presented within &#8220;Accounts payable and accrued expenses&#8221; in the accompanying consolidated balance sheets. During the nine months ended September&#160;30, 2020, $0.4 million of the Company&#8217;s contract liability accrued in 2019 has been recognized as revenue and $8.5&#160;million was repaid to CMS for AIPBP capitation received and not earned.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Information</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, the Company made a deposit of $4.0 million for future investment opportunities. The deposit was made with cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH. The deposit is included in &#8220;Other assets&#8221; in the accompanying consolidated balance sheets. Subsequent to September 30, 2020, an agreement was signed converting this deposit into a promissory note from a related party (see Note 17). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine Equity</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements. As of September&#160;30, 2020 and December&#160;31, 2019, APC's shares were not redeemable, nor was it probable the shares would become redeemable.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221262280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations and Goodwill</a></td>
<td class="text">Business Combinations and Goodwill<div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alpha Care Medical Group, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2019, APC and APC-LSMA completed their acquisition of 100% of the capital stock of Alpha Care from Dr. Kevin Tyson for an aggregate purchase price of approximately $45.1 million in cash, subject to post-closing adjustments. As part of the transaction the Company deposited $2.0 million into an escrow account for potential post-closing adjustments. As of September&#160;30, 2020, no post-closing adjustment is expected to be paid to Dr. Tyson and the full amount of the escrow account is expected to be returned to the Company. As such, the escrow amount is presented within prepaid expenses and other current assets in the accompanying consolidated balance sheets. </span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accountable Health Care, IPA, a Professional Medical Corporation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2019, APC and APC-LSMA acquired the remaining outstanding shares of capital stock (comprising 75%) in Accountable Health Care in exchange for $7.3 million. In addition to the payment of $7.3 million, APC assumed all assets and liabilities of Accountable Health Care, including loans payable to NMM and APC of $15.4 million, which have been eliminated upon consolidation and contributed the 25% investment totaling $2.4 million, total purchase price was $25.1 million (see Note 5). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subordinated loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net asset acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment contributed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">AMG, a Professional Medical Corporation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired AMG in September 2019, for total consideration of $1.6&#160;million, of which $0.4 million was in the form of APC common stock. The business combination did not meet the quantitative thresholds to require separate disclosures based on the Company&#8217;s consolidated net assets, investments and net income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acquisitions were accounted for under the acquisition method of accounting. The fair value of the consideration for the acquired company was allocated to acquired tangible and intangible assets and liabilities based upon their fair values. The excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired was recorded as goodwill. The determination of the fair value of assets and liabilities acquired requires the Company to make estimates and use valuation techniques when market value is not readily available. The results of operations of the company acquired have been included in the Company&#8217;s financial statements from the date of acquisition. Transaction costs associated with business acquisitions are expensed as they are incurred.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time of acquisition, the Company estimates the amount of the identifiable intangible assets based on a valuation and the facts and circumstances available at the time. The Company determines the final value of the identifiable intangible assets as soon as information is available, but not more than one year from the date of acquisition.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not deductible for tax purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2020, was as follows (in thousands);</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222832104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets, Net</a></td>
<td class="text">Intangible Assets, Net<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.865%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,748)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,517)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in depreciation and amortization on the accompanying consolidated statements of income is amortization expense of $4.0 million and $4.3 million for the three months ended September&#160;30, 2020 and 2019, respectively, and $12.3 million and $12.1 million for the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222842120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock', window );">Investments in Other Entities &#8212; Equity Method</a></td>
<td class="text">Investments in Other Entities &#8212; Equity Method<div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care, Inc.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LaSalle Medical Associates &#8212; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPA Line of Business</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA was founded by Dr. Albert Arteaga in 1996 and currently operates six neighborhood medical centers through its network of approximately 2,300 PCP and Specialists providers, treating children, adults and seniors in San Bernardino County, California. LMA&#8217;s patients are primarily served by Medi-Cal. LMA also accepts Blue Cross, Blue Shield, Molina, Care 1st, Health Net and Inland Empire Health Plan. LMA is also an IPA of independently contracted doctors, hospitals and clinics, delivering high-quality care to approximately 290,000 patients in Fresno, Kings, Los Angeles, Madera, Riverside, San Bernardino and Tulare Counties. During 2012, APC-LSMA and LMA entered into a share purchase agreement whereby APC-LSMA invested $5.0 million for a 25% interest in LMA&#8217;s IPA line of business. NMM has a management services agreement with LMA. APC accounts for its investment in LMA under the equity method as APC has the ability to exercise significant influence, but not control over LMA&#8217;s operations. For the three months ended September&#160;30, 2020, APC recognized income from this investment of $0.5 million. For the three months ended September&#160;30, 2019, APC recognized a loss from this investment of $0.4 million. For the nine months ended September&#160;30, 2020, APC recognized income from this investment of $28,000 in the accompanying consolidated statements of income. For the nine months ended September&#160;30, 2019, APC recognized a loss from this investment of $2.8 million in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $6.4 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the nine months ended September&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,012)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pacific Medical Imaging and Oncology Center, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Incorporated in California in 2004, PMIOC provides comprehensive diagnostic imaging services using state-of-the-art technology. PMIOC offers high-quality diagnostic services, such as MRI/MRA, PET/CT, CT, nuclear medicine, ultrasound, digital x-rays, bone densitometry and digital mammography, at its facilities.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July&#160;2015, APC-LSMA and PMIOC entered into a share purchase agreement whereby APC-LSMA invested $1.2 million for a 40% ownership interest in PMIOC.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC and PMIOC have an Ancillary Service Contract together whereby PMIOC provides covered services on behalf of APC to enrollees of the plans of APC. Under the Ancillary Service Contract, APC paid PMIOC fees of approximately $0.5 million and $0.7 million, for the three months ended September&#160;30, 2020 and 2019, respectively, and fees of approximately $1.5&#160;million and $2.1 million for the nine months ended September&#160;30, 2020 and 2019. APC accounts for its investment in PMIOC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over PMIOC&#8217;s operations. For the three months ended September&#160;30, 2020, APC recognized a loss from this investment of $52,000. For the three months ended September 30, 2019, APC recognized income from this investment of $31,000. For the nine months ended September&#160;30, 2020 and 2019, APC recognized income of $25,000 and $0.2 million, respectively, in the accompanying consolidated statements of income. The accompanying consolidated balance sheets include the related investment balance of $1.4 million at September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Universal Care, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UCI is a privately held health plan that has been in operation since 1985. UCI holds a license under the California Knox-Keene Health Care Services Plan Act to operate as a full-service health plan. UCI contracts with CMS under the Medicare Advantage Prescription Drug Program.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2015, UCAP purchased 100,000 shares of UCI class A-2 voting common stock from UCI for $10.0 million, which shares comprise 48.9% of UCI&#8217;s total outstanding shares and 50% of UCI&#8217;s voting common stock. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 30, 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value of approximately $36.2 million on the date of sale, included in investments in privately held entities. The fair value of the preferred shares was determined utilizing a market approach which includes significant unobservable inputs (Level 3) including forecasted revenue along with estimates of revenue multiples, volatility and time-to-liquidity. In addition, pursuant to the terms of the stock purchase agreement, APC has a beneficial interest in the equity method investment sold. The estimated fair value of such interest on April 30, 2020 was&#160;$15.7 million and is included in "Other assets" in the accompanying consolidated balance sheets. The beneficial interest is the result of a gross margin provision in the stock purchase agreement which entitles UCAP to potentially receive additional cash and preferred shares (currently held in an escrow account with cash of $15.6&#160;million and preferred shares with an estimated fair value of $6.4&#160;million, total estimated fair value of $22.0&#160;million on the date of sale) based on the gross margin of UCI for calendar year 2020 as measured against a target. The amount to be received varies dependent upon the gross margin as compared to the target but cannot exceed the amounts that are in the escrow account. Additionally, the stock purchase agreement includes a tangible net equity provision that may result in the receipt or payment of additional amounts based on a comparison of final tangible net equity of UCI on the date of sale (determined with the benefit of one year of hindsight) as compared to the estimated tangible net equity at the time of sale. It is expected that settlement of the beneficial interest will begin in the second half of 2021. The Company determined the fair value of the beneficial interest using an income approach which includes significant unobservable inputs (Level 3). Specifically, the Company utilized a probability weighted discounted cash flow model using a risk-free treasury rate to estimate fair value which considered various scenarios of gross margin adjustment and the impact of each adjustment to the expected proceeds from the escrow account and assigned probabilities to each such scenario in determining fair value. The gross margin adjustment is defined as three times any deficit in actual gross margin of UCI for the year ended December 31, 2020 below a target gross margin unless such deficit is within a specific collar amount.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares in Bright Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beneficial interest in UCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Carrying value of equity method investment on date of sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2019 APC recorded income from this investment of approximately $0.6 million. For the nine months ended September&#160;30, 2020 and 2019 APC recorded income from this investment of approximately $3.6 million and $6.2 million, respectively, in the accompanying consolidated statements of income. As a result of the sale, there was no investment balance as of September&#160;30, 2020 as compared to an investment balance of $1.4 million as of December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and nine months ended September 30, 2019 are as follows (in thousands):</span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Four Months Ended April 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2016, David C.P. Chen M.D., individually, and APC-LSMA, entered into a share purchase agreement whereby APC-LSMA acquired a 40% ownership interest in DMG.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in DMG under the equity method of accounting as APC has the ability to exercise significant influence, but not control over DMG&#8217;s operations. For the three months ended September&#160;30, 2020 and 2019, APC recognized income from this investment of $0.1&#160;million and $0.3 million, respectively, in the consolidated statements of income. For the nine months ended  September&#160;30, 2020 and 2019, APC recognized income from investment of $19,000 and $0.7 million, respectively, in the consolidated statements of income. The accompanying consolidated balance sheets include the related investment balances of $2.4 million and $2.3 million as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">531 W. College LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, College Street Investment LP, a California limited partnership (&#8220;CSI&#8221;), APC and NMM entered into an operating agreement to govern the limited liability company, 531 W. College, LLC and the conduct of its business, and to specify their relative rights and obligations. CSI, APC and NMM, each owns 50%, 25% and 25%, respectively, of member units based on initial capital contributions of $16.7 million, $8.3 million, and $8.3 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, 531 W. College, LLC closed its purchase of a non-operational hospital located in Los Angeles from Societe Francaise De Bienfaisance Mutuelle De Los Angeles, a California nonprofit corporation, for a total purchase price of $33.3 million. On April 23, 2019, NMM and APC entered into an agreement whereby NMM assigned and APC assumed NMM&#8217;s 25% membership interest in 531 W. College, LLC for approximately $8.3 million. Subsequently, APC has a 50% ownership in 531 W. College LLC with a total investment balance of approximately $16.8 million. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC accounts for its investment in 531 W. College, LLC under the equity method of accounting as APC has the ability to exercise significant influence, but not control over the operations of this joint venture. For the three months ended September&#160;30, 2020 and 2019, APC recognized losses of $0.1 million, respectively. For the nine months ended September&#160;30, 2020 and 2019, APC recorded losses of $0.4 million and $0.7 million in the accompanying consolidated statements of income, respectively. During the period ended September&#160;30, 2020, the Company contributed $0.5 million to 531 W. College LLC as part of its 50% interest and had investment balances of $16.8 million and $16.7 million, respectively, at September&#160;30, 2020 and December&#160;31, 2019. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the nine months ended September&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MWN LLC &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2018, NMM, 6 Founders LLC, a California limited liability company doing business as Pacific6 Enterprises (&#8220;Pacific6&#8221;), and Health Source MSO Inc., a California corporation (&#8220;HSMSO&#8221;) entered into an operating agreement to govern MWN Community Hospital, LLC and the conduct of its business and to specify their relative rights and obligations. NMM, Pacific6, and HSMSO each own 33.3% of the membership shares based on each member&#8217;s initial capital contributions of $3,000 and working capital contributions of $30,000. NMM invested an additional $0.3 million for working capital purposes in August 2019. For the three and nine months ended September&#160;30, 2020, NMM recorded loss and income from its investment in MWN LLC of $2,000 and $10,000, respectively. For the three and nine months ended  September&#160;30, 2019, NMM recorded loss from its investment in MWN LLC of $0.1 million, respectively, in the accompanying consolidated statements of income and had an investment balance of $0.2 million as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in privately held entities that do not report net asset value</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">MediPortal, LLC</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2018, APC purchased 270,000 membership interests of MediPortal LLC, a New York limited liability company, for $0.4 million or $1.50 per membership interest, which represented an approximately 2.8% ownership interest. In connection with the initial purchase, APC received a five-year warrant to purchase an additional 270,000 membership interests. Additionally, APC received a five-year option to purchase an additional 380,000 membership interests and a five-year warrant to purchase 480,000 membership interests, which MediPortal LLC will grant APC upon completion of its health portal. As of September&#160;30, 2020, the health portal has not been completed. As APC does not have the ability to exercise significant influence, and lacks control, over the investee, this investment is accounted for using a measurement alternative which allows the investment to be measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AchievaMed</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 1, 2019, NMM and AchievaMed, Inc., a California corporation (&#8220;AchievaMed&#8221;), entered into an agreement in which NMM would purchase 50% of the aggregate shares of capital stock of AchievaMed over a period of time not to exceed five years. As a result of this transaction NMM invested $0.5 million for a 10% interest. The related investment balance of $0.5 million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheets as of September&#160;30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Bright Health, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, UCAP completed the sale of its 48.9% ownership interest in UCI to Bright for approximately $69.2 million in cash proceeds (including $16.5 million as repayment of indebtedness owed to APC), plus non-cash consideration consisting of shares of Bright Health, Inc.&#8217;s preferred stock having an estimated fair value on the transaction date of approximately $36.2 million. The related investment balance of $36.2&#160;million is included in &#8220;Investment in privately held entities&#8221; in the accompanying consolidated balance sheet as of September&#160;30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodAndOtherEquityInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method And Other Equity Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodAndOtherEquityInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222622120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LoanReceivableTextBlock', window );">Loan Receivable and Loan Receivable &#8211; Related Parties</a></td>
<td class="text">Loan Receivable and Loan Receivable &#8211; Related Parties<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dr. Albert Arteaga</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 28, 2019, APC entered into a convertible secured promissory note with Dr. Albert H. Arteaga, M.D. (&#8220;Dr. Arteaga&#8221;), Chief Executive Officer of LMA, to loan $6.4 million to Dr. Arteaga.  Interest on the loan accrues at a rate that is equal to the prime rate, plus 1% (4.25% as of September&#160;30, 2020) and payable in monthly installments of interest only on the first day of each month until the maturity date of December 31, 2020, at which time, all outstanding principal and accrued interest thereon shall be due and payable in full. The note is secured by certain shares of LMA common stock held by Dr. Arteaga. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At any time on or before December&#160;31, 2020, and upon written notice by APC to Dr. Arteaga, APC has the right, but not the obligation, to convert the entire outstanding principal amount of this note into shares of LMA common stock, which equal 21.25% of the aggregate then-issued and outstanding shares of LMA common stock to be held by APC&#8217;s designee, which may include APC-LSMA. If converted, APC-LSMA and APC&#8217;s designee will collectively own 46.25% of the equity of LMA with the remaining 53.75% to be owned by Dr. Arteaga. The entire note receivable has been classified under loans receivable on the consolidated balance sheets in the amount of $6.4 million as of September&#160;30, 2020. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2020, the Company entered into an agreement to advance Dr. Arteaga $2.2 million in the ordinary course of business. As of September&#160;30, 2020 the advance was fully repaid.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed the outstanding loan receivable under the CECL model by assessing the party's ability to pay by reviewing their interest payment history quarterly, financial history annually and reassessing any insolvency risk that is identified. If a failure to pay occurs, the Company assesses the terms of the notes and estimates an expected credit loss based on the remittance schedule of the note.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan receivable </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> related parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Universal Care, Inc.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, APC advanced $5.0 million on behalf of UCAP to UCI for working capital purposes. On June 29, 2018, November 28, 2018, and December 13, 2019, APC advanced an additional $2.5 million, $5.0 million and $4.0 million, respectively. The loans accrue interest at the prime rate, plus 1.00%, or 4.25%, as of March 31, 2020, and 5.75% as of December&#160;31, 2019, with interest to be paid monthly. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LoanReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LoanReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665349601592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">Accounts Payable and Accrued Expenses<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665333295704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">Medical Liabilities</a></td>
<td class="text">Medical Liabilities<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=2560295<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665344161512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Credit Facility, Bank Loan and Lines of Credit</a></td>
<td class="text">Credit Facility, Bank Loan and Lines of Credit<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s credit facility for the years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company entered into a secured credit agreement (the &#8220;Credit Agreement,&#8221; and the credit facility thereunder, the "Credit Facility") with Truist Bank (formerly known as SunTrust Bank), in its capacity as administrative agent for the lenders (in such capacity, the &#8220;Agent&#8221;), as a lender, an issuer of letters of credit and as swingline lender, and Preferred Bank, JPMorgan Chase Bank, N.A., MUFG Union Bank, N.A., Royal Bank of Canada, Fifth Third Bank and City National Bank, as lenders (the &#8220;Lenders&#8221;). In connection with the closing of the Credit Agreement, the Company, its subsidiary, NMM, and the Agent entered into a Guaranty and Security Agreement (the &#8220;Guaranty and Security Agreement&#8221;), pursuant to which, among other things, NMM guaranteed the obligations of the Company under the Credit Agreement. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement provides for a five-year revolving credit facility to the Company of $100.0 million (&#8220;Revolver Loan&#8221;), which includes a letter of credit subfacility of up to $25.0 million. The Credit Agreement also provides for a term loan of $190.0 million, (&#8220;Term Loan A&#8221;). The unpaid principal amount of the term loan is payable in quarterly installments on the last day of each fiscal quarter commencing on December 31, 2019. The principal payment for each of the first eight fiscal quarters is $2.4 million, for the following eight fiscal quarters thereafter is $3.6 million and for the following three fiscal quarters thereafter is $4.8 million. The remaining principal payment on the term loan is due on September&#160;11, 2024.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds of the term loan and up to $60.0 million of the revolving credit facility were used to (i) finance a portion of the AP-AMH Loan, (ii) refinance certain indebtedness of the Company and its subsidiaries and, indirectly, APC, (iii) pay transaction costs and expenses arising in connection with the Credit Agreement, the AP-AMH Loan and certain other related transactions and (iv) provide for working capital, capital expenditures and other general corporate purposes. The remainder of the revolving credit facility will be used to finance future acquisitions and investments and to provide for working capital needs, capital expenditures and other general corporate purposes.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to pay an annual facility fee of between 0.20% to 0.35% on the available commitments under the Credit Agreement, regardless of usage, with the applicable fee determined on a quarterly basis based on the Company&#8217;s leverage ratio. The Company is also required to pay customary fees as specified in a separate fee agreement between the Company and SunTrust Robinson Humphrey, Inc. (now known as Truist Securities Inc.), the lead arranger of the Credit Agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts borrowed under the Credit Agreement will bear interest at an annual rate equal to either, at the Company&#8217;s option, (a) the rate for Eurocurrency deposits for the corresponding deposits of U.S. dollars appearing on Reuters Screen LIBOR01 Page (&#8220;LIBOR&#8221;), adjusted for any reserve requirement in effect, plus a spread of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, or (b) a base rate, plus a spread between 1.00% and 2.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio. As of September&#160;30, 2020, the interest rate on Term Loan A for the 2020 commitment and future commitments was 2.72% and 2.77%, respectively. As of September&#160;30, 2020, the interest rate on the Revolver Loan was 2.77%. The base rate is defined in a manner such that it will not be less than LIBOR. The Company will pay fees for standby letters of credit at an annual rate of between 2.00% and 3.00%, as determined on a quarterly basis based on the Company&#8217;s leverage ratio, plus facing fees and standard fees payable to the issuing bank on the respective letter of credit. Loans outstanding under the Credit Agreement may be prepaid at any time without penalty, except for LIBOR breakage costs and expenses. If LIBOR ceases to be reported, the Credit Agreement requires the Company and the Agent to endeavor to establish a commercially reasonable alternative rate of interest and until they are able to do so, all borrowings must be at the base rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company and its subsidiaries to comply with various affirmative covenants, including, without limitation, furnishing updated financial and other information, preserving existence and entitlements, maintaining properties and insurance, complying with laws, maintaining books and records, requiring any new domestic subsidiary meeting a materiality threshold specified in the Credit Agreement to become a guarantor thereunder and paying obligations. The Credit Agreement requires the Company and its subsidiaries to comply with, and to use commercially reasonable efforts to the extent permitted by law to cause certain material associated practices of the Company, including APC, to comply with, restrictions on liens, indebtedness and investments (including restrictions on acquisitions by the Company), subject to specified exceptions. The Credit Agreement also contains various other negative covenants binding the Company and its subsidiaries, including, without limitation, restrictions on fundamental changes, dividends and distributions, sales and leasebacks, transactions with affiliates, burdensome agreements, use of proceeds, maintenance of business, amendments of organizational documents, accounting changes and prepayments and modifications of subordinated debt.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement requires the Company to comply with two key financial ratios, each calculated on a consolidated basis. The Company must maintain a maximum consolidated leverage ratio of not greater than 3.75 to 1.00 as of the last day of each fiscal quarter. The maximum consolidated leverage ratio decreases by 0.25 each year, until it is reduced to 3.00 to 1.00 for each fiscal quarter ending after September 30, 2022. The Company must maintain a minimum consolidated interest coverage ratio of </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not less than 3.25 to 1.00 as of the last day of each fiscal quarter. As of September&#160;30, 2020, the Company was in compliance with the covenants relating to its credit facility.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Guaranty and Security Agreement, the Company and NMM have granted the Lenders a security interest in all of their assets, including, without limitation, all stock and other equity issued by their subsidiaries (including NMM) and all rights with respect to the AP-AMH Loan. The Guaranty and Security Agreement requires the Company and NMM to comply with various affirmative and negative covenants, including, without limitation, covenants relating to maintaining perfected security interests, providing information and documentation to the Agent, complying with contractual obligations relating to the collateral, restricting the sale and issuance of securities by their respective subsidiaries and providing the Agent access to the collateral.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains events of default, including, without limitation, failure to make a payment when due, default on various covenants in the Credit Agreement, breach of representations or warranties, cross-default on other material indebtedness, bankruptcy or insolvency, occurrence of certain judgments and certain events under the Employee Retirement Income Security Act of 1974 aggregating more than $10.0 million, invalidity of the loan documents, any lien under the Guaranty and Security Agreement ceasing to be valid and perfected, any change in control, as defined in the Credit Agreement, an event of default under the AP-AMH Loan, failure by APC to pay dividends in cash for any period of two consecutive fiscal quarters, failure by AP-AMH to pay cash interest to the Company, or if any modification is made to the Certificate of Determination or the Special Purpose Shareholder Agreement that directly or indirectly restricts, conditions, impairs, reduces or otherwise limits the payment of the Series A Preferred dividend by APC to AP-AMH. In addition, it will constitute an event of default under the Credit Agreement if APC uses all or any portion of the consideration received by APC from AP-AMH on account of AP-AMH&#8217;s purchase of Series A Preferred Stock for any purpose other than certain specific approved uses described in the following sentence, unless not less than 50.01% of all holders of common stock of APC at such time approve such use; provided that APC may use up to $50.0 million in the aggregate of such consideration for any purpose without any requirement to obtain such approval of the holders of common stock of APC. The approved uses include (i) any permitted investment, (ii) any dividend or distribution to the holders of the common stock of APC, (iii) any repurchase of common stock of APC, (iv) paying taxes relating to or arising from certain assets and transactions, or (v) funding losses, deficits or working capital support on account of certain non-healthcare assets in an amount not to exceed $125.0 million. If any event of default occurs and is continuing under the Credit Agreement, the Lenders may terminate their commitments, and may require the Company and its guarantors to repay outstanding debt and/or to provide a cash deposit as additional security for outstanding letters of credit. In addition, the Agent, on behalf of the Lenders, may pursue remedies under the Guaranty and Security Agreement, including, without limitation, transferring pledged securities of the Company&#8217;s subsidiaries in the name of the Agent and exercising all rights with respect thereto (including the right to vote and to receive dividends), collect on pledged accounts, instruments and other receivables (including the AP-AMH Loan), and all other rights provided by law or under the loan documents and the AP-AMH Loan.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, certain of the Lenders under the Credit Agreement and their affiliates have provided to the Company and its subsidiaries and the associated practices, and may in the future provide, (i) investment banking, commercial banking (including pursuant to certain existing business loan and credit agreements being terminated in connection with entering into the Credit Agreement), cash management, foreign exchange or other financial services, and (ii) services as a bond trustee and other trust and fiduciary services, for which they have received compensation and may receive compensation in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deferred Financing Costs</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, the Company recorded deferred financing costs of $6.5 million related to the issuance of the Credit Facility. This amount was recorded as a direct reduction of the carrying amount of the related debt liability. The deferred financing costs will be amortized over the life of the Credit Facility using the effective interest rate method. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Effective Interest Rate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s average effective interest rate on its total debt during the nine months ended September&#160;30, 2020 and 2019, was 3.79% and 1.31%, respectively. Interest expense in the consolidated statements of income included amortization of deferred debt issuance costs for the three and nine months ended September&#160;30, 2020 and 2019, of $0.3 million and 0.1&#160;million, respectively, and $1.0 million and $0.1 million, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lines of Credit &#8211; Related Party</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NMM Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, NMM amended its promissory note agreement with Preferred Bank (&#8220;NMM Business Loan Agreement&#8221;), which provides for loan availability of up to $20.0 million with a maturity date of June&#160;22, 2020. One of the Company&#8217;s board members is the chairman and CEO of Preferred Bank. The NMM Business Loan Agreement was subsequently amended on September&#160;1, 2018, to temporarily increase the loan availability from $20.0 million to $27.0 million for the period from September 1, 2018 through January 31, 2019, further extended to October&#160;31, 2019, to facilitate the issuance of an additional standby letter of credit for the benefit of CMS. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 5.625% as of December&#160;31, 2018. The loan was guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all of the assets of NMM. The amount outstanding as of June&#160;30, 2019, of $5.0 million was fully repaid on September&#160;11, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;5, 2018, NMM entered into a non-revolving line of credit agreement with Preferred Bank, which provides for loan availability of up to $20.0 million with a maturity date of September&#160;5, 2019. This credit facility was subsequently amended on April&#160;17, 2019, and July&#160;29, 2019, to reduce the loan availability from $20.0 million to $16.0 million and from $16.0 million to $2.2 million, respectively. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% as of September&#160;30, 2020, and 4.875% as of December&#160;31, 2019. The line of credit is guaranteed by Apollo Medical Holdings, Inc. and is collateralized by substantially all assets of NMM. NMM obtained this line of credit to finance potential acquisitions. Each drawdown from the line of credit is converted into a five-year term loan with monthly principal payments, plus interest based on a five-year amortization schedule.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 11, 2019, the NMM Business Loan Agreement, dated as of June&#160;14, 2018, between NMM and Preferred Bank, as amended, and the Line of Credit Agreement, dated as of September&#160;5, 2018, between NMM and Preferred Bank, as amended, were terminated in connection with the closing of the credit facility.&#160;Certain letters of credit issued by Preferred Bank under the Line of Credit Agreement were terminated and reissued under the Credit Agreement. As of September&#160;30, 2020,  outstanding letters of credit totaled $8.2 million and the Company has $10.2 million available under the revolving credit facility for letters of credit.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">APC Business Loan</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;14, 2018, APC amended its promissory note agreement with Preferred Bank, which provides for loan availability of up to $10.0 million with a maturity date of June&#160;22, 2020. This credit facility was subsequently amended on April&#160;17, 2019, and June&#160;11, 2019, to increase the loan availability from $10.0 million to $40.0 million and extend the maturity date through December&#160;31, 2020. On August&#160;1, 2019, and September&#160;10, 2019, this credit facility was further amended to increase loan availability from $40.0 million to $43.8 million, and decrease loan availability from $43.8 million to $4.1 million, respectively. This decrease further limited the purpose of the indebtedness under APC Business Loan Agreement to the issuance of standby letters of credit, and added as a permitted lien the security interest in all of its assets granted by APC in favor of NMM under a Security Agreement dated on or about September 11, 2019, securing APC&#8217;s obligations to NMM under, and as required pursuant to, the APC management services agreement dated as of July 1, 1999, as amended. The interest rate is based on the Wall Street Journal &#8220;prime rate,&#8221; plus 0.125%, or 3.375% and 4.875% as of September&#160;30, 2020 and December&#160;31, 2019, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, there was no availability under this line of credit.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;2, 2018, APAACO established a second irrevocable standby letter of credit with Preferred Bank (through the NMM Business Loan Agreement) for $6.6 million for the benefit of CMS. The letter of credit expires on December&#160;31, 2020, and is automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution to terminate prior to 90 days from any expiration date. APAACO may continue to draw from the letter of credit for one year following the bank&#8217;s notification of non-renewal. This standby letter of credit was subsequently amended on August&#160;14, 2019, to increase the amount from $6.6 million to $14.8 million and extended the expiration date to December&#160;31, 2020, with all other terms and conditions remain unchanged. In connection with the closing of the Credit Facility,&#160;this letter of credit was terminated and reissued under the Credit Agreement. As of September 30, 2020, APAACO terminated $6.6 million of the irrevocable standby letter of credit. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with Preferred Bank under the APC Business Loan Agreement for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221495576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Mezzanine and Stockholders' Equity</a></td>
<td class="text">Mezzanine and Stockholders&#8217; Equity<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mezzanine</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the redemption feature (see Note 2) of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as noncontrolling interest in APC as mezzanine or temporary equity. APC&#8217;s shares are not redeemable and it is not probable that the shares will become redeemable as of September&#160;30, 2020 and December&#160;31, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholders&#8217; Equity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, 302,732 holdback shares have not been issued to certain former NMM shareholders who were NMM shareholders at the time of closing of the merger between NMM and ApolloMed in December 2017 (the "Merger"), as they have yet to submit properly completed letters of transmittal to ApolloMed in order to receive their pro rata portion of ApolloMed common stock and warrants as contemplated under the merger agreement. Pending such receipt, such former NMM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the Merger. The consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and the Company is legally obligated to issue these shares in connection with the Merger.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See options and warrants section below for common stock issued upon exercise of stock options and stock purchase warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Options</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, stock options were exercised for 120,000 and 203,524 shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $0.3 million and $1.2 million, respectively. The exercise price ranged from $2.10 to $5.00 per share for the exercises during the nine months ended September&#160;30, 2020, and ranged from $1.50 to $10.00 per share for the exercises during the nine months ended September&#160;30, 2019.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, no stock options were exercised pursuant to the cashless exercise provision.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Members</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company grants restricted stock awards to employees which are earned based on service conditions. The grant date fair value of the restricted stock awards is that day&#8217;s closing market price of the Company&#8217;s common stock. During the nine months ended September&#160;30, 2020, the Company granted restricted stock awards totaling 97,447 shares with a weighted average grant date fair value of $17.58. The grant date fair value of the restricted stock was $1.6 million and will be recognized on a straight-line basis over the awards&#8217; vesting period of three years. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, the Company recorded approximately $0.6 million and $2.2 million of share-based compensation expense associated with the issuance of restricted shares of common stock and vesting of stock options which are included in general and administrative expenses in the accompanying consolidated statements of income, respectively. Unrecognized compensation expense related to total share-based payments outstanding as of September&#160;30, 2020, was $3.1 million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                                              $                     9.00 &#8211;11.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, common stock warrants were exercised for 800,709 and 133,221 shares, respectively, of the Company&#8217;s common stock, which resulted in proceeds of approximately $6.2 million and $1.2 million, respectively. The exercise price ranged from $9.00 to $11.00 per share for the exercises during the nine months ended September&#160;30, 2020 and 2019, respectively.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, common stock warrants were exercised on a cashless basis for 127,022 shares of the Company's common stock which resulted in the Company issuing 66,517 net shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Treasury Stock</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC owned 17,307,214 and 17,290,317 shares of ApolloMed&#8217;s common stock as of September&#160;30, 2020 and December&#160;31, 2019, respectively, which are legally issued and outstanding but excluded from shares of common stock outstanding in the consolidated financial statements, as such shares are treated as treasury shares for accounting purposes (see Note 1).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2019, APC established a brokerage account to invest excess capital in the equity market. The brokerage account is managed directly by an independent investment committee of the APC board of directors, from which Dr. Kenneth Sim and Dr. Thomas Lam have been excluded. As of September&#160;30, 2020, the brokerage account only held shares of ApolloMed totaling&#160;$7.6 million, and as such the ApolloMed shares in the brokerage account&#160;have been recorded as treasury shares.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020 and 2019, APC paid dividends of $49.5 million and $59.7 million, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended  September&#160;30, 2020 and 2019, CDSC paid dividends of $0.6 million and $1.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222857720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Matters</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing the Medicare program and healthcare generally are complex and subject to interpretation. The Company believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medi-Cal programs.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As risk-bearing organizations, APC, Alpha Care and Accountable Health Care are required to comply with California DMHC regulations, including maintenance of minimum working capital, tangible net equity (&#8220;TNE&#8221;), cash-to-claims ratio and claims payment requirements prescribed by the California DMHC. TNE is defined as net equity less intangibles, less non-allowable assets (which include unsecured amounts due from affiliates), plus subordinated obligations. At&#160;September&#160;30, 2020 and December&#160;31, 2019, APC, Alpha Care and Accountable Health Care were in compliance with these regulations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the Company&#8217;s payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standby Letters of Credit</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the APAACO participation with CMS, the Company must provide a financial guarantee to CMS, the guarantee generally must be in an amount equal to 2% of the Company&#8217;s benchmark Medicare Part A and Part B expenditures. The Company has established an irrevocable standby letter of credit under the Credit Agreement for a face amount of $8.2 million for the 2019 performance year (see Note 9).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC established irrevocable standby letters of credit with a financial institution for a total of $0.3 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alpha Care established irrevocable standby letters of credit with a financial institution for a total of $3.8 million for the benefit of certain health plans. The standby letters of credit are automatically extended without amendment for additional one-year periods from the present or any future expiration date, unless notified by the institution in advance of the expiration date that the letter will be terminated (see Note 9). </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings and other matters arising in the normal course of its business. The resolution of any claim or litigation is subject to inherent uncertainty and could have a material adverse effect on the Company&#8217;s financial condition, cash flows or results of operations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Prospect Medical Systems</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or about March 23, 2018, and April 3, 2018, a Demand for Arbitration and an Amended Demand for Arbitration were filed by Prospect Medical Group, Inc. and Prospect Medical Systems, Inc. (collectively, &#8220;Prospect&#8221;) against MMG, ApolloMed and AMM with Judicial Arbitration Mediation Services in California, arising out of MMG&#8217;s purported business plans, seeking damages in excess of $5.0 million, and alleging breach of contract, violation of unfair competition laws, and tortious interference with Prospect&#8217;s current and future economic relationships with its health plans and their members. By stipulation and order dated April 28, 2020, ApolloMed and AMM were dismissed without prejudice from the arbitration for lack of jurisdiction on the basis that neither of them were a party to any arbitration agreement with Prospect, subject, however, to Prospect reserving its rights against ApolloMed and AMM and tolling of applicable statute of limitation. MMG disputes the allegations and intends to vigorously defend against this matter. The resolution of this matter and any potential range of loss in excess of any current accrual cannot be reasonably determined or estimated at this time primarily because the matter has not been fully arbitrated and presents unique regulatory and contractual interpretation issues. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liability Insurance</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that its insurance coverage is appropriate based upon the Company&#8217;s claims experience and the nature and risks of the Company&#8217;s business. In addition to the known incidents that have resulted in the assertion of claims, the Company cannot be certain that its insurance coverage will be adequate to cover liabilities arising out of claims asserted against the Company, the Company&#8217;s affiliated professional organizations or the Company&#8217;s affiliated hospitalists in the future where the outcomes of such claims are unfavorable. The Company believes that the ultimate resolution of all pending claims, including liabilities in excess of the Company&#8217;s insurance coverage, will not have a material adverse effect on the Company&#8217;s financial position, results of operations or cash flows; however, there can be no assurance that future claims will not have such a material adverse effect on the Company&#8217;s business. Contracted physicians are required to obtain their own insurance coverage.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Company currently maintains liability insurance policies on a claims-made basis, which are intended to cover malpractice liability and certain other claims, the coverage must be renewed annually, and may&#160;not continue to be available to the Company in future years at acceptable costs, and on favorable terms.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665333295704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related-Party Transactions</a></td>
<td class="text">Related-Party Transactions<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 16, 2015, UCAP entered into a subordinated note receivable agreement with UCI, a 48.9% owned equity method investee (see Note 5), in the amount of $5.0 million. On June 28, 2018 and November 28, 2018, UCAP entered into two additional subordinated note receivable agreements with UCI in the amount of $2.5 million and $5.0 million, respectively. On April 30, 2020, the outstanding balance was fully repaid as part of UCAP's disposition of its 48.9% ownership interest in UCI to Bright (see Note 6).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM earned approximately $4.2&#160;million and $4.4 million, respectively, and  $12.6 million and $12.9 million, respectively, in management fees from LMA, which is accounted for under the equity method based on 25% equity ownership interest held by APC in LMA&#8217;s IPA line of business (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $0.5&#160;million and $0.7 million, respectively, and $1.5 million and $2.1 million, respectively, to PMIOC for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $1.2&#160;million and $2.0 million, respectively, and $3.8 and $5.8 million, respectively, to DMG for provider services, which is accounted for under the equity method based on 40% equity ownership interest held by APC (see Note 5).</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, APC paid approximately $0.1&#160;million, respectively, and $0.2&#160;million, respectively, to Advanced Diagnostic Surgery Center for services as a provider. Advanced Diagnostic Surgery Center shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately $7.1&#160;million and $6.7 million, respectively,  which include approximately $1.7&#160;million and $1.8 million, respectively, to shareholders who are also officers of APC. During the nine months ended September&#160;30, 2020 and 2019, APC paid an aggregate of approximately of $23.4 million and $23.1 million, respectively, to shareholders of APC for provider services, which include approximately $6.5 million and $6.9 million, respectively, to shareholders who are also officers of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately $0.3 million, respectively and $0.8 million, respectively, to Medical Property Partners (&#8220;MPP&#8221;) for an office lease. MPP shares common ownership with certain board members of NMM.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020, NMM paid approximately $0.4&#160;million and $1.1 million, respectively, to One MSO, Inc. ("One MSO") for an office lease. One MSO is indirectly 50% owned by Drs. Sim and Lam.  As of September&#160;30, 2020, the Company had $10.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with One MSO to be amortized over the remaining life of the lease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended September&#160;30, 2020 and 2019, the Company paid approximately $39,000 and $0.1 million, respectively, and paid approximately $0.3 million for both the nine months ended September&#160;30, 2020 and 2019, to Critical Quality Management Corporation (&#8220;CQMC&#8221;) for an office lease. CQMC shares common ownership with certain board members of APC.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For both the three and nine months ended September&#160;30, 2020 and 2019, SCHC paid approximately $0.1&#160;million, respectively, and $0.3 million, respectively, to Numen, LLC (&#8220;Numen&#8221;) for an office lease. Numen is owned by a shareholder of APC. As of September 30, 2020, the Company had $1.4&#160;million of ROU assets and lease liabilities, respectively, related to its office lease with Numen to be amortized over the remaining life of the lease.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreements with HSMSO, Aurion Corporation (&#8220;Aurion&#8221;), and AHMC Healthcare (&#8220;AHMC&#8221;) for services provided to the Company. One of the Company&#8217;s board members is an officer of AHMC, HSMSO and Aurion. Aurion is also partially owned by one of the Company&#8217;s board members. The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO and Aurion (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:44.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and AHMC have a risk sharing agreement with certain AHMC hospitals to share the surplus and deficits of each of the hospital pools. During the three and nine months ended September&#160;30, 2020 and 2019, the Company has recognized risk pool revenue under this agreement of $10.5 million and $11.0 million, respectively, and $31.5&#160;million and $31.9 million, respectively, for which $36.9 million and $40.4 million remained outstanding as of September&#160;30, 2020 and December&#160;31, 2019, respectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September&#160;30, 2020 and 2019, NMM paid approximately&#160;$0 and $0.1 million, respectively, and $27,000 and $0.2 million, respectively, to ApolloMed board member, Matthew Mazdyasni, for consulting services. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, affiliates wholly owned by the Company&#8217;s officers, including the Company's Co-CEOs, Dr. Sim and Dr. Lam, are reported in the accompanying consolidated statements of income on a consolidated basis, together with the Company&#8217;s </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries, and therefore, the Company does not separately disclose transactions between such affiliates and the Company&#8217;s subsidiaries as related-party transactions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For equity method investments, loans receivable and line of credits from related parties, see Notes 5, 6 and 9, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665344161512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the liability method of accounting for income taxes as set forth in ASC 740. Under the liability method, deferred taxes are determined based on differences between the financial statement and tax bases of assets and liabilities using enacted tax rates.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an interim basis, the Company estimates what its anticipated annual effective tax rate will be and records a quarterly income tax provision (benefit) in accordance with the estimated annual rate, plus the tax effect of certain discrete items that arise during the quarter. As the fiscal year progresses, the Company refines its estimates based on actual events and financial results during the quarter. This process can result in significant changes to the Company&#8217;s estimated effective tax rate. When this occurs, the income tax provision (benefit) is adjusted during the quarter in which the estimates are refined so that the year-to-date provision reflects the estimated annual effective tax rate. These changes, along with adjustments to the Company&#8217;s deferred taxes and related valuation allowance, may create fluctuations in the overall effective tax rate from quarter to quarter.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, due to the overall cumulative losses incurred in recent years, the Company maintained a full valuation allowance against its deferred tax assets related to loss entities the Company cannot consolidate under the federal tax consolidation rules, as realization of these assets is uncertain.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s effective income tax rate for the nine months ended September&#160;30, 2020 and September 30, 2019 were 28.8% and 25.5%, respectively, and differed from the U.S. federal statutory rate primarily due to state income taxes, income from flow through entities, nondeductible permanent items, and change in valuation allowance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company does not have any unrecognized tax benefits related to various federal and state income tax matters. The Company will recognize accrued interest and penalties related to unrecognized tax benefits in income tax expense.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income tax as well as income tax in California. The Company and its subsidiaries&#8217; state and Federal income tax returns are open to audit under the statute of limitations for the years ended December 31, 2015 through December&#160;31, 2018, and for the years ended December 31, 2016 through December&#160;31, 2018, respectively. The Company does not anticipate material unrecognized tax benefits within the next 12 months.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 27, 2020, the Coronavirus Aid, Relief and Economic Security Act (the "CARES Act") was signed into law. The CARES Act includes various income and payroll tax provisions that we are in the process of analyzing to determine the tax impacts. However, the benefits of the CARES Act are not expected to impact the Company&#8217;s annual estimated tax rate for the nine months ended September 30, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665333295704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is calculated using the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during a certain period, and is calculated by dividing net income attributable to ApolloMed by the weighted average number of shares of the Company&#8217;s common stock issued and outstanding during such period. Diluted earnings per share is calculated using the weighted average number of shares of common stock and potentially dilutive shares of common stock outstanding during the period, using the as-if converted method for secured convertible notes, preferred stock, and the treasury stock method for options and common stock warrants.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020 and December&#160;31, 2019, APC held 17,307,214 and 17,290,317 shares of ApolloMed&#8217;s common stock, respectively, which are treated as treasury shares for accounting purposes and not included in the number of shares of common stock outstanding used to calculate earnings per share.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,643,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,555,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,816,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,643,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,555,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,816,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221524520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Variable Interest Entities (VIEs)</a></td>
<td class="text">Variable Interest Entities (VIEs)<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is defined as a legal entity whose equity owners do not have sufficient equity at risk, or, as a group, the holders of the equity investment at risk lack any of the following three characteristics: decision-making rights, the obligation to absorb losses, or the right to receive the expected residual returns of the entity. The primary beneficiary is identified as the variable interest holder that has both the power to direct the activities of the VIE that most significantly affect the entity&#8217;s economic performance and the obligation to absorb expected losses or the right to receive benefits from the entity that could potentially be significant to the VIE.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows guidance on the consolidation of VIEs that requires companies to utilize a qualitative approach to determine whether it is the primary beneficiary of a VIE. See Note 2 &#8211; &#8220;Basis of Presentation and Summary of Significant Accounting Policies&#8221; to the accompanying consolidated financial statements for information on how the Company determines VIEs and its treatment.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assets of the Company&#8217;s other consolidated VIEs were not considered significant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222772792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases were $0.3 million, for both periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Discount Rate</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating and finance leases for corporate offices, doctors&#8217; offices, and certain equipment. These leases have remaining lease terms of 1 month to 5 years, some of which may include options to extend the leases for up to 10 years, and some of which may include options to terminate the leases within one year. As of September&#160;30, 2020 and December&#160;31, 2019, assets recorded under finance leases were $0.4 million and $0.5 million, respectively, and accumulated depreciation associated with finance leases were $0.3 million, for both periods. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the Company rents or subleases certain real estate to third parties, which are accounted for as operating leases.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the balance sheet.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Discount Rate</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2020, the Company does not have additional operating and finance leases that have not yet commenced.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222595992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent Events<div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, APC's board of directors declared an in-kind dividend of 5&#160;million shares of ApolloMed's common stock on a pro rata basis to APC's shareholders in November 2020. The shares being distributed is from the Excluded Assets that remain solely for the benefit of APC and its shareholders.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Promissory note</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, APC entered into a promissory note with AHMC, a related party of the Company, (the &#8220;2020 Note&#8221;) as payee for a principal sum of $4.0 million with a maturity date of two years from the date of the agreement. The contractual interest rate on the 2020 Note is 3.75%  per annum. The funds lent pursuant to the 2020 Note are the same funds that were deposited for investment opportunities in March 2020 (the "March Deposit"). As with the March Deposit, the 2020 Note was entered into using cash strictly related to the Excluded Assets that were generated from the series of transactions with AP-AMH.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232270696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated balance sheet at December&#160;31, 2019, has been derived from the Company&#8217;s audited consolidated financial statements, but does not include all disclosures required by generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). The accompanying unaudited consolidated financial statements as of September&#160;30, 2020, and for the three and nine months ended September&#160;30, 2020 and 2019, have been prepared in accordance with U.S. GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements, and should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2019 as filed with the SEC on March 16, 2020. In the opinion of management, all material adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been made to make the consolidated financial statements not misleading as </span></div>required by Regulation S-X, Rule 10-01.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The consolidated balance sheets as of September&#160;30, 2020 and December&#160;31, 2019, and the consolidated statements of income for the three and nine months ended September&#160;30, 2020 and 2019, &#160;include the accounts of ApolloMed, its consolidated subsidiaries, NMM, AMM, and APAACO, its consolidated VIE, AP-AMH, NMM's consolidated subsidiaries, and consolidated VIE, APC, APC&#8217;s subsidiary, UCAP, and APC&#8217;s consolidated VIEs, CDSC, APC-LSMA, ICC, and APC-LSMA&#8217;s consolidated subsidiaries Alpha Care and Accountable Health Care.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All material intercompany balances and transactions have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements and related disclosures in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period.&#160;Significant items subject to such estimates and assumptions include collectability of receivables, recoverability of long-lived and intangible assets, business combination and goodwill valuation and impairment, accrual of medical liabilities (incurred, but not reported (&#8220;IBNR&#8221;) claims), determination of full-risk and shared-risk revenue and receivables (including constraints and completion factors, including historical medical loss ratios (&#8220;MLR&#8221;)), income taxes, valuation of share-based compensation and right-of-use ("ROU") assets and lease liabilities. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. As future events and their effects cannot be determined with precision, actual results could differ materially from those estimates and assumptions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Reportable Segments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reportable Segments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as one reportable segment, the healthcare delivery segment, and implements and operates innovative healthcare models to create a patient-centered, physician-centric experience. The Company reports its consolidated financial statements in the aggregate, including all activities in one reportable segment.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash and cash equivalents primarily consist of money market funds and certificates of deposit. The Company considers all highly liquid investments that are both readily convertible into known amounts of cash and mature within 90 days from their date of purchase to be cash equivalents.</span></div>The Company maintains its cash in deposit accounts with several banks, which at times may&#160;exceed the insured limits of the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;). The Company believes it is not exposed to any significant credit risk with respect to its cash, cash equivalents and restricted cash.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Cash</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash consists of cash held as collateral to secure standby letters of credits as required by certain contracts.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Investments in Marketable Securities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Marketable Securities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The appropriate classification of investments is determined at the time of purchase and such designation is reevaluated at each balance sheet date. As of September&#160;30, 2020 and December&#160;31, 2019, investments in marketable securities amounted to approximately $118.3 million and $116.5 million, respectively, and consisted of equity securities and certificates of deposit with various financial institutions, reported at par value, plus accrued interest, with maturity dates from four months to 24 months (see fair value measurements of financial instruments below). Investments in certificates of deposits are classified as Level 1 investments in the fair value hierarchy.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock', window );">Receivables and Receivables &#8211; Related Parties</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables and Receivables &#8211; Related Parties</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables are comprised of accounts receivable, capitation and claims receivable, risk pool settlements and incentive receivables, management fee income and other receivables. Accounts receivable are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables &#8211; related parties are comprised of risk pool settlements, management fee income and incentive receivables, and other receivables. Receivables &#8211; related parties are recorded and stated at the amount expected to be collected.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation and claims receivable relate to each health plan&#8217;s capitation and is received by the Company in the month following the month of service. Risk pool settlements and incentive receivables mainly consist of the Company&#8217;s full risk pool receivable that is recorded quarterly based on reports received from the Company&#8217;s hospital partners and management&#8217;s estimate of the Company&#8217;s portion of the estimated risk pool surplus for open performance years. Settlement of risk pool surplus or deficits occurs approximately 18 months after the risk pool performance year is completed. Other receivables consists of recoverable claims paid related to the 2019 APAACO performance year to be administered following instructions from CMS, fee-for-services (&#8220;FFS&#8221;) reimbursement for patient care, certain expense reimbursements, transportation reimbursements from the hospitals, and stop loss insurance premium reimbursements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains reserves for potential credit losses on accounts receivable. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentrations, customer credit worthiness, current economic trends and changes in customer payment patterns to evaluate the adequacy of these reserves. The Company also regularly analyzes the ultimate collectability of accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected and adjustments are recorded when necessary. Reserves are recorded primarily on a specific identification basis.</span></div>Receivables are recorded when the Company is able to determine amounts receivable under applicable contracts and agreements based on information provided and collection is reasonably likely to occur. In regards to the credit loss standard, the Company continuously monitors its collections of receivables and our expectation is that the historical credit loss experienced across our receivable portfolio is materially similar to any current expected credit losses that would be estimated under the current expected credit losses (CECL) model.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risks</a></td>
<td class="text">Concentrations of RisksThe Company disaggregates revenue from contracts by service type and payor type. This level of detail provides useful information pertaining to how the Company generates revenue by significant revenue stream and by type of direct contracts. The consolidated statements of income present disaggregated revenue by service type.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Measurements of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements of Financial Instruments</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist of cash and cash equivalents, fiduciary cash, restricted cash, investment in marketable securities, receivables, loans receivable, accounts payable, certain accrued expenses, finance lease obligations, and long-term debt. The carrying values of the financial instruments classified as current in the accompanying consolidated balance sheets are considered to be at their fair values, due to the short maturity of these instruments. The carrying amounts of finance lease obligations and long-term debt approximate fair value as they bear interest at rates that approximate current market rates for debt with similar maturities and credit quality.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial Accounting Standards Board (&#8220;FASB&#8221;) Accounting Standards Codification (&#8220;ASC&#8221;) 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 820&#8221;), applies to all financial assets and financial liabilities that are measured and reported on a fair value basis and requires disclosure that establishes a framework for measuring fair value and expands disclosure about fair value measurements. ASC&#160;820 establishes a fair value hierarchy for disclosure of the inputs to valuations used to measure fair value.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This hierarchy prioritizes the inputs into three broad levels as follows:</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that can be accessed at the measurement date.</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level&#160;3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Unobservable inputs that reflect assumptions about what market participants would use in pricing the asset or liability. These inputs would be based on the best information available, including the Company&#8217;s own data.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Intangible Assets and Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Long-Lived Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives include network-payor relationships, management contracts and member relationships and are stated at cost, less accumulated amortization and impairment losses. These intangible assets are amortized on the accelerated method using the discounted cash flow rate.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with finite lives also include a patient management platform, as well as trade names and trademarks, whose valuations were determined using the cost to recreate method and the relief from royalty method, respectively. These assets are stated at cost, less accumulated amortization and impairment losses, and are amortized using the straight-line method.</span></div>Finite-lived intangibles and long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may&#160;not be recoverable. If the expected future cash flows from the use of such assets (undiscounted and without interest charges) are less than the carrying value, a write-down would be recorded to reduce the carrying value of the asset to its estimated fair value. Fair value is determined based on appropriate valuation techniques.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill and Indefinite-Lived Intangible Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under ASC 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles &#8211; Goodwill and Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, goodwill and indefinite-lived intangible assets are reviewed at least annually for impairment.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, at the Company&#8217;s fiscal year-end, or sooner if events or changes in circumstances indicate that an impairment has occurred, the Company performs a qualitative assessment to determine whether it is more likely than not that the fair value of each reporting unit is less than its carrying amount as a basis for determining whether it is necessary to complete quantitative impairment assessments for each of the Company&#8217;s three main reporting units (1) management services, (2) IPAs, and (3) ACOs. The Company is required to perform a quantitative goodwill impairment test only if the conclusion from the qualitative assessment is that it is more likely than not that a reporting unit&#8217;s fair value is less than the carrying value of its assets. Should this be the case, a quantitative analysis is performed to identify whether a potential impairment exists by comparing the estimated fair values of the reporting units with their respective carrying values, including goodwill.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized if the implied fair value of the asset being tested is less than its carrying value. In this event, the asset is written down accordingly. The fair values of goodwill are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At least annually, indefinite-lived intangible assets are tested for impairment. Impairment for intangible assets with indefinite lives exists if the carrying value of the intangible asset exceeds its fair value. The fair values of indefinite-lived intangible assets are determined using valuation techniques based on estimates, judgments and assumptions management believes are appropriate in the circumstances.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy', window );">Investments in Other Entities - Equity Method and Investments in Privately Held Entities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Other Entities &#8212; Equity Method</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the equity method of accounting when it is determined that the investment provides the Company with the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company has an ownership interest in the voting stock of the investee of between 20% and 50%, although other factors, such as representation on the investee&#8217;s board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment, originally recorded at cost, is adjusted to recognize the Company&#8217;s share of net earnings or losses of the investee and is recognized in the accompanying consolidated statements of income under &#8220;Income (loss) from equity method investments&#8221; and also is adjusted by contributions to and distributions from the investee. Equity method investments are subject to impairment evaluation. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments in Privately Held Entities</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for certain investments using the cost method of accounting when it is determined that the investment provides the Company with little or no influence over the investee. Under the cost method of accounting, the investment is measured at cost, adjusted for observable price changes and impairments, with changes recognized in net income. The investments in privately held entities that do not report NAV are subject to qualitative assessment for indicators of impairments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock', window );">Medical Liabilities</a></td>
<td class="text"><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Liabilities</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC, Alpha Care, Accountable Health Care, APAACO and MMG are responsible for integrated care that the associated physicians and contracted hospitals provide to their enrollees. APC, Alpha Care, Accountable Health Care, APAACO and MMG provide integrated care to HMOs, Medicare and Medi-Cal enrollees through a network of contracted providers under sub-capitation and direct patient service arrangements. Medical costs for professional and institutional services rendered by contracted providers are recorded as cost of services expenses in the accompanying consolidated statements of income.</span></div>An estimate of amounts due to contracted physicians, hospitals, and other professional providers is included in medical liabilities in the accompanying consolidated balance sheets. Medical liabilities include claims reported as of the balance sheet date and estimates IBNR claims. Such estimates are developed using actuarial methods and are based on numerous variables, including the utilization of healthcare services, historical payment patterns, cost trends, product mix, seasonality, changes in membership, and other factors. The estimation methods and the resulting reserves are periodically reviewed and updated. Many of the medical contracts are complex in nature and may&#160;be subject to differing interpretations regarding amounts due for the provision of various services. Such differing interpretations may&#160;not come to light until a substantial period of time has passed following the contract implementation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company receives payments from the following sources for services rendered: (i) commercial insurers; (ii) the federal government under the Medicare program administered by CMS; (iii) state governments under the Medicaid and other programs; (iv) other third-party payors (e.g., hospitals and IPAs); and (v) individual patients and clients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nature of Services and Revenue Streams</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue primarily consists of capitation revenue, risk pool settlements and incentives, NGACO All-Inclusive Population-Based Payments (&#8220;AIPBP&#8221;), management fee income, and FFS revenue. Revenue is recorded in the period in which services are rendered or the period in which the Company is obligated to provide services. The form of billing and related risk of collection for such services may&#160;vary by type of revenue and the customer. The following is a summary of the principal forms of the Company&#8217;s billing arrangements and how revenue is recognized for each.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capitation, Net</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Managed care revenues of the Company consist primarily of capitated fees for medical services provided by the Company under a capitated arrangement directly made with various managed care providers including HMOs. Capitation revenue is typically prepaid monthly to the Company based on the number of enrollees selecting the Company as their healthcare provider. Capitation revenue is recognized in the month in which the Company is obligated to provide services to plan enrollees under contracts with various health plans. Minor ongoing adjustments to prior months&#8217; capitation, primarily arising from contracted HMOs finalizing their monthly patient eligibility data for additions or subtractions of enrollees, are recognized in the month they are communicated to the Company. Additionally, Medicare pays capitation using a &#8220;Risk Adjustment&#8221; model, which compensates managed care organizations and providers based on the health status (acuity) of each individual enrollee. Health plans and providers with higher acuity enrollees will receive more and those with lower acuity enrollees will receive less. Under Risk Adjustment, capitation is determined based on health severity, measured using patient encounter data. Capitation is paid on a monthly basis based on data submitted for the enrollee for the preceding year and is adjusted in subsequent periods after the final data is compiled. Positive or negative capitation adjustments are made for Medicare enrollees with conditions requiring more or less healthcare services than assumed in the interim payments. Since the Company cannot reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are recognized when those changes are communicated by the health plans to the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PMPM managed care contracts generally have a term of one year or longer. All managed care contracts have a single performance obligation that constitutes a series for the provision of managed healthcare services for a population of enrolled members for the duration of the contract. The transaction price for PMPM contracts is variable as it primarily includes PMPM fees associated with unspecified membership that fluctuates throughout the contract. In certain contracts, PMPM fees also include adjustments for items such as performance incentives, performance guarantees and risk shares. The Company generally estimates the transaction price using the most likely amount methodology and amounts are only included in the net transaction price to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The majority of the Company&#8217;s net PMPM transaction price relates specifically to the Company&#8217;s efforts to transfer the service for a distinct increment of the series (e.g., day or month) and is recognized as revenue in the month in which members are entitled to service.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Pool Settlements and Incentives</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APC enters into full risk capitation arrangements with certain health plans and local hospitals, which are administered by a third party, where the hospital is responsible for providing, arranging and paying for institutional risk and APC is responsible for providing, arranging and paying for professional risk. Under a full risk pool sharing agreement, APC generally receives a percentage of the net surplus from the affiliated hospital&#8217;s risk pools with HMOs after deductions for the affiliated hospitals costs. Advance settlement payments are typically made quarterly in arrears if there is a surplus. The Company&#8217;s risk pool settlements under arrangements with health plans and hospitals are recognized using the most likely amount methodology and amounts are only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. The assumptions for historical MLR, IBNR completion factors and constraint percentages were used by management in applying the most likely amount methodology.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under capitated arrangements with certain HMOs, APC participates in one or more shared risk arrangements relating to the provision of institutional services to enrollees (shared risk arrangements) and thus can earn additional revenue or incur losses based upon the enrollee utilization of institutional services. Shared risk capitation arrangements are entered into with certain health plans, which are administered by the health plan, where APC is responsible for rendering professional services, but the health plan does not enter into a capitation arrangement with a hospital and therefore the health plan retains the institutional risk. Shared risk deficits, if any, are not payable until and unless (and only to the extent of any) risk-sharing surpluses are generated. At the termination of the HMO contract, any accumulated deficit will be extinguished.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s risk pool settlements under arrangements with HMOs are recognized, using the most likely methodology, and only included in revenue to the extent that it is probable that a significant reversal of cumulative revenue will not occur. Given the lack of access to the health plans&#8217; data and control over the members assigned to APC, the adjustments and/or the withheld amounts are unpredictable and as such APC&#8217;s risk share revenue is deemed to be fully constrained until APC is notified of the amount by the health plan. Risk pools for the prior contract years are generally final settled in the third or fourth quarter of the following year.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to risk-sharing revenues, the Company also receives incentives under &#8220;pay-for-performance&#8221; programs for quality medical care, based on various criteria. As an incentive to control enrollee utilization and to promote quality care, certain HMOs have designed quality incentive programs and commercial generic pharmacy incentive programs to compensate the Company for its efforts to improve the quality of services and efficient and effective use of pharmacy supplemental benefits provided to HMO members. The incentive programs track specific performance measures and calculate payments to the Company based on the performance measures. The Company&#8217;s incentives under &#8220;pay-for-performance&#8221; programs are recognized using the most likely methodology. However, as the Company does not have sufficient insight from the health plans on the amount and timing of the shared risk pool and incentive payments these amounts are considered to be fully constrained and only recorded when such payments are known and/or received.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, for the foregoing arrangements, the final settlement is dependent on each distinct day&#8217;s performance within the annual measurement period but cannot be allocated to specific days until the full measurement period has occurred and performance can be assessed. As such, this is a form of variable consideration estimated at contract inception and updated through the measurement period (i.e., the contract year), to the extent the risk of reversal does not exist and the consideration is not constrained.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NGACO AIPBP Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">APAACO and CMS entered into a NGACO Model Participation Agreement (the &#8220;Participation Agreement&#8221;) with an initial term of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY1NDk_53b4d94d-d3b0-4137-9a4f-8b17a2ad5296">two</span> performance years through December&#160;31, 2018, which term was extended for <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmU5NDg4MGEyZDVkZjQwZDJiNzYzZTNhMGJkZWY3OWMxL3NlYzplOTQ4ODBhMmQ1ZGY0MGQyYjc2M2UzYTBiZGVmNzljMV80MC9mcmFnOjZmYjM2OTA2ZmQ4MTRjNmZhNmI5ZjA1NDNhOTE4YTBhL3RleHRyZWdpb246NmZiMzY5MDZmZDgxNGM2ZmE2YjlmMDU0M2E5MThhMGFfMjY2MjU_f1481dac-c9bb-4d88-88bb-1ebdc5b0ad37">two</span> additional renewal years.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, the Company must submit to CMS its selections for risk arrangement; the amount of the profit/loss cap; alternative payment mechanism; benefits enhancements, if any; and its decision regarding voluntary alignment under the NGACO Model. The Company must obtain CMS consent before voluntarily discontinuing any benefit enhancement during a performance year.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the NGACO Model, CMS aligns beneficiaries to the Company to manage (direct care and pay providers) based on a budgetary benchmark established with CMS. The Company is responsible for managing medical costs for these beneficiaries. The beneficiaries will receive services from physicians and other medical service providers that are both in-network and out-of-network. The Company receives capitation from CMS on a monthly basis to pay claims from in-network providers. The Company records such capitation received from CMS as revenue as the Company is primarily responsible and liable for managing the patient care and for satisfying provider obligations, is assuming the credit risk for the services provided by in-network providers through its arrangement with CMS, and has control of the funds, the services provided and the process by which the providers are ultimately paid. Claims from out-of-network providers are processed and paid by CMS and the </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company&#8217;s shared savings or losses in managing the services provided by out-of-network providers are generally determined on an annual basis after reconciliation with CMS. Pursuant to the Company&#8217;s risk share agreement with CMS, the Company will be eligible to receive the savings or be liable for the deficit according to the budget established by CMS based on the Company&#8217;s efficiency in managing how the beneficiaries aligned to the Company by CMS are served by in-network and out-of-network providers. The Company&#8217;s savings or losses on providing such services are both capped by CMS, and are subject to significant estimation risk, whereby payments can vary significantly depending upon certain patient characteristics and other variable factors. Accordingly, the Company recognizes such surplus or deficit upon substantial completion of reconciliation and determination of the amounts. The Company records NGACO capitation revenues monthly. Excess over claims paid, plus an estimate for the related IBNR claims (see Note 8), and monthly capitation received are deferred and recorded as a liability until actual claims are paid or incurred. CMS will determine if there were any excess capitation paid for the performance year and the excess is refunded to CMS.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each performance year, CMS pays the Company in accordance with the alternative payment mechanism, if any, for which CMS has approved the Company; the risk arrangement for which the Company has been approved by CMS; and as otherwise provided in the Participation Agreement. Following the end of each performance year and at such other times as may be required under the Participation Agreement, CMS will issue a settlement report to the Company setting forth the amount of any shared savings or shared losses and the amount of other monies. If CMS owes the Company shared savings or other monies, CMS will pay the Company in full within 30 days after the date on which the relevant settlement report is deemed final, except as provided in the Participation Agreement. If the Company owes CMS shared losses or other monies owed as a result of a final settlement, the Company will pay CMS in full within 30 days after the relevant settlement report is deemed final. If the Company fails to pay the amounts due to CMS in full within 30 days after the date of a demand letter or settlement report, CMS will assess simple interest on the unpaid balance at the rate applicable to other Medicare debts under current provisions of law and applicable regulations. In addition, CMS and the U.S. Department of the Treasury may use any applicable debt collection tools available to collect any amounts owed by the Company.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company participates in the AIPBP track of the NGACO Model. Under the AIPBP track, CMS estimates the total annual expenditures for APAACO&#8217;s assigned patients and pays that projected amount to the Company in monthly installments, and the Company is responsible for all Part A and Part B costs for in-network participating providers and preferred providers contracted by the Company to provide services to the assigned patients.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As APAACO does not have sufficient insight into the financial performance of the shared risk pool with CMS because of unknown factors related to IBNR claims, risk adjustment factors, and stop loss provisions, among other factors, an estimate cannot be developed. Due to these limitations, APAACO cannot determine the amount of surplus or deficit that will likely be recognized in the future and therefore this shared risk pool revenue is considered fully constrained. Pursuant to the Participation Agreement, the Company received $19.8&#160;million in risk pool savings related to the 2019 performance year, and has recognized such amount as revenue in the risk pool settlements and incentives line of the accompanying consolidated statements of income for the three and nine months ended September 30, 2020.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For performance year 2020, the Company continues to receive monthly AIPBP payments at a rate of approximately $7.6 million per month from CMS, and will need to continue to comply with all terms and conditions in the Participation Agreement and various regulatory requirements to be eligible to participate in the AIPBP mechanism and/or NGACO Model. The Company has received approximately $22.9 million and $68.4 million in total AIPBP payments for the three and nine months ended September&#160;30, 2020, respectively, of which $14.8 million and $57.3 million has been recognized as revenue for the three and nine months ended September 30, 2020, respectively. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management Fee Income</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management fee income encompasses fees paid for management, physician advisory, healthcare staffing, administrative and other non-medical services provided by the Company to IPAs, hospitals and other healthcare providers. Such fees may be in the form of billings at agreed-upon hourly rates, percentages of revenue or fee collections, or amounts fixed on a monthly, quarterly or annual basis. The revenue may include variable arrangements measuring factors such as hours staffed, patient visits or collections per visit against benchmarks, and, in certain cases, may be subject to achieving quality metrics or fee collections. The Company recognizes such variable supplemental revenues in the period when such amounts are determined to be fixed and therefore contractually obligated as payable by the customer under the terms of the applicable agreement.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a significant service of integrating the services selected by the Company&#8217;s clients into one overall output for which the client has contracted. Therefore, such management contracts generally contain a single performance obligation. The nature of the Company&#8217;s performance obligation is to stand ready to provide services over the contractual period. Also, the Company&#8217;s performance obligation forms a series of distinct periods of time over which the Company stands ready to perform. The Company&#8217;s performance obligation is satisfied as the Company completes each period&#8217;s obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from management contracts is variable in nature because the majority of the fees are generally based on revenue or collections, which can vary from period to period. The Company has control over pricing. Contractual fees are invoiced to the Company&#8217;s clients generally monthly and payment terms are typically due within 30 days. The variable consideration in the Company&#8217;s management contracts meets the criteria to be allocated to the distinct period of time to which it relates because (i) it is due to the activities performed to satisfy the performance obligation during that period and (ii) it represents the consideration to which the Company expects to be entitled.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management contracts generally have long terms (e.g., 10 years), although they may be terminated earlier under the terms of the applicable contracts. Since the remaining variable consideration will be allocated to a wholly unsatisfied promise that forms part of a single performance obligation recognized under the series guidance, the Company has applied the optional exemption to exclude disclosure of the allocation of the transaction price to remaining performance obligations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fee-for-Service Revenue</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">FFS revenue represents revenue earned under contracts in which the Company bills and collects the professional component of charges for medical services rendered by the Company&#8217;s contracted physicians and employed physicians. Under the FFS arrangements, the Company bills the hospitals and third-party payors for the physician staffing and further bills patients or their third-party payors for patient care services provided and receives payment. FFS revenue related to the patient care services is reported net of contractual allowances and policy discounts and are recognized in the period in which the services are rendered to specific patients. All services provided are expected to result in cash flows and are therefore reflected as net revenue in the consolidated financial statements. The recognition of net revenue (gross charges less contractual allowances) from such services is dependent on such factors as proper completion of medical charts following a patient visit, the forwarding of such charts to the Company&#8217;s billing center for medical coding and entering into the Company&#8217;s billing system and the verification of each patient&#8217;s submission or representation at the time services are rendered as to the payor(s) responsible for payment of such services. Revenue is recorded based on the information known at the time of entering of such information into the Company&#8217;s billing systems, as well as an estimate of the revenue associated with medical services.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is responsible for confirming member eligibility, performing program utilization review, potentially directing payment to the provider and accepting the financial risk of loss associated with services rendered, as specified within the Company&#8217;s client contracts. The Company has the ability to adjust contractual fees with clients and possess the financial risk of loss in certain contractual obligations. These factors indicate the Company is the principal and, as such, the Company records gross fees contracted with clients in revenues.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration from FFS arrangements is variable in nature because fees are based on patient encounters, credits due to clients and reimbursement of provider costs, all of which can vary from period to period.&#160;Patient encounters and related episodes of care and procedures qualify as distinct goods and services, provided simultaneously together with other readily available resources, in a single instance of service, and thereby constitute a single performance obligation for each patient encounter and, in most instances, occur at readily determinable transaction prices. As a practical expedient, the Company adopted a portfolio approach for the FFS revenue stream to group together contracts with similar characteristics and analyze historical cash collections trends. The contracts within the portfolio share the characteristics conducive to ensuring that the results do not materially differ under the new standard if it were to be applied to individual patient contracts related to each patient encounter. Accordingly, there was no change in the Company&#8217;s method to recognize revenue under ASC 606 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the previous accounting guidance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimating net FFS revenue is a complex process, largely due to the volume of transactions, the number and complexity of contracts with payors, the limited availability at times of certain patient and payor information at the time services are provided, and the length of time it takes for collections to fully mature. These expected collections are based on fees and negotiated payment rates in the case of third-party payors, the specific benefits provided for under each patient&#8217;s healthcare plans, mandated payment rates in the case of Medicare and Medicaid programs, and historical cash collections (net of recoveries) in combination with expected collections from third-party payors.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The relationship between gross charges and the transaction price recognized is significantly influenced by payor mix, as collections on gross charges may vary significantly, depending on whether and with whom the patients the Company provides services to in the period are insured and the Company&#8217;s contractual relationships with those payors. Payor mix is subject to change as additional patient and payor information is obtained after the period services are provided. The Company periodically assesses the estimates of unbilled revenue, contractual adjustments and discounts, and payor mix by analyzing actual results, including cash collections, against estimates. Changes in these estimates are charged or credited to the consolidated statements of income in the period that the assessment is made. Significant changes in payor mix, contractual arrangements with payors, specialty mix, acuity, general economic conditions and healthcare coverage provided by federal or state governments or private insurers may have a significant impact on estimates and significantly affect the results of operations and cash flows.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Assets</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, revenues and receivables are recognized once the Company has satisfied its performance obligation. Accordingly, the Company&#8217;s contract assets are comprised of receivables and receivables &#8211; related parties.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="color:#211d1e;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s billing and accounting systems provide historical trends of cash collections and contractual write-offs, accounts receivable agings and established fee adjustments from third-party payors. These estimates are recorded and monitored monthly </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as revenues are recognized. The principal exposure for uncollectible fee for service visits is from self-pay patients and, to a lesser extent, for co-payments and deductibles from patients with insurance.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities (Deferred Revenue)</span></div>Contract liabilities are recorded when cash payments are received in advance of the Company&#8217;s performance, or in the case of the Company&#8217;s NGACO, the excess of AIPBP capitation received and the actual claims paid or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state income taxes are computed at currently enacted tax rates less tax credits using the asset and liability method. Deferred taxes are adjusted both for items that do not have tax consequences and for the cumulative effect of any changes in tax rates from those previously used to determine deferred tax assets or liabilities. Tax provisions include amounts that are currently payable, changes in deferred tax assets and liabilities that arise because of temporary differences between the timing of when items of income and expense are recognized for financial reporting and income tax purposes, changes in the recognition of tax positions and any changes in the valuation allowance caused by a change in judgment about the realizability of the related deferred tax assets. A valuation allowance is established when necessary to reduce deferred tax assets to amounts expected to be realized.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses a recognition threshold of more-likely-than-not and a measurement attribute on all tax positions taken or expected to be taken in a tax return in order to be recognized in the consolidated financial statements. Once the recognition threshold is met, the tax position is then measured to determine the actual amount of benefit to recognize in the consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a stock-based compensation program for employees, non-employees, directors and consultants. The value of share-based awards such as options is recognized as compensation expense on a cumulative straight-line basis over the vesting period of the awards, adjusted for expected forfeitures. From time to time, the Company issues shares of its common stock to its employees, directors and consultants, which shares may be subject to the Company&#8217;s repurchase right (but not obligation) that lapses based on time-based and performance-based vesting schedules.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings Per Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basic and Diluted Earnings Per Share</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net income attributable to holders of the Company&#8217;s common stock by the weighted average number of shares of common stock outstanding during the periods presented. Diluted earnings per share is computed using the weighted average number of shares of common stock outstanding, plus the effect of dilutive securities outstanding during the periods presented, using the treasury stock method. Refer to Note 14 for a discussion of shares treated as treasury shares for accounting purposes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MinorityInterestPolicyPolicyTextBlock', window );">Noncontrolling Interests</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interests</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company consolidates entities in which the Company has a controlling financial interest. The Company consolidates subsidiaries in which the Company holds, directly or indirectly, more than 50% of the voting rights, and VIEs in which the Company is the primary beneficiary. Noncontrolling interests represent third-party equity ownership interests (including equity ownership interests held by certain VIEs) in the Company&#8217;s consolidated entities. Net income attributable to noncontrolling interests is disclosed in the consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_TemporaryEquityPolicyTextBlock', window );">Mezzanine Equity</a></td>
<td class="text">Mezzanine EquityPursuant to APC&#8217;s shareholder agreements, in the event of a disqualifying event, as defined in the agreements, APC could be required to repurchase the shares from the respective shareholders based on certain triggers outlined in the shareholder agreements. As the redemption feature of the shares is not solely within the control of APC, the equity of APC does not qualify as permanent equity and has been classified as mezzanine or temporary equity. Accordingly, the Company recognizes noncontrolling interests in APC as mezzanine equity in the consolidated financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments-Credit Losses (Topic 326)-Measurement of Credit Losses on Financial Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2016-13&#8221;). The new standard requires entities to measure all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. ASU 2016-13 became effective for fiscal years beginning after December 15, 2019, with early adoption permitted. The Company adopted ASU 2016-13 on January 1, 2020. The adoption of ASU 2016-13 did not have a material impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, the FASB issued ASU No. 2018-17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Consolidation (Topic 810): Targeted Improvements to Related Party Guidance for Variable Interest Entities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2018-17&#8221;). This ASU reduces the cost and complexity of financial reporting associated with consolidation of VIEs. A VIE is an organization in which consolidation is not based on a majority of voting rights. The new guidance supersedes the private company alternative for common control leasing arrangements issued in 2014 and expands it to all qualifying common control arrangements. The amendments in this ASU became effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. The Company adopted ASU 2018-17 on January 1, 2020. The adoption of ASU 2018-17 did not have a material impact on the consolidated financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASU 2019-12&#8221;). This ASU simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2019-12 will have on the Company's consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the FASB issued ASU No. 2020-01, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2020-01&#8221;). This ASU clarifies the interaction between accounting for equity securities, equity method investments and certain derivative instruments. The amendments in this ASU are effective for fiscal years beginning after December 15, 2020, and interim periods within those fiscal years. The Company is currently assessing the impact that the adoption of ASU 2020-01 will have on the Company's consolidation financial statements.</span></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the standards discussed above, there have been no other new accounting pronouncements that have significance, or potential significance, to the Company&#8217;s financial position, results of operations and cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MinorityInterestPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Interest Policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MinorityInterestPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Receivables and receivables from related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_TemporaryEquityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_TemporaryEquityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareCostsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491204&amp;loc=d3e4879-115612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareCostsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120252992&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222804888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregated Revenue by Each Payor Type</a></td>
<td class="text">The following table presents disaggregated revenue generated by payor type for the three and nine months ended September&#160;30, 2020 and 2019 (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,737&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,123&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commercial</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other third parties</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,851&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510,397&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381,867&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Contributions to Revenue and Receivables by Payor</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed the following percentages of net revenue:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor A</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor B</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor C</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor E</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total net revenues</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had major payors that contributed to the following percentages of receivables and receivables &#8211; related parties:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,<br/>2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor D</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payor G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Less than 10% of total receivables and receivables &#8212; related parties, net</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of Carrying Amounts and Fair Values of Financial Instruments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of September&#160;30, 2020, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Money market funds*</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; certificates of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities &#8211; equity securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233,348&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and fair values of the Company&#8217;s financial instruments as of December&#160;31, 2019, are presented below (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds*</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116,469&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities &#8211; equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167,270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Included in cash and cash equivalents</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222948984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,636&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,585&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,795)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,334)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,616)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Net assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,056&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the acquisition date (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Assets acquired</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Network relationship intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,154)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subordinated loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,327)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net asset acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment contributed</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,250&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Change in Carrying Value of Goodwill</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in the carrying value of goodwill for the nine months ended September&#160;30, 2020, was as follows (in thousands);</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:79.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.402%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, January 1, 2020</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, September 30, 2020</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239,053&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221228088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2020, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.028%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.865%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,225)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,013)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,683&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,167)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">868&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85,748)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,781&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2019, the Company&#8217;s intangible assets, net, consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.134%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Useful</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Life</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net December 31, 2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortized intangible assets:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Network relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11-15</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,930&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,526)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management contracts</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,676)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Member relationships</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,352)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patient management platform</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trade names/trademarks</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176,529&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73,517)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103,012&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future amortization expense is estimated to be as follows for the following years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:86.162%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.638%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,781&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222772792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rollforward of Equity Method Investment (in thousands)</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Allocation of Income (Loss)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contribution</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sale</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LaSalle Medical Associates &#8211; IPA Line of Business</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,397&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pacific Medical Imaging &amp; Oncology Center, Inc.</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Universal Care, Inc.</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,560&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diagnostic Medical Group</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(351)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,847&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MWN, LLC &#8211; related party</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,291&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LMA&#8217;s summarized balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and summarized statements of operations for the nine months ended September&#160;30, 2020 and 2019, with respect to its IPA line of business are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">880&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,526&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,530&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,602)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,396&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,928&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.438%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.767%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,490&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,570&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,582&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income (loss)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,012)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UCI's balance sheet at December 31, 2019 and statements of income for the four months ended April 30, 2020 and nine months ended September 30, 2019 are as follows (in thousands):</span></div><div style="margin-top:1pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance Sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.426%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,890&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loan receivable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,021&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Stockholders&#8217; Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,330&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; deficit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,547)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and stockholders&#8217; deficit</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140,916&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operations</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.204%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Four Months Ended April 30, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30, 2019</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,308&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before benefit from income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,010)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,280&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,594&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">531 W. College LLC&#8217;s balance sheets at September&#160;30, 2020 and December&#160;31, 2019, and statements of operations for the nine months ended September&#160;30, 2020 and 2019, are as follows (in thousands):</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Balance sheets</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Assets</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,697&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,581&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total assets</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Liabilities and Members&#8217; Equity</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current liabilities</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,062&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders&#8217; equity</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total liabilities and members&#8217; equity</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,800&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,807&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Statements of Operation</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expenses</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss from operations</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(828)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(799)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(353)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock', window );">Equity Method Investment, Gain On Sale</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain on sale of equity method investment recognized in connection with this transaction was determined as follows (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.016%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.784%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred shares in Bright Health, Inc.</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beneficial interest in UCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Carrying value of equity method investment on date of sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,998)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of equity method investment</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,647&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentGainOnSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Gain On Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentGainOnSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665313672504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accounts Payable and Accrued Expenses</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s accounts payable and accrued expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.329%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,569&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,914&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Capitation payable</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subcontractor IPA payable</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,360&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional fees</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to related parties</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued compensation</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,238&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,892&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accounts payable and accrued expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,279&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222719224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of Medical Liabilities</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s medical liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, beginning of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,642&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Components of medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,194&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175,598&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230,925&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for medical care costs related to claims incurred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(178,796)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,580)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,231)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232,027)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquired (see Note 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical liabilities, end of period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,455&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,820&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222765960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock', window );">Schedule of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s credit facility consisted of the following (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Term Loan A</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revolver loan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion of debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,500)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Unamortized financing costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Future Commitments of Credit Facility</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following are the future commitments of the Company&#8217;s credit facility for the years ending December&#160;31 (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:82.917%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.883%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,688&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240,500&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665223418520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Transactions Under Stock Option Plans</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding stock options consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.917%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">607,346&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(120,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.45</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405,833&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.91&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September&#160;30, 2020, the Company granted 11,742 stock options with a vesting period of five-years to certain ApolloMed board members with an exercise price of $18.41, which were recognized at fair value, as determined using the Black-Scholes option pricing model and the following assumptions:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:81.158%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Members</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Market value of common stock</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annual dividend yield</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeiture rate</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s outstanding warrants consisted of the following:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.813%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Term</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Years)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Aggregate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intrinsic</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Value</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants outstanding at January&#160;1, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,154,590&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.96&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,700&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants granted</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants exercised</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(800,709)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants expired/forfeited</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants outstanding at September 30, 2020</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.052%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.642%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price&#160;Per Share</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants<br/>Outstanding</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual&#160;Life</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrants</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercisable</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exercise&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Per Share</span></div></td></tr><tr><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.04</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248,779&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.19</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">799,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$                                              $                     9.00 &#8211;11.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,353,881&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222727608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock', window );">Schedule of Fees Incurred and Revenue Earned from Related Party Transactions</a></td>
<td class="text">The following table sets forth fees incurred and revenue earned related to AHMC, HSMSO and Aurion (in thousands):<table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:44.501%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.949%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.953%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AHMC &#8211; Risk pool, capitation, claims payment, net</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,683&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,215&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,739&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HSMSO &#8211; Management fees, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,075)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aurion &#8211; Management fees</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(228)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(232)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,474&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,979&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,081&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221484008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share Computations</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,643,754&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.415%"><tr><td style="width:1.0%"/><td style="width:71.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.77&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Earnings per share &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,555,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,816,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of Shares Included in the Diluted Earnings Per Share Computations</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below is a summary of the shares included in the diluted earnings per share computations:</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,364,839&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,643,754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">960,806&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,337,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,551,740&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,792,266&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Weighted average shares of common stock outstanding &#8211; basic</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,149,692&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,555,124&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10% shares held back pursuant to indemnification clause</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,445&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">890,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,442,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares of common stock outstanding &#8211; diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,249,967&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,816,698&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221463624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock', window );">Schedule of Assets and Liabilities, Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes assets that can only be used to settle the liabilities of APC and its VIEs, including Alpha Care and Accountable Health Care, and to which the creditors of APC, including Alpha Care and Accountable Health Care, have no recourse to the Company, nor do creditors of the Company have recourse against the assets of APC, including Alpha Care and Accountable Health Care. These assets and liabilities, with the exception of the investment in a privately held entity that does not report net asset value per share and amounts due to affiliates, which are eliminated upon consolidation with NMM, are included in the accompanying consolidated balance sheets (in thousands).</span></div><div style="margin-bottom:5pt;margin-top:14pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Assets</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,751&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118,262&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123,948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net &#8211; related party</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loan receivable &#8211; related parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current assets</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,710&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294,481&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land, property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,439&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108,913&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310,491&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,315&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investment in privately held entities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,584&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investments in other entities &#8211; equity method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,268&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,654&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent assets</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592,923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554,810&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total assets</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877,633&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:99.707%"><tr><td style="width:1.0%"/><td style="width:71.773%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.658%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30,<br/>2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,<br/>2019</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fiduciary accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,986&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,027&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42,546&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,019&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,408&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,530&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amount due to affiliate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,058&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total current liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncurrent liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finance lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 11.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,512&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,742&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total noncurrent liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,574&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,976&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,499&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfVariableInterestEntitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5747-111685<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6228884-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5728-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfVariableInterestEntitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665305069272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Information Related to Lease Costs</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.551%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(206)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,416&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance lease cost</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of lease expense</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on lease liabilities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sublease income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(567)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(309)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total finance lease cost, net</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,694&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,612&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other information related to leases was as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.697%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplemental Cash Flows Information</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flows from finance leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows from finance leases</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchange for lease liabilities:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Remaining Lease Term</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.93 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.92 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.92 years</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Discount Rate</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance leases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Operating Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Finance Lease Payments After Adoption of 842</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments under non-cancellable leases as of September&#160;30, 2020 is as follows (in thousands):</span></div><div style="margin-bottom:5pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;vertical-align:top;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.145%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.914%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">September 30, 2020</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Leases</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Finance Leases</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020 (excluding the nine months ended September 30, 2020)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,303&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thereafter</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total future minimum lease payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: imputed interest</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total lease liabilities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,906&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Less: current portion</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,616&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665312334696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="5"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jul. 01, 1999</div></th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>primary_care_physician</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>specialty_care_physician</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>medical_center</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>plan</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>clinic</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
<th class="th"><div>Jun. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,743<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Preferred shares received from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,179<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 52,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="nump">$ 15,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember', window );">AP-AMH Medical Corporation | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 545,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Term of receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableStatedInterestRate', window );">Stated rate of note of loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate', window );">Interest rate in the event of default</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Affiliated Entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,015,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock subscriptions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage', window );">Proxy votes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement', window );">Fixed term of amended and restated management and administrative services agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Apollo Medical Holdings, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Concourse Diagnostic Surgery Center, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash consideration entitled to be received</a></td>
<td class="nump">15,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AP-AMH Medical Corporation | Affiliated Entity | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares purchased by related party | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Bright | Preferred Stock | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1', window );">Preferred shares received from sale of equity method investment</a></td>
<td class="nump">$ 36,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Maverick Medical Group, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_ApcLsmaMember', window );">APC LSMA | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (over)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFederallyQualifiedHealthPlans', window );">Number federally qualified health plans | plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Dr. Jay | Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfFamilyPracticeClinics', window );">Number of family practice clinics | clinic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Investment, ownership interest</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">$ 16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | Bright | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DescriptionOfBusinessLineItems', window );"><strong>Description Of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DescriptionOfBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DescriptionOfBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Modifications, Subsequent Default, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableStatedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Stated Interest Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableStatedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The initial fixed term of amended and restated management and administrative services agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFamilyPracticeClinics">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Family Practice Clinics</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFamilyPracticeClinics</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfFederallyQualifiedHealthPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Federally Qualified Health Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfFederallyQualifiedHealthPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodProxyVotesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Proxy Votes, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodProxyVotesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStores">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stores.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStores</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_APAMHMedicalCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ApolloMedicalHoldingsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_ConcourseDiagnosticSurgeryCenterLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MaverickMedicalGroupIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232249272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>segment </div>
<div>unit</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount deposit accounts exceeded FDIC insured limit</a></td>
<td class="nump">$ 321,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Amount of short-term marketable securities</a></td>
<td class="nump">118,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,309,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 116,539,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear', window );">Risk pool surplus or deficits, settlement period after risk pool performance year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of finite-lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportingUnits', window );">Number of main reporting units | unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment of goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of indefinite-lived intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RiskPoolSettlement', window );">Risk pool settlement</a></td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenueMonthlyAmount', window );">Payments received, monthly</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentOfRevenue', window );">Payments received</a></td>
<td class="nump">22,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="nump">14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">12,252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,252,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,892,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned', window );">Contract liability repaid, capitation received and not earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentDeposit', window );">Investment deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableInterestEntityOwnershipPercentage', window );">Voting rights held (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember', window );">Accounts Payable and Accrued Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Accrued contract liability recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember', window );">PMPM Managed Care Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">one year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember', window );">Management Fee Income Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_CMSMember', window );">CMS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport', window );">Expected period of payment upon termination of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MarketableSecuritiesCurrentMaturityPeriod', window );">Short-term marketable securities, maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of Deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Amount of short-term marketable securities</a></td>
<td class="nump">$ 118,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 118,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Repaid, Capitation Received And Not Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment Deposit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MarketableSecuritiesCurrentMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities, Current, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MarketableSecuritiesCurrentMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentOfRevenueMonthlyAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Of Revenue, Monthly Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentOfRevenueMonthlyAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Settlement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risk Pool Surplus Or Deficits, Settlement Period After Performance Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary Of Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121611835&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121599878&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfTiming">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfTiming</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=SL6759159-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=ameh_AccountsPayableAndAccruedExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_PerMemberPerMonthManagedCareContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_CMSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_CMSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665218119320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details) - Next Generation ACO Model Participation Agreement<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2017-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Remaining performance obligation, period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2017-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ameh_NextGenerationACOModelParticipationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2019-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231999016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 180,123<span></span>
</td>
<td class="nump">$ 156,060<span></span>
</td>
<td class="nump">$ 510,397<span></span>
</td>
<td class="nump">$ 381,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_CommercialMember', window );">Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">25,041<span></span>
</td>
<td class="nump">25,429<span></span>
</td>
<td class="nump">75,233<span></span>
</td>
<td class="nump">75,883<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">79,649<span></span>
</td>
<td class="nump">60,737<span></span>
</td>
<td class="nump">206,567<span></span>
</td>
<td class="nump">155,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">65,849<span></span>
</td>
<td class="nump">61,189<span></span>
</td>
<td class="nump">200,746<span></span>
</td>
<td class="nump">122,837<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember', window );">Other third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 9,584<span></span>
</td>
<td class="nump">$ 8,705<span></span>
</td>
<td class="nump">$ 27,851<span></span>
</td>
<td class="nump">$ 27,417<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_CommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_CommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_OtherThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232601640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">12.70%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.10%<span></span>
</td>
<td class="nump">14.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">16.20%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Net Revenue | Payor E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">16.70%<span></span>
</td>
<td class="nump">19.90%<span></span>
</td>
<td class="nump">14.20%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Receivables and Receivables-Related Parties | Payor G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsReceivableAndNetRevenueLineItems', window );"><strong>Accounts Receivable And Net Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsReceivableAndNetRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsReceivableAndNetRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121572278&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorFMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorFMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ameh_PayorGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ameh_PayorGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665218487928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">$ 115,039<span></span>
</td>
<td class="nump">$ 50,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">118,262<span></span>
</td>
<td class="nump">116,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">233,348<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">115,039<span></span>
</td>
<td class="nump">50,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">118,262<span></span>
</td>
<td class="nump">116,469<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">70<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">233,348<span></span>
</td>
<td class="nump">167,270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities &#8211; certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Marketable securities &#8211; equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121553693&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665233069096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49,403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 25,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Liabilities assumed</a></td>
<td class="nump">15,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember', window );">AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposit for potential post-closing adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care, IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | Accountable Health Care, IPA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Interest acquired</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Payments to acquire investments</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | AMG, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Value of shares transferred in acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AmgIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231487784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 30, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 239,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 49,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care, IPA | Dr. Jay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="nump">5,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Network relationship intangible assets</a></td>
<td class="nump">11,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">23,566<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(3,759)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="num">(12,154)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Subordinated loan</a></td>
<td class="num">(15,327)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="nump">9,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned', window );">Equity investment contributed</a></td>
<td class="nump">2,417<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="nump">$ 7,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember', window );">APC and APC-LSMA | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract', window );"><strong>Assets acquired</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Accounts receivable, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Network relationship intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,795)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities', window );">Medical liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,616)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Net assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,056<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_Dr.JayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_Dr.JayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665223409496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations and Goodwill - Summary of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, January 1, 2020</a></td>
<td class="nump">$ 238,505<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Adjustments</a></td>
<td class="nump">548<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Balance, September 30, 2020</a></td>
<td class="nump">$ 239,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230760072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Schedule of Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">$ (85,748)<span></span>
</td>
<td class="num">$ (73,517)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">90,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible Assets, Gross</a></td>
<td class="nump">176,529<span></span>
</td>
<td class="nump">176,529<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible Assets, Net</a></td>
<td class="nump">90,781<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">143,930<span></span>
</td>
<td class="nump">143,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(70,200)<span></span>
</td>
<td class="num">(60,526)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 73,730<span></span>
</td>
<td class="nump">$ 83,404<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember', window );">Network relationships | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember', window );">Management contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 22,832<span></span>
</td>
<td class="nump">$ 22,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(11,225)<span></span>
</td>
<td class="num">(9,676)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 11,607<span></span>
</td>
<td class="nump">$ 13,156<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember', window );">Member relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">12 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 6,696<span></span>
</td>
<td class="nump">$ 6,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,013)<span></span>
</td>
<td class="num">(2,352)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 3,683<span></span>
</td>
<td class="nump">$ 4,344<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember', window );">Patient management platform</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 2,060<span></span>
</td>
<td class="nump">$ 2,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,167)<span></span>
</td>
<td class="num">(858)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 893<span></span>
</td>
<td class="nump">$ 1,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trade names/trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Amortized intangible assets, Gross</a></td>
<td class="nump">$ 1,011<span></span>
</td>
<td class="nump">$ 1,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 868<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_NetworkRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_ManagementContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_MemberRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ameh_PatientManagementPlatformMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665217996792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 12.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221290584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets, Net - Future Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September 30, 2020)</a></td>
<td class="nump">$ 3,798<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2021</a></td>
<td class="nump">14,524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2022</a></td>
<td class="nump">12,673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2023</a></td>
<td class="nump">10,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2024</a></td>
<td class="nump">9,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">39,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total</a></td>
<td class="nump">$ 90,781<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230763224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="nump">$ 403,000<span></span>
</td>
<td class="nump">$ 2,054,000<span></span>
</td>
<td class="nump">3,291,000<span></span>
</td>
<td class="nump">$ 1,162,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">27,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates &#8211; IPA Line of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">6,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">1,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="nump">3,560,000<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">2,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(351,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">16,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsRollForward', window );"><strong>Equity Method Investments [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Beginning Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Allocation of Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Ending Balance</a></td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665205991560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Additional Information (Details)<br> $ / shares in Units, patient in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="6"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>primary_care_physician</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>specialty_care_physician</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>medical_center</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>provider</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>patient</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 23, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2016</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2012 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 403,000<span></span>
</td>
<td class="nump">$ 2,054,000<span></span>
</td>
<td class="nump">$ 3,291,000<span></span>
</td>
<td class="nump">$ 1,162,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,427,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash consideration paid for ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">2,949,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,743,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">896,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | MediPortal LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares', window );">Membership interests purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Payments to purchase membership interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest', window );">Membership interests acquired (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants received (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption', window );">Term of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests', window );">Options to purchase additional membership interests (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet', window );">Number of warrants available to purchase, contingent upon the portal completion date (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember', window );">Accountable Health Care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember', window );">Network Medical Management, Inc. | AchievaMed, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears', window );">Percentage of voting common stock, within five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment', window );">Duration of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost', window );">Investment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments', window );">Related investment balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember', window );">Pacific6 Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member', window );">Health Source MSO Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfStores', window );">Number of medical centers | medical_center</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfEmployees', window );">Number of employees (more than) | provider</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfPatients', window );">Number of patients | patient</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,397,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="num">(2,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,421,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,396,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC LSMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,000)<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember', window );">Pacific Medical Imaging &amp; Oncology Center, Inc. | APC | Ancillary Service Contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForFees', window );">Fees paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">3,560,000<span></span>
</td>
<td class="nump">6,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="nump">$ 4,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,438,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">52,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash and non-cash consideration entitled to be received</a></td>
<td class="nump">15,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Preferred Stock | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="nump">$ 36,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Additional cash and non-cash consideration entitled to be received</a></td>
<td class="nump">15,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | APC | Preferred Stock | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Investments in privately held entities</a></td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash', window );">Contingent consideration, cash held in escrow</a></td>
<td class="nump">15,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares', window );">Contingent consideration, preferred shares</a></td>
<td class="nump">6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue', window );">Contingent consideration, fair value</a></td>
<td class="nump">$ 22,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Bright</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed', window );">Ownership interest disposed</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investment</a></td>
<td class="nump">$ 69,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of indebtedness received</a></td>
<td class="nump">$ 16,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Voting Common Stock A Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsPurchaseOfShares', window );">Shares purchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Cash consideration paid for ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock', window );">Percentage of voting common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Universal Care Acquisition Partners, LLC | Ancillary Service Contract | Voting Common Stock A Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,353,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,334,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember', window );">Diagnostic Medical Group | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(351,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,847,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,698,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireRealEstate', window );">Purchase price of real estate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
<td class="num">(400,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | College Street Investment LP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Amount invested for interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">174,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentsContribution', window );">Contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Network Medical Management, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="num">$ (100,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Pacific6 Enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember', window );">MWN, LLC &#8211; related party | Health Source MSO Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MembersCapital', window );">Initial capital contributions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WorkingCapitalContribution', window );">Working capital contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentOwnershipPercentageDisposed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Disposed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentOwnershipPercentageDisposed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Cash</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Sale, Contingent Consideration, Preferred Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Contribution</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The proportion of investment in Voting common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased from equity method investment entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities without Readily Determinable Fair Value, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Employees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfPatients">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Patients</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfPatients</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WorkingCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the working capital contribution in equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WorkingCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MembersCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of member capital in limited liability company (LLC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MembersCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfStores">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of stores.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfStores</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for fees classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireRealEstate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireRealEstate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_MediPortalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_MediPortalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AccountableHealthCareIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ameh_AchievaMedInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ameh_AchievaMedInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Pacific6EnterprisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_HealthSourceMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApcLsmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApcLsmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PacificMedicalImagingAndOncologyCenterIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ContractTypeAxis=ameh_AncillaryServiceContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ameh_VotingCommonStockTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DiagnosticMedicalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CollegeStreetInvestmentLpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_MWNCommunityHospitalLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665227212232">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Summarized Balance Sheets and Statements of Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 230,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 230,299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 106,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">814,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">131,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">192,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,418<span></span>
</td>
<td class="nump">192,174<span></span>
</td>
<td class="nump">$ 207,848<span></span>
</td>
<td class="nump">$ 197,961<span></span>
</td>
<td class="nump">192,335<span></span>
</td>
<td class="nump">$ 186,089<span></span>
</td>
<td class="nump">$ 182,377<span></span>
</td>
<td class="nump">$ 181,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">814,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">180,123<span></span>
</td>
<td class="nump">156,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">510,397<span></span>
</td>
<td class="nump">381,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">142,767<span></span>
</td>
<td class="nump">145,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">455,770<span></span>
</td>
<td class="nump">360,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">37,356<span></span>
</td>
<td class="nump">10,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,627<span></span>
</td>
<td class="nump">21,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">130<span></span>
</td>
<td class="nump">2,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">2,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before benefit from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,175<span></span>
</td>
<td class="nump">14,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153,616<span></span>
</td>
<td class="nump">25,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">10,751<span></span>
</td>
<td class="nump">3,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,204<span></span>
</td>
<td class="nump">6,483<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25,424<span></span>
</td>
<td class="nump">$ 10,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109,412<span></span>
</td>
<td class="nump">18,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember', window );">LaSalle Medical Associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,490)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,602)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,490<span></span>
</td>
<td class="nump">144,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138,233<span></span>
</td>
<td class="nump">155,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257<span></span>
</td>
<td class="num">(11,012)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember', window );">531 W. College LLC</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">32,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(828)<span></span>
</td>
<td class="num">(780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="nump">427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (799)<span></span>
</td>
<td class="num">(353)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">882<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Deficit</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">128,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,547)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; deficit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Statements of Operations</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">372,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before benefit from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision (benefit) from income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,010)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="12"></td></tr>
<tr><td colspan="12"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $877.6&#160;million and $849.3&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $113.0&#160;million and $114.5&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21914-107793<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121646688&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929471&amp;loc=d3e21711-107793<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_LasalleMedicalAssociatesIpaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_FiveThreeOneW.CollegeLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231688408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Other Entities &#8212; Equity Method - Gain on Sale (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,743,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Preferred shares in Bright Health, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,075,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 896,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Less: Carrying value of equity method investment on date of sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,220,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,220,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,427,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Equity Method Investment, Realized Gain (Loss) on Disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">99,647,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)</a></td>
<td class="nump">$ 52,743,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet', window );">Beneficial interest in UCI</a></td>
<td class="nump">15,723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Less: Carrying value of equity method investment on date of sale</a></td>
<td class="num">(4,998,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,438,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Equity Method Investment, Realized Gain (Loss) on Disposal</a></td>
<td class="nump">99,647,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | Bright | Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue', window );">Preferred shares in Bright Health, Inc.</a></td>
<td class="nump">$ 36,179,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of Investment in privately held entity that does not report net asset value per share .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_BrightHealthCompanyOfCaliforniaInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232439416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Receivable and Loan Receivable &#8211; Related Parties - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 13, 2019</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
<th class="th"><div>Nov. 28, 2018</div></th>
<th class="th"><div>Jun. 29, 2018</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 16, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible', window );">Percentage of outstanding stock convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | APC and APC-LSMA | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion', window );">Ownership upon conversion of finance receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Secured Promissory Note | Dr. Arteaga | Prime Rate | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AdvancedForWorkingCapital', window );">Advance for working capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityAdditionalAdvances', window );">Additional advances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Prime Rate | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Dr. Arteaga</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableNet', window );">Amount of loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember', window );">Financing Receivable | Dr. Jay Loan | APC | Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on loan receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AdvancedForWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount advanced for working capital purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AdvancedForWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityAdditionalAdvances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of line of credit facility additional amount advances as a loan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityAdditionalAdvances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_Dr.ArteagaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_APCAndAPCLSMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_FinanceReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_DrJayLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231188808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 9,569<span></span>
</td>
<td class="nump">$ 6,914<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SpecialtyCapitationPayableCurrent', window );">Capitation payable</a></td>
<td class="nump">2,583<span></span>
</td>
<td class="nump">2,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SubcontractorIPAPayable', window );">Subcontractor IPA payable</a></td>
<td class="nump">3,413<span></span>
</td>
<td class="nump">3,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Due to related parties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">10,176<span></span>
</td>
<td class="nump">3,238<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="nump">12,252<span></span>
</td>
<td class="nump">8,892<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued expenses</a></td>
<td class="nump">$ 40,474<span></span>
</td>
<td class="nump">$ 27,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SpecialtyCapitationPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of specialty capitation payable current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SpecialtyCapitationPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SubcontractorIPAPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Subcontractor IPA Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SubcontractorIPAPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232001368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Liabilities - Schedule of Medical Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Medical Liabilities [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, beginning of period</a></td>
<td class="nump">$ 58,725<span></span>
</td>
<td class="nump">$ 33,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_MedicalCareCostsAbstract', window );"><strong>Components of medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current period</a></td>
<td class="nump">229,194<span></span>
</td>
<td class="nump">175,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior periods</a></td>
<td class="nump">1,731<span></span>
</td>
<td class="nump">2,875<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Total medical care costs</a></td>
<td class="nump">230,925<span></span>
</td>
<td class="nump">178,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentsForMedicalCareCostsAbstract', window );"><strong>Payments for medical care costs related to claims incurred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current period</a></td>
<td class="num">(178,796)<span></span>
</td>
<td class="num">(135,580)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior periods</a></td>
<td class="num">(53,231)<span></span>
</td>
<td class="num">(49,164)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="num">(232,027)<span></span>
</td>
<td class="num">(184,744)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions', window );">Acquired (see Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,404<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease', window );">Adjustments</a></td>
<td class="num">(168)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities, end of period</a></td>
<td class="nump">$ 57,455<span></span>
</td>
<td class="nump">$ 53,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_MedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_MedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentsForMedicalCareCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments For Medical Care Costs [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentsForMedicalCareCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230872584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">$ 240,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LinesOfCreditCurrent', window );">Less: Current portion of debt</a></td>
<td class="num">(9,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Less: Unamortized financing costs</a></td>
<td class="num">(4,949)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">226,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">180,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver loan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total debt</a></td>
<td class="nump">$ 60,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LinesOfCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LinesOfCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665218357608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2020 (excluding the nine months ended September 30, 2020)</a></td>
<td class="nump">$ 2,375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2021</a></td>
<td class="nump">10,688<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2022</a></td>
<td class="nump">14,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2023</a></td>
<td class="nump">15,437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2024</a></td>
<td class="nump">197,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Total</a></td>
<td class="nump">$ 240,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665209263288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th">
<div>Oct. 02, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 05, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($) </div>
<div>financial_ratio</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 14, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 29, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 11, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 17, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 01, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 14, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,466,000<span></span>
</td>
<td class="nump">$ 828,000<span></span>
</td>
<td class="nump">$ 8,007,000<span></span>
</td>
<td class="nump">$ 1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios', window );">Number of key financial ratios | financial_ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum', window );">Maximum consolidated leverage ratio (not greater than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange', window );">Consolidated leverage ratio, annual decrease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantLeverageRatioMinimum', window );">Consolidated leverage ratio minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum', window );">Minimum consolidated interest coverage ratio (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Default amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateDuringPeriod', window );">Average effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.79%<span></span>
</td>
<td class="nump">1.31%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Minimum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Maximum | London Interbank Offered Rate (LIBOR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | First Eight Fiscal Quarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Following Eight Fiscal Quarters Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember', window );">Credit Agreement | Following Three Fiscal Quarters Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal', window );">Principal payment on credit agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember', window );">NMM Line of Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDefaultLongtermDebtAmount', window );">Default amount of debt instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage', window );">Shareholder approval percentage (not less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_DebtInstrumentApprovedThresholdUseOfFunds', window );">Approved use of funds (not to exceed)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Revolving credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolver Loan | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Interest rate, 2020 commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.77%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember', window );">Term Loan A | Credit Agreement | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APAACO | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification', window );">Period of notification of termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityTerminatedAmount', window );">Line of credit, amount terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc. | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Required annual facility fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Line of Credit Agreement | NMM | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties', window );">Term of converted loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Line of Credit Agreement | NMM | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Business Loan Agreement | NMM | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="nump">5.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | NMM Business Loan Agreement | NMM | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum loan availability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Amount available</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | APC Business Loan Agreement | APC | Prime Rate | Preferred Bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.125%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentApprovedThresholdUseOfFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Approved Threshold Use Of Funds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentApprovedThresholdUseOfFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Interest Coverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Incremental Change</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentCovenantLeverageRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Leverage Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentCovenantLeverageRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_DebtInstrumentNumberOfKeyFinancialRatios">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Key Financial Ratios</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_DebtInstrumentNumberOfKeyFinancialRatios</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Expiration Period, Period Of Notification</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of guarantee given by related parties for line of credit facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LineOfCreditFacilityTerminatedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line Of Credit Facility, Terminated, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LineOfCreditFacilityTerminatedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDefaultLongtermDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDefaultLongtermDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section S45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68176171&amp;loc=SL68176184-208336<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=119993939&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payment applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_CreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ameh_PreferredBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=ameh_PaymentPeriodThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_NMMLineOfCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ameh_TermLoanAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ameh_TermLoanAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_ApaacoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_ApaacoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_NmmBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_NmmBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ameh_ApcBusinessLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232307944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesMerger', window );">Holdback shares not issued to former shareholders (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="nump">203,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod', window );">Options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="nump">$ 10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,558<span></span>
</td>
<td class="nump">$ 1,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,709<span></span>
</td>
<td class="nump">133,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds from warrants exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod', window );">Warrants exercised, cashless exercise provision (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised', window );">Shares issued for exercise of cashless warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">17,475,707<span></span>
</td>
<td class="nump">17,475,707<span></span>
</td>
<td class="nump">17,475,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,458,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember', window );">Allied Pacific of California Brokerage Account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, value</a></td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="nump">$ 7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">17,307,214<span></span>
</td>
<td class="nump">17,307,214<span></span>
</td>
<td class="nump">17,307,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,290,317<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49,500<span></span>
</td>
<td class="nump">59,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_CDSCMember', window );">CDSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Grant date fair value of restricted stock to be recognized straight-line</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price of exercises during period (in dollars per share)</a></td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 2.10<span></span>
</td>
<td class="nump">$ 1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00<span></span>
</td>
<td class="nump">9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercise price of exercises during period (in dollars per share)</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">5.00<span></span>
</td>
<td class="nump">10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice', window );">Exercise price of warrants exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember', window );">APC Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Proceeds of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding exercise price (in dollars per share)</a></td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="nump">$ 18.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Board Members | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement, By Share-Based Payment Award, Warrants, Cashless Exercise Provision, Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Cashless Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_StockIssuedDuringPeriodSharesMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_StockIssuedDuringPeriodSharesMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Issued During Period Value Stock Options Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificofCaliforniaBrokerageAccountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_CDSCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_CDSCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ameh_ApcStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665219471640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, beginning balance (in shares)</a></td>
<td class="nump">607,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted (in shares)</a></td>
<td class="nump">11,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised (in shares)</a></td>
<td class="num">(120,000)<span></span>
</td>
<td class="num">(203,524)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options forfeited (in shares)</a></td>
<td class="num">(12,228)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, ending balance (in shares)</a></td>
<td class="nump">486,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">607,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares)</a></td>
<td class="nump">405,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted (in dollars per share)</a></td>
<td class="nump">18.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised (in dollars per share)</a></td>
<td class="nump">2.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options forfeited (in dollars per share)</a></td>
<td class="nump">17.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">10.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.22<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 7.91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">3 years 5 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 5 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable</a></td>
<td class="text">2 years 9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Beginning balance</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Ending balance</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable</a></td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665218062712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details) - Board Members<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2020 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.43%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Market value of common stock (in dollars per share)</a></td>
<td class="nump">$ 10.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Annual dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the forfeiture rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232412136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Summary of Warrant (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_SharesWarrantsRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">3,154,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsGranted', window );">Warrants granted (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_NumberOfWarrantsExercised', window );">Warrants exercised (in shares)</a></td>
<td class="num">(800,709)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightCancelledInPeriod', window );">Warrants expired/forfeited (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">2,353,881<span></span>
</td>
<td class="nump">3,154,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedAverageExercisePriceWarrantsRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 9.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod', window );">Warrants granted (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod', window );">Warrants exercised (in dollars per share)</a></td>
<td class="nump">9.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod', window );">Warrants expired/forfeited (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Warrants outstanding, ending balance (in dollars per share)</a></td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm', window );">Warrants outstanding</a></td>
<td class="text">1 year 7 months 13 days<span></span>
</td>
<td class="text">2 years 3 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AggregateintrinsicvalueAbstract', window );"><strong>Aggregate Intrinsic Value (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, beginning balance</a></td>
<td class="nump">$ 26,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue', window );">Warrants granted</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue', window );">Warrants exercised</a></td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue', window );">Warrants expired/forfeited</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue', window );">Warrants outstanding, ending balance</a></td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">$ 26,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AggregateintrinsicvalueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AggregateintrinsicvalueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightCancelledInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of warrant or right, cancelled in period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightCancelledInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights exercised in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights forfeited in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights granted in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share of warrants or rights granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_NumberOfWarrantsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Warrants Granted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_NumberOfWarrantsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_SharesWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_SharesWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedAverageExercisePriceWarrantsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price, Warrants [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedAverageExercisePriceWarrantsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_WeightedaverageremainingcontractualtermyearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_WeightedaverageremainingcontractualtermyearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665233097048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Mezzanine and Stockholders' Equity - Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="nump">$ 9.96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember', window );">Warrant Exercise Price Range One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">305,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">305,812<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember', window );">Warrant Exercise Price Range Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">1,248,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">1 year 7 months 20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">1,248,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember', window );">Warrant Exercise Price Range Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">799,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">2 years 2 months 8 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">799,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightIssuedInPeriod', window );">Warrants Outstanding (in shares)</a></td>
<td class="nump">2,353,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm', window );">Weighted Average Remaining Contractual&#160;Life</a></td>
<td class="text">1 year 7 months 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantOrRightExercisable', window );">Warrants Exercisable (in shares)</a></td>
<td class="nump">2,353,881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants', window );">Weighted Average Exercise&#160;Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">9.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember', window );">Warrant Exercise Price Range Four | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise&#160;Price&#160;Per Share (in dollars per share)</a></td>
<td class="nump">$ 11.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercisable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Issued in Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ameh_WarrantExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665227175656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 03, 2018</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount', window );">General amount of guarantee (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Damages sought</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember', window );">Standby Letters of Credit | Alpha Care Medical Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityExpirationPeriod', window );">Term of facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities', window );">Standby letters of credit assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PercentageOfFinancialGuaranteeBenchmarkAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of financial guarantee on benchmark Medicare expenditure amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PercentageOfFinancialGuaranteeBenchmarkAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=121600890&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121647850&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_StandbyLettersOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlphaCareMedicalGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665348913960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2020</div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 28, 2018 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Jun. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 16, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 19,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">19,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">5,474<span></span>
</td>
<td class="nump">$ 10,979<span></span>
</td>
<td class="nump">23,081<span></span>
</td>
<td class="nump">$ 37,858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | Board Members</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentConsultingFees', window );">Consulting services paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember', window );">NMM | LMA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue from related parties</a></td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">4,400<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | PMIOC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC | DMG | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">3,800<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">5,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Amount of subordinated note receivable agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember', window );">Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsAndOtherReceivablesNetCurrent', window );">Amount of subordinated note receivable agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements', window );">Number of additional subordinated note receivable agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember', window );">APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">7,100<span></span>
</td>
<td class="nump">6,700<span></span>
</td>
<td class="nump">23,400<span></span>
</td>
<td class="nump">23,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember', window );">Advance Diagnostic Surgery Center | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember', window );">APC Shareholders and Officers | APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">6,500<span></span>
</td>
<td class="nump">6,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember', window );">Medical Property Partners | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember', window );">Critical Quality Management Corp</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember', window );">Numen LLC | SCHC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_PaymentMadeToRelatedParty', window );">Payments to related parties</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Recognized risk pool revenue</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">$ 31,500<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">$ 31,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCreditsAndOtherLiabilities', window );">Amount outstanding under agreement</a></td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember', window );">Universal Care, Inc. | APC | Universal Care Acquisition Partners, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember', window );">LMA | NMM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember', window );">PMIOC | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember', window );">DMG | APC Shareholders | APC | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member', window );">One MSO, Inc. | Dr. Sim And Dr. Lam</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accounts And Other Receivables, Number Of Additional Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentConsultingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment Consulting Fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentConsultingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_PaymentMadeToRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Credit/Duration (Amount paid to related party in relation to providing services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_PaymentMadeToRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsAndOtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsAndOtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCreditsAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCreditsAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_NetworkMedicalManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ApcShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AdvanceDiagnosticSurgeryCenterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_ShareholdersAndOfficersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_MedicalPropertyPartnersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_CriticalQualityManagementCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_NumenLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_SCHCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_SCHCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_UniversalCareIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_UniversalCareAcquisitionPartnersLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_LmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_PmiocMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_DmgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ameh_OneMSOInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_DrSimAndDrLamMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_DrSimAndDrLamMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665219929288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related-Party Transactions - Fees Incurred and Income Received (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Net total</a></td>
<td class="nump">$ 5,474<span></span>
</td>
<td class="nump">$ 10,979<span></span>
</td>
<td class="nump">$ 23,081<span></span>
</td>
<td class="nump">$ 37,858<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember', window );">AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet', window );">AHMC &#8211; Risk pool, capitation, claims payment, net</a></td>
<td class="nump">5,683<span></span>
</td>
<td class="nump">11,215<span></span>
</td>
<td class="nump">23,739<span></span>
</td>
<td class="nump">39,165<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty', window );">Net total</a></td>
<td class="nump">10,500<span></span>
</td>
<td class="nump">31,500<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="nump">31,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember', window );">HSMSO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">(109)<span></span>
</td>
<td class="num">(160)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
<td class="num">(1,075)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember', window );">Aurion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="num">$ (100)<span></span>
</td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (228)<span></span>
</td>
<td class="num">$ (232)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Services Revenue, Capitation, And Claims Payment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AHMCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_HSMSOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=ameh_AurionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665221515848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">28.80%<span></span>
</td>
<td class="nump">25.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665222829832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">APC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Treasury shares not included in the calculation of earnings per share (in shares)</a></td>
<td class="nump">17,307,214<span></span>
</td>
<td class="nump">17,290,317<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665218638872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Earnings Per Share Computations (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Earnings per share &#8211; basic (in dollars per share)</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.77<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Earnings per share &#8211; diluted (in dollars per share)</a></td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="nump">$ 0.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">36,364,839<span></span>
</td>
<td class="nump">34,643,754<span></span>
</td>
<td class="nump">36,149,692<span></span>
</td>
<td class="nump">34,555,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">37,551,740<span></span>
</td>
<td class="nump">37,792,266<span></span>
</td>
<td class="nump">37,249,967<span></span>
</td>
<td class="nump">37,816,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230754952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares of common stock outstanding &#8211; basic (in shares)</a></td>
<td class="nump">36,364,839<span></span>
</td>
<td class="nump">34,643,754<span></span>
</td>
<td class="nump">36,149,692<span></span>
</td>
<td class="nump">34,555,124<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares of common stock outstanding &#8211; diluted (in shares)</a></td>
<td class="nump">37,551,740<span></span>
</td>
<td class="nump">37,792,266<span></span>
</td>
<td class="nump">37,249,967<span></span>
</td>
<td class="nump">37,816,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage', window );">Shares held back pursuant to indemnification clause (as a percent)</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">187,843<span></span>
</td>
<td class="nump">299,536<span></span>
</td>
<td class="nump">178,445<span></span>
</td>
<td class="nump">307,665<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">38,252<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,341<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">10% shares held back pursuant to indemnification clause</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,511,332<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,511,332<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_EarningsPerShareLineItems', window );"><strong>Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Adjustments to weighted average shares of common stock (in shares)</a></td>
<td class="nump">960,806<span></span>
</td>
<td class="nump">1,337,644<span></span>
</td>
<td class="nump">890,489<span></span>
</td>
<td class="nump">1,442,577<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Shares Held Back To Secure Indemnification, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_EarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Earnings Per Share [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_EarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665219441144">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Variable Interest Entities (VIEs) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 166,082<span></span>
</td>
<td class="nump">$ 103,189<span></span>
</td>
<td class="nump">$ 230,299<span></span>
</td>
<td class="nump">$ 106,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,309<span></span>
</td>
<td class="nump">116,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">18,257<span></span>
</td>
<td class="nump">11,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">41,518<span></span>
</td>
<td class="nump">48,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,988<span></span>
</td>
<td class="nump">16,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,119<span></span>
</td>
<td class="nump">10,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">366,698<span></span>
</td>
<td class="nump">329,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">90,781<span></span>
</td>
<td class="nump">103,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">239,053<span></span>
</td>
<td class="nump">238,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,220<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">19,298<span></span>
</td>
<td class="nump">14,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,473<span></span>
</td>
<td class="nump">1,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">447,575<span></span>
</td>
<td class="nump">399,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">814,273<span></span>
</td>
<td class="nump">728,713<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,474<span></span>
</td>
<td class="nump">27,279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">57,455<span></span>
</td>
<td class="nump">58,725<span></span>
</td>
<td class="nump">$ 53,820<span></span>
</td>
<td class="nump">$ 33,642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">2,990<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">131,461<span></span>
</td>
<td class="nump">105,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,659<span></span>
</td>
<td class="nump">18,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">337<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,616<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">254,663<span></span>
</td>
<td class="nump">262,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">386,124<span></span>
</td>
<td class="nump">367,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember', window );">Variable Interest Entity, Primary Beneficiary</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">94,751<span></span>
</td>
<td class="nump">87,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investment in marketable securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">118,262<span></span>
</td>
<td class="nump">123,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,365<span></span>
</td>
<td class="nump">9,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Receivables, net &#8211; related party</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">39,506<span></span>
</td>
<td class="nump">42,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">734<span></span>
</td>
<td class="nump">744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,667<span></span>
</td>
<td class="nump">7,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetCurrent', window );">Loan receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,425<span></span>
</td>
<td class="nump">6,425<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableRelatedPartiesCurrent', window );">Loan receivable &#8211; related parties</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">284,710<span></span>
</td>
<td class="nump">294,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Noncurrent assets</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Land, property and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">8,877<span></span>
</td>
<td class="nump">9,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,107<span></span>
</td>
<td class="nump">81,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">109,460<span></span>
</td>
<td class="nump">108,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Investment in affiliates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">310,491<span></span>
</td>
<td class="nump">318,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue', window );">Investment in privately held entities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">36,584<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investments in other entities &#8211; equity method</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">27,268<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">746<span></span>
</td>
<td class="nump">746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,654<span></span>
</td>
<td class="nump">4,751<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">20,736<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total noncurrent assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">592,923<span></span>
</td>
<td class="nump">554,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">877,633<span></span>
</td>
<td class="nump">849,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,444<span></span>
</td>
<td class="nump">11,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FiduciaryAccountsPayableCurrent', window );">Fiduciary accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,986<span></span>
</td>
<td class="nump">2,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">42,546<span></span>
</td>
<td class="nump">49,019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,408<span></span>
</td>
<td class="nump">4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToAffiliateCurrent', window );">Amount due to affiliate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">22,131<span></span>
</td>
<td class="nump">28,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">485<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">99,402<span></span>
</td>
<td class="nump">96,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Noncurrent liabilities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">7,725<span></span>
</td>
<td class="nump">14,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">337<span></span>
</td>
<td class="nump">416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5,512<span></span>
</td>
<td class="nump">3,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total noncurrent liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,574<span></span>
</td>
<td class="nump">18,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 112,976<span></span>
</td>
<td class="nump">$ 114,499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The Company's consolidated balance sheets include the assets and liabilities of its consolidated variable interest entities ("VIEs"). The consolidated balance sheets include total assets that can be used only to settle obligations of the Company&#8217;s consolidated VIEs totaling $877.6&#160;million and $849.3&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively, and total liabilities of the Company&#8217;s consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $113.0&#160;million and $114.5&#160;million as of September&#160;30, 2020 and December&#160;31, 2019, respectively. See Note 15 &#8211; Variable Interest Entities (VIEs) for further detail.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FiduciaryAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FiduciaryAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToAffiliateCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(12)(b)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToAffiliateCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI http://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121593590&amp;loc=d3e4531-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665317516920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Additional information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease option to extend (up to)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable', window );">Operating lease, termination period, if applicable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable', window );">Finance lease, termination period, if applicable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Assets recorded under finance leases</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Accumulated depreciation associated with finance leases</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 76<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Remaining lease term, operating</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Remaining lease term, finance</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Finance Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Termination Period, If Applicable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231278168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="nump">$ 5,172<span></span>
</td>
<td class="nump">$ 3,832<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of lease expense</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(206)<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">(567)<span></span>
</td>
<td class="num">(309)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total finance lease cost, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">$ 1,416<span></span>
</td>
<td class="nump">$ 4,694<span></span>
</td>
<td class="nump">$ 3,612<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665232645976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 1,489<span></span>
</td>
<td class="nump">$ 1,677<span></span>
</td>
<td class="nump">$ 4,369<span></span>
</td>
<td class="nump">$ 3,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Operating cash flows from finance leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Financing cash flows from finance leases</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract', window );"><strong>Right-of-use assets obtained in exchange for lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 7,652<span></span>
</td>
<td class="nump">$ 15,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract', window );"><strong>Weighted Average Remaining Lease Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases</a></td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">6 years 11 months 4 days<span></span>
</td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases</a></td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
<td class="text">3 years 11 months 1 day<span></span>
</td>
<td class="text">4 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LeaseWeightedAverageDiscountRateAbstract', window );"><strong>Weighted Average Discount Rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases</a></td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.12%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
<td class="nump">6.12%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_CashPaidForLeaseLiabilitiesAbstractAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_CashPaidForLeaseLiabilitiesAbstractAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LeaseWeightedAverageRemainingLeaseTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LeaseWeightedAverageRemainingLeaseTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665231439912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Payments Under Non-cancelable Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the six months ended September 30, 2020)</a></td>
<td class="nump">$ 1,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">4,297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">3,529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">3,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">2,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">9,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">24,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">4,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">19,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">3,290<span></span>
</td>
<td class="nump">$ 2,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">16,616<span></span>
</td>
<td class="nump">11,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2020 (excluding the six months ended September 30, 2020)</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2021</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term lease liabilities</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665230923752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - APC - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 49.5<span></span>
</td>
<td class="nump">$ 59.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember', window );">Subsequent Event | Notes Receivable | AHMC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesReceivableGross', window );">Note receivable, amount</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableTermOfReceivable', window );">Note receivable, maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ameh_FinanceReceivableInterestRateStatedPercentage', window );">Note receivable, interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Interest Rate, Stated Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ameh_FinanceReceivableTermOfReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finance Receivable, Term Of Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ameh_FinanceReceivableTermOfReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ameh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 79<br> -URI http://asc.fasb.org/extlink&amp;oid=121647567&amp;loc=SL82922352-210448<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL82919230-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 55<br> -Paragraph 80<br> -URI http://asc.fasb.org/extlink&amp;oid=121647567&amp;loc=SL82922355-210448<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ameh_AlliedPacificOfCaliforniaIPAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=srt_AffiliatedEntityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.2</span><table class="report" border="0" cellspacing="2" id="idm139665217959400">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
<td class="nump">$ 485,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends Payable</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted Cash Equivalents, Current</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsCurrent</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">746,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted Cash Equivalents, Noncurrent</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
<td class="nump">$ 745,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>89
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M]W$^/$PSMTFZ9HJG%UT-;S,Q77^O?)4KTQ/*(_(@8[U.037@P?OX+E 6J/2
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M6)3]LK8]-.&U#ARFG$@5/J\^<<D A*^=V(.:]8'IVV9)"W8Z6@K6,/'(1F?
M=>#T-RC:';TA4Q(^?/K(?OZDM7K9;S^$E!J^(V&^TPRBK"AX5>E +&L5PZQI
M]S[.U2L5I;?SYZ94Y7K=Z("^I%4YXZ(NZ1A0<"OXC#7Z6%?YW+I6ON1"A3OU
M)2KB(,,\2_$PI%URB;]:)EL'66'2O).\^#[GU92)IMW02=\=8%%#G"1,G-I)
M5:9K="]C<!0=1Q'4>]#@D58K!E2V!\V<"O8.P"@:1]V_[I7RZI6<<U'^9-,Q
MP,DX3>-Q!M/6V7$\SJ-L',7I6IBO9"/5)S5Q8[7>*ZJ5_@E@.E:K]G$:=>WT
M8YPI-1&00C',2JV[.@5J!MLYO6-+R1;W3/SZ"TRB=^OCUK;U%2NV/_5'J6.@
MFB]9>PQ?.8L"8K.]Q:<N&0^=$E,.D' Y<#Z=EK)S2'W>\D8Y<D&7I4J*3IB.
M/<XD2ZSM1I=<G">19_.(&/8G^P[;)%6OU'J=JJ"J'YRD0ASKQCR%5MZUQ3#,
M?5NBQ' ["7-[1RG-5MC\U@?,6#NV2L=.T"[JSDADH78L2G,8$]]YM:%N$J9N
M3VIS8G4=G=GVM:72S..PL2'L^!#";@Y,2OWQM<VP".7$.FAUR,$<8>P[=#=,
M'(>9V*HRQF QH*<V?;QP6/8JU+E3YY +[=3%AF+C\'KUC@E=29PK8EL7J2U;
M!(@A-E0;AP_2_B?>B0VMQ>$3-0.YL2'W]MU_0R,HLHMLZXI&F!%[JUZ\Q*HF
MW\?)/V!5DY_C<'X^Q*J=AB1DU9#(+C*=E7??F(07AQ.>NVR_V-/JZYRIDFVQ
MI/7S;XTNJ1M>E=/VY/R>5NW2NKTQID^2=(G!@)RO3V/:&-_* KJ:*.5 RR,5
M9;L]O2DN-^=IKT9_WEPWH]?'0*,XJ.^M(P(%A$K%[C6X9V#5J$:\KIZ5"%!?
MI>J0WU?E0UN(MLBD&6GO*0.D&DS7@R:,HRQ-CY.N\%F4BD3Z]>M11O)C/'C_
MMQ12XU92#G/KX=A590Z>YF4Q!X5RV5)RT8 I5\M7">;TD>E;$GPE&FW&5J-:
M.C&A][M:Z74_2U'J:YW*JC6;E=U.O?IT!"$^CASV@) <Q_^$/8Z5!@:Z95V\
M.7S]<^U/-VM_NM[XD[;"Z]8,LY5HS^6FNL"JCEW)8+)U$W+!Q$-[HU2;=57+
M[@K?YNWFUNI%>[ES^#[.WEZJR+6_J.!37]J+KA/317=-]B,5#Z7RS(K-5'?1
M<:JRJ.ANGG8/DB_;NYCW7$J^:'_.&56)3@NH[S.N+-,_Z XV]W_/_@M02P,$
M%     @ 3*1F4<LU;U)H!0  A10  !@   !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6RU6%USVC@4_2L:FNDF,UFP#,;0$F;XR$XSTTTS)>D^[.R#, )K*EM4
MDD.SOWZO9&.#,8:T73^ +=U[=<[5QY$TV CY5864:O0]XK&Z:81:K]^U6BH(
M:4144ZQI##5+(2.BX5.N6FHM*5E8IXBW7,?IMB+"XL9P8,L>Y' @$LU93!\D
M4DD4$?DRIEQL;AJXL2WXS%:A-@6MX6!-5G1&]=/Z0<)7*X^R8!&-%1,QDG1Y
MTQCA=U/7-0[6X@NC&[7SC@R5N1!?S<?=XJ;A&$24TT";$ 3^GNF$<FXB 8YO
M6=!&WJ9QW'W?1O_#D@<R<Z+H1/"_V$*'-XU> RWHDB1<?Q:;#S0CY)EX@>#*
M_J)-9NLT4) H+:+,&1!$+$[_R?<L$><XN)F#6W+ G2,.[<RA?:Y#)W/HV,RD
M5&P>ID23X4"*#9+&&J*9%YM,ZPWT66SZ?:8EU#+PT\/)I_O9IX]WT]'C[12-
M1Q]']Y-;-/MP>_LX0Y=/]Z.GZ1W47*'+!R)IK$.J64#X%?H=/<VFZ/+B"ET@
M%J/'4"2*Q LU:&E 96*W@@S!)$7@'D$PH^LF:CO7R'5<I\)]6N\^I0&X8^..
M^_ON+<A%GA W3XAKXW6.)41$$8S'F1;!UVNT)A(]$YY0= DL%X)S(A5:4Y@Y
M(23DJHIN&M^W\<VT>QXZ3<?!@];S+JM35GO@VSGX]CG@50K>0E2()#H4DOU+
M%Y9$6EJ)/ WN[6#"3O:4T)]CN<>@DS/HO)X!K%=*P^AB\>H4A<X!L';7][T>
M]DL,*@R]OM-S/+^:@)<3\&H)/,+JJQ+YLL5^ J]WF$B_XWN^4\9;:>CU>OA(
MPKLYWFXMWI%25%=-VW&]W]_XGRH^J5-W!V8/=UR_76)S:.:[/1^WJ[GX.1>_
M%M-'1N:,,\UH):%ZYR.$_,-QTNMBMU,B5&'6];O>$4*]G%"O%M,7(H$2I^@N
MUA2&D$:WL6;ZY1H]2&9T&HUI3)<L8/!>L_CU\_;Z/S88)OT#?CW?[[;+_5IA
MUNF[_2/+&G8*E7)^HF<GF??N>,+8[?O=$KQ*NTZGWS^";T=%<2V^&94 #8V@
M7^B22@EKK560FC[!A2+A>DDJ8JH?5R5\GBR=--OG4 @3KE>F PZO%B=\J#E>
MI3:=8;A/HM F7"].QT@PI9(S"!Q*#DZ?,H'3AOL$"FW"]>)TC, K!!8?"M%!
M!]29[",O5 K7RTTVP<:OF6"%;.#ZI?_73##_O EVRFR?0Z$4N%XJ?L$$ZYT[
MP4X;[I,HY ?7Z\]/3K!#]?'L4\9_TF[_Y%"HE%NO4K]@>F4MU$VO6I-]Y$:_
M]DMVCD'UHE.]'1J?\'H,*8(M_)K$+[\I%(A8"<X61$-*YH23.*#(GE6A2^.
M)PN*X$B)B-UV(,@0XH70([%$3)>B/&]W1&R[(Z)F1V3,+QM?[FY5XZJ)#(JS
MVA::\&WK.B0:!21&<XH2!4XBYB]@@J!60X-BSMF*F,L*BTP73-^^Z;G8?U]"
M:L"D+9ANOX#M4K/[]@WN.N\CQKF]\P"^%[ _:K9+Y;8!.!=K&LVI3"NW)V3K
M!8?>W:KL]'N-("%K:F]2..P1C65*L935\[ OA42;D 4A"F!(,RU@"5P(% N-
M0O),H;% )%*9--J(*]B*2F@LM=ZVL\XVJO-BHVJJ+C!N-YV*?,!^K.G]'_EH
M0@2*[H6F"'O(\L;OT9$=MAU/)@M7-@W+1 (7B194$\:;5:+3VKF#B:A<V;LL
MD]8DUND!/B_-[\O&]EJI7.[B=Q.WJ@8F']38FZ56T41Z0?<GD2L&(Y/3)33G
M-'U8'F1ZYY5^:+&VMT!SH;6([&M(R8)*8P#U2P&9R3Y, _G-X_ _4$L#!!0
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M\JO8$N)MO+DLFNX_>NFQ@>YQOFZ4++>-]7&95_UG^G,KQ%X#'0=N0+8-B-F
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MAKL(7Z=5^MP-#%H(<7R;@@[5C++WCLE0 JB[!!P?$WM='0;F#3&#4!R;RUL
MI1=,EBV"8,'H@Q,ZI';J3NU?A3C5YO=T^Y3C6"ZC0WZDP7L'9,B+U+TR/3X@
M]DJ1!M0:$&!#'GOFVA1 18R:QAQ 8>+Q$?M!A[1-W6E[?!%^^!1PR(K,>^<X
ML"'QL;=L*+N>*6*[5@34M,<0BH36$T4;Q;"YXYP *!I8JX7IWG/Z4M3/W0L2
M#>J><_0/9W=G=R]A7':O'ACGO^#/,PR<C_'GI'_%8@C?O_%QG=;/>=6@0BQT
M5ZT]F:"Z?XFB/U!RU;TE\"25DF7W=2G23-0M0/^^D%*]'K0=[%YEN?@;4$L#
M!!0    ( $RD9E'G_L'=.0H  -T\   8    >&PO=V]R:W-H965T<R]S:&5E
M=#4N>&ULO5MI<]LX$OTK+.W4;E(UBHB;G'5<Y>@:SXZ/C>S=VOE&2[3%"D5J
M2,I.YM<O*"F"!#1 6E;EBZWCH=$XV.^AT3I[R8LOY3R.*^_K(LW*CYUY52U_
MZ?7*Z3Q>1.6'?!EG\IO'O%A$E7Q;//7*91%'LW6C1=K#OL][BRC).N=GZ\]N
MB_.S?%6E21;?%EZY6BRBXMNG.,U?/G90Y_L'GY.G>55_T#L_6T9/\22N[I>W
MA7S7VUF9)8LX*Y,\\XKX\6/G OTR%G[=8(WX3Q*_E'NOO7HH#WG^I7YS.?O8
M\6N/XC2>5K6)2/Y[COMQFM:6I!]_;HUV=GW6#?=??[<^6@]>#N8A*N-^GOXW
MF57SCYV@X\WBQVB55I_SEU_C[8!8;6^:I^7ZK_>RQ?H=;[HJJWRQ;2P]6"39
MYG_T=3L1>PT0L33 VP98:X"9I0'9-B!Z V%I0+<-J.Y28&G M@V8W@.U-.#;
M!EQK0&R#%ML&8KU8F]E=+\T@JJ+SLR)_\8H:+:W5+];KNVXM5R3)ZJTXJ0KY
M;2+;5>?]F^O)S>^7@XN[X<";W,E_5\/KNXEW,_*NAG_\<7%]>3WT+J[K[V[Z
M__KUYO?!\//D'][PW_>7=__SWMU?7]P/+F7;]U[7NY\,O'<_O?=^\I+,NYOG
MJS+*9N59KY)^UKWUIEN?/FU\PA:?[O(J2H%F?7>S?KY8Y-G?_X:X_\])E4^_
M;%[>K*JRDHXDV1-@<^"V>3&;)?4C$Z7>;93,NLG6?C]:)K"30[?!SW$EXT,\
M\X91D4F7H.D9N4U<Y]DTSZHB3^4W3]YE5L5%7%: H?%1AJ[BO_Z*I&_QH<6>
MW%F[[85WVPNONZ"6+H9_KI+JV\_>0_R49/5X9=Q(HVP:>U'E#>+I!X^@GSWL
MHP#:)AO;?&V[CJG/YRA C-*SWO/^MC!AA!U"!H EC@4FA[ A !,B" Y1(Q,5
MAAIF;&(P9@B)'>Q@.LEN.LF1T_E./G+E/)+K][[-U/8W_;#].:-,!+[OPQ[2
MG8?4Z>&U9,]W:5Y*-Q*YNQ8QM*[4Z)PQ7UL*$X.HAAF9&(HTS-C$=(EUE&PW
M2N8<Y>VJF,XE 7KYHU=)!5"NBF_;Z8?&RPP?="]-1)=:?.0['_FQ/N[O%FAS
M<-.;T#YI8N>0<#HTV?2=E.5*QC^IHKSX:UQ,DXV+^;*.LZ4G([7W$A5%E%6-
M?@ISCPBKF\'.S>#$;D)+'C1OWT$+S!C , 8/,-P-,&P>8+?6;S-//J%2U)91
M/2AH&"'@HA8T!RTP8Q.#?0P/ _E*NOA'#:1IVVS-'GICVS9H3TDAISN#Y#F9
MQ3;%@QIC  #I(M_NF.)@U(Z$X[4(VF?@JZC8T40(NHW-Q0TP$4*C8-2"@R%;
M7(85KD5^""="K+,P!*.^SL, "B-,";5,JF)BU(Z*M4G5>+AI@OL()&*?VI==
M,3$Z 14CDQ^)X(&^) "*4::OB(G"NL0: R >A-PR6$7(R,W(IR<79'(R(LR^
M+HJ7D9N83T,PR"1IP0+]D6L!&@,@9ANDXGK4@NQ;D@P">%Q_W =M0&, A'UB
M&8L2!,BM"-R!W63H;DBQ_F@TH X]4TR.W%1NC^R_K3(9>'Q'9 =H.^!^$.J1
M/6P1V0%;G 0AUL,(( ,0%42?+!/&=;_&H*V0!9;5QDI58+>J:!?8F^:WCTV1
M02@GH36 8"4TL%MHM KLV%03E#)MY88 B@A?.V"/ )1@2#_QFB". XM6Q7L)
M!+=X.7U@QY"FL1,N5I( NR7!:0([-A4!8K[V* V:4(=#4)H!NS7#:\(V!H[H
M1MAN QH#(.OQ "M)@!LD09T#],K50SDMDLWD@\-H/IT#$&:C2*QT &[0 6O_
MMKM%;MEIGF7;!/U+4LV]R'M8E;)-6=9+\9!D]I4P&=P8@@FAR"*"L6)Y[&;Y
M?EY67A&G426'4.7KP:RCI=SORR)^C(M"?F%/C&"3KPW'34@W\&V>*T[';^!T
M;+*UX19 Z,Q^6,.*TO&QE#Z)EVY*QP -AQ@)(U_:@M(A6YPQK%,Z@,,,Z>?#
M$62.&LD.""4X)I9))8K3R2DXO6F"^P3B='D<MBX[49Q.W)S>.E$.KCPQN5>N
M/-%7M;_%':R\=OP>0+98R/63]1# $13Z^J$0@(E ZW,,]<D#@2WJ@2CU0(Z]
M?W DS.&U-U4#8:$?^,R6T]]+ZKMU0RL]1TS"EP%<Z(L"H'RFGT8 5,CT)3$Q
M780XL@Q6*0SB5ABO3)T3,'^/]#W;@#KT52D(<G2:OTED$B"C+[=T:-LL2C60
M]FG][/ "+['?!'XBS1(!@'21]1%4&H'\Z+0_ 5(!#''K>BM10'Y$ZI^8TD#H
MO#EH !T.0(D'<KK4/@'(UC<R2$VHPTM"1<C43<A.^45-FC5N]4R(*U=.%0_3
M=CSLS)5C'W0;(F$1<BU8]6D+$H9L<>0'>KP'<)*5F"Z_ %@0Z =XJ$\F* DM
M<ZI(F!YU_V!/E8/SVZ<  W.?8F$C):H8F!Y[K]Y&?6V-'Y0-0.H+P)D+#YWK
M ?4%X"#U!<!,]07UZ5!?=*\6P,WUIU-?%+J <*DOJDB>ON7F8!J5\[0^@K<D
MIT_4)'[.F:WP@RK>IV[>;W4NM 0F;NP[C$.* GU_FC@B]/UIB@2Y5SC3*VD
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M3P14%YH,N( PU@>L*0CUP\L0P%'BZQG"$0 +L)[SA/Q'?AC8*G$5D_,3UQ3
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MA9YIAA1  SM 7S(F49+:1Z/#DX3ABFHSI-M1C[BA8;$'BK2!_73'YG@X%$S
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MJW_ ,Q+U.MXJUVW &"E[L4W\]T/M-K8%/ZYU)-0^.6C'/WCKN$6> UBL4AG
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MB)!8^%2=*CJ&IC_AW&-IHH!1"*\2$/-^R%W=[E9Q5^.KJV_V*X@!+P4[K\T
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MN)G"#S$/'BL" *BM-\42-,Q#T=25D 4,1_YO(Z/F<>T8WW((1;/L-\!N)/P
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MG ]*%2@($HT.)9"=6ZZKXN^]\T7_K5:?>IWP-0$4#(3ZZM7+H ??HUW[GE2
M/+T>5KFR'0JD6G183$D%1J)JP<5"H^F(XSNJ MIUL8TSJG&D=\.@1:]S")@+
M1R05NJRQ0*!$CQ!L@G[3LW\'+ ;$](^IFEH)509I/MP)59KS^"#7T> H)5:U
M<<!+N83QJ>@9##(IOR *6"'/-62&? VB* _A;P[Y))1!S19VA2HE1;9_=%C[
MUV+Z";&;;4)E>^Z0+:G"#.LMC3%()4JFN"4 CQA$,Q%\12YQE.V%VFPPQU>L
M[YMZEY7 3?S*,+SZFZ6[_Z!C2OV9AR,)L%/-,9;WED3=!!6Y.8!<J<D.YVM\
M-"G7#I!R*DQNKA@@,(^!M7M:*HL&CTE)106V<D?&A6C^0.)3Q+H2RP*+_J3&
MUB1)@6 D&>ROTG"IKJ<KDUCL^5H"U2+)7@Y ' =BU.MN: %YRP_@;P#^0]IW
MZ4,IW<B'!]0GCPUB,D?;Y#'<-Y,D#Q%-WB_=Q&!59KQ9J18,"07KB[P+?DY<
M@.4-*UO!-27UXK2>F4%/ JL_J;S.GBT&NKM66'%$+63ZC6C%7#_XIHCT+/E)
M:_WQT76%&7E:E\7J6.[^3BD7] Q/07N:%X)JBZ;DN&T:[A2P(>_7&>UOBOH!
M6QC9  N:KN^5NP$_@*LZ?"-5%VQLMK3H"&$*_PCP0[JMK<%V@ E7W\Y/0*+F
M[+!8DG)W5(!M<R6^-C*3N ?7=.-NVU:OSH04)# X(8ZK84'$.)\=1*Y #O7L
M;!QRK(K#HIEP!Z6O>(K 45P?&TN #.'BP -'<!@.?".&)-PSQ-ISO0X*.P+_
M4K9DT!%VQ_,2;'O,2?;GL9I@ #U(C_FAU3I:/)$F!R>'R?7MI4CC@]/#Y/+J
MUP';%:9B$V"6<^!C"$![\C30=RB6:JSP*?S%(5"&U&S!"[L]AZG)TR^=7S;8
M;"#32/I\3AZJP&#&F25W? .WPU#*0F5@2V(SVK)/[L/_!"N,(LFI[_S19Z::
MP^#'?:)R&G*AX:F70%/BU'L1P[/5>[1%8[3V,&IK?50]*>#Y:JB7M9A*ZIWE
MV/!J11%!$VN!A2/('46$]K.*J 6ZV MOD:1(S33P#-52A]?SJ>0_7,:6)&2,
MC2 1ITR@22O::QY_8R5-_NCS^U"H9D,,AF5\=3U9+$9M26P[DG"3TO0K1;9@
M<2B>K\,YR6WX*>LSK"$6J%"8LM^D)A_.)57X7/(0QQ9'1_"5F_KO=3C#?-JD
M]>")B[#]Q5T:^^';<MNSY.?Z$2W1],_.,2RP\&;<8%-?W@2\]1=,GFHAABGF
M\_GF$A0'7=BD*QRB%K*6@F]*40#3.1CM8(TV<#;=(SK(_C(T[>J7FYOX' C5
M<!!HF<&HOBM*D$ TFU^1*8#-8GF_T[).?_--:\T68-^O"@H@@I6(VF94_LV6
MU5L4Z#ZP</*2;E*!*W3#WE)45Z:9-FKE($DV6Q$>'!B)3HC+%8K+Q""H1*]-
MF+0V)^@K2[H(5=H"0D+ 6";W"2L%P&VPQ2-%M0(^!9H/=TC)%:]+L-D>I.Z'
M5W-N<,E6AR*0H5U)CC5:.2^(V<\BLD3(>,/+DH]8/ M^??!-A!$?:D) V]7+
MCT'\, #X68GEY/@[.NWGQ]]AJP=T=.[7PVN5XAZA0K1M&L2OUVF]/;"@))BO
MFJ$I!HE&NN8U-MR^=)Y%:X7.3"S\+XQ*!V>-9G1Q7U2$YU >KAYVH1="U3T3
M'3UI"=*U62VU #,==\-Y"BDA'6 ^E(![Q?^EC.UD71%7D^GM9'YV@&L>LKD7
MH\,PCB0)F<,I:&*VN]B%^@:]Z"07V<U#;T\&@GZ[;SF.880;Y-8D\YII)"YN
MF^*!ZZI_QL2*EQM_4D)0>.9?)A] ,'3LZZ)V\]P\P?:!6O="-*15LLA]*E9)
MU!\8U;2'1 [EM;PW& >#6KD#I-_&)(CDRZ3%RF)P^6;K#X0NHSD]$,*4].UA
M:SGYY?)OPT/?XW>P=44.:LTWUPRT,]&#9?+>9/RXI8;O9I'N:V61:B4\XN#F
MYB=QT=LM2B!-\Z'(O.=P).E;?^P 8[TLN,A%[R7KG7R.K\(WOB1=24.*(_ *
M>-5@^2I9IW\68)UT!&2=_'SS*QRF-Q-H!'PXNL+K\;HTVC4DRC,-'FL/"H%?
M%@#$LRR!\SH:W%61HD<-IFJI(IBV2$*#8T+*E'+ZIE[!&<,LF890_+TUO)VM
M]PFP1-TU1NP, 8NO[[3,->$23!M:6OPI(4I>F;U@HDDEJ72Q,'DR2(=W$5A5
M1GL..RCB+D]3[2>^L6(G(#R>1#IOZ TEO1KH-=#X%B476OAV MCB0L:#@3)H
M]$&.Q8,KZZWW*ZAU 36*83D6,@O>N:AZL$SQ"B->992BJCB!R\:GOTAJN@:$
MP(FIYQY>6T@E\DZ7'5+$>]XOL?O3)[!9N%8=S;;4!L@X*8(VDST_,758^,G&
M$2B[-PX)8*<&:1$5:O^Y>PK"2":%A@)A4+^E4Z1+(UHIY>G I&OD]ESI/I$X
MYNOV?"F*^D(9<<K](?CF#J !3+).,A1<@&_SHTC*FKXBLFP%U7J[5/$L9[Y_
M;@VV<P<1O !]O^X2U%HE7G+H%^CT4=B%D4%[Q7N_:W)9J-(DOM2FNP_]),0:
MT.K8#ZRB?-,JXW8Y\KF%'HQ)$E9HZ[[Q=2E#D?-]<E!@3S)?]LN7WIOV)7P!
MW]!4TBW@'C4Y]0PQ-?Q>^@)203QOXKM5(-"N;NYH+IB,9(^9IAW-4^2Q*,$9
M"92'0U^]4C3Y$7I^.RU'/7"S^YD11QP5O[UL#]FZ.X#!J%Y!%/7$.R3%18^5
M!4OO7YC0J+)!<,17:/D$[J@8OO6?1PTLY):Z5QM22?M5%U^Q&]=/J/,NR_+H
MFL.58"'<UEOIT';TAB3)K9ZRKW>[OGWC^R_NN5'*S/WNW9V"%,C*WF(4Z2LD
M"Y^XKX0G&%9!HJ>4CP8O6XL06VER1:.$<$6-!S:CT Y&==$)0^\?N=6TM"+$
MD:KV-V^(A'L+%C+C T:VS14%VV*(V$LN>PUO%:#!KUU[52#YJJ1$FB),Q[T]
MO,8"H/7PMD43HU=L2PVEV\NT<.Z@@_@6G9@UO@([7MD7_YH[59[><'8G'*X2
MU6/(WV(:7+*5RU%F#K,9L7CP,A+FA:-K^!L+KM'P7I^A619=&38(@3,2Y4 M
MSX#?*<[$%Z@L>%$A%.A/C#UAHL2;==(!.2Z DGI8,#V-!E48]\$T]D'YEO&?
MHFMZ!A:&@90Q'51<A$US4QI-FJ)"1T8Z<=CK=[1446N' J%$(W%20QKP7S)-
MHIM& "^>#)4 @:TAF"L:?P)JWCK87B%Q'JJWH^Z4>5[(32<RD6E*O?GD]YIZ
M4W4*H1U6*HN"W_05)>3RP<&#+2HK<0@[Z!?LLV,$K%Y\%%%(U\ O/<+4NZ?+
M8]HDQ[?S<@,JKIO[K!+SB_DXT'5$B'):J,C@[ ZR)7K[ASZ#9[2,HF2FS@V=
M\&!NH@1L5H2<2',9LJ%PHX8:*1G% @V+,=C?KA^_. [3(NIO#U 4=6W8DRS7
M_6*PF.Q'[X(S^CW)5%PFT$C5X54T,_$Y54PKJ7'6TB]#5 9$M<%,3.CXJ7LR
MAAMLBV0,7>:6&)(/ N!M67^955N FGOH1/F\F-P[QZZP,U"T>%GY@4,7>*N,
MLUG!!1Q<@R69B#!YXK38[ZASC7(+IS$19#I"#(AAIFK"P.?L%:4; N-H"V(U
M\#!D6BU=K!JXP1K6UM"-U"U6ZG.C1BRA"<"GWCR/$N5FHV(L8_R.G:9,#'V]
MWVCH9\CJ<DT7R=,'7H:\+CK("KT1_]_>W-[$[!E$9P@+4QE<EM %"8 -&Y81
M34BE!4I[;N(Y.8^,1AHN7=0E(%S#2/2:$_OL5$;?.FHC.NE(Z%)31\O]?;?>
MH#-"4ZO3PJQY/^H$2F"S_6)ZCDJ8"\<1TL+^BN!J4@,I:S>(B]SR&#(<3)R'
MZ+>OY*YV@ Y#ZX205=FCP]N%R I6!,5P7E?C)DNI72\J4C/<1=$H:;;)D79[
M-M9@ML_OP?\&E\OI72VD4XI'#Q)O@7J"1]]-HC2$3#?H5TL5@-1=L"M<E_7]
MCEU]+<%%_JX"ACT38TQQO(;0O?O44=U"*#P JEJ$5B/9Z')NTW(/3RE]XP8G
M;,WX%!75LR0U=X=$8T_.HY/:BK8N'[3)#=WM"]>71L8N@D]G-]X#V^JMO]I/
MR(T9.G0P6:VH*0I^C1.M1"IK-(UY)*<^VDL*PC:^$8F\1UU*V=O+P?!7:^AP
M(IN0A?O-TT:=<AV+;V#QDFV1N+',+3IN=P/'[=K3(88U<30;P# Z](VQ8M5Z
M":P@A#O60]N@K-%X-Y$U:>_7N)%CG27A8NT.7W0-ZP7?4X9/.@KULNU!\76&
M2KTN4#!D,5(XV$8I?1=7W.J?G#$*"N*$:I)DPT8[R+8T@?9FH([/AG-]R",S
METR51)!2?9<;C81DJQ78LID-58=^3KJPG L9R&PPY%B-*'D>O0HSGHECL1C?
MSA\XK!@:Z/B@#(6KO>-#UD-H&E00?6#W'4EM-DX]4]K(GD94DU$%\>E&Y#8B
M,Q,KB97X?YS@4^[[;R/F;"$'GJ@)I]Z\_Y!*W'?4:]BWL..6Q-'59BJ$IJMQ
MBYV-OA149EKNO@Z7R@R3GOA 8'#* UG"WSSBAK-D 9% 1+N#&BX+Z]JYN *>
M&T.,#)@]V0G,O'OS]F#?U(?BG?34\)<L2.\STGUJ/CD2+WAFDA9F%Z#?BG_E
M+?Y!/'P:-"R;"]#L$[@BX"7;#KO9*X$_)VT'9JO*VSU"D2-E_,LJ1O2%6/Y"
M;"8S9?@]%X*68<WV;(LWD059+\&NQJUJ50-F:HQ>%Y7>QQR*]QB/VM\K17D$
M7!5^Q$$N>VNL&X/Z%7DS!Q2TK8+N%VZG&G7PCW'>(Q7M(M?$/?!=.ZB C:RQ
MN)4X/@*J]X9DFDC2VQ?^"\ L%>B7(Y#$>[SZNJ^-WS=)3U8*D9Q,]PA*P]62
M5/FO$XNSY"?XDOFJS+CXA:^ZZN*6]C6@1-ZQS_ "AGSZWAM,+8+$QA)E=4DU
M6A>YRI^*QD3\<==6HRKZ2CS4T E,['W["Q#!BK>QNE -M'!D.^R";$9!0I0I
M3 F88!=&"T=9\HZ9V301M+Y=48>H'??',Q1+]>P%,W5'MJ.8F6R4P5#L)PH+
MB*;W/0Q\^!EG)%=)Q205V5A.T5AP7&LGG<;$# H^45P* [Q*3>N,GZ0Q,<VK
MT%;E/G_(Q%$.WD=F-$RYQ+L;X%!2'R8LLO6]%34_7)?3TIL$$\5)-W7G_'IQ
M5SQB,7+*N0^NR_V+824/-Y.G3UG1@13+9 MHVV"KMHDA4OC.T;\(G>QR1NY)
ML4&]R*\I&#;;3OGB%0H="H/P)RF"EGLT'I:VWVI.KPP%@CXHSU4,REM:<C(&
MOT$&]@W4K/,K$3G!2E8N22H&X_-S<?6I>:8EYC]#9E]E8D;VD"]/S>(R(Z\A
MB53:WI\!Z#3*PH8^B=;BU6MW<FT""1)_H.7>>Y9&^Y%6B+N'!E1R0,V(LE''
MD+%(\EH@[F='\B[R$*3G/ M/[1P*0ES%3>I%$ZIXR1 8996:&*?Q0DAH;M$>
MJ>BWLRA0[;UL<*-#"U%##=+?GM#&O[YENR)(X@^-F/#K#M@_S4?T/:E2>WP6
MRP0>NGL34]D[..P]&F"T3P-53)&EP/H"=\Q7(3*?2?1A+ST:ED+A>D/6F7Q[
MA3^%IU)**A1\P1 KO1&HTOT@2MRC+#],1TK=^22FU]S!R*-J5I^CC*"57OJ&
MC&::(<:,KT_@FE*IJYN[V,K-9,0-9D"XW3-Y"SC_I7K7R0$N+KR\YQW?@85-
M3I3]!94W:.RU>ZSI_^_TLM"PZVJLOS9@*$BP'Q&&@*-(]+]HRGIIZ&"\M"SL
MD[4U2-.G=(D$S.276+;KFBJS7 LGB-'HHMV\#.+756L$3MB&S5RN%<!O<_E5
M$E-%\E"76*O6H/8%]32H@3"('K19Q:W6"U)QN$\\4+X\0%:ZSHI16;II24T@
M.7ZR4V@ML%JNGXU0;&LJ#3@I+4LPMS+A4GX*:Z 7Z#>@T(%-#K3%G];4 29#
MSNK0W*0$ 9#?.T(+S+U<XWUATW=&@LD P<3EKMA?HJ4I23(JHF.A&\'.T\7;
MB;)>(>Z.^F!0NJB]0J(\N4G*Q3\14E1'6C;(_3;IYW_DT? '6<0F,RZ;=A&>
M2G^A502HE5(U>M.LY@$:+5)COR32'U&]B6TU3:<>(J #-5K8'V"Q1Z%]:H:G
M0LQFVAESMPE,!,/#=K431Y?@C3M\%2W'77RID_D-$%5GDZ4*4YCPDIG[Y0^<
M8>K53,$MJI 4[T6L[I[JXJ974QD,#\@[6NQ,WC\NPM1.OI0M+[ QNCF\F#8&
M(V5RU6Z8$>7B*+_\9$5]#BA^&)324[<?<S*3^/LL,/9VA4_Z\J].B;:7?E84
M"462JY84^2STYT")J6_[IL7+B?LB_L:%\_%<<U:6)+WO3K4'W-M7N9GV&+"P
M<)9&*6$F 0!_>4\!8OD4B21!>F0&3V0JR*XD5R+@6CNIQH*'A.NHC,$?KF0!
M1T0]%B9[.#[0PX@0?(]B#JL,R[5(?H&(V/IMAP8(]K?L3(#!%'SBX4F4B_NI
M2K>]K.*"*S.,Z&@K/\U)L3SUZ[S0 "+ $I0&[<ZEE</>7O.%I\/?PXU$'_D0
M(OW&/>EY<5N":>*YTD'>4#*5=@]_NBZ8&7LD+ZO7<:E?J^)]EKS]1(*$0B>F
M4[W^)HDIME82UJ(W4WS,OSOR"SK-%])+2_7'E-SGTN25:T*ONE PGIGN71*]
MXQ]<DZ6XP*;(?7RVH5]]  (FQ@Q7W'V*@D+?B!;'>S4@T40^C#+LP*_B3L:1
M,8#BF5F(Y,IG#$D$B2J!(GTV_B%G.L7/68,ANHF0LKS'R>D^V9;\_T@LOPSF
MO-4\8; %R/_DMY])"V$EVD6T_XB7Y[S,%F]KCQ&.2+$EPZ[*?=71)(JSCIE$
MJF;IM\&R5HNH_>7Z8,3N63@-5%" (J>JB>!<RE67@>S#%R3UIT=A>I;L)C2;
M/!&YIB021HG-5E=D_5VOV*1Z'-Q"&L]KQYF=H-DU("!R3,7K/95?=0N50_RC
M;K8>$!C6/61T&62(C1"F)&<\)5+?4K^&KS[MZ[CZD[:*X,>(&NP07QM5[62C
MD,"$YD6$D"/V)41\_;9'>UAE1>F-7B-E]9;)5ZVOOZZ7)=B>",U5^KDOHJ$A
M1.; .72 712WI0M71$7_]Q7;8W(S1"X_-70U)/QX ';X)V3[JB_ZH0HM[Y3&
MJCZC1H619?;(W!BF:?SO;K=1]#>-C$'ZP=X?\4>!.UL#\5M#\8@=\7'?L@0V
MDU,75U,PW5%(V[<-Y#!HR7T-JUUH1OLXJ@^.==\PV8@O<BB"(Y,"7N0(!X?4
MO,F[')3?U)S (L.3;C(!1BBDB=*58QS>"O+9AZB,7U1"1OC_0W[ @J7'0#:A
M02=:%!-A8 1+%" RPU\][5Z_>EJT\)\E_+^I'^&_=&/HQZS+7K^BB^97KJ3\
M/ZSRPY/Y$_,45=H/3R[GWU^>/'D*(\/KKU]MP<>^R9I[3,>5;@5#CV?GSY_P
M3\OJAZ[>XI1HPG7UAOY<NPSPB2_ ]ZL:S +Y@ N@_4C@O?[_4$L#!!0    (
M $RD9E']F/Z0YP<  #X4   8    >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
MW5A;<]NX&?TK&-7IQ#-<72A1LK.V9V1GF]VVSGK6:?O0Z0-$0B+6),$ H&7U
MU_=\ $A1\B7I3)_Z8HL@\-UPSL%'7&R5?C"Y$)8]E45E+@>YM?6'T<BDN2BY
M&:I:5'BS5KKD%H]Z,S*U%CQSB\IB%(_'\U')936XNG!C=_KJ0C6VD)6XT\PT
M9<GU[EH4:GLYF S:@=_D)K<T,+JZJ/E&W O[M_I.XVG46<ED*2HC5<6T6%\.
MEI,/US.:[R;\78JMZ?UFE,E*J0=Z^"6['(PI(%&(U)(%CG^/XD84!1E"&%^#
MS4'GDA;V?[?6_^1R1RXK;L2-*OXA,YM?#LX&+!-KWA3V-[7]681\$K*7JL*X
MOVSKYTZ3 4L;8U49%B."4E;^/W\*=>@M.!N_LB ."V(7MW?DHOS(+;^ZT&K+
M-,V&-?KA4G6K$9RL:%/NK<9;B77VZKHQ&#&&W:AR)2M.I3*,5QG[I%2VE45Q
M,;+P0[-':;!Y[6W&K]@\9[>JLKEA/U69R [7CQ!?%V3<!GD=OVGP7M1#-AU'
M+!['XS?L3;NDI\[>]+]*^I_+E;$:,/G7&RYFG8N9<S'[G];U39O$SP^FYJFX
M'(" 1NA',?@.1VQ9U#EG-UP+=BLRF?*"?=*JJ2/V2Y4.V:\5N^4[-IU0?2?G
M$5O>W3@#^/_#7^]OERQ595T(*S)F<R$UJ/2UD48Z6JDUFXS'[^@_7K*4U]+"
M 8";/M!@S_E:JY)]U$/V%_$H*_9E9[ >N@)GC&\V6FRX%:QN=)J#9ZS6,A5D
M@M>U5D\2%!3%CIW,DN$$5"@*<@\[*3=Y!%59_0ZF,ZM8K8S](2T4"K-A//L=
M+(*,0+O8TK"::]L&B]VN#/?R0,\H8<VK'5@-$Y+R/8F'XYXO&$>LPJ2$!IZF
MJJFLRZ!6%AXD$G_3.?P"RU:4*Z$[0$>L>C5F)@T33S42H^(KMD)9N'0_J9"^
MA+17%/ZZP6;ST@45,CP*];DU+6RC*__8*X&+UC0I"MLW4[96'/XJ,K.5-L<F
M8, %1N8K(SP"%=9JJ)C6E HW1EA#.T8F*23GBA).@5E5R(R3Q14O>(6==Z*&
MNGVAU%2!XX.F6KXJ1#A#Y+_AR,=G'3PRMN; YR,O&F':&@2_#K0:4RBR0O*5
M+(!@BM3 FL@B_.B6] !.0;'W+FK5&"PVIQ_8=8CQWAV<RR,/-T"D<T/09 *C
MB(A P$[8-$KFYVSI-\2@_JG 6^0$&,#49!Q-IW/VZTN5FT7S1<(^"TL''586
MGNRYK F:O-I(*DV8',?1'(8Z$8C/HN0LV3NN^<Y5\GT<+<Z34_91K(6FX"U_
M.BC/^SDBFIUVTG'P;I)$\\G\E()Z5N<3-DNB<3+WY7#HZ(9"&"Z"GP4O;.XD
M HITM\1&L#NMUA UI >/K><;I6NE7=(D6LMF Y8$&KVH6UTHM*=:4(]"$$)O
M8E"NC'Z;'&[=OA\JUWM"IY:.CHODW2G!]I6@Z95X@F95&^'$X&0QG+:B,83&
M@L^9QU(@&6KOR VO_;DA P]'QHG,H:1'B"59?:V LDJ+QJ56**A;M\]P_?GV
MMJV/<SU)AK.][VTNTYSE_%% %P12*F1)YPE":6K$ON>H#)J#$:OEJ@D' XN3
M=W#_*()T685R4B 0T9X?-WRL\EMP[R3N"_M[(P3[#%EER>G_FP8D9_'K"I!$
MDV3\L@!,SL^^E_Z3232;3'KT)]V9OT#_:;1(SE]C=XQ80/W[9J5T%L! L'+$
MG\:+'O'[O#^/YO,%^PG/=M='1!\P)RQ&A(L#<5A$,5)?WG[Z+@GXTCNQ.^=8
M3'S<G[)>&HB6'G@$8YF)8,/18#C?HQ,#G@@GXSUH'3S#N47?08Z (!$THL1;
MIQ@>HZNV&TOWW1C+D%RE+"L))V3C:\/1+%A.'R08@ #EJL@,<50+EP@S.$XU
MH2Z3AMJ"AE2*/C]PJAXT*W_\PUD\6?QH#L_0JM/CJ+<!7DGH'51"E<+'W .Z
M85NA1=LN$)50MP9=O'Y&B5* "YEKS_QL$#/PM*-?UQ0>U-SM16N-]BPT J[*
M4#V5\M"?[/6[0S?B?P[V8S;[.CG5\@UK3Q%\C-!KVJ407R=&1^!X#'D_SXAJ
M>!A41OW?6CI2O1!AFPGE",:#3J1"AFT"07U8&9IL7;:X";X.O;^2<N<@ ,@<
M-+2H9<D?]AKIUS?(F.QZ;U:D>26_DFAN<^@_M/4!67K':/D(P?39+]&#\T<N
M"TK5APUW^ AVY51UJ)[9;_X11?='C#^K1-9RZQC2:U2B2J4[E!&UA[#[BJ#9
M3I0=_CI4(IQ>2Y^BIW;2KF"C[57W%#W /9WCH7=U^P('.^8/=R?"&3IB3UY4
M\-AM=%#L?9$=R@_Z\6_ I",X[VU,U]XC+;]QJ=1I4U(/D])6MIO!^#["X8$\
MMK@*,5%=BT- ?PN_^!I0% OIH+\*<E]$/>\1*FN]SBE-LH9C0E6"[037W]BT
M[I0*, ,D&FPA^7=B@8X4%,4G4DO?T&P%V*1<:_<9T674LJK3&O1] G&Y6PE!
MMQ(O?H<Y 3*AT3!'!_Z/[8$?L3_SJN%ZQR9^(9UE4[378[37^P\^ELS.]DN>
MNW.KSM$-3]E+]PVCWIU.*?3&W5R1R@--_GJG&^TNQY;^3F@_W=^LW7*]D<!X
M(=98.AXND@'3_K;*/UA5NQNBE;)6E>YG#J8+31/P?JW0AX4'<M!=&5[]!U!+
M P04    " !,I&91_I6T)%4$  "A"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6S%5MMNXS80_96!NBAL@(U%W2RGMH%<NML%FB+89%L411]H:6P3
MD427I-=)O[XSDNTXUPW: GVQ26KFS.4,AS/>&'OCEH@>;NNJ<9-@Z?WJ>#!P
MQ1)KY8[,"AOZ,C>V5IZV=C%P*XNJ;)7J:A"%83:HE6Z"Z;@]N[33L5G[2C=X
M:<&MZUK9NU.LS&82R&!W\$DOEIX/!M/Q2BWP"OWGU:6EW6"/4NH:&Z=- Q;G
MD^!$'I\F+-\*_*)QXP[6P)',C+GAS<=R$H3L$%98>$90]/<%S["J&(C<^'.+
M&>Q-LN+A>H?^OHV=8IDIAV>F^E67?CD)\@!*G*MUY3^9S8^XC2=EO,)4KOV%
M32>;Q@$4:^=-O54F#VK==/_J=IN' X4\?$$AVBI$K=^=H=;+<^75=&S-!BQ+
M$QHOVE!;;7).-TS*E;?T59.>GWYLO&H6>E8AG#B'W@GX&?UXX F;)0;%%N>T
MPXE>P!G!A6G\TL$/38GE0_T!^;1W+-HY=AJ]"GB%JR.(0P%1&(6OX,7[0.,6
M+WX![X,QY497%:BFA"=1P[EV167<VB+\?C)SWE*Y_/&*V61O-FG-)O\ZOZ_B
M\-T\=BM5X"2@R^?0?L'@!7 X\4#9\UC/T.Y3*, O$<Y,O5+-W;??Y)$<?N]
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M81J [0:B;N/-JAU"9L;32-,NES1#HF4!^CXWQN\V;& _E4[_!E!+ P04
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M] *ETPVX/L^RTGV@!>H_%_/N7U!+ P04    " !,I&91B*23+U<&  #"#@
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MLC0RO7B@-PJU,Z#]G:(3&!07X/+J+?\!4$L#!!0    ( $RD9E':4EPA Q<
M  %+   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;.U<6W/;QI+^*U-:
M>TNJ0BB2NL>7*EFQ3YRRCU66L^=A:Q^&P)!$# (,+J)T?OU^W3TS&  D96>3
ML_NP+S8)SJ6GKU_W-/1R4Y1?JZ4QM7I897GUZF!9U^L?CX^K>&E6NAH5:Y/C
MEWE1KG2-K^7BN%J71B<\:94=3\?C\^.53O.#UR_YV6WY^F71U%F:F]M25<UJ
MI<O'-R8K-J\.)@?NP>=TL:SIP?'KEVN],'>F_G5]6^+;L5\E25<FK](B5Z69
MOSJXGOSXYI3&\X#_2,VF"CXK.LFL*+[2E_?)JX,Q$60R$]>T@L9_]^;&9!DM
M!#)^MVL>^"UI8OC9K?Z.SXZSS'1E;HKL'VE2+U\=7!ZHQ,QUD]6?B\W/QI[G
MC-:+BZSB?]5&QIY>'*BXJ>IB92>#@E6:R__ZP?(AF' YWC%A:B=,F6[9B*G\
M2=?Z]<NRV*B21F,U^L!'Y=D@+LU)*'=UB5]3S*M?WY0F26OU3L=IEM:/D7JC
M\Z_J0Z'!L#Q1'S"\4L5<R;B7QS7VI)G'L5W_C:P_W;'^E?I8Y/6R4F_SQ"3=
M^<>@U1,\=02_F>Y=\,ZL1^ID'*GI>#K>L]Z)9\ )KW>R8[V?S*Q6/Z55G!55
M4QKUG]>SJBZA+/^U9_%3O_@I+W[ZEW'WSUQ?]8:K+TNC;HK56N>/__YOE]/)
MQ8M*Q3)F[L;$!0RPJDU"Z]28,"\R6'*:+]1AFN-)T538JSKZ44$TM5G-3.GE
MH[Z8<B7T7*MG:G(YCL[&8_79W!?9/<9E],OY.!KCX9>BUAD,"N*8GLJX#Z:J
M?E0W35F:O%;KHF1#!AT\ZO"*!AW94;_F>D4#_@E*YVFN\YA(C(NJKM3A:71U
M>H611;[XH2:2>(%G:CH]C\9G$V9$>RX-->"3-C5I1%RL5FD-1U17C@=/,0W.
MDL<]&EU6RN0)+?N3B2UW)@/67:^*!D=DGAV:ASAK> JMD4.(:B5&9,B(MO#Y
MB,X2G5R<T;>)FHRC\\M+^CQ5D]-H>C:FSR=J<A:=GES0YU,UN;J(+LX<VY]Y
MGEL=N5Z4QM"9U?L\V' ZGEQ%(0M $A@*HM*\+I16E8D;^FHYHOTRAS2)&#8=
MO^CO$?'SR0M66AK7YR>>E:;!X4O9_*"GR0='<)OU4GTI&^BJ6,$A12Q39H_J
M:UYL8!"5NFMRC+ #CB+0K%((-=9KK(-M,$0G<+(I>0"*%J"?:'?BS(C_$"A)
MKVKBI9\I5-G37=,<>R)L0HO:F?B"':NJ 2>A29FI:UH.'QV[<'Z,KT@-R=:#
M>8FZ1;PR)3&7R(_4+[<?$8RQXLT28<D^_/OH>A2IC[^^^QLL@JPE?/RY>(2L
MF3OD%'2N$QVI=^F<6+=,2UF9-[LA?OQ=D\'9*7P2SX'@O!_DF3OQB#0&7B.W
M<9<%PT*%AR6E=C;45X)0K2(63-7,JC1) 19P@H\?(Z\?S.*^ZOVMT:7.28PY
MV0CTD,YPO54#GQC;2F_=E%6#D0I;;)9IO 01,$:<@G02Q.!$%5.G%K*F,4)C
M,<O2!3.P[S84:_)6)HS$)_=M<%T6]VD"7TZ:J.'?[LT/Y%L B\B3LJ?KFTS1
MV1(4/)N,QZ,Q0$26D5P.+2N\,R8WW1Z<#PO6DBLRHL*DK8&R0CI^-SQMUK3G
ML^E9N\>.T^BL*OI'8J_,X8 IO0HHC3RI031IM8VV:/*U3A.L"7K3-116BS^U
M?&\73RNUUH]ZEADR_M\AL9I=1)I7<(.9=?*Y6+N&IT@T'\YH,&,.E("U[2R.
M"T;"#&8$WCUB-RF4M21AWY5S)KR<BZ=IB7T8/?9VJ(C<9]/1:<L)YXG:8+5]
M(CM,/2<R:8V3T;F7.VG\<)EZ">D\M<SIZ+(KVM(0[J?YPW-:+G9XGS2&GK?Q
M9,+,FIXZ9A4QS*<:RHV(M@IV'BJQ';C;##8X@&HJLLD"?OO(8@-X]A!/L$^Y
M_>'ZX\^L7M"X%$/A;^W@V)2UIFB1$W P"6#5P*B)Q([32LEL\H3"3)*6\(89
MW-CU[0VOCN7!*(4XDU=:'*5@%5K&/"#GJFAZF;++3+=[U.TN-#@(K^:(%X]5
MFDP3F@MVEDT/T_LC9Y6L()1.,4OU.H5Q1.Z#D(>-$>AEJJP,GVQ*_!P7)5B+
M3<AYK@N<(U261'S($U*#>-6L%9R3@T5D.OX=<3YM:4_S>U-9B,8QHMAW$I63
MDOV/S^,$#[TN#0@JA582*W,^;S"YA80P+YQ[9NJ-,;D:CZ;CYS1\/#HY>^Z,
M1=_K-&/O%(+.W>$BPLX+72:9U4?@R86)6@71ZW66QKP@[9\8LBC@BH0VU('_
M0V*+8U!ZFSA:^A@W,P@26%X1-"H&+&"GWN>#)+"(W[1]Q=!F;>)TGG+49KBX
MULQ:(J\%BXY+??OR .YS,8/+!J4_-ZLU7!<LZWT>C]0AH%Z+]RP<M/&=[)$&
M'446S&F K1)FL&A5<AB/!9F#-T6)Y ]T[Y:&4UO$Y92A"?;6=: ,?%*P"!_!
M().2FD4T9!N_BW4MP4\?B;4PFZ#-;QNX2<Z)XD>(%!I);L>Y=&@K-EX7DG/X
MGW&^7T=W(Y7 XU-. LT G39V?38-N_L[V"&X_N']FT^?QQ-U2])VL9<?!J@V
M^:WAK)##-\2#34UY;YP*,#\@8C.?PVL!1V4-@0BI'(6&,!V-80@DW!/ZQ"CS
M3]332(&^P]D15J%9S,4^-8Z4B2=E^E>0 EUB.0S3-U%(KS,L:2P9)L].O)PA
MMLY!HODP3]V ].GH8NJ.<W'QG'P%61_E-=GC=Q-##SM0T>UQ\5Q\@6<O!WH*
MG<[(5U!_4TK&5"^A[JDUE;P@4U?LO?"#U;RN:^&!Y$O8@Q ;@-3R9/:X+7T:
M&-N_4M%8J<C?PZC$W6$O)A8>6IXX[&G!.:6"-'K&&5EN@Z(3T@!QCYCO.'!3
M\[(T=8\W6H%I,P)5AL$Q,P>((UT9#A!812'NZ8S25_,00Q&8O2P#-8-E?*7#
M#5$)$KRY'14;33 %QYD1Y82H3!)M)\<ZAFK@U-N$CIPBSJ/O2=GQ&:=$$E4M
M(1D&VV6< J23K]'P_<Q)D&_*7))U)_'6^1)JS.LTHST>N:[CV)\4JH+,-#EL
M]NR4QZD5Q18<Q;IDK]([$IF=1QK@0.R($ZRS1XG-]WA:D N: _VOA/JXN(<T
M8+R1S;I 4>0EE:6P;2T18=Z4.;C"XE\GC.9LQ8LR'X]?TEQJ]CQG+?Z9,X8'
MJN<Q!B:I@C]UQN?!SH30:@_IBS6@HX6QE"(U):&PR!Z%QO!I,KWI3:4JO,P"
M[BU* EO"*RZO@4FYV4 $*P@IC8,T7ZV,J7D,EH,0<2 I_X#Z99$E7?BP5<U8
M%T$@(7R;D8OKM 4DI@IVR*&O3='_9 E'#H8"P>[47<1&&$SEO(%YJ#G7)X]4
MDU#)Q^D-KZQY'0OD'6O@P:H"R]+8-96LT]CTTY) F23WZ--)AE*F-@^ #\I2
M&'G4S73Z$/NP7;,_O0/-9X\A*4 -X-AO<&Y$1"M)\3U[A,#0$OD/';[RMB-*
MGIM%SWS4+,U]\72?R)ZTL_[9YE @31114K DW(@UDI32C#P1+B54.DQG#<_!
M>75FK2<C3SG3\5<\[:1>;$'D!S(2)'Z=-276JUB#'0OPF!0 HG4ILK4W(WD1
MA;FFHFI_1?4ID./+U5PB3/_I*GD)H*-=4<<Q05M.C.0T8AL4+Q[;7&I5))!3
MW%:RP$.8-!P.Z1UIR??83L\1UIM"?85K;OT7!U-0QR626&=Q(_DJQV>ZC"BR
M5'P>A^@N6&#_[1P1.Y&'=-6LNO.Z<9M.1#@$9)-9"0XY&5V<$:F$" DG6)MZ
MHB(DM'S+GHF)2PF=,!&D@F>R')7T(ANQP$I.+),FEGR*4(NGR1>1>C4I>]4@
M)9L!MIL^P2TX[P'E/IB2@0W9UF*W$SK&'^#9?ASJ82!6Y"H(="=EG6_KRM[R
MN;;!IE](8;];5ABIVZ":2U.?* -' Q]"==ZEAKM9<*E7P(LM@+O;#UK"<XT8
M"XPAS$A+<MGF&T(\S4'J''\-XCF9$RU-]P>)]:UIV8U"@6<&J4=RH8"U2JH2
M6F=C$:;C05 N$O5XJHZ^,R82<[X!Z-#0H=M^DB7;Q=P!+*:D9!/,&<BABFQ!
M2*II'AB)T[8^49XXMBQ8 7I0AZ(015I*,,("?TB2Z&1&;JNDLID/(S8F45"0
M@%21,HK[KMH:A9=LD KTBXK!:5KX#(?.UM@G88=_]A$5OLD&"]O.\#0"U6E&
M*2<+X"L74VW5=[-$JI4T (EV+7+<3@M:$>Y ;Q'G'5(;1Q@BS&K%4E$>O^%R
M3<VQ.RZ+JOHAV$2,Q&.C$,!$G&&5S;J.'VD=*ATAC\UCP*,BMK44%H.#6+\U
MR:(-@>ZI952;<[V%<A2/AC+CVA4]WN>,/EO#B?D>8G)U<8J OBA9\R&W5<'7
MS/"<SR:=VPX@+<#>Q%ZKL ^E=#N,W# XPFD!)4\9+65J5C^1W_ &HD?.9F15
M 0*VWER716;39)_-;Y>:MKP)="B@K5-9=ZH#+0<>=87"%D71UAHIGZLK@<"T
MD.:##:- LA2VB=YE16]IWM*5(6E![Y*[-V-<($KGO%<(=2CZKG3B<_4;2H7X
M1U:4GVSE0,;:XLP=85J0="MU8G6W1,I)>0L8$60H5 )Q-P*BCOZ;\Q6DX%3"
MLS@R!:EIR5D4X0$V!M;W38IMV#+%'?O+%U&<.\,.XSJX.W:<#@0@S.)[6YW(
MGI&OT1#'D2$VM7E"R@/_ J;2!@U?9% ,M +M7KMP?PG6$$:"#0:R]=3-RV+E
MA,G91>SN]>2A+\:LFS+F:W#&$H-3WW$L]3IEY>/N<'$P9^(V+8FI0 H72_5>
MHC\Q50Q<W]I >W-&+LIP6MSDC(:ZL.@,MCUY3F01#T09I&:%K!!'DBA?"*]T
M;:MD5*2Q%,@34/'"W6DDHD(T@6H\E!G8N[&S\&[,4NI\CH09[EKHL+S/%.?O
MI:C;%G.Q?C$3'M$B0IUVT.:)DTD(ZO+4WBWSK9RU=)OXMKFFO8FCG[WB@MXP
MS7(&&A @>C4@PEV\R<E"C=DQ^/[(50IJ_6"Z49ZX9F_G6$F= @G D_0_R/.D
M#HT%*8FD21G"%^>/\*TQ5^B']U15LR9KZ6F^VRDO\A^61F?U,N;*EFQ,).3N
M_IM4D0II#Y0S(LYT+^??B]<;V#2'1)OU5QP(TKS97VR,.D"8M-*Y1V/!3%"=
MEN((#;+ZM355]\4;1C2<E'8JG]S"A<_'4BQT]WU:O+V]^)"6'O%IQ% 7&$GI
MP\4&M>2>-PP0(80Q,TN=S9VFV5-'?"+N%^&[3JQBJF^/T$]B+M8F<F<,=3.3
M+%J@FP[J/MXQ=I"C=0FY7AE_[;UPUPCF@8I4K-$[4P8JH_%%>AZVJ/%0$L)]
M41M7^;*NO WM1Q%C4EH'/'0GL(K-^!]&W;2HR]U7TS)4+ZOZVP:XXBCRJ8Z=
M)M1[CVEK:1![*Y$NK&IKT6%"]%XX)@6/DMHA(>!>P<5?L'?T85]HM%M1/N@K
M/Y)7MBZ^V&H5@T2 7?R6.F!K9"YBR2V1W2!BM]LZ6D;(K'MMM=(]"_D>]D-Y
M6$P%92[[6I:T/1O]-D!D-X;%Y[Q#LJVW@1N[)%-S;.AQD'2)S'RE<[VP]@.;
M-NF"R+$HUH&DH+K$-7#/'8XM[I$TZLT*=MQTMVD"+>0G<MF6 H%QK;I=BWL,
MN%^*[QE8D![)4 9I$ =\NBF.3XRC\V-'4"- 3 M>WOEVUAN^C'FB(U-*[ER;
MLPOT^V&IQ>I\=.:1@N\)::^E7%X:,/^=+Z-\6=*%OX08*LSX'9F% F8%JG:0
M'K(W#J;=YBRW.?MSF,+,;V)VG\ UB+0]OU2=$JM.Y[LH5TWE?(?<2Y,(NC>=
M*P//FXS46__[>_?[9_K]RQ87JVUA;->:A;29UFV#<]*4W]/>*Y>X+&AB]\GH
MXDIN,B>CD\G@8M<3;"_LG%YURGJ(?+7Q1>)4<E:+R!+'5MWV6[OL@:CW^B&R
M<%?3TD+&U9WO.Q.IXWATTNE0&X\F;48<GD\L]]DD +K\8.>$T: -G@4W>8&D
M733O%@GD(U>OWC@'QA?<GW+U2X.33$ZYH^]2VCRYO&[$&\.9KL"- MX@Y] 7
MM(+ CW4[=GTKQ7"G+8VGXD\Z79+B5:5%:-!V&2)_N5.@6HB C,2B?S[-="H"
M&.%\9A=JF!5T9[UBD7$;(BO04E,13QA^\_833>X>4:QVS_E8?RF& ?CA*S)>
MQ\YN6Z!C.'DDLZ+VJS+E-DVIF[?AN\,.!N)=5C!O+H('3EMM78&G##8F72Z:
MQ5+]HO.&?+UKZN3+5ZG&TFV=#=2?XKH(6S^9;EMUM@BXXU1UW@&EG7Z&H)W!
MD3HS.9($=I@W'^^$QUT/TV]5^ <!H;NZI+>Z?@%BH6VL\JU+RBVY#<9UW7/C
M NQG>O:<TY2ST3D^VAI^OZ_U4O;/7 =(T/5,.?N:\F+U$?13;>9GY&32(,W=
M63ZC<)5)]MR81AI14V6/KTC;@KE+:O -2F632!L] O0NE+)VBWMQ7N4L- J,
MFC=R!<L-$5L:4:EK]U/X^"RT_%Z_.>5?;0LCM^L'K2C[/,%?8]U]JJ]LH!XT
M5^XQP6NH1Z8F%XZ))+%?&HR97@6J+56H[S/"R7G/8\NXSF,^ZFBZRX__U7I_
M,CJY\'J_[4**R#X=75[L- [;]-W3A?0OLY*>>9"22HV&:T18I$=)T$J[+JC;
M@+L(@BM[ !\JOR>EWB341,E"JK<>"7 "N*=N[:%]*Z'MVV9=920 B@<]XI5M
MFO)"]<(,5^N $7HK-6DRT[/32>MY]P>@2 G^"5Q&&]Y=JQB'^2UOW!"\%5MI
M7T7Y8!DSK(B$&VWQ*-^S&7>Q[\^9.$!WW[ 97'_>V(1MV#G77BKV,$N;Q.XZ
MZ( X:?NQ*^Y[U67WS>_>THP ::IG7;:^PLO#94%+\(\N5H(1OKFZ)6IW"SJ[
MY&%5B(JN3Z%$KN3^493XW;%A\@>0WY\4%^C4(>3Y)G@VZ4>&TW$O,@BTXD6Z
M!W&HK.=V!<NJZV9!2?HDI#'P$./60^PXO(-V[MSAB7:=YG1PFI/V)1FAP35[
M[%XCF")K[,YE6')^14<QUPEM-X*_W)C;1MZ@D4L4?ZC#G?:Y/EK=V6]K:VZ)
MS_S;"C[?3O)E]YZ."+(-&\%<.X6]]L&8.7>!2F2S=.MM%YN)ZPZB@OR,BJ;;
MHH*0(3UP;8=]<(&/<_N-(O<>IG^=(:AZN7=L;H+:4U!#ZM'EP@RL";1,KJZN
M0L?^KX,T?>"R(Q\?X)EO;1K?-9L+QFQ<>=%5?>>#!R!EA-.*PGUH%<X&#UBY
MR[6FK;>]OK[YU#8+$]=)WE3(2TMR\/("S,XT:VNJ[ES-$W#BB-WSL_/@_;I]
M6=M@;_.PYE::X0N$#F]2I:VAEVAJPHK0(Y]X^HLZU^\G5WEM8EGD%D%)KENU
M:,YV5K@K65L:9F($9B7\FD1[H2F=FK:?,[4WPN[RS=_T0"'E,N9J3"U?=D.^
M8^HN/7)2HUJHO6"2MFP SP!T;LN(<2INE.N\O&BX5NTM6RB.??U*4K7<;*09
M!CS=K0W[HJ"-,*>[8I[-3<6MATK!@3IX?3*(<]9M]SA$,[9HA,1W?\M!K+<M
M*KY;P+YG!^%)&3SYSA>RVS\F(<:YC4%_+MJSNA LVN&="V3?8,N"ST)7L'M6
M]80+"/M7=L=+^_8REW;[=<PMGL!=F<B]+=RU=EW/>]YJH<O=_\,N@ )Z<A]>
M& QT>6E?J+#R<M7[5N(07+9>:G5#A_W?E%\(Q?Y??M\NOVU_+.<X^+-$*U,N
M^(\O4>$ /E+^0I%_ZO^^T[7\6:-VN/QQJ(^Z7%"K8F;FF#H>79P=R!6O^U(7
M:_XC1[.B!J?Y(V0$#: !^'U>(/.R7V@#_U>O7O\W4$L#!!0    ( $RD9E$0
M4"T)H H  %P?   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;,U9:V_;
M.!;]*X0WL], JF+)[TX:($T[F-F=S 9-9XK%8C_0$FT3D425I.*FOW[/)?6R
M8Z>/+1;[);$H\C[.O;SWD#K?*GUG-D)8]C'/"O-RL+&V?'%V9I*-R+D)52D*
MO%DIG7.+1[T^,Z46/'6+\NPL'@ZG9SF7Q>#BW(W=Z(MS5=E,%N)&,U/E.=</
MKT2FMB\'T: 9>"O7&TL#9Q?G)5^+6V'_*&\TGLY:*:G,16&D*I@6JY>#R^C%
MJS'-=Q/^E&)K>K\9>;)4ZHX>?DU?#H9DD,A$8DD"Q[][<26RC 3!C ^US$&K
MDA;V?S?2?W:^PY<E-^)*9>]E:C<O!_,!2\6*5YE]J[:_B-J?"<E+5&;<7[;U
M<T>S 4LJ8U5>+X8%N2S\?_ZQQJ&W8#X\LB"N%\3.;J_(6?F:6WYQKM66:9H-
M:?3#N>I6PSA94%!NK<9;B77VXEI\^L0+##)>I.S6JN1NH[)4:/,C>_.ADO;A
M_,Q"#\T^2VJ9K[S,^(C,!;M6A=T8]J9(1;J[_@SVM4;&C9&OXB<%WHHR9*-A
MP.)A/'Q"WJAU>N3DC8[).^ F^UU9P?YUN316(U7^_82:<:MF[-2,ORNVWRKS
MKW^9Q]'LI\:=;N*E878CL(-2D9=N*ZP$MY46[)D1POL=GS*U<M/,AFMAF#2L
M4)89E8GL 3EI-[)P[Q.$5B--,?WRYBIP8\*K]$,L5<(O_E#Q3*X>&#>L%-A!
MA2AL,Y>LW^#%4HB")1DW1JZD2&ENH8I:"9Q?,UE8 8LL?CCQF)&WOBG-++Q2
M&@6E%AW2K!H,T[B#/\XD @%5;9EY_*1M'"VU6KIAN^&V#\169AFL3%0N=E8;
M<A>)"?5+H=OL=&)?BZ0>C6@T6H1/1>KRB*@ O^)@-HH9K5ORY*ZQ:</OO3L.
M/6E,!>2L8HG0%G684:V&H-^OK_V*6B_;;A3; LS';VJ?+>HM&9-DRA#V=4Y
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MU(5Z.MHH1:;"SB++':_C9I-1<^C!JNXE';Z^VHQ@ITSO;> ]JWS7ND?7(PT
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M)N#]2F&/U@^DH/V@?O$?4$L#!!0    ( $RD9E$ME?\(W H  $P<   9
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M7#SS .8C.J%X^=V,LOS P,>M\R/S8A\?!4(;4"BTH=M> E649#;M>'9ZSS3
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M:(H:T[<W8_H@!OT- !^;UT C":?QG8U(0NZ)R26RFNY1M&>O>'BJF#L2 /P
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M ._7%OTO?:$-^A\0+WX'4$L#!!0    ( $RD9E&+JWN=?@@  /(;   9
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MC@8=HHHO3,6#D9G]J@-5I9&);<:,0H3" ?!^*4'_\@$7J#_S7?T)4$L#!!0
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M@/M+B?\EQHE5L'U8SO\"4$L#!!0    ( $RD9E$_]\3RJP<  !,2   9
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M/%;E$K@V-G@8R4*H#!JFC""*=%%GJ!0MEFU-=I'">TSL$,?P9AUW=!+S)(Q
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MI#I-P/>YE&;U0 J&[Y;G?P%02P,$%     @ 3*1F46^"*0JT P  !@@  !D
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M&I+JQY4ZI3IFWT#B!>LB<:W:#1INMSW#[<KC(7IR\&U6@.'M4(IFV:JU$EA
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MJ/FU[WR:8 L,5%>I#3OA4']%YL#9=8#-?':%"_5Y(O^[DO4Q:4PF]1XUW:2
M?:R6J6@D#&R?]46]+S6]4_I[^8@:)486Z3U38QBF]K?)-9'W=Q8I@W2]SP]X
MA5!K<R!^J\D?L2<Z[AKFP&9P:B9F$J9;<FG[[C7L!BVXO4ZY#SW1[@?YP;'L
MZP<;\4%V1;!G4I87&<+!(#5/\BY[Z3<5![!(\:3B#8 (N321N[*/(URYJ-&'
M*(U?1$)*\/]3>F(R]^CQ)E3H1(IB( R48/$"]-3P,2L5.YDAQ287]#3]^<:8
MJM9F"81M;"/-_U0Q';XW2;J]/.V)'..6(]HQ+,@S)DZA!WVETA?,=O>+$N$F
M?*.JOX,86:;B[>Y*=EYJR-PT^34*C=1"A%!1*&J-V^,&&IKA*:*CMHUJ8*T&
M92^CN7-%M4/-Y0<?8:/+>[:BFC2^H$K>FFJY.J):$G81,Q&/]6(LT5FNSNE'
M8_-F"$@3U3)NY($#>6AF34KJGK+,>N$_SKZ>O_+7%>2E#7Z*H!SKR3Q4O=2T
M-IOF)#W?X*27</68RI>$&OJHVOUI=;>?=^T?JY<#G8EO+K40%'<<DUO(PV;>
MP2PM^.^ISXC*IOB^B*_F+SWX=Z[63NF^8S4NG".WCL] )_8-8*2X%=D/HJM/
M2=$<X\/*!#VM<3R1/E6]5QW01XEZUK=A^3'']RJTQBHFW9^"+6*?Q% Y/Y]_
M'5^B\?+5_+G%4Q8+/4!_WIGWK^2 0V)-[A]GSPUQT#)>?&5N]_"*_'AFX9=8
M3=28^QT,(Q7DUZ,W#F"B/0"7M#]*I?7&EKWXU'L\@=D")ZWP9DB;EMQB)AME
M[$F62ZT-:]0L+ZORY-&E1,CFJ4=07(+'(XT4XF#B#G(.VH!8),H_XX(PIBS$
MY.R$;/M-U6'27,W-/VPNEBG\PN"[L^VW&^I!I=K.*O_HXGJ$F<G'PP>-#XPQ
M6D?&Q6K><DBPMADCMJ$H"T/-9,:E-PQ[NH]+7",HZ:0?5E@O,0KZ!7:/F3MM
M\+"SN)PEN4FR3AN^A8- :7P[8![F#IF\B?-C4^)F!$9#;X=UMOC=1@%M[_J(
MRP=#A-,&2VU5/P=+Z2!B6:F*$#<A"Z56J6]YK-CGV\('&Y:YHTJ3H!:GP;"*
MM%KM(Q!GV6A(@"0-UUD/7*T<K1J00K@_@^M*6<FBU+P[\KBBSV_7]?T&_'1P
M7*?^4A.&BG3]&.VA&'RY^!UU@CY<U\ P*'V]Z]CR)RHB.&A!-V E>*O8N';J
M,X;,6?I+."^*III]RIS:TTW2OZF3B02OM<('-T&W2N'$0V\,K;<Q"^:)QKVL
MTSOG6(=TNXX5!6[2UGAW#*PJ= 0-X9 YW9@<PKRD XP>JJW?P(X0?%BJ<>/D
M_:1]KJN(?/OFAA//%R.>*%5QZM'E8!E3,(.)3JPOT:/$,&FV2COS9^W7DI=W
M%:!$WSD^H)*P9M6OQ*B3+G'UMI]$G76NYR3@A4Z$_R?N*1^%_=9Q.U_GDYZT
M*;E-<"!G1(R('@\QQY1 F[>^0D+/#LOMI<E)R (T=R1&?>(DO#9PI!K$]#?>
MIGX95/.>\SR^2Y!>]F&AXM=IL9GO%?(:H51&C!/+ PR)+$^LQI(CE-*-LU/.
MICLV38[:C=NK_%*'/,  '@,4>0R+-[<@A HYT&[E]H4)O-"P4W2T*795Q?5W
M9:!YS%_+&\G*9)Z$&C+[H@[7D=G<)[\/86?K+B>O=6QZB!.:>NKA]]5.LG7=
M1\<I[-R,BA6182=QV8Z):(R6'P7PC*\<8/E.KM.1I@@^\\3T$[ XIE]) 6&_
M\GFTHAI5/35IB#DU/KG#)T[3)36E.,(PF+2>*G>W[4-&68YI*1+G!0!DBVH?
M?6^=6+CC8;I5O G\)M:!1]I5^,B(5])5'^>P.F:-PIP\HO=R\4OY: .,_@5&
M$S'N?K>0>>\4(R? ^'CD%)-._%AL8YK'(.-'O+L/%[KOP'Y?[GW7Y-#6>>@W
M&6LE,=Y[PB:7&;]7,6:G4.J_N2=-O.*L,7/[YK"HH(-*!W*6]+C-GF/CP4MQ
MU6@(75ND*YD.=+2N*6E),+G@Z[_' "D]Q.+H;C^GCW[U]2H$@!T1G@U^^M0:
MF+1M3")R&MLB,S7$[B7YB?QARXV^."'+M24&WS@<$>>RRA2[Z4>^ONN!<9I]
M ]#T;EDL0+?WC+*JQ>L.(7+,*FL:Z4W?ZY!G[Q\=1ZVT"=@/A'74' ^KW40G
M49B$4I2QIBI1EH'M)R^YGO&-J!XV.KA]XY'P:J+.X=9/ZKO#:DI07/+;9Z0/
MIFP!NJ[R>LM)6^3?,'TC?'VN>+^I,Y#-"N?&T[/0]I92X&KIZ.$U/U.E1+49
M2*I+RMD4@RQ0GV9:D@>YO[N!>" PA2)GD^XZKJ/V;UFRDIHD;FA*R?[MB)Q7
MH3- 88(6%4>E#NPC'Q92XWB1B/Z-G-Q*_:9W=G1\#$=M;D,.A#1DT0ZS')A!
MT<*-R(SV$*I9QBV;OL1\P*KQ5H.GFD%W";PS3NY:%NW9PC.^U0^3\!5O*$0S
M(P>J=_T]9/;<#":/NA.Y7=Y4F9.V3YHIB4E>&86NR-^RHH8TWDS ?L0\2B@$
M\[*JR;<@F]+255U#A51K;L-)(->;1/DB[Q#/PPI'ZNY%[B"OB%)D2X(X,M4L
M^%D6>]/5X$'MU7<5'_;Z4#<4Y?'KG.AKHZI,NLJ#%^R3;,BWW%=%.6P%4HA:
MRBPE")CE@YA&FH$BC'R:+M $ 9;+Y<RX/%6KK$XC]Z;!J0(Z=[L U%XS'KWD
M92Q-22X'M.6B<FMX\-;QO87^_C4SM*HW?KV<#D=:1&\R=.AW2RFI<65C##MF
MW*B[--KA$7EZK7QSM8ILI-+=L],#6[_FV+N<TW7$C%7#HAKIBF:6;Q3"\?,?
MIFIA7A"J3)5T )FTN[G;9M315<^L\]<?O#Q]Z:4JATOB4[L4!Z"I]=ZA7*GX
MTFOM*ZHFUCQY*]EM\"4J8Q93J(: ]:6/FJLY2PI4S\3;(+((<[997!L\%F-
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M;ZVK'6= JQ=C<.R/,L[U@T1 *>&?30%8O/LW* "=!#[,P/%K11E!X!#='A(
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MB\J^SCG#IF$68'XJA%[_, :Z3UG7_P-02P,$%     @ 3*1F45)X'.+M @
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M 8_:.=!YI90];AS!^,M8_0%02P,$%     @ 3*1F48A;E_(_ P   @<  !D
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M5<//D)=AP7(2TC0<9<RS5)*J8)S9B6/%-1(Y0ZL:&^X(6@75L7)"5GNML9[
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;'U576_;.@S]*X1W,32
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M>:"ZV=9MC&S</-E*0]/)J27]#E!9!SHOI#2'C4UP_,$L?@-02P,$%     @
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M^=B#?N!R5U-)&MR2JWEE'9!C7S<NM.AM+[41FCHS.ZVH%49I#.C_5@@]+4R
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M26@G@/.54G9^< YV'V3'_P-02P,$%     @ 3*1F468E<Z#S!   =1   !D
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M;"]W;W)K<VAE971S+W-H965T,S@N>&ULO5E;;]LV&/TKA+$!'=#&$BG?@B1
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M';-M:%%4UP=+H;7(JL>$45C'9@"\7PG80.N&N9%H+L5&_P%02P,$%     @
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MOMG,"$X)UP/4^1UC\GE'O^1WWYF6_P-02P,$%     @ 3*1F45ABHPI9 @
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ML"4M$OF-;W]A=8>\TM^<)Z+Z"[:U+9R >2$D3VNP8I#&V>X_?:T#L0=0?LP
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M,D4OJ.^T&?@O=-K*7/Q=]Y1UL%%K&[.PA6UX#<:/[<RK?"4677NBT%*I;$D
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M<8^B>B:+00&\.Y&!(XU\XX+<DJ*^SW15'U_2=XZ*N@41 @SN=F(P(&ZR.!#
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MLFS::CX8RPCF>;GZGWT=.B+$  T&2#.0#=L-\&" =0/B,""# 0EM@0X&--2
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MN28_7D?9#[*;<W/%PZ>6TV?O1J?MOM^AMW?CS&Z?9_]]9(]*S0<SV[>#7KT
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M[]H#+\S\/$_]A"5^(C!EB5P)<)',R;P /W+C>PZ\IV*6!P[N W<.G813S)L
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MM74LD-9"LJ(5*X*"E,T;/;>).!*X_@D!; 7PLP*O%7@FT(;,A+5"$BUFG!T
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M*V#>;X0IK&9A';1#__P_4$L#!!0    ( $RD9E&8'7U]HP(  -('   9
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ML?A"GS_CLD->%B^D,<__!\^EK34"X8X+FI3.$D%"TN(O>BD347.0<?0.L'2
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MYYH.MJD?BWKB=!D:]$([:O=A6-#[BL8;T/>EUNXP\0&:%WO\&U!+ P04
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ME19I*6P0I#PKGNRE)*(A0(='!&@I0/\0(.,C GXIX.<;+9#EV[IBFLUG4NQ
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M87P X?/4\R9>T YD4@&9] 6RX1(CUR3S%?(>G$SZ<C*MH$P_X#*8/_OZR_0
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MH$:\+0_#'ACKV!8BB2Y)QTFQ'S^2DD6EMB0GC5H_V!+%<^?WZ?B,MES<RA6
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MN)J+7Q3?F:W>(P(NR;@C4WP4FSX)XYG*XEG%I#/H]\OJ[W@7]QK'>8T)C!Z
M"=1'<=IN$+\6^([-<36=/POX_2<FT[$WKJ'OQI _./X@.H;'-11?"?V5@*H7
M.W'<3/QFP4\<\Y)JYGU1\)-]ML4EC11Q=$N.HMLG@3]363RO_>&0#$L. '&T
M3&CCV*\Q02SV->9WX!_489\XJB<U;?<SL)^I/#J7CM5)#:LW!?W,[E''T+$^
MJ6']*NB_YQM152!'SJ3?,/(=\Y*7;YS)?N=,:)<.!F7I=<Q*FF^>:TQ\^U+%
MM Y8U#$V??ENFNYWTY7)I([4Z4]JIS.[Y7^O'SOL.)Y^1TMMP(7^0Y?Z-,2;
MN*I<A3%'P]TU=91+?V!W3?>YN*0#HXZ&Z7>,*G:Y9_=UN7=$2AN>6U#'IO0'
M3B[H_NAB[ZWB%0::,8BEG?-*-.>;1*6SS7PUGR6?V@FJY[:G@^A+)I9A(E$$
M"RWJM_NZBB*=[:8WBJ_M>/2&*\5C>[D"%H P&_3S!>=J=V,,Y!/V\?]02P,$
M%     @ 3*1F40G08)9% P  @ P  !D   !X;"]W;W)K<VAE971S+W-H965T
M-C0N>&ULO5?1;M,P%/T5*P)I2-#$:;NU4UNII (F,6E:&3P@'KSDMK5([& [
M*Y/X>*Z3+"EJZE4;L(<U3GS.N3[7.74G6ZF^ZPV (3^S5.BIMS$F/_=]'6\@
M8[HG<Q#X9"55Q@P.U=K7N0*6E* L]<,@./4SQH4WFY3WKM1L(@N3<@%7BN@B
MRYBZ?PNIW$X]ZCW<N.;KC;$W_-DD9VM8@KG)KQ2._(8EX1D(S:4@"E93;T[/
M%W1L >6,SQRV>N>:V*7<2OG=#BZ2J1?8BB"%V%@*AA]W$$&:6B:LXT=-ZC6:
M%KA[_<#^KEP\+N:6:8AD^H4G9C/U1AY)8,6*U%S+[0>H%S2T?+%,=?F?;*NY
M9T./Q(4V,JO!6$'&1?7)?M9&[ #HX  @K 'AL8!^#>@?"QC4@$'I3+64TH<%
M,VPV47)+E)V-;/:B-+-$X_*YL'U?&H5/.>+,+))9Q@TVTFC"1$(B*0P7:Q Q
M!TW>D'F2<-L@EI(+46TSVZZ3!1C&4_T*I]PL%^3DQ:N);[ >R^K'M?;;2CL\
MH#W/58\$_=<D#.BH QZYX4O(>Z0?6'@8=, 7;O@"8H334GW\)]Q'$QLGP\;)
ML.3K'^'D?,_)KQ]Q.KDPD.EO#K%^(]8OQ08'Q-Z# (4]89DLA"%R1=8%4TP8
M '+"L)4D!Q5C+5UMB=S<82\(7CIJ'#0U#IP\\[JVPFB#6PN]Z*JEXC@M.6Q(
MW<W"03 ,[-_$O^N0'S;R0Z?\@F487)IH6>"KW[4[AWO2E>X!X=-&^-0IO+2K
MO;TG'\$84-HV)U* KQ'Y1>97D</9LT;A[-]OM5$C-OH+;1SM>=EW6#ENM,=.
M[4^@,NO?BL4\Y>:^2]G-0,D],.6P@09M4@9/ZZN+?2>'Z;_O*6W#BH;/[^JB
M)MEMZRAT])6V^47=(?/TEX2V^4,'_\'2-F^H.W".V:R/4#R^6]L0HL](H33?
M,!(Q!>02;\7X1?)>R2)_C=_Q<<\EWR84_0\11=N,HNZ0.LI[-\7CWK>I1=VA
M\^!]VGH?5]XSC0=L2#K+&^]'Z*CK7?-W3GOV;'[)U)H+C6HK1 8]>YA5U7&W
M&AB9EP? 6VGP.%E>;O G B@[ 9^OI#0/ WNF;'YTS'X#4$L#!!0    ( $RD
M9E%<20'W4P@  &LR   9    >&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;+6;
M;6_;-A" _PIA;, &M+%$B9)=) $<R6T2Q$U6K]N'81\8B[:%2J)+R4DS[,>/
M>HEIF12E>-:7Q"]WQ^/=\3F2ML^?*?N6K@G)P(\X2M*+P3K+-A^&PW2Q)C%.
MS^B&)/R=)64QSOA3MAJF&T9P4"C%T1 :AC.,<9@,+L^+UQ[8Y3G=9E&8D <&
MTFT<8_9R12+Z?#$P!Z\O? E7ZRQ_87AYOL$K,B?9U\T#X\^&.RM!&),D#6D"
M&%E>#";FAUO7R14*B3]"\ISN/0;Y5!XI_98_N0DN!D;N$8G((LM-8/[OB7@D
MBG)+W(_OE='!;LQ<<?_QJ_6/Q>3Y9!YQ2CP:_1D&V?IB,!J @"SQ-LJ^T.=K
M4DT(Y?86-$J+O^"YE'7= 5ALTXS&E3+W( Z3\C_^405B3P&:#0JP4H!=%:Q*
MP>JJ8%<*=E<%5"F@ P73;E!P*@6GZPANI> >*%A&@\*H4AAU'6%<*8R[*IC&
M:^:,HH+*E!?UXN,,7YXS^@Q8+L_MY0^*HBOT>9F$2;X^YAGC[X9<+[O\0B*<
MD>#] V;9"_B=X23%1>6FX#V8!$&8/\81N$G*M9C7]"\^R7 8I;^"GT"8@-_7
M=)OB)$C/AQGW*+<[7%2C7Y6CPX;1+3"C2;9.P30)2*#0]_7Z8XW^D$=B%P[X
M&HXKJ#4X)YLS8!GO #2@\77N@U]^^E7AEM?9BCENMN*?Q)?I27SYJ+<RV3#A
MBT+]DU[=)PNN;K8Y<:VW\ID^G0$X*JR,*BMXQ0CAO,X4YF[TYFZWB61.8>6V
M@U.F4UA!2BNU0K1VZ](JS%KZ=0FD=0G^NN.BX"8C<?JW9B![-Y!=#&0W#'2_
M(8POZV0%(L+[#&!Y0WE/E^^W_ E.4Y(IUW5IU"F,YCWXZ=(<P_'H?/BT7^"=
MI#XII&QH"ZG:O-!N7D@[K[MB-E&('\.(0XPH9U&:0#7_QH9S,(LVJ9I_SLX_
M1^O?%[*@JR3\A^>8A>DWL*&<_HP\D61+5*XZDA/(=NVZIYXC1](8N^.#^<BF
MH&6,S+K45+9EN2/4D!5W-VM7.^O/LQGX%UQ1S (P(_$C8:FFAD<[JZ-^%\MX
M-]!8Z[['^R+?>.6K)27L*5R0%&QPJ.I<5V,IRL9!MF0)Z!ZD2A8QC0,S4X69
M/9G:/$U#; N,#HFZFTTT43/W-AEFOPDRH1@*MJRK8@F!):,Q7T_EN!L^;@,"
M*G/[X;/A88P]A90)G4,Q7V7,EA*F-#9NS)EH&::EG?KDP>,Y>YC=W.?_YV6!
MZH(J>H1I]YP_@6U3S^T'_)*W\Q1DM%/Z9#@C.7L*@DM2OD+*E7,G"T&S,76B
M&9CZ;E"FSI]]ZI8X@5O3[3EQ@L'FZ*2)&RD6@9PY6<H:R9F3I;@I*76R%!HU
MIDZT!%/?$[XF_(#/4GY&\C C[_A):7&F.XD(!$.CW]Q!P6=HZLLOIMLD W0)
MTNTC94&8%",G-.,;0K(@X1-^C/AV4+/9OJV&<.HKL2&\4/ <ZGE>#R^8++YO
MP[0XE1:!2?A[[\#=G:>+@R H['G7#052H7[??8*07T-YYXRDNK]12$'4F!@!
M:J@']>=MOGW+)X#%-4&WN:2<<OJ)*2C;X*] +&Q'['S-:VA-HX!7#?>AI&X[
M;Z'@+>R9MU#P%IZ4MU"FGROM)3V%E",U05\A!2UYGZ,4:VR64! 7ZHD["9YP
MLB# #_$JH6D6+L!\RU:$O0"/1X079??46@+'5L\XM@2.+3V.WYC:RIKVE. I
MA*1VZW>Q-&VQ5)^SX+REY[RT/'$2@/OEDJ?O=:WJ8KMWK](SXBV!>$N/^+>F
MT9:#+ZT]3R4E[X@44HZTXYVJI!K/(9;H#):^,\Q($"YX,WA@=$/R*+\V:IY&
M?J[4Q5;0W')Z3J-@NJ6_LWAK&EUYRRIG4192)+&#I6F+I?J<17.Q],WEGH=P
M-K]OW<U: MK6N.<+34%J6W]W<>R5IJ& G]35_%:QNM<"^K8>^ITN+&T5H!4^
MMHG5?120MO60KI5%ZVJV!93MOF^[]ZZ[3PIE6T:D(MP*)C?N<VS!45O/48_Q
M.LA!^ML6\Y)X 3.<X%6Q:08>91M=/ 1([9Y!:@N0VB<%J:W W\%5MJ>0D38L
MOLJ0Q-$6H?J4!4=M/4?Y(8DD+<=36S#4[IFA2# 4]<)0I("CO%[:I.H^"X*B
M$Q 4*="H\+!%JNZAX"?2\W-7#OG9Q+O65042\$0]PQ,)>**3PA,IN"AMA11"
MTNKTNUB:MEBJSWGO<T0]A2?7,VV>!&E1SZ1%@K1(3]JW?KB(5!B5[]$KL=IG
M@HJ+=)4U4[Z/55IK/'X@P5RD9^[KS=HV2S-^B,P9MDWXD5)[Y715&:UY4SL,
M57/K)/9)(68W;\"0Z #HI)?-CN"]T_/MAB,P[>@Q??^<GP77X0:$^64-2977
MR2U&[-'9V/A9YX^ LO.6&^;=WK:\03K!];,C2.[T3')'D-QI^=I'ER1\;#'2
MG@1!6:?EZQJS2>MYPMG[;D7/J'4$:AT]:CL%\JK%"$1GQF$@JV]T'*GH'ZLX
M/4*Q'CH!:J?E!KOZI/I_W,P[@IQ.SWMG5[#4;=D[=RJ)%B.VT502QRKZQRI.
MCU"LAT[T!E>/]?(3\/]1$*[ O@M[+@C!=5?_Q8R.!:$WHBF((Q7]8Q6G1RC6
M0R?ZE-O2IPYNG'QV!N9A#"9)4#R^P[%N'-%_7-1S-8CFY.H_B.Q8#7HCJ#FI
M;U<L)S+<^Q9Y3-BJ^-5""A;Y;KK\XNKNU=TO(R;%[P$.7K\R/WBFXG7?_# M
M?_<@S)<_PYAAM@J3%$1DR8<RSO)DL?*7#>63C&Z*[[ _TBRC<?%P33!G0R[
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M=,3C\4']L\^=<GED!E=*_.2EK1;!IP!*W+)6V >U_X)]/MY@H83Q7]CWV"B
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M.\4"K.Y4ZH&@E;Z*5U3(BUV_9K*YPTP!Y/<UI>(P4 ':=G'\"U!+ P04
M" !,I&914,83ARD$   D$0  &0   'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6S%6%MOHS@4_BL6JUEUI)F"P=RZ2:0VR6@K[4A5J]T^K/;!!2=A"YBU33/[
M[]<V!!+BTDQ7T;P$<,[YSO%W;IC)EK)GOB%$@&]%7O*IM1&BNK)MGFQ(@?DE
MK4@I_UE15F A']G:YA4C.-5*16Z[CA/8!<Y*:S;1:W=L-J&UR+.2W#' ZZ+
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M2U7.>'6UJ0:2E>9DG3.ISFGSN5:W0> :H/XO&9,O WU8-_?+T1]02P,$%
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M7 >H]REC<MO0 ]3_5YC\!5!+ P04    " !,I&918LHB:NH#  !^#P  &0
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M=!*QW^SM3Q1ONOW2BBN]^^H.2[U!)L(,T/<WG*OW$[,%&[;<RY]02P,$%
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M'93#!C=4KMC^(W0^H>9EC KSB_;MW,!S4-8(R<HNK"HH2=4>\6MW'XX#84_
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M4$L! A0#%     @ 3*1F40=!36*!    L0   !               ( !
M &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !,I&91X[U6(^X    K @
M$0              @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4
M" !,I&91F5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O
M=&AE;64Q+GAM;%!+ 0(4 Q0    ( $RD9E$[LK"'104  )D5   8
M      " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M" !,I&91U.0E=E,*   ++   &               @(&(#0  >&PO=V]R:W-H
M965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 3*1F4<LU;U)H!0  A10  !@
M             ("!$1@  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4
M Q0    ( $RD9E$..HNAM@<  -8B   8              " @:\=  !X;"]W
M;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !,I&91Y_[!W3D*  #=
M/   &               @(&;)0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL
M4$L! A0#%     @ 3*1F47#*M_M+"@  (RX  !@              ("!"C
M 'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $RD9E%C&[U*
MAA4  "0]   8              " @8LZ  !X;"]W;W)K<VAE971S+W-H965T
M-RYX;6Q02P$"% ,4    " !,I&91P:G#2G@I  #XA@  &
M@(%'4   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 3*1F
M4?V8_I#G!P  /A0  !@              ("!]7D  'AL+W=O<FMS:&5E=',O
M<VAE970Y+GAM;%!+ 0(4 Q0    ( $RD9E'^E;0D500  *$*   9
M      " @1*"  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%
M  @ 3*1F4<M5[DG/%   .D8  !D              ("!GH8  'AL+W=O<FMS
M:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !,I&91B*23+U<&  #"#@
M&0              @(&DFP  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+
M 0(4 Q0    ( $RD9E'V3P0/W0(  $\&   9              " @3*B  !X
M;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 3*1F41WQUG<N
M P   0<  !D              ("!1J4  'AL+W=O<FMS:&5E=',O<VAE970Q
M-"YX;6Q02P$"% ,4    " !,I&91VE)<(0,7   !2P  &0
M@(&KJ   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $RD
M9E$04"T)H H  %P?   9              " @>6_  !X;"]W;W)K<VAE971S
M+W-H965T,38N>&UL4$L! A0#%     @ 3*1F42V5_PC<"@  3!P  !D
M         ("!O,H  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M    " !,I&91BZM[G7X(  #R&P  &0              @('/U0  >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $RD9E%?/TFY4@8  ,4/
M   9              " @83>  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL
M4$L! A0#%     @ 3*1F48.7D+"5!   9 X  !D              ("!#>4
M 'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !,I&91/_?$
M\JL'   3$@  &0              @('9Z0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Q+GAM;%!+ 0(4 Q0    ( $RD9E&+XR$>)@8  ,,<   9
M  " @;OQ  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @
M3*1F46^"*0JT P  !@@  !D              ("!&/@  'AL+W=O<FMS:&5E
M=',O<VAE970R,RYX;6Q02P$"% ,4    " !,I&91><[&9:$V   UO0  &0
M            @($#_   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4
M Q0    ( $RD9E'M=LCW1P4  *,.   9              " @=LR 0!X;"]W
M;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 3*1F41C]2SOS P
M^0D  !D              ("!63@! 'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6Q02P$"% ,4    " !,I&91,R(?#AH$   ("@  &0              @(&#
M/ $ >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $RD9E'/
M3< V#@<  -82   9              " @=1  0!X;"]W;W)K<VAE971S+W-H
M965T,C@N>&UL4$L! A0#%     @ 3*1F45)X'.+M @  /@8  !D
M     ("!&4@! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( $RD9E%[=DOZB0,  &@+   9              "
M@<=: 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ 3*1F
M4;YD/#_\!0  G T  !D              ("!AUX! 'AL+W=O<FMS:&5E=',O
M<VAE970S-2YX;6Q02P$"% ,4    " !,I&919B5SH/,$  !U$   &0
M        @(&Z9 $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0
M   ( $RD9E$=__B?8 D  #HV   9              " @>1I 0!X;"]W;W)K
M<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 3*1F48CZ/@F@!@  HAX
M !D              ("!>W,! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q0
M2P$"% ,4    " !,I&91D"&+_I "  "T!P  &0              @(%2>@$
M>&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( $RD9E&Q:,O$
MFP,  ' -   9              " @1E] 0!X;"]W;W)K<VAE971S+W-H965T
M-# N>&UL4$L! A0#%     @ 3*1F447='QKJ P  +!0  !D
M ("!ZX ! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !,
MI&91SAMJ>,4#  "A$   &0              @($,A0$ >&PO=V]R:W-H965T
M<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( $RD9E$EGUJ,500  " 3   9
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M970T-RYX;6Q02P$"% ,4    " !,I&91>VNQ&I4"  "]!@  &0
M    @($TG0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (
M $RD9E',(@[M;P4  %T;   9              " @0"@ 0!X;"]W;W)K<VAE
M971S+W-H965T-#DN>&UL4$L! A0#%     @ 3*1F45& [7V%#P  ,VD  !D
M             ("!IJ4! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"
M% ,4    " !,I&91VHD%'$H+  "'/0  &0              @(%BM0$ >&PO
M=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( $RD9E&N.SX-[@,
M -L.   9              " @>/  0!X;"]W;W)K<VAE971S+W-H965T-3(N
M>&UL4$L! A0#%     @ 3*1F42P L5)A!0  "QP  !D              ("!
M",4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    " !,I&91
MEM=PO0P#   N"0  &0              @(&@R@$ >&PO=V]R:W-H965T<R]S
M:&5E=#4T+GAM;%!+ 0(4 Q0    ( $RD9E%7F+FWF@,    ,   9
M      " @>/- 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%
M  @ 3*1F49@=?7VC @  T@<  !D              ("!M-$! 'AL+W=O<FMS
M:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !,I&91^R,;)W\"  !&!@
M&0              @(&.U $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+
M 0(4 Q0    ( $RD9E%R\<N'O@L  -U.   9              " @437 0!X
M;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ 3*1F40 "UA3^
M!@  02(  !D              ("!.>,! 'AL+W=O<FMS:&5E=',O<VAE970U
M.2YX;6Q02P$"% ,4    " !,I&91H [ RG<$  "P$0  &0
M@(%NZ@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( $RD
M9E&4CR&&_ (  +T'   9              " @1SO 0!X;"]W;W)K<VAE971S
M+W-H965T-C$N>&UL4$L! A0#%     @ 3*1F439QOXX3!   [P\  !D
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M=#8V+GAM;%!+ 0(4 Q0    ( $RD9E%C$%[E*0(  "\%   9
M  " @1 + @!X;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @
M3*1F48#2DIAB @  Q@4  !D              ("!< T" 'AL+W=O<FMS:&5E
M=',O<VAE970V."YX;6Q02P$"% ,4    " !,I&91=C:D%1L#   Z"@  &0
M            @($)$ ( >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4
M Q0    ( $RD9E%0QA.'*00  "01   9              " @5L3 @!X;"]W
M;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @ 3*1F4<J,OJ/J"@
M/3@  !D              ("!NQ<" 'AL+W=O<FMS:&5E=',O<VAE970W,2YX
M;6Q02P$"% ,4    " !,I&91[.$HT:L#   9$0  &0              @('<
M(@( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( $RD9E$-
MOV_\% ,  &L*   9              " @;XF @!X;"]W;W)K<VAE971S+W-H
M965T-S,N>&UL4$L! A0#%     @ 3*1F46-4_6/K P  8Q   !D
M     ("!"2H" 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4
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M  !B#   #0              @ $<. ( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( $RD9E&7BKL<P    !,"   +              "  9HZ @!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( $RD9E&H82LCW 4  #XS   /              "
M 8,[ @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !,I&91>NU.;58"  ".
M+0  &@              @ &,00( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " !,I&915:BY9Q("  !S+   $P              @ $:
L1 ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     50!5 $H7  !=1@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>502</ContextCount>
  <ElementCount>565</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>139</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2111103 - Disclosure - Business Combinations and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</Role>
      <ShortName>Business Combinations and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNet</Role>
      <ShortName>Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2121105 - Disclosure - Investments in Other Entities ??? Equity Method</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</Role>
      <ShortName>Investments in Other Entities ??? Equity Method</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2129107 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132108 - Disclosure - Medical Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilities</Role>
      <ShortName>Medical Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2140110 - Disclosure - Mezzanine and Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquity</Role>
      <ShortName>Mezzanine and Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Related-Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactions</Role>
      <ShortName>Related-Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2155114 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Variable Interest Entities (VIEs)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</Role>
      <ShortName>Variable Interest Entities (VIEs)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2163116 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2169117 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2312302 - Disclosure - Business Combinations and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables</Role>
      <ShortName>Business Combinations and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/BusinessCombinationsandGoodwill</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetTables</Role>
      <ShortName>Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/IntangibleAssetsNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2322304 - Disclosure - Investments in Other Entities ??? Equity Method (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables</Role>
      <ShortName>Investments in Other Entities ??? Equity Method (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/AccountsPayableandAccruedExpenses</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2333306 - Disclosure - Medical Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesTables</Role>
      <ShortName>Medical Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MedicalLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityTables</Role>
      <ShortName>Mezzanine and Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/MezzanineandStockholdersEquity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Related-Party Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsTables</Role>
      <ShortName>Related-Party Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/RelatedPartyTransactions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2356310 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/EarningsPerShare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</Role>
      <ShortName>Variable Interest Entities (VIEs) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEs</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2364312 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/Leases</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Description of Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails</Role>
      <ShortName>Description of Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails</Role>
      <ShortName>Business Combinations and Goodwill - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails</Role>
      <ShortName>Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails</Role>
      <ShortName>Business Combinations and Goodwill - Summary of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets, Net - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails</Role>
      <ShortName>Intangible Assets, Net - Future Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2424414 - Disclosure - Investments in Other Entities ??? Equity Method - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2425415 - Disclosure - Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Summarized Balance Sheets and Statements of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2426416 - Disclosure - Investments in Other Entities ??? Equity Method - Gain on Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails</Role>
      <ShortName>Investments in Other Entities ??? Equity Method - Gain on Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2428417 - Disclosure - Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails</Role>
      <ShortName>Loan Receivable and Loan Receivable ??? Related Parties - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails</Role>
      <ShortName>Medical Liabilities - Schedule of Medical Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails</Role>
      <ShortName>Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Summary of Warrant (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails</Role>
      <ShortName>Mezzanine and Stockholders' Equity - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related-Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails</Role>
      <ShortName>Related-Party Transactions - Fees Incurred and Income Received (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2454431 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457432 - Disclosure - Earnings Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails</Role>
      <ShortName>Earnings Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails</Role>
      <ShortName>Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Variable Interest Entities (VIEs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails</Role>
      <ShortName>Variable Interest Entities (VIEs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2465436 - Disclosure - Leases - Additional information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesAdditionalinformationDetails</Role>
      <ShortName>Leases - Additional information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Leases - Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2468439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails</Role>
      <ShortName>Leases - Future Minimum Payments Under Non-cancelable Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2470440 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ameh-20200930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - ameh-20200930.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - ameh-20200930.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ameh-20200930.htm">ameh-20200930.htm</File>
    <File>ameh-20200930.xsd</File>
    <File>ameh-20200930_cal.xml</File>
    <File>ameh-20200930_def.xml</File>
    <File>ameh-20200930_lab.xml</File>
    <File>ameh-20200930_pre.xml</File>
    <File>ex3112020093010-qng.htm</File>
    <File>ex3122020093010-qng.htm</File>
    <File>ex3132020093010-qng.htm</File>
    <File>ex322020093010-qng.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ameh-20200930.htm": {
   "axisCustom": 1,
   "axisStandard": 33,
   "contextCount": 502,
   "dts": {
    "calculationLink": {
     "local": [
      "ameh-20200930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ameh-20200930_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "ameh-20200930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ameh-20200930_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ameh-20200930_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "ameh-20200930.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd"
     ]
    }
   },
   "elementCount": 790,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 2,
    "http://xbrl.sec.gov/dei/2020-01-31": 5,
    "total": 7
   },
   "keyCustom": 111,
   "keyStandard": 454,
   "memberCustom": 83,
   "memberStandard": 37,
   "nsprefix": "ameh",
   "nsuri": "http://www.apollomed.net/20200930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.apollomed.net/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Intangible Assets, Net",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNet",
     "shortName": "Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121105 - Disclosure - Investments in Other Entities \u2014 Equity Method",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod",
     "shortName": "Investments in Other Entities \u2014 Equity Method",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:EquityMethodAndOtherEquityInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ameh:LoanReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129107 - Disclosure - Accounts Payable and Accrued Expenses",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses",
     "shortName": "Accounts Payable and Accrued Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132108 - Disclosure - Medical Liabilities",
     "role": "http://www.apollomed.net/role/MedicalLiabilities",
     "shortName": "Medical Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Credit Facility, Bank Loan and Lines of Credit",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2140110 - Disclosure - Mezzanine and Stockholders' Equity",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquity",
     "shortName": "Mezzanine and Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Commitments and Contingencies",
     "role": "http://www.apollomed.net/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Related-Party Transactions",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactions",
     "shortName": "Related-Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Income Taxes",
     "role": "http://www.apollomed.net/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
     "shortName": "CONSOLIDATED BALANCE SHEETS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155114 - Disclosure - Earnings Per Share",
     "role": "http://www.apollomed.net/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Variable Interest Entities (VIEs)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEs",
     "shortName": "Variable Interest Entities (VIEs)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163116 - Disclosure - Leases",
     "role": "http://www.apollomed.net/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2169117 - Disclosure - Subsequent Events",
     "role": "http://www.apollomed.net/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312302 - Disclosure - Business Combinations and Goodwill (Tables)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables",
     "shortName": "Business Combinations and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Intangible Assets, Net (Tables)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetTables",
     "shortName": "Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322304 - Disclosure - Investments in Other Entities \u2014 Equity Method (Tables)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables",
     "shortName": "Investments in Other Entities \u2014 Equity Method (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330305 - Disclosure - Accounts Payable and Accrued Expenses (Tables)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables",
     "shortName": "Accounts Payable and Accrued Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
     "shortName": "CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333306 - Disclosure - Medical Liabilities (Tables)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesTables",
     "shortName": "Medical Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2341308 - Disclosure - Mezzanine and Stockholders' Equity (Tables)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables",
     "shortName": "Mezzanine and Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Related-Party Transactions (Tables)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsTables",
     "shortName": "Related-Party Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356310 - Disclosure - Earnings Per Share (Tables)",
     "role": "http://www.apollomed.net/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Variable Interest Entities (VIEs) (Tables)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables",
     "shortName": "Variable Interest Entities (VIEs) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2364312 - Disclosure - Leases (Tables)",
     "role": "http://www.apollomed.net/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i64eda4f6d5c741969ca5c89cb4723762_D20190701-20190930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Description of Business - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
     "shortName": "Description of Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i910be3ba7abf4fbb8a6af6dcabd337ac_D20190901-20190930",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:FinanceReceivableTermOfReceivable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Additional Information, Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Disaggregation of Revenue by Each Payor Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i268f6180d8c0414395a4e02831546f91_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i1864ede366d9428596f507b1ccdf3055_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Contributions to Revenue and Receivables by Payor (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i1864ede366d9428596f507b1ccdf3055_D20200701-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Carrying Amounts and Fair Values of Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Business Combinations and Goodwill - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
     "shortName": "Business Combinations and Goodwill - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i400a89eea72d482f927a72d7ad593718_I20190830",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
     "shortName": "Business Combinations and Goodwill - Identifiable Assets Acquired and Liabilities Assumed (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i275a644f4ba94748b1661c63ce54b8bb_I20190830",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i30b785ad17374d349aaafe08c2aa1d7a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
     "shortName": "Business Combinations and Goodwill - Summary of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
     "shortName": "Intangible Assets, Net - Schedule of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Intangible Assets, Net - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420412 - Disclosure - Intangible Assets, Net - Future Amortization Expense (Details)",
     "role": "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
     "shortName": "Intangible Assets, Net - Future Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i30b785ad17374d349aaafe08c2aa1d7a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:EquityMethodInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentSoldCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i97e0bcf361384859a17578fb87321a54_I20181231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF MEZZANINE AND STOCKHOLDERS' EQUITY (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i0a4af3abe23145c5a803f5c3e52a8544_I20181231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424414 - Disclosure - Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i68c969400a494d9787143ded770b0181_I20180531",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425415 - Disclosure - Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Summarized Balance Sheets and Statements of Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ib1f9f8ea17ec45a094548fee58869526_I20191231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleOfEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426416 - Disclosure - Investments in Other Entities \u2014 Equity Method - Gain on Sale (Details)",
     "role": "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
     "shortName": "Investments in Other Entities \u2014 Equity Method - Gain on Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ameh:EquityMethodInvestmentGainOnSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ice81d4521d784ed1a5eb888d13598ef9_D20200430-20200430",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ib1163ece356545148c6d18c1e1d66912_I20151116",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428417 - Disclosure - Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
     "shortName": "Loan Receivable and Loan Receivable \u2013 Related Parties - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i7fec8536262a49a0b8b6bcb905d9ed73_I20190628",
      "decimals": "4",
      "lang": "en-US",
      "name": "ameh:EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431418 - Disclosure - Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "role": "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
     "shortName": "Accounts Payable and Accrued Expenses - Schedule of Accounts Payable and Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i30b785ad17374d349aaafe08c2aa1d7a_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "role": "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
     "shortName": "Medical Liabilities - Schedule of Medical Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Credit Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLineOfCreditFacilitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:LinesOfCreditCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Schedule of Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCredit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439422 - Disclosure - Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
     "shortName": "Credit Facility, Bank Loan and Lines of Credit - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i5db5598a4574417390ce80ed9d5745a1_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:DebtInstrumentCovenantInterestCoverageRatioMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ameh:StockIssuedDuringPeriodSharesMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "role": "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i30b785ad17374d349aaafe08c2aa1d7a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Schedule of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Stock Option Activity Under Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i9073078500b94eb28dba8fc53bc713cc_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i30b785ad17374d349aaafe08c2aa1d7a_I20191231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Mezzanine and Stockholders' Equity - Summary of Warrant (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Summary of Warrant (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:NumberOfWarrantsGranted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Mezzanine and Stockholders' Equity - Warrants (Details)",
     "role": "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails",
     "shortName": "Mezzanine and Stockholders' Equity - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "iccaa606008644356ae9b3ada3f0dee0a_I20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "ameh:PercentageOfFinancialGuaranteeBenchmarkAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Related-Party Transactions - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related-Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i9f86dff82b2e4e37819e44daed0c3927_D20200701-20200930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "ameh:PaymentConsultingFees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452430 - Disclosure - Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "role": "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
     "shortName": "Related-Party Transactions - Fees Incurred and Income Received (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i7fd7a1cf508a492198a37de4a319e248_D20200701-20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "ameh:InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454431 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457432 - Disclosure - Earnings Per Share - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
     "shortName": "Earnings Per Share - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i77442d7b99474e87b7b1f8813acc05e2_D20200101-20200930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Earnings Per Share - Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Description of Business",
     "role": "http://www.apollomed.net/role/DescriptionofBusiness",
     "shortName": "Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "role": "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
     "shortName": "Earnings Per Share - Shares Included in Diluted Earnings Per Share Computations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "ameh:BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Variable Interest Entities (VIEs) (Details)",
     "role": "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails",
     "shortName": "Variable Interest Entities (VIEs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfVariableInterestEntitiesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i5a96f004265e44acbef5c40e0a7274cb_I20200930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2465436 - Disclosure - Leases - Additional information (Details)",
     "role": "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
     "shortName": "Leases - Additional information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "lang": "en-US",
      "name": "ameh:LesseeOperatingLeaseTerminationPeriodIfApplicable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Leases - Other Information Related to Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails",
     "shortName": "Leases - Other Information Related to Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "ia60c5c5301fe4759a31dde02ea356424_D20200701-20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2468439 - Disclosure - Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "role": "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
     "shortName": "Leases - Future Minimum Payments Under Non-cancelable Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "icf38a8ac3d85467baeb00dcd1a446031_D20200901-20200930",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Dividends",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470440 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i3f78455bd0fb4d5fb9b5d8528a3164b8_I20201031",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NotesReceivableGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111103 - Disclosure - Business Combinations and Goodwill",
     "role": "http://www.apollomed.net/role/BusinessCombinationsandGoodwill",
     "shortName": "Business Combinations and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i52b79e80b0334de886124ca554069b1e_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - ameh-20200930.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - ameh-20200930.htm",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ameh-20200930.htm",
      "contextRef": "i6f15713b91eb402cbc19264dd2327c3d_I20200930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 139,
   "tag": {
    "ameh_AHMCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AHMC [Member]",
        "terseLabel": "AHMC",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AHMCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APAMHMedicalCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AP-AMH Medical Corporation [Member]",
        "label": "AP-AMH Medical Corporation [Member]",
        "terseLabel": "AP-AMH Medical Corporation"
       }
      }
     },
     "localname": "APAMHMedicalCorporationMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_APCAndAPCLSMAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "APC And APC-LSMA [Member]",
        "label": "APC And APC-LSMA [Member]",
        "terseLabel": "APC and APC-LSMA"
       }
      }
     },
     "localname": "APCAndAPCLSMAMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountableHealthCareIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accountable Health Care IPA [Member]",
        "terseLabel": "Accountable Health Care, IPA",
        "verboseLabel": "Accountable Health Care"
       }
      }
     },
     "localname": "AccountableHealthCareIPAMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsAndOtherReceivablesNumberOfAdditionalAgreements": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounts And Other Receivables, Number Of Additional Agreements",
        "label": "Accounts And Other Receivables, Number Of Additional Agreements",
        "terseLabel": "Number of additional subordinated note receivable agreements"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNumberOfAdditionalAgreements",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_AccountsPayableAndAccruedExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Payable And Accrued Expenses [Member]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedExpensesMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Line Items]",
        "terseLabel": "Accounts Receivable And Net Revenue [Line Items]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueLineItems",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AccountsReceivableAndNetRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounts Receivable And Net Revenue [Table]",
        "terseLabel": "Accounts Receivable And Net Revenue [Table]"
       }
      }
     },
     "localname": "AccountsReceivableAndNetRevenueTable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AchievaMedInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AchievaMed, Inc. [Member]",
        "label": "AchievaMed, Inc. [Member]",
        "terseLabel": "AchievaMed, Inc."
       }
      }
     },
     "localname": "AchievaMedInc.Member",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "label": "Additional Proceeds To Be Received From Sale Of Equity Method Investments, If Circumstances Met",
        "netLabel": "Beneficial interest in UCI",
        "terseLabel": "Additional cash consideration entitled to be received",
        "verboseLabel": "Additional cash and non-cash consideration entitled to be received"
       }
      }
     },
     "localname": "AdditionalProceedsToBeReceivedFromSaleOfEquityMethodInvestmentsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AdvanceDiagnosticSurgeryCenterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Advance Diagnostic Surgery Center [Member]",
        "terseLabel": "Advance Diagnostic Surgery Center"
       }
      }
     },
     "localname": "AdvanceDiagnosticSurgeryCenterMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AdvancedForWorkingCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount advanced for working capital purposes.",
        "label": "Advanced For Working Capital",
        "terseLabel": "Advance for working capital"
       }
      }
     },
     "localname": "AdvancedForWorkingCapital",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_AggregateintrinsicvalueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "AggregateintrinsicvalueAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_AlliedPacificOfCaliforniaIPAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allied Pacific Of California IPA",
        "label": "Allied Pacific Of California IPA [Member]",
        "verboseLabel": "APC"
       }
      }
     },
     "localname": "AlliedPacificOfCaliforniaIPAMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlliedPacificofCaliforniaBrokerageAccountMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allied Pacific of California Brokerage Account [Member]",
        "label": "Allied Pacific of California Brokerage Account [Member]",
        "terseLabel": "Allied Pacific of California Brokerage Account"
       }
      }
     },
     "localname": "AlliedPacificofCaliforniaBrokerageAccountMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AlphaCareMedicalGroupInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alpha Care Medical Group, Inc. [Member]",
        "label": "Alpha Care Medical Group, Inc. [Member]",
        "terseLabel": "Alpha Care Medical Group, Inc."
       }
      }
     },
     "localname": "AlphaCareMedicalGroupInc.Member",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AmgIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "AMG, Inc [Member]",
        "terseLabel": "AMG, Inc"
       }
      }
     },
     "localname": "AmgIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AncillaryServiceContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ancillary Service Contract [Member]",
        "terseLabel": "Ancillary Service Contract"
       }
      }
     },
     "localname": "AncillaryServiceContractMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApaacoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APAACO [Member]",
        "terseLabel": "APAACO"
       }
      }
     },
     "localname": "ApaacoMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Business Loan Agreement [Member]",
        "terseLabel": "APC Business Loan Agreement"
       }
      }
     },
     "localname": "ApcBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcLsmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC LSMA [Member]",
        "terseLabel": "APC LSMA"
       }
      }
     },
     "localname": "ApcLsmaMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcShareholdersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Shareholders [Member]",
        "terseLabel": "APC Shareholders"
       }
      }
     },
     "localname": "ApcShareholdersMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApcStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "APC Stock Option [Member]",
        "terseLabel": "APC Stock Option"
       }
      }
     },
     "localname": "ApcStockOptionMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ApolloMedicalHoldingsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Apollo Medical Holdings, Inc [Member]",
        "terseLabel": "Apollo Medical Holdings, Inc"
       }
      }
     },
     "localname": "ApolloMedicalHoldingsIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_AurionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_Aurion Member",
        "label": "Aurion [Member]",
        "verboseLabel": "Aurion"
       }
      }
     },
     "localname": "AurionMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BrightHealthCompanyOfCaliforniaInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bright Health Company Of California, Inc.",
        "label": "Bright Health Company Of California, Inc. [Member]",
        "terseLabel": "Bright"
       }
      }
     },
     "localname": "BrightHealthCompanyOfCaliforniaInc.Member",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Medical Liabilities",
        "negatedTerseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Shares Held Back To Secure Indemnification, Percentage",
        "label": "Business Combination, Shares Held Back To Secure Indemnification, Percentage",
        "terseLabel": "Shares held back pursuant to indemnification clause (as a percent)"
       }
      }
     },
     "localname": "BusinessCombinationSharesHeldBackToSecureIndemnificationPercentage",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_CDSCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CDSC",
        "label": "CDSC [Member]",
        "terseLabel": "CDSC"
       }
      }
     },
     "localname": "CDSCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CMSMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "CMS [Member]",
        "label": "CMS [Member]",
        "terseLabel": "CMS"
       }
      }
     },
     "localname": "CMSMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CashPaidForLeaseLiabilitiesAbstractAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Paid For Lease Liabilities [Abstract]",
        "verboseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "localname": "CashPaidForLeaseLiabilitiesAbstractAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ClassOfWarrantOrRightCancelledInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of warrant or right, cancelled in period",
        "label": "Class Of Warrant Or Right Cancelled In Period",
        "negatedLabel": "Warrants expired/forfeited (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightCancelledInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightExercisable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Exercisable",
        "label": "Class Of Warrant Or Right Exercisable",
        "terseLabel": "Warrants Exercisable (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightIssuedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class of Warrant or Right, Issued in Period",
        "label": "Class Of Warrant Or Right Issued In Period",
        "verboseLabel": "Warrants Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Grant In Period Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual\u00a0Life"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsGrantInPeriodWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrant Or Rights outstanding Weighted Average Remaining Contractual Term",
        "label": "Class Of Warrant Or Rights Outstanding Weighted Average Remaining Contractual Term",
        "verboseLabel": "Warrants outstanding"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsOutstandingWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights exercised in period.",
        "label": "Class Of Warrants Or Right, Exercises In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants exercised"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightExercisesInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights forfeited in period.",
        "label": "Class Of Warrants Or Right, Forfeitures In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants expired/forfeited"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightForfeituresInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights granted in period.",
        "label": "Class Of Warrants Or Right, Grant In Period, Aggregate Intrinsic Value",
        "verboseLabel": "Warrants granted"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightGrantInPeriodAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of warrants or rights outstanding.",
        "label": "Class Of Warrants Or Right, Outstanding, Aggregate Intrinsic Value",
        "periodEndLabel": "Warrants outstanding, ending balance",
        "periodStartLabel": "Warrants outstanding, beginning balance"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightOutstandingAggregateIntrinsicValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants",
        "periodEndLabel": "Warrants outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Weighted Average Exercise\u00a0Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrants",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights exercised during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Exercised In Period",
        "verboseLabel": "Warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsExercisedInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights forfeited during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Forfeited In Period",
        "verboseLabel": "Warrants expired/forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsForfeitedInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share of warrants or rights granted during the period.",
        "label": "Class Of Warrants Or Right, Weighted Average Exercise Price Of Warrants, Grant In Period",
        "verboseLabel": "Warrants granted (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightWeightedAverageExercisePriceOfWarrantsGrantInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_CollegeStreetInvestmentLpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "College Street Investment LP [Member].",
        "label": "College Street Investment LP [Member]",
        "terseLabel": "College Street Investment LP"
       }
      }
     },
     "localname": "CollegeStreetInvestmentLpMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommercialMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:CommercialMember",
        "label": "Commercial [Member]",
        "terseLabel": "Commercial"
       }
      }
     },
     "localname": "CommercialMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ConcourseDiagnosticSurgeryCenterLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Concourse Diagnostic Surgery Center, LLC [Member]",
        "terseLabel": "Concourse Diagnostic Surgery Center, LLC"
       }
      }
     },
     "localname": "ConcourseDiagnosticSurgeryCenterLlcMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract Type [Axis]",
        "terseLabel": "Contract Type [Axis]"
       }
      }
     },
     "localname": "ContractTypeAxis",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Contract Type [Domain]",
        "terseLabel": "Contract Type [Domain]"
       }
      }
     },
     "localname": "ContractTypeDomain",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contract with Customer, Liability, Repaid, Capitation Received And Not Earned",
        "label": "Contract With Customer, Liability, Repaid Capitation Received And Not Earned",
        "terseLabel": "Contract liability repaid, capitation received and not earned"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRepaidCapitationReceivedAndNotEarned",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_CreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Agreement [Member]",
        "label": "Credit Agreement [Member]",
        "terseLabel": "Credit Agreement"
       }
      }
     },
     "localname": "CreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_CriticalQualityManagementCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_Critical Quality Management Corp Member",
        "label": "Critical Quality Management Corp [Member]",
        "terseLabel": "Critical Quality Management Corp"
       }
      }
     },
     "localname": "CriticalQualityManagementCorpMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage",
        "label": "Debt Instrument, Approval Threshold Of Shareholders For Use Of Funds, Percentage",
        "terseLabel": "Shareholder approval percentage (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentApprovalThresholdOfShareholdersForUseOfFundsPercentage",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_DebtInstrumentApprovedThresholdUseOfFunds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Approved Threshold Use Of Funds",
        "label": "Debt Instrument, Approved Threshold Use Of Funds",
        "terseLabel": "Approved use of funds (not to exceed)"
       }
      }
     },
     "localname": "DebtInstrumentApprovedThresholdUseOfFunds",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DebtInstrumentCovenantInterestCoverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Interest Coverage Ratio, Minimum",
        "terseLabel": "Minimum consolidated interest coverage ratio (not less than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantInterestCoverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioIncrementalChange": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Incremental Change",
        "terseLabel": "Consolidated leverage ratio, annual decrease"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioIncrementalChange",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMaximum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum",
        "terseLabel": "Maximum consolidated leverage ratio (not greater than)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMaximum",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentCovenantLeverageRatioMinimum": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Leverage Ratio, Minimum",
        "label": "Debt Instrument, Covenant, Leverage Ratio, Minimum",
        "terseLabel": "Consolidated leverage ratio minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantLeverageRatioMinimum",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ameh_DebtInstrumentNumberOfKeyFinancialRatios": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Number Of Key Financial Ratios",
        "label": "Debt Instrument, Number Of Key Financial Ratios",
        "terseLabel": "Number of key financial ratios"
       }
      }
     },
     "localname": "DebtInstrumentNumberOfKeyFinancialRatios",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_DeferredTaxLiabilitiesAdjustedToGoodwill": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Adjusted To Goodwill",
        "label": "Deferred Tax Liabilities, Adjusted To Goodwill",
        "terseLabel": "Deferred tax liability adjustment to goodwill"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAdjustedToGoodwill",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DeferredTaxLiabilitiesWarrantsExercised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Warrants Exercised",
        "label": "Deferred Tax Liabilities, Warrants Exercised",
        "terseLabel": "Deferred tax liability adjustment related to warrant exercises"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "label": "Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationExcludingAmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_DescriptionOfBusinessLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description Of Business [Line Items]",
        "terseLabel": "Description Of Business [Line Items]"
       }
      }
     },
     "localname": "DescriptionOfBusinessLineItems",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DescriptionOfBusinessTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Description Of Business [Table]",
        "terseLabel": "Description Of Business [Table]"
       }
      }
     },
     "localname": "DescriptionOfBusinessTable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_DiagnosticMedicalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Diagnostic Medical Group [Member]",
        "terseLabel": "Diagnostic Medical Group"
       }
      }
     },
     "localname": "DiagnosticMedicalGroupMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DmgMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "DMG [Member]",
        "terseLabel": "DMG"
       }
      }
     },
     "localname": "DmgMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.ArteagaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Arteaga [Member]",
        "label": "Dr. Arteaga [Member]",
        "verboseLabel": "Dr. Arteaga"
       }
      }
     },
     "localname": "Dr.ArteagaMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Dr.JayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Jay [Member]",
        "label": "Dr. Jay [Member]",
        "terseLabel": "Dr. Jay"
       }
      }
     },
     "localname": "Dr.JayMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DrJayLoanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dr. Jay Loan [Member]",
        "terseLabel": "Dr. Jay Loan"
       }
      }
     },
     "localname": "DrJayLoanMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_DrSimAndDrLamMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Dr. Sim And Dr. Lam",
        "label": "Dr. Sim And Dr. Lam [Member]",
        "terseLabel": "Dr. Sim And Dr. Lam"
       }
      }
     },
     "localname": "DrSimAndDrLamMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_EarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Earnings Per Share [Table]",
        "label": "Earnings Per Share [Line Items]",
        "terseLabel": "Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareLineItems",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EarningsPerShareTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share [Table]",
        "label": "Earnings Per Share [Table]",
        "terseLabel": "Earnings Per Share [Table]"
       }
      }
     },
     "localname": "EarningsPerShareTable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquityMethodAndOtherEquityInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method And Other Equity Investments [Text Block]",
        "label": "Equity Method And Other Equity Investments [Text Block]",
        "verboseLabel": "Investments in Other Entities \u2014 Equity Method"
       }
      }
     },
     "localname": "EquityMethodAndOtherEquityInvestmentsTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethod"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "label": "Equity Method Investment, Conversion Of Finance Receivable, Ownership Percentage Upon Conversion",
        "terseLabel": "Ownership upon conversion of finance receivable"
       }
      }
     },
     "localname": "EquityMethodInvestmentConversionOfFinanceReceivableOwnershipPercentageUponConversion",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentGainOnSaleTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Gain On Sale",
        "label": "Equity Method Investment, Gain On Sale [Table Text Block]",
        "terseLabel": "Equity Method Investment, Gain On Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentGainOnSaleTableTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_EquityMethodInvestmentOwnershipPercentageDisposed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Disposed",
        "label": "Equity Method Investment, Ownership Percentage Disposed",
        "terseLabel": "Ownership interest disposed"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageDisposed",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Cash",
        "terseLabel": "Contingent consideration, cash held in escrow"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationCash",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Fair Value",
        "terseLabel": "Contingent consideration, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationFairValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentSaleContingentConsiderationPreferredShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "label": "Equity Method Investment, Sale, Contingent Consideration, Preferred Shares",
        "terseLabel": "Contingent consideration, preferred shares"
       }
      }
     },
     "localname": "EquityMethodInvestmentSaleContingentConsiderationPreferredShares",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Contribution",
        "label": "Equity Method Investments, Contribution",
        "terseLabel": "Contribution"
       }
      }
     },
     "localname": "EquityMethodInvestmentsContribution",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The proportion of investment in Voting common stock.",
        "label": "Equity Method Investments, Proportion of Ownership Interest in Voting Common Stock",
        "terseLabel": "Percentage of voting common stock"
       }
      }
     },
     "localname": "EquityMethodInvestmentsProportionOfOwnershipInterestInVotingCommonStock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquityMethodInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares purchased from equity method investment entities.",
        "label": "Equity Method Investments, Purchase Of Shares",
        "terseLabel": "Shares purchased (in shares)"
       }
      }
     },
     "localname": "EquityMethodInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquityMethodInvestmentsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments [Roll Forward]",
        "label": "Equity Method Investments [Roll Forward]",
        "terseLabel": "Equity Method Investments [Roll Forward]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsRollForward",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Term Of Option",
        "label": "Equity Securities Without Readily Determinable Fair Value Investment, Options Issued, Term Of Option",
        "terseLabel": "Term of option"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentOptionsIssuedTermOfOption",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Related investment balance"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Aggregate Cost",
        "terseLabel": "Investment amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsAggregateCost",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Duration Of Investment",
        "terseLabel": "Duration of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsDurationOfInvestment",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Membership Interest Acquired, Per Interest",
        "terseLabel": "Membership interests acquired (in dollars per share)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsMembershipInterestAcquiredPerInterest",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issued, Option To Purchase Additional Interests",
        "terseLabel": "Options to purchase additional membership interests (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuedOptionToPurchaseAdditionalInterests",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Options Issues, Options To Purchase Additional Interests, If Circumstances Met",
        "terseLabel": "Number of warrants available to purchase, contingent upon the portal completion date (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsOptionsIssuesOptionsToPurchaseAdditionalInterestsIfCircumstancesMet",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Proportion of Ownership Interest in Voting Common Stock, Within Five Years",
        "terseLabel": "Percentage of voting common stock, within five years"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsProportionofOwnershipInterestinVotingCommonStockWithinFiveYears",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "label": "Equity Securities Without Readily Determinable Fair Value Investments, Purchase Of Shares",
        "terseLabel": "Membership interests purchased (in shares)"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueInvestmentsPurchaseOfShares",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities without Readily Determinable Fair Value, Ownership Percentage",
        "label": "Equity Securities Without Readily Determinable Fair Value, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueOwnershipPercentage",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiduciaryAccountsPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of fiduciary accounts payable, due after one year or beyond the normal operating cycle, if longer.",
        "label": "Fiduciary Accounts Payable Current",
        "terseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "FiduciaryAccountsPayableCurrent",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Lease, Liability, To Be Paid, After Year Four",
        "label": "Finance Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FinanceReceivableInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Interest Rate, Stated Percentage",
        "label": "Finance Receivable, Interest Rate, Stated Percentage",
        "terseLabel": "Note receivable, interest rate"
       }
      }
     },
     "localname": "FinanceReceivableInterestRateStatedPercentage",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableModificationsSubsequentDefaultInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "label": "Finance Receivable, Modifications, Subsequent Default, Interest Rate",
        "terseLabel": "Interest rate in the event of default"
       }
      }
     },
     "localname": "FinanceReceivableModificationsSubsequentDefaultInterestRate",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableStatedInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Stated Interest Rate",
        "label": "Finance Receivable, Stated Interest Rate",
        "terseLabel": "Stated rate of note of loan receivable"
       }
      }
     },
     "localname": "FinanceReceivableStatedInterestRate",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FinanceReceivableTermOfReceivable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finance Receivable, Term Of Receivable",
        "label": "Finance Receivable, Term Of Receivable",
        "terseLabel": "Term of receivable",
        "verboseLabel": "Note receivable, maturity period"
       }
      }
     },
     "localname": "FinanceReceivableTermOfReceivable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible",
        "label": "Financing Receivable, Convertible To Common Stock, Percentage Of Outstanding Shares Convertible",
        "terseLabel": "Percentage of outstanding stock convertible"
       }
      }
     },
     "localname": "FinancingReceivableConvertibleToCommonStockPercentageOfOutstandingSharesConvertible",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_FiveThreeOneW.CollegeLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Five Three One W. College LLC [Member]",
        "terseLabel": "531 W. College LLC",
        "verboseLabel": "531 W. College, LLC \u2013 related party"
       }
      }
     },
     "localname": "FiveThreeOneW.CollegeLLCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_GainLossOnAssumptionOfLoan": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Assumption Of Loan",
        "label": "Gain (Loss) On Assumption Of Loan",
        "negatedTerseLabel": "Gain on loan assumption"
       }
      }
     },
     "localname": "GainLossOnAssumptionOfLoan",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_HSMSOMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "xxx_HSMSO Member",
        "label": "HSMSO [Member]",
        "verboseLabel": "HSMSO"
       }
      }
     },
     "localname": "HSMSOMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthCareCapitationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh_HealthCareCapitationRevenueMember",
        "label": "Health Care Capitation Revenue [Member]",
        "verboseLabel": "Capitation, net"
       }
      }
     },
     "localname": "HealthCareCapitationRevenueMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_HealthSourceMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Health Source MSO Inc. [Member]",
        "label": "Health Source MSO Inc. [Member]",
        "terseLabel": "Health Source MSO Inc."
       }
      }
     },
     "localname": "HealthSourceMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_IncreaseDecreaseInMedicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of medical liabilities.",
        "label": "Increase (Decrease) In Medical Liabilities",
        "verboseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalLiabilities",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOperatingLeaseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents increase in operating lease assets.",
        "label": "Increase (Decrease) In Operating Lease Assets",
        "verboseLabel": "Right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseAssets",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInOtherOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents increase in lease liabilities.",
        "label": "Increase (Decrease) In Other Operating Lease Liabilities",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLeaseLiabilities",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the value of prepaid expenses and other current assets.",
        "label": "Increase (Decrease) In Prepaid Expenses And Other Current Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesAndOtherCurrentAssets",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The initial fixed term of amended and restated management and administrative services agreement.",
        "label": "Initial Fixed Term Of Amended And Restated Management And Administrative Services Agreement",
        "terseLabel": "Fixed term of amended and restated management and administrative services agreement"
       }
      }
     },
     "localname": "InitialFixedTermOfAmendedAndRestatedManagementAndAdministrativeServicesAgreement",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_InsuranceServicesRevenueCapitationAndClaimsPaymentNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "label": "Insurance Services Revenue, Capitation, And Claims Payment, Net",
        "terseLabel": "AHMC \u2013 Risk pool, capitation, claims payment, net"
       }
      }
     },
     "localname": "InsuranceServicesRevenueCapitationAndClaimsPaymentNet",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentDeposit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment Deposit",
        "label": "Investment Deposit",
        "terseLabel": "Investment deposit"
       }
      }
     },
     "localname": "InvestmentDeposit",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of Investment in privately held entity that does not report net asset value per share .",
        "label": "Investment In Privately Held Entity That Does Not Report Net Asset Value",
        "terseLabel": "Preferred shares in Bright Health, Inc.",
        "verboseLabel": "Investments in privately held entities"
       }
      }
     },
     "localname": "InvestmentInPrivatelyHeldEntityThatDoesNotReportNetAssetValue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LasalleMedicalAssociatesIpaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LaSalle Medical Associates IPA [Member]",
        "terseLabel": "LaSalle Medical Associates \u2013 IPA Line of Business",
        "verboseLabel": "LaSalle Medical Associates"
       }
      }
     },
     "localname": "LasalleMedicalAssociatesIpaMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Right Of Use Assets Obtained In Exchange For Lease Obligations [Abstract]",
        "verboseLabel": "Right-of-use assets obtained in exchange for lease liabilities:"
       }
      }
     },
     "localname": "LeaseRightOfUseAssetsObtainedInExchangeForLeaseObligationsAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Weighted Average Discount Rate [Abstract]",
        "verboseLabel": "Weighted Average Discount Rate"
       }
      }
     },
     "localname": "LeaseWeightedAverageDiscountRateAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LeaseWeightedAverageRemainingLeaseTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lease Weighted Average Remaining Lease Term [Abstract]",
        "verboseLabel": "Weighted Average Remaining Lease Term"
       }
      }
     },
     "localname": "LeaseWeightedAverageRemainingLeaseTermAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_LesseeFinanceLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Finance Lease, Termination Period, If Applicable",
        "label": "Lessee, Finance Lease, Termination Period, If Applicable",
        "terseLabel": "Finance lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeFinanceLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LesseeOperatingLeaseTerminationPeriodIfApplicable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Termination Period, If Applicable",
        "label": "Lessee, Operating Lease, Termination Period, If Applicable",
        "terseLabel": "Operating lease, termination period, if applicable"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTerminationPeriodIfApplicable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LineOfCreditFacilityAdditionalAdvances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of line of credit facility additional amount advances as a loan.",
        "label": "Line of Credit Facility Additional Advances",
        "terseLabel": "Additional advances"
       }
      }
     },
     "localname": "LineOfCreditFacilityAdditionalAdvances",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LineOfCreditFacilityExpirationPeriodPeriodOfNotification": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Expiration Period, Period Of Notification",
        "label": "Line Of Credit Facility, Expiration Period, Period Of Notification",
        "terseLabel": "Period of notification of termination"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriodPeriodOfNotification",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LineOfCreditFacilityGuaranteeGivenByRelatedParties": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of guarantee given by related parties for line of credit facility.",
        "label": "Line Of Credit Facility, Guarantee Given By Related Parties",
        "terseLabel": "Term of converted loan"
       }
      }
     },
     "localname": "LineOfCreditFacilityGuaranteeGivenByRelatedParties",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_LineOfCreditFacilityTerminatedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line Of Credit Facility, Terminated, Amount",
        "label": "Line Of Credit Facility, Terminated, Amount",
        "terseLabel": "Line of credit, amount terminated"
       }
      }
     },
     "localname": "LineOfCreditFacilityTerminatedAmount",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_LmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "LMA [Member]",
        "terseLabel": "LMA"
       }
      }
     },
     "localname": "LmaMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_LoanReceivableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loan Receivable",
        "label": "Loan Receivable [Text Block]",
        "verboseLabel": "Loan Receivable and Loan Receivable \u2013 Related Parties"
       }
      }
     },
     "localname": "LoanReceivableTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_MWNCommunityHospitalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MWN Community Hospital LLC [Member]",
        "terseLabel": "MWN, LLC \u2013 related party"
       }
      }
     },
     "localname": "MWNCommunityHospitalLLCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ManagementContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Management Contracts",
        "label": "Management Contracts [Member]",
        "verboseLabel": "Management contracts"
       }
      }
     },
     "localname": "ManagementContractsMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MarketableSecuritiesCurrentMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Marketable Securities, Current, Maturity Period",
        "label": "Marketable Securities, Current, Maturity Period",
        "terseLabel": "Short-term marketable securities, maturity period"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrentMaturityPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_MaverickMedicalGroupIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maverick Medical Group, Inc [Member]",
        "terseLabel": "Maverick Medical Group, Inc"
       }
      }
     },
     "localname": "MaverickMedicalGroupIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MediPortalLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MediPortal LLC [Member]",
        "terseLabel": "MediPortal LLC"
       }
      }
     },
     "localname": "MediPortalLLCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:MedicaidMember",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medical Care Costs [Abstract]",
        "label": "Medical Care Costs [Abstract]",
        "terseLabel": "Components of medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "MedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MedicalPropertyPartnersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Medical Property Partners [Member]",
        "terseLabel": "Medical Property Partners"
       }
      }
     },
     "localname": "MedicalPropertyPartnersMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:MedicareMember",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MemberRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Member Relationships",
        "label": "Member Relationships [Member]",
        "terseLabel": "Member relationships"
       }
      }
     },
     "localname": "MemberRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MezzanineEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "MEZZANINE EQUITY [Abstract]",
        "verboseLabel": "Mezzanine equity"
       }
      }
     },
     "localname": "MezzanineEquityAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_MezzanineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Mezzanine [Member]",
        "terseLabel": "Mezzanine"
       }
      }
     },
     "localname": "MezzanineMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_MinorityInterestPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minority Interest Policy.",
        "label": "Minority Interest Policy [Policy Text Block]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "MinorityInterestPolicyPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_NMMLineOfCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NMM Line Of Credit Agreement [Member]",
        "label": "NMM Line Of Credit Agreement [Member]",
        "terseLabel": "NMM Line of Credit Agreement"
       }
      }
     },
     "localname": "NMMLineOfCreditAgreementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "label": "Net Income (Loss), Including Portion Attributable To Noncontrolling Interest And Temporary Equity",
        "terseLabel": "Net (loss) income"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributableToNoncontrollingInterestAndTemporaryEquity",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_NetworkMedicalManagementIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Network Medical Management, Inc. [Member]",
        "terseLabel": "Network Medical Management, Inc."
       }
      }
     },
     "localname": "NetworkMedicalManagementIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkMedicalManagementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Network Medical Management [Member]",
        "terseLabel": "NMM"
       }
      }
     },
     "localname": "NetworkMedicalManagementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NetworkRelationshipsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Network Relationships",
        "label": "Network Relationships [Member]",
        "terseLabel": "Network relationships"
       }
      }
     },
     "localname": "NetworkRelationshipsMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NextGenerationACOModelParticipationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Next Generation ACO Model Participation Agreement [Member]",
        "label": "Next Generation ACO Model Participation Agreement [Member]",
        "terseLabel": "Next Generation ACO Model Participation Agreement"
       }
      }
     },
     "localname": "NextGenerationACOModelParticipationAgreementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NmmBusinessLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "NMM Business Loan Agreement [Member]",
        "terseLabel": "NMM Business Loan Agreement"
       }
      }
     },
     "localname": "NmmBusinessLoanAgreementMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_NumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Employees",
        "label": "Number Of Employees",
        "terseLabel": "Number of employees (more than)",
        "verboseLabel": "Number of employees (over)"
       }
      }
     },
     "localname": "NumberOfEmployees",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFamilyPracticeClinics": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Family Practice Clinics",
        "label": "Number Of Family Practice Clinics",
        "terseLabel": "Number of family practice clinics"
       }
      }
     },
     "localname": "NumberOfFamilyPracticeClinics",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfFederallyQualifiedHealthPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Federally Qualified Health Plans",
        "label": "Number Of Federally Qualified Health Plans",
        "terseLabel": "Number federally qualified health plans"
       }
      }
     },
     "localname": "NumberOfFederallyQualifiedHealthPlans",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfPatients": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Patients",
        "label": "Number Of Patients",
        "terseLabel": "Number of patients"
       }
      }
     },
     "localname": "NumberOfPatients",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ameh_NumberOfWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants exercised",
        "label": "Number Of Warrants Exercised",
        "negatedLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumberOfWarrantsGranted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Warrants Granted",
        "label": "Number Of Warrants Granted",
        "verboseLabel": "Warrants granted (in shares)"
       }
      }
     },
     "localname": "NumberOfWarrantsGranted",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_NumenLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Numen LLC [Member]",
        "terseLabel": "Numen LLC"
       }
      }
     },
     "localname": "NumenLLCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OneMSOInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "One MSO, Inc. [Member]",
        "label": "One MSO, Inc. [Member]",
        "terseLabel": "One MSO, Inc."
       }
      }
     },
     "localname": "OneMSOInc.Member",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_OtherThirdPartiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh:OtherThirdPartiesMember",
        "label": "Other Third Parties [Member]",
        "terseLabel": "Other third parties"
       }
      }
     },
     "localname": "OtherThirdPartiesMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_Pacific6EnterprisesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pacific6 Enterprises [Member]",
        "label": "Pacific6 Enterprises [Member]",
        "terseLabel": "Pacific6 Enterprises"
       }
      }
     },
     "localname": "Pacific6EnterprisesMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PacificMedicalImagingAndOncologyCenterIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Pacific Medical Imaging and Oncology Center, Inc [Member]",
        "terseLabel": "Pacific Medical Imaging &amp; Oncology Center, Inc."
       }
      }
     },
     "localname": "PacificMedicalImagingAndOncologyCenterIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PatientManagementPlatformMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patient Management Platform",
        "label": "Patient Management Platform [Member]",
        "terseLabel": "Patient management platform"
       }
      }
     },
     "localname": "PatientManagementPlatformMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentConsultingFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Consulting Fees",
        "label": "Payment Consulting Fees",
        "terseLabel": "Consulting services paid"
       }
      }
     },
     "localname": "PaymentConsultingFees",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentMadeToRelatedParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit/Duration (Amount paid to related party in relation to providing services",
        "label": "Payment Made To Related Party",
        "terseLabel": "Payments to related parties"
       }
      }
     },
     "localname": "PaymentMadeToRelatedParty",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Revenue",
        "label": "Payment Of Revenue",
        "terseLabel": "Payments received"
       }
      }
     },
     "localname": "PaymentOfRevenue",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentOfRevenueMonthlyAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Of Revenue, Monthly Amount",
        "label": "Payment Of Revenue, Monthly Amount",
        "terseLabel": "Payments received, monthly"
       }
      }
     },
     "localname": "PaymentOfRevenueMonthlyAmount",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PaymentPeriodOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period One [Member]",
        "label": "Payment Period One [Member]",
        "terseLabel": "First Eight Fiscal Quarters"
       }
      }
     },
     "localname": "PaymentPeriodOneMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentPeriodThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period Three [Member]",
        "label": "Payment Period Three [Member]",
        "terseLabel": "Following Three Fiscal Quarters Thereafter"
       }
      }
     },
     "localname": "PaymentPeriodThreeMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentPeriodTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment Period Two [Member]",
        "label": "Payment Period Two [Member]",
        "terseLabel": "Following Eight Fiscal Quarters Thereafter"
       }
      }
     },
     "localname": "PaymentPeriodTwoMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PaymentsForMedicalCareCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments For Medical Care Costs [Abstract]",
        "label": "Payments For Medical Care Costs [Abstract]",
        "terseLabel": "Payments for medical care costs related to claims incurred:"
       }
      }
     },
     "localname": "PaymentsForMedicalCareCostsAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "label": "Payments To Acquire Equity Securities Without Readily Determinable Fair Value Investments",
        "terseLabel": "Payments to purchase membership interests"
       }
      }
     },
     "localname": "PaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValueInvestments",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_PayorAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor A [Member]",
        "label": "Payor A [Member]",
        "terseLabel": "Payor A"
       }
      }
     },
     "localname": "PayorAMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorBMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor B [Member]",
        "label": "Payor B [Member]",
        "terseLabel": "Payor B"
       }
      }
     },
     "localname": "PayorBMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor C [Member]",
        "label": "Payor C [Member]",
        "terseLabel": "Payor C"
       }
      }
     },
     "localname": "PayorCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payor D [Member]",
        "terseLabel": "Payor D"
       }
      }
     },
     "localname": "PayorDMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorEMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payor E [Member]",
        "terseLabel": "Payor E"
       }
      }
     },
     "localname": "PayorEMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorFMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor F [Member]",
        "label": "Payor F [Member]",
        "terseLabel": "Payor F"
       }
      }
     },
     "localname": "PayorFMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PayorGMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payor G [Member]",
        "label": "Payor G [Member]",
        "terseLabel": "Payor G"
       }
      }
     },
     "localname": "PayorGMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PerMemberPerMonthManagedCareContractMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per-Member-Per-Month Managed Care Contract [Member]",
        "label": "Per-Member-Per-Month Managed Care Contract [Member]",
        "terseLabel": "PMPM Managed Care Contract"
       }
      }
     },
     "localname": "PerMemberPerMonthManagedCareContractMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PercentageOfFinancialGuaranteeBenchmarkAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of financial guarantee on benchmark Medicare expenditure amount.",
        "label": "Percentage Of Financial Guarantee Benchmark Amount",
        "terseLabel": "General amount of guarantee (as a percent)"
       }
      }
     },
     "localname": "PercentageOfFinancialGuaranteeBenchmarkAmount",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_PmiocMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "PMIOC [Member]",
        "terseLabel": "PMIOC"
       }
      }
     },
     "localname": "PmiocMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_PreferredBankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Bank [Member]",
        "terseLabel": "Preferred Bank"
       }
      }
     },
     "localname": "PreferredBankMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Receivables and receivables from related parties.",
        "label": "Receivables And Related parties Receivables Policy Text Block [Policy Text Block]",
        "verboseLabel": "Receivables and Receivables \u2013 Related Parties"
       }
      }
     },
     "localname": "ReceivablesAndRelatedPartiesReceivablesPolicyTextBlockPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ameh_ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
        "label": "Reconciliation Of Cash Cash Equivalents And Restricted Cash [Abstract]",
        "verboseLabel": "Reconciliation of cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "ReconciliationOfCashCashEquivalentsAndRestrictedCashAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_RepaymentsOfBankLoanAndLinesOfCredit": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Repayments Of Bank Loan And Lines Of Credit",
        "label": "Repayments Of Bank Loan And Lines Of Credit",
        "negatedTerseLabel": "Repayment of bank loan and lines of credit"
       }
      }
     },
     "localname": "RepaymentsOfBankLoanAndLinesOfCredit",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing Of Satisfaction, Period Of Payment Upon Finalization Of Settlement Report",
        "terseLabel": "Expected period of payment upon termination of agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriodOfPaymentUponFinalizationOfSettlementReport",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_RiskPoolSettlement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk Pool Settlement",
        "label": "Risk Pool Settlement",
        "terseLabel": "Risk pool settlement"
       }
      }
     },
     "localname": "RiskPoolSettlement",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "label": "Risk Pool Surplus Or Deficits, Settlement Period After Performance Year",
        "terseLabel": "Risk pool surplus or deficits, settlement period after risk pool performance year"
       }
      }
     },
     "localname": "RiskPoolSurplusOrDeficitsSettlementPeriodAfterPerformanceYear",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ameh_SCHCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "SCHC [Member]",
        "label": "SCHC [Member]",
        "terseLabel": "SCHC"
       }
      }
     },
     "localname": "SCHCMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Cashless Options Exercises In Period",
        "terseLabel": "Options exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardCashlessOptionsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the forfeiture rate.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate",
        "verboseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Aggregate Intrinsic Value [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Exercise Price [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageExercisePriceAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Warrants, Cashless Exercise Provision, Exercises In Period",
        "label": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Warrants, Cashless Exercise Provision, Exercises In Period",
        "terseLabel": "Warrants exercised, cashless exercise provision (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsCashlessExerciseProvisionExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "label": "Share based Compensation Arrangement By Share based Payment Award Warrants Exercises In Period",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExercisesInPeriod",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "label": "Share-Based Compensation Arrangement By Share based Payment Award, Warrant Exercised, Exercise Price",
        "terseLabel": "Exercise price of warrants exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementBySharebasedPaymentAwardWarrantExercisedExercisePrice",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "ameh_ShareholdersAndOfficersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Shareholders And Officers [Member]",
        "terseLabel": "APC Shareholders and Officers"
       }
      }
     },
     "localname": "ShareholdersAndOfficersMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_SharesWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares, Warrants [Roll Forward]",
        "label": "Shares, Warrants [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "SharesWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SpecialtyCapitationPayableCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the amount of specialty capitation payable current.",
        "label": "Specialty Capitation Payable Current",
        "verboseLabel": "Capitation payable"
       }
      }
     },
     "localname": "SpecialtyCapitationPayableCurrent",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodProxyVotesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Proxy Votes, Percentage",
        "label": "Stock Issued During Period, Proxy Votes, Percentage",
        "terseLabel": "Proxy votes"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodProxyVotesPercentage",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesCashlessWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Shares, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for exercise of cashless warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodSharesMerger": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued during the period pursuant to merger.",
        "label": "Stock Issued During Period, Shares, Merger",
        "terseLabel": "Holdback shares not issued to former shareholders (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesMerger",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringPeriodValueCashlessWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "label": "Stock Issued During Period, Value, Cashless Warrants Exercised",
        "terseLabel": "Shares issued for cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCashlessWarrantsExercised",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringPeriodValueRestrictedStockAwardCancelled": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Restricted Stock Award, Cancelled",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Cancelled",
        "negatedTerseLabel": "Cancellation of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardCancelled",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents number of share issued exercise of option and warrants during the period",
        "label": "Stock issued during the period shares of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodSharesOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "ameh_StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "It represents value of stock issued during the period",
        "label": "Stock issued during the period value of exercise of option and warrants",
        "verboseLabel": "Shares issued for exercise of options and warrants"
       }
      }
     },
     "localname": "StockIssuedDuringThePeriodValueOfExerciseOfOptionAndWarrants",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SubcontractorIPAPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Subcontractor IPA Payable",
        "label": "Subcontractor IPA Payable",
        "verboseLabel": "Subcontractor IPA payable"
       }
      }
     },
     "localname": "SubcontractorIPAPayable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_TemporaryEquityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Temporary Equity [Policy Text Block]",
        "label": "Temporary Equity [Policy Text Block]",
        "terseLabel": "Mezzanine Equity"
       }
      }
     },
     "localname": "TemporaryEquityPolicyTextBlock",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ameh_TermLoanAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term Loan A [Member]",
        "label": "Term Loan A [Member]",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanAMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareAcquisitionPartnersLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Universal Care Acquisition Partners, LLC [Member]",
        "terseLabel": "Universal Care Acquisition Partners, LLC"
       }
      }
     },
     "localname": "UniversalCareAcquisitionPartnersLlcMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_UniversalCareIncMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Universal Care Inc [Member]",
        "terseLabel": "Universal Care, Inc."
       }
      }
     },
     "localname": "UniversalCareIncMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_VotingCommonStockTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Voting Common Stock A Two [Member]",
        "terseLabel": "Voting Common Stock A Two"
       }
      }
     },
     "localname": "VotingCommonStockTwoMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Four [Member]",
        "terseLabel": "Warrant Exercise Price Range Four"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeFourMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range One [Member]",
        "verboseLabel": "Warrant Exercise Price Range One"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeOneMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Three [Member]",
        "verboseLabel": "Warrant Exercise Price Range Three"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeThreeMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Warrant Exercise Price Range Two [Member]",
        "verboseLabel": "Warrant Exercise Price Range Two"
       }
      }
     },
     "localname": "WarrantExercisePriceRangeTwoMember",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ameh_WarrantIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Warrant Issued During Period Value Stock Options Exercised",
        "label": "Warrant Issued During Period Value Stock Options Exercised",
        "terseLabel": "Proceeds from warrants exercised"
       }
      }
     },
     "localname": "WarrantIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ameh_WeightedAverageExercisePriceWarrantsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "label": "Weighted Average Exercise Price, Warrants [Roll Forward]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceWarrantsRollForward",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WeightedaverageremainingcontractualtermyearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Remaining Contractual Term Years [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "WeightedaverageremainingcontractualtermyearsAbstract",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ameh_WorkingCapitalContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the working capital contribution in equity method investee.",
        "label": "Working Capital Contribution",
        "terseLabel": "Working capital contribution"
       }
      }
     },
     "localname": "WorkingCapitalContribution",
     "nsuri": "http://www.apollomed.net/20200930",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_AffiliatedEntityMember": {
     "auth_ref": [
      "r311",
      "r460",
      "r461",
      "r464",
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Affiliated Entity [Member]",
        "terseLabel": "Affiliated Entity",
        "verboseLabel": "AHMC"
       }
      }
     },
     "localname": "AffiliatedEntityMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399",
      "r560"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r66",
      "r122"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Director [Member]",
        "terseLabel": "Board Members"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r203",
      "r292",
      "r297",
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r314",
      "r316",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r543",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r314",
      "r316",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r543",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r203",
      "r292",
      "r297",
      "r545"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r201",
      "r292",
      "r295",
      "r480",
      "r542",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r201",
      "r292",
      "r295",
      "r480",
      "r542",
      "r544"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r303",
      "r314",
      "r316",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r543",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r303",
      "r314",
      "r316",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r543",
      "r546"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r204",
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsAndOtherReceivablesNetCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.",
        "label": "Accounts and Other Receivables, Net, Current",
        "terseLabel": "Amount of subordinated note receivable agreement"
       }
      }
     },
     "localname": "AccountsAndOtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "terseLabel": "Accounts payable and accrued expenses",
        "totalLabel": "Total accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "verboseLabel": "Receivables and Receivables-Related Parties"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r33",
      "r205",
      "r206"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Receivables, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r60",
      "r126",
      "r461",
      "r464"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Receivables, net \u2013 related parties",
        "verboseLabel": "Receivables, net \u2013 related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r25",
      "r500",
      "r525"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "verboseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r34",
      "r349"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r346",
      "r347",
      "r348"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "verboseLabel": "Additional Paid-in\u00a0Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "negatedTerseLabel": "Cost related to issuance of preferred shares"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r39",
      "r207",
      "r218"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r75",
      "r105",
      "r435"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r105",
      "r233",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Treasury shares not included in the calculation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r118",
      "r183",
      "r193",
      "r199",
      "r215",
      "r392",
      "r398",
      "r423",
      "r498",
      "r523"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r64",
      "r118",
      "r215",
      "r392",
      "r398",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r118",
      "r215",
      "r392",
      "r398",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent assets",
        "verboseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r209",
      "r211",
      "r223",
      "r505"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable securities \u2013 certificates of deposit"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r319",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r410",
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r313",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r313",
      "r315",
      "r373",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned": {
     "auth_ref": [
      "r383"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of equity interests (such as common shares, preferred shares, or partnership interest) issued or issuable to acquire the entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Value Assigned",
        "terseLabel": "Equity investment contributed"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestIssuedOrIssuableValueAssigned",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Interest acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r379",
      "r380",
      "r381"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r379",
      "r380"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Value of shares transferred in acquisition"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combinations and Goodwill"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets [Abstract]",
        "terseLabel": "Assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities": {
     "auth_ref": [
      "r375",
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of financial liabilities assumed (as defined) which have been recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Financial Liabilities",
        "negatedTerseLabel": "Subordinated loan",
        "terseLabel": "Standby letters of credit assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedFinancialLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Network relationship intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r376"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r1",
      "r129",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "verboseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r42",
      "r107"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r14",
      "r108",
      "r114"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r14",
      "r108",
      "r114",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r99",
      "r107",
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period",
        "totalLabel": "Total cash, cash equivalents, and restricted cash shown in the statement of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r99",
      "r424"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "verboseLabel": "Supplemental disclosures of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashUninsuredAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.",
        "label": "Cash, Uninsured Amount",
        "terseLabel": "Amount deposit accounts exceeded FDIC insured limit"
       }
      }
     },
     "localname": "CashUninsuredAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of Deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r116",
      "r118",
      "r145",
      "r146",
      "r147",
      "r149",
      "r151",
      "r160",
      "r161",
      "r162",
      "r215",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise\u00a0Price\u00a0Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "verboseLabel": "Number of warrants received (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquitySummaryofWarrantDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r277",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r55",
      "r253",
      "r509",
      "r531"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r130",
      "r131"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "10% shares held back pursuant to indemnification clause",
        "verboseLabel": "Common\u00a0Stock\u00a0Outstanding"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r31",
      "r267"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 100,000,000 shares authorized, 36,775,817 and 35,908,057 shares outstanding, excluding 17,475,707 and 17,458,810 treasury shares, as of September\u00a030, 2020 and December\u00a031, 2019, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r169",
      "r170",
      "r203",
      "r421",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r169",
      "r170",
      "r203",
      "r421",
      "r422",
      "r553"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r166",
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Risks"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r169",
      "r170",
      "r203",
      "r421",
      "r422"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": {
     "auth_ref": [
      "r114",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.",
        "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Other Entities - Equity Method and Investments in Privately Held Entities"
       }
      }
     },
     "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r293"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "verboseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails",
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Accrued contract liability recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r480"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of services"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDefaultLongtermDebtAmount": {
     "auth_ref": [
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.",
        "label": "Debt Instrument, Debt Default, Amount",
        "terseLabel": "Default amount of debt instrument"
       }
      }
     },
     "localname": "DebtDefaultLongtermDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Credit Facility, Bank Loan and Lines of Credit"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCredit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r24",
      "r25",
      "r26",
      "r499",
      "r502",
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r53",
      "r434"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Average effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on loan receivable"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r54",
      "r124",
      "r268",
      "r271",
      "r272",
      "r273",
      "r433",
      "r434",
      "r436",
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Revolving credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r261",
      "r435"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Less: Unamortized financing costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "auth_ref": [
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "terseLabel": "Deferred financing costs"
       }
      }
     },
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCreditsAndOtherLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total carrying amount as of the balance sheet date of unearned revenue or income, not otherwise specified in the taxonomy, which is expected to be taken into income in future periods and obligations not separately disclosed in the balance sheet (other liabilities).",
        "label": "Deferred Credits and Other Liabilities",
        "terseLabel": "Amount outstanding under agreement"
       }
      }
     },
     "localname": "DeferredCreditsAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r353",
      "r354"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxesAndTaxCredits": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) and income tax credits.",
        "label": "Deferred Income Taxes and Tax Credits",
        "verboseLabel": "Deferred tax"
       }
      }
     },
     "localname": "DeferredIncomeTaxesAndTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r105",
      "r180"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "verboseLabel": "Schedule of Disaggregated Revenue by Each Payor Type"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Dividends": {
     "auth_ref": [
      "r274",
      "r516"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.",
        "label": "Dividends",
        "terseLabel": "Dividends declared",
        "verboseLabel": "Dividends paid"
       }
      }
     },
     "localname": "Dividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r10",
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividend payable",
        "verboseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r25",
      "r28",
      "r501",
      "r524"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividend declared included in dividend payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToAffiliateCurrent": {
     "auth_ref": [
      "r23",
      "r120",
      "r461",
      "r555"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payable due to an entity that is affiliated with the reporting entity by means of direct or indirect ownership. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Affiliate, Current",
        "terseLabel": "Amount due to affiliate"
       }
      }
     },
     "localname": "DueToAffiliateCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r45",
      "r126",
      "r461"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "verboseLabel": "Due to related parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r73",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r143",
      "r145",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r512",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Earnings per share \u2013 basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r73",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r145",
      "r149",
      "r150",
      "r151",
      "r156",
      "r157",
      "r512",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Earnings per share \u2013 diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r152",
      "r154"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "verboseLabel": "Basic and Diluted Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r152",
      "r154",
      "r155",
      "r158"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesScheduleofAccountsPayableandAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r217",
      "r267",
      "r274",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "auth_ref": [
      "r43"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Aggregate Cost",
        "terseLabel": "Amount invested for interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentAggregateCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeAxis": {
     "auth_ref": [
      "r0",
      "r118",
      "r215",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Axis]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Axis]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentNonconsolidatedInvesteeDomain": {
     "auth_ref": [
      "r0",
      "r118",
      "r215",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nonconsolidated equity method investee. Excludes information consolidated by reporting entity.",
        "label": "Equity Method Investment, Nonconsolidated Investee [Domain]",
        "terseLabel": "Equity Method Investment, Nonconsolidated Investee [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvestmentNonconsolidatedInvesteeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Ownership interest",
        "verboseLabel": "Investment, ownership interest"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r76",
      "r77",
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedLabel": "Gain on sale of equity method investments",
        "terseLabel": "Equity Method Investment, Realized Gain (Loss) on Disposal"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "negatedTerseLabel": "Sale"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r43",
      "r184",
      "r212"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "negatedLabel": "Less: Carrying value of equity method investment on date of sale",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Investments in other entities \u2013 equity method",
        "verboseLabel": "Investment in other entities \u2013 equity method"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investments and Joint Ventures [Abstract]",
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "verboseLabel": "Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Marketable securities \u2013 equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI) and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value",
        "verboseLabel": "Investment in privately held entities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EscrowDeposit": {
     "auth_ref": [
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.",
        "label": "Escrow Deposit",
        "terseLabel": "Escrow deposit for potential post-closing adjustments"
       }
      }
     },
     "localname": "EscrowDeposit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r412",
      "r413",
      "r414",
      "r416",
      "r417"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "verboseLabel": "Schedule of Carrying Amounts and Fair Values of Financial Instruments"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r413",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r310",
      "r312",
      "r413",
      "r470"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r310",
      "r312",
      "r413",
      "r471"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r413",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r312",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesCarryingAmountsandFairValuesofFinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r114",
      "r418",
      "r420"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r440",
      "r447",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "verboseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r442",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "verboseLabel": "Operating cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Finance Leases"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r439",
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "netLabel": "Less: current portion",
        "terseLabel": "Finance lease liabilities",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Finance Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in remainder of current fiscal year.",
        "label": "Finance Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended September 30, 2020)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r441",
      "r450"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Payment of finance lease obligations",
        "verboseLabel": "Financing cash flows from finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "Assets recorded under finance leases"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r440",
      "r447",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Accumulated depreciation associated with finance leases",
        "verboseLabel": "Amortization of lease expense"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails",
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinanceReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due the Company from customers, clients, lessees, borrowers, or others under the terms of its agreements therewith. Such amount may include accrued interest receivable in accordance with the terms of the agreements. The agreements also may contain provisions and related items including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Financing Receivable [Member]",
        "terseLabel": "Financing Receivable"
       }
      }
     },
     "localname": "FinanceReceivablesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r385",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Axis]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r385",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support to Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity [Domain]"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r239"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r241"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r234",
      "r235",
      "r239",
      "r242",
      "r481",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r239",
      "r482"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Amortized intangible assets, Gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r234",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r239",
      "r481"
     ],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetFutureAmortizationExpenseDetails",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r224",
      "r226",
      "r496"
     ],
     "calculation": {
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Balance, September 30, 2020",
        "periodStartLabel": "Balance, January 1, 2020",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r229",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "verboseLabel": "Goodwill and Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r105",
      "r225",
      "r227",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Impairment of goodwill"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillSummaryofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HealthCareCostsPolicyPolicyTextBlock": {
     "auth_ref": [
      "r558"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for  accruing health care costs for a prepaid health care service provider.",
        "label": "Health Care Costs, Policy [Policy Text Block]",
        "verboseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "HealthCareCostsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_HealthCareOtherMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided for maintenance, diagnosis and treatment of physical and mental health, classified as other.",
        "label": "Health Care, Other [Member]",
        "terseLabel": "Risk pool settlements and incentives"
       }
      }
     },
     "localname": "HealthCareOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCarePatientServiceMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Service provided to patient for maintenance, diagnosis and treatment of physical and mental health. Excludes service to resident in health care facility.",
        "label": "Health Care, Patient Service [Member]",
        "terseLabel": "Fee-for-service, net"
       }
      }
     },
     "localname": "HealthCarePatientServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r105",
      "r243"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangibles"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r105",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-lived",
        "terseLabel": "Impairment of finite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r105",
      "r243"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of indefinite-lived intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r105",
      "r246",
      "r248"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Impairment of Long-Lived Assets Held-for-use",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r245",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "verboseLabel": "Intangible Assets and Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r125",
      "r183",
      "r192",
      "r195",
      "r198",
      "r200"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income before benefit from income taxes",
        "totalLabel": "Income before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r71",
      "r105",
      "r181",
      "r212",
      "r510",
      "r533"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedLabel": "Income from equity method investments",
        "netLabel": "Income (loss) from equity method investments",
        "terseLabel": "Income from equity method investments",
        "verboseLabel": "Allocation of Income (Loss)"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Statements of Operations"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r357",
      "r358",
      "r361",
      "r365",
      "r367",
      "r369",
      "r370",
      "r371"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r119",
      "r141",
      "r142",
      "r182",
      "r355",
      "r366",
      "r368",
      "r536"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes",
        "verboseLabel": "Provision (benefit) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r114",
      "r351",
      "r352",
      "r358",
      "r359",
      "r360",
      "r362",
      "r559"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r101",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "verboseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Receivables, net \u2013 related parties"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities, net of business combinations:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "verboseLabel": "Fiduciary accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible Assets, Gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r232",
      "r237"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r70",
      "r179",
      "r432",
      "r435",
      "r513"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r96",
      "r100",
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r82",
      "r178"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r454",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total finance lease cost, net"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Information Related to Lease Costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, finance"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r455"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Operating Lease Payments After Adoption of 842"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the six months ended September 30, 2020)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Remaining lease term, operating"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease option to extend (up to)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesAdditionalinformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LetterOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit).",
        "label": "Letter of Credit [Member]",
        "terseLabel": "Letter of Credit"
       }
      }
     },
     "localname": "LetterOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r49",
      "r118",
      "r194",
      "r215",
      "r393",
      "r398",
      "r399",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "terseLabel": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r38",
      "r118",
      "r215",
      "r423",
      "r504",
      "r529"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and stockholders\u2019 deficit",
        "totalLabel": "Total liabilities, mezzanine equity and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Deficit",
        "verboseLabel": "Liabilities, mezzanine equity and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r52",
      "r118",
      "r215",
      "r393",
      "r398",
      "r399",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "terseLabel": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r26",
      "r27",
      "r118",
      "r215",
      "r393",
      "r398",
      "r399",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Noncurrent liabilities",
        "verboseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r537",
      "r540"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "periodEndLabel": "Medical liabilities, end of period",
        "periodStartLabel": "Medical liabilities, beginning of period",
        "terseLabel": "Medical liabilities"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "terseLabel": "Medical Liabilities"
       }
      }
     },
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cost of settling unpaid claims after deduction of reinsurance recoveries related to the acquisition of a business. Includes, but is not limited to, claims which have been incurred but not reported.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions",
        "terseLabel": "Acquired (see Note 3)"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "negatedLabel": "Current period"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "negatedLabel": "Prior periods"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "totalLabel": "Total medical care costs"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Medical Liabilities [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of increase (decrease) in the liability for unpaid claims and claims adjustment expense.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Period Increase (Decrease)",
        "terseLabel": "Adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpensePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r26",
      "r502",
      "r521"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-term Line of Credit",
        "terseLabel": "Total debt",
        "totalLabel": "Total",
        "verboseLabel": "Amount outstanding"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r47",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]",
        "terseLabel": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Required annual facility fee"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period remaining on line of credit facility before it terminates, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Line of Credit Facility, Expiration Period",
        "terseLabel": "Term of facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Interest rate"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Interest rate, 2020 commitments"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility.",
        "label": "Line of Credit Facility, Lender [Domain]",
        "terseLabel": "Line of Credit Facility, Lender [Domain]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum loan availability"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the required periodic payment applied to principal.",
        "label": "Line of Credit Facility, Periodic Payment, Principal",
        "terseLabel": "Principal payment on credit agreement"
       }
      }
     },
     "localname": "LineOfCreditFacilityPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Amount available"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r47",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LinesOfCreditCurrent": {
     "auth_ref": [
      "r24",
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current portion of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Line of Credit, Current",
        "negatedTerseLabel": "Less: Current portion of debt"
       }
      }
     },
     "localname": "LinesOfCreditCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r26",
      "r262",
      "r502",
      "r526"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r128",
      "r259"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r128",
      "r259"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r128",
      "r259"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r128",
      "r259"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LineOfCredit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2020 (excluding the nine months ended September 30, 2020)"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditScheduleofMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt, net of current portion and deferred financing costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r54",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r253",
      "r254",
      "r255"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Damages sought"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementFeeExpense": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses related to the managing member or general partner for management of the day-to-day business functions of the limited liability company (LLC) or limited partnership (LP).",
        "label": "Management Fee Expense",
        "negatedLabel": "Management fees"
       }
      }
     },
     "localname": "ManagementFeeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ManagementServiceMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractually stipulated right to receive compensation for operating and managing business.",
        "label": "Management Service [Member]",
        "terseLabel": "Management fee income",
        "verboseLabel": "Management Fee Income Contract"
       }
      }
     },
     "localname": "ManagementServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r5",
      "r50"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Amount of short-term marketable securities",
        "verboseLabel": "Investment in marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "verboseLabel": "Investments in Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MembersCapital": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of member capital in limited liability company (LLC).",
        "label": "Members' Capital",
        "terseLabel": "Initial capital contributions"
       }
      }
     },
     "localname": "MembersCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r118",
      "r215",
      "r423",
      "r503",
      "r528"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Dividends"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "auth_ref": [
      "r274",
      "r390",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "negatedTerseLabel": "Purchase of noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Ownership interest"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r163",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Description of Business"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r99"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r99",
      "r103",
      "r106"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r72",
      "r106",
      "r118",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r141",
      "r142",
      "r148",
      "r183",
      "r192",
      "r195",
      "r198",
      "r200",
      "r215",
      "r423",
      "r511",
      "r534"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Apollo Medical Holdings, Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r67",
      "r68",
      "r141",
      "r142",
      "r396",
      "r407"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "verboseLabel": "Net income attributable to noncontrolling interest"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "verboseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction.",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received",
        "terseLabel": "Preferred shares received from sale of equity method investment"
       }
      }
     },
     "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r274",
      "r387"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "verboseLabel": "Noncontrolling Interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other (expense) income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other (expense) income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesAndLoansReceivableNetCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r32",
      "r205",
      "r206",
      "r506"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as current. Includes, but is not limited to, notes and loan receivable.",
        "label": "Financing Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Loan receivable",
        "verboseLabel": "Loan receivable"
       }
      }
     },
     "localname": "NotesAndLoansReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableGross": {
     "auth_ref": [
      "r220",
      "r221",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of financing receivable.",
        "label": "Financing Receivable, before Allowance for Credit Loss",
        "terseLabel": "Note receivable, amount"
       }
      }
     },
     "localname": "NotesReceivableGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics.",
        "label": "Notes Receivable [Member]",
        "terseLabel": "Convertible Secured Promissory Note",
        "verboseLabel": "Notes Receivable"
       }
      }
     },
     "localname": "NotesReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesReceivableNet": {
     "auth_ref": [
      "r33",
      "r205",
      "r220"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of financing receivable. Excludes financing receivable covered under loss sharing agreement.",
        "label": "Financing Receivable, after Allowance for Credit Loss",
        "terseLabel": "Amount of loan"
       }
      }
     },
     "localname": "NotesReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r60",
      "r126",
      "r461"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amounts due from parties associated with the reporting entity as evidenced by a written promise to pay, due within 1 year (or 1 business cycle).",
        "label": "Notes Receivable, Related Parties, Current",
        "terseLabel": "Loan receivable \u2013 related parties"
       }
      }
     },
     "localname": "NotesReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportingUnits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of reporting units tested for impairment of goodwill. A reporting unit is an operating segment or one level below an operating segment.",
        "label": "Number of Reporting Units",
        "terseLabel": "Number of main reporting units"
       }
      }
     },
     "localname": "NumberOfReportingUnits",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfStores": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the number of stores.",
        "label": "Number of Stores",
        "terseLabel": "Number of medical centers"
       }
      }
     },
     "localname": "NumberOfStores",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r183",
      "r192",
      "r195",
      "r198",
      "r200"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r448",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Less: current portion",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r439"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term lease liabilities",
        "verboseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/LeasesFutureMinimumPaymentsUnderNoncancelableLeasesDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r443",
      "r450"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r438"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets",
        "verboseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r453",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r452",
      "r456"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r22",
      "r497",
      "r522"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r508"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r43",
      "r532"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-term Investments",
        "terseLabel": "Investment in affiliates"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "verboseLabel": "Other income"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables",
        "verboseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentOfFinancingAndStockIssuanceCosts": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.",
        "label": "Payment of Financing and Stock Issuance Costs",
        "negatedTerseLabel": "Cost of debt and equity issuance costs"
       }
      }
     },
     "localname": "PaymentOfFinancingAndStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForFees": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for fees classified as other.",
        "label": "Payments for Other Fees",
        "terseLabel": "Fees paid"
       }
      }
     },
     "localname": "PaymentsForFees",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r102",
      "r539"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "negatedTotalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of shares"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r93"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "negatedTerseLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r88",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to acquire business"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payments for business acquisition, net of cash acquired",
        "terseLabel": "Cash paid"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "negatedTerseLabel": "Purchases of investments \u2013 equity method",
        "verboseLabel": "Cash consideration paid for ownership interest"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "terseLabel": "Payments to acquire investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r210"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireRealEstate": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow from the acquisition of a piece of land, anything permanently fixed to it, including buildings, structures on it and so forth; includes real estate intended to generate income for the owner; excludes real estate acquired for use by the owner.",
        "label": "Payments to Acquire Real Estate",
        "terseLabel": "Purchase price of real estate"
       }
      }
     },
     "localname": "PaymentsToAcquireRealEstate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToFundLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r87",
      "r460"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with extending a long-term loan to a related party. Alternate caption: Payments for Advances to Affiliates.",
        "label": "Payments to Fund Long-term Loans to Related Parties",
        "negatedTerseLabel": "Advances on loans receivable"
       }
      }
     },
     "localname": "PaymentsToFundLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r40",
      "r41"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromCollectionOfLongtermLoansToRelatedParties": {
     "auth_ref": [
      "r85",
      "r460"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with collection, whether partial or full, of long-term loans to a related party. Alternate caption: Proceeds from Advances to Affiliates.",
        "label": "Proceeds from Collection of Long-term Loans to Related Parties",
        "terseLabel": "Proceeds from repayment of loans receivable \u2013 related parties"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfLongtermLoansToRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": {
     "auth_ref": [
      "r86",
      "r98"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.",
        "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital",
        "terseLabel": "Dividend received"
       }
      }
     },
     "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from common stock offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r92"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Borrowings on line of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "terseLabel": "Repayment of indebtedness received"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investment",
        "verboseLabel": "Cash proceeds (excludes proceeds to settle indebtedness owed to APC from UCI)"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of stock options and warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other income"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r67",
      "r68",
      "r97",
      "r118",
      "r133",
      "r141",
      "r142",
      "r183",
      "r192",
      "r195",
      "r198",
      "r200",
      "r215",
      "r389",
      "r395",
      "r397",
      "r407",
      "r408",
      "r423",
      "r514"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r65",
      "r247",
      "r447"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Land, property and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r18",
      "r19",
      "r247",
      "r530"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Land, property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r74",
      "r219"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "terseLabel": "Provision for doubtful accounts",
        "verboseLabel": "Provision for doubtful accounts"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Receivables [Abstract]",
        "terseLabel": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r311",
      "r460",
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r311",
      "r460",
      "r461",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty": {
     "auth_ref": [],
     "calculation": {
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the sum of all other revenue and income realized from sales and other transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party during the period.",
        "label": "Related Party Transaction, Other Revenues from Transactions with Related Party",
        "totalLabel": "Net total",
        "verboseLabel": "Recognized risk pool revenue"
       }
      }
     },
     "localname": "RelatedPartyTransactionOtherRevenuesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Related Party Transactions [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r311",
      "r460",
      "r464",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails",
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r458",
      "r459",
      "r461",
      "r465",
      "r466"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "verboseLabel": "Related-Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of term loan"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r2",
      "r14",
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r2",
      "r14",
      "r113"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash \u2013 current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r22",
      "r113",
      "r557"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "periodEndLabel": "Restricted cash \u2013 non-current"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r8",
      "r22",
      "r113",
      "r557"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      },
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash",
        "verboseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted stock awards"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r35",
      "r274",
      "r349",
      "r527",
      "r550",
      "r551"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r217",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r547",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "verboseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r176",
      "r177",
      "r191",
      "r196",
      "r197",
      "r201",
      "r202",
      "r203",
      "r291",
      "r292",
      "r480"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Revenues",
        "terseLabel": "Revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesDisaggregationofRevenuebyEachPayorTypeDetails",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r115",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r302"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r79",
      "r556"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue from related parties"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfTiming": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Description of timing for satisfying performance obligation in contract with customer. Includes, but is not limited to, as services are rendered, and upon shipment, delivery or completion of service.",
        "label": "Revenue, Performance Obligation, Description of Timing",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfTiming",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Remaining performance obligation, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in CCYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenues [Abstract]",
        "verboseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolver loan",
        "verboseLabel": "Revolver Loan"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditCreditFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r451",
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "verboseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesOtherInformationRelatedtoLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense, Activity in Liability [Abstract]"
       }
      }
     },
     "localname": "RollForwardInLiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r169",
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "verboseLabel": "Net Revenue"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesContributionstoRevenueandReceivablesbyPayorDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accounts Payable and Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/AccountsPayableandAccruedExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r373",
      "r374"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillAdditionalInformationDetails",
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillIdentifiableAssetsAcquiredandLiabilitiesAssumedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r151"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r0",
      "r118",
      "r214",
      "r215",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodEquityMethodInvestmentsDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r234",
      "r238",
      "r481"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r234",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Intangible Assets, Net"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r229",
      "r231"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Change in Carrying Value of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of Medical Liabilities"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": {
     "auth_ref": [
      "r47",
      "r124"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Schedule of Line of Credit Facilities [Table Text Block]",
        "terseLabel": "Schedule of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Future Commitments of Credit Facility"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Estimated Fair Values of Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BusinessCombinationsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r121",
      "r462",
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.apollomed.net/role/RelatedPartyTransactionsFeesIncurredandIncomeReceivedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.",
        "label": "Schedule of Related Party Transactions [Table Text Block]",
        "verboseLabel": "Schedule of Fees Incurred and Revenue Earned from Related Party Transactions"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "verboseLabel": "Schedule of Contributions to Revenue and Receivables by Payor"
       }
      }
     },
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r319",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r323",
      "r331",
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock Option Transactions Under Stock Option Plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Schedule of Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r57",
      "r116",
      "r160",
      "r161",
      "r264",
      "r265",
      "r266",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r277",
      "r317"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTextBlock": {
     "auth_ref": [
      "r400",
      "r401",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table Text Block]",
        "verboseLabel": "Schedule of Assets and Liabilities, Variable Interest Entities"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).",
        "label": "Schedule of Weighted Average Number of Shares [Table Text Block]",
        "verboseLabel": "Schedule of Shares Included in the Diluted Earnings Per Share Computations"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "verboseLabel": "Schedule of Future Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r114",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Reportable Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesAPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series A Preferred Stock [Member]",
        "terseLabel": "Series A Preferred Stock"
       }
      }
     },
     "localname": "SeriesAPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Preferred Stock"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/RelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Annual dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "verboseLabel": "Exercise price of exercises during period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r325",
      "r345"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding, ending balance (in shares)",
        "periodStartLabel": "Options outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, beginning balance (in dollars per share)",
        "terseLabel": "Options outstanding exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r317",
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r114",
      "r319",
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "verboseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Market value of common stock (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Grant date fair value of restricted stock to be recognized straight-line"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r339",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityStockOptionActivityUnderBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Equity, ending balance (in shares)",
        "periodStartLabel": "Equity, beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StandbyLettersOfCreditMember": {
     "auth_ref": [
      "r257",
      "r258",
      "r386",
      "r554"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation.",
        "label": "Standby Letters of Credit [Member]",
        "terseLabel": "Standby Letters of Credit"
       }
      }
     },
     "localname": "StandbyLettersOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r116",
      "r118",
      "r145",
      "r146",
      "r147",
      "r149",
      "r151",
      "r160",
      "r161",
      "r162",
      "r215",
      "r267",
      "r423"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodGainonSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r59",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r142",
      "r159",
      "r217",
      "r267",
      "r274",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r547",
      "r548",
      "r549"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r159",
      "r480"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFINCOMEUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssued1": {
     "auth_ref": [
      "r110",
      "r111",
      "r112"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value of stock issued in noncash financing activities.",
        "label": "Stock Issued",
        "terseLabel": "APC stock issued in exchange for AMG"
       }
      }
     },
     "localname": "StockIssued1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of shares purchased by related party"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r30",
      "r31",
      "r267",
      "r274",
      "r328"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised (in shares)",
        "terseLabel": "Stock options exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityScheduleofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueAcquisitions": {
     "auth_ref": [
      "r59",
      "r267",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued pursuant to acquisitions during the period.",
        "label": "Stock Issued During Period, Value, Acquisitions",
        "terseLabel": "Stock issued in connection with a business combination"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueAcquisitions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r30",
      "r31",
      "r267",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Stock subscriptions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/DescriptionofBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r30",
      "r31",
      "r267",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "terseLabel": "Shares issued for vesting of restricted stock awards"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r30",
      "r31",
      "r274",
      "r318",
      "r332"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r59",
      "r267",
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Proceeds of options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r31",
      "r36",
      "r37",
      "r118",
      "r208",
      "r215",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholders' equity, parent"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r118",
      "r130",
      "r131",
      "r132",
      "r134",
      "r140",
      "r215",
      "r217",
      "r274",
      "r346",
      "r347",
      "r348",
      "r363",
      "r364",
      "r387",
      "r388",
      "r406",
      "r423",
      "r425",
      "r426",
      "r430",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Equity, ending balance",
        "periodStartLabel": "Equity, beginning balance",
        "terseLabel": "Stockholders\u2019 deficit",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED",
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED",
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodSummarizedBalanceSheetsandStatementsofIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r117",
      "r274",
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Mezzanine and Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r449",
      "r456"
     ],
     "calculation": {
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r431",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r431",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r431",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r431",
      "r468"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r467",
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "verboseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MedicalLiabilitiesScheduleofMedicalLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests": {
     "auth_ref": [
      "r56",
      "r118",
      "r215",
      "r423"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Including Portion Attributable to Noncontrolling Interests",
        "terseLabel": "Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trade names/trademarks"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/IntangibleAssetsNetScheduleofIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r31",
      "r267",
      "r274"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedLabel": "Purchase of treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r58",
      "r275",
      "r276"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury stock, value"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/MezzanineandStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r267",
      "r274",
      "r275"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "negatedLabel": "Purchase of treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFMEZZANINEANDSTOCKHOLDERSEQUITYUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestments": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment.",
        "label": "Unrealized Gain (Loss) on Investments",
        "negatedLabel": "Unrealized loss (gain) from investment in equity securities"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWSUNAUDITED"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r164",
      "r165",
      "r167",
      "r168",
      "r171",
      "r172",
      "r173"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Variable Interest Entities (VIEs)"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEs"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityOwnershipPercentage": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).",
        "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage",
        "verboseLabel": "Voting rights held (more than)"
       }
      }
     },
     "localname": "VariableInterestEntityOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "auth_ref": [
      "r392",
      "r393",
      "r398",
      "r399",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "terseLabel": "Variable Interest Entity, Primary Beneficiary"
       }
      }
     },
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CONSOLIDATEDBALANCESHEETSUNAUDITEDParenthetical",
      "http://www.apollomed.net/role/VariableInterestEntitiesVIEsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/CreditFacilityBankLoanandLinesofCreditAdditionalInformationDetails",
      "http://www.apollomed.net/role/LoanReceivableandLoanReceivableRelatedPartiesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of warrant"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/InvestmentsinOtherEntitiesEquityMethodAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Adjustments to weighted average shares of common stock (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r144",
      "r151"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r143",
      "r151"
     ],
     "calculation": {
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Weighted average shares of common stock outstanding \u2013 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.apollomed.net/role/EarningsPerShareEarningsPerShareComputationsDetails",
      "http://www.apollomed.net/role/EarningsPerShareSharesIncludedinDilutedEarningsPerShareComputationsDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 15
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4297-108586"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04.(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1278-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2626-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70229-108054"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8672-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8813-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4647-111522"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4428-111522"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121593590&loc=d3e4531-111522"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=121611835&loc=d3e5074-111524"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26610-111562"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121553693&loc=d3e26853-111562"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599878&loc=SL82895884-210446"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919249-210447"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL82919230-210447"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "79",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922352-210448"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "80",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121647567&loc=SL82922355-210448"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121555522&loc=d3e12021-110248"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=121596127&loc=d3e12803-110250"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=d3e1835-112601"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=120520924&loc=SL6031897-161870"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=65877616&loc=d3e177068-122764"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21553-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21484-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32247-109318"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e32280-109318"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32705-109319"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32857-109319"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330215-122817"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121600890&loc=d3e2207-128464"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121647850&loc=d3e4845-128472"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=121598580&loc=d3e5263-128473"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569655-111683"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4616395-111683"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5728-111685"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6759159-111685"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5747-111685"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=SL6228884-111685"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL7498348-110258"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13279-108611"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13531-108611"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=121572278&loc=d3e13537-108611"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28541-108399"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28551-108399"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=119993939&loc=d3e28555-108399"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=68176171&loc=SL68176184-208336"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918638-209977"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121568110&loc=SL77918982-209971"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61929-109447"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62059-109447"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62395-109447"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e62479-109447"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=SL6807758-109447"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=68064819&loc=d3e61872-109447"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(7))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62652-112803"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=108315417&loc=d3e61044-112788"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/subtopic&trid=2560295"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491204&loc=d3e4879-115612"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.27(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r562": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r563": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r564": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r565": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3367-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21D",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=SL94080555-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001628280-20-015999-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-20-015999-xbrl.zip
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M/JM'<DP'[__.W]S.]<?2#Q=:REN 3G__[ _1PAVX>'41EK=WNKK %;?TP!]
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MO/[;FQZ\F1F]0S*QL:7/[0!J0S$A6>\-M%Y17K+48*1" *,([Z"2V\K2YW;
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MJ?#SR;&>\K@]TW>73;FEQYY= 7[Q*_YV,Q?^@N?].EW5I"O"W>PWO7FN[SS
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M7%.6/(;9E.-!<  *MBB&$0MP"R#D<RDU8,@D&$HK.(+5P''"O9TEN3[EN)G
M-OH&26TKD7#PT:J-M8GI(E,^1+7\QS[1Q9:D9_.S197#9X]ONL.'S6O3M5F?
MOX9G+8L:246$7"HFFV9[NCD#C!&-2]\T?K/:1[:8+&4Y$C0<F!0AJ#SD"+1:
M>RPQLD T"7SPPT5C3>',X0^/>JNKLYF>^(_Y\F1R2M,;C6;^>N)Z*)RI(*DZ
M4U-R%4H.A,AB/&4UJMY"VG-FW9P9KWY!0?2UI>")@=3IZE-L0#6,.M<&8MYS
M9=U<&:]GX$M&DRL6ZSTT\1@H6G;,U<28:[M<IAQ@7\>Q<F5;M@C7UN:P8C3%
M1;*BOKTA6QR(S34Z7Q#5N;D]:P"[39[MKP  !-! Q;+Q&8*)5'(BZYV0.,=O
M-N ,.4>T9]HHTE.$-A17O9I!!^ H<VPVD#3,N2NUV[.&?GN8MIT5]!@\I&QS
MD]( :RK9<,U!6N_,![Z-(!&Z9]HH<K"QY9A,]=XW)18346\N4@(9JGT#V'"7
MQO8$V]:JG&O12'/!AVI!E5,!<C4U]?=3,93K<-?!]YS9UA)\S!H1(AA#@,"8
M<K*J;H13,J4GFBYW10RTM<+C7WI/S*/)R;LD4#">S!<W#?TV=\2LJ44"53%6
MU42&W" Q%0W3JC'J28O$F*\V-X2KS0U[$@RGTNJ"!A^],2*L9Y),HF:E;PBN
M+D,"C>F-4&Z5')48*UYF'#72&@M1[M2CB;RBP[[H_^F]*0=G*=X/DSY!6P3?
MBB^.?;7JD?;Z86+DUM>R8L14WH^R]R085@SS)Z+E=T_]%&V!)1?H-9E!P&:7
M6[182T)T&0.V8?NCMX8H-^)7]K9+S;&U7 A*RZ415HXE^U1RY '7Y.X;+W^@
MA&X_Q&"=@F(:D49@-C!5P-SW@8502PL./-I\M8@;71Z:H%R!?:?6SLOEH_FI
M+!_.:;:\,^-O)S.:U<GLY5.I,GE%92IWS]_^_79VW-555I]^>\*ZR/I4IKVB
MLX]/.'^^T'NCVL<I+/O-O#WR;K^7Q1=W%J="+VGW:-MM>SQP>0VT394HH&67
M2H,L5%()/9-0J7HO<0RK>U<4^1<M)IUR3Y4.[ZLQ/;N_O2XV[D5EV**R_;5,
M6XW)K:5(U8"+D&-+/E3&8!V9B_JO88O3GN/#YOB->#'6^9J88W#HP7##["BH
MR\^M&B)G]U[,6&F[IG#HX?%-"M"3>PJ6_OOPV>%H'*@F-0<?770$2*;D$DLM
M: *C</)[B=E9NGZT< Z%J\%(+ %S9)/!4R#CT0A#GTM4+<O>*1FH=A^*>^"J
M!H@MI6@,J%=K,C$7!X:\KUS>9(+=KBN[BP_(VU,^M"UE%SCDUJ.$,E-%")A:
M0XBQIY(KDOAH@TDFA97!#$.LB!HZAP::\1Y>P&3#^O8$*FU+BT5#)8)$E3"D
M2L$HR:WU]JKN)CK<LWG/YANK)%('$=?A(*80<],K@B\@MF9J"4QBS!98"7ZY
M:]'N[?N>S3>XK]*NR=-0=6PY$WH?H**@UR#=>E]"=L(-KFJO[>#:O^[9O"ML
M7E6%VW7TI273O,M<BOK($+V@6(D:JW/3D$S5]/LK=7ZX#O3H5NKV$C2>!3R_
MIA+9(MDV(Z&$ B68@J)NO8\DKF0Q[C+5,6 IVU-_E-2_GG3QZPE3"SE/W%S.
MQ4"U#:VIK;$OU9*'C,/=AK9G\W#8_-%@_84LYG_3>4?UYIVQ]31SLYR*BE$0
MEP"#RS4&QB+&>G8<KE92!CB.^H^)<8V"=ZIR=CGIJ'6L>@GUP^E0)DQLN"9W
MF_H?UE2=6K!E"=U=*0"FQ\4A]-D6*0H&.X)RI'L+X<GIMPK"]#IMG\OBN&N.
ML938A)9:CK8Z:PKDT @P^=[WVJL!+HCCA.*MYG\UG[Y2BWS]I)%@TWRV$J*(
M#>H5-76/4E;_GP(U@1:N]D;A@/M"7 %Q7\KI WT2B[/^P7>'&JZ N?-R(:OB
M_W69_$&0XOV]4KCQ?@^)K6DNA2P10#R7Y*ISEFQVDD7R93G0GCAOON_A?/92
M#>]Q_][?.NP/)S/U%"Z^>J>H>KW 9TWZ"\E+ >9BJ@?CG,9V+1@VQ4=7++D]
M^X;-OH=RJC?SD=\X%-*E4K&::BA8AN(3Y=@;Q*F;R;XRU3WIUN[+;I[>0R%;
M!+6KD,GI?T%J*(%2[BXUA9+,Q>RKO8?V$=_W5%B.3U;Q_>KI7^NZ?-[/N'C_
M\>Q#:S&C]--R'RJ4DC,2JU+*%HW#3,):(AO"9/<\6C./GO\RWT4>V0S&9HPI
M) <L"9-Z6P&$78PUFKCGT;IYU(>W["*3>KMXZK,$0F/52)Z"BU7=^.;8JY+:
M1XZW*(YKU-B1L84P0&V!H%$LF6+&+.KG[+7*[^;PG]+LY:6+VU\>3F:3X[/C
MG506I5EU>H58>A)9*(508^[!ET,RM"?(1Q&$7N\J081"1-^D$@)(,V22QDF<
MA+W/;'!$!/GC:C&-;GD^>]#7[0K-?G[<FBAG^GD/']Q]_/1F')6]"EN3"DM,
M.58+Z#*@M;FH&NO3T0P&-7A[AHZ$H;NK0Y.)V:96L5F!&@+:%IT#(I>:AGQC
MF'V]S=7S[3=A2<6J#6R^F."A-"B*HPA:*KTKNQM3<Z/!VZ"U1&W/-&#B<GZQ
M#+*\N=3T *B)QC/8'-$8P,"4;.^K&:TOSL42]M1<G_'94_-#U.R=]E>\;!<%
MM33]]X).)_,WE#L66IXMY +7]TZZNN;5.5>O^T5_/V>*0KE(*(8MY$8854%+
M;M4(N[>E];M/^4]*-ZVS)(V+>C>9("0 FSR:*EG!0-8W MU".SD6P;T.8R9/
M*6,PT4+K34A!38EEJ"E+<'QK,LA#2>/ZA*YY F);0*(@J85GWP-=\:KU=D&N
M'AT>OEM&L-,"1LZU2$$"@@.#2.JL5:A<)$-C&$$5]0!@O)G&1.P:D0FQH7K5
M52,]:GW&00G)JV>-(QCHMGT=N/UI:9BS3U+4<J%Z(J9AX1"3+1Y:XA3;"*;:
M#@O&[8R,54'TG,%SM%;UI%"4A%"QB8,D7D8PR'-8,&YG2F8MK0F&"*T!J M#
M)9JLL5IV)8)]V]O(PE#1>]>D_4[R\\UX@[LT^^3I!A]5WWL#]<1_;-*/C^^>
M+?4;EZO]LFO+P_SY<2<WZJZONA]96(,3$2,4MK&OD4+?[8.I%,^U0<"8HIA+
MON/P!B+M^7ZK^([KF026T%N*5(/KD\"(R38TU;0$U"CBY=S WA3@X.J/H1)_
M@QUE=EG&UD[UK4GUISI<^7JK@/\\EO':J9_@<#D7@O->R!F&W RI]\Q$N3CK
M UN\;+\W8#G<9>'8&Z W#?K6U$7#9 ,BKC)@A61KL2D8C0^+<1HLAC?3)H8;
M'N[YOOM\7_7?7\]Z +CF))F<L4 ?JFFLE!C)"QLDA#<!1MCS?>_\;"DK?QE@
MA'5DY6T$FZMUE Q8+%1+S+E8<*ERS\I?Z'>P:<_W/=^WQ7?L799L6@/?L7AK
M POF8"%DSA+0APRN<,[JWER-51]N,_@]WV\%W]-ZVL6+-R4KW1VF"@XBUNQ<
M5N)["7"Y36TD]0W[!-)>QL9?H ))Q;&X5GVNX&,I.?:P.JG08Q4)PR]0V0O'
MC@K'C93]<&@0^XX<-A8\^4S58+/)@O&]Y]7PVQKO^;[S?%]CVV&H#1-$8=<L
M2(H:5S<QPLU!]>SY8L6N)Y .]IFD/?&W[@6]GTOZS\MHUT[]E+U52M9L@Z_L
MDAH"0,C!!S4*+=I2)0[?"]IX%\3U">-07 .'MD\MJ\$1@<2*$;)I-4D()8=J
M]B08O$;>6#/,-=(."SEK2PS.92!;*,>HI&LQDT 6W-=,#GI)\\Y)W?"2YG:G
M1JZE;C+W,0)L$JA+"MX%*BS)]?XSX'R%_3+/GO,#X?SZEGJ:(]=*K;DX#YP#
M-1ML28[5X0@B;TI7[#[SL.?\MCFO>GXMLZY]Z6-C4O5<^FR#3,E6<#7T35OI
M8NB1<C[OZ^/WG-\ZY_-Z:N1#81,IIF"# ,>:;20N&DABS9GRE9Y'.]@P<L_Y
M6\-Y/+!KZ3Z;$'T-:(E /7C IMSWI7*&9AJ,J>_9?EE_+V>[L;2OPL%]4E^"
M N"-OBK<4$J3B-51&7X^<R\@.RP@-Y),30T*H?78JEJBC%@J5/(N"6; ,H*I
MQ7O.WPK.KW&)7X/I$DM 1[4OZK=L@O@^+)2ZWL_Q<@^@,6[/^?](A1.B^J&1
M,VN1J4UUAKR^!4^UK%L#W4PRSI/85 -!SD"B_]? 6>3<Q-C+/>!*MX,][VXG
M[][?%_TN\SZP+_K=4S_!]RU]3A>+06LK2.9LJO>M6J=O%[)TE7C<+ZK>-FZ^
MG_-;RWJF@3XVHR!$:$#14$X60K>_$DJQ;1]J[>FVQBBG)O'H/>72]]!$F]GF
MG!QY+%)B&G"YVHTXXGM")#9]EWC,1KTQGX2**9)-TM"73;@8[C3P_.N>&=O/
M&$:6FE/RC9B@.,C!,9)2RD+OSKC/&'XT8T^.Z!XMY+)J^[O%_.SDP:Q^L4MT
MO1%%UANW>D!VT*<V4V]_'=BZB*VG[01&H,CV5+R%FC/7W@*OVF*BA^1+YB!@
M(#3KI0BZ][I);R(!_6?C]#_5OGE=_<O 1W89@]5G!<FE4D-C+LTZ8K4];@3R
MWJ?*/)^<3E78'\QX\FK"9S2]GM-^=CJO/S]>C2K>1?)7J9)MK1): 710:I&(
MZG@*<*V)1]!*?4@@;J>1>BB88TBE@*F0(F.OU -F \:(CWZXOM\FAV#>3#@O
MWA&AANYL@2!D"L*5D\9OV-#6<3WZCQJP-91'[Y)-A93ZC8(JJX2N8I"42B@6
MNK\YV $XVV']&D?=Y,2EU!R0,H -4(1*]&0:>E]SH7$]^IMG_1H?/9KD3<K!
MF((@Q64NE%L-OM1D?:WC]KKZH?N3A=33^6(7W2T$+^"-*]8$R$;Z#*^0,O7=
M@]GX/ +TK@+$.[_0@I^?G[Q7:?G-\<ET?B[R\2[7GB__(3GL(3"G&C,1>.5(
ME"R2Q&<0#SS@X8E; ^UF? TOACT&3'VVL*G%B2IA(YAKBD[&-#/Q#^3VJ2Q/
M%Y-Z*KR2W%T4II8L6YLL10Y@&N5:L$'28$G?]B3#%:9M8W<S^>+&$K(B81-
M:34W=>5KB1*XSU^G$8W_&HI,;7[X5ZU$T41C<@3P(9)@Z<-%?#,L8FCX,O7L
MB!9REY;"]^;')WJT3SF>K=Y=WCD[/9HO)K\*?S]C6;SCTSR9TFQY]_R;U[*H
MDZ4\49CEG;ABE7CZ@18+E8W?GO-X]J%]*$.1T18<(I)4)Q5R]>12=AA2[,UV
MW*@V!^T*SMNWH\:R<[WY,30#42A[YL9<0U5%X,?0<6D+7'C^RX=JHX8B\TC@
MJO%LFTJX&N1<2$(LT21)1NR8YACO"L[;EWGBT(H$\50\2+58BZ'B8JU<LO<C
M&(:\#2X<+60LECXTE[QOOGBC+CFX+,%@[H4;(M4@[Z5^"TAO7^X3NPC(+1OV
MT,A1L-$XT)"9BUJ'-%RY_\N++$/FV;?SL[&DS&)VZC94J[012(Z+9P3'?0)8
M3((#SK;\Y36B/7/6L[KH30HME$ -0="3=ZU)<BWE2JWM3=$6@-Z^):H873#J
M;GH;($2;R7*Q.<98I5';9YI&+O7< F.L@2@X4#.1:_,Q8(LI-6M+&$DEVJ;J
M.K9?==9\LH9\S;U!G&.330B(E,!"X-;>KYL="V W50VR?<!"R,+.N2H^ +J:
M(X=L#%6F5*$..&\WO!X0ZRPA]"[Z9E7SE0:N8&:()C0-KEP&R7ZX?4^&!\L:
M6W/T9L9<:XN*#K OZ"QD#DDH:/@;!RPM78W=FY_I;UF<J%XY?Z20_!$V\W>P
MN;N8_RP+4FU8:__X2.0G)5#SDPHB))675%*Q+6?KJ5839 S[$(8B2-OW\ELV
MWC+'$F. 6"TIBC;Y' S;6!A&X%0,$<PM.1P*8$I2:DD,/E1,EBAYC>4I2 MC
MV!'XQV#>N__LWDY*H"_!9F>2 0)"ORJPQTA1T<&4ZJ@E\.9!VXZD5=.0R!HT
ML0&[BC$H*1('! .1:+@^Y)#VHM[,%+<<:].0R[I,X-F6T P5,;:)EPH#SEMM
MMZW#MY,9S>J$IL_.3D[FB]/G\T?SF3[9Y7PZ8143_LVM[<8N>DY.362*F1M(
MB6A* JL!>\^*VS"&'0)[W@S>Q@NS>MB]R[<'\K[T/)Y%Q@*F13/@5=U;WBWA
MAH;G>1=$U4[R"1#4[2M) GNGABK9*B-7.;> %MO7* BUM*K4*-6"](7;T/IH
M/*=Z)9@DE[-JO?,7LVK!^*$UT<@'1F_.?XSCGOMD*>/7\-R*M5'=0/$A!@@6
M<HUL<[5B.49UV%>.>[!ZUM!$KF<9G^DW\EG?X_7-_YSI31W*Z=&<'\Q>R?*T
M7^:W[XJ\EXW\?C9YI;)!TRZC*I<WZM6' VL/;%R#SO0A^YQJLQ0BD'.H&E-?
M]"[]+308,&YO-Z=,NS?TI&>(GR]HMJ3:EYN7=\_?/3)*I,YFDPN8Z*H)^1L0
MCH669PNY^$5O#E]=Y^KHU>M^H=^%7TPBP98 4@0)#BUKZ,TN6''&7P1U-EN-
M^783_CM5)7LY6=4GZ'DS/?!P>K.,R)T1+J]CP8"D))5-K%WAJN'RG&J(?;*Z
M-23Y:FKK'KPU@F?BFL"K*FT@'*$"E&!R;*&(LVSZL._*(]@U>+$^]S8@7?FL
M$UF^@]?#8_I4_W3M8^G7X)=N87\BD9.4K-* P9$O+DJPV++CF$H;0SKE]M)E
M"UU4'002J DB@2V-))!ARN@#&&2\7/Q( U[\N)UTZ6LI'ZE=UKCL @A(E41#
M7@/-Y^QL;X3X_]E[\Z8XDB1]^*ND,?/.=IM5T'$?TJS,:$!JYJ<J)$"MA7]D
M<8I"=3!U",&G?SVR"B@NB;L.<G9%0QV9D>'NCS_N$>'.A&)4$3HO>Q9?IKI,
M8<<D\<R!CCB7<I)$:BZ%5"PQJ8-,>,:+Q3U"L+\@FO0TQVZ5#,0HXZD*W'IO
MP.$XIQ1G+G$SZS75*N6X=A'YT3;'1XVCM(2X? Q/.VV-H%Y2(['7U,G%B'H^
MM)O=7\6A#XV1+R7H8^][TS^X*^PL;OF:3KPEB1+$JT@%SGW%B,XE"C&.7(!_
M$PPO1KQ5*>K<1WJ<!1:42#9HRC6+3FC"@DTZ)**\9XL1Z56*.O<Q9C*,1FXD
M! F$$Z4LXUI;94W0Q@-#7(P8LU+4N8]NG;=923G'47/MO?5)1NREBREQ(<7"
M1[?/H<,W+_'D-@?Y*/%^MQ5BKU_9THS%]YE,$(!P+Y3FWFOK8TA&>2 BF-I1
M]='9A>_*/"KS>-(,!PN!)&FH!E[.C17:1O C).]&#-'S>5C7G89.W():K;6_
M+HKF33^_$:A4."1'&?'<,VDUQD!VN,38"HK3'.0W*C5=_.R&98HHBG4@E/(
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M\!_"F!^U;(#HDU32N:5TP'8(18P\@G1,TC*DE#.PD4>F0"R1\V!CP)X9JN:
MD^:]\CO-0=XHO]$)S>_-,+2MD33R6VO-7O2#[H/+B\[:4:_IL%V#'3A0KU@T
MC%,/#-=B2G$*5$7GW3QD&UZPODQA;Y?20B1A*%7 HC6V$7Z#T)='HZ,U<0ZB
MHQ>J+].)NP23+@D?*'.2XT2<23E=0FEBPGLS#[5@7K"^3*.<>O34I^2)2\!?
MI$Z.Y\Z@CG! G7A97V:19LY_E;$+9/0AI9=CXA;FU5&%.=',)A&5Q81HIQ/!
M;@[(Z&G,L )7",W6<-#\'K>C'_;*MH#K/WQK&&)XV^NV5[OMP^' YDAB,ZU;
M$&OG:_]#[)6UF?X\OOX"%\O<K;</6]WC&+<'7?]M\W"PH!G6X+VTV72MMCPF
MY0R&5Y3VP82HM9H##K'8:C&E39F*2BNLB)Y)#HAA,!7:6^XT23JP-$=HL0T"
M+UWTZ$QWUH%N!_Z\)-C/MM>SBQE7"BZXBH1:&1R7TCN!98H08D9-O6?SU"9Y
MEH0Y'<L,CEJOO1%$*Z!A7!LN;534!UT2^CFRS&<![*W8'_2:?A!#"=F+:-\X
M6JS!D;M *9>):4J8I$D2IRA+S,Z1?2^>2DP'):04@0O+@=P%'@T$9]*!DB0=
MM2!!S4,J\8Z0#Z^WNYUGLO'GS_51ISW&3$<E!,<A64EM2@9K9;7 @L]![F96
M!3J=Y(I4! 08DC#!<NR84Y)RCUUP,4_Y/&V"6,S :TI=#2Q+U/#<P0!S"OH@
MX/]9\B&:))+S<V3GBZD6TT&+*),@+.2*HI@'9FR00A*B:<HG?J*=([28I1!N
M2I4\O%5)>@C@O.,D14>,,U[+%*+D<D3.YL3&9TF84UHD21QT(W"GC>%:< C.
M,<L%U300\"3='%GFX@5?4[)O2P"I+254.RY(=#P(;"6S!EX/8IYV0BZ>2DP'
M)1C#23D:<; &(-^9K!@XPB^*1B[&'=?S"NJS+:7>?=XN+$4^SZIE,#P&)Q4%
M6LQI\+FC=T@I"IEB(/@TVPD6]&SH>@\(FE2BYX$@GYBVVGH6P"7E8F'181Q\
M(!:>"C-R.F\S[)5F<>E^)*%GW^>5E.9"N(#S!@R1T4. 7*FVC$@@'J,]V 3/
MWO:+,YHX=/WXWV'FB=_AQ\[Q8;S45.[B!QZZ?^?,?7G?'0(;;70'L?^^:SNY
M(]/;9L=V/+BIK>AC\[MUK9AW&Y_^?G5PY;?//_!TFXMFK9]5WE*UDE*SU<QO
MC(;[Q#OC"7ZDO=?$8Z>(]UX3[H-P-C?3PPZ[)(4VXYHU!(\!L#*>RGCFTG@N
M>2>";^V=+EC:;;U3\\>K7G[2_-#[S</"]GROV[IH$ODKR]W>US^ 5[ _QI_X
M(\%4H=3M#CJ@$$M%@M!A*Z9^YGCL[V.WUOW^GFY]WV7U83A8_[[WSAQLMC^)
MQMI77G^W?KRW]O>WO8./1WMK_VDV3G9/]G8:^_5W__FV]WF7;7ZN_WC/&JW=
MD\/6YLY'OKGVYWZ]_9'LO=O%]7<?CW<//*W33R>[.W\V]][]W6Z<M [J?^OC
M>M.T??MM9_/ X_J:%_7V%GS_TS'<A^Y]7N<-NG=0/]E@]<];S<8[N.Z[=;C/
MUOYN^T=K\^#C26/M$X?/DCIM[._M;+5W=]XV-W="JP%C:*S5V>[."FGL?&*G
MWX%[#??H)PGOX<;.?AN^?[)+W[8:[_;VZY\W1(-^(O"\N'X2]NMK\/M.2(V=
M^J"^C7^\WUD?U%>^*&V3$2XB9EE / '#,,'";U'SQ(-B1O*BFM!?3>CQV81:
MHX5Q,)<62XVX8 )IYQE*.G >P5,HZZH)_=F$U@^^36HHR6F-Y!6242K$/02T
M#C.-A,%1.863L;Z:T%].Z+F&$FF 4R2&? 2[Y\ECY'@V^8 %I4DJZ=A2T6IV
MOFW]'(A+%,Z?6RH&W?F$WE;\:^MX[W,X=)3+QLG'H\;)M^.]=S#6G?_ W.ZU
M=G>^LKUV_:1^X'_LO=O >_ ,(*-4W]DX@O%1>%W _8X;.QM?I-5*>(&1B@JF
M4RJ+M(:)=9K*%#5+PJ6EHML+L?>_2YD<_G')^9V^TN\.>S[V1W_N1QM*5QZ:
MW]_\&WZ,UV\,UQI;FDLO<QRH4Y)%9K$+,2GCR9?R!F??Z0^.LRS;S0[:C\VO
M^X-73!X.7A\UPV#_%9#6_V^I_-R;?_</;>?-OUWO#_CVZ/?11:Y>RO:^PM5<
M=S#HME\)N-CXE4'W,/\)%QQD?G;Z>5<^./+=5LL>]N.KTU]>AV;_L&6/@9N#
M+D54?NGU]]@KB[$C(%U?.Z_@FN=C7<:C\0Y@5@;A]/KCMY?+M_X8A*OO&;UL
M\,UOXV5R]MX?Y;5[IQ\XG;+14X4"QI[GYG^7P% N/MYX.LCAH.AW6\U0_ .7
M_WL]?C]/#KWRYJ$- 1CP*UR0\A;G8_BCG(Z;IS]?3\/<9S(UGBL/["[VED:B
M//TXC+C;>W5ZOP3L"R7;;K:.7_W/#K#2?M&(1\56MVT[_U/K PU%?>!K:?3!
M?O,DPKS#7<H_CT:3H> ZI<#&DT-HGMI/C8V=];5B>V=E9WW[H@9-#'Y61KN]
MOOII:V-G8WV[6&FL%>O_M_K72N/=>K&Z6:]O;&]O;#9FZ!'XM8_PV0)R=+X.
MNIU:L;:\NEQ0++BY<=@SJC9O-[?J18X%.MU.KF7;:_IB'"* 8\DK( !P)FH(
MMQGC^1R!)#2WI! <2^-(O&Y1K.C8'%OG &^MZW.%W#+471HG@J?CJ7Z\IWO'
MNY^]W#W8/]C=V3AIG.P=[.U\Q(VU7;Q[\O5XM_T6KO=WJ[ZV<;*Y]A4\>/U[
M>/<W#W_]I[5'6]_=P6%S\QV,XZ#.&NU&J[$&WSW8.MB$,>Y^AK%__G0$[\%X
M/I$Z <^X]E5\H5B)!+X=&>XYXL2!SX].H"AQ<E)2&X-<>@,!W,?2YYQ+X4WQ
M*U6:(P= EY4RM\+_.[D5L8SIS5^]QJW<Y$-.W0 ]_)$=P:1UMF(:7#,G2X^%
M22N]IFT5GSI-WPVQJ&\_#)0>W9)3M]>V _@V/& _^E>NVVTYVVIU!Z[[XSI#
M_SBT/9B UO%6/.SV!G-I\V^;[MTG63]9.6H<K/"]SXUOC1/_H[$&S)ZNT]W/
M?[?W=OYST#@);1@WK7_^./[.WW OT=G;Z9[4UU9H?6V_M4L_LL;).F[0=1C;
MWO[>Y[U6O0WX07>/=G=V?^R]U4?O=U;&8=?*%^8 +XCC*!CXP2V$6PZ$@7)]
M.R.(Q5;:I3?_^H=17+Z^C!B7>./8)AY1W:?CHCY^6MG:6=]ZOUMLK7_8W-HI
M/GS:VOZTTM@I=C8+(!([P!8*PHK-K8*(W\+OQ>;;8N>O]6*"8YSQBY75G?PV
M,8Q?,UNW)GYR*A[\>I-_V^T5@_U8_/?4\(I1QJ^(G1##X_OV"41X%?*6(;CB
M?K#'Q]'V8N<Z2/A0CF=]E)><2T"X-PGX43]8@>?9/8;P%D+<75'_^"4WTTR>
M<L1R2H5[Z9$1G" 9@K.>.> %&!AR/!R,DM<,UXH\_8]$$'1%$"J",$6"4"ZV
M-'/F9>X90F.M3NJ?_V[M[7B^>[ +X_1'=?H6QOBVO?OYX\EN^R.  0!#>_<R
M0\#UDT\_]N"[C9/]9N/@&VZ<K)SL?MYJUS\#2UAK-/?65H[K[?\T]UH7&0)6
M.F%F$S*6>L0=2\@2KY 6Q%B>DM<JC1D"?RD,86=KI;&]4?* BB+\A"(,SDSO
ME"/DM;OB7_\@$K_^\N7+Z)=!MX#?E^<MDY$/&37[>9&W>-L$W];H+C]E8F.T
M"ISO!%<'-SV7,/:@Y ;_$I)R+(J 1% 1<6D"TF4&/IH4,/$,8YVW4A#$%#/T
MS@3F^52,WTK%GER=MN+79C];Z2!WJ']Q*O5-?%&,Y8.M'@6)%>(A:*0) _>F
MG7/ E8T)<>G-RB$PU&XQ+MU4_-5M96_5KQ6Y<?OMU6Q6\/FW]1_6#TIM*+JI
MZ)UI06'[1?\PYGTP$,HU.T5ST"_\?AGH_7YO^G^M/<U80,!OOV3T1)>]?T0P
MFM/+TS(2Q_-K&'X6VM_/IX<.>]WO68DOI@%&T :6V>T!WR_77,NS1JMY2UKO
M>!7"FKE$NG&6\/,G6C_8WP=D:^VU\]Z!5G,3_M7?U?,]CQKOWAXT#NH_=D^N
MQ  _]G9VCS??K=,&C&5O[2O>_+S!X=_1[DE^OA6\^[E.ZR?P_4LQ0$R< C^5
M.66@$:>:(9<T1EY8Q[D@/A  R;78LD>V%V\, NY%_U^"<E_6W1W[8V.\^].7
M^CO'E.^YM7;]3&M# (+H&$:$28(X>'H(6I5")@D938PR>+?TQ@C$N:(L+Z7^
M1&\7"IU_*_&P@"AM$\*T7O&?8:_9!VJ356WAK/6WC>6MY>WE8GS<N[>X8@4J
M=\'K_;YPLKR(BL4(%G^_*M%YVTSSY!YE)81>[/?'_WD/ R!SZ4T>%.VQ+]13
MH1,1B&F(\;A3 CEN**+<!D8=-MCFW1%2Z@(0XYWM01S4"L7*]]@97N$UM:=/
M]UP5&WUY8L-?*(XLV>@1,1'<M;($:<.!A.J@<TT+(BFH<Y[^)L@IK.0XP6),
M282@/D(<+P.W6#*2*'Q<8F*96GIS)3]TBB./B@!R6=P" EX?=D>)TO$VT>_Q
M=<8HQ,IO7X9@VX_Y B/<&#_V"!%'#9I_]>B7IHI8*A.)PD9K.5 D2[CQ3&OC
MA(F,IJ4WG5#.U>2MGF:V[H"75Y_[U\]1O&UUN[VKS_)\IKP*OV[V=KI'G9=G
MR.2+P$*+0"SR-%K$A?2 OS@B';EV0GB<"%YZL]+:MVW7L\\ N'=.*XS%6!+H
MS=X'^&2SX^<SG_ @61Y]P1+3(*Q$%D(KD*7B2*O$$<&<1I=P\!QD>7Z6[FJ:
M])E,[D,7I-K::Q[.;>;G09+Z\84K(90F%!EN$K">8)'&0J!HK W6J2"I@$"8
MZ'S^;^YRV6,IYT3V80^,L7EH6T7\$7U9. 1>AG !;F<[H3AI'A9Y5\,O4]FS
M%A_\]H2VDCW22B_:EVD=QU]24)%Z)Q %0 -R23$RF!/$HC!<JL1T"DMO))67
M;>/WIT2P]UW@>Q_VNYV7NMS[C7\)6FL;<4+*)8(XH< 6!)6(V) $$R(&"9*A
MFB),M9Y#Z#I??OW7/S0EZG6_&,16/,QB+SJEW&L%0%IKF',TA04K'>'7:./$
M+5%L2D^7F^SXG&9TQX7?C_Y; </Z5ASMQS+GF/>'3"P\_D9^+_9MOTC-5@R%
M;;7@S;Q;JP___>^PV8,7!]W"Q?$'X)K;L<Q7YFTVW=YXFPWX@'S=\VI1Q?H/
MOV\[7V.QX@?Y[;S-I@CP+LQG_NAA+_I8SBZA1;FUM%_\!M<#SE+TAWZ_Z.]W
M\^KGZ0:6P;X=7![[D;TXRCS$T9?'S_![K70_O]'1,SI@EO"^.X GR)\O/YI/
M^\,HQM?)&]?ZY2#*0=K^H#"X"/:X_VHD^]'/XHY!V./N[3O;%OX<@>#U0RB*
MIZ>1J\->#\0QVCT(,LK<?]A_>8!\\B4DF"I%.1(A[P4,"8BD% ;%($1NH!XM
M=DMO=F/_,A9/ZNR,Z2]_7=QU%(^JP8WN(L%XAC= MG9S,  L!%_F![UN)^>N
M6L=%_!Y[Q\5&]KBY^ F0\S4[L*/=<Y=0_OP:A\->?Y@O#6]L#>&3'(L,Y. [
MAZ,#U<4VVBE^RPJE7E-&E\<?&.PWR[TKAWGORE-#_FB\9T@>^[\OSYB>3QFG
M)V?CR1%[0L6RAHT!_,4A]E?V)8IDM>8,:6(AN!'<(L-,0$S(E!(-EGM5(?9+
M1FP 25NT8-RQL-X#8O=RS:D2Q'J9ME[[:@&:@JY]H]\&J(>[]$[9$IAW&R;A
M.)-TN!HPVSQ%7XNOO>[18/_TW67@[+$<6HBIV2F70LJ43@Z,*#SE#0,LWR:O
M3S_VRP_<.+RS#V:B/O[P#6,]_62S,W)(A#I$3T./R7CCEUO:Y^C %)?+F,I[
M[8_\V7MT62KV^+LNGVZP8@JGN\ZV7#S#@9?K(>7]]>;W5,=[[O7 3^)I9NH)
M'U6D3[Z4-BH]6.I)]D9?N[WCZQ;4,OOOK8X_,)<4;;S#\=U6JPZ?V5S;;^6:
M7(VUM^W=?,X.OIMK4=4_P_T^U\GN0?WR#L>CO7>?X'H;?!/^VZ#K\/F]YF:^
M[\''7(OJ1WZVW9._FT#KCM[O;)R?WC>2!DX\LD3Z7#'-Y=/[&/F\$NZ9#L*G
MI3<K5\WV>4[IS8H9R^O,>-$@NG$=(UMTR2XR0&_?1%5GZI$7Y;3XR!F5<_[G
ML \#Z\]GAO=9G1$XH?J9,U*Y?ZB@##%+!>):&F2#IRA*0XSW3H>\Z>[V!\5O
M"= 7*ND]VD?G!B76KX]1*XQX,HPXG?%WY82OCN:[PHI?8<7Q)%9$EI1E.""E
M64+<Z(3RP6X4N&$N41)=<G?&BEMN^I]65B[])/V55_FO3=HUTW4K+.6Z"G"\
M3K=<%AGV1ZDS,(-1#:9KZBYT>^6]6L?YYD=-N'7.R77@V;J98GQO]DO.6%;H
M!V.UHP+^^<.YCT*PO= O\K[(9KBT)G.^#/^;_?W:+-A,I(P7+F7;WX^MUEER
M]3?0BC)S.CJV_?.\Y.^O9B&7/VT<W\X3.,_P_:#%?/J%!BJE4QR)%!3P-1.0
ME4JC&(*- BM%L;P1@Z>[ K,;^U=7IJ:/,M-=8AW;]*U7IV9F<^O$;JT1R,7>
M]3YF](2$_N;.' V@V:L%JEO+V#)E]ZM+]XNU$O/XJRQ$+!NCYF2PE"QKK9_D
MLN:IZWO\*A";WK[6&\JC-0>MLK#,NO7[Q6K+]OMWCD>?-E:?N1GKV7)#TO9Q
MVW5;CS=9\M9="Q9H,AOCLD:E]IWQ7@A1/N\WX96M,Q]S]Z331&^'!T_A8];L
MG.V5P7/F/7;UQQ":E" QE[Q[7(OS8!<WVEO[N[0N]@[^_@;CI'OM_WS;W7G;
MVCOX=E1?^[-5?[?+]G:N5#2AC=RKYMW;@]V35KOQ^2/>7-MK[\*UZI__;F_N
MK!S5WWTZVCL(K48KIUC/Z_"0H"@AUB+,J,K5NH&R"T)0<MZ%H+PF,8T*$^9=
MD;DA<JWX9R8CI#BTO>*[;0UCS@A \/BS.CV/B-&5P3S,8,:.8>07*FNYA;6<
MKX[3Z*@FPB'!<X ;J4/:*8J4L%I1@7D08>G-2GW]KZ>SA"L.^,Z6<'T5EI$M
M3&6=V?:#_6^Q:@^; PB@Z[;W+0[N78%E2@^Q4NXM;'2_EQ7/1W$E'54]K^6X
MLA>+H_QC;-EO>Z-FG<6PTQS9=0F@_:6+MDX9BTX8%;51'&OGC/5!BEQG*I"
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M3_VR_]N84E=\>N&50S[:L9J*?\V"2$6U)V3!Q+D6DRTWZWTZS*T)8Z?9[4W
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M#KS6[!>AZX?YQ'K1W[>M5K%OO\>R')<-!S9+H6C'7(_T:[_HQT$NUC78AVO
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MC=5%P_-RT\M&)MF=4BUR;LIV?.R=Q4LO:C5OX\.BY:SR[N;#6&YQ+@Y[UL/
M8F''.:L%EN3[A<LMO[?;%ECVF3DN?N*QOG!,JVYA-$W_[27M9*I_6+2=AJ?"
M^]#K'L*PCHL/XUAV4478>+=X:^H-&%OQ+G;&K?B*R8W>Y6;#S=Y7VVF>++27
M;"S<[J5&'!QU>]]>W/:E#RL+MYSSP?IF:OIBI>WR5NYN[WCR!,9"K^1\J&]L
M+JHX3RUSHVV_EJ?;.J'8[.11?#U?I5MD4]U>7;BT\'9WF(M^=":336"KO<%8
MH O+C#ZMKBP:N_W4:<)P^F4F"&C0BO_OL#DZ8GW&<Q<:>S^M+MKJW$6)+C:X
M_KVQOF#2^VY[S3(J:68DC?U!$7/#VN.K$KRQMD-590$&R6ZNLC#=@@DW%4BX
MJ73&+>M!L*5K[C6KQ1DV&CM;FVN?5G<VMW:+QN;.^M7'_O43_*).R7,KW*=.
M*_;[9=D%#Q_.^09@OH.<L2VZF2X=-?N QKV8P*P['EX]K=[P<0B.-O9:Q\56
M/.P"BP+?^[;;:Q<$HX_%H%M>\U__T)3BU^.MB[7R3_+Z].6C>/F58?_R*]UA
M[^RES,+[39@%VRL@@ [](CO_B;'!72^=#/JKVRH[0-7.EAK7 $^.\O<F%AIK
MY:6;@WZ>!,".9BAW1?>'KM\,3<"V<1E\FU*SU2S?*_$-7H>OPGN'A[WN82^_
M4X,)\JUAONG5"]X D_GROXV?%WQ#?_R\OY?W'+]^=I#M=#+*Q_[U(R^ CN9"
M(W?99'<VEZOU[;.I+*N+=+J#(E<IB4<@C+R7MI\UO3QR7:J_A7N'6VIXB'W?
M:[HLYZSI>9])TS</1XFZ;BHNG(<Y&]+HZ,_9J,I;Q>).>;ZS:Y49S[-+U;LA
MMA9"W#T;0%2V/3:Z0?X;AO^M/)J2I^MT)_2IT5ZPT](N<DL+L S KPA37%X%
M[M&#-_N'T6<Z44 HW\W6"[,+&%,<CO/DR\7.KV6?J]F,]:7(+&V\*CVX./(_
M0%<O#KY$5/AF'GZ)'4?[3;]?CJ'4H=-<_>@Y+XZW>Y2CFN7B<RQ"M]3D#"+P
M9'GTP]R?HU>,MS9<<ZNL)D2]_OD0 ;M2-HM:GKMF^["5IQ@@*G1[_='&1_AX
M_S C6KDG+M]GV"\<V-$0'F/BN7+]'Q#0B+O!Y_.'CYJ#_6*\@1T&UX_G7[B7
MVDZ+"ZA<UB>[_V+ES\U/.\7;S:W/*UMKZ/WFYO_;:+PKMG=6=M;KZXV=[0<8
MXY1L[U__(!*_OOKS%C8QMH?^J<,"I 8W&U"KV_V60?(<:D\]6%:(,0".*SV=
M&OB'7O,[?'JR"\U[^,_7$?YMQ5RU%4"RW-1'C!&U_,GR/:I63B\R\>6SCS(V
M\M?MO-L@%+]-<)2+'S^%U1$S.+LZ6;_FZNL__+[M?(T3M^$WWF;RPZ<W62Y6
M6JU)7S0RWL%^J0#GKZ8"Q##H]DHWGRS<K?2"MYWO[#L/AT!Z^J-6/RD&<#BM
M$:W*GR[ZYP\%)*D_P65JA1L.2M0YW1L[Z-8F!V==%SXP@<[_TR^^#H'W #$K
M[YS?.H[ W&!.\OC6HH]M!X_)2*V@F.+:98\\NF2&-S?L@ZH"3_WMG%SEZP%&
MV=&<Y[\H)J9H=+_'<AL0(/+W9@_@Z;?5S;\WUA QOX.3!GFTFSYK[N1U0<RI
MV8&A-F$Z0)%'B XP=EAZ9+@; '%NME$K %\[&>#<P0B7X??X(V/TN/)9Z9,R
M,)=_CI[I;![*:Y:^YF"D45D.< ';ZXP8&Y"3V!F66#[2@?-AP:2WX1,ETH)N
MC7U6O@X(P]M\UJO4T=3KM@M@/K>;]+,[C7B^'?N3-!P,0;5:S?_"T"&.GV2U
MWO;WB]3J'HTY,3S@X;AN35$6A"SO^D_!Q3(N *-:>52M+NCR$1AZ=C_@7?)-
M@.K6BM'I[]>79=]-HPN/9KL//FH0OY[2\//)SY]KG^_+SX\\'OI8='F*3Z>L
M!!JX3B]/9_<P0]BP,]+VLD8=#,_%5A-$ "+-Q^;RY?) QQI]99"@*3Z6HBM=
M=S>7\.F/26@-"")H8O>P_&@-$"X?\1E7QCO+5O:O7+,7OX(5GRHX&$"VYU-]
M+1G?B.F5KG@\+3[[\$[?^E]=\GRJQGR@7V0R7(+!:-JNZ#(\6$E!1M1[>/7J
M(RL]_5AF*C9T#T]9< >N;D=L=@Q*G6!SY 87BRF5%X:/C3"Q#"ZO^_1/'NET
MW""+;K;L,^LM;P%*4%;X!CE=IV*EN-.URM?O#]N'H^N,JIP>C]:!3NE+GH[X
MM0LOCN+2D;E.7*14J8S/&30OX3;0N+<WPO5IK<1F)N+-E$]G \/*MQR.NK!=
M1GK0Z/:YEH_=@>V,PY$K,39,;RM<>=%V+K\$P[CR4J8*EU\\[)9H9UM7WNCE
MR.S*Y_O[UPT @N%F^YK1CA3RZJ5+Y+O\\MA\+[^<:<:W*Y=H77WDV/G>S.?<
M+[\^8MI7)S*KZ?#J[8#=Q:N/'>.5,90I%^#9USRW&P:X2+QRTR, U"NO79C0
M<;0#IO?5CB*'-%*.4D]J8TTM4Q%C.^E,O'_N>DXS+=UQ&-$KP]$R[P)N<+]G
M2QK1*[_6[)1+HSEXRL3^9BX"0 $?Z(S<^JG,QXYDPN2ZG1Q[G 5\.7LR^OV7
M-+2\$E@=Q(190[*O&8'+0T+C&6/C/\&.9N=[MP4R[S7[WT;3.LP^*C/SLV:.
M>7I<66^N.V+?0/IZ628C.+R.T8PO<5%&DZYWN=CNMDO>DDNYGFK<S1><O%#&
MNPR2I[X99BA?*+\,6@K(#)+(J_( :2#TDM\ A@X!2\>L#&Z>[S;IE. 1_YO/
M[9W")S!%4!6XPIFGJ)5:'7/Z#1"C^ J\L=?)WQXSXD'T^Z56GZ%VMS=&]1)!
M@0>5>#Q!(\^(RO$H KXPR-+C?1^YABY$ZN#\>F>/?/I<@WT@$=D+EB3L1C$O
M%Z>-E,?5=<MSXN,!]<I0K-<$PEY2K5(2H_N=9G SE8LC2G_JH29I_6@4H=GW
MP_ZX8&\>STJGDY_GJM7]O]H5LIGSE%E5+Q%.8C+3;L$URVQ &4BMK^9KU6T/
MADGD:2PP$7GD3V5]/A/"^<C.^>9^M"4?&$/B9+/I4V!LCA:'BXU:438.V%C)
MW^S%;H+Y7&G!4P^_[D^RP')N\\4OJ&\OIM:(=?]23N/\M.U#, +@6;NL$B-%
M^JDNG'/\K%'9:D8W'C.17^G)YCF9OR;"*17]3#_3!&DNX]>C"+:<XUBXU\TW
MJ5V/M[5QNO[,=F_$I"LV-9ZE<RI7RT08S'4,8*<C_K4=Y<SP8(0 _8L0<8T[
MN.6:E7S(FM64*GA?OZ#U865KI]@HWFXT5AJK&ROOBXW&V\VM^LK.QF;CCJ7R
M;SEWYA9S-ZW5O9WU>D&6B]7-QO;F^XVUE9WUM8FI.<_J%:CXU%CYM 9?6*MZ
M!OR,O_#'Z!E Z6/T#-#DFO7O2PHXGGJJIC1A/VOUL5.2[USZI5LFE_KW7*]_
M;JM:^;#Y_OUF45]?VU@%*_IK\_W:1N/=-GC@QNK-C'Q61G\!"_Y<>0]8L%YL
M_[6^_I/<_O./_7KC^VVC4>S\M?EI>Z6Q!O.]_G^KZQ]V8/ K6^L%O%1\6-\:
M_P6/M_+[[#_/&>C>/-:9:?]@S#*5YC[M'Q1>5NKFM^_;_H'098;IO2[[\UL2
M*IYFL.PQ>U7@O(/NY\?"?[+=;NQ5KVT8]<RP--K)' \'XZ@*UTI"EF.F.VPI
M7*SIF(PQQ[-!S'5[1R^1,\++27CP5(TQH^2OAX.BW.Y3G#[V/:;\26XY,YUG
MGY9N]/OQ"C=Z0!_/VXCBV:]Q#VW^99.\>PUR'J[QK'H_#?1;'2=O[475GR6%
M?42EO[=2C.58Y/_*45 ^ R*]J8!5?W^4=L^_Q/\.F]]MZTI?F'-:=*N'Q\4\
M'"3XYX,><?+1RMJI,_5L_V[^R$6'WO9&"_5%WGRPE;MF#OMAZ73[=?E"4R8B
M%&'.D.@XIMYY8JCD(5!&E6?ART9F?-@PO%2$Z)MMV^K_[Q(">Q@UM(9+_!B\
MZ@S;H3L8O[]4[OK+-T-?K3U\E95LI1/R?];/-6QEL&I[O;S6_;=M#2/8%TQ>
M+"VM3-<$]O>Q6^M^?T^WON^R^C <K'_?>V<.-MN?1&/M*Z^_6S_>6_O[V][!
MQZ.]M?\T&R>[)WL[C?WZN_]\V_N\RS8_UW^\9XW6[LEA:W/G(]]<^W._WOY(
M]M[MXOJ[C\>[!Y[6Z:>3W9T_FWOO_FXW3EH'];_U<;UIVK[]MK-YX'%]S8MZ
M>PN^_^D8[D/W/J_S!MT[J)]LL/KGK6;C'5SWW3K<9VM_M_VCM7GP\:2Q]HG#
M9TF=-O;W=K;:NSMOFYL[H=6 ,336ZFQW9X4T=CZQT^_ O89[]).$]W!C9[\-
MWS_9I6];C7=[^_7/&Z)!/Q%X7EP_"?OU-?A])Z3&-O[Q?F=]4-_&1U^2HE@G
M1I"T42'.M$!.>(UL#(XHJ73D;ND-D;*&-?WW'Q=58[SR]Q!;.,6Z.]C$8_KM
M"ID6%)D8=DH+&XABB@?&C;4V1:P]M98$93,R$4,H(Q4RS1(RG9PA4[3>,<T-
MBB9*Q!-SR'"BD9#2V92"BS0 ,F%6(]K,$#(]$I.?"P:X%?N#7G.\M;._?R.K
MIW=[_&N1=J[AZ'&(TDGL=0/,\V4D.A=#!J-QI%4ASUV0ISG!B0P3,H!6HJ %
M1ESKA S!'"4&)(F3E(P6>=>3IH2^?BCR_,3ZGXH3W38&?O%6>W\24=GGH]OG
M.3-PU-#$8D)26X>X<A@9Q2G"RCEB$]$^Z*4W2LR0:;ZDM-!$Q?IFI\@G]N)X
M[?+LV,Z]B,)M0[*YAIQGR*C4SR1R?CBLPJ1[8-+Q!&<@3%FCF$ 0F7C$K>%(
MTT@0\\&)$$0*Q$*T0G2-X5F*5AY[_>/%&_ S)!XJ WXT SXG%=IZ$XQSR$K%
M$4\&?M.$($XQL'YC2 JE <N:8+-DP"\KW>!C\WM6_'ZMZ,2;^^B]^,CE&6C$
MN/A'_UPHC3BH8.CN,+2Y.L$CN&54)JF1%1AX!$\.&<LUBB$ZD;#Q*4)L S2"
M"C5#\4V5>I@_&E$9\.,9\,2R1<11^VR[@I/\ PQ8.8.H]5H)&QG3//.(&L9\
MA@SX)24H+M.(\C >*6N5M>QI/[TJ2S%K]&)K))T/(^%40'4/H)K<^0'S[A4.
M&C'K(P0\/B!MB$9*>.DCC\%%M_2&DYH@>H;BG2IAL0A,H[+E1[#E<]*!K7;<
M0=3@$^>(TT"182:BP)-EP#FD,QAL6=<(DS-DRR\I=[%9%BOIG5./*GDQ1791
M2F."!U:1S[U J+ZSD@%H1"I6ODB=M&#.H2P=Q*5VR'+X83QG5H?(.)=+;UC-
MZ <SBBIW,;OV^PR,HK+?Q[/?XS/[Q8$;PSG0".89XCH0I",E*"J<$H[*8Q[S
M9O":UM7FBBEU?NK%PUQ$/)?ZZ?1/"TV.BBC?[H35BP]XGH%>C*6T/A+22B>4
M>#4Z]5GAU'UP:GV29]@DO?(Q(.*P1)Q'@QQ/!D7/DPA*$>GRUG!:(V26EFJK
MU,7\$8W*DI_ DL\9A\!<&>\5PC98Q).*R/ $C,/%X"S3W J3#WG4&'DPXZ@2
M%_?KE9Y+8I_G+:JTQ11Y1:,[B'T H2R3:MWVX5BT,<DJN"98^""1%<DA'JQ"
MSFJ35T6P3R"WE.32&UGC=):"GRI[,7^DHC+C1S?C<TK!!4T8!R 2V 7$!:/(
MA9#/MHN(@TS&"35[9OR2<AB7&$6U_6*V3I.6Z%0MU3XF0-4O\ Q,&/>4HQ2<
M 8""F$>G))#"4BKMM+.1/=KQTBI],;MF_%Q,H[+E1[;E";+!A"6:QKS= B-N
M@D>6*XT(YE%)E:PN=WO*FL!XADSY44KS/6(IM<<J33EC@WPD4C<SQ2QO:(3:
MS;U(;EA]NKZTY8N'_N?80%OEJ.^-\9\F^1H#<L9T#"A@RR&,9!)9PCV2*1+E
M(;Y,FBZ]85+6I*EVRBZPT3['3MG*:!]BM.?$+) 0C!0<!6' :*,@R%J=2X88
M2H5+.,ALM-34L)PEHZV8V>(QLVF46VYT.[?<#U15SIZ?S&E5;^_)^?7/*G>=
M&U7EFN_DFK].\FD'<K%.2>04IH@;'!"P:XZPI$8:I0E58NF-X@\^J5*MLLZN
M@3Y-:;W*0.]OH.?<V05@QSQ8X,[4@X%RG@U4H(1-%,)&2=G,&>B+6C^UG5#+
M'5</843'Y0[PW'SA,)?<NW]=G!<1PC_+WN^17#ZT;&>PT@GKIZ*!W]^6O6WC
M^VC[<2L_P6;ZU(]ET+^2^T.N>#]L#\LUFK5XV(,;E!T6X9LK[2Y,^$GY9X5M
M=\*V;Q>.J%%G90@!&6,%XHD;!*['(Q(Q49@;0:4O-YP:6FT=7V @>):MXQ40
MS!H03) <2:+ 3B.J4D3<4PWQB$J(:DZD9* )UH[.D+ 97+E]$=F.C<[ =KXV
M\Q:Q40ZK*OHW;7)S+I+12D4C#M9_^-8PS^J[;C<<-5NM"I7N@DH'%T[0$\=
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MEXR#8J$HC/?1^KA5",@*+K[MBF[:-D Z+#@T!"\#P3,;'Z0C2S%",54&))1
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MH")7Q3,[!L0CEAQ9:6^-M5;YXIEUGYN6'V\D*:QN7DDCA4Z1PLQX:96Y("M
M:B[KU), 3BH!V?O@$]?&Y7HB&_LHVJ"$C22%U8T]::30)5*8D>$PNU0>@0A<
MJD(*+B!8S3R4W+X\%2EJIFN)F))]S>\\=+ZQ0A=9877C4QHK=(H5+D,%KC/S
MTC*PEBQ@XA%(! VR[I#++!6E.@];]4L4T152Z)JTUSYCC3[C(<AL/S=AK>O"
M6G%X9_M2WZ63E ?MW/-\3NS*Q%[4E@N)'BB'#*B=!$_2 W/.:IN"B+R>>V9]
MHUJ^NY$ 7KX(U@!\9P"_GU6QA:^E79$Q 2CK*$ L7S*3(D9BD<54]Y>U[<RY
MAX;?]=:K&G[OBM_9MKU)*Z,R 7I'-8MT)9\,"HS!^A/FK--;VXA]P=KYPXT$
M\/*EI0;@.P-XQ@$[7CMN(ZA8CQM&H\!2(B@!4V"!I1BLW=K6?;2R*_CMF@JT
MH65);9&MP.M6RI.H'F,_W:G7].;[R64J33^/AL4MULV3YAKG<HU7ICL9%(RT
M2$ R)$ =-'CG)'#K/#,)7=9FND,B6FR[D9A=IKC4,/OUF+T,9\DRKG3,X+1B
M@.0S^,*FP,@I8I04!9P*PK(S!Q8:9M=54&J8_6K,SAX3+!P;DG206 $NLE0\
M;E09@F06/6)AWEPQZ_K(FPJ\D:!=IHC40/OUH)V=^!"CM E!):\!;0F3/5)Y
M9%'$VO_5*UUW7FW?J28<?5E)D.5ZXO"M/TY=UCO:*I>_RLT2CS[Q%!^)1STZ
M/1T-_-M3JC?F=-@KM%$]Q6AX7-[VJKQJ6B':1*:5BTS%:)=%NCLS9CL<[E\Q
M6AOP\%7N]DK+]:"3\<6O F9I2XRL2X8;A072I(R0+);<MHY'-;S5.6TDLI?:
MSJHA^[Z1/1-("Y<9H@1240(&'\"AC^!XD(84F6#5UK;I,]F.\6XDLI?:YJHA
M^YZ1/:-K,4^22 3(P2*@MZ9@W$4@XPN;I\RCB,5G\[YFG4F1&[375=9JT+YW
M:,_TIF26<B(+);V*=8(*@?<J WGFG!))&5.@S7F_9%U=@7:'U:]-*O9IBVQE
M4[<_L/<9Y6OG3>'K86\OQ;K8WH_#XWI5XWZOT/RCN[#'M4ZV2YK@Y,[\KSM=
MXA>)<:77M@Z*7@L/Y@H/KO2=MR6\MR$A&)$UH!2U<JRD^#E2YMD)Q[DNX8'N
M&[[:R/\"!8L,_AL7;2@7K4R#;%PT+Q?-5,1IPTWP%DRN;?2)2_"2:S!1"TG(
M9?2NGK T*SZ@U:BH4=$:B*:-BN:DHME&9,EY:V4H$5&)C9"8 V*6P%BIO1!$
M.M4A=Z9OV6J+<QL7-2Y: Y6W<=&\7'09%DEGDY$Q04+' 5$E(!<M!!F<\9PT
MUH,"IB]7/)KD*A5U6,/=K*J[MLI6P3B/CON41B=5G>V]206=1S1*O?_W_[&"
M\V][GL:#L!2]=G5[HO<<"71SL_?G-'I>+;U8Q59\[/+/'ZWS/_==?9XN7#]K
MKO^+KG]_]\KDA!R8$(8<L"QJQ14)L"%K",1%" XM)K^US1YA9_J>=CD#::33
M!=*YHS3;2.=^2&>FS),3URX3&)X\(,L2K$(/*27IA63,*E9)9^/JMQOI;"SI
MW%&$;:1S+Z0S([CJ$G(R%1 PJT(Z3@OPRAA@UI<(2",JFI".,8UT&NFL!^G<
M46UMI',_I',9Z6C!G<_60=!*%.;A);W*@H.)V1H;;-8Y5M+IS@2JKJFJ[3/6
MZ#,>N+H9!\=O3U-L^N:#<<#WK6_N3I^HYH+G<L%7QF+D2$;7N%]X7SLJ>076
M6P3K3"9GA5&!3Q3.33M2VFAG8VGGOA7.1CM?23N7D7^H&RMQTB%5UF$>J=".
MB@;0":FL9MHS.=$X6:.=1COK03OWK7$VVODZVIGM'RDY1NL3B%Q/VY 1X+37
M(*.)C%LB)B?[N:9%.XUVUH1V[EOE;+3SE;0SVP&SI%%>E:S*&@^8I(42D2J0
M-DAA25)6DR1+=";:F4A5WTP.&)?_QL'?V_]3OIS_W=<T>C4XF1[09E=Y(J3:
M,V)%S0$/CU*/0AB^+G_[?>T!>#(\+9]>1:BRF-H0\-6(CGMO:'3:&^;>Z5$:
MIP(Q>AL'Y0FOL)J<-:?ZCSPXH9,P*"\?GY8?3(9(7YZE_OB.G"T#17$=9:EO
MAN-!-=_C43JFT\'?Z=MW@WAZ= [RF3=.Q;K'[/(MY,LB"N)N?,LG=WMZ_P<G
ML?SKL=03XE_%[3=7;\_LU[K\"6LDA]8R$E'%C"R6D$G+)(GYF+)Q@;\4=NO\
M34<7.OL;>I7 CQ+]!93+%3^FXW?T?KSUS=7'LCR3'QGBIGMX]@2?W7UA5G3/
MII8K9#R<SCM_7*"<1O55Y6&>G.XOCVF=BUZ?ONON;J= >?VXEYV?#W[ZZ:"W
M]W3WV9.=GWH_'ORT^VS_A^?]WK/])S<#JBNK?W*P__S@IV>[.X=/=WO/#\M_
M]I[N'S[O'7Q?KNB//W;VG^T_[>WLU]\=//G?]>*>_OI\HGB;;WM/?_GMV>&+
M#EWC];C]U[/]WN&/![\]+]=1[/+T_SQY^O-A[_F/.[\^[94+W_EW]Z_@M_V=
MWW:?%1O=O-:KD*_D,(,8-=W FT#N@IDGY>OE$H[IS3@]/O_FVS@8OSFF]X\'
M)Y.%3-YTC2L]XQ[G'EDE*_V<[?R<??P9,SV:,--'?OWL=^Z1L_+&7[-'_.:W
M?N9CRWKLS;_]W*=^_G=*BH6OU3XRS+6U/NAGH*WU_M9J;O6I-Q0]J,\4/=QF
M#WTT?'?3V^;=Z5ZF2S*/U*TBA[WTX0.53#JMSGO>=JE/_^_;P>G[::IYMEO?
M_45?;578_?6>-U.<WN;!R?2_.S\_^2BNOUGUFZ,PY0&_=,-IY==T2N6'L?L/
M_+F0N.;/]U>4_"UR=6XCG^(GP]>OAV<4^/QT&/Z:?GOP]G1\2B?Q$T)?%">(
MC;R;.^52JGQ$Q]UGA9]I$.'<^SVA-X/3CU>] E>QF8_%ND9(#?JWOV>3+;JC
MX7%,H_&9[-A]0T_SC6O,O&)?.[/!?IL6Q'-MDW?1#I.'Y_;QV<*:1S^(F[OS
M>OCV9+%<MK+@]ZO//ZRNDN13,UU?<?$='=-)J#VU>_^AD[<T>M_C_5XMT+KU
MIOL\;<M776!SV]MR^PJ;N:]^%>4WM[WL.7JY89 9M74:(R$7R1,QBSHIEA,K
M/WKYK);;<"'Y5[=PFV1&9\Y]ZC.?G83CM_56_CP<U06NU?2.@R?GE3O?#_[X
M_;_E/?\Y/OC]-W&P^^OK/?$4]W:/CU_\^<N'/W9_$W_LEK]W^/3]9>5.>'^P
M^_WK%X>OQ+XH?^/#KW_N_?F;.OC]F7KQ>UGCX3/<+VM]\?O^T<>5._L?GN'>
M[W\<'>R^D.5Z_MS_8>_]_N%?ZL6?Q^5US_C>GZ]86<O1"_%]OJA1?L[>O=0^
MJ^!8!&4) 86.0,7J(((7D@1/<C)N6MN^$7>N&)P71_=:3GC;HW"?&]JS$%I<
M&X*8G'4;?\017 3!A8E6VX39FMIA.6<NC3=!.,NOYXAG^]_/0Q*3/SRCG'2F
M4F]-\/[A N](UF'.!$R2 K19 C'#P1K!;4S"^Q2WMJ7J.V;[3-VY%<(Z0;Y%
M/RWZN3.SU>BGA3BKISQ^07E6Y^22DN!MM(#!2G J&="1,9N#1YM"H;P[][=K
M5->HKDN7/<]<)1]EC$HEJ3U*CTX9ZTJ4H$(PTDO=$KTU94%YP8)"D!;6.%"$
M&9!' ]:J$@*J%+44-H9H2J*G7%\SVZBP4>$#I4+E<A!2AW+]&JE@(1JE-1=)
M1>],_DS4UZBPTU2H+J@P:,P^AL*"$C6@"00^V_*=< %]TLED*@$A+SGP@Y*\
M&A,V)IQA0N_)E @A"B8".J9),$.,"CA(*$ZNY;]=IKM_9CH@Q60-"AE $A76
M2TH#(;.08\Y9>.^L=5O;QK84N+'=0V4[R7QA.XK<2(-1HJ."E<1L$$0E6:(6
M]ZTM$5YV*3#*N>@S!\YJ<Q3M2N0G)8=0LF,AA4*4=;?3B;Z4ZQ'Z+:GAY@HQ
M7(?"_^MX.![_^VPV_,<&N-5.[6V;P'2-P?XU!X4)2V153,:[\B!'HN2,5$I+
MZXB%R#[NSB0_Y;)QN=SRW2U(K7PYNCJ [VO(;.<D'J;7;X8C&KV?4F*CMSGH
M;?_)3"F']$;8J!E(Q0C0:PXV60+B4@5"(;SRA=SZ7'_::_K?MV:UCG5]VFCP
M3ZJ=Q;?KW9>K6:A9J%FH66@A)1G6.R>(12DB*HM69899\*24R,7AW2+":8'-
MF@0VEWI]#+K$,.2!1U>RMIPD.*,B&,^TL\XRJM.)L<^4Z$ISN8;[A>(^BE22
M:>),)8=)84EG!&<F"9,*R)6Z!>X;N+L$[EEUVF@>M$(%H@K3*+4"YUD&4N09
MCY1\C%O;;M/ZU39LGPFOV@B?7!1H)&K&G?->Q.QXM-X;3\VG;Q+L+[78&'EP
M4B'PD"6@=QF<2%6X2%IKJ;AE$Z_.L3/S^)9Z5'!RFG+9X)WV+W@["D<TGG3F
M/!TE&K\=O9\..OK20=I;G)59.RK[N@3R>LNOQ6FFM;/0S1KY]2>63"R!)(M<
ME.0QD;':2X$A61E4#E%_P>',=W3I\ P_D[V_Z3FFG5!\QZA#[<;7PGD\GSG$
MY*63S(8$1!X!+7=@8Y3%DU@CK4RL&+0>6NQ;]ZGON+W4W3#<6+99Z&MV(LLE
M)AY(N* ]1FTK8(6/4D?'=12WS]>OI='_TO';=,ZB/]-H\N^]='HTC"T@GX]3
M+\\'8'!)>AU!2E,X59<$W&?T]4@XBE ';BBWM2W97?8.&UP;H38+-0NMBX7F
M<7D+D+&:RUN&RYO5H$J($B-% H&2 X:(Q>FE"%D%18%;$HEUQ>EM?J7?K.YT
M<D6!G0PVNM(W\2&(Z$NN_;M*/WN#D^%H4J(\O?.[*51"2M^/AJ]_33&]?E.7
M-&[L,P_[#&;*]6*VH5@G@;#U%!HQ A\2@Y(J.2%B4BR4@)M?TW6I%>MU$:VM
MT*A9J%FH6:A9J%FH6:A9J(O%,1_2:!AI?-2"_>4$^S-20ZJGZ;,,D+EA@"$S
M(*TU1.>S)44RVG@!W@=9\+(2+$ZWY'N#\?AMG8@\'/72/VD4!E,58CA][GMT
M$GOO:#2BV1FU#T$!;1IUURW4P=J72;7E1+9^-H'5[MM1N:6'1^GG<HW#>-;-
M-S\] ]I!/IC ;.<D_GZ&L58:,X^CF>WO*T5400@'SEH#F*4$J[P%3M)2<4'$
M63T$JGA?7Z-J-YQW%N>-B;MNH574QWR!:B?;A+=CVA;2WXII+PMF9 A.B2 @
M29%*0.\-6"X%9*=9R(9;9?G6MA%W/I/6,-Q8MEFH66A=++2*HIGF!Y?L!V>E
MK6P8VB \L. <(%H$FPBA.$=%*!UE<IWRA)M?2C/)L<'3.-4K?/TFG8RIWO$'
M53_3=D*:A9J%FH4VVT++E1WF:W8Z&XS-1&(3[_1==4Y/9GQ3"\'F",$.GLQ(
M$=%SG7)PH)41@-F5 ,SQ!$):QKV):G)VA_>9NO-DCX;LQKW-0LU"ZV*ACC6B
M:=YQ6=YQ5J#@9(+T*8 TV0-*(TMJC!'(.99"4 (M=<P_;G[ES>[@[T%,)_%A
M%=0L^4S/K0GI<Q6 NX/QM#E6K86ZJ3G6C].Y!HVFYJ&IYS/G@53PNG@?#26B
MX("Q?&=USL#)18\\>J\J2;%^>4([<!RQ[82TO:IFH6:A9J%FH6:A9J%FH?64
M*;[F2%!+".XQ(9C1+50=.^R\!LZS 732@$N,@4]2R)(.1+1Z86>&6G'%;?OC
M?D?'=!)2CTY[>S0*1SW)^[V*M7E5H@<Z8G+NJ]\0YA:*IQ0<8<H)+5?DB/,"
M;RM8,#'9.F)R$;IR&S&YU!&3ASNG,],,$K=**68!E510?'0"IPMG!T;(A+,1
M^>0 CNFC= M2F[LQ;W>!VTQW(\:UH8AKC^A9$[#&<\D'PF 3"6MLB%IE):1#
M?CU+S->5^NP(WMO3\2F=U)O9#MS-B_C+*$WDI(Q2&K*I0V5-RN =!@@A,IZ%
MC"CLUK;4?8:B;ZX9OKC!H&\14(N [LQMGS:G:V'.2DAO_S+,<3KXR!P#)Y$#
M<F: +!=0-R<S"4^2\TIZC>P:V3U0LG.,.Q,*/IC(R'-V/FB>N5&8!'*M6KJW
MMCQX&?P9R[D65/*[E".@CJX$?R:!49%G92W9>O:):]YG=E%SK!H9-C+LQ&7/
M08;,H3->8J:HT-ELR4CC E?:"7*H&QFN*QD>7 :%Y"4EGE0)"J4'C,& TR43
MSE(I6;)?%K0O0:'J.]6XL''A0^5"[IS *(1W6J*1EC+FP*PR,:K,HV]9<*<)
M;V]:L5E(;^<E4XQ\8AD$:EW"/R' :N% <;)6L>!9"EO;UC;1K]'=0Z4[ADEG
M):*F;-$YYK7.E*Q*0F?T,K70;WV9<.^""7.P*&T6Y7D3==\S9'#9*V"(I$D&
MZT-A0NY,WZW)%LCF'\'93Z>]P60D^H,Z@S-/R4;67IMDC<L&-9$CE[+5BKD4
M*>OS?JEX7FRG)6O#Z=>3SI[.5G$0RQ@S*8C&2$ *$BPO;":")Q:,065*)FMD
M7^L[9[*MSK950C<+-0LU"S4++3W T48PIV/*1DAT(I)3/"E/R&.23N86X&Q0
M@#,CU2LN#(^!01"ACOL6"!1L "M]8&02<<5*@-,OZ5N+;S82^>1$D-'8$M%F
MU)(\4['@7V V":VE6R"_P;M3\+XB3#,>2YK*@'PL^$XN \6"=!<IA8R2^9BW
MMH5K,R V$]U&B,B$\$$SB9S0*<,5.H-$);<UO/GUC0+^I0Y+62=>'F]PF *@
M=03.D -F9<C1D^,HJF.7\M/!PNW$8)MLWKTN2'>78-NPP_MGH6=7Y--(.B>?
MP6>7 )450,I'$"KI:(TW2O(ZV_S3\O VV[R+>&U]+IN%FH6:A9J%FH6:A9J%
MNBA1M-GF2P[W9T2'8,E0<@@L* ?(;03G0@9$)9F.@CRUX>9=&&[^=P% 51V&
MN5>Q,!J$TU1O]3#\U:-W-'I@W9C;5G;7+31?[Q1%5B(YCRHZ+*[$"2]=DM9%
MG9B)Z@LN9<XF*M?W\)^"[M<+=$U>ME.Q]<-H.&ZCS>?S,WNSG5:"5I*4(_ 8
M$J"S!%;$\L493@7)0:#?VA;8+VZG*^)V WFCX6:A9J%FH6:A9J%N6ZA[XL7G
MYD1].<1L4L8M0\S9^HE /H>$@%)I0(L"7#0)R"7#6"!GO&\]ESL@9:2S8>Y5
MRQA.-;P>G<3>N[.)[@^JH*()XUVW4 >%C$G]WB<>YO HS0H9!_GI&= .\L$$
M9CLG\?<SC#4Q8RY/\\NLF)&+(_&4)7#B')"1 :^M!1]*!&&#2TJH*F:(OG"+
M:A3=D-ZXN%EHK@/@"7.0''WT"BER<I(YG4P)!(7Z,A'?OH[Z9AZ>!/NWH^$6
M\-^.AO=G9\-ZI4TT$'SMU^^9!9O1 A/>4"1R-LM"PWUA[RPI-X@W$FX6:A9:
M%PMU\;A1<Y/+S%9F=+$2ZP@32KJ2F"WIBM<&2'L!1F06N+?)1-8Q/_E "GS
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M@+]W 7QT%)#[!#H& 878 S@A U#B26*2F7%;';O1=]Z1:B<(.S:T\@'T95N
M'MOF2ZR"I9[.JJM9))>1*Q QE.A$"PYD% .!2I0DM$2F#+>V5>O_O D@OO;<
MF[5<VD A1.=0Y$1>Z2C1Y^A5<(E] <=M:F5707ZY(>PY-TIP#IG7DFEC!+C
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M,-7&\$C (J3BQ#)) HT\N 8%GRH*[A]->FK!WT^.C0@TJ1"1"LHAGE1$QM*
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M<E3<19$4P3D*K!=$@9N:[F=AW0^6SMQ8]\-8]Y2W@#A#BE2CI&Q.=<Z\1=.
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M0>5)P))IK3:V%IV^-+5RS\)J'S5CI#'H%1GTU4S+#L)LT@:%Q WB0"Z0C8'
M/_!7Z4!!N"HS,OGS&NW]%/C&@F21(>AY)AYS)&.&AC1Y(6L1UY@Y-WX'$CM,
M#7*M KGFF@U9IZ0W3",#VQ'B6%#D/.6(D&@P<TP&8_.\F[;B-X,;32[(LS'L
M1\@%:6QZI38]D_^!G731@J24!_>"^X"TQQ;90&SN:*H,7]V9ZOH%09[3Z<OY
M()?S T?)0ZTR73F?XR=-LZ''BHJ\K07SMFM[H^U>>#V630-<2P'77!<A:55*
MEA!$!,_GQ0[("*<4&2=A'R+84!&!C(@UR;AOXB)K&!=I[/:A[':V@MXFB5E
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M,<NY9!91&A7BP5FD@P$*"#*CSB2&G7O&76P;?'JF^/004?@&I'XH2$UIHB/
MYI6*"%O%$%?1(T.905X$$243*2BZL45(6RP8@_CHP?D7D_+Y;:8XB%V;2_>
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M1+T?MEOEJ0"MVO#UG;/,!<IGI_C2;@W/8Y9];3G^8A2K]YS6)I7_V@5=[%7
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M+R'"9E0]4-D%I[OS_^OU_T'_+P)MG",,]1[8>@M7 %91@)(8)39;KS.0PKT
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M<QM5)@RRF@C$C,)4."ZD\!FN-Q>,VOT*8M\]1/*D_":Z?GY3A7%3F+S5_"K
MO3YMB2KB+6<JF3SP75HEL, $2+60F$JZD$Y/[7#OX+<EG*<"C'O#(:#0[D4^
MD7P+Z] /[\J-P1J5EZ;%B_CE620YN#PV*CIN#44)4XZX\PI9K@U2N:8>.R/
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MOQIGML=<8!A*AISM J<+5SD.E<<@G<$FG%/-ELU$(M$F)RP3C'/!C;9:12\
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MV J;7&!]HE@QL2Q&&F(&0QAXK-@UC(\,)DH<APUO#+;)\R2;PGMOO;"@BA=
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M%E[DB2!.4T-XD6LB<Z<(YR*5#E.K# ]XQ=E9+H?;P*LK"X\^_.^7$A[W0[.
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M^"PQ@%W94/RX<+)]AJ#^@-?:AS1Y)C,AI%3<\T2G )"":0H"BY0%ZX63.W7
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M+G=)HGJ9Z1;!HI&9<DTS;8PB0B<)"$XB(RK+')'>@J3+;:JL +!(?UQF^E7
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M>;#Y=:8,"SH^Q9,-_Y6K$I=HA-X&@.SZB*O!R11MVZ&G<K,^[NMH#N_5I^'
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M*&@QCS%Q:+#\J7[KQZ"#8WVLH,6_7NKYR([4;.3F+V;!3_9\ @KY(JCNS:5
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M2O]]\-OH(2+&,5KV,7I_@J:?V?P/^ *^"8]R%@WS@P]H89H$H%_6AJ5:80$
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M8MY\_9I 94!4QYAR:6O30#6GEJT IA4P!FL15'$5M8\6B V5??>?9;#)!+$
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M-F;)ZI_!GS3MH3ILU9:,JFJG*YYC<+$-8+Y>VX[+PQE/""A*LUX_SU(]:&R
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M804K$K!P$FNUFY^+1ZAH57R@+M?/C;9=//F24PQG P.-1"YJPSP-H8SGV.%
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MXO'A<O54L7F23,U0U2<.QE,'U66'Y]]!:&JO&F^FMBJ;+HO9=,MIY)>>$K6
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MH$88!2%(;NI,O>==>\!'JL37"2(\K!9W081;T>MI$,%(17'R$J50#D4T0SJ
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M,C.7I0E900,RP1"'E74BL"Y[Y;%J<I>]\BB6Z1J BZTE1*? 1# Y.]_DPK'
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MI\0TJ1!SSACSE8]N- <D]0P3K;@U3-UF]E@'G!UP/C/@O$["_'T:I1V#V=V
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M7.NM@]T]'01Z8W1LGF$E6,']Y;RGPL="RB[T1+!TEE##17@ '[MK"XX&J>Z
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MMJL;)3>'DKO0HLIAQZC1#F$?,W-U&%FN-=*444&$%9R01W*J/67!RQ-EM35
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M2TP)G^9:0Q.-83XIP6S@%JQN[A+CL(H*."C(2+.&C[Z&L%D,3E8C;&'W\<C
ME(8'C@2@._7:"<:!:+%E/*/W[^TO%.I]W!]\R[;!HT#USQ01^+'_R^?Z:L?R
ML3YUK6]95GZT?@!F!Q6# O4?52 (0!:(0$Y52T0D('<L!!SGRW?YB7JW6<R;
M%U.$ ):KA754/F96%Y!5 C9^))8:RV*RBZ. F\6\>3$M@WU$-$561C"T8F*
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M<$:6!XJ(C#1('!SA\WE6:)(X)BJ8\ 1DUCENJ5=PBASSM-I?,Y*M6<N'KV4
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MX!A6I=C_D[2V"46J"=, R'WG>Q:HB02UCPZ C/G[R\N4;@)>YW\)1X/C_B"
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MN#9[0] LV<;XS0X[PX^'P#3#5N]O.^AD(?H 5TL6QI_^]'+TXQ/?=0Y3$9A
M$90@XH8EY!RU"#./DP(V3UUV@<WPI%\_$VKF"A./L4Y)2>LQIY)KF103/AA!
MJ,5U'^)[+.Q$9O-:?LP=?\("!N.?86EW3G>9LTRIH#);@Z6ES""3;$2$!*&Q
M@#<)7UKE*_2J=_,?-YO0_RK4[-">%DH&QGGI"@?&>P?6Q7:[4UV7SA %WAW#
M2NH,X)5@3_,GZE$%^>L@/Z-.MQYM8$<YE'YZYI\\&PM4]VG)D3S H#HK,J>C
M+>=,W:I_7K&0\:CG.X< 4*6@HH!8.+\>.,L@PO4,]_,77:S"4;Q\4^FHVZV]
M7T7M N)--+([K4!ECFRG-^6I!>V9(XL'^:BU.S9[,N"C%T#VY?&6-0#^WFF=
M]5>7^KL(:CO.[*!35@8>8TDL/X8U! LW/[Z<  V/(C.>BVJG9D$Y83PO?'%V
M+U?N:%0G&,)+YW.*"C<9$Z3R5O82P75<L^P'.=O[+!6M7L),LJY?L4G.?*W8
MYIQX="\*Q"\8G+]W>A:NOK=WSG/6S_G@=G\J+_8<Y+;25*%.W4=EZDMO%P*W
MMM=.=ZFW(1)I$74X#\U0.#?KCRB #:FP4J!Y  (IF8V!5Q)FX:\>ZI3RN'J&
MUI3DW0 $=;W ! Y WL\B."'F*H=<L%!+WH$]G?A*\^?0GQ];:RO59IJ(?<XQ
MG[Q>)Y_/.%A=Y 'PT)UTR[O'!"]"F<_EM8(:QG%(1E,KDC4A>6PM)7>1Y]FQ
MZ%HZAR7OMI;X>"[O,Q(?/@&4G'_G[0IT;JRP]=<N=U9QX1D"DB\0#US5">"Y
M9UUR6C(9)&AU>:-(Q[(R$V$]:Z8PB >@T[(TS\G>4_1:,)E3/+FQV&DGG7<&
MBV!B4*P1EJ<7%CC^WF[ -*JD+?+")L2UT8!_RB 2G7$J<:)2KA9@*VJ6L-2X
ME3-FKO*8[7/]6U3KN;^I*/.Z\BMW/^BD#GR]^+^+03F<_NB8$=Z49S<)_9RI
M\WD<$V ,2R>,E@%KSJRPF!D< Z>)8$]"?(2NCHUC8DKH-D7[KUV1E$J$6.2P
MLHBS0)&-6"-"@U6:2<*PNL4U<7, [P62Z*U>]7MT@R,[.!T[ ">5D^OC<:77
MUW_EO\/WLB>FMN!<^P!X$&QWI23&'(QOK&T(L+K8,N:#.\N IHV#[G'V04L
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M1JYVKFT ?AS88>A5;' R@IW8F/$E>W+2Z_K\P(0B(2;)#/8TI!?:.5N/LR,
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MG"%>@%9D9#0H@L)J4BLYD=Q(=S,,+*564T4/7FJN?8WVO@629J\ZOZJ&\\1
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M,H;K]TGP.%@I4) Z]>22'CD9+6(B]:=W7.,BI*!^MJ2$?&T8N[*(Y^I!_T$
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M3!W@.9XA..0OY]:APNR9E;CTY/;E!T:NO__9\28*SJ@1\%-GF1UWDFOM-/?
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M>*G6%_3Z.WMJ#?.FZF'<8?:@C_7H;;,[OM;ZVATTV1#X\E&_^.ZPY@GDPXK
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M7%%%7B(32VV^CX\#X;'F+60:?TZE>M3)AZ\:#O1X8HK?752^G.[$4)2-7!
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M@,QA7--X/%+DBM E29&!S.DE,MI:9YL-WQX6N%14^LP9F'S)E/+. #Y0S8$
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M8VWR5[U@ 0N"V1.#H]V]J558:\&P *W N'<Q @5+#0"*!JKRQV9@#=M X[7
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MW'O"@LLYIU2W83D;)+LOS0^QU?G6";$?BA/BT5IM7$QYL5GN 39S!90HD9Z
M2D"*>H=X= %IXR62W$:NL>8.YW,,W:36@<75T!B64.3S0>1S2@:L\2D*0Y$G
M$<@ LPXY)C6RVBM,<"):5SWS&IC__6(\"F\[?=OW<=)FHT1"/"(CF$Q]57[_
MXIRTP,Y=8,?/T@(G!3<,>(#UC"-.#4'.!0>&B#5:$NI!/ZQM$$P;9( 4YT%#
M:4$1TF4*Z>F,DR\!=$:.L,C<G1N)M$\)A%0;6!_"M Q-$]*7YB6XW(3KONS@
M1=@CC]Y\JZ#2O5!IKF2>#DDHP0FRW $J26*14U(@(3 &6J$]-SB7WV>X2:>@
MQ:?0&/)09'A%,CP3"NFT,XE2Y$25/64$<LP)Y!U)1 2M2*)5"PW=I!"D!M>=
MF\^G;6+-N=N,\!F69?Y1\PS_@])SI7W&JC-<2B6<.R'][M;F'%OSQ'@O)(+=
M&1#W@2,CB$(*2T6C2D%9N[9A3)O?WXPL=*VY@ON(>2Q%<.\NN%.*%E40"> 6
MF2K!'1.,+(X.$>.HUQ3HF_4@N+)-=9,$]\EPM"=!TQK#U%91XV7:B:<4!WZ&
MIZI;,458W9 SO2X6^+0<J:XR3'NR)'4*WK[]/J/2=TO#\P75^5P^>6)6$6\\
MDBQAX.&1(1N%0IHH+@VVPEF^MJ':BMX[$JL<N397B!\C7KL(\7*%>"8!+$A'
M*:$HN$@15YP@EPQ'W&+FO8;UTVEM@_ V%B6#O('Q6NU6/XYS =1S7GDT&.:U
M*2>U*XGC*JTV[PA*<_GDW AODC&(8I8=!8DA[5G.#,O_BXDF[]<V&&M2%:WB
MWFL,KRAR^J!R.B4/U#/-F<)(F01R2@5!6B:)0J)."VV%8&YM@Y,FU:M\:3Z)
M'T1S+94[O A;9W517@6P[@A8<SGF(3 C@M2(.N+!VE$,6:DLTL%0J05-59ZJ
M: O2I #4XK)H#+4H8KPZ,9[R#D&Y Q. ($. <G"I)=)5JU$134[SH& QY$K9
MBC=)C)=RCKC$(YN'.T=<Z2"71/">2L17_\='BHL'?;T(#?"X05\%]>^(^G,)
M?IH:3X.*R#F26S0R@72B$5D><W$@(UWEJF9MH9YAB\8BNZN)^RJR>W?9G>E>
MF*@6"G.D*75@>&FPN8P32.!H(@O28IR3<W6;DL9U+RR4K5"V^\=_S5"VG_*T
M6P;731J?,9CD,#C.302OZWSV3/OU+C8'ST;Y/2YQ+2IO(97W=3Y-(=KH D$L
M69VCG0FR2G)$O9/)4V<EE[EA+VT;M:Q^&PL)1<-[CA>0>[$@][@,OX#<HB W
M4^M+"2:=L\AKDNI:?$;SB P&+FB)D4RY#'*\S<VRXL<>!>3F^Y9?Z5!>\[6K
M#:(KTHOG82CWN^FDT\<7NYIR'L:6'8WB>)1/>L?PU^M!#\9Q^G_^/PW&UB_P
M,KPXS )8,74[CJ'UG^TWH]9)',96?S"NWNK E,,;(WB@3H)9ZX_7+W'7:[NX
M5_(4#=<:6QI$2!P'ZI1DD5GL0DS*>/*W%FL_G]+)_&U4O7'GO[OTB[_4+UZ7
M?O'WZ!=_USVX&IN2R/4:1Z_^G*C<W>,>W-I?,B1 #$W4V&'&>(@ZETCCW@K!
ML32.Q+^W*D."8(*F%L4E'1H!5^+\2>=H'[[AU^[ ?UVQ,MW]<*Y,/Y]^ZKWA
MN_M_XKW]?W\Y.'O_9>>L>[A[MO-]=\MC^)?OT#_)SMEG!HJQ&W]_#\HR'#G*
MY=[6OWL'^Y_)[M:?8J>W^V7WMYVSO8]OV,X9*.*S/^'?SV>?MOXZV]L*:6=_
MD^S\^;?F*F&;<QP948@K') -S*(H9;!)2JQUK-D. &4,FYFK"(TU<S#)1"K@
M.<$J'[&.#-,(RI6XM58$AG*4$6=X'"^8U,,NZVS8W(M>U+T__P8C.T58#Z1]
M[NN: D?.Q(@DCX9ZFH"(BLN+&G6.H[=>,2^Y$-)YXJ/BE%L-6C"8RXM:3_0Y
M19JL[<;5OV<QYY+*K=?FY[MI?J",4,*YBMYBQC'0-.8M?)#*Y+32G*[=\#T_
M?\!+NSPWJB/8^Q DIU18I3RU#"<2C=;.7:M+FLFG)@RJ=6B!/5W$U]E^:*79
M./U1-D=@%H9'61-EM0/,*8?=A8$?#X:C"0.;OI[OX(&5VDZ_%?_WN'.4VR2N
MM^ K1Q>W/+3?8FL8>W#--*@/M'>OXG<_A 9GM!3*.8X]5S(813SG(6!X4-@:
M;-9U-&-'P43Y5^%XV(-['?X<*]Z?#ZWZ:Q\&]N(PXT#\#=8/\4)2E'02@!@X
MES^. 3EK+''.VY#43X#\P59K7F&7]<KK%;!U0?N(A P8<2HUTH'F.$% LF0<
M=S)7C_H9/+>J:<]-FGZTM#XR"A0A.AD(MSP'2L?@@\(J9ST0_Y.E/8UV6.3P
M%NN:+4L+,J2\1I[":G)'/3(\)Y88K*4WSIB$?RR'#[9810RO+I=-1, ,)UBD
MD+,150+3E 8D/'4R4F]]3&L;XJ=BF&<=].DH=UT%K7ARV/&'K9X];77ZOGL<
MX,6C3&1&65)AI2/HW>P9F=':QT<_DV()8U6$.4,B8#3UP'\,E8#0E%'E65C:
MQNC'$]M]B3OBRY_X;YP820XPV6,,U)N%W-R8&H!H;8UST1(F?RS #[9.\VA[
ML4KD)2X3XPY$DTK$(XZ($P9\AUF* #,UT/P4&,OZ$]]6<C,3OI7T9N8+ZP#L
M>D: 3SKC0Z#02[>3K]D>)X-A&,7^^0Z!'X?7BO'^9)PP[G<PFD'83IM'1]V.
MSPZIE[9CSK;/_@:E2JWG#D7!<\LP)Y"A5B'/< "9EP*TZP.X.A9:PED)+PMX
M:0&EC-9IIA!3@2'N1:;,H+5M2EY2;*,,>FUCT(^53/],\-=;FY4!^R$>C6//
MQ6'MP62XW<J+5P'"5O2S;Y'\%C'M\^.-8?;XAAA:E;_WLBE>G6;\UP*'D(OH
MC9E#2+' (>2<!LD^AKWTURANYL>Y.)24+VYO?:9_6RZ5\0KV%L6YQ9?%2&,"
M&PRH )%$.F7%V@9>OQKGV^IUNMV\LGG#+++<##NEA0U$,<4#X\9:FR+6'H"*
M!&5O.',NRWW?Y?YZ]K>3BO"8&%). H6@#"-+(D:*DV =TYK:E)?[:AVA\^5N
M@_2/CJ+/1WS=TYH_6.^/>\?=ZD SQ". AT[MO@2\&.3?X?7,%.Z-%(SAI!R-
M.%C#@:T:QP7!$7Y1-')ALB*JMPYZR#VTV<OINV?5,[[8_03W(<!&.3?.$A28
MR15B@64X)37RT9K*\,>)+A:08G@,L$NI98G3X*W4/J04A4PQ$!PF5 -T 7I(
MI5!6^'R%8?J]\;D[M,T*PBA88:\)Z(N0^1]W6OB,&.P*8OP 0K+=[P8 "$<5
MP1NMMVX,,VCL\<1F=S1HSX9YM'+J E"K86N4@V0JA#L_8QA&VVW%T;@RG\"6
M.NP,0^O(#NOB +7=90$, 4ES WK RSQ%<X<>]1W7G]Y$_3$U%4%;@&G9&7=@
M-K(]F7DHH;4OMYJY+E@#U43D:)@+F@F0D>?9V6ZE/4:',5X.BGGH@UIXA->#
MT;B*:GC)9[2Y9E"D2C''$;4TMW^#>;/" 1Y3+#VGW$6E+Q])RF08(SYP&P+7
M5&JF,0V<)V5,=)%<.7A_"AL['U!ZD'VPO/IUT%=]1AB_'\4^_+>B-S9[.;O=
MP<FH]8].WL>#8_C.,/KGJY])\B2Z)\<!S4R!J#-BJNB:BX"J*DP/'KMKCT;Q
MU?DOOX3.Z*AK3U]U^M7@JP]=#L:#>T[#C-9Q'6HTR1"9W'_R]GKUUJ78P?H]
MI=>UNOEMO$YN?.]'M]7K@IL[W?7'[PGV(&,5MQO/3W)P?IH89*Y<>DU$]B1,
MKDDEF?</AS&V=FJL?]//P'[A@V@QW)Z+3KWO),V$R_^TC<G3F+ZLFVY3OWHI
M?66>S9P1<]VVNIQFR'^09KB,:5MP^A_T*U?0I^>:,-[5:N[+I;H\4+L%$P1O
M6QGP":?&7/>(SR;SQ4KLA0<F0%+D2AC+2 @1TVB9D,!B)U:!FK,*EE*B*-L1
MC<F$N:,-46?"?('K?_OKY-.7 ['W<;NR(0[V=_BGCSNG.Q_??-_=WSD]V/]/
M;V?+?[^<";.S_QE_VO\5+(ZOXN#+7W#_[N'.V2&,?_O[P?X;^)Y_'^Y^/#C9
M/7N;+K)@/N"3OXD53.!(460B^R.H1#K%A"R6D47**#8YV:^M]+U+4S2O9FE!
MHV>*1I+'8'F207C%B9'&6^&U\8XKRI2DM6-[@D;P2T&C5:+1V04:^1B22 2
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MN5.(RGS^(*R4D%ASY TA"%B%RHV'.4J>2JUA@;R7:QN\+<VRBON4_,&"=,\
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M_SO@__8L31-646RD0,1:ACC\1":!W>F3H<YYR8C+^"_;DBS9D;0$,5JQIZD
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MRB<'=WXAVX*! +(B5((0")WBO"B,HX@'2P)H>> DK2.C&@HT..?+AV5I"'R
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M^=$=9BUA2[=<%FW<C>U 8&8: *'EH+&^1Q7 ,SDF?RFMBP2.E6HR4^C 5IV
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MYFL:C\(8VT,<U^O#P?ORX"$=W-8.SKJ,1D_B.&;2:7;H>V#LS\#4^H$V!C
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M=C##&JT@%,H4[\>A@V8[>1U<L87F&0:V\/_[ NO.,$?HNP^LL2C)"%J(\^[
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M]MJM6>?G*RW[Q.R]-4=1,SJ?2-3N2,=<L2!>I6?"3O?YQ<^)ZR53.]:8J79
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M>.?=+[+[YM8ID'ZEB#>7-K3<K2\.+;_K^\,9_-\XFKB__7]02P,$%     @
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M[_EU\SQISI A!7H4A!$(W!7Z  =!/"\&\")R%BT7\(PV.J6M($'N"DX/M [
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M=;E4)/8C-YM0H!:GRU9C%_;$*O;):',D<8Z@3AR.K^@3CB*C\"AJI8S^#%"
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M+);]KI*'XIZP[U->?0?$*^.X":1MCE+3ZCLFSW)/2;60-J!H &A=PS^A\'F
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M5'-1H]K3!!B6=<D^]-U^1:4.:+[=;I2\AR@]H634ADJ^^.2'4DRG.^0G8[E
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M9Q."1;2@*L:PON^84K(E%NU-EVSZ;< -R1ILRKCFFFG&F<O1B_*9?FVAQ%H
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MD',\+X?S_-.K,6U>-45\MEJ^S9C&DWJOG["2X4\+UG,<S_^.DU4>>1ZE0"-
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MR:T"^4L392>M-(CR'J4T$[X??/#]]&9X[,_[4S_H:>_!R\@)]:45<\J9>"$
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MJ/I[2O?WI/EMA%M1X[.T]M_ #Z:GQVAV'/OS_G06P%S4W"V';=E(M0R9: 6
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MWL*YF":X -HSI9^ 8I8D!;PTL)7$1H=D-A*=%X-?YB:%-/=@.BQ>["#O!MG
MJUG,KR 6L+/>?!\AX4XWRW[N*6WLK(6)\4$0*3G"! 1L,O/4.K2T:)/4H([X
M7CQ%6NBA0?;PC,'ST=6O+L;EY(1Q?Y3FG/Z(N,?].%U,+#CZTX_3K^.2[2:,
MTBGG2&B8U8IR04*FB="LM?<^:-6F./-Q<%\\F?:@I089S!M0S\[-S:!!",,
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M&A#4<R*,M27<94A@(J$1DU(&34TV3>J*]L6)!P;>/1TEMA%\Y3C"4<[]0;\
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MMZ%.^F?G WA(VSL][\?K9=Y>_N*AMTC1?,'P;0K#!.G[[_KII^_[+.$.+@2
MI4E&R$&@[Q^=IBY#X#'T:BU]CQI^*DT_&XUWTGP(TCMJ/%7*RNQX4"$RK;*Q
MAD*.L)/FGY@!,V]H[_I?//6IM;]N\2NZ5](#4.EI]EDRIESF@@8\FQ75R2:W
MD^[OBF&/FK_NF?UFF$?CL]G??@53WQ_LG0_W8GEJEG07U IW(CB9(G?4H1T7
MJ'4F*IX,<BAF(1S?B3OWHMK!_EL\_>3^I[^]ZM0MA4NFY)=PJBE:.HFA]1,\
M"<YPYB&IX'(G$W'+!]>:_GIR/IL^,/SR:=ZQ>]+S*8A$I2,V*T.DIA(78W%9
MSG,>F-(A-!DYLA'1GIOTMV3 IB&QNVFA08[T$MA'.!^-9X[:%;(H;)))2N)#
M0%^!BS)!SC#"<S!)&*XI-!EBM!G27X @.^JA12F-GYS^/NP/)Q=C2/-Y)KT0
MP' HZS/"$BE\)L%Z3;A&OQT)3=%Y:%)+<Q?+ 7-B5\E73&NYFESOQW_ @I[Q
M8HR2ALGQQ7@VJ9YGKH&%<NE46EB %20D8$0)9=&BE$J;)@56]V Z8'+4TD3M
MAKGWX'KGI^4'EQ]@W!^EGA!  WJ:N'HH5$81A%*6K)E$XU$$*SIV]>G\R .D
M0T.9UV[+^[$_^>/#:#3X=#$^'UQ,3L:O4 &Q/YU\@NET/D]FCO(H3V&,7\[,
M_6&$_PU^W LJ)"ER(DF4WG:6!A0.F\W,810<>JVF6]/EG6 <*H/VIYN*Q3C+
MK? (O> _"YA?1N-7HXLPS1>#A90F\]E8Y=58;HXQ<*MM$D1[CV"!<N)5:7VL
M%#/>*453DP+ K5 >(,_::ZMBNN<2[)NS<]\?%_J?Y#?#J1]^Z2.XH\D$II-?
MBDY@4":O]8Q+C'NTR)@NP[R23<1YIHG'LQ:]. #P36R?CO@.F$XM--0@:>4F
MS+>CX9>W!=0<Y6\P2/@N_#Z!7K*.:P:)"!=1$-PI=/KPH$Y*0Z1),J%X:QIM
M1/<7(5$=[=RET,[CIV^'"% &Z!M.)SV+S)7&12)*]81D)8 4$&0JQK\';2F3
M+3BS'LX!DZ2"_.^R8N>ITK^.1NG/_F!P3>&WH\FDIT$P:<"3+*TA$I=%;,J1
M*$99LI92:KMDKV_-BO5P#I@5%>2_)FBW<USWOF/QS7"A@?G1^/I;'%R4HLCE
M4GJ"*NLD'HZ04T!Y,/02<>,CVL0,+*;H<Y-,N%U 'S#%]J;+-42LT)?Q*PPO
MX(;+>!(&_2^+:[P;><N?^V>(N^=T"BZ4M*)0,MFE#L2#X"1%@]@-&FZLR:W4
MEC@/F&XM-;:&8;OUFEZ _0A%AD44ZU"__G8.<0II#AB%B#^=Y'D[S'E8XR1_
M\)?E#?O]?#1$M\$/^O_R\U5>1T#F!W_/2&I!BK!HHJBSQZU]UKF9ZQ3+R/:.
MR8+[QWZ K'T)+%C#^MV"[%?ANBM4/9!.1*X$ 5_V>8JF1\@HR@!<9D@I"-TM
M/^'N9Q\L:W:3XAJM[A8@7Y"O>!@S.K\;#:>G@\O%S1\+6=@$@:!3@=LLUT"L
MQ64F)!KUAN7H'\Q=>O@QAZKK>K)=H_;=YN&M0NOYI'00'+<6/$S+<#Z#)%2:
MQ)1\3A;--MVM>''UD_\JRMU*@FOTN7/8^!C9-<:3Y3_[T]/CB\ET= ;CMWT?
M^H/^]/+JL(HC%,N_(/62!>7 .@196O"E+(@-R1)G-$>=EESL)C6,V\$\0/;L
M05]KZ+5S,/E>N,N;$QUUE#)R BKB4681KM62E:(/%)6*6?,FW>^[@/NK4NDQ
MNEE#H$>'DI<MD>XC^[GOIV-_WI_GZ<YOY" =#=/[T?2U'P^1_UPH$YTM->:Q
M# DH<VJ<5^@ EEGWR40\-#L=4#M#.4 B/8&.UE#LT7'I&?SKQGVOT%N:]*<]
MRS18R3S)&C'AB1Q(D.@NY:B8TUP%V;&5U9V//E0*[";#-;E_.\>4_^G'_7(W
M_Z8T3D-L\UD05ZTHT(>.);W_"_2TTX8Y(XATQ?[B)A"KG"0"5 K:9.I<DT;;
MG1$>(&G::FD-GW:KMNXFDGD3"Q]E2&6P""B3B,P^$Z\])2P8+BP/):&Q8NW%
M[*$5&>('@Z?>3%I)>UV^^7=%$&GZCS@832#]]/UT? '7/\2##;Y-7\_C+3]]
M/YEGN==(4L?CK_RK]!G\Z@<E=7[>L( %].RY(=Y(E)D(I3&YCT138,"X] J:
MS(+9#.E)>L0T8\":I/4*FF@R(6PR'?=+!'@]QO4_79:\=\#>=L[<X\$_3;>9
M6D2X<SNU9RT^.R8&1:ETAB0O[7R\@LW<$L&U99(%'E2CX9C/C8$/=+!YE@3<
M0GDM:KE@/)WM_5.8G.2%7[$<VQ&]]^A#$).R0VA"DJ"\)@PMCARHBQR:V.SW
M8'J*F7G[4N[JL5E),Q5+1&<#C/WPR[S)OI?.ZQP4L3QS4CHR$Y=L)%Q"Z1W
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M30\_<;>PXB]%-O"V__5N^>#;JW0)SJ-VEFD2N0A$,G#H/:52+*!E,$Q$MVX
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M<AK45I-CQ2CA MA;5+DO2 Y\&,._?WH]P3WG'-Z_?[V$!I9Y)ETD3 153CR
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M+SB% ?<I*HFVK8!0"G5I0ZR5FG >G-%9N"":7(U^"MC):5431C:HS-[![17
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MF7V"" @1_?%?8?[Z:CHM5::3#-DJ4PP%YM#L*YYYUD!D%,Q0% W:_4V6BT=
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M.&YM R5X,I2#(%[CK*1+@C@MT&9/U@3#N ;;)>GC5+OL[6M5])9UQ4C,;@V
MNH#\T;OL[43D7KW3]F'A:%WV)#=<2*&(DEZ4ZGJ9A,6;PJU65IMLS8_:9:^]
MINPB_.-UV1..96-QGPNAU-9F&C^)X E+WF;F(DVBVW'5B^^RMQ-?^W79VT78
M#:K=/])Z/%$+7BEBC!0E'Q*-'Y&* )A*S.-_N<U5CFV(3M#ZJ,M"@\C_AE[6
M71"US']_".DXZ>V5.%NO=%!'X"U*7#Q$YH6@0C%'( A#)'>2A-**7B,LX1F
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MU.J0%#8HB?)^,C[_ M.+@FT0N%..>8YRH+@<!AX(ND&",)Z"8,P%3=LL/7=
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M8<2*;,I% 8>[E:0DT)0S]3HKZ';?=^/CCWV0LZ_H)U7E5KO%\Z^__'+7VG@
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MLNS29>Q%%WDZI"(\61)J%T*.7,RG"]0_2T+MSFJ/JC[[4')D+8*8'13(6=N
MKX_EQ+(LD?>HH\M)9M[%IWXYVK-S2:A#*<\N3%16FK7*-LEJX05CA(9$T;D)
MB027#4DT:_S*<1:[=/D[N<)!.S&TO7#0+N)]'IDA5Q<7?OI]DI=EM-N=^F\9
MZ #G^5VFN'92'V/V44+D&IP,+-FH% T.F E9JQ">.JE_>K)565S50&_&WOH
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M9]'/S$VR6[9#.G![D(/9L+O+^]@G2(\?WUUWLCJ[FG^=3$MWY$7"_YV+ *6
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M9:Z=(EQ9B19 N2*<0!+*([/::_G@H//%-]O:F\&]!;?U':R;$HQVX<5POKB
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M<Z6<V5^SNUYY0<IN)MGFSL2WM)CK^N?TBIXVO[?( #D8XK9&.F0Z"60@H3!
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M)[)*Y^*P.2@K#WW=2CI4.LT_I-L9R>R^BD@[HU("1F\E(+[FM.8D&&2T2B4
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M3GPSLH\DR.6G.P1?3SK[',#S,-L78Q&#+/5(=9YL'UW!2210"F,,4\%K.C'
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M+79I2KP%SZL_;EO*NT,!R 982]L? FR/-)H6!G&.D[JI_IZWB2.$WZ&$;#O
M9%WR)25F4JH#>,@O"3;0+P&#2RD'WZ<=W(FM8LNI?QZCV$?F_8WA/D^%%J1X
MS"P;X^JP!<NB5< PE)1-SLZD+CTC-Z(Y>]CF4&WMMH$#1-V!,=R/:EJ$CS],
M85)'[]P%F<:3KX]AIE]^K 0>[[\()X/PJD0FL6:7!CHU01 GEHY(<20:%+#+
M?G$,Z(OA'B?37(? X,^(EM_6$$P]N<DF4.>A):=3[9-9WHWTTN&DVHC-T-&K
MDQ*L8 Y,Q]I]&:1@ICA$)T'"NL?ZVFSE&;+RLDQE'W5T,)&U.]#E"<LQ9:%M
M8> \@7+1,"@RTH]"\>R*0--E\.=&-*<G,\<K:O=-\P%2[L!CEMF"GV%V\^./
M&7T&D*I8Y]7N'_]F8?4JV2@4&;SSF=>:&+)ZJY ):;4T(BN1NK3(& [Q8CA*
M)ZUTZ(V]BF?YC0Q!U)>/K$,Z#QOII<0=MG*$!KHPCR?(<N!.T*;&@E*$#-"Q
MD&K$UQ@>M"M:RRYI:J>RB6=8Q_E,8A_!-ZZ!>IA&>=>>\[YC)BH@SU_S.G&.
M''BM' -))*H ")L"#P*&.,&#2FDV0S@'ISA.,=.F4MVW#^GRC^LO$>;XO__'
M_P-02P,$%     @ 3*1F41!LBACG@@$  \X/ !4   !A;65H+3(P,C P.3,P
M7VQA8BYX;6S4O7MSXSB2+_K_^12X,Q%[>B*,:3Y $IA]G'"]=AVWJNU353US
M-CIN*/"T>5J6/*1459Y/?P$^]+ D"J! FK.ST25+))#Y _E#(I'(_+?_]>-Q
M#K[)HLR7BW__0_CGX ] +OA2Y(O[?__#KU\_0/R'__4?_^-__-O_ ^'_>?/Y
M(WBWY.M'N5B!MX6D*RG ]WSU /XF9/D[4,7R$?QM6?R>?Z,0_D=UT]OETW.1
MWS^L0!1$P<M?B[_(A,L0B1 BR21$+$P@3HF"%,>*2)FP@*JK^[\H%48L4 PF
M*(@ARG@,:9PJJ"A!21 &J11)U>@\7_S^%_,?1DL)M'*+LOKSW__PL%H]_>7G
MG[]___[G'ZR8_WE9W/\<!4'\<WOU'YK+?QQ<_SVNK@X)(3]7OVXN+?-C%^IF
MPY__SZ>/7_B#?*0P7Y0KNN"F@S+_2UE]^7')Z:K"_*Q<X.05YB_87@;-5S",
M8!S^^4<I_O ?_P. &HYB.9>?I0+FWU\_WYSLDOQLKOAY(>_-R-[)(E^*+RM:
MK#Y2)N=:^JJUU?.3_/<_E/GCTURVWST44AUO=EX4>ZT:*8F1,DR-E'\\U=G/
M%XCO2=[5H:P>A*O4_<67C%V8_N)-W*^:'^3P N]T<['(]0/U?B'&>G8W75TL
M^O 2^WHLEBLZ'^&QV':S(_+<?/%1?VJZ,0UUD&G53T/=.Z+*'RNY$+)FR[VF
M02[^_0_ZTVQ=PGM*GV9?'F@AWVBB%6^7CT]R45;\?5T4='$OS93XYGE[R1U]
M-E]=?Z>%>/_W=;YZOM&30%%-G>7MZD$67Q_HXO;)-%'^IVYB5=XLZ@=I%@0R
MPQ%.H<HBI><Z+"".HQ2F(4\P20A":3I;;=Z5F5S 7[^T:E6ROX[@?W 8B=4)
M1BEDN5P7?#L7/\Z/3;!Z;C6S,?YY01]E^42;&[3VQFRI ?F/SU(+GG-CI)2K
M)?\=4*-4">Z-U/K+G_(%*(WBY9_^[><M>!-Z$N;_M.,['W9H*WV@L7H$V%4:
M[&@-V#/8O:[1'%2J7X%:>;"C/:C4!RNM/V@ N (U!$ _*C4()Y^4)=_3=F[L
MNV7Q<MB6_-6&;8^'JR%3M&05YHU(/QL3_6<Y7Y7M-]!\ X.PL2G_.+KL/Q^\
MC==%"S0M^)E'L;GB9[[4UO?3"NX]E6:U\KHCLEJ^[HM</ZD:I#^ 92%DH==_
M1P _H#\]Z<KR5ND%H,A7;]=%H7N<885(%!$&@Q0E$*F80$:8@"R*TSA2&:4<
MS0[LO+/<=JPO*QZR,V!]<M)'699_ 8V,X&E95(2T5$!(MG*;8(XB;#<9] 9L
M'.(VXAE,:OFN6KC\L6J7_CX9\&@_H[)5EZ8OF:7SVGXL<,WY<JU)Y9?E2I8?
MEW117B_$AWQ!%SQ?W'^67.;?*)O+-\_;SU]U5]<_\G(694*%89; ("("(HDT
M4<@4P2A2. XXQ8HE+B;N)<),SVQM)01&1/";$?+_<R.0BP;'CFC&@GQ@0G)$
MVYF/?,#DD[<NDF=4?O.!W$L>]-)F/[[L;=PU)MSM>F6\R,8Q?[/0Z]I%F?._
MTOE:SE1(,QQ(X_BE$B).*:2,$:B0U$97Q)-01K.G%P[6X5:5Y^1U>?E?2CT<
M#[R1]_EBH84%C,Z-LWXDE\#9T8T8)X1F%*J$11 1G$!"4PQ1JO^7R2"62=R,
M;NN"_&<:V^,>6I\C^[Z2<VK#.K!KQ^= 3=^7L_'6[.A[!38:@TKE"7AN;$=E
M$JZ:L\+^<_AF;#'WYHRQ[K"?':&E><Q7E9='VRYOEXN5[D%J^T66[_*2SY?E
MNI!?Y8_5&PW?[S,:B20)5 C#)-7& 0UCR%2L(,9)2 1F-$N%RTK+K?NIK:UV
MI =Z;,">_&Y3@^,XV/']<.@.3.*=P(*M[. W(SVHQ/>XRNJ'FT^:=91@5.[L
MA\Y+0NS92C^6^RSGU=:Z-OR?OVK*+2FO6-4LS+:_5.X*$=$(!8&VC=,XT08R
M%9")((,AXFD241HG2KHPG'W74V.W1CY0"=C+;^0 NQVA#0/FX#XA!QR=N<H=
M$I\\Y=#[J!SECLI+?NK10D]/CEZXRO+Z3H^*+ HIOIC@@D_RD<EBI@P9A0;Y
MR&R#(8J@?L80#/22G6:9X @QI]B-TWU-C7UJ4<$UV @+*FD=5]P=X%JNF?U
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M("$!QG&/(#Q7.:;&?JT:H-&C"M9HTZPT>8'<4]+T&B$[?AP!]X$)LA/R'2W
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M@7H&B<[MTU/WCK=Y>D;ZO:W3<]?VK:U)5U6<],=\(6_TQU*3GP@1#1%,XS2
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MLQ!2Y8M\)>?&6?7^!Y^O3>;U_UPNQ?=\/I\)$B&*J8)$8E-<(C,TQ[4-2EE
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MOJ4/PTHX-1K8U?]Z,7+:7(1&4+L$ZUH]L-[J=W.@^XWSZ[!=_]JS-HX+>"8
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M&B*2:8CC1$.F100IES)CBFH5>YS1^ X_-0/VJ!7UK*K!U$C?U 6?@4(#MM7
MYQ3!>W)<3F^&A'SHPYM+59KV%-C6T7^OP=TXJ/L<W0R)_D@G-P/,@N<Q35\0
MNT]IO)\ZXB%-7XT/SVAZ/R5P:]RY<2_R+&82,B5M3A@SZP>Q75JDRE%.8L%)
MZM_)\LQ(7NO%6"TM W7"O;4#[H2(O;/S[0CM;H>PBB\/-HWVMI<LU.LW](R
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MF&]-A<.J+,+3DS$3RXV9J/VBNN!/_T%BA/X"9*UE_Q!LW_F+,Q3S)!=01U1
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M+3XR%J]Q9C%DB0U:0CR'A'(*D60ZI21'FCNU3O 9=&HV<7>]EAYU^[UFP,W
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MRN=9]>D(.U=_KR\B@_MPKF#T<,;.Z1S6P3H8862GZ9QVIX[0V:OZ]_S=-%U
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M$.;'MD:KI(HF.(<JM]GU>9Y!FA/S$^;FY>!88^K>3K9SJ*D1P-VG>[ O<+4
MMR)[&$3=^#I8I\%0&Y@+#L"ZVP,K=/%7)T ZK8[N)XQG33AI<F EN-W1OZ.(
MM3'^IMAB\^W>#/3^TUWSGJ81D5HP#K,D3B#.A(8L9AA&6J1IQ")N:S6[^\/=
MHTW/T=V3%]0" RNQ?]>02_AF0I'([EMRS!7$$:*0(R9A+&)DN)91E6G?7BT!
MT!VQ=\(QMC-@) X'L /1AH-MZ#.*\XA9P((7VG;"Q*7[RJ5'C-YWY8HNYSJN
M7+NEWR&&/;Y\JS1[66SV3S3OGNR0\TR**(YY O,("XC3C$$F)(<,ZRQ%)$T3
M[)6ATCG:U#BA$12P2CJ;S2"-K*!8EIMU90+['6ET(^UVKA$,OZ%=,@O4^RU0
MLRH\ 322ST M;[A##B=80IYT= \XZG&'D^['9QYN-_5CE'NUWA3&(F0;9<OU
MJN=566R:!9 CQ% L$IA9NPU3X\EQ+CB469QPK% 4<^'#)QUC38U-]D6MZD;7
MPOIQ2!>V;@P2"+&!^>,"6 $-"P\\0A)'UW"CTH:#WL>DX7*+_Y;O+\M-L?GQ
MKEBH];UY\N-J_6.N-<VP,NZ=Q"*%F&L**5<<\I0RGB4Z,BSBNME[YOE3HX9:
M1%#)"%HAW?=WSR%X?6?W1EP&)@ _2+PV<SL4OV$;]]Q31]O [5!I?^NVZ[*>
M:_WJZ6FU_+)9B7\UJY"*LCQ1F$.;4V4^W5099\&L\$IE&=8DPSAQC%FX.,;T
M=F9J$?_T'RB+_E()6O^X5[;*<YD_A57E"N<H@7&2&U@CG$.NTA0JAJ6@*LNY
M\BI0<A.H8W BBO[ONBYE";ZIA02<B7^!YY=U^<*,+[99 9M3_+2LUZ-BM01B
MP5Y*S]Y)IS@[&E&WH#>TZ53)!BKAAK"7+JD>U$HZ&61<V^B2CB<6T<4+_?/:
M/ZU7\D541>^^J/7W0JBR2;M&.&:9C"+#H4I ;"OJLS2*H2*,I!G-&6?.*>T7
M1YG:]]\(6AUX-9+V2&B_#&KWAQX,JH$_]EXH>66R7T7AUB3VRP.,EK]^5<?]
MU/7K%_>I1L_*;[9ZRKO5^J"*1K'+*MM&0&<"XRA%"E)DH\LU9Y CCB"/LE1I
M:4O."Y]:\^Y#3]#P,L)7?<F 7JV;C=K2F :V;I"2MNZBK1ST9/1Z6:LJ1F2E
M3VN<_4^?NN0>,^5PW#,0^D/;&!9V*S8P<M?E@/:[+@<-9.\+4W<!<(_GC5C>
MVU_+P^+=/>[OZ_<9;6Q_#FMZ?R[*?[U12_'MB:W_U2RO@J-$J3B#FE,",>$Q
M9$DJ#5UE*$MPFN6YWT;OE0&G9KX<R NLP& KL:<=XXRYJ^\2#LG!79E;0.SA
MVK@A$];3N3+FR(Z/&P*G?I#C?3W[LJY70BE9VK9 IY6#[+*^;0KYL'Y;&(8K
M^$M52N.SVKRLEP_ZGCT7&[:8YTAJBA6#FI((XASEQFR*4AC+!"N=T$@1[$-+
MP22;&G^U8C?1_LJW\6NP&7,CM5>9A^%]NTJG.LFBU@K4:H']\F7[ZMCJBU:?
MJA%VK5' MK2A00[:S#:8<..VP V-Z4GCW. #]'!O/ZK-[ZOUOWY5LA!L\2M;
MLL?*&VOC.B522@@",TT0Q$E&(,F9A(SH+$F3C'&BG.,.N\>:&L]^_/57#^?S
M"HX._F8X= 9FOT90T$@*=J*&CBYT@Z33G;SRB/$\2#==#IQ&QUMZ^XGE:E'(
MRC#\\L++0A9L;?S1AW758V''0N7N4B6K@\JBS3.;<\I8A WG<ZH9Q#1!D.6(
MP82:_Y,IIXA[MMP.(M?TML/VQ-[U'&F%!O#(B+";QD=W?%H7WXVBBQ_@;_;0
MK;W5VU$-,.G.WNRX$SF\R[O39P;V-;)-^>H9W5-J!O;5VD[8K$VI'K0C;E#P
M WO5 00;V_4.A^49_SS@PV]O@G/43]"8G56$^V<SZ">UMEL)<\$C%)O/!4JE
MC*=.I#:>>LPA3>*$2QUCC&_HB7-=@.F1^T&+G!OZLCB [\:]PP$Z,,D>=6TY
MZ6K;2@^L^#/0*#!,'Q=WX(9JZ^(@P:MU>7%'IZOIB\=3;ND!LS]DW?6@;8I0
M]=-$B:"QP#$DW/ 8)IA SE$.-491(C*NC+/KW^VE>]"IN;M;"9M#6)MX, .Z
MUJ%/\Y8KF+L166@D!Z:OMB'+$8WML*T/9,-V,_7!*'QWE2OCOD(?%3<DSG=,
M<;RW'Q=]80M;J^6[6KXHX]NW)10H8E(F&<0QTA"G:0H)2324.27<,% 6Y]K/
MG#H[SO2L)B,::*3TXY?S.+H1RLW8#,P@C6C[IZG! T4[,0C)$.<'&I42.G4]
MYH#NBWM^].*;DB\+]:#/[_&7'XJE>K]13^4\DCGC6$E(J#!FB$HY9&FLH-2Y
MYI(FE&+F8X:X#STU8Z25W!Z673I>*\%O5GY0*> 9L.$Q*8ZT,@C4 W--0)3]
M.<@;L*#$Y#[ZN&SEC<H)A?D_H7]U@ET:^?NEH04SA'7<OFRJTG2U^V:<NCF2
MF&.-&%1QAB&6G$*:9RF,$H2Y4%ED7E3?4@5N0T^-UUI9P=K("59+L%BQY5[9
M1O^R!8Y3X,9BPP [,(N=%#38@ESO$=6B@YWL88L;^.$5NM*!X^BCESWP0^5<
M#03/)_0DL3; XA/[8;^_MD<!(QF+<Z%@C"/KD[$,$AE3R$0J<(*E(KE7,-J%
M<:9&3]O0LN=:3$\ZN@"FS#G)%%:02T8AYI&"U)BY,-4TC1C.,IFF?@YN #C'
M<7&W@H9%U)'-;T=I:.K>PM.(.$!?C2LH!"7D"T.-R[[=^IY0[97+^_%JXT-O
M=] ,8>O5^LENK3WP1?%8G7;^\L>S$H;-OQ9/YI('_<7\:ZF9L+^KBY>B.56*
MR#3.(*<B,:8CBB#A7,$LEG'&M8PR[11_%EJPJ3'W;H?Y>:<16&U5FME_-X+[
M\4^P:70CK->8G'&V\_:/ /:T @][$]0J!FK-K%.^K]NL*9X<CAE#PQV22H/)
M-BKWAD;TF*R#/[\?NW]<;?9KSO]UO2K+N4X3P9.80Y2;&<7<./F$JA2F-.,)
MRVDB_>H1GAMD:JQK9=SSWF=-FJL?R9Y%TXTP;\5H8/*K#],LEWW>PX@K\\XJ
M<+=8K'ZO2-#F!]^OE2PVX(-1(!S!=<$3DJS.CC,J\71I>DPBG=?VR"#X)UNO
MV7+SRQ_&*2]*]6E="/79O ;J8:G:+(($29YG"")L:Y7F(H=4&S<PPS@B,551
M'B<>>?'71YR>)]C(#%JA024UJ,0&1FZ/5 ,'P+OI8P 0!V:2:^B%3CQP!Z<S
M^<#A,>,E(+CK=)"$X'%;7VMB*5CY[6%MF]DT?S%>J2HWQ>9EK>K"IP_:1K\:
M3[5)9&U2']&<XR@G.560I,)0BZ8YY)@@&,LT(9%&"4%.A=&#2#,U^^23>3F5
M\>=E6Z^K31FM$Q=+5I_]J?KL[ZD^^RNV9T6^=LPM\^AJ\(PT.P/S62.ZS1NP
MFH#V[WNZM*68JWS1?7W YVMYOST,I0"PAK6H;A%H9-,K ':G-EJ(A]X:L++7
M9.S'5[,(E+4367ZU=N.N&1^)XQPK*2%.,;7'NQGD:<(@3@1"5%%,&?4,8/,4
M87KFWGYHQ3MEF/?]LNJ@+9L^F'60E^UOVI+Q?A_,'V!?U[ZA+8[3Y\:\0T[)
MP&2[/Q>740:_50H,DX[5%[UA8EX<97BER!<_A"['OW@^IX?G^XG]J$)JWJW6
M38ZN;?]QORHWVZ).<YY(EL:9A$BG"<14(TA9G$"B.9>&+W,:.9TDNPXX.1.T
M$;G:Y7EJ,L:%[48CK-C;#J6;E2T36SQ5)>(JIO0I_>8R$PX^<6!\!^:U+;2V
MTEN;C%\U^JDD]F[P[HRD1_?=P(B.U%LW +)^^PT>,'5N.+@\9[P=!P^M#K8<
M?.[K0=N'T47W*V.+L>7F@ZI3T#[;=\M8:W512C/T-[O9,8^-+<OR*(4(Q\3P
M.+'MEJB$,<(1B1(B\R1WYO$^$DR-V ^2VQ>-Z*!R16;&R%V^F$]&*J,$<RW]
MW7]R'*A]:,@'YOJ3(,=6@QEH=0"?:^SWU "U'D/#[[$>##T-(RT0PTR'WYIQ
M"Y2=BTBO!X^WJMRB]\$R<].#>I=+M!6J=P6JJQH/S:%-3N*<*YU#B;F$.)<2
M\C1F,%$LPCQ)HR3U"I/O&FQJJTE=/<68_JLGSQC)3DC=]C9" 36TO7]:47[6
ME)T)GR/H@DG@(H&7QQN[[M]5S<^4\KM^3\_M6-O"XGU9OBCY]F5=!_T4*UDU
M>BZK7SX\5_L:[0F=G",4L8PP!C&*A/D/1Y 1&L$D4Y1BK'(E8J\\0F\1ID8O
M=<N552TE4*V8X*=BV1R-_=ESE]5_5HS"4M,<0:4S#3&C%#+&*4QU'$<IM5W4
M]'RI'JU!_?75)X?6DW,BSX!+P*O.CN,N^*!?PM#[X%9*R)F%]G[U]*R697V@
M>&=/^)L*COP'V+^N<<7!W>]L+<UJ4VLWVP9BU*7I @>F]D<YZ'ZYOQ3C[ICW
M1NEDS[S_DWILOUS(2_UD7O-OYIU[T/6X<Y1+K;(80R*06<HDCLP[R3@D69YS
MJG629TY]"GP&G=RZ58=M/#=B]J!$+\@=]E$& ')@VKN8V3X#K=3@0=>LYWC6
MZ@6JQ^[( .".M"'R]9L"RQ=K[MI3UO+XM:U.N"^%&0'5%#/\.=#.B">,G9LA
MKL\:;__#4[N#+0_?>WN6%F;E-_L_.]IWMK C?%:V?+E-2["_,'[2X3_L75FO
M/=7&BY'H;;.#_+[J&V66IE_^$-5&C$T&_D5K)3;S&-N2 BJ&B2+&W<$XA40C
M!866N4Y1;+,2YIO5ABW<+.IQQ?=:<K9*#!B:IC9V'Z82VQIW-O1H5OVW^H ;
M-:M-B/46A.KWGJ6(QWU)W.S[Z4[]P(OD?37+5?.P/8ULVMIVBJM?UM%+A_]V
M<$,- FA1 #^U./RYV@JOH0 M%E6)!E"C$;#X\:O,8M JR>-J,&XYY5>9G9.Z
MRZ\C1;\%]<U+62Q561JOG1?+RI2SE5(7*]L[<1?)IY,L3G-"(5'68\+,IDU'
M%.:$9)(1I!'U2L%S&W9J/E,K-=@3NUZO_KI:R=^+Q>6^.[> [[; A(=TX(7A
M')I@)S+X;9!X23^80C*OX\BC,J8?&L=,YWEW[R2>U7,5B+Y\?%^=XMDTY&6I
MYCSF1"O*H$K,?W F..0J)@9ZA"4EJ< B\['.+XXT-4/ZJQT#K*KSN9]4+>.?
MFR/.&5@J__2:"PB[,4\0W 8FFWT902TD^*D1\_)^5Y]TEVXH J>R7!AL[#25
M;IW/I*!<N:'/WB];V[H%UH"J=AJJ6.RY1K'*%250&%<>8B13R%&J8*YCCFB,
M5*J=[);+0TS-1FF%M.Y2O?/8I!_XA.J>!]-E#_=6B(;>L1T.'9_-V%M1&FGK
MM0=:GMNI74!T;YZ>O7/$K=(NR0\W1CNO[&<3_?+TO%C]4&KO!*VMAY :NP?%
M,31S2XU-%!'CLL6&]:2B*$TUC9#PRYB[.);/"SM2:MQ^+(:?#70943<;* A*
M(Y[2;T_?=P?T[1G\ "%?5]$):19='FQ4L^BJSL=FT?4;>H9YO?!2_=>+F>%?
MOMLMIFVR3<9EC+)(0JPS 3%/C?\4IPPF J,HY1'CS*L4Z:6!IF8B[>0$M:#>
M^4Q7H74CC1" #<T9?;#R#\NY D30X)M+8XT;8G-%XY- FFO7]TDRW=8Z?M!-
M02VV^.L+LT59E-JV":E+ LQCSFVK"(-G'BM#&88M",HC*'"6:$QPGB:I>[JI
MS]!3XX^_JJ7Q7A=-238;E?#82@Y^8B5@MB*F5<\GD,9O,AQ<L<$@'IAQ=G+;
MV)FMY& K.M@UL+GS*(K7 V6?;-2AT!XK+W6'NGF?]1;UW9MM#$.^!;Y.GC3^
M8+7[**O2(<WW$"K4IA>BW2FL7D\<,9FUCZ:'::V]GN"W9)3KS?SA=\-\Y;?B
M^>W*U@F="Z&5T%) AFQ;(1$)2!764.=)&B<ZCW3NE%=TYME3(_VM>."W6D!'
M4_$<;-WL?2,8 ].S!P[.WWN'QAV6G[EKS^HS?SNV^,X]=I2OND.?]K/MNJ2?
MF]?VLOC$"OE1;>:*BTC:VDE"*0IQFB!((HQL_5QD_E_37&<^WMW1\Z?V?5;Q
M0L]&MJH<2-$(Z^?.'4/HYL7= ,S W^JV78T5S696M$%2]^RYV+!%\6\EMSUM
M[/9/>T!V)S;%]RIP-IR/=P&FD*[=\1"C>G07]#MVY"Y=UL-_.^TK:CN)-@?Q
M32"1OGM^7AA3S9Y0**H4CGD$=1(91D@0AHP0";-841[KB*;**7FOS^!3HXN#
MONJSJB5Q&X)2MS.8@4(#MI7?P\?PG18'7VY L >FH MMB_?$;^(Z9^"]!G=C
MX.WAU0V(^TA^77#\_9RXG@!VNG&^SQS/D>NI[8$KU_<9-Z2 ?ULMS!UEG<&Q
M#37]M%K;(>\VFW7!7S95:;N5+1BZ6FX,(HLJ>*->R^8B8BA-,PE5S+5963+C
M$>9<0<:C*%))GL:2^$1BA1'+:\T9+6RKW-/M3_]!8I3_I<E?ZI&)?/O4R8CD
M*3?F%$NQ,E.7&A<^$2GD>1)G6D82<3JOE\0O&[;>3'4"CT4<,"JBTL=VFW@L
MEE7?'<X6]FM]E?E+<RJY0!PJC0G$>99#PFUI%QH+'&=$1EG4S-\O2SGMV6L%
M''[N[)[E*T^<Y(CJ%&-;]HU#S% &&36S)U1.:2:$BF*O_F.OP)ECE=<X8DNI
M="$*3]\^T*PY'NR./A=#'P/O*?0_0/L5[;*N&JW OEJV\.JA8MN]AL %'8(A
M';S(P^V2C5_X(1B:9XM!A'MZ/XOW3LK"#L46=@?F_;+9"IO'B%!.L5DX>8PA
MCA,&B1:YL6@)HT0IAG+N0\<7QID:O^[$K#9/89666TGJ1Z^78'7CRP!@#4R
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MR]NV-(N'OZ"G*71PRKS^Q/2L_>JV5%L)02TBJ&4$NT+N=K+=RKF)V:E[6MV
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MY1Q+D29(*>S7A<>)KL^B&BKLU/);&O6U!+XG,">\'8]:H3'L^TQ5\0LV#-^
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M0&Q\6JQF%[":7_!<,>QAP%P"V,&0"0A;[]JH0:QA%=2\@IK9@,AY5!D(B.!
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MDD60RRCB<9[QG$NOEAY=N!B;YC&?'O9LQM )?#>ETSND/6NCLKV#%0!8"6Y
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M1$8R:38?FMJ]2#-(68*@9CS/8F-,2,R;(&\W=Z@C9:<%MQ_0W?/.L[W;7]Z
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M)K-3R[=7$4<_W-TL_^!H]KR<]X$LN_66+->E&X%E&NKYPE;(#'<*\$(IY%'
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M*KQ[SH?;!A$>XYZU_!;<KQ6XAF=;O;OBNE;>AN]*S0<LP^@%5- :C&Z4ARW
MZ(7&4?5%O[<[9 Y\*B\,%ZI.=\.Y43X$QU )9JMJF[\1E'*H\T0(DN!$YMHY
M]G]_[+$9KPUW'O'=!V"U*XXK(>A9.S2,=<DU/H#!(U"].QP#A9I;+O]]G\M
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M_-<V;7_.L$BB%",8X#34+*ZM1Y)D#"8H#D2:91%7CHT?G668WF6 5@'DE0Z
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M(DAQF"9V%;TZ1YF:N7OS5,4="[UV-:W25EI'-_Q)/"W][M>B-+2CO49F(^$
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MU#/P)/_\DRY-UJBL8_H-790[FE2F&OZOYM>N^;<7)B3$D0HY26"8Q9JF99C
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M(5R4?FK6RV]R_;U8_0%6LJX^63[FSR#?YG/7MUNOUSCA\M?!CA$G.\D#,^U
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M5U50-]*_*5:KXGO=@DK_;OUSGBDI!6<A#)(H@@@G,<Q$G$#%DB!-M5T58J?
M?;?AIV;[-->@]!O-%^XIM([0V_D,AP-T8(O""&X,Q%ITT,J^NQ]LQ >M_!Z;
MK?3"S6O7%3<)QFV_T@N=HSXL_=[BM1)-757E-_F]^E4Y)T@I'L089EA)B$@<
M0A*@# 98Q8B%-"4!\U!ZYF#8J1'9M@QAG9H+GO6;'ZND3_:SKHEL3GATU;'D
MKID%.V[SC^W G-951*:6VB0V?:\_,7S)F#- C5 CYG#D*12%.8.&9168<T_W
M\(%]E'_^234%MI>#&><T0C*",HTT)<F4P8QF# J64FUQD33 R-I!=?#RJ1'/
M1CR'P_PA7A:^FBM0&)@B-I+Y#GHXHW+G"?'PF?&.;V>DW3M;G?M,CR5W\\S;
M2-(/!5W>M$[)YALE-2P9R1*8D%"?<A!3D*$@@B+DF,61"BD7UBNP>ZRI+<B;
M3[=@$Q)MY 4W/3RV%_"U6+'^4!MX 7< YGM)VV'2N<(OO&*\!6^GR][ZMWRD
M=]>F?"T_F,+HAV7OZ[*'- QIQ ("LXABB"C6!P5IPJ)2&29A2(*8.AT4+@TX
M.6)X*E;KJE/&45>42R4/^P%N=R;P">/ 3%&+"BM93S4.\5PWTA89STV@NL<<
MNQ^4%0(G6D/9/=<WQOO7MO9@K)(HD P&&".(@B2!&4DR* 0C4<!8H$\";C'>
MOT[3JJ@#>W]UC7#^U=Y>Z*O]P&N^4;QWC'>+@&N,=P\D1HWQMD"D1XSWKPZ6
MT-X#(\=X_]IAY9S\0#^;YM.J^):7>C;?%ZNWQ0M;JY?%#>?FSJ*<!R0C:103
MF*9(GW$D(I"( ,$T0J%,I4@4=:JHTC78Y.BHE;5*7!.-M( VXKH9,ITHATS@
ME D&29 RD\43Z[^)$ K. LR") VD<BL@Y@OG<4J(C8>TG;GH"[VA#Y6-2#LU
ML&;MS=@';8&T[8/!+^;">572Q?EBFLZ&HPU&/HW&SO%&-1AM-#\T%JV>Z6$H
MWBWYRO0F?2OK/^^6GU;RF>9BTZYX*:JR7$TAKMH^G0O-WDHEFF;"A$.$HA@R
MDE+(DRQF5)$ !=%\6:4K"@NCLI\45BN)U"MI5Y8A>:B2>M.:O.KH6%1EYG@M
MN5.'SVMFR,*8'1#U<?BK50#\TJKP-WWB!>TL;)J?:SV:?IF-)LUA>/A9<#"H
MAY^-D4SOAT<)\LW,B,W,B/IF4JL 5E5,D?E7$\Z;+ZN??S--#ZK87MN%]'=/
MAOUUZ'<> 7J^>KS#PG6Z[QTKKGQ5OP/(YSIPX).)&WA8T659Q[B5FS*""<.*
MQ01#&N,4(BPH)%F*81K'"E-"91A%+H>02P-.[2#2R LJ@<&NQ#9E!OMA;F<H
M^T1RX,WF.A"=S6-;9'R:R!?''-5,MD7@T%2V?J[W%8Z)L_U@Z*UJAGFO_E'6
M?MMYG*0LIAF!$A%]#H]C BF)!40A52()(Y:X-:#L&&MJ'-/T,E]);L 4X&6I
M(06J5@ LC ;N5S=G@;:^M?$!W_ 7-A5&E9BSN@$O+!34HM9VZ@Q0I:<0Z//>
MR]-+S4+-/5EERGF]S+D$F.=[G+/#C7V%<TGO$[<W%Q_I<1Y_D*NGZMJYC=)"
M$4(HD)"&DD*4I9I1@E"#F2F58AGRP*X*V*F73XU"C'A-;(/#R>P0,8N#[Q4X
M#,P%.Q#TN<PYQ,+A^'D%)F.=*UVP<3O]G5&^\UAW^,QXY[4STNX=Q,Y]IF?Z
MCM2\)N_U89V:4WM%>A]RRJK8^H]T;;J%_WPP_N,'^6/]1DOZQSR5$5*8<<BC
M6-M"FL9,[[L "G/CG"8T"Y53;9\>,DR-X+[P1RE>%I6'X_V+:5@$/N;+_.GE
M"6STJLV -J.P!#?UUB^*YS:W66\)CAE /6;/SL :>$X&)MM:^MDA]C.P46$&
M6B7 [Y4:P.@!*D4\GO6N@-%K:E /,<;-#^J/TU&2T!6OZF'67=N):E/\\6ZY
M7N7+,N=5?]B-MR5*&492!! K'$&D5 )IK&<X9$PDB ;Z!]C:3!Q8V*FQ\K82
MZD;>NO=RU41P_5B\E'0I;/L(CC+=%C;NA"9Q8!JOU !ONGL,OFEZ##:?V^LQ
MV+88!.>_":YNTE&^!0[6_82^#2.=%GQVGKSJ>^%V$AEIHCI/-D/+,-Y):20T
M]TY>8XW9L^<%+?/R7C6A(R;/L%CD_&?]WZWYSR1F+)0(LHB'$"6XNCOC4$4A
M1Q(E%#LVOK :=FJ6026U.7)]TF]M*<NQUX4=WG;'+?\H#KPU;P#<BCP#M;C@
M]^;/04Y4;DAY;8%A-_*X?3"<T#AJAN'V=#]>^I<T/G0I;K[I$]E765<*N%=U
M_O/]R[I<:QO<U&_0PO!Y%$5)&D4<,ISHXPXC0A.5U,<=*7$4<,ZBD+C%NSJ-
M[[+"Q@F ;<4'M):_+;!@^C463T_:["FK(@'%5A/PG_^116'X7X 9E?HW3'>;
M.3NB&VPV!N:[S30T@H-MQ8M:=K C_ Q4XOLCO5ZH^>0^-P%&I<!>V!PR8;^7
M7%U8)IPC%0<,<PX%#PA$*):0FM9  :.21X*I"#OU MI]^=2,+I/I7)-57E<T
MT<0D?_!'8SY7X?TW'RTSO$Y":4= ?0$:VM6Q4^EED#HNX1"TL/?^UZK)$IY;
MU"<_TV_-OI5L?;?4Y[3*P5'935^>5Y**^^4_Z2HWWN3/^F 7S@FA6#%]LF(B
M2+7](B-HDC2A5!EEG,HD2*TJ/[@./+6U7I\/RDI4H(V4;XVP8*6E=5ODUMC;
M$< 0B Y,#D9DL)6Y-B]*\&6#;BLX^-R%KC-]N$+EDUJLQQZ5=EP1.:0DY^=[
MW$C]BQJ/U/K=#[GB>2D_K7*N7ZKWV(?O11,]DDB::)+",)49AD@?K" C3,%$
M1%RH0"8TYG:G+,L1)WBNJF4&K="@DAI48@,MM\-M@ 7@%M<Z?D$<^CAT 3W?
M83SVX'3ZORU>,YX+VUZG/2^TPV,]SR=]W=SO:;ZJ/=K:YGJJ?=Z?\_*/]RMI
M7-Y5:QK#;G.<1$EB_#L*I29UG B8L4Q"F0I%LTS&-';R00\N\=2L*R,C5*:]
M\*;EC[M=-?P\6Y[(IC1[8]QH7W=W:;1N[BAW]#;1Y>4?P*@.6MT]6X.CS9/7
M$^K@0H][[!UK#H[.TJ,-/-"F55ZXG'U?K)3,3>1F>=<4T3]P"N[MN'.69G$L
M60*#F 80<9%"IA(..1(B8IB&H5V1U==28&I;6ANIHVHU-.^9>PM1+!9T59ID
MXOH.P_$*8_2OA:<M[Q4G>P([8&D;OK,#@W$FMZ6QCRYK]H\I(VZ) \WCJ#ND
M;QVFM6$.-$/.^^=0<KAMI^5J/=]TZKOYD9=S1&.,8H2AHJF *(HI9"(FIA15
MH)(L8(&T*O-U].;);4";EI*_&_$LPT&/ >O> :Z"86!JMD; FB?/:MM!8/J9
M'?+2_SHDKN.7CL(H9W5IE_KY#_1)*SC=->#3JOCQ\Y_%6I;;-IISE/(DBU@
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M"X@4T9NZ?I,^-8>!C*6();%J<&\[X-26\.ZM"6UN35@C\I5W3X=0][QVN@+
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M#&PTNP&];J!5SIC7;?6Z$F7G>#/(8ML&ID,O8?0(=K#5\XAX0X(=-C0.(MG
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MT)2C,N5,*:<= (M)Q^:VK&4VA4!KJ4$OMLU!C?\"6$;3@6&-'?->CZA[(.H
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MGHF(XA!!(.&1*K1WR1$9'/..6D,'N>ZX]=!^@&CX9'-W$3:2$?[;=!7][/^
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MI&9<1V=X'.TO\@9P\]XO_P'KXOMM\__0Y[]D)4D?M&:.J)0C+@&JB$^*DLA
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M)@XB<%7'1;]/R[BW<K4\\3UEWH!!>N!H(QO-I$9A<+"X22OI42*2$U$2(#2
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M+D2#;.@J[:<?)J>9D_*!\32 \-N* &_:6R$CLV4N;_!H;R%*XET&PD/P(EL
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MRYQ[624 >92B1G"T@YH?0\Q>,F\ /#?I?[TX]=/Y).(^KYP-Q/K2_X-Q3UQ
MN00-7&0>J&!53,Y]4AJ!RWXZOGNYL)_ &X#,)U@6!^_V9=Q[. VPG*@L/22,
M8FP(&$P8G9 I="&S,N@ZTN"DK'+%\ 1-XX)H7W7?M3L#R;X9&+UZD!5KG Q)
MX1:N5"!2<TY"-I:(H"+W5!E>:>-ZG*9Q;T>KP&A_V8\(H]5R/3E<S%>+V325
MRXDWI2-_61O%0&.(*1'VJ%_#!)'9%0.=$\:T8+3B/G'1YWP?GW$#._C37=P\
M1<38U^E[^SJ#2;A!E&S7D$C>T1QP#3&12C^8TG:/9D(#1@P@'0?=IT/8SC@9
MT\T93KW?P<L.LFY@>_H/OYR6I7-Y3MIQ<W&\G)[ZY<4KF'=WH?CR<O,5ENF$
MUAC-9,E[EVB(K:%$)$6USUXE725=['EDMH6T78"Q>#$M-8#!!]IP,\-84,J2
MP"(N3/!E_(<HC?F3R8PR2^O@[#XI8Z?O#!_+[R;E!G!RVX\[]LNC9<=4ZM+7
MCF'YZ0L*=1*DDDH AJTI8]@J D//#ED#"]J;$ S55;KT]".OD6!_1Q \F:DZ
MB$::2%Z]S5?'Q.K@?/UEL9S^$]+$"RJ0\D" Z=):KQL2P($ 32Q$SAQ7+Y T
M?9>L1CSQ&LC:2P/-6:X--V]7JW/DQ.1 M0)#A"A#0;/DQ/G2X<J M2DF:EF5
MZI''26IDQZN'HQTDWZQ5.CI?K]9^7K(A)DD( 9(+HDI!F&26$:< 703(B0E+
M4V15TDZ_0]?8.:?5\;2K#AHP3#=J ![=O3$TT2;21!C/@4CN!/$* Q?%-0?#
MH^6^2G_Q'K2-G58Z*+2&UD5;\+JWA:.8G-.<$>J=*^U!//&!*6(,E%8>RD+R
ME6&UDP=5,8.T%ISVDGV+,+II<54*LOR7N%B:P@10Q/(R,U0JXRG+WLHJ63)/
M$35V\F9=(.TJ_2:<J,]+\*OSY47'SY:UCJL)!(,Q*DJF]/; F,("\4EDPF0,
MU#$70Z6.!8]1-&YGZ(%1-(S<&S!&VXF1B7,:8HI$"R>)-)82&YPG":C(":++
MMDK^[3/F;U;K_SPP-':0: ,XN-EK2D6>J-&.6*-%&0$32"CS(Y/C2AC!DE2U
M&X/W.U>D/P@D=A7N8+BHF4W]Z3/^^?[-A\^?CGY[^^'PZ/V;J\SC?;.HG_KJ
MX;.G>S,R4-;TIL7R%=2NDF*5E4F4?'N;5+$<752D4VD\R'G0UGM>)97O$7H&
MSHW6TC+<#R-1DF/,9R@ESCL@((T00:6L;97XNZ7<Z"$T_YUTZ.>(>>14C^/E
M(IW']='R$RR_3B-TN0S>20\B,>(,0U$XFE$40A*>5;:2^\3L8,E #Q'0R,76
M#LI<#"C9-I#1U25M.+A,/S Q(0OH3AD>&$I$XDIAN!O')'GRG@'O=2OZ''C<
MIV*\Q(S]%7L?)7M*>>SAMW\#/UM_.431;3IQ%#5\A*\P/X=M'HFWD6H9,M$*
M #VX,NH)O2ZB0XC:"R^LI]_S3OH]:G1@[*O+137!-G%J<LW2T?H+++=L2&9"
M$J6LU[HRG:?$\($:XD +GVQ0653Q3!ZD9ISK[^$A-)S(&PB2W_NY/^GVY:UD
MMFQ0[@$DAG,H!DMD]*K<O:+Y]1)71 299)7:_$?H&>?*NQYVAA![ ^BY7@+'
MJ(Q[W-C(@*52S<^IW'05\+AIH]HS$QYH,KQ*^<339(USW?T2=FAO)30 J:V,
MKD5TT[@R4"R9'$IC%-R646C$T6)<T0\,)F?MZ\SW>XJH<:ZXZ\%I, 4T *8'
M#CVMUN"TDR0J[C>7&<X((,)Q8RA&%8[5K=E_]ZS$Y9<JS-DE'A](R@W@9.O\
MKZZ/K;1@P8(BQJ=2PQ@%"3*AT4Q2<QN-%;9*+]2[A#1R9K.C8N^U]-M#RDU$
M65L.?D-)E7$3A8F_3W'O/5^M%Z>P?/-MV_>H7)CA_])G_VTB6.;<960RQ$RD
MI6@R@S1$61%!2V]8G3UK!UK'1=M^\'@8:]4TU00<KZ;"O?EV!O/5#=%Q91S$
MJ EU":-0#"M(<&7*K[<TZ.0HV"J[W*,4-;+9#6/(AI%[ _O>X6*U/LJ_+Q;I
MIA/Y:3%+$V-T\I1R@OX>+QEH"5U(7 QEY0G#$J>J4M;68R2-:YT&TOF]U*U!
M%-  E'Z'.0IHAEP<I-/I?%J$LYY^A:VX)HQI&U, PATKO4H<)=X)3ZC*AJ80
M2^Y #3Q]AZYQ[5(=4 VIBO%G8[T&?'"<=CK!US/HE(.\G9;FDO_LWK_>SF^\
M>93+=,M22U+&\Y:5MIIX!2HZ#R0)F4N-KR6AM#+'\,>#M*5QUYT*C$<N3(:D
M:MQZGF$Q.*[*&K"#Q\O%U^D*>?EML7R]. _K?#X[B+',;EI-(@<G0S"$98$>
MK6.1>)F &*EC9&5ZIJQ4 /0X4>-6_]2Q@(,IH0% O3T]\]/EINW@6]3,_&0:
M9K!)R;Q:1,6#^',ZFTUR#DE'$(1S83&&":'$3)ID9L$Q$:)(53K*/XO*<:N"
MZD"NGIH:P&!GB=& 7TIL8@3UW*!1]E1A] 0IXRN?B7(JYXP>JI*Q5G1PDY!Q
M"X+JQ00["[N!SMA74MGD!+Y;K%:3+$,93Y]([J;3 ]?$)\D(XP'C&)F<CU42
M$1Z@I;GJZ4%.(G:4=0-P^;"8+VYSL07^U6(RU%(?2OP+)0M,4TVL=9&D%(2U
M(=-0)XOENY0U5SB]#Y2&U4,#F];UDBBGP)O.[^]A_661WLZ_PFHS.'H2@P7)
M;""@#3(ENK$#2I3%DU5,V7)?Q27O1=VX1UX#(^*NPS2X>AK W,-L? 0_*V6]
MO_OIO#!\-'\]79TM5GXV": ]SXX12#&4%K[H"$:=2;:::R]P?X]5.M4\E]!Q
MS\GJ(K&JTAH Y553NNWY'U59I)P%$1$HD5Y+8C-PHC#VX&7>4*95<OONT#&N
M(U;;N.TN\N<CQFT0,X>3TI!B(,Q<KH.-<*[&].B(T8N!,M @8&3#E"/>E"Z)
MQBOJ8XJ<5XG\'B-H7!^L-HH&4$(#!JC+('M45)/,@C2&)>(<ZEUZ'XBCSA%J
M2U89H^!$G<OJ)\D:]Y"J+K &5$@3B1"/L^),C DP#F:F=%K5J@Q+P(A("14@
M ;<L5ND"L!^LJIU8U875,&IHX$SB=FQ2$HBF\W-D:GO<LIBO7D%>+&'SN<_^
M&ZSNSG0\F*=^$8XMR94<0118YABSA]#-"B(T)4IID-'5Z5/Q@CPVUP5LGW.2
M5K'1S+)!EK?+?M/X>CW)I2(J,4^2CH[(<C9I;?)$J(2N+[?"ZRIU((_0TUP7
ML?WAN)_,&W 1CY<+I+H[O[:621NY*LVJ$E+N%/%1(/*#H%JPR*2N8A"O26BN
M.]@^ -E1L@V8DP^POC:3O6;(@F;:E0@;J P8%\5(G,K(98HJ!LNUK0.=9U/:
M7.>PO6X.JNJIC0#C)HL3FH+QJ0SISI82"4&00%%8C#-CK/'"U2F.O45%<QW&
M!H/0L^3;@)UZXY=S1/?JL@GL*[^:QHF@R3CI&0E"EVM8:XCU3).4@^+)1Y-L
ME9Y'#U+37O.Q?="RO\";,"IWV7@]G9VO(4UL$"(J:@@#U+ T##!8M@(C<JE\
M8DPJJ'(E^0@]_;#SHQ2A#2'T ='S4FWLWK_YS_\\^/#VPYN##_C^T>'_^MO1
MN]=O/GYZ\^]_O/W\?ZJTM^O[R+IM[W9B?/@AXD],NE<4C%/6DNPQ/I,\2@SR
M=2(B94FYP9>Y;ONXIZ@;N%5>DJ(,<</]W*@R'1L8[O&*$2\5MRES9:%*%4A+
MK?*&1\5W&N<]1^@-' 5<4;^1R.'B]&PQ+\=A74NPG'7V&<V^]L81J5- $RUP
MJY>)"Q=\Q+>K(N@AJAH!U [J?@PY>\N^ 2#=X6';&X-JP37/E@0I!9'!EXZ4
MI<6<U-Y",A)\E;$&#U+3"'#VU_:#*37[B+X!_-SHJ[]M?P)!Z41UUTC%E[XJ
MCC@!B7A=YEHS!E%7J:ZX1\FXN!E NX^/,-A!U$U$<P<I38L"_.S83]/;^::U
MX.QRXB>7U)O2#$Z),A?&1Q(81AO">T,-MS*H*E;G2:K&3>H;'D7#J: )1'V$
M-4H$TF7(>MF#R3@3'%#"DDU$2JY(X-P0;53B)OH8M:P!I8?)&3>+;W@,#2#T
M)L#S\,G[99M!J8V+ <G7UN#6;LH, !6)1R:5C^#ZM:+>)2OF4:+&3>0;'DB#
M*6!4."683M[!B9^]Z29:;[HR&PPLE*/$IM($KE2XN1" 6&TH=PJD]0^D@*XN
MX;."^,O)XNNO^-4;Y."+NX!YX+&-=)#9/<;:5Y0C>L2%] W5E[/2T>!QC70[
MI4N&(-K$(&0B.B0#P&T,Z8%13,^&P,UGCN/R[JVTQ0 2'+L1^7OXYS\][H:7
M+45E2)R#1O\I)S2+& X29P,EILQ^X0S9T'<2=A_IHG'GB\=3\>ZJ60PDIP;B
MW0=N6J#4IU-AT>T)O/C,&(!Y#23;;%P9_P5UPI8=NV76+]L=\(AM-RDW@9.[
MI]9OY]L&!\>EEPNJI$\2B'(Q,5QJA'/?W>*IXOZ46!^H0K?:*UKI+F (\ALY
MN=L11/<P^>(:W1G'9["<+A(*8+D>!LWW1F9:[@WUB)TRY8'([,OU,@62L@U6
M@Q6IDM';:4KI2S9-W MC>\EY=+AT&_RM-*5=ELC!/'T&C#&7?GFQ66@3D)FE
MLFA,XI9(13VQW@3">*(\)1&=<+V<J0K$-;+I[@? )C37P+9]:\!K-[7\("(C
M2,BQ7W8_;PH0)B(8IZ(T!*(LJ3 QEZJ#3+A0'G_CN#-5ZO'Z$MA<VXU]S&(5
MK3110GR+L^V$\RUK$U/:7"EF25* $LM.$AL=+ATC30X&7^8J5<1/T-1<D=)@
MJ-I#]DT Z6[YU&N(A;VNN?='2&B5N[*KB=+&=CW]C ^BG-$C8QBO$Y.9I]:A
M9TJK9-SVI*^YLJ-] %9#)_N"[?.P$6YI0PKI]?FR. H;+[);2!^1W>4TX@.[
MCQW\Z9?I]V7)6Q=&Z91S)#1T?4&X("'31&C6VGL?M*K36&,W<INK<MH[@JVK
ML09<N$>X[-R$QYD$(0P##*RR\QK]5,Z*P=?$4FT4RTH(^<!A?358/DUM<Y51
M%5 YH+[&OAIX<MT=^M67&:Q6?_?+I9^7/JBPC-,5^B"4!QN#RP0L.B+2!=P6
M2F^O(()W(3%![V9Q/A+T[O;\YFJG=HYK7T#^C4*L6T2/<YA=4A;C)9)2Z;CD
M6&F^*A.RZ3BN+N,I]_L@[.G'MU=O-33"!A1_<P#[_ 5N+J.C?,G743XZV_:R
MOV2Y3%-0T6M.?.(&PRF+3&*(1;C*VF.D!8Y^MX1F?S+:*](:#G#5U#'^<(O'
M>>W6U].L!J5CM@J(82*6>VIT$3371"GA-&4AF;SC)OH,*OH!K_5+BI=51A,)
M@D_9]<NJ6D@E(P[FJTZAN+9<8 $,\=:'8M0=L=8HHA7W-B0M%%0YM7L^J?U0
MV?K-Q0NIJF4X;DS^(TP:,$Q*G@DKA0)2:&37J$0,9<I*D;D550JE=Z"U'R!_
ME$N+VLIJ&9'=JOL ?W:_64T<,!DIYZ4+IR0R(&_6X$(3,?,L'4\IO_CARA5U
M_5#WHUQJ#*^0QH_TNBN;U71SDNX]3[X,*\JL3&VCI7D3RQA6Z<BHU,DP7ZGP
MM1^!_;#VH]QO5%%+ W [F'6?@?2PE=XVD?L ZZ-<1N("]]F5^V:N+8K0EY;#
MD"5&4S;H8**)L8IU>QZ9_:#WHUQE5%31^#=LWSU2>NA8_+!, YS-RKFEH11"
MLB1H7'*2LT"",1*]7&V3I#G'?.>&;8=3O2=)Z(>UUB\H7E -XV.NSYWUZS(E
MM>2 %:/^6 [8WS89LA-J@5H7$@E6E^Q676I*72:61B,3>$=%E:$=0S'0#\.M
MWW^,JM9V4#U0[C9501OK+.$N8GA&LR#! 4H@"DY!4!UDE:KB%\S&YZW?MXRH
MTCWSJ]_,ATGUNI\D'E).EM'2@)Y2(BV@?PU6DZ1! F/H7ILJ25T[)N.W?L,R
MC* '1<M+M< [//CTM]_>'?W]4Y5N=P]\>]W&=M]C9_@>=N6V][?9XL_K,:>4
M!VDC "*EE/FPK$A@&(6H'*/T4;M(JV2*/T74 *U^RW=V(Z11?*\N_L  [.W\
M:M+F05Q/OV+P?V/:JT&O-PF()$+&I2.$)I9+1E( D8%*)VD5?_#YI#92M;8O
MEAYH'UQ39TT<1]_HXTZI IH3+TVS+8;\(J*CRDL&MW(4>$BRSE'@,SODUQM,
M65G=CW?0?X[D6SCM2_]UOITE\GGQ$=!)C-,9W*J%^KQXMBB#1U&JTJU=IG+
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M"3FCV4 =$2>%)E[Y$)/G'JU7<PMCW,.H-G'^+$WN#-NS;C6A!);K!L KDA7
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M!Y8NPS9=SNO^B#],1&GY'TK?1Y,1_ E9"2QG N6\W3 48.YWBMSC8:VEI=<
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MIU2'?0CO*2GAH36O'XA-*27)6*N'R6%5VH C((!R-J7 4,4V!=Q/$77L&?3
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MW^+9@B0V$<&[F,B59='7;'6M(6IRDH476095@N5-'D5N43&Z($(_*#I<TB.
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M0L^+:W:R$^IOI)9WB^6?89DG5FD?(ZMO!ZZF*-$6#271MK4AZ*0=<M$DT/T
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M)N4,@J7+0\:")64I5+#/F8HO/*%O+X7NE]"WCW2'#\/MFUAF.7EJDL=:\JQ
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MJN'*5HY7_**U%H:V9EXOIU^_K;?/BXOO9V%^<2MEX3ITR$KRR6U:A%6YA2+
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MPKRON3#T-][/[^6!3VIFL-2<0"2BK<.S+434!DR2J&RT,MZ=B[?GL;<G0=U
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MU\O>*D9JGWRRX.C2KH=RC?D8!L:+H!*3C/9=D_SM+M0-B[)CU'\W$;MW78P
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MTUE?C=0W,F!N]ZN6Q0<N)9CB!3E<04!0M>A+H^0L^J+;5!+?)V7HF["-TI_
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MG6M"O-0"G:0-1R5,SLV2DML(ZBD-L[NB7\3-GE*?VJG=)-$_+W$],V9C+(,
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MS+9\CEV,/ M.V\S'4I]:Q<P@<<-$T85'6UPP^X05NU,R81+PR%!LI)U>P3C
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MOS-\4XIH+.2L_<- Q-R0:SXE=RJFR0]% VDH&:Y%Y!L:\0<'G\ ]=SOU+I^
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M8=P5FP:>,7 &AI1.7L 8V" 4&N0$-$N@.WC"N";3L0C'Q&3XL^P_Y9KG1C"
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M96@M,C R,# Y,S N>'-D4$L! A0#%     @ 3*1F44#D'M58-P  YF$" !4
M             ( !QJ # &%M96@M,C R,# Y,S!?8V%L+GAM;%!+ 0(4 Q0
M   ( $RD9E%[Y1;S9\$  )47"  5              "  5'8 P!A;65H+3(P
M,C P.3,P7V1E9BYX;6Q02P$"% ,4    " !,I&91$&R*&.>" 0 #S@\ %0
M            @ 'KF00 86UE:"TR,#(P,#DS,%]L86(N>&UL4$L! A0#%
M  @ 3*1F4?9-IG=__0  R#L+ !4              ( !!1T& &%M96@M,C R
M,# Y,S!?<')E+GAM;%!+ 0(4 Q0    ( $RD9E''MM>BG0@  -0L   7
M          "  ;<:!P!E>#,Q,3(P,C P.3,P,3 M<6YG+FAT;5!+ 0(4 Q0
M   ( $RD9E%6!XBFB@@  ',L   7              "  8DC!P!E>#,Q,C(P
M,C P.3,P,3 M<6YG+FAT;5!+ 0(4 Q0    ( $RD9E$6 P*M<@@  ,\K   7
M              "  4@L!P!E>#,Q,S(P,C P.3,P,3 M<6YG+FAT;5!+ 0(4
M Q0    ( $RD9E$8 _2": 4  $\J   6              "  >\T!P!E>#,R
H,C R,# Y,S Q,"UQ;F<N:'1M4$L%!@     *  H G0(  (LZ!P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
